<SEC-DOCUMENT>0000721371-21-000116.txt : 20211109
<SEC-HEADER>0000721371-21-000116.hdr.sgml : 20211109
<ACCEPTANCE-DATETIME>20211109090719
ACCESSION NUMBER:		0000721371-21-000116
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211109
DATE AS OF CHANGE:		20211109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CARDINAL HEALTH INC
		CENTRAL INDEX KEY:			0000721371
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		IRS NUMBER:				310958666
		STATE OF INCORPORATION:			OH
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11373
		FILM NUMBER:		211390101

	BUSINESS ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017
		BUSINESS PHONE:		6147573033

	MAIL ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CARDINAL DISTRIBUTION INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cah-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:2425d19b-e3e9-4a9a-b18c-4fd89ecf0bc7,g:620f6444-992f-4a20-8893-967dcaed6c73,d:1938304362d7436fbafe0221fdeb43e5--><html xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:cah="http://www.cardinal.com/20210930" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cah-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV80L2ZyYWc6ZGRmMDhlOTY3ZTk0NGI3ZGE1MTA3YTI1ZTNmMTNlZDYvdGFibGU6Njc5ODczY2NlYWQ1NDU0YTgzMWUxMTFlMGM1ZGE1YWYvdGFibGVyYW5nZTo2Nzk4NzNjY2VhZDU0NTRhODMxZTExMWUwYzVkYTVhZl8yLTEtMS0xLTA_f96ab262-fb3b-450d-a696-24eb0932a14e">0000721371</ix:nonNumeric><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV80L2ZyYWc6ZGRmMDhlOTY3ZTk0NGI3ZGE1MTA3YTI1ZTNmMTNlZDYvdGFibGU6Njc5ODczY2NlYWQ1NDU0YTgzMWUxMTFlMGM1ZGE1YWYvdGFibGVyYW5nZTo2Nzk4NzNjY2VhZDU0NTRhODMxZTExMWUwYzVkYTVhZl8zLTEtMS0xLTA_6c6c8c61-fde5-4b75-afb2-77a88e65ff58">--06-30</ix:nonNumeric><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV80L2ZyYWc6ZGRmMDhlOTY3ZTk0NGI3ZGE1MTA3YTI1ZTNmMTNlZDYvdGFibGU6Njc5ODczY2NlYWQ1NDU0YTgzMWUxMTFlMGM1ZGE1YWYvdGFibGVyYW5nZTo2Nzk4NzNjY2VhZDU0NTRhODMxZTExMWUwYzVkYTVhZl80LTEtMS0xLTA_66444a80-f147-4f23-99f3-e08aea0c035c">2022</ix:nonNumeric><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV80L2ZyYWc6ZGRmMDhlOTY3ZTk0NGI3ZGE1MTA3YTI1ZTNmMTNlZDYvdGFibGU6Njc5ODczY2NlYWQ1NDU0YTgzMWUxMTFlMGM1ZGE1YWYvdGFibGVyYW5nZTo2Nzk4NzNjY2VhZDU0NTRhODMxZTExMWUwYzVkYTVhZl81LTEtMS0xLTA_fa4a0fae-1106-4715-90fd-b71077bf3ee6">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV80L2ZyYWc6ZGRmMDhlOTY3ZTk0NGI3ZGE1MTA3YTI1ZTNmMTNlZDYvdGFibGU6Njc5ODczY2NlYWQ1NDU0YTgzMWUxMTFlMGM1ZGE1YWYvdGFibGVyYW5nZTo2Nzk4NzNjY2VhZDU0NTRhODMxZTExMWUwYzVkYTVhZl82LTEtMS0xLTA_3fe0e7f4-b43a-4f48-84bb-f39f3bf6b816">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cah-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i69b6e01c61e147bea8030d462af3a3bc_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf64c21f338848a589b8d482d67160ff_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia948c3e5ec6f4bec8e7f879a025a4df5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08d940f3e6e149168d29549187b0c935_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac6fdb45d09c424594b1a7bb495c5d01_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i695097f71a9b487091fa06cabd23f062_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e1d62562ca244c38872c9cd9f2d56d4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie839ddea5fe24b80978766903acfb01d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia86d33171aed42cebf549309afad5112_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2352ec975b7b4dc3a57ecbebd33ecc7c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icec93b4af83f4695949286d23b67ad01_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia991af9ea6734d9083e76f365cd48a8d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i954dd0951ce9473ea15bb33f2f8caec7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e29ade5dda14bfab570a6115c5476c8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic178968d51e943dfb82c89ad5adcb211_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf7bc38abb2a4471b3588c1876befe2b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a286add769446a6929995db38cf0158_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6acc8dd1eef4390892185a561efdeef_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5014be6e8244864b10d1e1aa7df0341_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if05b260cc3734bb0880248ead532a4be_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7ce698d5e7544a6b287f38be1c72b5f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c33d8f65b3b43cd8bc1cbe9d77c7e55_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i392aa0279fd84587b4a7422ec0b66687_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe913233736944e3bcf988a459159180_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i163ce554361540e0a609c2fd0c186340_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebeac2f399c74f29a931725a06a2073a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a679feb77be4335bffc03ffaca2dd77_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40062e4a7eef43cca2bffc1aa8b87712_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i891d482236f444278ce33e2e68e222ef_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9d099974be34de59535e552a582515a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id62fb91e9cb944639c928bf48edbe8ec_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8fbd60c13564882aea3ce4f031ac439_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdda9bbed4994da0971162f929b72100_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6acbbe6b726149c8bb61fc9ac5b6a503_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01b3c57121b8495d8065ad7fce4a9b2d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i196f17b7be4b4ddd93ed4aca9bcc505d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9de9a16f990643ea9672976a861c7419_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ae9641dcdf64751a47407f1c250d242_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a95952d91f24a96acde3076dc633d9c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib92ed0577dac4bbc9b8ad80b5f67b420_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaddf0bca9420410db9178ce7262fc4d7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcfd5d7a31364ca9903baa61bbbb046b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e6de765995148a588beb68d12e77abd_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6abff27b2a984366ad5cc02faa9ea0f8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91113dadf04744e2ad236c765eb25aa8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacaa4d2e469a4a02ae9218aa67d40c64_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e5bb242480346b0b189d9c91c958e6c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa0b5e3b96bc4154b048e676455845f3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f4e5c6594c84545986f558f8997e266_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee7a3bfba2ad48c9b5b2b1646931e919_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib71d7e3c32bb4a169cea90f54c789e35_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf622980e47e43b0b3979cfd30243861_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e0815e6302b4d62b7c5d4e8d1168325_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0346feda6c3043a68c4a5ff7af149304_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55bcf168ab754a59940d4801f6fa8bc8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85771b30728a4925a481cfb73f86c250_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96c38f0127214920937fcab46ec74b11_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfe31bf069634c55be5450be71e3f036_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic77dd428b1ff4601871e6896e86dd282_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic758f5072c934983b122d89f93601f02_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2616NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iece19fdd095e453a867d2238196e3c8e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89c1a8ce62804d04a9257ca991dbc676_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if36f5f5d5c97414c9f7c71d8c7230c33_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbd8c1e471554454b0fa1b9c40012912_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaba53fd0a02e4df1a2c874629b263ee5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61d8bd08ced14bfaa33ff22a90a9d2ca_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e5595e73ee346d2a2b82eb33142c333_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>cah:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="ic7bc766a995e48b4954e62dc20520496_I20211104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i089f62a751ee489da5e10d6b58b6adc9_I20211104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsStateDomain</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="stateag"><xbrli:measure>cah:StateAG</xbrli:measure></xbrli:unit><xbrli:context id="ie46ae6d3a39f4f97bd6436e7342a9a4d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i638a4b60fc7140b7b4525502482b8b12_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28701b9327404d53941d5dd148cdf77c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie546f3bca04b4fe2b2764f97ebc4ad00_I20211104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if11b202b8ca343b0a9e421d1841eebd6_I20211104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if50f5130dc374149935c142a609db653_D20211104-20211104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-04</xbrli:startDate><xbrli:endDate>2021-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>cah:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="i73badf44a1bd45889e11d4037d77a5a5_D20211104-20211104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:AlamedaCountyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-04</xbrli:startDate><xbrli:endDate>2021-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i987d5b5da3a84e95a610a63bb8f2de3a_D20211104-20211104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-04</xbrli:startDate><xbrli:endDate>2021-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ae57499f11845a387078309fc16ffc6_D20211104-20211104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:OtherJurisdictionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-04</xbrli:startDate><xbrli:endDate>2021-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i224e04590a6a4682baab9a6e6d77ce88_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab6062bf74dd4e29a56a98ea3760db61_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63cac0f2590c417e85f3d03334418831_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:DOJInvestigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b29eeee66ff478fa0d4886f822b6a59_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19d2a3c94ab340b884ea4bca21d04b54_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if54e4cb700254d5493fff77ca38ac9ef_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i424036b844734cb19b42015632d7a6f2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i3e9abc9dd3db43cc9b26b208cbdb777c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc981e52c59246c48326101ada65bb8b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i658749f8d08c4de3bd8ca178ca6268c4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i406b689ab44d4833a222efac0f41c896_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ff0423111af46e796881f5bffabb11e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2c2db2160bf4119bcf457d76b23d394_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddc20db237214f5184481bac8f6153dc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie17b5134d5df4708a1d031b82fbcd4f4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e2495c58af141e0b5b5d488b2935e1a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i150d8e19b4da44c7a10fc5832479dab4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibce62dee245a48b29809b554a26358b2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1376d1860df846879ab972c82dc8cbb9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie58736b6311e43b89041dc436c54fde9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72e76abd2c8d45b7930ed6de435b0dee_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc2293adf8c64ed9925346fe6e72f47c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a025dd5a49343da902e9c0daf87d367_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9cb0d331acd45e9a57603b0a7ac9478_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic590157c0c22464e839daa43f09f244d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i028247a5bde846f48b6ee152d76c2b8a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeb6754446a54c41bf8d158d19745b40_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90f84269f6144c8183e95a9e6a7c25eb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92892038fe0545f0844bfb3e0c3e12db_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i262b04e9d11d48e58b8a57b9ab73f4e4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ff1053e5ba649348bc766dea62879d6_D20200701-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cd4350b18ea48f3b33db6247ab8f74e_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fe42d24cb094502a3486fea0c6fc0df_I20211004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff81891dbe0e4df49e09522cba431ade_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie756e95338db4f58953d714720e792ab_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ffff5afcbf04bf6bdee0da00d3f865a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14182b7268e14c209c705768a780f9d0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a50bb415d6a42b6b624e81424aefc10_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80a6c9c0ca9b46349d58b2c256d04d1f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f3db035e1db41b1a0fa80e065300460_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3c87fae83994349b2c47f4e40df266f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie36e8fee435f4698b1f72b0de63b4f97_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cah:segment</xbrli:measure></xbrli:unit><xbrli:context id="iefb0192320f84cfda947570718acc52f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i695daf356dd24a7f8a07c54cd6667482_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb22d9ed2a2a48baa6338106943e33db_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i643e811d7ea24162a6e23957fa7b8020_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2589a59e7c8147fb90fc1516771ba4c2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3b3f2699d6140d3a9e1c4884e78c829_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6582c36519d04664abfb836348244e53_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a173f94955146cf8459ca2fc0f76a88_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i260095721ed44bfa8813a4ea26fe309e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93278c2e2d4e42ff9942bc487ad10984_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia19a7508f5d64fa8b59c18df01e2fb5a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1be6ae19d08940a8a9cc5b7717ec3ae5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5ff458415a4478c9e01d28e78e58858_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ad9f408a4c44aeb8a44818cd8464a81_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida3d87ac199c44409567f200919b5238_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2b8a8b2269b4ec6b13d67f67f63e6de_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86109f8fb89f41a5b8bd3da54e768eb3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e1c40e4b0da424cbb1f9ef2eec48d5d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id59a8d61ab224417a39a8f45243726b0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4a68ab932984e5c81cf1ec9c6d852ee_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf9b1163079c47d1b91c576edc8b1a8b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dc4e83510674b0bac2dc681fd406ecd_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0eb34e93d9354dfabdb815166d96003b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia067d8f29be54d07bf02fce520fc3f4c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5857bb7827354cf887e8a93a6c60a3d2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5fcface43a14646b53fcb8c4afba8d4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4520b1ea4514c88b03060a55539c44e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa2d5d99524d44f1810ced80bd09e54b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17c1a096a6384157896d5f66dfc3de76_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib23ff3fa19d64f74860e3a433d7fe8a5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9cd1675b513491fb7ce8cd5c3b5a391_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8be3f11faae246dc81f8ac9ec37aed05_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1569a630e924c95afa6b719377b7025_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b18c3fa14da40a09bb0bf1cd8763c77_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e6d62cc5ac7432b86e6e4ed282c63d5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i391a019a0c87456d8f0328ccefc57190_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic10011e202de4b40a88998de77fc7694_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf166df979c64f28abf562745a86e1d8_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d137a22c5e34b8289f6e4b71689c66a_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4af342838d3b4e8183c8fd3d425f8a54_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i453244191a32475ea14a9891190b3277_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e27bef357c84648b27ccce1e084f1c5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib69f1eb355b548178f5017ddcca5b762_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d5d341ebc974f369b72b8f04af882c0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1938304362d7436fbafe0221fdeb43e5_1"></div><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl84NA_ccc6338d-7656-4951-8015-be4faa8c9609">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6YmE3NzYxMGZlZjZjNDMyMGFlMjg4NmU3ZjRmYWY4N2MvdGFibGVyYW5nZTpiYTc3NjEwZmVmNmM0MzIwYWUyODg2ZTdmNGZhZjg3Y18wLTAtMS0xLTA_cf87d4d1-a237-437c-be98-c81a9cc26201">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl8xMjE_473ad0a8-d0c3-449a-a773-f176eebd844b">September&#160;30, 2021</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6NDVlYzkxNGYyNTc4NDgyMTg2Mjc1MTUyNTc5MmI0NmQvdGFibGVyYW5nZTo0NWVjOTE0ZjI1Nzg0ODIxODYyNzUxNTI1NzkyYjQ2ZF8wLTAtMS0xLTA_a093dddd-d7a9-4124-8c1f-6cf66c3623fe">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from ________ to ________</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl8xOTA2_8fe17d2d-43b0-4ee1-af18-f53530efb532">1-11373</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl8xOTA3_3b80d83c-f8fe-473d-967a-4f7487c6685f">Cardinal Health, Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:566.25pt"><tr><td style="width:1.0pt"></td><td style="width:145.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:31.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6NDZhMTJmNDViMGNhNGUxY2FiMDk5N2EwYjU2MTMwMjUvdGFibGVyYW5nZTo0NmExMmY0NWIwY2E0ZTFjYWIwOTk3YTBiNTYxMzAyNV8wLTAtMS0xLTA_3b413f94-8623-46d2-a16c-6e8fc4a74279">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6NDZhMTJmNDViMGNhNGUxY2FiMDk5N2EwYjU2MTMwMjUvdGFibGVyYW5nZTo0NmExMmY0NWIwY2E0ZTFjYWIwOTk3YTBiNTYxMzAyNV8wLTYtMS0xLTA_03e72029-ddca-4884-9862-0d59dc4c703e">31-0958666</ix:nonNumeric></span></td></tr><tr style="height:23pt"><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6NDZhMTJmNDViMGNhNGUxY2FiMDk5N2EwYjU2MTMwMjUvdGFibGVyYW5nZTo0NmExMmY0NWIwY2E0ZTFjYWIwOTk3YTBiNTYxMzAyNV8zLTAtMS0xLTA_b7c3205a-3cb6-40ba-be21-fbd51f70307e">7000 Cardinal Place</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6NDZhMTJmNDViMGNhNGUxY2FiMDk5N2EwYjU2MTMwMjUvdGFibGVyYW5nZTo0NmExMmY0NWIwY2E0ZTFjYWIwOTk3YTBiNTYxMzAyNV8zLTItMS0xLTA_4e15947d-34b4-458f-8fc5-ea24b8df4935">Dublin</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6NDZhMTJmNDViMGNhNGUxY2FiMDk5N2EwYjU2MTMwMjUvdGFibGVyYW5nZTo0NmExMmY0NWIwY2E0ZTFjYWIwOTk3YTBiNTYxMzAyNV8zLTQtMS0xLTA_7b03104b-3ba7-4d27-b205-c15d03b7096c">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6NDZhMTJmNDViMGNhNGUxY2FiMDk5N2EwYjU2MTMwMjUvdGFibGVyYW5nZTo0NmExMmY0NWIwY2E0ZTFjYWIwOTk3YTBiNTYxMzAyNV8zLTYtMS0xLTA_f6a59970-6915-498d-8243-6a520207e625">43017</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl8xOTA4_73b2bf28-e61e-4780-86c7-81cac9345be3">614</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl8xOTAx_bf5d31b9-51bc-46ec-9f56-cae766317484">757-5000</ix:nonNumeric> </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.75pt"><tr><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:138.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6MWZmZWYzN2RmMjhmNGY1MDhmNGQ0Yjc1MzI2ZWFhZWUvdGFibGVyYW5nZToxZmZlZjM3ZGYyOGY0ZjUwOGY0ZDRiNzUzMjZlYWFlZV8yLTAtMS0xLTA_8f6868f8-44aa-4ef4-a4e5-a33fafef42a2">Common shares (without par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6MWZmZWYzN2RmMjhmNGY1MDhmNGQ0Yjc1MzI2ZWFhZWUvdGFibGVyYW5nZToxZmZlZjM3ZGYyOGY0ZjUwOGY0ZDRiNzUzMjZlYWFlZV8yLTEtMS0xLTA_8649651a-7bfd-461a-9963-806d4ea19eab">CAH</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6MWZmZWYzN2RmMjhmNGY1MDhmNGQ0Yjc1MzI2ZWFhZWUvdGFibGVyYW5nZToxZmZlZjM3ZGYyOGY0ZjUwOGY0ZDRiNzUzMjZlYWFlZV8yLTItMS0xLTA_5504e517-8f04-49b0-bd38-4d0218225a02">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl8xOTAy_312a2b96-4c76-49c4-82ca-3dbab2a0fb67">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl8xOTAz_ce873f33-10c7-4122-b718-150c559a12e7">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6ZTUwNmQ4NDgzMzc3NDE2OTk5MDU0NDNmNjAwMDFjNzUvdGFibGVyYW5nZTplNTA2ZDg0ODMzNzc0MTY5OTkwNTQ0M2Y2MDAwMWM3NV8wLTAtMS0xLTA_a0a8830a-08ec-491c-a660-d7333d1cca88">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6ZTUwNmQ4NDgzMzc3NDE2OTk5MDU0NDNmNjAwMDFjNzUvdGFibGVyYW5nZTplNTA2ZDg0ODMzNzc0MTY5OTkwNTQ0M2Y2MDAwMWM3NV8xLTQtMS0xLTA_146d737e-a3c4-419d-9afa-767042624df1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6ZTUwNmQ4NDgzMzc3NDE2OTk5MDU0NDNmNjAwMDFjNzUvdGFibGVyYW5nZTplNTA2ZDg0ODMzNzc0MTY5OTkwNTQ0M2Y2MDAwMWM3NV8yLTQtMS0xLTA_a77c3266-e0f5-4c9a-a7a6-010df5fa122c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl8xOTA0_6d2d2622-4dab-43d6-97f3-6df10c8945a6">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="margin-bottom:1pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of the registrant&#8217;s common shares, without par value, outstanding as of October&#160;31, 2021, was the following: <ix:nonFraction unitRef="shares" contextRef="i69b6e01c61e147bea8030d462af3a3bc_I20211031" decimals="0" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl8xODk5_df39b915-97b0-4423-8d07-5ae44b18e63e">281,788,002</ix:nonFraction>.</span></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_7"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:22pt;font-weight:700;line-height:100%">Cardinal Health</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:100%"> </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:18pt;font-weight:700;line-height:100%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Q1 Fiscal 2022 Form 10-Q                                                                                                                                   </span></div></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:91.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_13">2</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_31">Explanation and Reconciliation of Non-GAAP Financial Measures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_31">15</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_40">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_40">18</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_43">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_43">18</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_46">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_46">19</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_49">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_49">20</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_52">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_52">21</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_58">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_58">22</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_118">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_118">39</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_121">Form 10-Q Cross Reference Index</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_121">40</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_124">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_124">41</a></span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">About Cardinal Health</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health, Inc., an Ohio corporation formed in 1979, is a globally integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. We manage our business and report our financial results in two segments: Pharmaceutical and Medical. As used in this report, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2022 and fiscal 2021 and to FY22 and FY21 are to the fiscal years ending or ended June&#160;30, 2022 and June 30, 2021, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2021 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations ("MD&amp;A"), but there are others in this Form 10-Q, which may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results, trends or guidance, statements of outlook and various accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Risk Factors, Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (our &#8220;2021 Form 10-K&#8221;). Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the "Overview of Consolidated Results" section of MD&amp;A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the &#8220;Explanation and Reconciliation of Non-GAAP Financial Measures&#8221; section following MD&amp;A in this Form 10-Q. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below is concerned with material changes in financial condition and results of operations between the periods specified in our condensed consolidated balance sheets at September&#160;30, 2021 and June&#160;30, 2021, and in our condensed consolidated statements of earnings/(loss) for the three months ended September&#160;30, 2021 and 2020. All comparisons presented are with respect to the prior-year period, unless stated otherwise. This discussion and analysis should be read in conjunction with the MD&amp;A included in our 2021 Form 10-K. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Overview of Consolidated Results</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the three months ended September&#160;30, 2021 increased 13 percent to $44.0 billion due to sales growth from pharmaceutical distribution and specialty pharmaceutical customers, which primarily consisted of branded pharmaceutical sales to large customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Operating Earnings/(Loss)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">415</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(624)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs/(income)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP operating earnings</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">527</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had GAAP operating earnings of $415 million during the three months ended September&#160;30, 2021. We had a GAAP operating loss of $624 million during the three months ended September 30, 2020 due to a $1.02&#160;billion pre-tax charge for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications. See further description of opioid lawsuits in the Significant Developments in Fiscal 2022 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_94">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 15 percent decrease in non-GAAP operating earnings to $527 million was primarily due to a decline in Medical segment profit resulting from increased supply chain costs, primarily related to commodities, transportation, and labor, and the adverse impact of the prior-year net favorable impact due to COVID-19.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Diluted EPS </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.193%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">($ per share)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2) (3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.94</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.86)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.04</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.03</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.05</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.03</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP diluted EPS </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.29</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.51&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Diluted earnings/(loss) per share attributable to Cardinal Health, Inc. ("diluted EPS" or "diluted loss per share").</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures." </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) First quarter fiscal 2021 GAAP diluted loss per share attributable to Cardinal Health, Inc. ("GAAP diluted EPS") and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the quarter. First quarter fiscal 2021 non-GAAP diluted EPS is calculated using a weighted average of 295 million common shares, which includes potentially dilutive shares.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021 and 2020, we had GAAP diluted earnings per share attributable to Cardinal Health, Inc. ("GAAP diluted EPS") of $0.94 and GAAP diluted loss per share attributable to Cardinal Health, Inc. of $(0.86), respectively. GAAP diluted EPS in the three months ended September&#160;30, 2020 was due to the charge we recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications. This opioid charge had a $(1.87) after tax impact on GAAP diluted EPS during the three months ended September&#160;30, 2020. Refer to the Significant Developments in Fiscal 2022 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_94">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021, non-GAAP diluted EPS decreased 15 percent to $1.29 per share. This decrease was primarily due to the factors discussed above impacting non-GAAP operating earnings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cash and Equivalents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and equivalents balance was $2.5 billion at September&#160;30, 2021 compared to $3.4 billion at June&#160;30, 2021. The decrease in cash during the three months ended September&#160;30, 2021 was due to net cash used in operating activities of $646 million, primarily driven by increases in working capital and the payment into escrow of our first annual settlement payment under the Proposed Settlement Agreement related to state and local governmental opioid claims. See the Significant Developments in Fiscal 2022 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_94">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional detail related to opioid lawsuits and claims. In addition, we deployed cash of $587 million for early debt repayment and $500 million for share repurchases, which was partially offset by proceeds of $927 million, net of cash transferred, received from the divestiture of the Cordis business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Significant Developments in Fiscal 2022 and Trends</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Opioid Lawsuits Development</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement (the &#8220;Proposed Settlement Agreement&#8221;) and settlement process that, if all conditions are satisfied, would result in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the three distributors determined that enough states had agreed to participate in the Proposed Settlement Agreement to proceed to the next phase of the settlement process, which is the subdivision sign-on period. However, the Proposed Settlement Agreement is still subject to contingencies and will not become effective unless and until the three distributors each make separate independent determinations that a sufficient number of political subdivisions, including those that have not sued, have agreed to participate in the Agreement (or otherwise have had their claims foreclosed) to proceed to effectiveness. Prior to that determination, the participating states will also have an opportunity to make a determination as to whether a sufficient number of political subdivisions have agreed to the Proposed Settlement Agreement (or otherwise had their claims foreclosed) to proceed with the Proposed Settlement Agreement. This process is currently contemplated to end in February 2022, although it may be extended by agreement. It is possible that a sufficient number of subdivisions will not agree to the Proposed Settlement Agreement or that other required contingencies will not be satisfied.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the required contingencies are satisfied, the Proposed Settlement Agreement would become effective 60 days after the distributors determine that there is sufficient participation to proceed to effectiveness. During this 60-day period, the participating states and the distributors would cooperate to obtain consent judgments embodying the terms of the Settlement in each participating state.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Proposed Settlement Agreement includes a cash component, pursuant to which the Company would pay up to approximately $6.37&#160;billion, the majority of which would be paid over 18 years. The exact payment amount will depend on several factors, including the participation rate of states and political subdivisions, the extent to which states take action to foreclose opioid lawsuits by political subdivisions (e.g., laws barring or limiting opioid lawsuits by political subdivisions), and the extent to which political subdivisions in participating states file additional opioid lawsuits against the Company after the Proposed Settlement Agreement becomes effective.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Proposed Settlement Agreement also includes injunctive relief terms related to distributors&#8217; controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating controlled substances monitoring programs; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring. A monitor will be selected to oversee compliance with these provisions for a period of five years. In addition, we and the two other settling distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting, which distributors will fund for ten years.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Proposed Settlement Agreement, we and the two other national distributors entered into settlements with each of the States of New York and Ohio and their participating subdivisions. If the Proposed Settlement Agreement becomes effective, New York and Ohio and their participating subdivisions will become a part of the broader agreement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups. In September 2021 we announced that we, along with two other national distributors, had reached an agreement with the Cherokee Nation in connection with ongoing negotiations toward a broader agreement with Native American tribes.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, a trial before a federal judge in West Virginia, brought by Cabell County and City of Huntington against the Company and two other national distributors, concluded in July 2021. The judge has not yet issued a decision. A trial in the case brought by the Washington Attorney General against the Company and the same two other national distributors is scheduled to begin in November 2021, and the Washington Attorney General has issued a press release stating that Washington will not agree to the Proposed Settlement Agreement. A trial in the case brought by the Rhode Island Attorney General against the Company and the same two other national distributors is scheduled to go to trial in January 2022 and a trial in the Dallas County case is scheduled to begin in Texas in February 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021, we paid into escrow the majority of our first annual payment under the Proposed Settlement Agreement. We also made certain payments under the separate New York and Ohio settlements. In total, we have $6.68 billion accrued at September&#160;30, 2021, of which $441 million is included in other accrued liabilities, and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_94">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Increased Supply Chain Costs</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment profit was negatively impacted by increased supply chain costs, primarily related to commodities, transportation (including ocean and domestic freight) and labor, during the three months ended September&#160;30, 2021. We expect these increased costs to continue to adversely impact Medical segment profit for the remainder of fiscal 2022. While we expect these costs will continue to adversely impact fiscal 2022, we are also taking cost-savings measures and price increase actions, which we expect to partially mitigate the impact. If these increased costs are greater than we expect, continue beyond our expectations, or we are unable to increase prices or achieve the cost-savings measures that we expect, our results of operations will be adversely impacted to a greater extent than we currently anticipate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Pharmaceutical segment, we also experienced increased costs, primarily related to transportation and labor, during the three months ended September&#160;30, 2021. However, we do not expect the impact to be meaningful to Pharmaceutical segment profit for fiscal 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") had a net negative impact on our consolidated operating earnings during the three months ended September&#160;30, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Pharmaceutical segment, volumes within our generics program continue to be lower compared to levels prior to COVID-19, which negatively impacted Pharmaceutical segment profit. However, on a year-over-year basis, the impact to segment profit was favorable due to improvement in volume during the three months ended September&#160;30, 2021. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment profit was negatively impacted by COVID-19 during the three months ended September&#160;30, 2021 and on a year-over-year basis primarily due to increased supply chain costs as discussed above, which we expect to continue to have an adverse impact on Medical segment profit for the remainder of fiscal 2022. In addition, while lower demand for surgical products resulting from reduced elective procedures continued to have a modest adverse impact on Medical segment profit, we expect demand to continue to improve during fiscal 2022. Higher volumes in our laboratory business continued to positively impact Medical segment profit, but did not have a meaningful impact on a year-over-year basis due to relatively higher volumes in the prior period.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently anticipate that the negative impact of the COVID-19 pandemic on consolidated operating earnings will be less in fiscal 2022 than in the prior year, which included an inventory reserve of $197&#160;million for certain Medical segment personal protective equipment ("PPE") during the fourth quarter of fiscal 2021. As a result, we expect the COVID-19 impact for fiscal 2022 will be positive in comparison to prior year. However, we cannot estimate the length or severity of the COVID-19 pandemic or of the related U.S. or global economic consequences on our businesses and results of operations, including whether and when historic economic and operating conditions will resume, or its impact on our business, financial position, results of operations or cash flow. Its impact may be greater or less than we anticipate.</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cordis Divestiture</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we sold our Cordis business to Hellman &amp; Friedman for proceeds of $927 million, net of cash transferred, and we retained certain working capital accounts and certain liabilities. The purchase price is subject to adjustments based on working capital requirements as set forth in the agreement. Cardinal Health will retain product liability associated with lawsuits and claims related to inferior vena cava ("IVC") filters in the U.S. and Canada, as well as authority for these matters discussed in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_94">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." In connection with the closing, we entered into a Transition Services Agreement ("TSA") with the buyer to provide support functions for a period of up to twenty-four months following the sale. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_1213">Note 2</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As anticipated, Medical segment revenue and Medical segment profit were adversely impacted during the three months ended September&#160;30, 2021 due to the divestiture of the Cordis business. We expect the divestiture will decrease Medical segment revenue by approximately $700&#160;million and adversely impact Medical segment profit by approximately $70&#160;million in fiscal 2022. The divestiture of the Cordis business resulted in a decrease in amortization of acquisition-related intangible assets during the three months ended September&#160;30, 2021, which we expect to continue for the remainder of fiscal 2022. The divestiture of the Cordis business is subject to risks and uncertainties that may further adversely impact Medical segment profit. For example, the TSA period may be extended beyond our current expectations or could have unintended consequences, and the costs associated with the exit or disposal activities and stranded costs could be greater than anticipated. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20210930_g1.jpg" alt="cah-20210930_g1.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/><img src="cah-20210930_g2.jpg" alt="cah-20210930_g2.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.705%"><tr><td style="width:1.0%"></td><td style="width:75.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,822</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,112&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,149</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,971</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,069&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,968</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,065&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.230%"><div style="margin-bottom:3pt"><span><br/></span></div></div><div style="display:inline-block;max-width:3.539%;min-width:2.539%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.231%"></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical Segment </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment revenue increased during the three months ended September&#160;30, 2021 due to sales growth from pharmaceutical distribution and specialty pharmaceutical customers, which together increased revenue by $4.7 billion and primarily consisted of branded pharmaceutical sales to large customers.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Segment</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment revenue increased during the three months ended September&#160;30, 2021 primarily within products and distribution, which increased revenue by $129 million. The increase was primarily due to the positive impact of PPE, higher volumes in our laboratory business and improvement in volume of surgical products used in elective procedures, partially offset by the impact of the divestiture of the Cordis business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold increased 13 percent to $42.3 billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due to the factors affecting the changes in revenue and gross margin.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.230%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div></div><div style="display:inline-block;max-width:3.539%;min-width:2.539%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.231%"></div></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.230%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Gross Margin</span></div></div><div style="display:inline-block;max-width:3.539%;min-width:2.539%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.231%"></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><img src="cah-20210930_g3.jpg" alt="cah-20210930_g3.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/><img src="cah-20210930_g4.jpg" alt="cah-20210930_g4.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,642</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin during the three months ended September&#160;30, 2021 decreased primarily due to the impact of the divestiture of the Cordis business and increased supply chain costs in the Medical segment. COVID-19 had a minimal net impact on gross margin during the three months ended September&#160;30, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gross margin rate declined 66 basis points during the three months ended September&#160;30, 2021 primarily due to changes in pharmaceutical distribution product mix resulting from branded pharmaceutical sales, which have a dilutive impact on our overall gross margin rate. The performance of Medical segment products and distribution, which includes increased supply chain costs, and the divestiture of the Cordis business also had an adverse impact on gross margin rate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Distribution, Selling, General, and Administrative ("SG&amp;A") Expenses</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.705%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SG&amp;A expenses</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,114</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,137&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended September&#160;30, 2021, SG&amp;A expenses decreased due to the divestiture of the Cordis business, partially offset by investments in information technology infrastructure and higher costs to support sales growth. The year-over-year comparison was also favorably impacted by the prior-year judicial decision relating to a $41 million assessment on prescription opioid medications that were sold or distributed in New York state in calendar year 2017 and 2018, which was recognized during the three months ended September&#160;30, 2020. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_94">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on the New York Opioid Stewardship Act.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_112">Note 12</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20210930_g5.jpg" alt="cah-20210930_g5.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/><img src="cah-20210930_g6.jpg" alt="cah-20210930_g6.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.705%"><tr><td style="width:1.0%"></td><td style="width:75.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">406</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">529</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total consolidated operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">415</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(624)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in Pharmaceutical segment profit during the three months ended September&#160;30, 2021 was primarily due to improvement in volume compared to the prior-year period, which was adversely impacted by COVID-19, largely offset by increased expenses related to investments in information technology infrastructure. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The decrease in Medical segment profit during the three months ended September&#160;30, 2021 was largely due to increased supply chain costs, primarily related to commodities, transportation, and labor. Medical segment profit also reflects an adverse impact related to the prior-year net positive impact of COVID-19 and the impact of the divestiture of the Cordis business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Corporate</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Corporate during the three months ended September&#160;30, 2021 are due to the factors discussed in the Other Components of Consolidated Operating Earnings/(Loss) section that follows.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.967%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Components of Consolidated Operating Earnings/(Loss)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to revenue, gross margin, and SG&amp;A expenses discussed previously, consolidated operating earnings/(loss) were impacted by the following:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:74.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Employee Severance</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021 and 2020, restructuring costs primarily related to the implementation of certain enterprise-wide cost-savings measures. Restructuring costs during the three months ended September&#160;30, 2021 also included costs related to the divestiture of the Cordis business.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization and Other Acquisition-Related Costs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquisition-related intangible assets was $78 million and $115 million for the three months ended September&#160;30, 2021 and 2020, respectively. The decrease in amortization of acquisition-related intangible assets was primarily due to the divestiture of the Cordis business.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation (Recoveries)/Charges, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020, we recognized a pre-tax charge of $1.02&#160;billion associated with certain opioid matters. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_94">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" and the Significant Developments in Fiscal 2022 and Trends section in this MD&amp;A for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021, we recognized $26 million of estimated losses and legal defense costs associated with the IVC filter product liability claims. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_94">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021, we recognized income of $17 million for recoveries in class action antitrust lawsuits in which we were a class member.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Earnings/(Loss) Before Income Taxes</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the items discussed above, earnings/(loss) before income taxes was impacted by the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">40</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss on Early Extinguishment of Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During three months ended September&#160;30, 2021, we recognized a $10 million loss in connection with the debt redemption as described further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_91">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Condensed Consolidated Financial Statements.&#8221;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Provision for/(Benefit from) Income Taxes</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021 and 2020, the effective tax rate was 26.3 percent and 61.8 percent, respectively. The decrease in the effective tax rate for the three months ended September 30, 2021 compared to the prior year period was primarily due to the treatment of the tax impacts of the opioid litigation accrual recognized during the three months ended September&#160;30, 2020. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_97">Note </a><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_97">7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion; contractual obligations; tax payments; current and projected debt service requirements, dividends and share repurchases; and potential opioid litigation settlement payments associated with the Proposed Settlement Agreement. If we decide to engage in one or more acquisitions, depending on the size and timing of such transactions, we may need to access capital markets for additional financing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cash and Equivalents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and equivalents balance was $2.5 billion at September&#160;30, 2021 compared to $3.4 billion at June&#160;30, 2021. At September&#160;30, 2021, our cash and equivalents were held in cash depository accounts with major banks or invested in high quality, short-term liquid investments. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021, cash used in operating activities was $646 million, primarily driven by increases in working capital and our first annual settlement payment under the Proposed Settlement Agreement related to opioid lawsuits and claims. For additional information, see Proposed Opioid Litigation Settlement Agreement section below. We also deployed cash of $587 million for early debt repayment and $500 million for share repurchases, which was partially offset by proceeds of $927 million, net of cash transferred, received from the divestiture of the Cordis business.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in working capital, which impact operating cash flow, can vary significantly depending on factors such as the timing of </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customer payments, inventory purchases and payments to vendors in the regular course of business, as well as fluctuating working capital needs driven by customer and product mix.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash and equivalents balance at September&#160;30, 2021 included $646 million of cash held by subsidiaries outside of the United States. </span></div></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Financing Arrangements and Financial Instruments</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Credit Facilities and Commercial Paper</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity at September&#160;30, 2021 include a $2.0 billion commercial paper program, backed by a&#160;$2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. At&#160;September&#160;30, 2021, we had no amounts outstanding under our commercial paper program, revolving credit facility or our committed receivables sales facility. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. At September 30, 2021, we were in compliance with this financial covenant. </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of&#160;$5.7 billion and $6.2 billion at September&#160;30, 2021 and June&#160;30, 2021, respectively. During the three months ended September 30, 2021, we redeemed all outstanding $572 million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $10&#160;million loss on early extinguishment of debt. The early redemption was funded with available cash.</span></div></div></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Anticipated Capital Resources</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax Effects of Self-Insurance Pre-tax Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a tax benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss as described further in our 2021 Form 10-K, we have filed for a U.S. federal income tax refund of $974 million, which we expect to receive within 12 months. Accordingly, we have a current asset for this amount in our condensed consolidated balance sheet at September&#160;30, 2021.</span></div><div style="margin-bottom:3pt"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt"><span><br/></span></div></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Capital Deployment</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Proposed Opioid Litigation Settlement Agreement</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $6.68 billion accrued at September&#160;30, 2021 related to certain opioid litigation, as further described within the Significant Developments in Fiscal 2022 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_94">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." We expect the majority of the payment amounts to be spread over 18 years. During the three months ended September&#160;30, 2021, we paid into escrow the majority of our first annual payment under the Proposed Settlement Agreement, which is reflected in prepaid expenses and other assets in our condensed consolidated balance sheets. If the Proposed Settlement Agreement does not become effective, this payment will be returned to us. We also made certain payments under the separate New York and Ohio settlements. We expect to make subsequent annual payments under the Proposed Settlement Agreement beginning in July 2022. The amounts of these future payments may differ from the payment made during the three months ended September&#160;30, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures during the three months ended September&#160;30, 2021 and 2020 were $67 million and $78 million, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On each of May 5, 2021 and August 4, 2021, our Board of Directors approved a quarterly dividend of $0.4908 per share, or $1.96 per share on an annualized basis, which were paid on July 15, 2021 and October 15, 2021 to shareholders of record on July 1, 2021 and October 1, 2021, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2021, our Board of Directors approved a quarterly dividend of $0.4908 per share, or $1.96 per share on an annualized basis, payable on January 15, 2022 to shareholders of record on January 3, 2022.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021, we repurchased $500 million of our common shares under an accelerated share repurchase ("ASR") program. We funded the ASR program with available cash. The program concluded on October 4, 2021, reducing the amount remaining under our existing share repurchase authorization to $243 million. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_106">Note 10</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2021, our Board of Directors approved a new $3.0 billion share repurchase program, which will expire on December 31, 2024.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Items</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Other Items</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MD&amp;A in our 2021 Form 10-K addresses our contractual obligations and off-balance sheet arrangements, as of and for the fiscal year ended June 30, 2021. There have been no subsequent material changes outside the ordinary course of business to those items.</span></div><div id="i1938304362d7436fbafe0221fdeb43e5_28"></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Critical Accounting Policies and Sensitive Accounting Estimates</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below are supplemental disclosures to the critical accounting policies and sensitive accounting estimates specified in our consolidated balance sheets at </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This discussion and analysis should be read in conjunction with the Critical Accounting Policies and Sensitive Accounting Estimates included in our 2021 Form 10-K.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and (ii) require the use of complex and subjective estimates based upon past experience and management&#8217;s judgment. Other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Because estimates are inherently uncertain, actual results may differ, including due to the risk factors discussed in "Risk Factors" and other risks discussed in our 2021 Form 10-K and our other filings with the SEC since June 30, 2021.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of our inventories are valued at the lower of cost, using the last-in, first-out ("LIFO") method, or market. These are primarily merchandise inventories at the core pharmaceutical distribution facilities within our Pharmaceutical segment (&#8220;distribution facilities&#8221;).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our remaining inventory, including inventory in our Medical segment, that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method ("FIFO"), or net realizable value. We reserve for the lower of cost or net realizable value using the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Due to the unprecedented demand for certain PPE as a result of COVID-19, our Medical segment manufactured and sourced inventory at higher costs than </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in periods prior to COVID-19. As selling prices and customer demand decreased compared to the peak of COVID-19, we recorded a reserve of $197&#160;million in fiscal 2021, primarily related to certain categories of gloves, to reduce the carrying value of certain PPE to its net realizable value. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continued to monitor and assess changes in selling prices and customer demand related to PPE during the three months ended September 30, 2021. While we consider our assumptions continue to be reasonable and appropriate, our estimates for selling prices and demand are inherently uncertain and if our assumptions decline in the future, additional inventory reserves may be required. </span></div></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased goodwill is tested for impairment annually or when indicators of impairment exist. Goodwill impairment testing involves a comparison of the estimated fair value of reporting units to the respective carrying amount, which may be performed utilizing either a qualitative or quantitative assessment. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is determined that it is more likely than not that the fair value does not exceed the carrying amount, then a quantitative test is performed. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. A reporting unit is defined as an operating segment or one level below an operating segment (also known as a component).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reporting units are: Pharmaceutical operating segment (excluding our Nuclear and Precision Health Solutions division); Nuclear and Precision Health Solutions division; Medical operating segment (excluding our Cardinal Health at-Home Solutions </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">division) (&#8220;Medical Unit&#8221;); and Cardinal Health at-Home Solutions division. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. Our qualitative evaluation considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount.</span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Items</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Unit Goodwill Qualitative Assessment</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2021, the fair value of our Medical Unit exceeded its carrying value by approximately 3 percent. If we were to increase the discount rate by a hypothetical 0.3 percent or decrease the terminal growth rate by a hypothetical 1 percent, the carrying value would have exceeded the fair value for the Medical Unit by approximately 1 percent. Additionally, the estimated tax rate used in goodwill impairment testing is a market-based assumption, which is impacted by the U.S. federal statutory tax rate. If the U.S. federal statutory tax rate were to increase to 28 percent and no other inputs were changed, the carrying value would have exceeded the fair value of the Medical Unit.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, we assessed that it was more likely than not that the fair value of our Medical Unit exceeded its carrying value. We considered the impact of increased supply chain costs being experienced by the Medical segment as well as other assumptions used to arrive at the estimate of fair value during the fourth quarter of fiscal 2021. </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we consider these assumptions to be reasonable and appropriate, they are complex and subjective, and additional adverse changes in one key assumption or a combination of key assumptions during fiscal 2022 may significantly affect future estimates. These assumptions include, among other things, a failure to meet expected earnings or other financial plans, or unanticipated events and circumstances, such as changes in assumptions about the duration and magnitude of increased supply chain costs and our planned efforts to mitigate such impact, including price increases or surcharges; the impact of the Cordis divestiture; the COVID-19 pandemic, including estimated demand and selling prices for PPE; an increase in the discount rate; a decrease in the terminal growth rate; increases in tax rates; or a significant change in industry or economic trends. Adverse changes in key assumptions may result in a decline in fair value below the carrying value in the future and therefore, an impairment of our Medical Unit goodwill in future periods, which could adversely affect our results of operations.</span></div></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The "Overview of Consolidated Results" section within MD&amp;A in this Form 10-Q contains financial measures that are not calculated in accordance with GAAP.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Exclusions from Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors&#8217; assessment of the business for the reasons identified below: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">LIFO charges and credits </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies&#8217; financial results. We did not recognize any LIFO charges or credits during the periods presented.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Surgical gown recall costs or income</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes inventory write-offs and certain remediation and supply disruption costs, net of related insurance recoveries, arising from the January 2020 recall of select Association for the Advancement of Medical Instrumentation ("AAMI") Level 3 surgical gowns and voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for Presource Procedure Packs containing affected gowns. Income from surgical gown recall costs represents insurance recoveries of these certain costs. We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies&#8217; financial results.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">State opioid assessments related to prior fiscal years</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals when the underlying assessments were invalidated by a Court or reimbursed by manufacturers. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Restructuring and employee severance costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are excluded because they are not part of the ongoing operations of our underlying business.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Amortization and other acquisition-related costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity&#8217;s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Impairments and gain or loss on disposal of assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Litigation recoveries or charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount. During fiscal 2021, we incurred a tax benefit related to a carryback of a net operating loss. Some pre-tax amounts, which contributed to this loss, relate to litigation charges. As a result, we allocated substantially all of the tax benefit to litigation charges. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">(Gain)/Loss on sale of equity interest in naviHealth</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was incurred in connection with the sale of our remaining equity interest in naviHealth in fiscal 2020. The equity interest was retained in connection with the initial sale of our majority interest in naviHealth during fiscal 2019. We exclude this significant gain because gains or losses on investments of this magnitude do not typically occur in the normal course of business and are similar in nature to a gain or loss from a divestiture of a majority interest, which we exclude from non-GAAP results. The gain on the initial sale of our majority interest in naviHealth in fiscal 2019 was also excluded from our non-GAAP measures. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Transitional tax benefit, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the Tax Cuts and Jobs Act is excluded because it results from the one-time impact of a very significant change in the U.S. federal corporate tax rate and, due to the significant size of the benefit, obscures analysis of trends and financial performance. The transitional tax benefit includes the initial estimate and subsequent adjustments for the re-measurement of deferred tax assets and liabilities due to the reduction of the U.S. federal corporate income tax rate and the repatriation tax on undistributed foreign earnings. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect for each of the items listed above, other than the transitional tax benefit item, is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations. </span></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Definitions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth rate calculation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP operating earnings:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> operating earnings/(loss) excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, and (7) litigation (recoveries)/charges, net. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP earnings before income taxes: </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earnings/(</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before income taxes excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt and (9) (gain)/loss on sale of equity interest in naviHealth. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP net earnings attributable to Cardinal Health, Inc.:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ne</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t earnings/(loss)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt and (9) (gain)/loss on sale of equity interest in naviHealth, each net of tax, and (10) transitional tax benefit, net. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP effective tax rate: </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provision for/(benefit from) income taxes adjusted for (1) LIFO charges/(credits), (2) surgical gown recall costs/(income), (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt and (9) (gain)/loss on sale of equity interest in naviHealth, each net of tax, and (10) transitional tax benefit, net divided by (earnings before income taxes adjusted for the first nine items). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">GAAP to Non-GAAP Reconciliations</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.703%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.687%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per common share amounts)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings/(Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings Growth Rate</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings/(Loss) Before Income Taxes</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Provision for/ (Benefit from) Income Taxes</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings/(Loss)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings/(Loss)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Growth Rate</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1,2</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Growth Rate</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">415</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">369</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">97</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.94</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.04</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">58</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.03</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.05</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.03</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">527</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">491</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">372</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.29</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(624)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(663)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.86)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs/(income)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.91&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.51&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Attributable to Cardinal Health, Inc.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:107%;position:relative;top:-3.15pt;vertical-align:baseline">2&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:107%">First quarter fiscal 2021 GAAP diluted loss per share attributable to Cardinal Health, Inc. ("GAAP diluted EPS") and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the quarter. First quarter fiscal 2021 non-GAAP diluted EPS is calculated using a weighted average of 295 million common shares, which includes potentially dilutive shares</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:107%">.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">3&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Litigation (recoveries)/charges, net includes a pre-tax charge of $1.02 billion recorded in the first quarter of fiscal 2021 related to the opioid litigation. For fiscal 2021, including the tax effects of the opioid litigation charge in the calculation of the estimated annual effective tax rate increased the amount of tax benefit in the first quarter by approximately $450 million. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span><br/></span></div><div id="i1938304362d7436fbafe0221fdeb43e5_40"></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in the quantitative and qualitative market risk disclosures included in our&#160;2021&#160;Form 10-K since the end of fiscal&#160;2021&#160;through&#160;September&#160;30, 2021.</span></div><div id="i1938304362d7436fbafe0221fdeb43e5_43"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of September&#160;30, 2021. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of September&#160;30, 2021, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended&#160;September&#160;30, 2021&#160;that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Pharmaceutical Segment Information Technology Initiative</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment is in a multi-year project to implement a replacement of certain finance and operating information systems. During the three months ended September&#160;30, 2021, we transitioned selected processes to the new systems and are in process of transitioning additional processes to the new systems throughout the remainder of fiscal year 2022. If these new systems are not effectively implemented, or fail to operate as intended, it could adversely affect internal control over financial reporting. It is possible that changes in connection with these process transitions may result in a material change in internal control over financial reporting.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the proceeding described below, the legal proceedings described in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_94">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, Melissa Cohen, a purported shareholder, filed an action on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation. In December 2019 and January 2020, similar complaints were filed in the U.S. District Court for the Southern District of Ohio by purported shareholders, Stanley M. Malone and Michael Splaine, respectively. In January, 2020, the court consolidated the derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation and in March 2020, plaintiffs filed an amended complaint. The amended consolidated derivative complaint seeks, among other things, unspecified money damages against the defendants and an award of attorneys' fees. In February 2021, the court granted in part and denied in part defendants' motion to dismiss. The court dismissed the claim with respect to executive compensation but declined to dismiss the failure to monitor claim.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_49"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the information in this Form 10-Q, including the risk factors below, and the risk factors discussed in "Risk Factors" and other risks discussed in our 2021 Form 10-K and our filings with the SEC since June&#160;30, 2021. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We depend on direct and indirect suppliers to make their products and raw materials available to us and are subject to fluctuations in costs, availability and regulatory risk associated with these products and raw materials. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing businesses use oil-based resins, pulp, cotton, latex and other commodities as raw materials in many products. Prices of oil and gas also affect our distribution and transportation costs. Prices of these commodities are volatile and can fluctuate significantly, causing our costs to produce and distribute our products to fluctuate. Beginning in the fourth quarter of fiscal year 2021, we have experienced higher supply chain costs, primarily related to international freight and commodities, which had a negative impact on Medical segment profit in fiscal 2021 and the first quarter of fiscal 2022. We expect these cost increases to continue to have a negative impact on segment profit, primarily in the Medical segment, in fiscal 2022. Due to competitive dynamics and contractual limitations, we may be unable to pass along cost increases through higher prices. If we cannot sufficiently offset cost increases through other cost reductions, or recover these costs through price increases or surcharges, Medical segment profit could be negatively impacted to a greater extent than we currently anticipate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on others to manufacture some products that we market and distribute. Our operations are also dependent on various components, compounds, raw materials and energy supplied by others. We purchase many of these components, raw materials and energy, and source certain products from numerous suppliers in various countries. In some instances, for reasons of quality assurance, cost effectiveness, or availability, we procure certain components and raw materials from a sole supplier. Our supplier relationships could be interrupted, become less favorable to us or be terminated and the supply of these components, compounds, raw materials or products could be interrupted or become insufficient. These supply interruptions or other disruptions in manufacturing processes could be caused by events beyond our control, including natural disasters, supplier facility shut-downs, defective raw materials, the impact of epidemics or pandemics, such as COVID-19, and actions by U.S. or international governments, including export restrictions or tariffs.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, due to the stringent regulatory requirements regarding the manufacture and sourcing of our products, we may not be able to quickly establish additional or replacement sources for certain components, materials or products. A sustained supply reduction or interruption, and an inability to develop alternative and additional sources for such supply, could result in lost sales, increased cost, damage to our reputation, and may have an adverse effect on our business.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Potential employee attrition due to COVID-19 vaccine mandates may have an adverse impact on our business and results of operations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we announced that we would be requiring certain groups of U.S. and Canadian employees, including salaried and office-based employees and sales teams, to be fully vaccinated against COVID-19 by December 2021. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, an executive order was issued requiring all employers with U.S. Government contracts to ensure that their U.S. based employees, contractors and subcontractors that work on or in support of U.S. Government contracts are fully vaccinated against COVID-19 by December 2021. Additionally, the Occupational Health and Safety Administration ("OSHA") was directed to develop an emergency temporary standard mandating either full vaccination or weekly testing of employees for employers with 100 or more employees. These orders increase the number of our employees who will be required to be vaccinated against COVID-19 and are applicable to certain employees working in distribution centers and manufacturing facilities who would not have otherwise been covered by our company's vaccination requirement. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Implementation of these mandates may result in attrition, including attrition of key or critical employees, and difficulty in attracting or securing new employees, which could have an adverse impact on our business, financial condition or results of operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:15.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number<br/>of Shares<br/>Purchased&#160;(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid&#160;per Share (2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares<br/>Purchased<br/>as Part of Publicly Announced Programs&#160;(2,3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate<br/>Dollar Value of<br/>Shares That May<br/>Yet be Purchased<br/>Under the Program&#160;(3)<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.01&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aug 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,762,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,762,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sept 2021</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,869&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.51&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,765,967</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51.53</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,762,468</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">343</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Reflects 1,396, 234 and 1,869 common shares purchased in July, August and September 2021, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">On August 19, 2021, we entered into an accelerated share repurchase ("ASR") program to purchase common shares for an aggregate purchase price of $500 million and received an initial delivery of 7.8 million common shares using a reference price of $51.53. The program concluded on October 4, 2021 at a volume weighted average price per common share of $51.10 resulting in a final delivery of 2.0 million common shares. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_106">Note 10</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">On November 7, 2018, our Board of Directors approved a $1.0 billion share repurchase program that expires on December 31, 2021. The ASR program concluded on October 4, 2021, which reduced the amount remaining under our existing share repurchase authorization to $243 million. On November 4, 2021, our Board of Directors approved a new $3.0 billion share repurchase program, which will expire on December 31, 2024.</span></div><div id="i1938304362d7436fbafe0221fdeb43e5_55"></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2020 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Earnings/(Loss)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:75.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per common share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMi0xLTEtMS0w_3180b5c7-3881-46c8-bb7b-8a959f69047d">43,968</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMi0zLTEtMS0w_24a6153a-ff34-4d4f-af61-7dc3af4074b6">39,065</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMy0xLTEtMS0w_6d2144ef-3ce3-4a53-82ec-9cb4cea71586">42,326</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMy0zLTEtMS0w_c16dd45d-51bf-41db-ae9f-933600941daf">37,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfNC0xLTEtMS0w_a8836ce1-b372-4a38-aa24-b86e30bc352e">1,642</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfNC0zLTEtMS0w_4a832da3-4d89-4315-8706-21f7e20f85e7">1,715</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution, selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfNy0xLTEtMS0w_247c55f9-7655-4625-8263-a6d2e1d7312c">1,114</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfNy0zLTEtMS0w_885037d9-a758-4f5b-a706-5bce207f2b63">1,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfOC0xLTEtMS0w_13a61f57-b1eb-42cf-92ee-eb0dd32dfba8">18</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfOC0zLTEtMS0w_389680a0-3abe-4384-b33d-5315aaad2b9d">37</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfOS0xLTEtMS0w_5e750d28-de1e-444b-a7d9-3431ae04293d">79</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfOS0zLTEtMS0w_5129e853-84f3-4309-8ff0-810e9c1897a5">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTAtMS0xLTEtMA_6f588c03-9846-49d4-b867-a8b29bfdcc47">2</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTAtMy0xLTEtMA_824de8fb-edc1-4253-8c7f-1aaee8e7264c">9</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTEtMS0xLTEtMA_6e392ab8-ed4f-4de0-94e9-d1a80aaafea9">18</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTEtMy0xLTEtMA_6d437d78-124d-40f4-bebe-080e4e5bc875">1,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating earnings/(loss)</span></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTItMS0xLTEtMA_bcd76dbc-9d99-464f-8bef-e82864ef004b">415</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTItMy0xLTEtMA_d69f48f8-550a-47e9-b17f-38851c3864e8">624</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTQtMS0xLTEtMA_758d976b-d54a-4d66-b7bd-d5fead7718d7">4</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTQtMy0xLTEtMA_c695e248-7142-461c-a8dd-865088a1f4b4">7</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTUtMS0xLTEtMA_80ed179c-12d0-4388-b5d5-23176007e11f">40</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTUtMy0xLTEtMA_47053e80-3562-425f-870e-0ebbba190b59">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTYtMS0xLTEtMA_d26bcde2-3098-44dd-b35b-8ac62c9e1748">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="cah:LossOnEarlyExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTYtMy0xLTEtMA_d3a79a93-8036-48f8-bf9a-1aa589e2401e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings/(loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTctMS0xLTEtMA_616db4de-16aa-4c8e-ab19-fc353e95f016">369</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTctMy0xLTEtMA_ffecd50b-b943-4506-b5d5-6ad2a35b197d">663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for/(benefit from) income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTktMS0xLTEtMA_a6508780-8281-48e7-9403-5cc91cc9e0c3">97</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTktMy0xLTEtMA_8f1f1e3c-e1d6-4ec3-9ae5-a4025fa18c53">410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMjAtMS0xLTEtMA_215f4c56-f4fd-4290-8a00-1dda1327df87">272</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMjAtMy0xLTEtMA_e7722f6b-e1cc-4fef-b61a-cf41d593f0f0">253</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Less: Net earnings attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMjUtMS0xLTEtMA_bd34877d-74d5-4754-8bea-cb275f71666d">1</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="2" style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMjUtMy0xLTEtMA_ba719671-8cb5-480c-9348-c4664ba896a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net earnings/(loss) attributable to Cardinal Health, Inc. </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMjYtMS0xLTEtMA_cbed7b79-d7e1-491e-a455-1da27d50f179">271</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMjYtMy0xLTEtMA_4b379d96-34ad-4f30-81cb-7be268b712bb">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#c4c4c4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings/(loss) per common share attributable to Cardinal Health, Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#c4c4c4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMjktMS0xLTEtMA_766eeca8-08c2-4793-bd37-1332e6a6717d">0.94</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td style="background-color:#c4c4c4;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c4c4c4;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMjktMy0xLTEtMA_8a224997-bdb2-4fb1-9392-f8a38d5a21da">0.86</ix:nonFraction>)</span></td><td style="background-color:#c4c4c4;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMzAtMS0xLTEtMA_5a88b1e2-1eec-4003-8791-e76717895a33">0.94</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMzAtMy0xLTEtMA_00b00cc7-17f6-4121-a8a0-ee269e072327">0.86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average number of common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMzMtMS0xLTEtMA_e8f14262-989e-4077-a76d-957af362bf48">287</ix:nonFraction></span></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMzMtMy0xLTEtMA_49ad7097-b79b-4b34-879c-131ae50c9eb1">293</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMzQtMS0xLTEtMA_311f75af-973e-4782-9047-26d5c0c0d7ff">289</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMzQtMy0xLTEtMA_0ef68a2a-f333-42d0-bae2-206e799b047e">293</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td><td colspan="3" style="background-color:#c4c4c4;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared per common share</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMzYtMS0xLTEtMA_e5c28cff-0018-48d8-8c82-c6df0c557b02">0.4908</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMzYtMy0xLTEtMA_14c29115-d93a-4342-8525-001e4f797193">0.4859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Income/(Loss) </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfMi0xLTEtMS0w_215f4c56-f4fd-4290-8a00-1dda1327df87">272</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfMi0zLTEtMS0w_e7722f6b-e1cc-4fef-b61a-cf41d593f0f0">253</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfNS0xLTEtMS0w_ae0f5ab7-b975-4d27-be15-f255bb3d9ab4">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfNS0zLTEtMS0w_85219802-e5b1-4376-8f38-406eefa76a27">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gain/(loss) on derivative instruments, net of tax</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfNi0xLTEtMS0w_95e494d1-6b2e-4311-8063-23b588684e05">2</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfNi0zLTEtMS0w_92a45ff6-4dc4-4239-b608-ad38e37879e0">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income/(loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfNy0xLTEtMS0w_5b8c6d9c-a398-4479-81fd-f80ca0b83395">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfNy0zLTEtMS0w_ec0d350e-b96b-4241-976c-8d214efff6af">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total comprehensive income/(loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfOS0xLTEtMS0w_f899cf71-33a9-44cd-ba3a-aaa0e656f1e1">245</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfOS0zLTEtMS0w_3f77a05d-0eea-43ee-bde2-36fb3564fe27">236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfMTEtMS0xLTEtMA_ec655fbd-4104-44cc-a48b-59a10d38d216">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfMTEtMy0xLTEtMA_d1bf2ad9-097f-4854-935c-c8c22fef7c01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total comprehensive income/(loss) attributable to Cardinal Health, Inc. </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfMTMtMS0xLTEtMA_e02a1e72-a658-4746-ba6e-c28b817f5e4f">244</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfMTMtMy0xLTEtMA_da09e3a8-763f-47ae-92a3-3d6aaaa0a0e8">236</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMy0xLTEtMS0w_e2df75b5-6e68-4f3f-a26f-f98b81b21cba">2,463</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMy0zLTEtMS0w_cc28383b-c8ca-4066-aff0-3fc7577dc01f">3,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfNC0xLTEtMS0w_c75feead-4937-442a-b53f-0a911c453f55">9,305</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfNC0zLTEtMS0w_82b3e6e7-8699-4e81-9400-5052eeeade9f">9,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfNS0xLTEtMS0w_4857f414-d6f6-409a-8f6e-26d1711cfe92">14,720</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfNS0zLTEtMS0w_d5631ae9-4cb4-48cf-b7b3-c52beb1efe30">14,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfNi0xLTEtMS0w_f024f3b8-0059-4052-b842-847f5e21bf55">3,243</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfNi0zLTEtMS0w_0140b70f-40bb-4dd4-b7a9-8c3409c65176">2,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfNy0xLTEtMS0w_7a680e18-7abe-4377-876d-e9cd2c084367">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfNy0zLTEtMS0w_e3fc676f-821f-4c3f-a5a5-f686b9abeb65">1,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfOC0xLTEtMS0w_84975b6c-4a37-490a-9d33-d02b28c0ba09">29,731</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfOC0zLTEtMS0w_167d610c-b2b2-40b1-97aa-86859e57a82a">31,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTAtMS0xLTEtMA_e2485204-edff-4a1a-bac7-2c70735466ca">2,336</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTAtMy0xLTEtMA_6d4bd7e2-9838-44eb-a286-96fa8b0290c7">2,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill and other intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTEtMS0xLTEtMA_157559fc-7b41-46c0-8975-b7f3513c7d1a">10,005</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTEtMy0xLTEtMA_9317f2e6-f4d9-4dec-9e39-0c13aea0b2eb">10,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTMtMS0xLTEtMA_30a51ccf-ce1f-4a61-be57-e5235bbe3552">921</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTMtMy0xLTEtMA_3fce8636-23d5-4061-844a-1b2a03930943">951</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTQtMS0xLTEtMA_ff1e4830-7f67-4a4e-9039-9f7258f3a346">42,993</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTQtMy0xLTEtMA_c3658c4a-539b-4c42-a5d4-f4175612e56c">44,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTgtMS0xLTEtMA_6da966e8-a90b-4705-a8d5-ad4461961dfc">23,408</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTgtMy0xLTEtMA_2b5f39c8-50f5-4b65-81bc-9abae59484fe">23,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term obligations and other short-term borrowings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTktMS0xLTEtMA_24e3d029-65ec-45c6-8a49-6aeac12cd5cd">301</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTktMy0xLTEtMA_0b585ed1-bd39-4509-bf89-914b7b76ba4e">871</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjAtMS0xLTEtMA_58f097c9-622d-40a0-87da-3ca323193e19">2,790</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjAtMy0xLTEtMA_16b5ec53-85f8-4c31-989f-49a43c5e68ad">2,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities related to assets held for sale</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjEtMS0xLTEtMA_9874bc74-207b-4684-9987-47d868bbf549">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjEtMy0xLTEtMA_87fe1405-61a6-495a-9e5a-e9dd3f790bd9">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjItMS0xLTEtMA_b930c0e8-2c03-480d-840a-b938198b7964">26,499</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjItMy0xLTEtMA_e538ec5f-3b88-4840-b147-bca1d9587db2">27,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjQtMS0xLTEtMA_0e21649b-6561-4483-995d-6c03bee903ed">5,353</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjQtMy0xLTEtOTMzMg_8dfc2357-f312-4ca2-9fb1-aee6b00f5cd5">5,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes and other liabilities</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjUtMS0xLTEtMA_16fafd65-8aa0-4102-b1ab-1719101cf598">9,745</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjUtMy0xLTEtOTM0Nw_6a341ed4-101c-460f-ada4-72a678064308">9,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred shares, without par value:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjg4NTZjMWU1OWRkNzQwNmJiMmU3N2M2YjFhNDFjZTQzXzE1_22b68081-4a81-46e2-85f8-8f3e1eea77ed"><ix:nonFraction unitRef="shares" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjg4NTZjMWU1OWRkNzQwNmJiMmU3N2M2YjFhNDFjZTQzXzE1_77613cea-57a6-4927-9906-51eaad209863">500</ix:nonFraction></ix:nonFraction> thousand</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> shares, Issued&#8212;<ix:nonFraction unitRef="shares" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjg4NTZjMWU1OWRkNzQwNmJiMmU3N2M2YjFhNDFjZTQzXzMz_00e81e12-f5f5-4aae-b5bd-3284ecd37a2a"><ix:nonFraction unitRef="shares" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjg4NTZjMWU1OWRkNzQwNmJiMmU3N2M2YjFhNDFjZTQzXzMz_471c1673-d167-43e1-9c24-0ab8c4f7708c">none</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjktMS0xLTEtMA_a9711db2-a081-4325-a064-f28b9b492565">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjktMy0xLTEtMA_f8b176cc-e77a-47d8-838e-5339c198e558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares, without par value:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized&#8212;<ix:nonFraction unitRef="shares" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM5Y2Q2YWY2YjU4NDRhNjJiNWRlZGIyODRjMGUxYzlmXzE1_6b53dfab-0bab-42b0-9bb0-6de03b7ba115"><ix:nonFraction unitRef="shares" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM5Y2Q2YWY2YjU4NDRhNjJiNWRlZGIyODRjMGUxYzlmXzE1_e13e4714-9ba4-49cf-b142-7de1b54301ae">755</ix:nonFraction></ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">shares, Issued&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM5Y2Q2YWY2YjU4NDRhNjJiNWRlZGIyODRjMGUxYzlmXzMz_538bfc6d-c484-493e-9ef8-c67610b0be37"><ix:nonFraction unitRef="shares" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM5Y2Q2YWY2YjU4NDRhNjJiNWRlZGIyODRjMGUxYzlmXzMz_b417735b-8d96-461a-8605-2bf994568256">327</ix:nonFraction></ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> shares at </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">and June 30,2021</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzEtMS0xLTEtMA_e0764b55-72af-43ff-8b9a-644a60dd853a">2,666</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzEtMy0xLTEtMA_28558df1-dbbd-4847-84d9-d1e2fc07719e">2,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzItMS0xLTEtMA_54307110-f753-413b-b146-21dab46e85bb">1,335</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzItMy0xLTEtMA_4fe54292-7829-46f9-910d-27190df450a7">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares in treasury, at cost:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> <ix:nonFraction unitRef="shares" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjVjODQ5ZTRiZDE2NDQ0MGZiMGRiYjFlYjdiZTc1MTQxXzQw_6668be9c-3cc3-45e2-a2c4-3dc531fdaf2c">43</ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> shares and <ix:nonFraction unitRef="shares" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjVjODQ5ZTRiZDE2NDQ0MGZiMGRiYjFlYjdiZTc1MTQxXzU0_f38fac44-a870-4774-8530-841d17f044f6">36</ix:nonFraction> million shares at </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> and June 30, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzMtMS0xLTEtMA_6401e9a9-f3fe-4638-9fc5-19b8e45d5436">2,547</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzMtMy0xLTEtMA_161cd9fe-da37-41cc-8436-a4de5d7f6193">2,186</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzQtMS0xLTEtMA_35c2245a-e21f-48c6-8754-ddcf8ac46849">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzQtMy0xLTEtMA_e2579a98-7943-43d3-a716-6e793ad72f76">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Cardinal Health, Inc. shareholders' equity</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzUtMS0xLTEtMA_a9a996c3-8768-4a23-b472-0c0bc6dd4bea">1,393</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzUtMy0xLTEtMA_dd745ca6-0115-4d3d-909c-6d9503219a53">1,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzYtMS0xLTEtMA_a5bf8324-4a46-43e9-824b-bb6ded39f972">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzYtMy0xLTEtMA_3e7ce439-b3b5-4772-8e18-f914b247f55d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzctMS0xLTEtMA_4d4fffe1-4ab5-4350-bdd6-dd0f603f6517">1,396</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzctMy0xLTEtMA_b55d9192-606f-4a5b-9acf-0147005186be">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzgtMS0xLTEtMA_cf9dbcd8-d109-495f-98d7-68498581d02a">42,993</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzgtMy0xLTEtMA_1d2ce725-cf93-43a8-a535-3e2019d0dc6d">44,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders' Equity</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:33.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Shareholders&#8217;<br/>Equity</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia948c3e5ec6f4bec8e7f879a025a4df5_I20210630" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMy0xLTEtMS0w_1cce03a2-3bea-4206-94d9-bd5b2273116a">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia948c3e5ec6f4bec8e7f879a025a4df5_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMy0zLTEtMS0w_7218fc90-5200-47de-8c66-c6397a34077d">2,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08d940f3e6e149168d29549187b0c935_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMy01LTEtMS0w_51805c0f-85dd-47b4-b743-a44fb2cf37f6">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iac6fdb45d09c424594b1a7bb495c5d01_I20210630" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMy03LTEtMS0w_f91cc3e2-05f6-45a6-8588-fc4552a033b4">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac6fdb45d09c424594b1a7bb495c5d01_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMy05LTEtMS0w_284ca568-03ce-44b8-bab0-5885ea135814">2,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i695097f71a9b487091fa06cabd23f062_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMy0xMS0xLTEtMA_1d137f4c-3d71-4e98-b1bf-14dc66e6ce9c">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1d62562ca244c38872c9cd9f2d56d4_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMy0xMy0xLTEtMA_44a76862-555f-4291-8f53-a99a164235bf">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMy0xNS0xLTEtMA_076db29b-5329-4c22-9393-b08b57306f24">1,794</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNC01LTEtMS0w_cbed7b79-d7e1-491e-a455-1da27d50f179">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie839ddea5fe24b80978766903acfb01d_D20210701-20210930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNC0xMy0xLTEtMA_2e54f96e-0959-4b54-9017-6c6874f39a83">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNC0xNS0xLTEtMA_eb45b453-8c0b-402e-980b-c25caadd01bd">272</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia86d33171aed42cebf549309afad5112_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNS0xMS0xLTEtMA_f7113617-5126-4cbe-abff-fc99377f4f93">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNS0xNS0xLTEtMA_7a636a2e-061f-4239-bd78-7b1410a8fba5">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2352ec975b7b4dc3a57ecbebd33ecc7c_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNy0xLTEtMS0w_7b6d8685-8078-48d5-9c71-bf068559da94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2352ec975b7b4dc3a57ecbebd33ecc7c_D20210701-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNy0zLTEtMS0w_2427e99e-e56e-47a3-9206-90935e7900a2">40</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icec93b4af83f4695949286d23b67ad01_D20210701-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNy03LTEtMS0w_23658923-3c48-4cec-8224-ad88e2a87082">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icec93b4af83f4695949286d23b67ad01_D20210701-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNy05LTEtMS0w_484dfa53-1613-450c-8125-1827d9599bad">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNy0xNS0xLTEtMA_e76af622-af5a-4aec-8ff7-25d2821e736c">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2352ec975b7b4dc3a57ecbebd33ecc7c_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfOC0zLTEtMS0w_5343c881-3924-4c4a-8fe8-9b671e342b13">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icec93b4af83f4695949286d23b67ad01_D20210701-20210930" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfOC03LTEtMS0w_c7822e70-60be-49f7-b020-4ea04901fcde">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icec93b4af83f4695949286d23b67ad01_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfOC05LTEtMS0w_70d53ff1-b22c-442d-8892-9dc33a293641">400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfOC0xNS0xLTEtMA_99736234-5bc0-4b52-93a7-5a42a3460606">500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia991af9ea6734d9083e76f365cd48a8d_D20210701-20210930" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfOS01LTEtMS0w_00cc40fe-fcf7-4f08-8090-6f9cbd9b2b69">141</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfOS0xNS0xLTEtMA_faae49ce-b2d1-46c6-84cb-b89b5752eb69">141</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie839ddea5fe24b80978766903acfb01d_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTAtMTMtMS0xLTA_94d15aeb-7fcd-4820-9e57-4a152328b77c">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTAtMTUtMS0xLTA_1e6440d3-b08f-4020-bace-fa84b159e325">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i954dd0951ce9473ea15bb33f2f8caec7_I20210930" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTItMS0xLTEtMA_cefe23d1-1b06-48a3-b13e-2c6bc52a24a0">327</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i954dd0951ce9473ea15bb33f2f8caec7_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTItMy0xLTEtMA_1eedebf6-2bfa-4221-8ce0-c9fd4dc402ce">2,666</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e29ade5dda14bfab570a6115c5476c8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTItNS0xLTEtMA_4651b989-14ca-45b9-8fda-dac93c8d659a">1,335</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic178968d51e943dfb82c89ad5adcb211_I20210930" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTItNy0xLTEtMA_db0f33aa-bccb-410f-8ba0-e44b9bee277a">43</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic178968d51e943dfb82c89ad5adcb211_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTItOS0xLTEtMA_6f34d568-2b2d-4b65-aefe-b241147535ca">2,547</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf7bc38abb2a4471b3588c1876befe2b_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTItMTEtMS0xLTA_851e9d1a-2408-4901-a445-969983a4cdf7">61</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a286add769446a6929995db38cf0158_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTItMTMtMS0xLTA_d24e026d-26f5-4b27-adce-385cb701ca97">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTItMTUtMS0xLTA_270bc959-c6a9-4c16-a1f6-9ebb5b9e2c3b">1,396</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:33.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6acc8dd1eef4390892185a561efdeef_I20200630" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMS0xLTEtMS0w_8de8599e-d106-4611-a47f-b48fc525e061">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6acc8dd1eef4390892185a561efdeef_I20200630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMS0zLTEtMS0w_6d20800f-d60b-4408-840a-1b876793ad62">2,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5014be6e8244864b10d1e1aa7df0341_I20200630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMS01LTEtMS0w_0f644ecb-c33d-4bae-bfea-adfb78d969c8">1,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if05b260cc3734bb0880248ead532a4be_I20200630" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMS03LTEtMS0w_3762a9af-9561-43b7-81fe-6f69df824295">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if05b260cc3734bb0880248ead532a4be_I20200630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMS05LTEtMS0w_556ea6f1-48fc-44c7-b816-bfaef7077907">2,066</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ce698d5e7544a6b287f38be1c72b5f_I20200630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMS0xMS0xLTEtMA_88e2e674-3ea6-4df2-8e3b-7b8deaed59ad">104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c33d8f65b3b43cd8bc1cbe9d77c7e55_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMS0xMy0xLTEtMA_53e6400a-7138-4d6e-bfe3-4e0bfcea8908">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392aa0279fd84587b4a7422ec0b66687_I20200630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMS0xNS0xLTEtMA_2bfaf531-b2d9-407c-a7a0-666c939e921b">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMi01LTEtMS0w_80c59f74-9143-43a1-80c4-8ecfb05cb5b8">253</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe913233736944e3bcf988a459159180_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMi0xMy0xLTEtMA_0f87e947-3fab-4f73-bd46-f5cd6656d177">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMi0xNS0xLTEtMA_d464d6b9-5d63-43d7-b115-8b2a494ec74e">253</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i163ce554361540e0a609c2fd0c186340_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMy0xMS0xLTEtMA_73b6bab6-6551-4ac5-8881-ed46af2aea2e">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMy0xNS0xLTEtMA_a676f16c-d158-474b-a5d1-711538e5d650">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iebeac2f399c74f29a931725a06a2073a_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfNS0xLTEtMS0w_e011cee5-fc72-41af-aa50-917671fbef97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebeac2f399c74f29a931725a06a2073a_D20200701-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfNS0zLTEtMS0w_65cdb73a-0143-4377-8746-8413dac4c3d1">29</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a679feb77be4335bffc03ffaca2dd77_D20200701-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfNS03LTEtMS0w_c3ae6d50-85f7-4aa8-80ce-78f908db2aaa">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a679feb77be4335bffc03ffaca2dd77_D20200701-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfNS05LTEtMS0w_650cb777-44c9-4cd5-8a5b-787aef43df43">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfNS0xNS0xLTEtMA_561d9513-a2ce-4335-810e-90c8ed55a1f7">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40062e4a7eef43cca2bffc1aa8b87712_D20200701-20200930" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfNy01LTEtMS0w_8e1faaf6-7c97-4c88-8620-56c6f7534c29">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfNy0xNS0xLTEtMA_3487370f-d6b5-4da5-9e58-60da953dfc90">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i891d482236f444278ce33e2e68e222ef_I20200930" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMTAtMS0xLTEtMA_add725b2-0b17-4d0a-99bd-d94b99b6c54f">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891d482236f444278ce33e2e68e222ef_I20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMTAtMy0xLTEtMA_e08fb3a5-8e68-447a-931c-8cbe67b13cf5">2,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9d099974be34de59535e552a582515a_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMTAtNS0xLTEtMA_4d52261d-de3d-4949-80ef-6df2f405155a">771</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id62fb91e9cb944639c928bf48edbe8ec_I20200930" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMTAtNy0xLTEtMA_c66e3205-486d-4117-b851-5d277e9ad09a">33</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id62fb91e9cb944639c928bf48edbe8ec_I20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMTAtOS0xLTEtMA_938db50d-7eeb-4334-b445-ea1d1c1937c4">2,022</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8fbd60c13564882aea3ce4f031ac439_I20200930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMTAtMTEtMS0xLTA_72722542-c258-4af1-83d2-30b1a3ccadc1">87</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdda9bbed4994da0971162f929b72100_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMTAtMTMtMS0xLTA_4ef163a1-2776-4482-8682-4df9eef544aa">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6acbbe6b726149c8bb61fc9ac5b6a503_I20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMTAtMTUtMS0xLTA_dd6ab6a0-a170-41e8-8280-0b39066067f8">1,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMy0xLTEtMS0w_215f4c56-f4fd-4290-8a00-1dda1327df87">272</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMy0zLTEtMS0w_e7722f6b-e1cc-4fef-b61a-cf41d593f0f0">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings/(loss) to net cash provided by/(used in) operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfNi0xLTEtMS0w_5bd13468-20f7-4e5d-ac7d-51fc8cd35f6b">168</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfNi0zLTEtMS0w_96acdc85-a820-414a-8c3a-149d36ece1c0">205</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfOC0xLTEtMS0w_4458609d-6ff6-4205-8fba-b3d52009f6da">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfOC0zLTEtMS0w_6635782d-a306-497a-8cbc-62e087b5904b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfOS0xLTEtMS0zMzkwNg_9769dd31-3033-46f3-b967-c079fd0fe97e">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfOS0zLTEtMS0zMzg5Nw_4d61f3f4-d83d-49aa-85ac-c1ec1301294a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfOS0xLTEtMS0w_8c350fae-f71f-48a6-a69b-3f88d97adf87">24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfOS0zLTEtMS0w_be8bf10c-cbe2-47e3-a159-9c6da5410dcf">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for bad debts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTAtMS0xLTEtMA_ca8e1ff1-40bd-4564-940b-69010067e98a">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTAtMy0xLTEtMA_c55f3e87-a57d-4e02-8327-726408dd6ccd">16</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in trade receivables</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTMtMS0xLTEtMA_ea3b74aa-b606-4e7b-bdd0-fb8b98f9d600">214</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTMtMy0xLTEtMA_b304a5fa-78bb-46e9-b025-126476b886be">388</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTQtMS0xLTEtMA_a90ddacc-81c3-4664-88e8-9fdba869110f">129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTQtMy0xLTEtMA_bc034e57-8aca-4c21-bc8f-b6d7fc7b70e4">245</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase/(decrease) in accounts payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTUtMS0xLTEtMA_7c73413d-ac25-4c8a-a83d-ea796e9315c3">292</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTUtMy0xLTEtMA_b63c7d97-0993-458b-b181-7a0842be3672">313</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities and operating items, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTYtMS0xLTEtMA_c19d11f0-46ee-40fe-9278-f901eb3588cd">495</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTYtMy0xLTEtMA_5ea0984c-2efd-4a96-83b4-47a1bfa42523">585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by/(used in) operating activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTctMS0xLTEtMA_ff72d83f-2d54-46e7-899e-f0db8ad5b7f9">646</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTctMy0xLTEtMA_9e744e5e-7f3a-490c-bfb0-7212e71ea922">270</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from divestitures, net of cash transferred, and disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjItMS0xLTEtMzc2NDc_35de2128-e02b-4677-84bd-ca1ffb36a3c5">927</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjItMy0xLTEtMzc2NDc_c69e2dd5-b834-4935-b1bc-cb817ba52c9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjEtMS0xLTEtMA_aa21cf0c-793f-4bf7-ad6d-d8df8496e495">67</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjEtMy0xLTEtMA_eea184b3-fd56-4d97-9bb0-fe1524ebcbdf">78</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="cah:Purchaseofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjItMS0xLTEtMA_48fb014a-827c-4802-92d9-a28a1fb4fcf8">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="cah:Purchaseofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjItMy0xLTEtMA_8317a952-f940-4f97-ace2-1dbecbc14516">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjMtMS0xLTEtMA_a0896649-91d9-49e8-9b19-009fc1c2c058">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjMtMy0xLTEtMA_9dfc10c4-34b9-46e4-b023-7c9fc84df00c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjYtMS0xLTEtMA_8dac207c-5a2d-4be5-b466-19dc36b26b6c">862</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjYtMy0xLTEtMA_cf138b18-9261-470c-872a-1b4ae38ed131">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of long-term obligations</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzEtMS0xLTEtMA_0c4cee78-0977-4e6e-9a55-d41381d1fd17">587</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzEtMy0xLTEtMA_4f5eb9ba-1729-4214-b5ae-5d908bc35e65">40</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net tax withholdings from share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" sign="-" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzMtMS0xLTEtMA_eb54f970-ea38-42fe-be31-c9c1907796e0">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzMtMy0xLTEtMA_140ab5a7-610e-4241-b543-be78aa0b3ac3">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends on common shares</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzQtMS0xLTEtMA_e9f1c37a-56e7-49ab-94b2-304ea54407dd">149</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzQtMy0xLTEtMA_749f4b15-9dab-4fd0-a344-abfb24b4c32d">146</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzUtMS0xLTEtMA_49432759-16fa-4d05-80ba-c3f386322498">500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzUtMy0xLTEtMA_9125b9d3-dc52-4390-ad66-ba3a1a8c6fcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzYtMS0xLTEtMA_3eab2f3f-fbd0-4d67-bb68-acfa1f94342d">1,264</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzYtMy0xLTEtMA_f0c5e13f-fba8-4748-a5d4-4d7c0b194801">198</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzgtMS0xLTEtMA_646769a8-9e6f-45cf-b711-39b745d78fd5">5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzgtMy0xLTEtMA_76784ff1-60f6-4996-969d-262d9415df5f">3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash reclassified from assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="cah:CashReclassifiedtoAssetsHeldforSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzktMS0xLTEtNjgyMg_e6e94caf-87b5-4bac-a6b1-617e5af5c82c">109</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="cah:CashReclassifiedtoAssetsHeldforSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzktMy0xLTEtNjg0NA_d7bc06b2-c507-4004-aff7-6b3bfa13ef90">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net decrease in cash and equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfNDAtMS0xLTEtMA_64e0f200-55a9-4deb-b78b-65496815586a">944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfNDAtMy0xLTEtMA_4b1b5008-189e-41a4-bb21-b97cc1968b68">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents at beginning of period</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfNDItMS0xLTEtOTI5MA_baaadd47-ff66-42b2-ba2f-b0ac2c2f565c">3,407</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392aa0279fd84587b4a7422ec0b66687_I20200630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfNDItMy0xLTEtOTI3OA_1a8f7ea3-0c44-4a67-b96d-4cc3464670f7">2,771</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and equivalents at end of period</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfNDItMS0xLTEtMA_3fdd1850-dbde-45d7-ac81-04801d1edba8">2,463</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6acbbe6b726149c8bb61fc9ac5b6a503_I20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfNDItMy0xLTEtMA_79c8c1e2-708f-4e0a-ae21-b337c47d0bef">2,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements </span></div><div style="margin-bottom:1pt;text-align:center"><span><br/></span></div><div id="i1938304362d7436fbafe0221fdeb43e5_76"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83Ni9mcmFnOjEzODJmZTgzNTRmYzRmM2E5NzVlOWQ3YTY5NTU4YTUxL3RleHRyZWdpb246MTM4MmZlODM1NGZjNGYzYTk3NWU5ZDdhNjk1NThhNTFfMzgwNg_1a4a02b1-1f38-4d25-b1e3-483bb8cdd15d" continuedAt="i149b39931b414ab09b85e93db572f6e1" escape="true"><div style="margin-bottom:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83Ni9mcmFnOjEzODJmZTgzNTRmYzRmM2E5NzVlOWQ3YTY5NTU4YTUxL3RleHRyZWdpb246MTM4MmZlODM1NGZjNGYzYTk3NWU5ZDdhNjk1NThhNTFfMzgwOA_b91dc61b-f0d4-40dc-ae60-12f1e1642b85" continuedAt="i5ff459772d29408994d6f19c94ae51c3" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2022 and 2021 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2022 and June 30, 2021, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5ff459772d29408994d6f19c94ae51c3">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2022 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2022. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the "2021 Form 10-K").</ix:continuation> </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i149b39931b414ab09b85e93db572f6e1"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83Ni9mcmFnOjEzODJmZTgzNTRmYzRmM2E5NzVlOWQ3YTY5NTU4YTUxL3RleHRyZWdpb246MTM4MmZlODM1NGZjNGYzYTk3NWU5ZDdhNjk1NThhNTFfMzI5ODUzNDkwMTM5NA_34bd5660-2f19-41a7-b3ea-49c460f185d5" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards Not Yet Adopted </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the three months ended September 30, 2021.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i1938304362d7436fbafe0221fdeb43e5_1213"></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMjEzL2ZyYWc6MjAwMTU1M2I3ZTM0NDJkMjkwOWU5Nzk3MWMxZmZjOTYvdGV4dHJlZ2lvbjoyMDAxNTUzYjdlMzQ0MmQyOTA5ZTk3OTcxYzFmZmM5Nl8zMjk4NTM0ODg5NjU1_5fe75baf-ea2b-4cb2-a504-4f65644f9685" escape="true"><div style="text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Divestitures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we sold our Cordis business to Hellman &amp; Friedman for proceeds of $<ix:nonFraction unitRef="usd" contextRef="i01b3c57121b8495d8065ad7fce4a9b2d_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMjEzL2ZyYWc6MjAwMTU1M2I3ZTM0NDJkMjkwOWU5Nzk3MWMxZmZjOTYvdGV4dHJlZ2lvbjoyMDAxNTUzYjdlMzQ0MmQyOTA5ZTk3OTcxYzFmZmM5Nl8zMjk4NTM0ODg4NjI1_20449f40-bbec-4e68-b1f2-584b1cda93c7">927</ix:nonFraction> million, net of cash transferred, and we retained certain working capital accounts and certain liabilities. The purchase price is subject to adjustments based on working capital requirements as set forth in the agreement. Cardinal Health will retain product liability associated with lawsuits and claims related to inferior vena cava ("IVC") filters in the U.S. and Canada, as well as authority for these matters discussed in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_94">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Cordis business operated within our Medical segment.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="i1938304362d7436fbafe0221fdeb43e5_79"></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RleHRyZWdpb246N2FmNmZkMThkYTM2NDczODg2Zjk2MWY4NmJhZGMzNWNfOTIw_632860be-08cf-4e8c-94dd-ad270dfd2873" continuedAt="i1d7d8d70d9e6438093dad3b3dbafa005" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Restructuring and Employee Severance </span></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RleHRyZWdpb246N2FmNmZkMThkYTM2NDczODg2Zjk2MWY4NmJhZGMzNWNfOTU1_cc47d4ed-e4e5-460c-b326-407b1715622c" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance costs:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related costs</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjAwOGM1NTNiZTY3ODQxOThhMjA5OWJkMGM5NDUwZDc1L3RhYmxlcmFuZ2U6MDA4YzU1M2JlNjc4NDE5OGEyMDk5YmQwYzk0NTBkNzVfMi0xLTEtMS0w_0b2ff880-ab7f-432b-b09a-04a00a211364">8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjAwOGM1NTNiZTY3ODQxOThhMjA5OWJkMGM5NDUwZDc1L3RhYmxlcmFuZ2U6MDA4YzU1M2JlNjc4NDE5OGEyMDk5YmQwYzk0NTBkNzVfMi0zLTEtMS0w_1adef815-5fc9-421f-91a0-fe43c6d0ec6f">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjAwOGM1NTNiZTY3ODQxOThhMjA5OWJkMGM5NDUwZDc1L3RhYmxlcmFuZ2U6MDA4YzU1M2JlNjc4NDE5OGEyMDk5YmQwYzk0NTBkNzVfMy0xLTEtMS0w_767f900f-dcb4-4ab8-a3d0-59d6784975da">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjAwOGM1NTNiZTY3ODQxOThhMjA5OWJkMGM5NDUwZDc1L3RhYmxlcmFuZ2U6MDA4YzU1M2JlNjc4NDE5OGEyMDk5YmQwYzk0NTBkNzVfMy0zLTEtMS0w_87f4e097-88d1-4e62-9982-c68868dbf1f1">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjAwOGM1NTNiZTY3ODQxOThhMjA5OWJkMGM5NDUwZDc1L3RhYmxlcmFuZ2U6MDA4YzU1M2JlNjc4NDE5OGEyMDk5YmQwYzk0NTBkNzVfNC0xLTEtMS0w_13a61f57-b1eb-42cf-92ee-eb0dd32dfba8">18</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjAwOGM1NTNiZTY3ODQxOThhMjA5OWJkMGM5NDUwZDc1L3RhYmxlcmFuZ2U6MDA4YzU1M2JlNjc4NDE5OGEyMDk5YmQwYzk0NTBkNzVfNC0zLTEtMS0w_389680a0-3abe-4384-b33d-5315aaad2b9d">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of professional, project management and other service fees to support divestitures, vendor transition fees, accelerated depreciation, lease costs associated with vacant facilities, project consulting fees, and certain other divestiture-related costs.</span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i1d7d8d70d9e6438093dad3b3dbafa005"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021 and 2020, restructuring costs primarily related to the implementation of certain enterprise-wide cost-savings measures. Restructuring costs during the three months ended September&#160;30, 2021 also included costs related to the divestiture of the Cordis business.</span></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RleHRyZWdpb246N2FmNmZkMThkYTM2NDczODg2Zjk2MWY4NmJhZGMzNWNfOTU2_405edb60-9c0b-4b90-b7bd-b0e8b1a06503" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i196f17b7be4b4ddd93ed4aca9bcc505d_I20210630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfMS0xLTEtMS0w_44cc5b19-85e2-4eb4-abfa-75255ca17f07">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9de9a16f990643ea9672976a861c7419_I20210630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfMS0zLTEtMS0w_e3a8e674-54b3-4fcd-889b-bea627827e87">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfMS01LTEtMS0w_3cbc11c7-a294-4fad-a091-3e3c3f2a34b8">79</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae9641dcdf64751a47407f1c250d242_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfMi0xLTEtMS0w_fd7d21b8-ac8b-4d17-beba-dd09f4fd26f4">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a95952d91f24a96acde3076dc633d9c_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfMi0zLTEtMS0w_99358bff-25ea-443e-adf9-e4a5fd968577">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfMi01LTEtMS0w_8cb0b5b3-02dd-42ae-a58e-b300a3dbf1e2">9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ae9641dcdf64751a47407f1c250d242_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfMy0xLTEtMS0w_53788172-2994-46d2-80f2-771abc4536d5">12</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a95952d91f24a96acde3076dc633d9c_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfMy0zLTEtMS0w_998d673e-a718-4771-90c6-dedaf811c67d">2</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfMy01LTEtMS0w_ba8bb02c-3615-4e7a-bc26-9d1fd5ace6e1">14</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92ed0577dac4bbc9b8ad80b5f67b420_I20210930" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfNC0xLTEtMS0w_4e61bac3-16c6-40a8-a7dd-ab8ae33f16a9">49</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaddf0bca9420410db9178ce7262fc4d7_I20210930" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfNC0zLTEtMS0w_c8927ec9-7f2f-4afc-8dcd-3d67f5d2cf0b">25</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfNC01LTEtMS0w_f8583051-0b22-4d34-b9ca-cca52aebb1fb">74</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i1938304362d7436fbafe0221fdeb43e5_82"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Goodwill and Other Intangible Assets</span></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfNDcy_5634b079-acbb-43ba-9923-de8c69218cf1" continuedAt="ib78956ff455646f086c9c4fc70e4def1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfNDc4_82938f00-33a9-468e-9124-e7a5e73f0d4f" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.283%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcfd5d7a31364ca9903baa61bbbb046b_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfMS0xLTEtMS0w_85c3969c-ba4c-42b3-b9bd-58ac906aaea5">2,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e6de765995148a588beb68d12e77abd_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfMS0zLTEtMS0w_8a600d60-436e-4090-9317-7778e8d638a6">5,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfMS01LTEtMS0w_249e1201-5719-494e-9662-68e6a2f0cbf6">7,989</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6abff27b2a984366ad5cc02faa9ea0f8_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:GoodwillTransfers" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfMi0xLTEtMS0w_f852d04a-82da-456e-8933-6aa180625dba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91113dadf04744e2ad236c765eb25aa8_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:GoodwillTransfers" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfMi0zLTEtMS0w_1ec58b30-9c3b-4833-bb36-823ee1fbe92d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:GoodwillTransfers" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfMi01LTEtMS0w_9c0f3479-f4e0-483f-b711-992536d82202">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6abff27b2a984366ad5cc02faa9ea0f8_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfMy0xLTEtMS0w_24e4d5c1-7901-498e-87eb-af363919a57d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91113dadf04744e2ad236c765eb25aa8_D20210701-20210930" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfMy0zLTEtMS0w_409778c0-aa22-4164-882b-983ca5123348">10</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfMy01LTEtMS0w_66715601-640e-4ed7-ae6c-aa1bca52bea8">10</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacaa4d2e469a4a02ae9218aa67d40c64_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfNC0xLTEtMS0w_0c74bd92-2089-4c3c-9494-37ca83e4e29b">2,659</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e5bb242480346b0b189d9c91c958e6c_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfNC0zLTEtMS0w_fcf3e354-04f6-4ca4-b2f1-979f7eef8549">5,320</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfNC01LTEtMS0w_84b386f2-b0f1-4303-804b-e8196983b380">7,979</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="ib78956ff455646f086c9c4fc70e4def1"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfNDgw_8131af5b-68a8-4b1d-af78-5c917528dd4c" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:24.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0b5e3b96bc4154b048e676455845f3_I20210930" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfMy0xLTEtMS0w_7feba8d8-1078-4329-92be-f00d48ee3473">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0b5e3b96bc4154b048e676455845f3_I20210930" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfMy01LTEtMS0w_89e26c18-7a37-44b2-b17c-d99f43257836">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfNC0xLTEtMS0w_18066296-3174-4c77-ac77-9f158c0b90ef">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfNC01LTEtMS0w_d29d6571-9d6c-469d-b072-e8d41126fd1e">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f4e5c6594c84545986f558f8997e266_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfNy0xLTEtMS0w_7aeac0d4-8eca-410f-bb1a-d0709f285477">3,325</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f4e5c6594c84545986f558f8997e266_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfNy0zLTEtMS0w_3d8fb712-de63-46e1-957f-b188f5b49dc6">2,039</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f4e5c6594c84545986f558f8997e266_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfNy01LTEtMS0w_f1afe355-0cd7-440c-9872-238e3477adb3">1,286</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iee7a3bfba2ad48c9b5b2b1646931e919_D20210701-20210930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfNy03LTEtMS0w_35dd3e4a-1f94-41bc-88f2-6f526327f378">11</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib71d7e3c32bb4a169cea90f54c789e35_I20210930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfOC0xLTEtMS0w_e030695c-e185-4da8-af05-313359fcca2b">552</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib71d7e3c32bb4a169cea90f54c789e35_I20210930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfOC0zLTEtMS0w_cb248066-4390-421f-8abd-56a3ef093a9e">336</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib71d7e3c32bb4a169cea90f54c789e35_I20210930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfOC01LTEtMS0w_a1d6e556-6ab3-4c2e-815f-9bfcb21597f0">216</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibf622980e47e43b0b3979cfd30243861_D20210701-20210930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfOC03LTEtMS0w_8e4a3bef-c199-4bb4-9cf1-a6805e1e6c19">9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e0815e6302b4d62b7c5d4e8d1168325_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfOS0xLTEtMS0w_e3b89ebb-b6f7-421d-8f46-95c3228a85ad">1,038</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e0815e6302b4d62b7c5d4e8d1168325_I20210930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfOS0zLTEtMS0w_48ba2d8c-b6c1-4b3b-bcb4-101ee2518c6f">526</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e0815e6302b4d62b7c5d4e8d1168325_I20210930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfOS01LTEtMS0w_f9eb8da4-67b4-4c0a-85d5-4e0fbc4b8c6e">512</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0346feda6c3043a68c4a5ff7af149304_D20210701-20210930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfOS03LTEtMS0w_2c13507c-db20-4bef-8d0e-6a0e4b834a72">9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfMTAtMS0xLTEtMA_45470289-4b3c-423d-9e34-bc19114c30d9">4,915</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfMTAtMy0xLTEtMA_9c167248-01e9-46e8-9343-eb120c3204ff">2,901</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfMTAtNS0xLTEtMA_a2ba06a6-df68-4ae3-9167-4ab691247f22">2,014</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfMTAtNy0xLTEtMA_0e9c52dc-146f-4fba-bee7-8cf1c9615f77">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfMTEtMS0xLTEtMA_05040cd5-fb6c-4f27-8848-9c600f4e95e2">4,927</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfMTEtMy0xLTEtMA_57fc362c-a49f-46f1-856e-f07c5fc19c71">2,901</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfMTEtNS0xLTEtMA_cb875480-bc2e-4adf-8e07-5d9af69ce4fa">2,026</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:42.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55bcf168ab754a59940d4801f6fa8bc8_I20210630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfMy0xLTEtMS0w_2067407c-ef78-4e75-8fdf-d44cc0ef6c28">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55bcf168ab754a59940d4801f6fa8bc8_I20210630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfMy01LTEtMS0w_195bae28-21c6-4512-ac8f-6aa52ece5da8">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfNC0xLTEtMS0w_6535aad3-e513-43a7-aebd-2ac52df7f675">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfNC01LTEtMS0w_10874446-b838-4573-8955-6734fef2c5b5">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85771b30728a4925a481cfb73f86c250_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfNy0xLTEtMS0w_1bab3939-257b-4f8f-8339-86d716ede392">3,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85771b30728a4925a481cfb73f86c250_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfNy0zLTEtMS0w_94467006-ba05-41c3-9f5d-879c279ea46f">1,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85771b30728a4925a481cfb73f86c250_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfNy01LTEtMS0w_edbb0d9b-1679-43d1-926d-c1d5e960e684">1,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c38f0127214920937fcab46ec74b11_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfOC0xLTEtMS0w_6638d681-8448-461e-b1b6-12e237acf54c">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c38f0127214920937fcab46ec74b11_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfOC0zLTEtMS0w_e50e34da-cd45-40fb-bf9e-1954d41e0cc8">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c38f0127214920937fcab46ec74b11_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfOC01LTEtMS0w_3f74bf2a-4aa3-4d80-92d2-70aea32dea7b">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfe31bf069634c55be5450be71e3f036_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfOS0xLTEtMS0w_f7b5c9c4-eec6-4964-b623-c68e5fe4e157">1,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfe31bf069634c55be5450be71e3f036_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfOS0zLTEtMS0w_4c633092-fdcb-41af-a86d-00b26c51ffd9">506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfe31bf069634c55be5450be71e3f036_I20210630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfOS01LTEtMS0w_1be267a7-4ed4-48d0-858e-7ba8bc002e07">529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfMTAtMS0xLTEtMA_d265e434-538d-4024-96f2-2518eeb3518f">4,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfMTAtMy0xLTEtMA_8adffed0-cb28-4c4a-9e55-090aa3f30b93">2,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfMTAtNS0xLTEtMA_e117e4ae-627a-412c-9fe0-fa9db7ddf507">2,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfMTEtMS0xLTEtMA_843153a3-fa51-4a9a-9698-7882f023fb89">4,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfMTEtMy0xLTEtMA_7ada9826-0a19-46e3-9c61-c74e6cf7e957">2,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfMTEtNS0xLTEtMA_7070d9f4-614a-4315-b00d-592d8b33c4ca">2,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfMjYz_3165fb71-9770-4b85-b667-d1ae6fdaaecd">78</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfMjcw_03cfb3df-5a85-4df8-9093-8bbf8783e440">115</ix:nonFraction> million for the three months ended September&#160;30, 2021 and 2020, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2022 through 2026 is as follows: $<ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfNDMz_113f4147-3069-411a-aee1-87fd12e439f1">236</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfNDM3_f8e907b8-9ee3-46c6-babe-a9487c83e2e6">287</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfNDQx_2408c61e-d59c-4988-8ed6-bd9aad993575">264</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfNDQ1_0f4fbdaa-d393-4241-8e6b-70ecdc044160">238</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfNDUz_2aab06c1-8375-465e-9d79-367984dd1f8f">212</ix:nonFraction> million.</span></div></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfMTk1MQ_55c7170d-6e70-45cc-89b9-43f00be0c40c" continuedAt="i6334f6d8e0a446758b61cc8acde8e036" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Long-Term Obligations and Other Short-Term Borrowings </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of $<ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfMTI2_e3c22127-f926-4b24-acea-2852624db167">5.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfMTMz_fa47e711-ec90-403c-b591-c25678cf05b5">6.2</ix:nonFraction> billion at September 30, 2021 and June 30, 2021, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $<ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfMzI5ODUzNDg5MTE3OA_e44e5ce5-ee13-4133-8efc-9d0cde21bab7">23.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfMzI5ODUzNDg5MTE3NA_ab8292e2-2804-4193-8149-6a5eacf65016">23.7</ix:nonFraction> billion at September 30, 2021 and June 30, 2021, respectively. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we redeemed all outstanding $<ix:nonFraction unitRef="usd" contextRef="ic77dd428b1ff4601871e6896e86dd282_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfMzI5ODUzNDg4NjQzOA_47f75466-2650-4155-be14-58c8106e7262">572</ix:nonFraction> million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $<ix:nonFraction unitRef="usd" contextRef="ic758f5072c934983b122d89f93601f02_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfMzI5ODUzNDg4NjQ3Ng_eed16355-333b-46f0-931c-b04c183a02ab">10</ix:nonFraction>&#160;million loss on early extinguishment of debt. The early redemption was funded with available cash.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020, we early repurchased a total of $<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfMzI5ODUzNDg4NjQzMg_5db07834-e4b7-4153-9262-07a021d032cd">37</ix:nonFraction> million of notes due in 2022 with available cash.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$<ix:nonFraction unitRef="usd" contextRef="iece19fdd095e453a867d2238196e3c8e_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfNzkw_08cfec6b-21ce-4e7e-9af3-91e305f7aa28">2.0</ix:nonFraction> billion&#160;commercial paper program backed by a $<ix:nonFraction unitRef="usd" contextRef="i89c1a8ce62804d04a9257ca991dbc676_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfODMw_ac555cfa-6755-4b76-a4d0-d1b35684273a">2.0</ix:nonFraction> billion&#160;revolving credit facility. We also have a&#160;$<ix:nonFraction unitRef="usd" contextRef="if36f5f5d5c97414c9f7c71d8c7230c33_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfODc1_ea5e4c35-b166-415a-b9e3-b115ae52ec97">1.0</ix:nonFraction> billion committed receivables sales facility. At September 30, 2021, we had <ix:nonFraction unitRef="usd" contextRef="ibbd8c1e471554454b0fa1b9c40012912_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:OtherShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfMzI5ODUzNDg5MTE5MQ_f1dd2acf-8e24-4d6e-8168-bd2e0a054267">no</ix:nonFraction> amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#8220;CHF&#8221;) through September 30, 2022. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose-bankruptcy remote entity whose assets are available solely to satisfy the claims of its creditors. </span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6334f6d8e0a446758b61cc8acde8e036">Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. At September 30, 2021, we were in compliance with this financial covenant.</ix:continuation> </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div id="i1938304362d7436fbafe0221fdeb43e5_94"></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfMTQ3ODU_9c141e91-ae13-4659-8645-2cd5b2630a6e" continuedAt="ia852b694143f412bb1fcedf18f5cbfb0" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Commitments, Contingent Liabilities and Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of <ix:nonNumeric contextRef="iaba53fd0a02e4df1a2c874629b263ee5_D20210701-20210930" format="ixt-sec:duryear" name="us-gaap:LongtermPurchaseCommitmentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfMjUz_34bd3fb5-dcea-48b1-b18c-ce1d75ec3c19">10</ix:nonNumeric> years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $<ix:nonFraction unitRef="usd" contextRef="i61d8bd08ced14bfaa33ff22a90a9d2ca_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="cah:AggregateAnnualAssessment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNjk0_6afefd75-1892-4696-a965-38bcdfafd2b0">100</ix:nonFraction> million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. In October 2021, the U.S. Supreme Court declined to review the decision. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $<ix:nonFraction unitRef="usd" contextRef="i6e5595e73ee346d2a2b82eb33142c333_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfMTgyOA_edb50336-735f-4500-bfd2-5584110706f1">41</ix:nonFraction> million for calendar years 2017 and 2018 during the three months ended September 30, 2020 based on the probable estimated payment amount, which is our best estimate of the OSA payments probable at September 30, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="ia852b694143f412bb1fcedf18f5cbfb0" continuedAt="i7aa8c1a6378d47c696459831dce3e809"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible product quality, regulatory or compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings/(loss).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately <ix:nonFraction unitRef="lawsuit" contextRef="ic7bc766a995e48b4954e62dc20520496_I20211104" decimals="0" format="ixt:num-dot-decimal" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4Mzg1MA_3e0512d6-957d-4b0f-a14a-2c306b9c69f6">3,300</ix:nonFraction> lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="lawsuit" contextRef="i089f62a751ee489da5e10d6b58b6adc9_I20211104" decimals="0" format="ixt:num-dot-decimal" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4Mzg1NA_0eb624af-787d-46bc-83e4-3d12512be896">2,900</ix:nonFraction> of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the &#8220;MDL&#8221;).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, <ix:nonFraction unitRef="stateag" contextRef="ic7bc766a995e48b4954e62dc20520496_I20211104" decimals="0" name="cah:NumberofStateAttorneysGeneralfilinglawsuits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4Mzg1OA_d7563ae9-90f5-4347-85d0-cefd5c9d9330">25</ix:nonFraction> state attorneys general have filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general; the framework is designed to resolve pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). We continued to build out the Settlement Framework and to negotiate the terms of the settlement with the leadership group and other representatives of states and political subdivisions. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July, 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement (the &#8220;Proposed Settlement Agreement&#8221;) and settlement process that, if all conditions are satisfied, would result in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. The settlement process does not contemplate participation by any non-governmental or non-political entities or individuals. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the three distributors determined that enough states had agreed to participate in the Proposed Settlement Agreement to proceed to the next phase of the settlement process, which is the subdivision sign-on period. However, the Proposed Settlement Agreement is still subject to contingencies and will not become effective unless and until the three distributors each make separate independent determinations that a sufficient number of political subdivisions, including those that have not sued, have agreed to participate in the Agreement (or otherwise have had their claims foreclosed) to proceed to effectiveness. Prior to that determination, the participating states will also have an opportunity to make a determination as to whether a sufficient number of political subdivisions have agreed to the Proposed Settlement Agreement (or otherwise had their claims foreclosed) to proceed with the Proposed Settlement Agreement. This process is currently contemplated to end in February 2022, although it may be extended by agreement. It is possible that a sufficient number of states and subdivisions will not agree to the Proposed Settlement </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="i7aa8c1a6378d47c696459831dce3e809" continuedAt="i7014c383d728456f859eebae99818bed"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement or that other required contingencies will not be satisfied.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the required contingencies are satisfied, the Proposed Settlement Agreement would become effective sixty (60) days after the distributors determine that there is sufficient participation to proceed to effectiveness. During this 60-day period, the participating states and the distributors would cooperate to obtain consent judgments embodying the terms of the Settlement in each participating state. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Proposed Settlement Agreement includes a cash component, pursuant to which the Company would pay up to approximately $<ix:nonFraction unitRef="usd" contextRef="ie46ae6d3a39f4f97bd6436e7342a9a4d_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4Mzg3NQ_e3528a1b-d99f-488a-8b52-456eb4ca1aef">6.37</ix:nonFraction>&#160;billion, the majority of which would be paid over 18 years. The exact payment amount will depend on several factors, including the participation rate of states and political subdivisions, the extent to which states take action to foreclose opioid lawsuits by political subdivisions (e.g., laws barring or limiting opioid lawsuits by political subdivisions), and the extent to which political subdivisions in participating states file additional opioid lawsuits against the Company after the Proposed Settlement Agreement becomes effective. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Proposed Settlement Agreement also includes injunctive relief terms related to distributors&#8217; controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating controlled substances monitoring programs; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring. A monitor will be selected to oversee compliance with these provisions for a period of five years. In addition, we and the two other settling distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting, which distributors will fund the for ten years.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors entered into a settlement with each of the States of New York and Ohio and their participating subdivisions. If the Proposed Settlement Agreement becomes effective, New York and Ohio and their participating subdivisions will become a part of it. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups. In September 2021 we announced that we, along with two other national distributors, had reached an agreement with the Cherokee Nation in connection with ongoing negotiations toward a broader agreement with Native American tribes. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial before a federal judge in West Virginia brought by Cabell County and City of Huntington against us and two other national distributors concluded in July 2021. The judge has not yet issued a decision. In addition, a trial in the case brought by the Washington Attorney General against the Company and the same two other national distributors is scheduled to begin in November 2021 and the Washington Attorney General has issued a press release stating that Washington will not agree to the Proposed Settlement </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement. A trial in the case brought by the Rhode Island Attorney General is scheduled to begin in January 2022 and a trial in the Dallas County case is scheduled to begin in Texas in February 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we paid into escrow the majority of our first annual payment, which is reflected in prepaid expenses and other assets in our condensed consolidated balance sheets. We also made certain payments under the separate New York and Ohio settlements. In total, we have $<ix:nonFraction unitRef="usd" contextRef="ie46ae6d3a39f4f97bd6436e7342a9a4d_I20210930" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:LitigationReserve" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4Mzk2NA_dd97305c-0755-47c7-92bc-45a4bb7d2fdb">6.68</ix:nonFraction>&#160;billion accrued at September&#160;30, 2021, of which $<ix:nonFraction unitRef="usd" contextRef="i638a4b60fc7140b7b4525502482b8b12_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LitigationReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNzE0NjgyNTcwNTg1MQ_c0b7acbf-a8e6-414e-8a78-b2c2ce84bff9">441</ix:nonFraction>&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. During the three months ended September 30, 2020, we recorded total pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="i28701b9327404d53941d5dd148cdf77c_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfMzI5ODUzNTAxOTUyNA_9458ba26-399c-473f-aa6c-c6b583914744">1.02</ix:nonFraction>&#160;billion in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings/(loss). </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Proposed Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately <ix:nonFraction unitRef="lawsuit" contextRef="ie546f3bca04b4fe2b2764f97ebc4ad00_I20211104" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4Mzg5OQ_b8898d63-9343-4532-9a68-666b07ef82ce">446</ix:nonFraction> lawsuits as of November 4, 2021. Of these, <ix:nonFraction unitRef="lawsuit" contextRef="if11b202b8ca343b0a9e421d1841eebd6_I20211104" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4MzkwMw_d2836ea4-f7c3-411f-bc70-7267798e1494">129</ix:nonFraction> are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are vigorously defending ourselves in these matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above. In October 2020, we filed a complaint for declaratory </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="i7014c383d728456f859eebae99818bed" continuedAt="i53a1d52ff89143e7add6218ef87577ee"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgment against National Union Fire Insurance Company of Pittsburgh, PA (&#8220;National Union&#8221;) seeking a declaration that National Union is obligated to reimburse us for defense costs incurred in connection with the lawsuits described above. In January, 2021, Swiss Re International SE commenced an arbitration in London seeking a determination that it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of September&#160;30, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis IVC Filter Matters </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability Lawsuits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 4, 2021, we are named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="if50f5130dc374149935c142a609db653_D20211104-20211104" decimals="0" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4MzkwNw_cd2af0df-ab79-45dd-91ce-0977065cf313">434</ix:nonFraction> product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately <ix:nonFraction unitRef="plaintiff" contextRef="i73badf44a1bd45889e11d4037d77a5a5_D20211104-20211104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4MzkxMQ_fdb99e21-1e86-4115-b1d1-944ea7831e16">5,614</ix:nonFraction> plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products. Another <ix:nonFraction unitRef="lawsuit" contextRef="i987d5b5da3a84e95a610a63bb8f2de3a_D20211104-20211104" decimals="0" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4MzkxNQ_32d7205a-d79b-4296-8d3d-2615993fa3cd">33</ix:nonFraction> lawsuits involving similar claims by approximately <ix:nonFraction unitRef="plaintiff" contextRef="i0ae57499f11845a387078309fc16ffc6_D20211104-20211104" decimals="0" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4MzkxOQ_e8737483-405f-4172-8cba-5ccd8c761274">38</ix:nonFraction> plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately <ix:nonFraction unitRef="lawsuit" contextRef="i987d5b5da3a84e95a610a63bb8f2de3a_D20211104-20211104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyClaimsSettledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfMzI5ODUzNTAxOTYxMg_56e56d19-1549-403a-8c6c-3bcfe439ec89">1,300</ix:nonFraction> claims. This agreement is subject to certain contingencies. We continue to vigorously defend ourselves in these lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2021, we had a total of $<ix:nonFraction unitRef="usd" contextRef="i224e04590a6a4682baab9a6e6d77ce88_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4MzkyMw_6037d218-481d-41de-8317-d405a3f39a06">547</ix:nonFraction>&#160;million net of estimated insurance recoveries, accrued for losses and legal defense costs, related to the Cordis IVC filter lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $<ix:nonFraction unitRef="usd" contextRef="iab6062bf74dd4e29a56a98ea3760db61_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4MzkzMg_e2cd4103-58a3-43ef-9b23-b1327bda0ce6">1.07</ix:nonFraction>&#160;billion, net of estimated insurance recoveries. The sale of the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Action </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations made are similar to those made in the product liability lawsuits, described above. We intend to vigorously defend ourselves against these claims. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEC Investigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we received a subpoena from the U.S. Securities and Exchange Commission requesting the production of documents from 2015 through 2019 relating to inventory in the Cordis business, analysis of goodwill of the Medical segment and other matters. We are cooperating with this inquiry and related </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requests and cannot predict the outcome or duration of the investigation. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In November 2020, we filed a motion to dismiss the amended complaint, which was denied in September 2021. We dispute these allegations and intend to vigorously defend against them.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specialty Solutions DOJ Investigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the United States Attorney&#8217;s Office for the District of Massachusetts (the "USAO") commenced an investigation pertaining to the U.S. federal healthcare fraud and abuse laws. These requests sought, among other things, documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. We are cooperating with these requests and are engaged in resolution discussions with the USAO and Department of Health and Human Services, Office of Inspector General. In connection with these discussions, we recorded $<ix:nonFraction unitRef="usd" contextRef="i63cac0f2590c417e85f3d03334418831_D20200701-20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4MzkzOQ_adb2c308-7bda-42b0-8c94-0d8dbaa4dffc">13</ix:nonFraction> million of expense within litigation (recoveries)/charges, net in our consolidated statements of earnings/(loss) during the fiscal year ended June&#160;30, 2021. We cannot predict the outcome of the discussions and it is possible that we may incur additional losses or agree to other remedial measures; however, we are not currently able to estimate a range of reasonably possible additional losses.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i53a1d52ff89143e7add6218ef87577ee" continuedAt="i79460fdc082b4222b414ed3b5549334b"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Active Pharmaceutical Ingredient Impurity Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. </span></div></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i79460fdc082b4222b414ed3b5549334b">In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the &#8220;Sartan MDL&#8221;) alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We are vigorously defending ourselves in this matter.</ix:continuation> </span></div><div id="i1938304362d7436fbafe0221fdeb43e5_97"></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNjYyOQ_ff7ac685-56c8-4ac0-b7c6-32ed341df01d" continuedAt="i1bfcb5396d8b4029bce645763a1f5bdf" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Income Taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our provision for/(benefit from) income taxes as a percentage of pre-tax loss (&#8220;effective tax rate&#8221;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis Divestiture</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we completed the divestiture of the Cordis business. In connection with the closing, we recorded net tax expense of $<ix:nonFraction unitRef="usd" contextRef="i01b3c57121b8495d8065ad7fce4a9b2d_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzI5ODUzNDkxMjMwNA_19bded08-9389-4a4c-a486-9619ba6a636f">9</ix:nonFraction>&#160;million. The tax effects of these matters during the three months ended September 30, 2021 were included in our full year effective tax rate forecast. We currently estimate that the tax expense associated with this matter for the full fiscal 2022 will be $<ix:nonFraction unitRef="usd" contextRef="i0b29eeee66ff478fa0d4886f822b6a59_D20210701-20220630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzI5ODUzNDkxMjMxNg_5219bd7e-c285-43dc-a54d-f32a90b2b15e">38</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Opioid Litigation Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the $<ix:nonFraction unitRef="usd" contextRef="i28701b9327404d53941d5dd148cdf77c_D20200701-20200930" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzA3_3a365e69-9002-4840-96a9-c700895053b8">1.02</ix:nonFraction>&#160;billion pre-tax charges for the opioid litigation during the three months ended September 30, 2020, the net tax benefit was $<ix:nonFraction unitRef="usd" contextRef="i28701b9327404d53941d5dd148cdf77c_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzI5ODUzNDkxMjIzNQ_5e006ce8-95fa-494b-b9a9-d0d9d3f88478">450</ix:nonFraction>&#160;million for the three months ended September 30, 2020, and $<ix:nonFraction unitRef="usd" contextRef="i19d2a3c94ab340b884ea4bca21d04b54_D20200701-20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzI5ODUzNDkxMjI0OQ_93026598-a1cd-455a-9c6b-6e08c04d71a1">228</ix:nonFraction>&#160;million for fiscal 2021. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="if54e4cb700254d5493fff77ca38ac9ef_I20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNzU0_8dae2889-a612-4ae6-b9e3-07051d2e1f34">34</ix:nonFraction> million during the three months ended September 30, 2020, and $<ix:nonFraction unitRef="usd" contextRef="i424036b844734cb19b42015632d7a6f2_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzI5ODUzNDkxMjI2Mw_d0339b18-f8bc-4d40-8cec-e221508f236e">219</ix:nonFraction>&#160;million for fiscal 2021. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible Congress or the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit may differ materially from these estimates.</span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i1bfcb5396d8b4029bce645763a1f5bdf"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021 and 2020, the effective tax rate was <ix:nonFraction unitRef="number" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzUxOA_8e77bd76-c6b7-4b1f-b3e1-c3a600f98396">26.3</ix:nonFraction> percent and <ix:nonFraction unitRef="number" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzUzMw_961c5e60-7397-4cc3-84d2-cc721f30b4d8">61.8</ix:nonFraction> percent, respectively. The decrease in the effective tax rate for the three months ended September 30, 2021 compared to the prior year period was primarily due to the treatment of the tax impacts of the opioid litigation accrual recorded in prior year.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $<ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzg0OQ_cb16e6ff-9e6e-4e4e-9eba-b864eb947fe6">931</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzg1Ng_3d2b1add-3d6d-49aa-a812-00b0cdca0dd2">932</ix:nonFraction> million of unrecognized tax benefits at September 30, 2021 and June&#160;30, 2021, respectively. The September 30, 2021 and June&#160;30, 2021 balances include $<ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzk0Nw_5f0ddb01-98ed-46f5-9d04-da7727d0819d">848</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzk1NA_c5bd4a8e-491e-46cd-a36e-5f1ecc93cd2e">849</ix:nonFraction> million, respectively, of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021 and June&#160;30, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNDA5MQ_4e38ddbb-d24f-4b6c-b144-68c4da853951">51</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNDA5OA_67a5d94b-a930-48cc-aa9c-83523192014a">49</ix:nonFraction> million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between <ix:nonFraction unitRef="usd" contextRef="i3e9abc9dd3db43cc9b26b208cbdb777c_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNDk1Ng_b5fb1f64-d257-4611-8c98-616d5e4892c7">zero</ix:nonFraction> and a net decrease of $<ix:nonFraction unitRef="usd" contextRef="ibc981e52c59246c48326101ada65bb8b_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfOTg5NTYwNDY1OTUzOA_8ff60503-d01d-4216-9600-de95d588957c">20</ix:nonFraction> million, exclusive of penalties and interest.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years <ix:nonNumeric contextRef="i658749f8d08c4de3bd8ca178ca6268c4_D20210701-20210930" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNTI1Mw_35f4459e-bd77-4688-ba97-0c3b1b9db955">2015</ix:nonNumeric> through <ix:nonNumeric contextRef="i406b689ab44d4833a222efac0f41c896_D20210701-20210930" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzI5ODUzNDkxMjI3Nw_50860d4a-edab-4a5c-8b97-f9f1eefc41e9">2020</ix:nonNumeric>. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), which has been acquired by Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $<ix:nonFraction unitRef="usd" contextRef="i7ff0423111af46e796881f5bffabb11e_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="cah:IndemnificationReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNTk4Ng_2f51c73d-3e12-47a8-a3a7-905f7dc58e3b"><ix:nonFraction unitRef="usd" contextRef="ib2c2db2160bf4119bcf457d76b23d394_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="cah:IndemnificationReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNTk4Ng_69d0e7e3-862a-4315-a619-733ee2ca00e5">72</ix:nonFraction></ix:nonFraction> million at both September&#160;30, 2021 and June&#160;30, 2021, and is included in other assets in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition. The indemnification receivable was&#160;$<ix:nonFraction unitRef="usd" contextRef="iddc20db237214f5184481bac8f6153dc_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="cah:IndemnificationReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNjMzOA_47f5389f-9937-40d6-89cd-e69c4d4d6c36"><ix:nonFraction unitRef="usd" contextRef="ie17b5134d5df4708a1d031b82fbcd4f4_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="cah:IndemnificationReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNjMzOA_c7e16f89-57bc-44ea-8a55-d8c4545fbde7">12</ix:nonFraction></ix:nonFraction> million at both September&#160;30, 2021 and June&#160;30, 2021, and is included in other assets in the condensed consolidated balance sheets.</span></div></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_100"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90ZXh0cmVnaW9uOjY3ZDBlOTg1N2UyMDRmMWQ4NTk3NmU0ZTE0OTM2MWMyXzEyNjI_ea8e323a-f57e-4570-8222-32f0a5c70f34" continuedAt="i6cfb74e18a734406bd1ec8a4bc18bb9f" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Fair Value Measurements </span></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90ZXh0cmVnaW9uOjY3ZDBlOTg1N2UyMDRmMWQ4NTk3NmU0ZTE0OTM2MWMyXzEyNDg_733face2-27b6-45dc-9198-26a4c2b0198f" continuedAt="i6dd31abea2ad475a8ab3b763ec6e307b" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e2495c58af141e0b5b5d488b2935e1a_I20210930" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzMtMS0xLTEtMA_11556b6a-fbd1-4b38-8c7e-7f1e26314b58">812</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i150d8e19b4da44c7a10fc5832479dab4_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzMtMy0xLTEtMA_422a6a3c-c575-4405-aa88-f755d062f1f8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce62dee245a48b29809b554a26358b2_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzMtNS0xLTEtMA_c3672f97-707b-4d63-86ab-53fde3ece487">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1376d1860df846879ab972c82dc8cbb9_I20210930" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzMtNy0xLTEtMA_52e14edf-aad5-4038-a1a6-c0b2cd647a04">812</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e2495c58af141e0b5b5d488b2935e1a_I20210930" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzQtMS0xLTEtMA_6d32285b-71c0-47ef-be2b-9fb152e902dc">119</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i150d8e19b4da44c7a10fc5832479dab4_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzQtMy0xLTEtMA_900d8fb2-bbe9-4b7f-a996-6d3c6ca8ee99">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce62dee245a48b29809b554a26358b2_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzQtNS0xLTEtMA_6722b770-a182-440a-9884-9d7fc6f698b1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58736b6311e43b89041dc436c54fde9_I20210930" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzQtNy0xLTEtMA_a476e535-79ba-44de-850a-0592f8620b46">119</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e2495c58af141e0b5b5d488b2935e1a_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzYtMS0xLTEtMA_18431d0f-3397-4baa-a732-aae18674d141">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i150d8e19b4da44c7a10fc5832479dab4_I20210930" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzYtMy0xLTEtMA_214fc881-dc1a-40d5-be1d-fcc67937d338">47</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce62dee245a48b29809b554a26358b2_I20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzYtNS0xLTEtMA_dd7ab771-7670-4414-bf80-d938258960e0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58736b6311e43b89041dc436c54fde9_I20210930" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzYtNy0xLTEtMA_052751f4-8dc4-4d88-9952-0ca231f0ceb8">47</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e76abd2c8d45b7930ed6de435b0dee_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzMtMS0xLTEtMA_b1704b12-c52b-4293-9178-5ce57336601a">1,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc2293adf8c64ed9925346fe6e72f47c_I20210630" decimals="-6" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzMtMy0xLTEtMA_a129429d-b07c-431e-a951-48bd2d1ef4d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a025dd5a49343da902e9c0daf87d367_I20210630" decimals="-6" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzMtNS0xLTEtMA_9b3b2f3c-a21a-41e7-b52e-7c54a52f18a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9cb0d331acd45e9a57603b0a7ac9478_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzMtNy0xLTEtMA_bdb356a0-0c16-4257-8b18-665b3e506955">1,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e76abd2c8d45b7930ed6de435b0dee_I20210630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzQtMS0xLTEtMA_4dbf3792-54b3-4ecc-8c09-79a61479705b">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc2293adf8c64ed9925346fe6e72f47c_I20210630" decimals="-6" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzQtMy0xLTEtMA_b2e248d0-508f-4375-9b42-4eb2958386ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a025dd5a49343da902e9c0daf87d367_I20210630" decimals="-6" format="ixt:fixed-zero" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzQtNS0xLTEtMA_1edfcb19-555c-4b03-a123-b9eeb2f027ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic590157c0c22464e839daa43f09f244d_I20210630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzQtNy0xLTEtMA_e4c48b3f-6d5a-402b-9051-92615f56fe72">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72e76abd2c8d45b7930ed6de435b0dee_I20210630" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzYtMS0xLTEtMA_3ccde15d-85b5-4d91-858d-cddf090f39e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc2293adf8c64ed9925346fe6e72f47c_I20210630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzYtMy0xLTEtMA_a0fbfa2b-43c7-4dbf-800f-f8fcd288b90b">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a025dd5a49343da902e9c0daf87d367_I20210630" decimals="-6" format="ixt:fixed-zero" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzYtNS0xLTEtMA_dcf8ab1e-b433-4418-8bab-efef2360b731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic590157c0c22464e839daa43f09f244d_I20210630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzYtNy0xLTEtMA_75a014c5-9f3b-45d5-8c97-3e5bf1ba828c">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i6cfb74e18a734406bd1ec8a4bc18bb9f"><ix:continuation id="i6dd31abea2ad475a8ab3b763ec6e307b">(2)   The fair value of interest rate swaps, foreign currency contracts and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</ix:continuation></ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i1938304362d7436fbafe0221fdeb43e5_103"></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90ZXh0cmVnaW9uOmYyNmJlZjUyNTg0YTQ1Mjk4NGY3NGE1ZmNiNTdlOTE2Xzc3MTY_5671f09b-6a51-4db0-af22-20f753ce7fbe" continuedAt="i7861983bfe144058b2cabd996caa6f1f" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i7861983bfe144058b2cabd996caa6f1f" continuedAt="i6016de25e2c744d69683eab1420b04ae"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three months ended September&#160;30, 2021 and 2020, there was <ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90ZXh0cmVnaW9uOmYyNmJlZjUyNTg0YTQ1Mjk4NGY3NGE1ZmNiNTdlOTE2XzMyNzU_46aaf093-41f5-4183-9f46-756fc3d51c6f">no</ix:nonFraction> gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During three months ended September&#160;30, 2021, we entered into a pay-floating interest rate swap with a total notional amount of $<ix:nonFraction unitRef="usd" contextRef="i028247a5bde846f48b6ee152d76c2b8a_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90ZXh0cmVnaW9uOmYyNmJlZjUyNTg0YTQ1Mjk4NGY3NGE1ZmNiNTdlOTE2XzEwOTk1MTE2Mjg2Mjg0_0686939d-fe16-4fab-a7f4-e09f020c1743">100</ix:nonFraction> million. This swap has been designated as a fair value hedge of our fixed rate debt and is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. </span></div></ix:continuation></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i6016de25e2c744d69683eab1420b04ae" continuedAt="i7dc9778763824889ba55760ba8cee1e0"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains and losses recognized in other comprehensive loss were immaterial during the three months ended September&#160;30, 2021 and 2020. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three months ended September&#160;30, 2021 and 2020. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $<ix:nonFraction unitRef="usd" contextRef="ibeb6754446a54c41bf8d158d19745b40_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90ZXh0cmVnaW9uOmYyNmJlZjUyNTg0YTQ1Mjk4NGY3NGE1ZmNiNTdlOTE2XzU3NTQ_2f78397a-b25e-4da0-8255-9e7f759f3b5d">5</ix:nonFraction>&#160;million gain and a $<ix:nonFraction unitRef="usd" contextRef="i90f84269f6144c8183e95a9e6a7c25eb_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90ZXh0cmVnaW9uOmYyNmJlZjUyNTg0YTQ1Mjk4NGY3NGE1ZmNiNTdlOTE2XzU3Njg_9d196719-5d22-4e50-9b45-0681bd89f323">25</ix:nonFraction>&#160;million loss during the three months ended September&#160;30, 2021 and 2020, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $<ix:nonFraction unitRef="usd" contextRef="ibeb6754446a54c41bf8d158d19745b40_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90ZXh0cmVnaW9uOmYyNmJlZjUyNTg0YTQ1Mjk4NGY3NGE1ZmNiNTdlOTE2XzEwOTk1MTE2Mjg2MzIy_45452dd7-14c4-4d2c-9ba4-c5db6d71f79d">6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i90f84269f6144c8183e95a9e6a7c25eb_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90ZXh0cmVnaW9uOmYyNmJlZjUyNTg0YTQ1Mjk4NGY3NGE1ZmNiNTdlOTE2XzEwOTk1MTE2Mjg2MzI5_f9bfff39-762b-4b1c-917b-a064a9e687bd">5</ix:nonFraction>&#160;million during the three months ended September&#160;30, 2021 and 2020, respectively.</span></div></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i7dc9778763824889ba55760ba8cee1e0"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. The gain and losses recognized in the three months ended September 30, 2021 and 2020 were immaterial. The principal currencies managed through foreign currency contracts are Euro, Chinese renminbi, and Canadian dollar.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2021 and June 30, 2021 approximate fair value due to their short-term maturities.</span></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90ZXh0cmVnaW9uOmYyNmJlZjUyNTg0YTQ1Mjk4NGY3NGE1ZmNiNTdlOTE2Xzc3MTU_70d8d2bf-9895-444b-a720-b3ff84e6b571" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92892038fe0545f0844bfb3e0c3e12db_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90YWJsZTpiMDZjZTNiNjM5MDY0MzE5YTE5MmI5Y2IxMGVmZWQxNS90YWJsZXJhbmdlOmIwNmNlM2I2MzkwNjQzMTlhMTkyYjljYjEwZWZlZDE1XzEtMS0xLTEtMA_17486ed6-3edc-4c64-a0bb-e2740dc2a661">6,132</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i262b04e9d11d48e58b8a57b9ab73f4e4_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90YWJsZTpiMDZjZTNiNjM5MDY0MzE5YTE5MmI5Y2IxMGVmZWQxNS90YWJsZXJhbmdlOmIwNmNlM2I2MzkwNjQzMTlhMTkyYjljYjEwZWZlZDE1XzEtMy0xLTEtMA_62bff652-522e-4479-802c-7d0b7ad7e368">6,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90YWJsZTpiMDZjZTNiNjM5MDY0MzE5YTE5MmI5Y2IxMGVmZWQxNS90YWJsZXJhbmdlOmIwNmNlM2I2MzkwNjQzMTlhMTkyYjljYjEwZWZlZDE1XzItMS0xLTEtMA_05d3343f-b9d3-4212-acc3-7576b6d269fd">5,654</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90YWJsZTpiMDZjZTNiNjM5MDY0MzE5YTE5MmI5Y2IxMGVmZWQxNS90YWJsZXJhbmdlOmIwNmNlM2I2MzkwNjQzMTlhMTkyYjljYjEwZWZlZDE1XzItMy0xLTEtMA_7219fc51-3e1d-4c59-9753-cf6b988e279e">6,236</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div></ix:continuation><div id="i1938304362d7436fbafe0221fdeb43e5_106"></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90ZXh0cmVnaW9uOjEwNTViYTJiMzMyNjQyYjFhOTg0NjUxNDdhNDIxZjkxXzc1Ng_40c7f49b-93b9-4505-b340-9aacade226c5" continuedAt="iaea4d6b923734e1c88cbed00042fddc7" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Shareholders' Equity </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i4ff1053e5ba649348bc766dea62879d6_D20200701-20201231" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90ZXh0cmVnaW9uOjEwNTViYTJiMzMyNjQyYjFhOTg0NjUxNDdhNDIxZjkxXzE2Ng_4594374b-f0f6-4970-943a-4b82967dd7c9">500</ix:nonFraction> million. We received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="i9a679feb77be4335bffc03ffaca2dd77_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="cah:TreasuryStockAcquiredShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90ZXh0cmVnaW9uOjEwNTViYTJiMzMyNjQyYjFhOTg0NjUxNDdhNDIxZjkxXzIwNQ_75155d13-6f44-42f4-add4-9b96251a9333">7.8</ix:nonFraction> million common shares using a reference price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9a679feb77be4335bffc03ffaca2dd77_D20200701-20200930" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90ZXh0cmVnaW9uOjEwNTViYTJiMzMyNjQyYjFhOTg0NjUxNDdhNDIxZjkxXzcxNDY4MjU1ODM4NDA_5eafd946-bf03-434a-a8b7-19cd763768d6">51.53</ix:nonFraction>. The program concluded on October 4, 2021 at a volume weighted average price per common share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0cd4350b18ea48f3b33db6247ab8f74e_D20210701-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90ZXh0cmVnaW9uOjEwNTViYTJiMzMyNjQyYjFhOTg0NjUxNDdhNDIxZjkxXzI2OTM4MDM0ODg0MDA1_36c1f8ec-cd9e-4cc4-a2d5-8db080e16421">51.10</ix:nonFraction> resulting in a final delivery of <ix:nonFraction unitRef="shares" contextRef="i1fe42d24cb094502a3486fea0c6fc0df_I20211004" decimals="-5" format="ixt:num-dot-decimal" name="cah:FinalSharesReceivedfromASRProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90ZXh0cmVnaW9uOjEwNTViYTJiMzMyNjQyYjFhOTg0NjUxNDdhNDIxZjkxXzI2OTM4MDM0ODg0MDEz_9fee92cb-fd80-443a-ba77-3840c3397533">2.0</ix:nonFraction>&#160;million common shares. We funded the repurchases with available cash. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="iaea4d6b923734e1c88cbed00042fddc7"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90ZXh0cmVnaW9uOjEwNTViYTJiMzMyNjQyYjFhOTg0NjUxNDdhNDIxZjkxXzc2Mw_f1f305cd-1b41-45b1-ae28-d1295f513f85" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff81891dbe0e4df49e09522cba431ade_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzEtMS0xLTEtMA_d7379fcf-ad3c-4a66-9d26-ef27ae174dc3">46</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie756e95338db4f58953d714720e792ab_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzEtMy0xLTEtMA_27cd6b1f-0a0f-4d9d-8acd-1e1e807ed9f2">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ffff5afcbf04bf6bdee0da00d3f865a_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzEtNS0xLTEtMA_523ef2bb-bb64-4d85-a76d-7ea8fe45aceb">34</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14182b7268e14c209c705768a780f9d0_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzItMS0xLTEtMA_85cef895-5e54-44cd-9d45-8350558f9b2b">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a50bb415d6a42b6b624e81424aefc10_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzItMy0xLTEtMA_586e9187-d300-4657-bb5a-87ee31e509f5">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia86d33171aed42cebf549309afad5112_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzItNS0xLTEtMA_326b6c03-0454-4f89-b6bd-5b83e496eb6f">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14182b7268e14c209c705768a780f9d0_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzMtMS0xLTEtMA_8b63f1c1-be92-4a22-8531-602b81d2b593">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a50bb415d6a42b6b624e81424aefc10_D20210701-20210930" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzMtMy0xLTEtMA_1c654581-d86e-41dd-b663-91783007920a">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia86d33171aed42cebf549309afad5112_D20210701-20210930" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzMtNS0xLTEtMA_75d89327-99ac-4cad-bf84-7df9e7e3d371">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14182b7268e14c209c705768a780f9d0_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzQtMS0xLTEtMA_290e186a-35d4-4601-ad74-25458f050069">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a50bb415d6a42b6b624e81424aefc10_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzQtMy0xLTEtMA_913a41a3-6692-4b6a-8f09-9ff8aa766abd">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80a6c9c0ca9b46349d58b2c256d04d1f_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzQtNS0xLTEtMA_822b27eb-6a53-4b9a-ae6f-abe2313de854">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f3db035e1db41b1a0fa80e065300460_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzUtMS0xLTEtMA_1667ec2f-ceb1-420c-be3f-24814e981a1d">71</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c87fae83994349b2c47f4e40df266f_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzUtMy0xLTEtMA_a75d93a9-b5e5-4280-b808-f4e41539cbe6">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie36e8fee435f4698b1f72b0de63b4f97_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzUtNS0xLTEtMA_0a63d09a-032e-4b27-8b72-b33264ce600e">61</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i1938304362d7436fbafe0221fdeb43e5_109"></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90ZXh0cmVnaW9uOmU0OWQ2NWY2OTBlMzRkNWViMDAxYjMzYzE4NDQxY2ZkXzcwNQ_6ca40200-6ad2-44e3-aa6d-2bab70810116" continuedAt="i636696d6d9c24f498078e9c4fe6d7f43" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc. </span></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90ZXh0cmVnaW9uOmU0OWQ2NWY2OTBlMzRkNWViMDAxYjMzYzE4NDQxY2ZkXzY5OQ_e313885a-a600-441c-9d61-d922bdd5881f" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90YWJsZTplMzM4ZjJhZWJjYWU0MWE5YTVjYmUyMGU3OTYzMjUxMi90YWJsZXJhbmdlOmUzMzhmMmFlYmNhZTQxYTlhNWNiZTIwZTc5NjMyNTEyXzItMS0xLTEtMA_01a716dc-1f32-47b1-8698-c35f1481837d">287</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90YWJsZTplMzM4ZjJhZWJjYWU0MWE5YTVjYmUyMGU3OTYzMjUxMi90YWJsZXJhbmdlOmUzMzhmMmFlYmNhZTQxYTlhNWNiZTIwZTc5NjMyNTEyXzItMy0xLTEtMA_4b4ea1e0-fcc4-45a9-aa30-d24b11b94a71">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units, and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90YWJsZTplMzM4ZjJhZWJjYWU0MWE5YTVjYmUyMGU3OTYzMjUxMi90YWJsZXJhbmdlOmUzMzhmMmFlYmNhZTQxYTlhNWNiZTIwZTc5NjMyNTEyXzQtMS0xLTEtMA_8161d933-e515-4097-ba16-be763ddc0f45">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90YWJsZTplMzM4ZjJhZWJjYWU0MWE5YTVjYmUyMGU3OTYzMjUxMi90YWJsZXJhbmdlOmUzMzhmMmFlYmNhZTQxYTlhNWNiZTIwZTc5NjMyNTEyXzQtMy0xLTEtMA_c6302186-ef01-463f-9405-7d6cd4734cda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90YWJsZTplMzM4ZjJhZWJjYWU0MWE5YTVjYmUyMGU3OTYzMjUxMi90YWJsZXJhbmdlOmUzMzhmMmFlYmNhZTQxYTlhNWNiZTIwZTc5NjMyNTEyXzUtMS0xLTEtMA_56800089-f6df-4c0f-a88d-1f98f14a787d">289</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90YWJsZTplMzM4ZjJhZWJjYWU0MWE5YTVjYmUyMGU3OTYzMjUxMi90YWJsZXJhbmdlOmUzMzhmMmFlYmNhZTQxYTlhNWNiZTIwZTc5NjMyNTEyXzUtMy0xLTEtMA_bf6a76af-dda7-4938-8d2c-aaf5bb4bbc60">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for the three months ended September 30, 2021 were <ix:nonFraction unitRef="shares" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="cah:Numberofsharesexcludedfromcalculationofdilutedshares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90ZXh0cmVnaW9uOmU0OWQ2NWY2OTBlMzRkNWViMDAxYjMzYzE4NDQxY2ZkXzcxNDY4MjU1ODIyNDE_405b9708-5226-4a4a-a9eb-2f7ca69311d1">4</ix:nonFraction> million.</span></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i636696d6d9c24f498078e9c4fe6d7f43">For the three months ended September 30, 2020, <ix:nonFraction unitRef="shares" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="cah:Numberofsharesexcludedfromcalculationofdilutedshares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90ZXh0cmVnaW9uOmU0OWQ2NWY2OTBlMzRkNWViMDAxYjMzYzE4NDQxY2ZkXzcxNDY4MjU1ODMxNTA_b1fff4f6-a32a-4904-9c03-e5470f7120de">7</ix:nonFraction>&#160;million employee stock options, restricted share units and performance share units were excluded from the calculation of diluted shares outstanding, <ix:nonFraction unitRef="shares" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="cah:Sharesthatwouldbeantidilutiveasaresultofnetloss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90ZXh0cmVnaW9uOmU0OWQ2NWY2OTBlMzRkNWViMDAxYjMzYzE4NDQxY2ZkXzcxNDY4MjU1ODMxNjE_c0ce5c54-b773-45bf-8d0e-83bc3d6da262">2</ix:nonFraction>&#160;million of which would be anti-dilutive as a result of the net loss for the period.</ix:continuation> </span></div><div id="i1938304362d7436fbafe0221fdeb43e5_112"></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzQ3NjM_635e770e-b8fb-423b-a3c4-ade6934245d8" continuedAt="ib7b105d6a4d24dbfb08ba5146abf1846" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Segment Information </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of <ix:nonFraction unitRef="segment" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzEwMg_5989b91f-c7b1-4b09-a5dd-a8abe42ed83a"><ix:nonFraction unitRef="segment" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzEwMg_820c1016-1c5c-4574-82b7-a0e7acbd6e8e">two</ix:nonFraction></ix:nonFraction> operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="ib7b105d6a4d24dbfb08ba5146abf1846" continuedAt="if65672f2f0df417cba66cf0f71cd1569"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzQ3NjU_83984fc7-beb2-44a8-bec9-b010f77e058e" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefb0192320f84cfda947570718acc52f_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzItMS0xLTEtMA_309d2967-f1c6-490b-a8d8-ebfa19dcc262">39,614</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i695daf356dd24a7f8a07c54cd6667482_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzItMy0xLTEtMA_bc1a576c-e57d-4d45-ae86-cedee15dbc81">34,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb22d9ed2a2a48baa6338106943e33db_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzMtMS0xLTEtMA_2fa29564-a811-4d17-8592-4f457189d83f">208</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i643e811d7ea24162a6e23957fa7b8020_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzMtMy0xLTEtMA_cd145ec2-5464-484d-b0be-7b7901d58f95">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2589a59e7c8147fb90fc1516771ba4c2_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzQtMS0xLTEtMA_6c0129b7-a5bd-4680-b1a4-da0eb9e5f9c9">39,822</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b3f2699d6140d3a9e1c4884e78c829_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzQtMy0xLTEtMA_85e1941b-6a3c-4a65-8fae-a5d0899473f2">35,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6582c36519d04664abfb836348244e53_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzUtMS0xLTEtMA_54825faa-2491-451d-945d-405ac1178c0d">3,567</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a173f94955146cf8459ca2fc0f76a88_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzUtMy0xLTEtMA_0d37574a-52b3-4367-979d-b9b72eeb672f">3,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i260095721ed44bfa8813a4ea26fe309e_D20210701-20210930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzYtMS0xLTEtMA_459db73a-ac43-4830-bafd-baeab8a1fbd1">582</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93278c2e2d4e42ff9942bc487ad10984_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzYtMy0xLTEtMA_7d47b100-8e3b-4695-be43-92839ccbbf15">519</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia19a7508f5d64fa8b59c18df01e2fb5a_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzctMS0xLTEtMA_a4fca1c7-dcb2-44f1-be9f-f5e279e69db8">4,149</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be6ae19d08940a8a9cc5b7717ec3ae5_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzctMy0xLTEtMA_bc3346d5-6784-4783-bb43-06f08959cc84">3,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5ff458415a4478c9e01d28e78e58858_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzgtMS0xLTEtMA_cbdfb69b-6248-42c9-ab58-25b4991efcc2">43,971</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ad9f408a4c44aeb8a44818cd8464a81_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzgtMy0xLTEtMA_d470de8d-27a3-41a0-832b-43aaacb8b3fa">39,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida3d87ac199c44409567f200919b5238_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzktMS0xLTEtMA_afd9e376-ccfc-45ae-8c87-d93f62255c29">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2b8a8b2269b4ec6b13d67f67f63e6de_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzktMy0xLTEtMA_1883ee8f-d166-4c36-8618-b5d9145c9ddf">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzEwLTEtMS0xLTA_3180b5c7-3881-46c8-bb7b-8a959f69047d">43,968</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzEwLTMtMS0xLTA_baa20b98-5702-4f8b-8b91-86392bccde40">39,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services".</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></ix:nonNumeric></ix:continuation></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="if65672f2f0df417cba66cf0f71cd1569" continuedAt="ib8f375a388594279a2e49ed9849af9d8"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzQ3Njc_c0ee1828-ea69-460d-af80-3095b8df8840" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86109f8fb89f41a5b8bd3da54e768eb3_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzItMS0xLTEtMA_52480599-0025-4589-9baa-31e597886dd7">42,841</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e1c40e4b0da424cbb1f9ef2eec48d5d_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzItMy0xLTEtMA_85d8fa02-821d-416b-9c40-1990f7094b03">37,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id59a8d61ab224417a39a8f45243726b0_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzMtMS0xLTEtMA_1d97ca26-725e-4ec7-8be3-57d1467c8d93">1,130</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4a68ab932984e5c81cf1ec9c6d852ee_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzMtMy0xLTEtMA_bb7d50cb-ae59-43e1-9a7b-dc46d20c00e3">1,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5ff458415a4478c9e01d28e78e58858_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzQtMS0xLTEtMA_cbdfb69b-6248-42c9-ab58-25b4991efcc2">43,971</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ad9f408a4c44aeb8a44818cd8464a81_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzQtMy0xLTEtMA_c18b3731-13f8-416a-9444-6b61760f81d5">39,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida3d87ac199c44409567f200919b5238_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzUtMS0xLTEtMA_afd9e376-ccfc-45ae-8c87-d93f62255c29">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2b8a8b2269b4ec6b13d67f67f63e6de_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzUtMy0xLTEtMA_1ed4ad8e-5f50-4827-bd91-b1b680e9560f">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzYtMS0xLTEtMA_3180b5c7-3881-46c8-bb7b-8a959f69047d">43,968</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzYtMy0xLTEtMA_679762ec-cf54-4574-ab06-085bd78f1c9a">39,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">last-in first-out, or ("LIFO"), inventory charges/(credits); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">surgical gown recall costs/(income);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">restructuring and employee severance;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">amortization and other acquisition-related costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">impairments and (gain)/loss on disposal of assets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">litigation (recoveries)/charges, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">state opioid assessment related to prior fiscal years;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other (income)/expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">interest expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">loss on early extinguishment of debt; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">(gain)/loss on sale of equity interest in naviHealth; or</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">provision for income taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="cah:ProjectCostsOnInvestmentAndOtherSpending" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzQzMTI_2692f6ce-7d04-49f0-9181-8335a07e2a53">7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" format="ixt:num-dot-decimal" name="cah:ProjectCostsOnInvestmentAndOtherSpending" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzQzMTk_08680e86-1dcd-42f3-8501-1f47ec7f4f05">5</ix:nonFraction> million for the three months ended September 30, 2021 and 2020, respectively.</span></div></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="ib8f375a388594279a2e49ed9849af9d8"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the opioid litigation as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_94">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i28701b9327404d53941d5dd148cdf77c_D20200701-20200930" decimals="-7" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzQ0ODc_081e769a-e931-4f5b-8d9a-cf528467cdac">1.02</ix:nonFraction>&#160;billion during the three months ended September 30, 2020 which was retained at Corporate. </span></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzQ3Njg_0be4470a-9df1-4b8b-9349-c55395207957" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2589a59e7c8147fb90fc1516771ba4c2_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzItMS0xLTEtMA_1f7c795b-e911-4d3a-8db5-74e634cb0fe8">406</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b3f2699d6140d3a9e1c4884e78c829_D20200701-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzItMy0xLTEtMA_6f98de88-6494-4791-8090-92ab8c557057">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia19a7508f5d64fa8b59c18df01e2fb5a_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzMtMS0xLTEtMA_b9437bb4-40d5-4101-9d0a-371a6413e4e0">123</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be6ae19d08940a8a9cc5b7717ec3ae5_D20200701-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzMtMy0xLTEtMA_d1bffc7d-a0b3-41fa-bb3c-77dd8e35f37c">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5ff458415a4478c9e01d28e78e58858_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzQtMS0xLTEtMA_ea7c6ae0-eb9f-4c10-88db-5902871fa170">529</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ad9f408a4c44aeb8a44818cd8464a81_D20200701-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzQtMy0xLTEtMA_4e3abbd8-5f2e-4a4b-8a7c-d73ce44f5f08">632</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida3d87ac199c44409567f200919b5238_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzUtMS0xLTEtMA_9510bdfe-aa1e-458d-8bc1-238cbd19e2fd">114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2b8a8b2269b4ec6b13d67f67f63e6de_D20200701-20200930" decimals="-6" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzUtMy0xLTEtMA_9f598847-e134-4a5b-aa08-08da92cf27e7">1,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzYtMS0xLTEtMA_bcd76dbc-9d99-464f-8bef-e82864ef004b">415</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzYtMy0xLTEtMA_8fef9461-b78c-47ee-9b2d-e2a0fce115ee">624</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzQ3NzA_43e28a45-cc3d-4f1a-b146-2a2542a34f07" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:52.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf9b1163079c47d1b91c576edc8b1a8b_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo2ZjQ4YTg5NDlmMjg0OTQzODU4MmM5NzVlMGFjZWVjNS90YWJsZXJhbmdlOjZmNDhhODk0OWYyODQ5NDM4NTgyYzk3NWUwYWNlZWM1XzEtMS0xLTEtMA_f60d2b91-8b9a-4d0c-8bd8-f04acc20eab5">23,955</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc4e83510674b0bac2dc681fd406ecd_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo2ZjQ4YTg5NDlmMjg0OTQzODU4MmM5NzVlMGFjZWVjNS90YWJsZXJhbmdlOjZmNDhhODk0OWYyODQ5NDM4NTgyYzk3NWUwYWNlZWM1XzEtMy0xLTEtMA_21e35c9c-5e2a-48d8-b0d1-1e082135a8fd">23,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb34e93d9354dfabdb815166d96003b_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo2ZjQ4YTg5NDlmMjg0OTQzODU4MmM5NzVlMGFjZWVjNS90YWJsZXJhbmdlOjZmNDhhODk0OWYyODQ5NDM4NTgyYzk3NWUwYWNlZWM1XzItMS0xLTEtMA_474f2cc8-9629-4678-b97d-d280a0a134d1">14,156</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia067d8f29be54d07bf02fce520fc3f4c_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo2ZjQ4YTg5NDlmMjg0OTQzODU4MmM5NzVlMGFjZWVjNS90YWJsZXJhbmdlOjZmNDhhODk0OWYyODQ5NDM4NTgyYzk3NWUwYWNlZWM1XzItMy0xLTEtMA_c2039b8e-2a30-4169-8e30-c8b13e4c63c0">15,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5857bb7827354cf887e8a93a6c60a3d2_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo2ZjQ4YTg5NDlmMjg0OTQzODU4MmM5NzVlMGFjZWVjNS90YWJsZXJhbmdlOjZmNDhhODk0OWYyODQ5NDM4NTgyYzk3NWUwYWNlZWM1XzMtMS0xLTEtMA_a97bcf1a-e83c-4de4-a7eb-31f0290560c1">4,882</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5fcface43a14646b53fcb8c4afba8d4_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo2ZjQ4YTg5NDlmMjg0OTQzODU4MmM5NzVlMGFjZWVjNS90YWJsZXJhbmdlOjZmNDhhODk0OWYyODQ5NDM4NTgyYzk3NWUwYWNlZWM1XzMtMy0xLTEtMA_2b9b6464-6a85-4766-b476-d4acdd8bf1bc">5,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo2ZjQ4YTg5NDlmMjg0OTQzODU4MmM5NzVlMGFjZWVjNS90YWJsZXJhbmdlOjZmNDhhODk0OWYyODQ5NDM4NTgyYzk3NWUwYWNlZWM1XzQtMS0xLTEtMA_ff1e4830-7f67-4a4e-9039-9f7258f3a346">42,993</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo2ZjQ4YTg5NDlmMjg0OTQzODU4MmM5NzVlMGFjZWVjNS90YWJsZXJhbmdlOjZmNDhhODk0OWYyODQ5NDM4NTgyYzk3NWUwYWNlZWM1XzQtMy0xLTEtMA_a728458b-41eb-45f4-b317-7eeb3aa3a692">44,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Assets of $<ix:nonFraction unitRef="usd" contextRef="ie4520b1ea4514c88b03060a55539c44e_I20210630" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzMyOTg1MzQ4ODg1NzM_968c3752-9250-43e2-9e24-62897325f0bb">1.1</ix:nonFraction> billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021.</span></div></ix:nonNumeric></ix:continuation><div id="i1938304362d7436fbafe0221fdeb43e5_115"></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzIzNDI_ef65d762-0e33-49d4-9886-1778d7e3e5b3" continuedAt="i821c66db4a3f4eaa9a04d34ceb748ed2" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13. Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors and employees. </span></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzIzNjA_7035fdab-b4c3-4f9e-8dd7-c98722b172ed" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTowMzAwNzBiOTVkYzI0OGViOWNkNmFiMmNhMzc4YTFlZi90YWJsZXJhbmdlOjAzMDA3MGI5NWRjMjQ4ZWI5Y2Q2YWIyY2EzNzhhMWVmXzItMS0xLTEtMA_e0923625-cdac-4916-8b35-83ab341b562f">18</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa2d5d99524d44f1810ced80bd09e54b_D20200701-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTowMzAwNzBiOTVkYzI0OGViOWNkNmFiMmNhMzc4YTFlZi90YWJsZXJhbmdlOjAzMDA3MGI5NWRjMjQ4ZWI5Y2Q2YWIyY2EzNzhhMWVmXzItMy0xLTEtMA_e07f1b3f-ce53-4643-bc0b-4dd1a57c480f">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock option expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c1a096a6384157896d5f66dfc3de76_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTowMzAwNzBiOTVkYzI0OGViOWNkNmFiMmNhMzc4YTFlZi90YWJsZXJhbmdlOjAzMDA3MGI5NWRjMjQ4ZWI5Y2Q2YWIyY2EzNzhhMWVmXzMtMS0xLTEtMA_da311572-6024-494b-b274-ecc51edbb276">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23ff3fa19d64f74860e3a433d7fe8a5_D20200701-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTowMzAwNzBiOTVkYzI0OGViOWNkNmFiMmNhMzc4YTFlZi90YWJsZXJhbmdlOjAzMDA3MGI5NWRjMjQ4ZWI5Y2Q2YWIyY2EzNzhhMWVmXzMtMy0xLTEtMA_47117b8b-9fb0-4d60-91e9-6db837a18328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTowMzAwNzBiOTVkYzI0OGViOWNkNmFiMmNhMzc4YTFlZi90YWJsZXJhbmdlOjAzMDA3MGI5NWRjMjQ4ZWI5Y2Q2YWIyY2EzNzhhMWVmXzQtMS0xLTEtMA_37da2d4c-0da7-42a9-93de-4222e0b2e711">6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9cd1675b513491fb7ce8cd5c3b5a391_D20200701-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTowMzAwNzBiOTVkYzI0OGViOWNkNmFiMmNhMzc4YTFlZi90YWJsZXJhbmdlOjAzMDA3MGI5NWRjMjQ4ZWI5Y2Q2YWIyY2EzNzhhMWVmXzQtMy0xLTEtMA_2f844311-a2cc-4e18-a8a9-77577ab76432">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTowMzAwNzBiOTVkYzI0OGViOWNkNmFiMmNhMzc4YTFlZi90YWJsZXJhbmdlOjAzMDA3MGI5NWRjMjQ4ZWI5Y2Q2YWIyY2EzNzhhMWVmXzUtMS0xLTEtMA_18f4a0d2-ac73-4e05-87c1-7447a7cdd265">24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTowMzAwNzBiOTVkYzI0OGViOWNkNmFiMmNhMzc4YTFlZi90YWJsZXJhbmdlOjAzMDA3MGI5NWRjMjQ4ZWI5Y2Q2YWIyY2EzNzhhMWVmXzUtMy0xLTEtMA_3c2d68ca-79b1-4165-a3e5-bc00f04ca47b">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $<ix:nonFraction unitRef="usd" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzI5MQ_5eee497a-cc51-4ab4-9bf1-dbbabf1d384a">4</ix:nonFraction> million for both the three months ended September&#160;30, 2021 and 2020 respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over <ix:nonNumeric contextRef="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzQ1Nw_e460a5ee-754e-4822-b06b-3b8d6367367c">three years</ix:nonNumeric>. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><ix:continuation id="i821c66db4a3f4eaa9a04d34ceb748ed2"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzIzMDM_f002ad91-1a44-4838-b7d7-4225c91cb993" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8be3f11faae246dc81f8ac9ec37aed05_I20210630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzEtMS0xLTEtMA_f9d63228-7eec-49a6-bfd3-06d58eeeca4f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8be3f11faae246dc81f8ac9ec37aed05_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzEtMy0xLTEtMA_a0fd5ace-2352-40e2-b8f3-240f17e0217e">49.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzItMS0xLTEtMA_7e0d6316-234a-4fbb-adf5-f9728c156f2a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzItMy0xLTEtMA_f7e3cdbd-ac47-457e-8cf6-ad54a353f011">51.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzMtMS0xLTEtMA_f1acacc6-580d-4bf1-95cc-ba5b1fe0d0a6">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzMtMy0xLTEtMA_6aeee790-2944-4f9d-806a-3eb8bd68cbe2">48.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzQtMS0xLTEtMA_bc81052e-07fa-46d6-975c-7e260299a23a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzQtMy0xLTEtMA_163f18ef-4dbf-4b42-be73-bf5c8633d4de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1569a630e924c95afa6b719377b7025_I20210930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzUtMS0xLTEtMA_8432596a-6098-4081-b7e9-5e10ccff234c">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic1569a630e924c95afa6b719377b7025_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzUtMy0xLTEtMA_d0432ad0-ec89-45f0-97d6-b7f6100abc20">50.67</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="ic1569a630e924c95afa6b719377b7025_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzgwNA_23b2e4fe-695e-4a3d-a054-8068cee46bb6">116</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0Xzk4OTU2MDQ2NTI2NzY_3cd22fd5-3305-4855-9b5b-2c695307ca13">two years</ix:nonNumeric>.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock options granted under the Plans generally vest in equal annual installments over <ix:nonNumeric contextRef="i17c1a096a6384157896d5f66dfc3de76_D20210701-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0Xzk5MQ_3c992bd4-c8a5-45f5-be71-bcb3df2ade0d">three years</ix:nonNumeric> and are exercisable for <ix:nonNumeric contextRef="i17c1a096a6384157896d5f66dfc3de76_D20210701-20210930" format="ixt-sec:durwordsen" name="cah:ExercisablePeriodOfPlansInYears" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzEwMTg_e7b6998a-dc6f-4a97-a8ce-e52310b34ba4">ten years</ix:nonNumeric> from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.</span></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzIzNjE_f1504cf2-b85c-4983-a4c8-84c7510b2941" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all stock option transactions under the Plans:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"></td><td style="width:51.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price per<br/>Common Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzEtMS0xLTEtMA_19f29bfe-67b0-4bb1-8f50-c078357c1b9f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzEtMy0xLTEtMA_8cb3478f-b174-48d3-a79b-8270fe908a5d">68.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzItMS0xLTEtMA_e793415f-e8b1-455d-9e31-343e551bcdad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzItMy0xLTEtMA_b6cfa978-9d58-4ff4-8e3b-a29501cd3309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzMtMS0xLTEtMA_b0dab17c-1ff4-43a0-8367-a7f04bfea748">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzMtMy0xLTEtMA_b2791f32-0e93-4c90-9117-880391df8a2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzQtMS0xLTEtMA_779e5579-9634-4fc2-9718-a23921816ef1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzQtMy0xLTEtMA_ea344b01-98f9-424d-ba27-ab83ea0a87c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzUtMS0xLTEtMA_d41c3105-36d4-4946-b911-7df7e74c7e23">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzUtMy0xLTEtMA_a3e09bda-abdf-4b61-a811-caf51e6366c6">69.31</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzYtMS0xLTEtMA_b8a76693-b322-4d46-b93d-85a1f7dab4ca">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzYtMy0xLTEtMA_813504fa-80f4-4f1f-82c2-ec4e349f17b5">69.48</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="i2b18c3fa14da40a09bb0bf1cd8763c77_I20210930" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzEwOTk1MTE2MjgwNTAy_b2c86b37-1b9f-4634-aaa5-a20f7a55bff8">0.3</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i17c1a096a6384157896d5f66dfc3de76_D20210701-20210930" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzEwOTk1MTE2MjgwNDgy_8ae515ae-5f05-4ae4-990b-2cbb883c70a7">two years</ix:nonNumeric>.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="cah:AdditionalStockOptionPlanDataTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzIzNDk_297a3dd3-178d-456c-99f4-99287be1c84e" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide additional detail related to stock options:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of outstanding options at period end</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b18c3fa14da40a09bb0bf1cd8763c77_I20210930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTpmMjJlZTVlYmZhODk0YjM2YjljZWQ3OTRiYTNjMDFhMS90YWJsZXJhbmdlOmYyMmVlNWViZmE4OTRiMzZiOWNlZDc5NGJhM2MwMWExXzEtMS0xLTEtMA_5b570df3-bd27-414b-8deb-b13d123fd195">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6d62cc5ac7432b86e6e4ed282c63d5_I20210630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTpmMjJlZTVlYmZhODk0YjM2YjljZWQ3OTRiYTNjMDFhMS90YWJsZXJhbmdlOmYyMmVlNWViZmE4OTRiMzZiOWNlZDc5NGJhM2MwMWExXzEtMy0xLTEtMA_ed70dd09-c3e4-4e0d-97d2-2cc215502bce">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of exercisable options at period end</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b18c3fa14da40a09bb0bf1cd8763c77_I20210930" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTpmMjJlZTVlYmZhODk0YjM2YjljZWQ3OTRiYTNjMDFhMS90YWJsZXJhbmdlOmYyMmVlNWViZmE4OTRiMzZiOWNlZDc5NGJhM2MwMWExXzItMS0xLTEtMA_849c66b2-cc57-43bc-b935-d13ae155d422">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6d62cc5ac7432b86e6e4ed282c63d5_I20210630" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTpmMjJlZTVlYmZhODk0YjM2YjljZWQ3OTRiYTNjMDFhMS90YWJsZXJhbmdlOmYyMmVlNWViZmE4OTRiMzZiOWNlZDc5NGJhM2MwMWExXzItMy0xLTEtMA_9b08f1d6-93fe-4825-aa6d-eefb0a8e2822">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of outstanding options</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i17c1a096a6384157896d5f66dfc3de76_D20210701-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTozZWMxMGRjNTdlZmM0NjYyOTM0ZWMwNzIwNmVmNDU1YS90YWJsZXJhbmdlOjNlYzEwZGM1N2VmYzQ2NjI5MzRlYzA3MjA2ZWY0NTVhXzEtMS0xLTEtMA_b7ae1499-b058-445c-a359-2a837be432a6">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i391a019a0c87456d8f0328ccefc57190_D20200701-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTozZWMxMGRjNTdlZmM0NjYyOTM0ZWMwNzIwNmVmNDU1YS90YWJsZXJhbmdlOjNlYzEwZGM1N2VmYzQ2NjI5MzRlYzA3MjA2ZWY0NTVhXzEtMy0xLTEtMA_ff5ae56e-b214-47dc-9fa0-9e6a4f49b758">4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of exercisable options</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i17c1a096a6384157896d5f66dfc3de76_D20210701-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTozZWMxMGRjNTdlZmM0NjYyOTM0ZWMwNzIwNmVmNDU1YS90YWJsZXJhbmdlOjNlYzEwZGM1N2VmYzQ2NjI5MzRlYzA3MjA2ZWY0NTVhXzItMS0xLTEtMA_2859bd80-fa67-43b9-be81-8f28bf7552da">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i391a019a0c87456d8f0328ccefc57190_D20200701-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTozZWMxMGRjNTdlZmM0NjYyOTM0ZWMwNzIwNmVmNDU1YS90YWJsZXJhbmdlOjNlYzEwZGM1N2VmYzQ2NjI5MzRlYzA3MjA2ZWY0NTVhXzItMy0xLTEtMA_6365f516-8ff6-4c4b-a413-9ecf10f77ccf">4</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a <ix:nonFraction unitRef="number" contextRef="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930" decimals="INF" name="cah:VestingPeriodinyearsforShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzE2MDI_e80e4e5b-bf22-402d-8767-00034001ee59">3</ix:nonFraction>-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from <ix:nonFraction unitRef="number" contextRef="ic10011e202de4b40a88998de77fc7694_D20200701-20210630" decimals="2" format="ixt:fixed-zero" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzMyOTg1MzQ4ODYzMzM_823d2988-d63e-41fe-8390-47ce65a53381"><ix:nonFraction unitRef="number" contextRef="idf166df979c64f28abf562745a86e1d8_D20190701-20200630" decimals="2" format="ixt:fixed-zero" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzMyOTg1MzQ4ODYzMzM_a633ab1c-cdaf-4ea0-b08b-5073eedc0959">zero</ix:nonFraction></ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i9d137a22c5e34b8289f6e4b71689c66a_D20190701-20200630" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzMyOTg1MzQ4ODYzMzc_6a532076-4e3d-4863-a039-f77d790c0930"><ix:nonFraction unitRef="number" contextRef="i4af342838d3b4e8183c8fd3d425f8a54_D20200701-20210630" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzMyOTg1MzQ4ODYzMzc_6f1ab47b-ef83-4a87-8e6b-c46bc9d8911e">240</ix:nonFraction></ix:nonFraction> percent of the target award amount for the fiscal 2020 and 2021 grants and <ix:nonFraction unitRef="number" contextRef="i453244191a32475ea14a9891190b3277_D20210701-20210930" decimals="2" format="ixt:fixed-zero" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzMyOTg1MzQ4ODYzMTQ_49dad06a-da0c-4080-9583-edccd74a267d">zero</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i1e27bef357c84648b27ccce1e084f1c5_D20210701-20210930" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzMyOTg1MzQ4ODYzMjE_b090e25b-a27d-4310-8b41-5630a7389b92">234</ix:nonFraction> percent for the fiscal 2022 grant. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><ix:nonNumeric contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzIzMzQ_e04828f1-24bb-4361-8ede-f40115b28c6e" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:49.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.023%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib69f1eb355b548178f5017ddcca5b762_I20210630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzEtMS0xLTEtMA_0db622ce-2cb2-49b3-ab70-128e56c306cb">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib69f1eb355b548178f5017ddcca5b762_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzEtMy0xLTEtMA_6b0d6882-187c-4bfe-bf2f-6953af2b747b">54.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzItMS0xLTEtMA_651611dc-95ac-4a8c-8780-9017b266525f">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzItMy0xLTEtMA_79ae65d8-cc53-4177-a774-7ee8a79af20c">51.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzMtMS0xLTEtMA_7bf71a85-9da1-4ba1-9230-5b4aedd6919b">0.3</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzMtMy0xLTEtMA_7c354635-4622-4786-a652-8195d2035f7d">52.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzQtMS0xLTEtMA_c941cbf5-af54-4356-9a3e-372ced09905d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzQtMy0xLTEtMA_62d59891-a4c6-4ef5-a842-2370ab48f357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d5d341ebc974f369b72b8f04af882c0_I20210930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzUtMS0xLTEtMA_4069ba25-62f3-4cf9-9699-dc6411bc7067">1.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2d5d341ebc974f369b72b8f04af882c0_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzUtMy0xLTEtMA_876e6e4d-93bb-4637-9719-530b2e6afe7b">51.31</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="i2d5d341ebc974f369b72b8f04af882c0_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzIxODA_cdcc1444-a5ff-4a98-81e4-8edc6d6fe434">36</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzIyNTM_7d2333e6-20ed-4ec8-84a2-8e0be707ea5f">two years</ix:nonNumeric> if the performance goals are achieved.</span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.857%"><tr><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/721371/000119312508230011/dex31.htm">Amended and Restated Articles of Incorporation of Cardinal Health, Inc., as amended (incorporated by reference to Exhibit 3.1 to Cardinal Health&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="restatedcodeofregulationsn.htm">Cardinal Health, Inc. Restated Code of Regulations, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="performanceshareunitsagree.htm">Form of Performance Share Units Agreement under the Cardinal Health, Inc. 2011 Long-Term Incentive Plan</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a22q1_10qx093021xexhibit311.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a22q1_10qx093021xexhibit312.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a22q1_10qx093021xexhibit321.htm">Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a22q1_10qx093021xexhibit991.htm">Statement Regarding Forward-Looking Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - formatted in Inline XBRL (included as Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Cardinal Health Website</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health&#160;uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when we post news releases,&#160;SEC filings and certain other information on its website.</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:27.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form 10-Q Cross Reference Index</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Form 10-Q Cross Reference Index</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I. Financial Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_58">Financial Statements </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_58">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_40">Quantitative and Qualitative Disclosures about Market Risk </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_40">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_43">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_43">18</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II. Other Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_46">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_46">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_49">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_49">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_52">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_52">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_118">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_118">39</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_124">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1938304362d7436fbafe0221fdeb43e5_124">41</a></span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:3.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div></div><div id="i1938304362d7436fbafe0221fdeb43e5_124"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Information</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.005%"><tr><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;MICHAEL C. KAUFMANN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Michael C. Kaufmann</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ JASON M. HOLLAR</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jason M. Hollar</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">|</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Q1</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2022 Form 10-Q</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>2
<FILENAME>restatedcodeofregulationsn.htm
<DESCRIPTION>EX-3.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic1073c013d5a4fd0a58f92256cd619a4_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 3.2</font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RESTATED CODE OF REGULATIONS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">OF</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CARDINAL HEALTH, INC.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:144%">AMENDED NOVEMBER 5, 2021</font></div><div><font><br></font></div><div id="ic1073c013d5a4fd0a58f92256cd619a4_4"></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">TABLE OF CONTENTS</font></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Page</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;Meetings of  Shareholders</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;1.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;Annual Meeting</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;1.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Special Meetings</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;1.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Place of Meetings</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;1.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notice of Meetings</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;1.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notice of Shareholder Business and Nominations</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;1.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Proxy Access for Director Nominations</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;1.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Waiver of Notice</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;1.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Quorum</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;1.9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Conduct of Meetings</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;1.10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Voting Standards</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;1.11</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Record Date</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;Board of Directors</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">General Powers of Board</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Number of Directors</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Compensation and Expenses</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Election of Directors</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Term of Office</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Removal of Directors</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vacancies</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Organization of Meetings</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Calling of Meetings</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notices of Meetings</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.11</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notice of Adjournment of Meeting</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.12</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Quorum and Manner of Acting</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.13</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Order of Business</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.14</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Action in Writing in Lieu of Meeting</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Committees</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.16</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Emergency Regulations</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 3 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Officers</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;3.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Number and Titles</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;3.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Election, Terms of Office, Vacancies</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Shares and Their Transfer</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;4.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Certificates for Shares</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;4.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Transfer of Shares</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;4.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regulations</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;4.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Lost, Destroyed or Stolen Certificates</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indemnification and Insurance</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;5.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Costs Incurred</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;5.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Advance Payment of Costs</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;5.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Requested Service</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;5.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Non-Exclusive</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;5.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insurance</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;5.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Survival</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;5.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Successors</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;5.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Elimination or Impairment of Indemnification Rights</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Fiscal Year</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Control Share Acquisitions</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Forum for Adjudication of Disputes</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 9   </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Amendment of Regulations</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic1073c013d5a4fd0a58f92256cd619a4_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 1</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Meetings of Shareholders</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;1.1  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Meeting</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The annual meeting of shareholders (the &#34;Annual Meeting&#34;), for the purpose of electing directors and transacting such other business as may come before the meeting, shall be held on such date and at such time during the first six months of each fiscal year of Cardinal Health, Inc. (the &#34;Company&#34;) as may be fixed by the board of directors and stated in the notice of the meeting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;1.2  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Special Meetings</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)  A special meeting of shareholders may be called by the chairman of the board, the chief executive officer or the president, or a majority of the directors acting with or without a meeting.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)  A special meeting of shareholders shall be called by the Company upon the request of the holders of shares entitling them to exercise 10 percent of the voting power of the Company entitled to be voted at the meeting.  Upon delivery to the chairman, president or secretary of a proper request in writing for a shareholders&#8217; meeting, which request must specify the purposes of the meeting and include</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the information that would be required to be set forth in a shareholder&#8217;s notice with respect to an Annual Meeting pursuant to Section&#160;1.5(c) of these regulations</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company shall give notice to the shareholders.  Any such meeting shall be held on a date and at a time and location fixed by the board of directors, the chairman, the president or the secretary, which date shall not be less than 14 days nor more than 80 days after receipt of a proper request.  If this notice is not given within 20 days after receipt of a proper request by shareholders entitled to call a meeting, the persons making the request may fix the time of the meeting by giving notice in the manner provided in Section&#160;1.4 of these regulations or cause such notice to be given by their designated representative.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;1.3  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Place of Meetings</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   All meetings of shareholders shall be held at such place or places, within or without the State of Ohio, as may be fixed by the board of directors or such officers as provided for in Section 1.2(b) of these regulations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;1.4  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Meetings</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   A notice of each annual or special meeting of shareholders shall be given to shareholders in accordance with and to the extent required by applicable law by the chairman, chief executive officer, president or secretary not less than seven nor more than 60 days before the date of the meeting.  A record date may be fixed for determining the shareholders entitled to notice of any meeting of shareholders, in accordance with the provisions of Section&#160;1.11 of these regulations.  Only the business provided for in such notice shall be considered at the meeting.  Notice of the adjournment of a meeting need not be given if the time and place to which the meeting is adjourned are fixed and announced at the meeting.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;1.5  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Shareholder Nominations and Business</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Meeting of Shareholders</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)  Nominations of persons for election to the board of directors of the Company may be made at an Annual Meeting (A)&#160;by or at the direction of the board of directors of the Company, (B)&#160;by any shareholder of the Company who (1)&#160;is a shareholder of record at the time of giving of notice provided for in this Section&#160;1.5 and at the time of the Annual Meeting, (2) is entitled to vote at the meeting, and (3)&#160;complies with the notice procedures set forth in this Section&#160;1.5 as to such nomination, or (C)&#160;by any Eligible Shareholder (as defined in Section&#160;1.6(b)(ii) below) whose Shareholder Nominee (as defined in Section 1.6(a) below) is included in the Company&#8217;s proxy statement and form of proxy for that Annual Meeting pursuant to Section&#160;1.6.  In order to assure that shareholders and the Company have a reasonable opportunity to consider director nominations proposed to be brought before an Annual Meeting and to allow for full information to be distributed to shareholders, compliance with clauses (B) and (C) of this Section 1.5(a)(i) shall be the exclusive means for a shareholder to make director nominations at an Annual Meeting.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)  Proposals of other business to be considered by the shareholders may be made at an Annual Meeting (A)&#160;by or at the direction of the board of directors of the Company or (B)&#160;by any shareholder of the Company who (1)&#160;is a shareholder of record at the time of giving of notice provided for in this Section&#160;1.5 and at the time of the Annual Meeting, (2) is entitled to vote at the meeting, and (3)&#160;complies with the notice procedures set forth in this Section&#160;1.5 as to such business.  In order to assure that shareholders and the Company have a reasonable opportunity to consider other business proposed to be brought before an Annual Meeting and to allow for full information to be distributed to shareholders, compliance with clause (B) of this Section 1.5(a)(ii) shall be the exclusive means for a shareholder to submit other business at an Annual Meeting (other than matters properly brought under Rule 14a-8 under the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)). </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)  For any nominations or any other business to be properly brought at an Annual Meeting by a shareholder pursuant to Section&#160;1.5(a)(i)(B) or Section&#160;1.5(a)(ii)(B) of these regulations, the shareholder must have given timely notice thereof in proper written form to the secretary and such other business must otherwise be a proper matter for shareholder action.  To be timely, a shareholder&#8217;s notice must be delivered to the secretary at the principal executive offices of the Company not later than the Close of Business (as defined below) on the 90th day nor earlier than the Close of Business on the 120th day prior to the first anniversary of the preceding year&#8217;s Annual Meeting&#59; provided, however, that in the event that the date of the Annual Meeting is more than 30 days before or more than 60 days after such anniversary date, notice by the shareholder to be timely must be so delivered (A) not earlier than the Close of Business on the 120th day prior to such Annual Meeting and (B) not later than the Close of Business on the later of the 90th day prior to such Annual Meeting or the 10th day following the day on which a Public Announcement (as defined below) of the date of such meeting is first made by the Company.  In no event shall an adjournment or recess of an Annual Meeting, or a postponement of an Annual Meeting for which notice of the meeting has been given, commence a new time period (or extend any time period) for the giving of a shareholder&#8217;s notice as described above.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Special Meetings of Shareholders</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  &#160;&#160;&#160;&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)  As provided under Section 1.4 of these regulations, only business set forth in the notice of meeting may be conducted at a special meeting of shareholders and no shareholder may bring any nominations of persons for election to the board of directors or any other business before a special meeting of shareholders other than the nominations and business specified by the shareholders requesting the special meeting of shareholders in the meeting request required by Section&#160;1.2(b) of these regulations.  If the notice of special meeting of shareholders indicates that persons may be elected to the board of directors of the Company, then nominations of persons for election to the board of directors may be made (A)&#160;by or at the direction of the board of directors of the Company or (B)&#160;by any shareholder of the Company who (1)&#160;is a shareholder of record at the time of giving of notice provided for in this Section&#160;1.5 and at the time of the special meeting of shareholders, (2)&#160;is entitled to vote at the meeting, and (2)&#160;complies with the notice procedures set forth in this Section&#160;1.5 as to such nomination.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)  For any nominations to be properly brought before a special meeting of shareholders by a shareholder pursuant to Section&#160;1.5(b)(i)(B) of these regulations, the shareholder must have given timely notice thereof in proper written form to the secretary.  To be timely, a shareholder&#8217;s notice must be delivered to the secretary at the principal executive offices of the Company (A)&#160;not earlier than the Close of Business on the 120th day prior to such special meeting of shareholders and (B)&#160;not later than the Close of Business on the later of the 90th day prior to such special meeting of shareholders or the 10th day following the day on which a Public Announcement of the date of such meeting and of the nominees proposed by the board of directors of the Company to be elected at such meeting is first made by the Company.  In no event shall an adjournment or recess of a special meeting of shareholders, or a postponement of a special meeting of shareholders for which notice of the meeting has been given, commence a new time period (or extend any time period) for the giving of a shareholder&#8217;s notice as described above.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:138%">(c)  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:138%;text-decoration:underline">Shareholder&#8217;s Notice</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:138%">.  To be in proper written form, a shareholder&#8217;s notice given to the secretary pursuant to Section&#160;1.5(a)(i)(B), Section&#160;1.5(a)(ii)(B) or Section&#160;1.5(b)(i)(B) of these regulations must&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)  set forth, as to the shareholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)  the name and address of such shareholder, as they appear on the Company&#8217;s books, and the name and address of such beneficial owner&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)  the class and number of shares of the Company that are held of record by such shareholder as of the date of the notice, and a representation that the shareholder will notify the Company in writing within five business days after the record date for such meeting of the class and number of shares of the Company held of record by such shareholder on such record date&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)  the class and number of shares of the Company that are held of record or are beneficially owned (within the meaning of Section&#160;13(d) of the Exchange Act) by such beneficial owner as of the date of the notice, and a representation that the shareholder will notify the Company in writing within five business days after the record date for such meeting of the class and number of shares of the Company that are held of record or are beneficially owned by such beneficial owner on such record date&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(D)  any other information relating to such shareholder and beneficial owner, if any, that would be required to be disclosed in a proxy statement or other filings required to be </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">made in connection with solicitations of proxies for, as applicable, the proposal or for the election of directors in a contested election pursuant to Section&#160;14 of the Exchange Act and the rules and regulations promulgated thereunder&#59; and </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(E)  such shareholder&#8217;s and beneficial owner&#8217;s written consent to the public disclosure of information provided to the Company pursuant to this Section 1.5&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)  set forth, as to the shareholder giving the notice or, if given on behalf of a beneficial owner, as to the beneficial owner on whose behalf the nomination or proposal is made&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)  any agreements, arrangements or understandings entered into by the shareholder or beneficial owner, as appropriate, and its affiliates with respect to equity securities of the Company, including any put or call arrangements, derivative securities, short positions, borrowed shares or swap or similar arrangements, specifying in each case the effect of such agreements, arrangements or understandings on any voting or economic rights of equity securities of the Company, in each case as of the date of the notice and in each case describing any changes in voting or economic rights which may arise pursuant to the terms of such agreements, arrangements or understandings&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)  to the extent not covered in clause (A)&#160;above, any disclosures that would be required pursuant to Item&#160;5 or Item&#160;6 of Schedule 13D under the Exchange Act (regardless of whether the requirement to file a Schedule 13D is applicable to the shareholder or beneficial owner)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C) a representation that the shareholder will notify the Company in writing within five business days after the record date for such meeting of the information set forth in clauses (A)&#160;and (B) above as of such record date&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)  if the notice relates to any business other than a nomination of a director or directors that the shareholder proposes to bring before the meeting, set forth, as to each proposal&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)  a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting and any material interest in such business of such shareholder and the beneficial owner, if any, in such business&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)  the text of any proposal or resolution proposed for consideration, including the language of any proposed amendment to the articles or these regulations&#59; and </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)  a description of all agreements, arrangements and understandings between such shareholder and beneficial owner, if any, and any other person or persons (including their names) in connection with the proposal of such business by such shareholder&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)  if the notice relates to nomination of a person for election or reelection to the board of directors of the Company, set forth, as to each nominee in an attachment signed by the nominee&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)  all information relating to such person that is required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors in a contested election pursuant to Section&#160;14 of the Exchange Act and the rules and regulations promulgated thereunder (including such person&#8217;s written consent to being named in the proxy statement as a nominee and to serving as a director if elected)&#59; </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)  a description of all direct and indirect compensation and other material monetary agreements, arrangements and understandings during the past three years, and any other material relationships, between or among such shareholder and beneficial owner, if any, and their respective affiliates and associates, or others acting in concert therewith, on the one hand, and each proposed nominee, and his respective affiliates and associates, or others acting in concert therewith, on the other hand, including, without limitation, all information that would be required to be disclosed pursuant to Item 404 of Regulation S-K if the shareholder making the nomination and any beneficial owner on whose behalf the nomination is made, if any, or any affiliate or associate therewith or person acting in concert therewith, were the &#8220;registrant&#8221; for purposes of such rule and the nominee were a director or executive officer of such registrant&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)  a written representation by each proposed nominee that the person is not and will not become a party to (1)&#160;any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how the person, if elected as a director of the Company, will act or vote on any issue or question that has not been disclosed to the Company (a &#8220;Voting Commitment&#8221;) or (2)&#160;any Voting Commitment that could limit or interfere with such nominee&#8217;s ability to comply, if elected as a director of the Company, with such nominee&#8217;s fiduciary duties under applicable law&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(D)  a written representation by each proposed nominee that the person is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the Company with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director that has not been disclosed to the Company&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(E)  a written representation by each proposed nominee that the person, if elected as a director of the Company, will comply with all of the Company&#8217;s corporate governance, conflict of interest, confidentiality and stock ownership and trading policies and guidelines, and any other Company policies and guidelines applicable to directors&#59;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)  set forth a representation that such shareholder intends to appear in person or by proxy (such proxy to be delivered to the Company no later than the Close of Business on the third business day prior to the making of a nomination or proposal) at the meeting to bring such nomination or other business before the meeting&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)  set forth such other information as may reasonably be required by the board of directors of the Company as described in the Company&#8217;s proxy statement for the preceding year&#8217;s Annual Meeting&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)  be followed, within five business days after the record date for such meeting, by the written notice providing the information described in clauses (i)(B) and (i)(C) and clause (ii)(C)&#160;above. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this Section&#160;1.5(c), if a shareholder or beneficial owner is an entity, information required of such entity by clauses (i), (ii) and (iii)(C) must also be provided as to each director, executive officer, partner, managing director or similar control person (regardless of title or position) of the entity and of each entity that controls or has the ability to control such entity.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the shareholder providing the notice intends to nominate a person for election or reelection to the board of directors of the Company, the Company may require any proposed nominee to furnish, and such </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">nominee must promptly (but in no event within five business days after such request) furnish, completed and signed questionnaires that the Company requires of its own director nominees and such other information as may reasonably be required by the Company to determine the eligibility of such proposed nominee to serve as an independent director of the Company or that could be material to a reasonable shareholder&#8217;s understanding of the independence, or lack thereof, of such nominee.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)  Except as otherwise provided by law, the articles or these regulations, the board of directors of the Company (or a designated committee thereof or the chairman of the meeting appointed pursuant to Section&#160;1.9 of these regulations) shall have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made, or proposed, as the case may be, in accordance with the procedures set forth in this Section&#160;1.5 or Section&#160;1.6 of these regulations and, if any proposed nomination or business is not in compliance with this Section&#160;1.5 or Section&#160;1.6, as the case may be, to declare that such defective proposal or nomination shall be disregarded. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)  For purposes of this Section&#160;1.5 and Section&#160;1.6 of these regulations, the &#8220;Close of Business&#8221; shall mean 5&#58;00 p.m. local time at the principal office of the Company on any calendar day, whether or not the day is a business day, and a &#8220;Public Announcement&#8221; shall mean disclosure in a press release reported by a national news service or in a document publicly filed by the Company with the Securities and Exchange Commission (the &#8220;SEC&#8221;) pursuant to Sections&#160;13, 14 or 15(d) of the Exchange Act and the rules and regulations promulgated thereunder. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)  Notwithstanding the foregoing provisions of this Section&#160;1.5, a shareholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth in this Section&#160;1.5&#59; provided, however, that any references in this Section&#160;1.5 to the Exchange Act or the rules promulgated thereunder are not intended to and shall not limit the requirements applicable to nominations or proposals as to any other business to be considered pursuant to Section&#160;1.5(a)(i)(B), Section 1.5(a)(ii)(B) or Section&#160;1.5(b)(i)(B) of these regulations.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)  Nothing in this Section&#160;1.5 shall be deemed to affect any rights of shareholders to request inclusion of proposals in the Company&#8217;s proxy statement pursuant to Rule 14a-8 under the Exchange Act by satisfying the notice and other requirements of Rule 14a-8 in lieu of satisfying the requirements of this Section&#160;1.5.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;1.6  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Proxy Access for Director Nominations</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Eligibility</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions of these regulations, in connection with an Annual Meeting at which directors are to be elected, the Company shall include in its proxy statement and on its form of proxy the names of, and shall include in the proxy statement the Additional Information (as defined below) relating to, a number of nominees, as specified pursuant to Section&#160;1.6(b)(i), for election to the board of directors submitted pursuant to this Section&#160;1.6 (each nominee, a &#8220;Shareholder Nominee&#8221;) if&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)  the Shareholder Nominee satisfies the eligibility requirements in this Section&#160;1.6&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)  the Shareholder Nominee is identified in a timely notice (the &#8220;Shareholder Notice&#8221;) that satisfies this Section&#160;1.6 and is delivered by a shareholder that qualifies as, or is acting on behalf of, an Eligible Shareholder (as defined below)&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)  the Eligible Shareholder expressly elects at the time of the delivery of the Shareholder Notice to have the Shareholder Nominee included in the Company&#8217;s proxy materials&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)  the additional requirements of these regulations are met.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)  The maximum number of Shareholder Nominees appearing in the Company&#8217;s proxy materials with respect to an Annual Meeting (the &#8220;Authorized Number&#8221;) may not exceed the greater of (A)&#160;two or (B)&#160;20 percent of the number of directors in office as of the last day on which a Shareholder Notice may be delivered pursuant to this Section&#160;1.6 with respect to the Annual Meeting, or if the amount is not a whole number, the closest whole number (rounding down) below 20 percent, except that the Authorized Number will be reduced (Y)&#160;by the number of Shareholder Nominees submitted for inclusion in the Company&#8217;s proxy materials pursuant to this Section&#160;1.6 but whom the board of directors decides to nominate as a board nominee</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and (Z)&#160;by the number of nominees elected to the board of directors as a Shareholder Nominee at any of the preceding two Annual Meetings and who is nominated for election at the Annual Meeting by the board of directors as a board nominee.  The Authorized Number will also be reduced, but not below one, by the number of directors in office or director nominees that in either case will be included in the Company&#8217;s proxy materials with respect to the Annual Meeting as an unopposed (by the Company) nominee pursuant to an agreement, arrangement or other understanding between the Company and a shareholder or group of shareholders (other than any agreement, arrangement or understanding entered into in connection with an acquisition of capital stock from the Company), other than any director who at the time of the Annual Meeting will have served as a director continuously, as a nominee of the board of directors, for at least two annual terms.  In the event that one or more director vacancies occurs for any reason after the date of the Shareholder Notice but before the Annual Meeting and the board of directors resolves to reduce the size of the board of directors, the Authorized Number will be calculated based on the number of directors in office as so reduced.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)  To qualify as an &#8220;Eligible Shareholder,&#8221; a shareholder or a group as described in this Section 1.6</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">must&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)  Own and have Owned (as defined below), continuously for at least three years as of the date of the Shareholder Notice, a number of shares (as adjusted to account for any stock dividend, stock split, subdivision, combination, reclassification or recapitalization of shares) that represents at least three percent of the outstanding shares of the Company that are entitled to vote in the election of directors as of the date of the Shareholder Notice (the &#8220;Required Shares&#8221;)&#59; and </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)  thereafter continue to Own the Required Shares through the Annual Meeting.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of satisfying the percentage ownership requirements of this Section&#160;1.6(b)(ii), the shares that one or more shareholders or beneficial owners individually Owned continuously for at least three years as of the date of the Shareholder Notice may be aggregated if the number of shareholders and beneficial owners does not exceed 20 and all requirements and obligations for an Eligible Shareholder set forth in this Section&#160;1.6 are satisfied by each such shareholder or beneficial owner (except with respect to aggregation).  No shares may be attributed to more than one Eligible Shareholder and no shareholder or beneficial owner (including any of its affiliates) may qualify as or constitute more than one Eligible Shareholder (either on its own or as a member of a group) under this Section&#160;1.6.  A group of any two or more collective investment funds that are (X)&#160;under common </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">management and investment control, (Y)&#160;under common management and funded primarily by a single employer or (Z)&#160;publicly offered and part of the same Family of Funds (as defined below), will be treated as one shareholder or beneficial owner for purposes of the limitation on aggregation set forth in this Section&#160;1.6.  For purposes of this Section&#160;1.6, the terms &#8220;affiliate&#8221; or &#8220;affiliates&#8221; have the meanings ascribed to them under the rules and regulations promulgated under the Exchange Act and the term &#8220;Family of Funds&#8221; means two or more investment companies or funds (whether organized in the U.S. or outside the U.S.) that hold themselves out to investors as related companies for purposes of investment and investor services.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)  For purposes of this Section&#160;1.6&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)  A shareholder or beneficial owner is deemed to &#8220;Own&#8221; only those outstanding shares of the Company as to which the person possesses both (1)&#160;full voting and investment rights pertaining to the shares and (2)&#160;full economic interest in (including the opportunity for profit and risk of loss on) the shares, except that the number of shares calculated in accordance with clauses (1) and (2) does not include any shares (I)&#160;sold by the person in any transaction that has not been settled or closed, (II)&#160;borrowed by the person for any purposes or purchased by the person pursuant to an agreement to resell or (III)&#160;subject to any option, warrant, forward contract, swap, contract of sale, derivative or other instrument, agreement or understanding entered into by the person, regardless of whether the instrument, agreement or understanding is to be settled with shares or with cash based on the notional amount or value of outstanding shares of the Company or otherwise, if the instrument, agreement or understanding has, or is intended to have, or if exercised would have, the purpose or effect of (y)&#160;reducing in any manner, to any extent or at any time in the future, the person&#8217;s full right to vote or direct the voting of the shares or (z)&#160;hedging, offsetting or altering to any degree any gain or loss arising from the full economic ownership of the shares by the person, other than any such arrangements solely involving an exchange-listed multi-industry market index fund in which shares of the Company represent at the time of entry into such arrangement less than 10 percent of the proportionate value of such index.  The terms &#8220;Owned,&#8221; &#8220;Owning&#8221; and other variations of the word &#8220;Own,&#8221; when used with respect to a shareholder or beneficial owner, have correlative meanings and the term &#8220;person&#8221; includes its affiliates.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)  A shareholder or beneficial owner &#8220;Owns&#8221; shares held in the name of a nominee or other intermediary so long as the person retains the right to instruct how the shares are voted with respect to the election of directors and the right to direct the disposition thereof and possesses the full economic interest in the shares.  The person&#8217;s Ownership of shares is deemed to continue during any period in which the person has delegated any voting power by means of a proxy, power of attorney or other instrument or arrangement that is revocable at any time by the shareholder.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)  A shareholder or beneficial owner&#8217;s Ownership of shares continues during any period in which the person has loaned the shares if the person has the power to recall the loaned shares on five business days&#8217; notice</font><font style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)  For purposes of this Section&#160;1.6, the &#8220;Additional Information&#8221; referred to in Section&#160;1.6(a) that the Company will include in its proxy statement is&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)  the information set forth in the Schedule 14N provided with the Shareholder Notice</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">concerning each Shareholder Nominee and the Eligible Shareholder that is required </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to be disclosed in the Company&#8217;s proxy statement by the applicable requirements of the Exchange Act and the rules and regulations thereunder&#59; and </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)  if the Eligible Shareholder so elects, a written statement of the Eligible Shareholder (or, in the case of a group, a written statement of the group), not to exceed 500 words, in support of its Shareholder Nominee(s), which must be provided at the same time as the Shareholder Notice for inclusion in the Company&#8217;s proxy statement for the Annual Meeting.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary contained in this Section&#160;1.6, the Company may omit from its proxy materials any information or statement that it, in good faith, believes is untrue in any material respect (or omits a material fact necessary in order to make the statements made, in light of the circumstances under which they are made, not misleading) or would violate any applicable law, rule, regulation or listing standard.  Nothing in this Section&#160;1.6 limits the Company&#8217;s ability to solicit against and include in its proxy materials its own statements relating to any Eligible Shareholder or Shareholder Nominee.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Shareholder Notice and Other Information Requirements</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)  The Shareholder Notice must set forth all information, representations and agreements required under Section&#160;1.5(c)(i), (ii) and (iv) of these regulations (and for these purposes, references in Section&#160;1.5(c) to the &#8220;beneficial owner&#8221; on whose behalf the nomination is made refers to the &#8220;Eligible Shareholder&#8221; and, in the case of a group, the information, representations and agreements must be provided for each shareholder or beneficial owner whose shares are aggregated for purposes of constituting an Eligible Shareholder).  In addition, the Shareholder Notice must include&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)  a copy of the Schedule 14N that has been or concurrently is filed with the SEC under the Exchange Act&#59;  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)  a statement of the Eligible Shareholder (and in the case of a group, the written agreement of each shareholder or beneficial owner whose shares are aggregated for purposes of constituting an Eligible Shareholder), which statement(s) must also be included in the Schedule 14N filed with the SEC&#58; (1) setting forth and certifying to the number of shares of the Company the Eligible Shareholder Owns and has Owned (as defined in Section&#160;1.6(b)(iii) above) continuously for at least three years as of the date of the Shareholder Notice, (2) agreeing to continue to Own the shares through the Annual Meeting and (3) setting forth whether or not it intends to maintain Ownership of the Required Shares for at least one year following the Annual Meeting&#59;  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)  the written agreement of the Eligible Shareholder (and in the case of a group, the written agreement of each shareholder or beneficial owner whose shares are aggregated for purposes of constituting an Eligible Shareholder) addressed to the Company, setting forth the following additional agreements, representations and warranties&#58;  </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)  it will provide (I)&#160;within five business days after the record date for the Annual Meeting, both the information required under Section&#160;1.5(c)(i)(B) and Section&#160;1.5(c)(i)(C) and notification in writing verifying the Eligible Shareholder&#8217;s continuous Ownership of the Required Shares, in each case, as of the record date and (II)&#160;immediate notice to the Company if the Eligible Shareholder ceases to Own any of the Required Shares prior to the Annual Meeting&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)  it (I)&#160;acquired the Required Shares in the ordinary course of business and not with the intent to change or influence control at the Company, and does not presently have this intent, (II)&#160;has not nominated and will not nominate for election to the board of directors at the Annual Meeting any person other than the Shareholder Nominee(s) being nominated pursuant to this Section&#160;1.6, (III)&#160;has not engaged and will not engage in, and has not been and will not be a participant (as defined in Item&#160;4 of Schedule&#160;14A under the Exchange Act) in, a solicitation within the meaning of Rule 14a-1(l) under the Exchange Act, in support of the election of any individual as a director at the Annual Meeting other than its Shareholder Nominee or a nominee of the board of directors, (IV)&#160;will not distribute to any shareholder any form of proxy for the Annual Meeting other than the form distributed by the Company, (V)&#160;will provide facts, statements and other information in all communications with the Company and its shareholders that are and will be true and correct in all material respects and do not and will not fail to state a material fact necessary in order to make the statements made not misleading and (VI)&#160;will otherwise comply with all applicable laws, rule and regulations in connection with any actions take pursuant to this Section&#160;1.6&#59; and </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)  it will (I)&#160;assume all liability stemming from any legal or regulatory violation arising out of the Eligible Shareholder&#8217;s communications with the shareholders of the Company or out of the information that the Eligible Shareholder provided to the Company, (II)&#160;indemnify and hold harmless the Company and each of its directors, officers and employees individually against any liability, loss or damages in connection with any threatened or pending action, suit or proceeding, whether legal, administrative or investigative, against the Company or any of its directors, officers or employees arising out of the Eligible Shareholder&#8217;s communications with the shareholders of the Company or out of the information that the Eligible Shareholder provided to the Company, (III)&#160;comply with all laws, rules, regulations and listing standards applicable to any solicitation in connection with the Annual Meeting, (IV)&#160;file with the SEC any solicitation or other communication by or on behalf of the Eligible Shareholder relating to the Company&#8217;s Annual Meeting, one or more of the Company&#8217;s directors or director nominees or any Shareholder Nominee, regardless of whether the filing is required under Regulation 14A under the Exchange Act or whether any exemption from filing is available for the materials under Regulation 14A under the Exchange Act and (V)&#160;provide to the Company any additional information that it may reasonably request within five business days after the request&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(D)  in the case of a nomination by a group, the designation by all group members of one group member that is authorized to act on behalf of all members of the group with respect to the nomination and matters related thereto, including withdrawal of the nomination.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)  To be timely under this Section&#160;1.6, the Shareholder Notice must be delivered by a shareholder to the secretary at the principal executive offices of the Company not later than the Close of Business (as defined in Section&#160;1.5(d)(ii) above) on the 120th day nor earlier than the Close of Business on the 150th day prior to the first anniversary of the date (as stated in the Company&#8217;s proxy materials) that the definitive proxy statement was first sent to shareholders in connection with the preceding year&#8217;s Annual Meeting, except that in the event that the date of the Annual Meeting is </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">more than 30 days before or more than 60 days after the anniversary date, or if no Annual Meeting was held in the preceding year, to be timely, the Shareholder Notice must be delivered (A)&#160;not earlier than the Close of Business on the 150th day prior to the Annual Meeting and (B)&#160;not later than the Close of Business on the later of the 120th</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">day prior to the Annual Meeting or the 10th day following the day on which a Public Announcement (as defined in Section&#160;1.5(d)(ii) above) of the date of the meeting is first made by the Company.  In no event will an adjournment or recess of an Annual Meeting, or a postponement of an Annual Meeting for which notice of the meeting has been given, commence a new time period (or extend any time period) for the giving of the Shareholder Notice as described above. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)  An Eligible Shareholder must&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)  within five business days after the date of the Shareholder Notice, provide to the Company one or more written statements from the record holder(s) of the Required Shares and from each intermediary through which the Required Shares are or have been held, in each case during the requisite three-year holding period, specifying the number of shares that the Eligible Shareholder Owns, and has Owned continuously in compliance with this Section&#160;1.6&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)  in the case of any group, within five business days after the date of the Shareholder Notice, provide to the Company documentation reasonably satisfactory to the Company demonstrating that the number of shareholders or beneficial owners within the group does not exceed 20, including whether a group of funds qualifies as one shareholder or beneficial owner within the meaning of Section&#160;1.6(b)(ii).  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The information provided pursuant to this Section&#160;1.6(c)(iii) is deemed part of the Shareholder Notice for purposes of this Section&#160;1.6.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)  Within the time period for delivery of the Shareholder Notice, a written representation and agreement of each Shareholder Nominee must be delivered to the secretary at the principal executive offices of the Company, which must be signed by each Shareholder Nominee and must set forth all information, representations and agreements required under Section&#160;1.5(c)(iv) above with respect to director nominees and also represent and agree that the Shareholder Nominee consents to being named in the Company&#8217;s proxy statement and form of proxy as a nominee and to serve as a director if elected.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, at the request of the Company, the Shareholder Nominee must promptly, but in any event within five business days after the request, submit all completed and signed questionnaires required of the Company&#8217;s directors and provide to the Company other information as it may reasonably request.  The Company may request additional information as necessary to permit the board of directors to determine if each Shareholder Nominee satisfies the requirements of this Section&#160;1.6.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)  In the event that any information or communications provided by the Eligible Shareholder or any Shareholder Nominee to the Company or its shareholders is not, when provided, or at any point thereafter ceases to be, true, correct and complete in all material respects, the Eligible Shareholder or Shareholder Nominee, as the case may be, must promptly notify the secretary and provide the information that is required to make the information or communication true, correct, complete and not misleading&#59; it being understood that providing the notification does not cure any defect or limit the Company&#8217;s right to omit a Shareholder Nominee from its proxy materials as provided in this Section&#160;1.6.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Proxy Access Procedures</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)  Notwithstanding anything to the contrary contained in this Section&#160;1.6, the Company may omit from its proxy materials any Shareholder Nominee, and the nomination will be disregarded and no vote on the Shareholder Nominee will occur, notwithstanding that proxies in respect of a vote may have been received by the Company, if&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)  the Eligible Shareholder or Shareholder Nominee breaches any of its agreements, representations, or warranties set forth in the Shareholder Notice (or otherwise submitted pursuant to this Section 1.6), any of the information in the Shareholder Notice (or otherwise submitted pursuant to this Section 1.6) was not, when provided, true, correct and complete, or the Eligible Shareholder or applicable Shareholder Nominee otherwise fails to comply with its obligation pursuant to these regulations, including, but not limited to, its obligations under this Section 1.6&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)  the Shareholder Nominee (1)&#160;is not independent under any applicable listing standards, any applicable rules of the SEC, and any publicly disclosed standards used by the board of directors in determining the independence of the Company&#8217;s directors, (2)&#160;is or has been, within the past three years, an officer or director of a competitor, as defined in Section 8 of the Clayton Antitrust Act of 1914, as amended, (3)&#160;is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses) or has been convicted in a criminal proceeding (excluding traffic violations and other minor offenses) or (IV)&#160;is subject to any order of the type specified in Rule 506(d) of Regulation D promulgated under the Securities Act of 1933, as amended&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)  the Company has received a notice (whether or not subsequently withdrawn) that a shareholder intends to nominate any candidate for election to the board of directors pursuant to the advance notice requirements for shareholder nominees for director in Section&#160;1.5(a)(i)(B) of these regulations&#59; or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(D)  the election of the Shareholder Nominee to the board of directors would cause the Company to violate the articles, these regulations or any applicable law, rule, regulation or listing standard. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)  An Eligible Shareholder submitting more than one Shareholder Nominee for inclusion in the Company&#8217;s proxy materials pursuant to this Section&#160;1.6 must rank the Shareholder Nominees based on the order that the Eligible Shareholder desires the Shareholder Nominees to be selected for inclusion in the Company&#8217;s proxy statement and include the specified rank in its Shareholder Notice submitted to the Company.  In the event that the number of Shareholder Nominees submitted by Eligible Shareholders pursuant to this Section&#160;1.6 exceeds the Authorized Number, the Company will determine which Shareholder Nominees will be included in the Company&#8217;s proxy materials in accordance with the following provisions&#58; the highest ranking Shareholder Nominee of each Eligible Shareholder who qualifies for inclusion in the Company&#8217;s proxy materials will be selected for inclusion until the Authorized Number is reached, going in order of the number (largest to smallest) of shares of the Company that each Eligible Shareholder disclosed as Owned in its Shareholder Notice submitted to the Company.  If the Authorized Number is not reached after each Eligible Shareholder has had one Shareholder Nominee selected, this selection process will repeat as many times as necessary, following the same order each time, until the Authorized Number is reached.  Following this determination, if any Shareholder Nominee who satisfies the eligibility requirements in this Section&#160;1.6 is nominated by the board of directors, is not included in the Company&#8217;s proxy materials </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or is not submitted for director election for any reason (including the Eligible Shareholder&#8217;s or Shareholder Nominee&#8217;s failure to comply with this Section&#160;1.6), no other nominee or nominees will be included in the Company&#8217;s proxy materials or otherwise submitted for election as a director at the applicable Annual Meeting in substitution for the Shareholder Nominee.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)  Any Shareholder Nominee who is included in the Company&#8217;s proxy materials for a particular Annual Meeting but withdraws from or becomes ineligible or unavailable for election at the Annual Meeting for any reason, including for the failure to comply with any provision of these regulations, will be ineligible to be a Shareholder Nominee pursuant to this Section&#160;1.6 for the next two Annual Meetings.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)  The board of directors (and any other person or body authorized by the board of directors) has the power and authority to interpret this Section&#160;1.6 and to make any and all determinations necessary or advisable to apply this Section&#160;1.6 to any persons, facts or circumstances, in each case acting in good faith.  Notwithstanding the foregoing provisions of this Section&#160;1.6, unless otherwise required by law or otherwise determined by the chairman of the meeting or the board of directors, if the shareholder who delivered the Shareholder Notice does not appear at the Annual Meeting in person or by proxy (such proxy to be delivered to the Company no later than the Close of Business on the third business day prior to the making of a nomination or proposal) to present its Shareholder Nominee or Shareholder Nominees, the nomination or nominations will be disregarded, notwithstanding that proxies in respect of the election of the Shareholder Nominee or Shareholder Nominees may have been received by the Company.  This Section&#160;1.6 is the exclusive method for shareholders to include nominees for director election in the Company&#8217;s proxy materials.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;1.7  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Waiver of Notice</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   Any shareholder, either before or after any meeting, may waive any notice required by law, the articles or these regulations.  Waivers must be in writing and filed with or entered upon the records of the meeting.  Notice of a meeting will be deemed to have been waived by any shareholder who attends the meeting either in person or by proxy, and who does not, before or at the commencement of the meeting, protest the lack of proper notice.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;1.8  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Quorum</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The holders of shares entitling them to exercise a majority of the voting power of the Company entitled to vote at a shareholders meeting, present in person or by proxy, shall constitute a quorum for the transaction of business, except when a greater number is required by law, the articles or these regulations.  In the absence of a quorum at any shareholders meeting or any adjournment of the meeting, the chairman of the meeting or the holders of shares entitling them to exercise a majority of the voting power of the Company entitled to vote at a shareholders meeting, present in person or by proxy, may adjourn the meeting from time to time.  At any adjourned meeting at which a quorum is present, any business may be transacted which might have been transacted at the meeting as originally called.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;1.9  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Conduct of Meetings</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   At each shareholders meeting the chairman of the board, or, in the chairman&#8217;s absence, any officer whom the board of directors or the chairman of the board appoints, shall act as chairman of the meeting, and the secretary of the Company, or, in the secretary&#8217;s absence, any person whom the chairman of the meeting appoints, shall act as secretary of the meeting.  Unless otherwise determined by the board of directors prior to the meeting, the chairman of the meeting shall determine in his or her sole discretion the order of business of each shareholder</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">s</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> meeting and the rules of procedure therefor, and shall have the authority to regulate the conduct of any such meeting as he or she deems appropriate.  Such rules may include, without limitation&#58; (i)&#160;an agenda for the meeting&#59; (ii)&#160;rules and procedures for maintaining order at the meeting and the safety of those present&#59; (iii)&#160;limitations on attendance at, or participation in, the meeting to only shareholders entitled to vote at the meeting, their duly authorized and constituted proxies and such other persons as the chairman of the meeting shall permit&#59; </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;restrictions on entry to the meeting after the time fixed for the commencement of the meeting&#59; (v)&#160;limitations on the time allotted for consideration of each agenda item and for questions and comments by participants&#59; (vi)&#160;regulations for the opening and closing of the polls for balloting and matters which are to be voted on by ballot (if any)&#59; and (vii)&#160;procedures (if any) requiring attendees to provide the Company advance notice of their intent to attend the meeting.  Subject to any rules and regulations adopted by the board of directors, the chairman of the meeting may convene and, for any or no reason, from time to time, adjourn or recess any meeting of shareholders.  The chairman of the meeting, in addition to making any other determinations that may be appropriate to the conduct of the meeting, shall have the power and duty to declare that a nomination or other business was not properly brought before the meeting if the facts warrant, and if the chairman of the meeting should so declare, that nomination shall be disregarded or that other business shall not be transacted.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;1.10  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Voting Standards</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   Except as otherwise expressly provided by law, the articles or these regulations, at any meeting of shareholders at which a quorum is present, all business properly brought before such meeting to be approved by a vote of the shareholders (including by non-binding or advisory vote) shall be approved if authorized by the affirmative vote of a majority of the votes cast (and for purposes of this provision an abstention is not a vote cast), whether in person or by proxy.</font></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;1.11  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Record Date</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The board of directors may fix a record date for any lawful purpose, including without limitation the determination of shareholders entitled to&#58; (a) receive notice of or to vote at any shareholders meeting&#59; (b) receive payment of any dividend or other distribution&#59; (c)&#160;receive or exercise rights of purchase of, subscription for, or exchange or conversion of, shares or other securities, subject to any contract right with respect thereto&#59; or (d) participate in the execution of written consents, waivers or releases.  Any such record date shall not be more than 60 days preceding the date of the meeting, the date fixed for the payment of any dividend or other distribution, or the date fixed for the receipt or the exercise of rights, as the case may be.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 2</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board of Directors</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;2.1  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">General Powers of Board</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   All of the authority of the Company shall be exercised by or under the direction of the board of directors, except as otherwise provided by law, the articles or these regulations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.2  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Number of Directors</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The number of directors of the Company shall be fixed from time to time by the board of directors&#59; provided, however, that in no case shall the number of directors be decreased to fewer than nine nor increased to more than 16&#59; and provided, further, that no decrease in the number of directors shall have the effect of shortening the term of any director. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;2.3  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation and Expenses</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The directors shall be entitled to such compensation as the board of directors may from time to time determine.  No director shall be precluded from serving the Company as an officer or in any other capacity or from receiving compensation for so serving.  Directors may be reimbursed for their reasonable expenses incurred in the performance of their duties, including the expense of traveling to and from meetings of the board.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.4  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Election of Directors</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The articles set forth voting standards applicable in the election of directors at each meeting of shareholders to elect directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.5  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Term of Office</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   Directors shall be elected at the Annual Meeting.  A director is elected to serve until the next Annual Meeting and until his or her successor is elected and qualified or until his or her earlier resignation, removal from office or death.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.6  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Removal of Directors</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   All the directors or any individual director may be removed from office, without assigning any cause, by the affirmative vote of the holders of record of not less than a majority of the shares having voting power of the Company with respect to the election of directors.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.7  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vacancies</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   A vacancy in the board of directors, including a vacancy created by an increase in the number of directors, may be filled by a majority vote of the remaining directors, even though they are less than a quorum.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;2.8  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Organization of Meetings</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   At each meeting of the board of directors, the chairman of the board, or, in his or her absence, the lead director (if one is designated by the directors), or, in his or her absence, a chairman chosen by a majority of the directors present, shall act as chairman.  The secretary of the Company, or, if the secretary shall not be present, an assistant secretary or any other person whom the chairman of the meeting shall appoint, shall act as secretary of the meeting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;2.9  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Calling of Meetings</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   Meetings of the board of directors shall be held whenever called by the chairman of the board, if any, the lead director (if one is designated by the directors), the chief executive officer or by one-third of the directors.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;2.10  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notices of Meetings</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   Unless waived, notice of each board of directors meeting or a meeting of any committee of directors shall be given to each director by the person calling such meeting in any of the following ways&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)  By orally informing him or her of the meeting in person or by telephone not later than 12 hours before the date and time of the meeting.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)  By delivering notice by fax, electronic mail or other electronic communication not later than one day before the date of the meeting.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)  By delivering notice by U.S. mail or overnight courier at least two days before the meeting addressed to him or her at the address furnished by him or her to the secretary of the Company, or to such other address as the person sending the notice shall know to be correct.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise required by law, the articles or these regulations, the notice of any meeting need not specify the purposes of the meeting.  Notice of any meeting of the board of directors may be waived by any director, either before, at or after the meeting, in writing or by any other legally sufficient means.  Notice of a meeting will be deemed to have been waived by any director who attends the meeting, and who does not, before or at the commencement of the meeting, protest the lack of proper notice.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;2.11  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Adjournment of Meeting</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   Notice of adjournment of a meeting of the board of directors need not be given if the time and place to which it is adjourned are fixed and announced at the meeting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;2.12  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Quorum and Manner of Acting</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   A majority of the number of directors established pursuant to Section</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2 of these regulations as of the time of any meeting of the board of directors must be present at such meeting in order to constitute a quorum for the transaction of business&#59; provided, that meetings of the directors may include participation by directors through any communications equipment if all directors participating can hear each other, and such participation in a meeting shall constitute presence at such meeting.  The act of a majority of the directors present at any meeting at which a quorum is present shall be the act of the board of directors.  In the absence of a quorum, a majority of those present may adjourn a meeting from time to time until a quorum is present without further notice or waiver thereof.  The directors shall act only as a board of directors.  Individual directors shall have no power as such other than in connection with a director&#8217;s actions as the sole member of a committee of the board of directors.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;2.13  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Order of Business</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The order of business at meetings of the board of directors shall be such as the chairman of the meeting may prescribe or follow, subject to modification by a majority of the directors present.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;2.14  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Action in Writing in Lieu of Meeting</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   Any action which may be authorized or taken at a meeting of the directors may be authorized or taken without a meeting with the affirmative approval of, and in a writing or writings signed by, all the directors.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A fax, electronic mail or an electronic or other transmission capable of authentication that appears to have been sent by a director and that contains an affirmative vote or approval of the director is a signed writing for the purposes of this </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.14.  The date on which that fax, electronic mail or electronic or other transmission is sent is the date on which the writing is signed.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;2.15  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Committees</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The directors may create and from time to time abolish or reconstitute one or more committees of directors each to consist of one or more directors, and may delegate to any such committee or committees any or all of the authority of the directors, however conferred, other than that of filling vacancies in the board of directors or in any committee of directors and other than the authority to adopt, amend or repeal these regulations.  The directors may adopt, or authorize the committees to adopt, provisions with respect to the governance of any such committee or committees which are not inconsistent with applicable law, the articles or these regulations.  An act or authorization of any act by any such committee within the authority properly delegated to it by the directors shall be as effective for all purposes as the act or authorization of the directors.  Meetings of committees shall be held whenever called by the chairman of the committee or by a majority of the committee members.</font></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;2.16  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Emergency Regulations</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   Notwithstanding any other provision in this Article 2, in the event of any emergency, as defined in Section&#160;1701.01 of the Ohio Revised Code, as a result of which a quorum cannot readily be convened for action, a meeting of the directors may be called by any officer or director.  Notice of the time and place, if any, of such meeting shall be given to such of the directors as it may be feasible to reach at the time and by the means of communication, written or oral, personal or mass, as may be practicable at the time.  The director or directors present at any such meeting that has been duly called and notice of which has been duly given shall constitute a quorum for such meeting.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 3</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Officers</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;3.1  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Number and Titles</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The officers of the Company shall be a chief executive officer, a president, a secretary, a treasurer and such other officers and assistant officers as the board may select, including a chairman of the board.  If there is more than one vice president, the board of directors may, in its discretion, establish designations for the vice presidencies so as to distinguish among them as to their functions or their order, or both.  Any two or more offices may be held by the same person, but no officer shall execute, acknowledge, or verify any instrument in more than one capacity if such instrument is required to be executed, acknowledged or verified by two or more officers.  For purposes of these regulations and Ohio law, the chief executive officer shall serve all of the functions of, and shall be deemed, the president unless the board of directors specifically designates a president.</font></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;3.2  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Election, Terms of Office, Vacancies</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The officers shall be elected by the board of directors.  Each shall be elected for an indeterminate term and shall hold office at the pleasure of the board of directors.  The board of directors may delegate to any officer or committee the power to appoint any subordinate officer, agents or committees.  Any vacancy in any office may be filled by the board of directors.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 4</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Shares and Their Transfer</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;4.1  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Certificates for Shares</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   Every owner of one or more shares of the Company shall be entitled to a certificate or certificates, which shall be in such form as may be approved by the board of directors, certifying the number and class of shares in the Company owned by him or her.  The certificates for the respective classes of such shares shall be numbered in the order in which they are issued and shall be signed in the name of the Company by the chairman or the president and the secretary&#59; provided, that if such certificates are countersigned by a transfer agent or registrar, the signatures of such officers upon such certificates may be facsimiles, stamped or printed.  If an officer who has signed or whose facsimile signature has been used, stamped or printed on any certificates ceases to be such officer because of death, resignation or other reason before such certificates are delivered by the Company, such certificates shall nevertheless be conclusively deemed to be valid if countersigned by any such transfer agent or registrar.  The board of directors may provide by resolution that some or all of any or all classes and series of shares of the Company shall be uncertificated shares to the extent permitted by Ohio law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;4.2  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transfer of Shares</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   Shares of the Company shall be transferable in person or by attorney (and, if issued in certificated form, upon the surrender of the certificate to the Company or any transfer agent for the Company (for the class of shares represented by the certificate surrendered) and cancellation of the certificate), if properly endorsed for transfer or accompanied by a duly executed assignment and power of transfer provided in connection therewith, together with such assurances as the Company or its transfer agent may require as to the genuineness and effectiveness of each necessary instrument.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;4.3  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Regulations</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The board of directors may make such rules and regulations as it may deem expedient or advisable, not inconsistent with these regulations, concerning the issue, transfer and registration of shares.  It may appoint one or more transfer agents or one or more registrars, or both, and may require all certificates for shares to bear the signature of either or both.</font></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;4.4  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Lost, Destroyed or Stolen Certificates</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   A new share certificate or certificates or uncertificated shares may be issued in place of any certificate theretofore issued by the Company which is alleged to have been lost, destroyed, or wrongfully taken upon&#58; (a) the execution and delivery to the Company by the person claiming the certificate to have been lost, destroyed or wrongfully taken of an affidavit of that fact in form satisfactory to the Company, specifying whether or not the certificate was endorsed at the time of such alleged loss, destruction or taking, and (b) the receipt by the Company of a surety bond, indemnity agreement or any other assurances satisfactory to the Company and to all transfer agents and registrars of the class of shares represented by the certificate against any and all losses, damages, costs, expenses, liabilities or claims to which they or any of them may be subjected by reason of the issue and delivery of such new certificate or certificates or uncertificated shares or with respect to the original certificate.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 5</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification and Insurance</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;5.1  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Costs Incurred</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The Company shall, to the fullest extent authorized by law, including but not limited to the laws of the State of Ohio, indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">reason of the fact that he or she is or was a director, officer or employee of the Company, or is or was serving at the written request of the Company as a director, trustee, officer, employee, member or manager of another corporation, domestic or foreign, nonprofit or for profit, limited liability company, partnership, joint venture, trust or other enterprise, against expenses, including attorneys&#8217; fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him or her in connection with such action, suit or proceeding.  The Company shall indemnify a director, trustee, officer, employee, member or manager seeking indemnity in connection with an action, suit or proceeding (or part of an action, suit or proceeding) initiated by such person only if the action, suit or proceeding (or part of the action, suit or proceeding) initiated by such person was authorized by the board of directors of the Company.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;5.2  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Advance Payment of Costs</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The Company shall pay expenses, including attorneys&#8217; fees, incurred by an officer of the Company in defending any action, suit or proceeding referred to in Section&#160;5.1 of these regulations as they are incurred, in advance of the final disposition of such action, suit or proceeding, upon receipt of an undertaking by or on behalf of the officer to repay such amount if it shall ultimately be determined that he or she is not entitled to be indemnified by the Company.  The Company shall pay expenses, including attorneys&#8217; fees, incurred by a director of the Company as specified in the Ohio Revised Code or any successor.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;5.3  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Requested Service</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   Any person shall be deemed to be serving at the written request of the Company if such person (a) is serving as a director, trustee, officer, employee, member or manager of another organization of which a majority of the outstanding voting securities representing the present right to vote for the election of its directors or equivalent executives is owned directly or indirectly by the Company (a &#8220;Subsidiary&#8221;), (b) is serving as a director, trustee or manager of any employee benefit plan of the Company or a Subsidiary, or (c) is appointed by the Company or a Subsidiary as a director, trustee or manager of another organization of which the Company or a Subsidiary has the right to appoint a member or members of the board of directors or similar governing body of such organization.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;5.4  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Exclusive</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The indemnification authorized in this Article&#160;5 shall not be deemed exclusive of any other rights to which persons seeking indemnification may be entitled under any agreement, vote of shareholders or disinterested directors, or otherwise, both as to action in his or her official capacity and as to action in another capacity while holding such office.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;5.5  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The Company may purchase and maintain insurance on behalf of any person who is or was a director, officer or employee of the Company, or is or was serving at the request of the Company as a director, trustee, officer, employee, member or manager of another corporation, domestic or foreign, nonprofit or for profit, limited liability company, partnership, joint venture, trust or other enterprise against any liability asserted against him or her and incurred by him or her in any such capacity or arising out of his or her status as such, whether or not the Company would have the power to indemnify him or her against such liability under this Article 5 or under Chapter 1701 of the Ohio Revised Code.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;5.6  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The indemnification authorized in this Article&#160;5 shall continue as to a person who has ceased to be a director, trustee, officer, employee, member or manager.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#167;5.7  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   The indemnification authorized in this Article&#160;5 shall inure to the benefit of the heirs, executors and administrators of any person entitled to indemnification under this Article&#160;5.</font></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#167;5.8  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Elimination or Impairment of Indemnification Rights</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   No amendment, termination or repeal of this Article 5, nor, to the fullest extent permitted by law, any modification of law, shall adversely affect or impair in any way the rights to be indemnified or to advancement of expenses pursuant to this Article 5 with respect to any actions, omissions, transactions or facts occurring prior to the final adoption of such amendment, modification, termination or repeal.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 6</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Year</font></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The fiscal year of the Company shall begin on the first day of July and end on the last day of June each year.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 7</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Control Share Acquisitions</font></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Section 1701.831 of the Ohio Revised Code shall not apply to control share acquisitions of shares of the Company.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 8</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Forum for Adjudication of Disputes</font></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless the Company consents in writing to the selection of an alternative forum, the sole and exclusive forum for (a) any derivative action or proceeding brought on behalf of the Company, (b) any action asserting a claim of breach of a fiduciary duty owed by any director or officer or other employee of the Company to the Company or to the Company&#8217;s shareholders, (c) any action asserting a claim against the Company or any director or officer or other employee of the Company arising pursuant to any provision of Chapter 1701 of the Ohio Revised Code or the articles or these regulations, or (d) any action asserting a claim against the Company or any director or officer or other employee of the Company governed by the internal affairs doctrine shall be the United States District Court for the Southern District of Ohio, Eastern Division, or in the event that court determines that it lacks jurisdiction to hear such action, the Franklin County, Ohio Court of Common Pleas.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE 9</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment of Regulations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;These regulations may be amended or repealed or new regulations may be adopted&#58;  (a)&#160;at any meeting of the shareholders held for such purpose by the affirmative vote of the holders of record of shares entitling them to exercise a majority of the voting power on such proposal&#59; (b)&#160;without a meeting of the shareholders, by the written consent of the holders of record of shares entitling them to exercise a majority of the voting power on such proposal&#59; or (c)&#160;by the board of directors (to the extent permitted by the Ohio Revised Code).</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>performanceshareunitsagree.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib76c31f9f5184d0d8355e093f24ef411_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">CARDINAL HEALTH, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">PERFORMANCE SHARE UNITS AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This Performance Share Units Agreement (this &#8220;Agreement&#8221;) is entered into in Franklin County, Ohio.  On &#91;grant date&#93; (the &#8220;Grant Date&#8221;), Cardinal Health, Inc., an Ohio corporation (the &#8220;Company&#8221;), has awarded to &#91;employee name&#93; (&#8220;Awardee&#8221;) &#91;target # of units&#93; performance-based Stock Units (the &#8220;Performance Share Units&#8221; or &#8220;Award&#8221;).  The Performance Share Units have been granted pursuant to the Amended Cardinal Health, Inc. 2011 Long-Term Incentive Plan (the &#8220;Plan&#8221;), and are subject to all provisions of the Plan, which are incorporated in this Agreement by reference, and are subject to the provisions of this Agreement.  Capitalized terms used in this Agreement which are not specifically defined have the meanings ascribed to them in the Plan.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">Vesting of Performance Share Units</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Subject to the provisions of this Agreement, zero to &#91;maximum percentage&#93; of the Performance Share Units vest when the Administrator certifies the payout level (&#8220;Payout Level&#8221;) as a result of achievement of specific performance criteria (the &#8220;Performance Goals&#8221;) for a performance period (&#8220;Performance Period&#8221;) set forth in </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> attached hereto.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Performance Share Units are not transferable.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">Termination of Employment</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Except to the extent that vesting occurs pursuant to Paragraphs 3(b), (c), (d) or (e) or Paragraph 5, if a Termination of Employment occurs prior to the &#91;applicable payment date in Paragraph 6(a) (the &#8220;Payment Date&#8221;)&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> &#47; &#91;First Payment Date (as defined in Paragraph 6(a))&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">2 </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">associated with a Performance Period, any Performance Share Units allocated to that Performance Period, whether vested or unvested, are forfeited by Awardee.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">Death or Disability</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  If a Termination of Employment by reason of Awardee&#8217;s death or Disability occurs at least 6 months after the Grant Date, then the outstanding unvested Performance Share Units for a Performance Period will vest as if Awardee had remained employed through the &#91;First&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Payment Date.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:10.35pt">&#91;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Retirement</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  If a Termination of Employment by reason of Awardee&#8217;s Retirement occurs at least 6 months after the Grant Date, then the outstanding unvested Performance Share Units for a Performance Period will vest in an amount equal to the number of Performance Share Units that would have vested if Awardee had remained employed through the &#91;First&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Payment Date multiplied by a fraction, the numerator of which is the number of days in the Performance Period up to the date of such Termination of Employment, and the denominator of which is the total number of days in such Performance Period.&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">3</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">Involuntary Termination with Severance</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  If (i) neither Paragraph 3(c) nor Paragraph 3(e) is applicable, but Awardee has attained either (A) age 53 and at least eight years of continuous service with the Company and its Affiliates (collectively, the &#8220;Cardinal Group&#8221;), or (B) age 59 and at least four years of continuous service with the Cardinal Group, in each case including service with an Affiliate of the Company prior to the time that such Affiliate became an Affiliate of the Company, (ii) a Termination of Employment by the Cardinal </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> For awards without deferred settlement.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> For awards with deferred settlement.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> This provision is an alternative that may not be included in every award agreement.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Group (other than a Termination for Cause) occurs at least 6 months after the Grant Date, and (iii) no later than 45 days after the Termination of Employment, Awardee enters into a written separation agreement and general release with the Cardinal Group (in such form as may reasonably be presented by the Company) (a &#8220;Separation Agreement&#8221;), and Awardee does not timely revoke such Separation Agreement, then the outstanding unvested Performance Share Units for a Performance Period will vest in an amount equal to the number of Performance Share Units that would have vested if Awardee had remained employed through the &#91;First&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Payment Date multiplied by a fraction, the numerator of which is the number of days in the Performance Period up to the date of such Termination of Employment, and the denominator of which is the total number of days in such Performance Period.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">Involuntary Termination After Completion of a Performance Period</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  If a Termination of Employment by the Cardinal Group (other than a Termination for Cause) occurs after the completion of a Performance Period but prior to the &#91;First&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Payment Date, then the Performance Share Units for the applicable Performance Period will vest as if Awardee had remained employed through the &#91;First&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Payment Date.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">Special Forfeiture and Repayment Rules</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This Agreement contains special forfeiture and repayment rules intended to encourage conduct that protects the Cardinal Group&#8217;s legitimate business assets and discourage conduct that threatens or harms those assets.  The Company does not intend to have the benefits of this Agreement reward or subsidize conduct detrimental to the Company, and therefore will require the forfeiture of the benefits offered under this Agreement and the repayment of gains obtained from this Agreement, according to the rules specified below.  Activities that trigger the forfeiture and repayment rules are divided into two categories&#58; Misconduct and Competitor Conduct.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">Misconduct</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  During employment with the Cardinal Group and for three years after the Termination of Employment for any reason, Awardee agrees not to engage in Misconduct.  If Awardee engages in Misconduct during employment or within three years after the Termination of Employment for any reason, then</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-22.91pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee immediately forfeits the Performance Share Units that have not yet vested or that vested at any time within three years prior to the date the Misconduct first occurred and have not yet been paid pursuant to Paragraph 6, and those forfeited Performance Share Units automatically terminate, and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-25.09pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee shall, within 30 days following written notice from the Company, pay to the Company in cash an amount equal to&#58; (A) the gross gain to Awardee resulting from the payment of the Performance Share Units pursuant to Paragraph 6 that had vested at any time within three years prior to the date the Misconduct first occurred less (B) $1.00.  The gross gain is the Fair Market Value of the Shares represented by the Performance Share Units on the &#91;Payment Date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> &#47; &#91;applicable payment date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="padding-left:72pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Misconduct</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">A.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:8.71pt">disclosing or using any of the Cardinal Group&#8217;s confidential information (as defined by the applicable Cardinal Group policies and agreements) without proper authorization from the Cardinal Group or in any capacity other than as necessary for the performance of Awardee&#8217;s assigned duties for the Cardinal Group&#59;</font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">B.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:8.71pt">violation of the Standards of Business Conduct or any successor code of conduct or other applicable Cardinal Group policies, including but not limited to conduct which would constitute a breach of any representation or certificate of compliance signed by Awardee&#59;</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">C.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:8.17pt">fraud, gross negligence or willful misconduct by Awardee, including but not limited to fraud, gross negligence or willful misconduct causing or contributing to a material error resulting in a restatement of the financial statements of any member of the Cardinal Group&#59;</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">D.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:8.17pt">directly or indirectly soliciting or recruiting for employment or contract work on behalf of a person or entity other than a member of the Cardinal Group, any person who is an employee, representative, officer or director in the Cardinal Group or who held one or more of those positions at any time within the 12 months prior to Awardee&#8217;s Termination of Employment&#59;</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">E.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:8.71pt">directly or indirectly inducing, encouraging or causing an employee of the Cardinal Group to terminate his&#47;her employment or a contract worker to terminate his&#47;her contract with a member of the Cardinal Group&#59;</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">F.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.26pt">any action by Awardee and&#47;or his or her representatives that either does or could reasonably be expected to undermine, diminish or otherwise damage the relationship between the Cardinal Group and any of its customers, prospective customers, vendors, suppliers or employees known to Awardee&#59; or</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">G.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:7.62pt">breaching any provision of any employment or severance agreement with a member of the Cardinal Group.</font></div><div style="padding-left:108pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Nothing in this Agreement will prevent Awardee from testifying truthfully as required by law, prohibit or prevent Awardee from filing a charge with or participating, testifying or assisting in any investigation, hearing, whistleblower proceeding or other proceeding before any federal, state or local government agency (e.g., Equal Employment Opportunity Commission, National Labor Relations Board, Securities and Exchange Commission, etc.), or prevent Awardee from disclosing Cardinal Group&#8217;s confidential information in confidence to a federal, state or local government official for the purpose of reporting or investigating a suspected violation of law.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">Competitor Conduct</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  If Awardee engages in Competitor Conduct during employment or within one year after the Termination of Employment for any reason, then</font></div><div style="padding-left:108pt;text-indent:-22.91pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee immediately forfeits the Performance Share Units that have not yet vested or that vested at any time within one year prior to the date the Competitor Conduct first occurred and have not yet been paid pursuant to Paragraph 6, and those forfeited Performance Share Units automatically terminate, and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:108pt;text-indent:-25.09pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee shall, within 30 days following written notice from the Company, pay the Company an amount equal to&#58; (A) the gross gain to Awardee resulting from the payment of Performance Share Units pursuant to Paragraph 6 that had vested at any time since the earlier of one year prior to the date the Competitor Conduct first occurred or one year prior to the Termination of Employment, if applicable, less (B) $1.00.  The gross gain is the Fair Market Value of the Shares represented by the Performance Share Units on the </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#91;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Payment Date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> &#47; &#91;applicable payment date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="padding-left:72pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Competitor Conduct</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means accepting employment with, or directly or indirectly providing services to, a Competitor in the United States.  If Awardee has a Termination of Employment and Awardee&#8217;s responsibilities to the Cardinal Group were limited to a specific territory or territories within or outside the United States during the 24 months prior to the Termination of Employment, then Competitor Conduct is limited to that specific territory or territories.  A &#8220;Competitor&#8221; means any person or business that competes with the products or services provided by a member of the Cardinal Group for which Awardee had business responsibilities within 24 months prior to Termination of Employment or about which Awardee obtained confidential information (as defined by the applicable Cardinal Group policies or agreements).</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">      c.  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-22.91pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:18pt">Nothing in this Paragraph 4 constitutes or is to be construed as a &#8220;noncompete&#8221; covenant or other restraint on employment or trade.  The provisions of this Paragraph 4 do not prevent, nor are they intended to prevent, Awardee from seeking or accepting employment or other work outside the Cardinal Group.  The execution of this Agreement is voluntary.  Awardee is free to choose to comply with the terms of this Agreement and receive the benefits offered or else reject this Agreement with no adverse consequences to Awardee&#8217;s employment with the Cardinal Group.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-25.09pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee agrees to provide the Company with at least 10 days written notice prior to accepting employment with or providing services to a Competitor within one year after Termination of Employment.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-27.27pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">iii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee acknowledges receiving sufficient consideration for the requirements of this Paragraph 4, including Awardee&#8217;s receipt of the Performance Share Units.  Awardee further acknowledges that the Company would not provide the Performance Share Units to Awardee without Awardee&#8217;s promise to abide by the terms of this Paragraph 4.  The parties also acknowledge that the provisions contained in this Paragraph 4 are ancillary to, or part of, an otherwise enforceable agreement at the time this Agreement is made.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-27.83pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">iv.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:18pt">Awardee may be released from the obligations of this Paragraph 4 if and only if the Administrator determines, in writing and in the Administrator&#8217;s sole discretion, that a release is in the best interests of the Company.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">Valuation</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  In the event of a Change of Control prior to &#91;a Payment Date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> &#47; &#91;the First Payment Date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, the Administrator, as constituted immediately before such Change of Control, shall determine and certify the Payout Level (the &#8220;Change of Control Payout Level&#8221;) based on (i) actual performance through the most recent date prior to the Change of Control for which achievement of the Performance Goals can reasonably be determined&#59; and (ii) the expected performance for the remainder of the Performance Period based on information reasonably available.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">Vesting and Substitute Awards</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:180pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.09pt">In the event of a Change of Control prior to &#91;a Payment Date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> &#47; &#91;the First Payment Date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, the percentage of the Performance Share Units determined in accordance with Exhibit A at the Change of Control Payout Level vests unless an award meeting the requirements of Paragraph 5(b)(ii) (a &#8220;Substitute Award&#8221;) is provided to Awardee to replace or adjust the Award.  If a Substitute Award is provided, any Performance Share Units that (A) except to the extent that clause (B) applies, would vest in accordance with Paragraphs 3(b) or (c) in connection with Awardee&#8217;s Retirement or Disability if Awardee&#8217;s Termination of Employment occurred on the date of the Change of Control or (B) are eligible to vest in accordance with Paragraph 3(d) as a result of Awardee&#8217;s Termination of Employment that actually occurs prior to the Change of Control, vest at the time of the Change of Control.  No Substitute Award will be provided in the event of Awardee&#8217;s Termination of Employment by reason of death, Disability, Retirement or the circumstances described in Paragraph 3(d) prior to a Change of Control.</font></div><div style="padding-left:144pt"><font><br></font></div><div style="padding-left:180pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:10.91pt">An award meets the conditions of this Paragraph 5(b)(ii) (and hence qualifies as a Substitute Award) if, as determined by the Administrator as constituted immediately before the Change of Control, (A) it has a value at the time of grant or adjustment at least equal to the value of the Performance Share Units that would vest under Paragraph 5(b)(i) if there were no Substitute Award&#59; (B) it is paid in publicly traded equity securities of the Company or its successor in the Change of Control or another entity that is affiliated with the Company or its successor following the Change of Control&#59; (C) it is a restricted stock unit award with vesting and payment not conditioned on the achievement of any performance criteria or conditions&#59; (D) it vests in full upon (1) a Termination for Good Reason by Awardee, (2) a Termination of Employment by the Company or its successor in the Change of Control other than a Termination for Cause, or (3) Awardee&#8217;s death or Disability, in each case, occurring at or during the period of two years after the Change of Control&#59; (E) if Awardee is subject to U.S. federal income tax under the Code, the tax consequences to Awardee under the Code of the Substitute Award are not less </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">favorable to Awardee than the tax consequences of the Award&#59; and (F) its other terms and conditions are not less favorable to Awardee than the terms and conditions of the Award (including the provisions that would apply in the event of a subsequent Change of Control).  Without limiting the generality of the foregoing, the Substitute Award may take the form of a continuation of the Award if the modifications required by the preceding sentence are satisfied.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">Payment</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  &#91;The Company shall pay Performance Share Units in Shares.  Subject to the provisions of Paragraph 4 and Paragraphs 6(b) and (c), Awardee is entitled to receive from the Company (without any payment on behalf of Awardee other than as described in Paragraph 10) one Share for each vested Performance Share Unit not later than the 60</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> day after the end of a Performance Period, except that if Awardee&#8217;s Termination of Employment occurs due to death after the end of the Performance Period, Awardee is entitled to receive the corresponding Shares from the Company on the date of death.&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> &#47; &#91;The Company shall pay Performance Share Units in Shares.  Subject to the provisions of Paragraph 4, Awardee is entitled to receive from the Company (without any payment on behalf of Awardee other than as described in Paragraph 10) one Share for each vested Performance Share Unit. Subject to the provisions of Paragraph 6(b) and (c), payment with respect to any vested Performance Share Units shall be made in three installments.  The first installment, which shall be with respect to &#91;percentage&#93; of the total number of vested Performance Share Units, shall be paid no later than the 60</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> day after the end of the Performance Period (the &#8220;First Payment Date&#8221;).  The second installment, which shall be with respect to &#91;percentage&#93; of the total number of vested Performance Share Units, shall be paid on the first anniversary of the last day of the Performance Period.  &#91;The third installment, which shall be with respect to &#91;percentage&#93; of the total number of vested Performance Share Units, shall be paid on the second anniversary of the last day of the Performance Period.&#93;  Notwithstanding the above, in the event of an Awardee's death after the end of the Performance Period, Awardee is entitled to receive, with respect to any Performance Shares Units which are not subject to a &#8220;substantial risk of forfeiture&#8221; as determined for purposes of Section 409A of the Code on the date of Awardee&#8217;s death, the corresponding Shares from the Company on account of any vested Performance Share Units which have not yet been paid as soon as practical following the date of death.  Payment shall be made at each of the times specified above unless the Administrator makes a finding that the number of vested Performance Share Units shall be reduced pursuant to Paragraph 4 due to Misconduct or Competitor Conduct.&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">2</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Notwithstanding Paragraph 6(a), to the extent that the </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">performance and service vesting requirements have been satisfied for</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> the Performance Share Units on the dates set forth below, payment with respect to such Performance Share Units will be made as follows&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.09pt">On the date of a Change of Control, Awardee is entitled to receive one Share for each vested Performance Share Unit, subject to any adjustments made pursuant to Section 16(a) of the Plan, from the Company&#59; provided, however, that if such Change of Control would not qualify as a permissible date of distribution under </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 409A(a)(2)(A)(v) of the Code and the regulations thereunder, and where Section 409A of the Code applies to such distribution as a deferral of compensation, Awardee is entitled to receive the corresponding Shares from the Company on the date that would have otherwise applied pursuant to Paragraphs 6(a), 6(b)(ii), or 6(b)(iii).  </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">ii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:10.91pt">If Awardee&#8217;s separation from service occurs during the period of two years following a Change of Control (and such Change of Control constitutes a change of control event as defined in accordance with Section 409A(a)(2)(A)(v) of the Code and the regulations thereunder), Awardee is entitled to receive one Share for each vested Performance Share Unit from the Company on the date of Awardee&#8217;s separation from service&#59; provided, in such event that if Awardee on the date of separation from service is a &#8220;specified employee&#8221; (certain employees of the Cardinal Group within the meaning of Section 409A of the Code determined using the identification methodology selected by the Company from time to time), Awardee is entitled to receive the corresponding Shares from the Company on the first day of the seventh month after the date of Awardee&#8217;s separation from service or, if earlier, the date of Awardee&#8217;s death.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">iii.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:8.73pt">On the date of Awardee's Termination of Employment due to death following a Change of Control, Awardee is entitled to receive one Share for each vested Performance Share Unit from the Company on the date of death.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:10.35pt;text-decoration:underline">Elections to Defer Receipt</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Elections to defer receipt of the Shares beyond the &#91;Payment Date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> &#47; &#91;applicable payment date&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> applicable payment date may be permitted in the discretion of the Administrator pursuant to procedures established by the Administrator in compliance with the requirements of Section 409A of the Code. &#91;Any election to defer will be valid only if the elected payment date is a date that is later than the date payment would have otherwise occurred.&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">2</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Awardee is not entitled to receive cash dividends on the Performance Share Units but will receive a dividend equivalent payment from the Company in an amount equal to the dividends that would have been paid on each Share underlying the Performance Share Units if it had been outstanding between the Grant Date and the &#91;applicable&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> payment date of any such Share (i.e., based on the record date for cash dividends).  Subject to an election to defer receipt as permitted under Paragraph 6(c), the Company shall pay dividend equivalent payments in cash as soon as reasonably practicable after the &#91;applicable&#93;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> payment date of (and to the same extent as) the Performance Share Units to which such dividend equivalents relate.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">Right of Set-Off</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  By accepting the Performance Share Units, Awardee consents to a deduction from, and set-off against, any amounts owed to Awardee that are not treated as &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code by any member of the Cardinal Group from time to time (including, but not limited to, amounts owed to Awardee as wages, severance payments or other fringe benefits) to the extent of the amounts owed to the Cardinal Group by Awardee under this Agreement.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">9.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">No Shareholder Rights</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Awardee has no rights of a shareholder with respect to the Performance Share Units, including no right to vote any Shares represented by the Performance Share Units, until such Shares are paid to Awardee.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">10.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:4.33pt;text-decoration:underline">Withholding Tax</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">Generally</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Awardee is liable and responsible for all taxes owed in connection with the Performance Share Units (including taxes owed with respect to the cash payments described in Paragraph 7), regardless of any action the Company takes with respect to any tax withholding obligations that arise in connection with the Performance Share Units.  The Company does not make any representation or undertaking regarding the tax treatment or the treatment of any tax withholding in connection with the grant, vesting or payment of the Performance Share Units or the subsequent sale of Shares issuable pursuant to vested Performance Share Units.  The Company does not commit and is under no obligation to structure the Performance Share Units to reduce or eliminate Awardee&#8217;s tax liability.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.8pt;text-decoration:underline">Payment of Withholding Taxes</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Prior to any event in connection with the Performance Share Units (e.g., vesting or payment) that the Company determines may result in any domestic or foreign tax withholding amounts being paid by the Company, whether national, federal, state or local, including any employment tax obligation (the &#8220;Tax Withholding Obligation&#8221;), Awardee is required to arrange for the satisfaction of the minimum amount of such Tax Withholding Obligation in a manner acceptable to the Company.  Awardee&#8217;s acceptance of this Agreement constitutes Awardee&#8217;s instruction and authorization to the Company to withhold on Awardee&#8217;s behalf the number of Shares from those Shares issuable to Awardee under this Award as the Company determines to be sufficient to satisfy the Tax Withholding Obligation.  In the case of any amounts withheld for taxes pursuant to this provision in the form of Shares, the amount withheld may not exceed the amount legally required and withholding above the minimum withholding requirements shall be available only if and to the extent that the Administrator has authorized such.  The Company has the right to deduct from all cash payments paid pursuant to Paragraph 7 the amount of any taxes which the Company is required to withhold with respect to such payments.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:4.33pt;text-decoration:underline">Governing Law&#47;Venue for Dispute Resolution&#47;Costs and Legal Fees</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This Agreement is governed by the laws of the State of Ohio, without regard to principles of conflicts of law, except to the extent superseded by the laws of the United States of America.  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:112%">The parties agree and acknowledge that the laws of the State of Ohio bear a substantial relationship to the parties and&#47;or this Agreement and that the Performance Share Units and benefits granted in this Agreement would not be granted without the governance of this Agreement by the laws of the State of Ohio.  In addition, all legal actions or proceedings relating to this Agreement must be brought exclusively in state or federal courts located in Franklin County, Ohio and the parties executing this Agreement hereby consent to the personal jurisdiction of such courts.  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Awardee acknowledges that the covenants contained in Paragraph 4 are reasonable in nature, are fundamental for the protection of the Company&#8217;s legitimate business and proprietary interests, and do not adversely affect Awardee&#8217;s ability to earn a living.  In the event that it becomes necessary for the Company to institute legal proceedings under this Agreement, Awardee is responsible to the Company for all costs and reasonable legal fees incurred by the Company in connection with the proceedings.  Any provision of this Agreement which is determined by a court </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">of competent jurisdiction to be invalid or unenforceable</font><font style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or to disqualify the Award under any Applicable Law should be construed or limited in a manner that is valid and enforceable and that comes closest to the business objectives intended by the provision, without invalidating or rendering unenforceable the remaining provisions of this Agreement.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">12.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:4.33pt;text-decoration:underline">Defend Trade Secrets Act Notice</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Under the U.S. Defend Trade Secrets Act of 2016, Awardee will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that&#58; (a) is made (i) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney, and (ii) solely for the purpose of reporting or investigating a suspected violation of law&#59; (b) is made to Awardee&#8217;s attorney in relation to a lawsuit for retaliation against Awardee for reporting a suspected violation of law&#59; or (c) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">13.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:4.33pt;text-decoration:underline">Action by the Administrator</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The parties agree that the interpretation of this Agreement rests exclusively and completely within the sole discretion of the Administrator.  The parties agree to be bound by the decisions of the Administrator with regard to the interpretation of this Agreement and with regard to any and all matters set forth in this Agreement.  In fulfilling its responsibilities under this Agreement, the Administrator may rely upon documents, written statements of the parties, financial reports or other material as the Administrator deems appropriate.  The parties agree that there is no right to be heard or to appear before the Administrator and that any decision of the Administrator relating to this Agreement, including whether particular conduct constitutes Misconduct or Competitor Conduct, is final and binding.  The Administrator may delegate its functions under this Agreement to an officer of the Cardinal Group designated by the Administrator, to the extent permitted under the Plan.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">14.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:4.33pt;text-decoration:underline">Prompt Acceptance of Agreement</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Performance Share Units grant evidenced by this Agreement will, at the discretion of the Administrator, be forfeited if this Agreement is not manually executed and returned to the Company, or electronically executed by Awardee by indicating Awardee&#8217;s acceptance of this Agreement in accordance with the acceptance procedures set forth on the Company&#8217;s third-party equity plan administrator&#8217;s web site, within 90 days of the Grant Date.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">15.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:4.33pt;text-decoration:underline">Electronic Delivery and Consent to Electronic Participation</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Company may, in its sole discretion, decide to deliver any documents related to the Performance Share Unit grant under and participation in the Plan or future Performance Share Units that may be granted under the Plan by electronic means or to request Awardee&#8217;s consent to participate in the Plan by electronic means.  Awardee hereby consents to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company, including the acceptance of performance share unit grants and the execution of performance share unit agreements through electronic signature.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">16.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:4.33pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  All notices, requests, consents and other communications required or provided under this Agreement to be delivered by Awardee to the Company will be in writing and will be deemed sufficient if delivered by hand, nationally recognized overnight courier, or certified or registered mail, return receipt requested, postage prepaid, and will be effective upon delivery to the Company at the address set forth below&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Cardinal Health, Inc.</font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7000 Cardinal Place</font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Dublin, Ohio 43017</font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Attention&#58;  Chief Legal and Compliance Officer</font></div><div style="text-indent:72pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">All notices, requests, consents and other communications required or provided under this Agreement to be delivered by the Company to Awardee may be delivered by e-mail or in writing and will be deemed sufficient if delivered by e-mail, hand, facsimile, nationally recognized overnight courier, or certified or registered mail, return receipt requested, postage prepaid, and will be effective upon delivery to Awardee.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">17.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:4.33pt;text-decoration:underline">Employment Agreement, Offer Letter or Other Arrangement</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  To the extent a written employment agreement, offer letter or other arrangement (&#8220;Employment Arrangement&#8221;) that was approved by the Human Resources and Compensation Committee or the Board of Directors or that was approved in writing by an officer of the Company pursuant to delegated authority of the Human Resources and Compensation Committee provides for greater benefits to Awardee with respect to vesting of the Award on Termination of Employment by reason of specified events than provided in this Agreement or in the Plan, then the terms of such Employment Arrangement with respect to vesting of the Award on Termination of Employment by reason of such specified events supersede the terms of this Agreement to the extent permitted by the terms of the Plan.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">18.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:4.33pt;text-decoration:underline">Recoupment</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This Agreement will be administered in compliance with Section 10D of the Exchange Act and any applicable rules or regulations promulgated by the Securities and Exchange Commission or any national securities exchange or national securities association on which the Shares may be traded.  In its discretion, moreover, the Administrator may require repayment to the Company of all or any portion of this Award if the amount of the Award was calculated based upon the achievement of financial results that were subsequently the subject of a restatement of the Company&#8217;s financial statements, Awardee engaged in misconduct that caused or contributed to the need for the restatement of the financial statements, and the amount payable to Awardee would have been lower than the amount actually paid to Awardee had the financial results been properly reported.  This Paragraph 18 is not the Company&#8217;s exclusive remedy with respect to such matters.  Except as otherwise required by Applicable Law, this Paragraph 18 will not apply after a Change of Control.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">19.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:4.33pt;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Any amendment to the Plan is deemed to be an amendment to this Agreement to the extent that the amendment is applicable hereto&#59; provided, however, that no amendment may impair the rights of Awardee with respect to an outstanding Performance Share Unit unless agreed to by Awardee and the Company, which agreement must be in writing and signed by Awardee and the Company.  Other than following a Change of Control, no such agreement is required if the Administrator determines in its sole discretion that such amendment either (a) is required or advisable in order for the Company, the Plan or the Performance Share Units to satisfy any Applicable Law or to meet the requirements of any accounting standard or (b) is not reasonably likely to significantly diminish the benefits provided under the Performance Share Units, or that any such diminishment has been adequately compensated, including pursuant to Section 16(c) of the Plan.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">20.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:4.33pt;text-decoration:underline">Adjustments</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The number of Shares issuable for each Performance Share Unit and the other terms and conditions of the Award evidenced by this Agreement are subject to adjustment as provided in Section 16 of the Plan.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">21.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:4.33pt;text-decoration:underline">Compliance with Section 409A of the Code</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  To the extent applicable, it is intended that this Agreement comply with the provisions of Section 409A of the Code.  This Agreement shall be administered in a manner consistent with this intent, and any provision that would cause this Agreement or the Plan to fail to satisfy Section 409A of the Code shall have no force or effect until amended to comply with Section 409A of the Code (which amendment may be retroactive to the extent permitted by Section 409A of the Code and may be made by the Company without the consent of Awardee).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">22.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:4.33pt;text-decoration:underline">No Right to Future Awards or Employment</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The grant of the Performance Share Units under this Agreement to Awardee is a voluntary, discretionary award being made on a one-time basis and it does not constitute a commitment to make any future awards.  The grant of the Performance Share Units and any payments made under this Agreement will not be considered salary or other compensation for purposes of any severance pay or similar allowance, except as otherwise required by law.  Nothing contained in this Agreement confers upon Awardee any right to be employed or remain employed by the Company or any of its Affiliates, nor limits or affects in any manner the right of the Company or any of its Affiliates to terminate the employment or adjust the compensation of Awardee.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">23.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:4.33pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Without limiting Paragraph 2, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, administrators, heirs, legal representatives and assigns of Awardee, and the successors and assigns of the Company.</font></div><div><font><br></font></div><div style="text-indent:234pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">CARDINAL HEALTH, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:234pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                       </font></div><div style="text-indent:234pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Its&#58;  </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                       </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:36pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">ACCEPTANCE OF AGREEMENT</font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Awardee hereby&#58; (a) acknowledges that he or she has received a copy of the Plan, a copy of the Company&#8217;s most recent annual report to shareholders and other communications routinely distributed to the Company&#8217;s shareholders, and a copy of the Plan Description pertaining to the Plan&#59; (b) accepts this Agreement and the Performance Share Units granted to him or her under this Agreement subject to all provisions of the Plan and this Agreement, including the provisions in this Agreement regarding &#8220;Special Forfeiture and Repayment Rules&#8221; set forth in Paragraph 4 and &#8220;Recoupment&#8221; set forth in Paragraph 18&#59; (c)  represents that he or she understands that the acceptance of this Agreement through an on-line or electronic system, if applicable, carries the same legal significance as if he or she manually signed the Agreement&#59; and (d) agrees that no transfer of the Shares delivered in respect of the Performance Share Units may be made unless the Shares have been duly registered under all applicable Federal and state securities laws pursuant to a then-effective registration which contemplates the proposed transfer or unless the Company has received a written opinion of, or satisfactory to, its legal counsel that the proposed transfer is exempt from such registration.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                                                        &#91;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                       </font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                                                        Awardee&#8217;s Signature</font></div><div><font><br></font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                       </font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                                                        Date&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-indent:36pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>a22q1_10qx093021xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i5198cf40ff07463388b9e00a2e8a5c52_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.1</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael C. Kaufmann, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;9, 2021 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:470.25pt"><tr><td style="width:1.0pt"></td><td style="width:147.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:319.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; MICHAEL C. KAUFMANN</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael C. Kaufmann</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>a22q1_10qx093021xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i646250798ca945149eccf6990e0d1a60_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.2</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jason M. Hollar, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;9, 2021 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:136.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:372.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> JASON M. HOLLAR</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>a22q1_10qx093021xexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i06a95d2998fa4f1ebf3989c000c18736_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 32.1</font></td></tr></table></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael C. Kaufmann, Chief Executive Officer of Cardinal Health, Inc. (the &#8220;Company&#8221;) and Jason M. Hollar, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the Periodic Report on Form 10-Q for the quarter ended September 30, 2021 containing the financial statements of the Company (the &#8220;Periodic Report&#8221;), which this statement accompanies, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d))&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; November&#160;9, 2021 </font></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; MICHAEL C. KAUFMANN</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael C. Kaufmann</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer </font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JASON M. HOLLAR</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>7
<FILENAME>a22q1_10qx093021xexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i854ea6a933014955bc3ea267474d5552_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 99.1</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Statement Regarding Forward-Looking Information </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this exhibit, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2021 (the &#8220;2021 Form 10-K&#8221;), and our quarterly reports on Form 10-Q, including this one, and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement is first made) about future events, prospects, projections or financial performance. The matters discussed in these forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied in or by such statements. These risks and uncertainties include&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from the COVID-19 pandemic, including the possibility that we will experience additional inventory reserves as a result of future decreases in demand or selling price&#59; the risk that we may not be able to offset significant cost increases for certain personal protective equipment (PPE) products or inflationary pressures impacting our Medical segment&#59; the possibility that sustained reduced demand for generic pharmaceutical product may continue to adversely impact our pharmaceutical generics program&#59; and the possibility that we could experience employee attrition as a result of our COVID-19 vaccine mandate or the expected governmental mandates&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">competitive pressures in the markets in which we operate, including pricing pressures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the pricing of and demand for generic pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the timing, frequency and profitability of generic pharmaceutical launches or other components of our pharmaceutical generics program&#59;  </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in manufacturer approaches to pricing branded pharmaceutical products and risks related to our compensation under contractual arrangements with manufacturers being set as a percentage of the wholesale acquisition cost of branded pharmaceuticals and where a part of our compensation is based on branded pharmaceutical price appreciation, changes in the magnitude of such price appreciation&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in the timing or frequency of the introduction of branded pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the resolution and defense of the lawsuits and investigations in which we have been or will be named relating to the distribution of prescription opioid pain medication, including risks associated with the proposed settlement agreement and process designed to resolve lawsuits and claims brought by states and local governmental entities, including the risk that we could fail to reach a final resolution and that any injunctive or non-monetary relief that we may agree to could have unintended consequences&#59; and the risk that the outcome of other opioid-related lawsuits and investigations could have a material adverse effect on our results of operations, financial condition, cash flows or liquidity or the operations of our business&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">potential damage to our reputation, adverse operational impacts or other effects that may result from the national opioid epidemic, the allegations that have been made about our role in such epidemic and the ongoing unfavorable publicity surrounding the lawsuits and investigations against us&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the tax benefit from our self-insurance loss claims, including risks associated with the letter certain industry participants, including us, received from the U.S. House of Representatives' Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including the net operating loss carryback provisions under the CARES Act and deductibility under the Tax Act&#59; the possibility that we may receive additional negative or unfavorable publicity or that the IRS may not agree with our underlying assumptions and judgments&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">potential adverse impact to our financial results from enacted and proposed state taxes or other assessments on the sale or distribution of opioid medications&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our high sales concentration with certain key customers, including CVS Health Corporation and OptumRx&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain the benefits of our generic pharmaceutical sourcing venture with CVS Health Corporation&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">costs or claims resulting from quality issues, whether related to the manufacture of some of our sterile surgical gowns or pre-filled syringes, or other potential errors or defects in our manufacturing of medical devices or other products or in our compounding, repackaging, information systems or pharmacy management services that may injure persons or damage property or operations, including costs from recalls, remediation efforts, and related product liability claims and lawsuits, including class action lawsuits&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement Administration, certain agencies within the U.S. Department of Health and Human Services (including the U.S. Food and Drug Administration, Centers for Medicare and Medicaid Services, the Office of Inspector General and the Office for Civil Rights), the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance authorities, state health departments, state insurance departments, state Medicaid departments or comparable regulatory bodies or governmental authorities or foreign equivalents that, in each case, could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning letters, recalls, seizures, injunctions or monetary sanctions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">any compromise of our information systems or of those of a third-party service provider, including unauthorized access to or use or disclosure of company or customer information, disruption of access and ancillary risks associated with our ability to effectively manage any issues arising from any such compromise or disruption&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">significantly increased costs for commodities and other materials used in the Medical segment manufacturing, including various components, compounds, raw materials or energy such as oil-based resins, pulp, cotton, latex and other commodities and the possibility that we may not successfully offset or mitigate these increases&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shortages in commodities, components, compounds, raw materials or energy used by our businesses, including supply disruptions of radioisotopes&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily available&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties related to our Medical segment's Cardinal Health Brand products, including our ability to manage cost, infrastructure and to retain margin or improve its performance&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the realignment of our Medical segment's supply chain and other businesses, including our ability to achieve the expected benefits from such realignment&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to our cost-savings initiatives or IT infrastructure activities, including the ability to achieve the expected benefits from such initiatives, the risk that we could incur unexpected charges, and the risk that we may fail to retain key personnel&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">difficulties or delays in the development, production, manufacturing, sourcing and marketing of new or existing products and services, including difficulties or delays associated with obtaining or maintaining requisite regulatory consents, whether our own or third parties', or approvals associated with those activities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">manufacturing disruptions, whether due to regulatory action, including regulatory action to reduce Ethylene Oxide emissions, production quality deviations, safety issues or raw material shortages or defects, or because a key product is manufactured at a single manufacturing facility with limited alternate facilities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with industry reliance on ethylene oxide (&#34;EtO&#34;) to sterilize certain medical products that we manufacture or distribute, including the possibility that regulatory actions to reduce EtO emissions could become more widespread, which may result in increased costs or supply shortages&#59; and risks that the lawsuits against us alleging personal injury resulting from EtO exposure could become more widespread&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the possibility that we could be subject to adverse changes in the tax laws or challenges to our tax positions, including the possibility that the corporate tax rate in the U.S. could be increased&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of healthcare fraud and abuse laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of the U.S. Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from our collecting, handling and maintaining patient-identifiable health information and other sensitive personal and financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses being Medicare-certified suppliers or participating in other federal and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program, which businesses are subject to accreditation and quality standards and other rules and regulations, including applicable reporting, billing, payment and record-keeping requirements&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses manufacturing pharmaceutical and medical products or repackaging pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs, which businesses are subject to federal and state laws that establish eligibility for reimbursement by such programs and other applicable standards and regulations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">material reductions in purchases, pricing changes, non-renewal, early termination, or delinquencies or defaults under contracts with key customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties due to possible government healthcare reform, including proposals related to Medicare drug rebate arrangements, possible repeal or replacement of major parts of the Patient Protection and Affordable Care Act, proposals related to prescription drug pricing transparency and the possible adoption of Medicare-For-All&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">reductions or limitations on governmental funding at the state or federal level or efforts by healthcare insurance companies to limit payments for products and services&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in manufacturers' pricing, selling, inventory, distribution or supply policies or practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in legislation or regulations governing prescription drug pricing, healthcare services or mandated benefits&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in hospital buying groups or hospital buying practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in distribution or sourcing models for pharmaceutical and medical and surgical products, including an increase in direct and limited distribution&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes to the prescription drug reimbursement formula and related reporting requirements for generic pharmaceuticals under Medicaid&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">continuing consolidation in the healthcare industry, which could give the resulting enterprises greater bargaining power and may increase pressure on prices for our products and services or result in the loss of customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">disruption, damage or lack of access to, or failure of, our or our third-party service providers' information systems, our critical facilities, including our national logistics center, or our distribution networks&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks to our business and information and controls systems in the event that business process improvements, infrastructure modernizations or initiatives to use third-party service providers for key systems and processes are not effectively implemented&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the results, costs, effects or timing of any commercial disputes, government contract compliance matters, patent infringement claims, </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions, government investigations, shareholder lawsuits or other legal proceedings&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">possible losses relating to product liability lawsuits and claims regarding products for which we cannot obtain product liability insurance or for which such insurance may not be adequate to cover our losses, including the product liability lawsuits we are currently defending relating to alleged personal injuries associated with the use of Cordis inferior vena cava filter products&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain adequate intellectual property protections&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the costs, difficulties and uncertainties related to the integration of acquired businesses, including liabilities relating to the operations or activities of such businesses prior to their acquisition, and uncertainties relating to our ability to achieve the anticipated results from acquisitions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the divestiture of the Cordis business, including the risk that the costs associated with exit or disposal activities could ultimately be greater than we currently expect or that we could incur greater stranded costs than expected&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to manage and complete divestitures or other strategic business combination transactions, including our ability to find buyers or other strategic exit opportunities and risks associated with the possibility that we could experience greater dis-synergies than anticipated or otherwise fail to achieve our strategic objectives&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">bankruptcy, insolvency or other credit failure of a customer or supplier that owes us a substantial amount&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to introduce and market new products and our ability to keep pace with advances in technology&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">significant charges to earnings if goodwill or intangible assets become impaired&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to general political, business, industry, regulatory and market conditions&#59; and</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other factors described in the &#8220;Risk Factors&#8221; section of the 2021 Form 10-K.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The words &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;likely,&#8221; and similar expressions generally identify &#8220;forward-looking statements,&#8221; which speak only as of the date the statements were made, and also include statements reflecting future results or guidance, statements of outlook and expense accruals. We undertake no obligation to update or revise any forward-looking statements, except to the extent required by applicable law.</font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>cah-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2425d19b-e3e9-4a9a-b18c-4fd89ecf0bc7,g:620f6444-992f-4a20-8893-967dcaed6c73-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cah="http://www.cardinal.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardinal.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cardinal.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofEarnings" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings">
        <link:definition>1001002 - Statement - Condensed Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1003004 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofShareholdersEquity" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity">
        <link:definition>1004005 - Statement - Condensed Consolidated Statement of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2403401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Divestitures" roleURI="http://www.cardinal.com/role/Divestitures">
        <link:definition>2104102 - Disclosure - Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresTables" roleURI="http://www.cardinal.com/role/DivestituresTables">
        <link:definition>2305301 - Disclosure - Divestitures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDetails" roleURI="http://www.cardinal.com/role/DivestituresDetails">
        <link:definition>2406402 - Disclosure - Divestitures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeverance" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance">
        <link:definition>2107103 - Disclosure - Restructuring and Employee Severance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceTables" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables">
        <link:definition>2308302 - Disclosure - Restructuring and Employee Severance (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails">
        <link:definition>2409403 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails">
        <link:definition>2410404 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceNarrativeDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails">
        <link:definition>2411405 - Disclosure - Restructuring and Employee Severance Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssets" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets">
        <link:definition>2112104 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsTables" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables">
        <link:definition>2313303 - Disclosure - Goodwill and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails">
        <link:definition>2414406 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>2415407 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsNarrativeDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails">
        <link:definition>2416408 - Disclosure - Goodwill and Other Intangible Assets Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowings" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings">
        <link:definition>2117105 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails">
        <link:definition>2418409 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigation" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation">
        <link:definition>2119106 - Disclosure - Commitments, Contingent Liabilities and Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails">
        <link:definition>2420410 - Disclosure - Commitments, Contingent Liabilities and Litigation Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2421411 - Disclosure - Income Taxes Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cardinal.com/role/IncomeTaxes">
        <link:definition>2122107 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.cardinal.com/role/FairValueMeasurements">
        <link:definition>2123108 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables">
        <link:definition>2324304 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2425412 - Disclosure - Fair Value Measurements Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.cardinal.com/role/FinancialInstruments">
        <link:definition>2126109 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables">
        <link:definition>2327305 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>2428413 - Disclosure - Financial Instruments Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails">
        <link:definition>2429414 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.cardinal.com/role/ShareholdersEquity">
        <link:definition>2130110 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://www.cardinal.com/role/ShareholdersEquityTables">
        <link:definition>2331306 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails">
        <link:definition>2432415 - Disclosure - Shareholders' Equity Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2433416 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthInc" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc">
        <link:definition>2134111 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncTables" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables">
        <link:definition>2335307 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails">
        <link:definition>2436417 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails">
        <link:definition>2437418 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.cardinal.com/role/SegmentInformation">
        <link:definition>2138112 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.cardinal.com/role/SegmentInformationTables">
        <link:definition>2339308 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails">
        <link:definition>2440419 - Disclosure - Segment Information Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenuebyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails">
        <link:definition>2441420 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSegmentProfitbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails">
        <link:definition>2442421 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAssetsbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails">
        <link:definition>2443422 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" roleURI="http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails">
        <link:definition>2444423 - Disclosure - Segment Information Disaggregated Revenue Within Reportable Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenuebyGeographicalSegmentsDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails">
        <link:definition>2445424 - Disclosure - Segment Information Revenue by Geographical Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.cardinal.com/role/ShareBasedCompensation">
        <link:definition>2146113 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables">
        <link:definition>2347309 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>2448425 - Disclosure - Share-Based Compensation Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails">
        <link:definition>2449426 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails">
        <link:definition>2450427 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails">
        <link:definition>2451428 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails">
        <link:definition>2452429 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails">
        <link:definition>2453430 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cah_VestingPeriodinyearsforShares" abstract="false" name="VestingPeriodinyearsforShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_PharmaceuticalSegmentAxis" abstract="true" name="PharmaceuticalSegmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_MedicalSegmentDomain" abstract="true" name="MedicalSegmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_A2616NotesMember" abstract="true" name="A2616NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_NuclearPrecisionHealthServicesMember" abstract="true" name="NuclearPrecisionHealthServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_LossContingencyLawsuitsNumber" abstract="false" name="LossContingencyLawsuitsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_MedicaldistributionandproductsMember" abstract="true" name="MedicaldistributionandproductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PharmaceuticalDistributionandSpecialtyMember" abstract="true" name="PharmaceuticalDistributionandSpecialtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PlaintiffTypeDomain" abstract="true" name="PlaintiffTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PharmaceuticalSegmentDomain" abstract="true" name="PharmaceuticalSegmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_Purchaseofavailableforsalesecuritiesandotherinvestments" abstract="false" name="Purchaseofavailableforsalesecuritiesandotherinvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_CareFusionMember" abstract="true" name="CareFusionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_OpioidLitigationAxis" abstract="true" name="OpioidLitigationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_SegmentRevenuebyGeographicTable" abstract="true" name="SegmentRevenuebyGeographicTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_TrademarksAndPatentsMember" abstract="true" name="TrademarksAndPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CordisDivestitureMember" abstract="true" name="CordisDivestitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" abstract="false" name="EstimatedLiabilityForNewYorkOpioidStewardshipAct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_Netproceedstaxwithholdingsfromsharebasedcompensation" abstract="false" name="Netproceedstaxwithholdingsfromsharebasedcompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" abstract="false" name="Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_SegmentRevenuebyGeographicLineItems" abstract="true" name="SegmentRevenuebyGeographicLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_OpioidLitigationDomain" abstract="true" name="OpioidLitigationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_NewYorkOpioidStewardshipActMember" abstract="true" name="NewYorkOpioidStewardshipActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" abstract="true" name="BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" abstract="false" name="Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_MedicalMember" abstract="true" name="MedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_ShortTermCreditFacilitiesMember" abstract="true" name="ShortTermCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" abstract="false" name="ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cah_IndemnificationReceivable" abstract="false" name="IndemnificationReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_DOJInvestigationMember" abstract="true" name="DOJInvestigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_FinalSharesReceivedfromASRProgram" abstract="false" name="FinalSharesReceivedfromASRProgram" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cah_AggregateAnnualAssessment" abstract="false" name="AggregateAnnualAssessment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_CordisDivestitureAxis" abstract="true" name="CordisDivestitureAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_OpioidLawsuitsStateDomain" abstract="true" name="OpioidLawsuitsStateDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_AdditionalStockOptionPlanDataTableTextBlock" abstract="false" name="AdditionalStockOptionPlanDataTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cah_CVSHealthMember" abstract="true" name="CVSHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PrivatePartiesMember" abstract="true" name="PrivatePartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_TaxMatterDomain" abstract="true" name="TaxMatterDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_Numberofsharesexcludedfromcalculationofdilutedshares" abstract="false" name="Numberofsharesexcludedfromcalculationofdilutedshares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cah_CommittedReceivablesSalesFacilityProgramMember" abstract="true" name="CommittedReceivablesSalesFacilityProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PlaintiffTypeAxis" abstract="true" name="PlaintiffTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_ProductLiabilityLawsuitsMember" abstract="true" name="ProductLiabilityLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CardinalHealthAtHomeSolutionsMember" abstract="true" name="CardinalHealthAtHomeSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_LossOnEarlyExtinguishmentOfDebt" abstract="false" name="LossOnEarlyExtinguishmentOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_ClassActionLawsuitsMember" abstract="true" name="ClassActionLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_AlamedaCountyMember" abstract="true" name="AlamedaCountyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_NumberofStateAttorneysGeneralfilinglawsuits" abstract="false" name="NumberofStateAttorneysGeneralfilinglawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_ExercisablePeriodOfPlansInYears" abstract="false" name="ExercisablePeriodOfPlansInYears" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cah_FacilityExitAndOtherCosts" abstract="false" name="FacilityExitAndOtherCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" abstract="false" name="Sharesthatwouldbeantidilutiveasaresultofnetloss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cah_LawsuitTypeAxis" abstract="true" name="LawsuitTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_CordisDivestitureDomain" abstract="true" name="CordisDivestitureDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_TreasuryStockAcquiredShares" abstract="false" name="TreasuryStockAcquiredShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cah_IPRDTrademarksandOtherMember" abstract="true" name="IPRDTrademarksandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_MedicalSegmentAxis" abstract="true" name="MedicalSegmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_TotalOpioidLitigationMember" abstract="true" name="TotalOpioidLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_A2.616Notesdue2022Member" abstract="true" name="A2.616Notesdue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_CarryingAmountofLongTermandotherShortTermBorrowings" abstract="false" name="CarryingAmountofLongTermandotherShortTermBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_CashReclassifiedtoAssetsHeldforSale" abstract="false" name="CashReclassifiedtoAssetsHeldforSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_Amortizationandotheracquisitionrelatedcosts" abstract="false" name="Amortizationandotheracquisitionrelatedcosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_NotesPayableRepurchased" abstract="false" name="NotesPayableRepurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_ProjectCostsOnInvestmentAndOtherSpending" abstract="false" name="ProjectCostsOnInvestmentAndOtherSpending" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_OpioidLawsuitsMember" abstract="true" name="OpioidLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PatientRecoveryBusinessMember" abstract="true" name="PatientRecoveryBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_TaxMatterAxis" abstract="true" name="TaxMatterAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_OtherJurisdictionsMember" abstract="true" name="OtherJurisdictionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_LitigationTypeDomain" abstract="true" name="LitigationTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cah_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>cah-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2425d19b-e3e9-4a9a-b18c-4fd89ecf0bc7,g:620f6444-992f-4a20-8893-967dcaed6c73-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20210930.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_41160c81-b176-4aa5-90d0-210f1d5d2e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_63bade01-0be7-44f3-b7d3-1c454564407b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_41160c81-b176-4aa5-90d0-210f1d5d2e56" xlink:to="loc_us-gaap_Revenues_63bade01-0be7-44f3-b7d3-1c454564407b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e9a4a8eb-c072-4e42-b48f-4bf8d315480f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_41160c81-b176-4aa5-90d0-210f1d5d2e56" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e9a4a8eb-c072-4e42-b48f-4bf8d315480f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_77dc68ff-1d61-44cd-bb1c-1c598bd63eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_ad1b8206-72c7-4229-8ce3-6d835288bbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_77dc68ff-1d61-44cd-bb1c-1c598bd63eb4" xlink:to="loc_us-gaap_GrossProfit_ad1b8206-72c7-4229-8ce3-6d835288bbcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6daf91ea-1a0e-4d03-8006-1f0b5e06575b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_77dc68ff-1d61-44cd-bb1c-1c598bd63eb4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6daf91ea-1a0e-4d03-8006-1f0b5e06575b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_25867f8d-b0e0-460d-89a2-2589fe619cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_77dc68ff-1d61-44cd-bb1c-1c598bd63eb4" xlink:to="loc_us-gaap_RestructuringCharges_25867f8d-b0e0-460d-89a2-2589fe619cc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_70cbc9e5-d14d-4de3-b563-62e1db9a4832" xlink:href="cah-20210930.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_77dc68ff-1d61-44cd-bb1c-1c598bd63eb4" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_70cbc9e5-d14d-4de3-b563-62e1db9a4832" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_5c2a7378-aac2-461f-ba88-864bf891f378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_77dc68ff-1d61-44cd-bb1c-1c598bd63eb4" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_5c2a7378-aac2-461f-ba88-864bf891f378" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_b0c45c86-4a35-4aad-bfbc-e345c4e0f6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_77dc68ff-1d61-44cd-bb1c-1c598bd63eb4" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_b0c45c86-4a35-4aad-bfbc-e345c4e0f6ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_97620aec-5217-442a-9c84-cd099821fa2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e0509272-d46c-4c68-84a7-a27dbb9599df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_97620aec-5217-442a-9c84-cd099821fa2a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e0509272-d46c-4c68-84a7-a27dbb9599df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_42c40e19-44ce-4bdc-95a2-56dc6f8ab6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_97620aec-5217-442a-9c84-cd099821fa2a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_42c40e19-44ce-4bdc-95a2-56dc6f8ab6b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8b3e6994-3158-4082-b275-eefb42f9464f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2d8d78ab-cb81-4160-ae40-f040f35ec629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8b3e6994-3158-4082-b275-eefb42f9464f" xlink:to="loc_us-gaap_ProfitLoss_2d8d78ab-cb81-4160-ae40-f040f35ec629" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5a8b440b-d2d3-4914-88b6-5f1b3ffd8246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8b3e6994-3158-4082-b275-eefb42f9464f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5a8b440b-d2d3-4914-88b6-5f1b3ffd8246" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6143f2da-bc95-448b-9696-d995a8e010e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d4e4e59d-8356-492d-8e09-494e0f219f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6143f2da-bc95-448b-9696-d995a8e010e6" xlink:to="loc_us-gaap_OperatingIncomeLoss_d4e4e59d-8356-492d-8e09-494e0f219f0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_96b6b72e-bd29-40b8-95dc-5315b8d4c7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6143f2da-bc95-448b-9696-d995a8e010e6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_96b6b72e-bd29-40b8-95dc-5315b8d4c7ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8df93f3b-5678-4517-8328-62fbe94248ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6143f2da-bc95-448b-9696-d995a8e010e6" xlink:to="loc_us-gaap_InterestExpense_8df93f3b-5678-4517-8328-62fbe94248ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5da42e8a-d9ad-4aa1-ad1d-e083ce1f78b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6143f2da-bc95-448b-9696-d995a8e010e6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5da42e8a-d9ad-4aa1-ad1d-e083ce1f78b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossOnEarlyExtinguishmentOfDebt_b84c93a7-a8fc-4415-b1bc-80655843dbfc" xlink:href="cah-20210930.xsd#cah_LossOnEarlyExtinguishmentOfDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6143f2da-bc95-448b-9696-d995a8e010e6" xlink:to="loc_cah_LossOnEarlyExtinguishmentOfDebt_b84c93a7-a8fc-4415-b1bc-80655843dbfc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20210930.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8e8a1dd7-d3e2-467d-920b-b6795aac9678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b306b9f2-87f7-4e5b-b7df-bdfb586896d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8e8a1dd7-d3e2-467d-920b-b6795aac9678" xlink:to="loc_us-gaap_ProfitLoss_b306b9f2-87f7-4e5b-b7df-bdfb586896d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_88e73a11-f9fd-4404-b426-b68d9501a204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8e8a1dd7-d3e2-467d-920b-b6795aac9678" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_88e73a11-f9fd-4404-b426-b68d9501a204" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_41f59acb-9f27-43e0-bfb3-252abc5ead04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_acc878b8-68ab-4fb7-8b3a-2e45e8e633e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_41f59acb-9f27-43e0-bfb3-252abc5ead04" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_acc878b8-68ab-4fb7-8b3a-2e45e8e633e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_613f1b4d-c5e7-4d04-9103-8c97b84d3dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_41f59acb-9f27-43e0-bfb3-252abc5ead04" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_613f1b4d-c5e7-4d04-9103-8c97b84d3dcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ce023b2f-7d49-4680-af28-3c4f834d4c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_07a1ecb6-82d4-4773-bcc5-537d9e4d8b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ce023b2f-7d49-4680-af28-3c4f834d4c87" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_07a1ecb6-82d4-4773-bcc5-537d9e4d8b28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3a733e80-3252-4078-9d6a-a552a374c9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ce023b2f-7d49-4680-af28-3c4f834d4c87" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3a733e80-3252-4078-9d6a-a552a374c9fc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20210930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dbeab0df-3a86-424b-a12c-bc2626510228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9c894a7b-2eb4-4cd9-95e6-dcd7a1d10b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dbeab0df-3a86-424b-a12c-bc2626510228" xlink:to="loc_us-gaap_StockholdersEquity_9c894a7b-2eb4-4cd9-95e6-dcd7a1d10b0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a41308a5-0579-4e1e-8c53-ea55d7387e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dbeab0df-3a86-424b-a12c-bc2626510228" xlink:to="loc_us-gaap_MinorityInterest_a41308a5-0579-4e1e-8c53-ea55d7387e8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_de369764-c26f-436d-ad00-214a1cfcb1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4765e245-a105-483b-aab1-18f914540b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_de369764-c26f-436d-ad00-214a1cfcb1c8" xlink:to="loc_us-gaap_LiabilitiesCurrent_4765e245-a105-483b-aab1-18f914540b51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_724a800b-f869-46fc-a567-030112de3e18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_de369764-c26f-436d-ad00-214a1cfcb1c8" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_724a800b-f869-46fc-a567-030112de3e18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_50201bab-db72-4855-90fe-4e66ac140491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_de369764-c26f-436d-ad00-214a1cfcb1c8" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_50201bab-db72-4855-90fe-4e66ac140491" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0a9626dd-e54f-4aeb-90d2-b198d49908be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_de369764-c26f-436d-ad00-214a1cfcb1c8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0a9626dd-e54f-4aeb-90d2-b198d49908be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_99891447-447b-4487-ba1c-ccd1ca8dab31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_068e6b8d-0363-45e1-aea8-538f4829c390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_99891447-447b-4487-ba1c-ccd1ca8dab31" xlink:to="loc_us-gaap_AssetsCurrent_068e6b8d-0363-45e1-aea8-538f4829c390" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d8ea4643-7c0a-4799-ba5a-f851772959a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_99891447-447b-4487-ba1c-ccd1ca8dab31" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d8ea4643-7c0a-4799-ba5a-f851772959a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_9b43e879-8a13-4f35-aa47-67af143e2bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_99891447-447b-4487-ba1c-ccd1ca8dab31" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_9b43e879-8a13-4f35-aa47-67af143e2bcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_29467fff-4c79-4255-a861-5032d75236b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_99891447-447b-4487-ba1c-ccd1ca8dab31" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_29467fff-4c79-4255-a861-5032d75236b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a0dbfad8-6827-45b2-bcc3-580e457dc79d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b08d8a9e-93bd-46fa-bc05-5fb1c7ac132f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a0dbfad8-6827-45b2-bcc3-580e457dc79d" xlink:to="loc_us-gaap_PreferredStockValue_b08d8a9e-93bd-46fa-bc05-5fb1c7ac132f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_072ee19c-11a4-49e4-935e-54157ba6754a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a0dbfad8-6827-45b2-bcc3-580e457dc79d" xlink:to="loc_us-gaap_CommonStockValue_072ee19c-11a4-49e4-935e-54157ba6754a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1a5e9d0d-c48b-449c-8b87-30e18334b0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a0dbfad8-6827-45b2-bcc3-580e457dc79d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1a5e9d0d-c48b-449c-8b87-30e18334b0a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_9741d1b8-174a-4f51-a71a-ba2348d40b19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a0dbfad8-6827-45b2-bcc3-580e457dc79d" xlink:to="loc_us-gaap_TreasuryStockValue_9741d1b8-174a-4f51-a71a-ba2348d40b19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bdfafaf5-1556-428e-a959-bd5a6501427d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a0dbfad8-6827-45b2-bcc3-580e457dc79d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bdfafaf5-1556-428e-a959-bd5a6501427d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f705210b-2ca3-4120-a2af-975673c42901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5df097a3-9e43-4163-ab24-72ef0d58d8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f705210b-2ca3-4120-a2af-975673c42901" xlink:to="loc_us-gaap_AccountsPayableCurrent_5df097a3-9e43-4163-ab24-72ef0d58d8a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_fe67b78c-32ae-4bcf-ae16-cd67421e4456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f705210b-2ca3-4120-a2af-975673c42901" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_fe67b78c-32ae-4bcf-ae16-cd67421e4456" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a05ab6e5-69f8-4c2c-b4e2-37b44ed76d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f705210b-2ca3-4120-a2af-975673c42901" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a05ab6e5-69f8-4c2c-b4e2-37b44ed76d45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_e75304c2-e5e5-48ec-8d93-9738b9f6d331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f705210b-2ca3-4120-a2af-975673c42901" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_e75304c2-e5e5-48ec-8d93-9738b9f6d331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_823516f8-1e0b-48f0-a0f8-6302d284c1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_5f74e954-a15a-4f04-8d5c-65eba39794b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_823516f8-1e0b-48f0-a0f8-6302d284c1ca" xlink:to="loc_us-gaap_ReceivablesNetCurrent_5f74e954-a15a-4f04-8d5c-65eba39794b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_04d892f6-9517-4441-b0cf-7346bad7ce5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_823516f8-1e0b-48f0-a0f8-6302d284c1ca" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_04d892f6-9517-4441-b0cf-7346bad7ce5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_4e83ff03-8094-4eb0-ab34-d6e2ea296034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_823516f8-1e0b-48f0-a0f8-6302d284c1ca" xlink:to="loc_us-gaap_OtherAssetsCurrent_4e83ff03-8094-4eb0-ab34-d6e2ea296034" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ea0e17bc-3646-471b-bc69-c6e8b897a933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_823516f8-1e0b-48f0-a0f8-6302d284c1ca" xlink:to="loc_us-gaap_InventoryNet_ea0e17bc-3646-471b-bc69-c6e8b897a933" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_81d7af9c-4fa8-4484-bace-28b9c63c6967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_823516f8-1e0b-48f0-a0f8-6302d284c1ca" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_81d7af9c-4fa8-4484-bace-28b9c63c6967" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20210930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_405f24d6-ad88-427e-99e3-1b8f26b29dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_523490df-902f-46ca-8948-2c94559d16e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_405f24d6-ad88-427e-99e3-1b8f26b29dab" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_523490df-902f-46ca-8948-2c94559d16e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_02f27e76-359a-4b1e-bbe9-ea6363b3d1fa" xlink:href="cah-20210930.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_405f24d6-ad88-427e-99e3-1b8f26b29dab" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_02f27e76-359a-4b1e-bbe9-ea6363b3d1fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_9b19286c-c75e-453f-a019-462595311546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_405f24d6-ad88-427e-99e3-1b8f26b29dab" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_9b19286c-c75e-453f-a019-462595311546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1411f8a9-7f71-42ce-b2f1-028fdb55f17c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_405f24d6-ad88-427e-99e3-1b8f26b29dab" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1411f8a9-7f71-42ce-b2f1-028fdb55f17c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e2919777-ed03-4300-bb55-474ad11cfac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_448f3899-bd5e-4750-81fd-42823ad141c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e2919777-ed03-4300-bb55-474ad11cfac9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_448f3899-bd5e-4750-81fd-42823ad141c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_efce4e7e-38c0-45ad-98f8-ccb27fc2a893" xlink:href="cah-20210930.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e2919777-ed03-4300-bb55-474ad11cfac9" xlink:to="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_efce4e7e-38c0-45ad-98f8-ccb27fc2a893" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_0f96fba5-d38e-4df1-8a94-7f0882d1c706" xlink:href="cah-20210930.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e2919777-ed03-4300-bb55-474ad11cfac9" xlink:to="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_0f96fba5-d38e-4df1-8a94-7f0882d1c706" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_e13df250-441f-48c2-b286-a98c3079a08c" xlink:href="cah-20210930.xsd#cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e2919777-ed03-4300-bb55-474ad11cfac9" xlink:to="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_e13df250-441f-48c2-b286-a98c3079a08c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a149482-ff61-42d6-a7e2-1774bed9299e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2624ee5b-9e6a-400a-9f46-f39cb7b0f41d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a149482-ff61-42d6-a7e2-1774bed9299e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2624ee5b-9e6a-400a-9f46-f39cb7b0f41d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35a670c8-303b-4f32-a3e9-2c9127c32bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a149482-ff61-42d6-a7e2-1774bed9299e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35a670c8-303b-4f32-a3e9-2c9127c32bac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5dd586c-8acf-42c6-822a-6f4835e4cccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a149482-ff61-42d6-a7e2-1774bed9299e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5dd586c-8acf-42c6-822a-6f4835e4cccf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_7e647ad4-5933-484e-813a-1cbb78204325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a149482-ff61-42d6-a7e2-1774bed9299e" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_7e647ad4-5933-484e-813a-1cbb78204325" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedtoAssetsHeldforSale_5e4ebf8c-7e85-498e-a638-6110146f5d7f" xlink:href="cah-20210930.xsd#cah_CashReclassifiedtoAssetsHeldforSale"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a149482-ff61-42d6-a7e2-1774bed9299e" xlink:to="loc_cah_CashReclassifiedtoAssetsHeldforSale_5e4ebf8c-7e85-498e-a638-6110146f5d7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1898b54-b3a9-41b3-b964-6fc14f0c2bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f0939be4-8f79-4dd8-83e9-9d0d5fe20d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1898b54-b3a9-41b3-b964-6fc14f0c2bb1" xlink:to="loc_us-gaap_ProfitLoss_f0939be4-8f79-4dd8-83e9-9d0d5fe20d6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f1d5fcee-cc1b-4ffc-9b0a-7b697df0ef87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1898b54-b3a9-41b3-b964-6fc14f0c2bb1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f1d5fcee-cc1b-4ffc-9b0a-7b697df0ef87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_a538cb4c-ea7f-4beb-a6ae-ae400460232b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1898b54-b3a9-41b3-b964-6fc14f0c2bb1" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_a538cb4c-ea7f-4beb-a6ae-ae400460232b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4faad4a0-8059-4181-86c3-68ea828926d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1898b54-b3a9-41b3-b964-6fc14f0c2bb1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4faad4a0-8059-4181-86c3-68ea828926d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4f4972d9-33ee-41f0-ad80-d7477cd483a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1898b54-b3a9-41b3-b964-6fc14f0c2bb1" xlink:to="loc_us-gaap_ShareBasedCompensation_4f4972d9-33ee-41f0-ad80-d7477cd483a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_5a2b909a-0f39-49d8-ac7f-63e23e59525e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1898b54-b3a9-41b3-b964-6fc14f0c2bb1" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_5a2b909a-0f39-49d8-ac7f-63e23e59525e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_db0ce8e3-92b9-4750-9e2f-202e0bdc246b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1898b54-b3a9-41b3-b964-6fc14f0c2bb1" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_db0ce8e3-92b9-4750-9e2f-202e0bdc246b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f5cf12e9-1987-49eb-a20c-52e0e1f65005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1898b54-b3a9-41b3-b964-6fc14f0c2bb1" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f5cf12e9-1987-49eb-a20c-52e0e1f65005" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eb053272-c825-44cb-a61a-ebd9e9b7c0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1898b54-b3a9-41b3-b964-6fc14f0c2bb1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eb053272-c825-44cb-a61a-ebd9e9b7c0ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_f64c8a2a-ba8d-4178-9444-8be6046b6c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1898b54-b3a9-41b3-b964-6fc14f0c2bb1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_f64c8a2a-ba8d-4178-9444-8be6046b6c97" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_fca1d1a4-f903-4f95-871e-ec8eab47fae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_6d6769cb-4075-4a28-ae08-4e8fd63a8a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_fca1d1a4-f903-4f95-871e-ec8eab47fae3" xlink:to="loc_us-gaap_SeveranceCosts1_6d6769cb-4075-4a28-ae08-4e8fd63a8a85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_42f1b9f2-12c7-45c3-bcda-3c19b67ab430" xlink:href="cah-20210930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_fca1d1a4-f903-4f95-871e-ec8eab47fae3" xlink:to="loc_cah_FacilityExitAndOtherCosts_42f1b9f2-12c7-45c3-bcda-3c19b67ab430" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c24eeb7a-b1be-45d5-81c0-469183c9ff53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_cc1cc650-d65d-485d-ab3b-d8f7b4245102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c24eeb7a-b1be-45d5-81c0-469183c9ff53" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_cc1cc650-d65d-485d-ab3b-d8f7b4245102" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_2e6dceea-b80c-4bb3-9387-06f04c0148dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c24eeb7a-b1be-45d5-81c0-469183c9ff53" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_2e6dceea-b80c-4bb3-9387-06f04c0148dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1fba93c9-9f16-465d-b16d-39479f93b26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f96c392a-4c41-4188-9026-00ffa8532ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1fba93c9-9f16-465d-b16d-39479f93b26d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f96c392a-4c41-4188-9026-00ffa8532ff3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_92552b9b-4774-47e3-ad53-2eb7aefe6203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1fba93c9-9f16-465d-b16d-39479f93b26d" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_92552b9b-4774-47e3-ad53-2eb7aefe6203" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>cah-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2425d19b-e3e9-4a9a-b18c-4fd89ecf0bc7,g:620f6444-992f-4a20-8893-967dcaed6c73-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" xlink:type="simple" xlink:href="cah-20210930.xsd#CondensedConsolidatedStatementofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" xlink:type="extended" id="if37e58f6183b4ceb8c042b01f9df23fa_CondensedConsolidatedStatementofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_475ad43a-5713-454c-8e4b-5ae1c55ed64a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_CommonStockSharesIssued_475ad43a-5713-454c-8e4b-5ae1c55ed64a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_984d6519-f427-4497-95b6-8a1a5188cd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_984d6519-f427-4497-95b6-8a1a5188cd4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_f8a55ad6-2107-4e55-82be-460b4278c6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_TreasuryStockShares_f8a55ad6-2107-4e55-82be-460b4278c6c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_efb2b240-8d39-4369-b749-04f7a54c5500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_TreasuryStockValue_efb2b240-8d39-4369-b749-04f7a54c5500" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d6debebb-8aa9-4267-91d9-01c1e5cdb825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_NetIncomeLoss_d6debebb-8aa9-4267-91d9-01c1e5cdb825" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_003b9a86-8fb1-459d-90b5-efcddf1c2925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_ProfitLoss_003b9a86-8fb1-459d-90b5-efcddf1c2925" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_312f94ed-5529-48e8-9a60-8a2ed3f73ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_312f94ed-5529-48e8-9a60-8a2ed3f73ac7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6493b5f6-9232-4141-8ad7-a6171721a15d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6493b5f6-9232-4141-8ad7-a6171721a15d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c9265f62-b0e8-43cb-aabc-15731d758d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c9265f62-b0e8-43cb-aabc-15731d758d8e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_b84504a6-084b-43ac-94fd-e84a549ba32a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_b84504a6-084b-43ac-94fd-e84a549ba32a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_18c3742e-16ba-4649-a947-28e4de08c146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_18c3742e-16ba-4649-a947-28e4de08c146" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_2aafeb15-8a79-43e3-808c-65a0e776a346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_Dividends_2aafeb15-8a79-43e3-808c-65a0e776a346" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_60991d95-08fe-4ba4-8967-4f7a94d549b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_StockholdersEquityOther_60991d95-08fe-4ba4-8967-4f7a94d549b4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cd0a4e69-ee5a-4323-986f-0961dd6b97ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a04b1d9e-9be3-4824-960b-912b7a4afc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_25d1802f-4cdf-4c96-bd0e-3730379b27b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_891e6a61-32c4-4f87-ae18-90b8167cf0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_7703b549-fc3b-4d78-98db-68284a99bef1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_7703b549-fc3b-4d78-98db-68284a99bef1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f43dae98-17ff-406b-92d3-08b528e47fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_7703b549-fc3b-4d78-98db-68284a99bef1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f43dae98-17ff-406b-92d3-08b528e47fc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f43dae98-17ff-406b-92d3-08b528e47fc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f43dae98-17ff-406b-92d3-08b528e47fc5" xlink:to="loc_us-gaap_EquityComponentDomain_f43dae98-17ff-406b-92d3-08b528e47fc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6f8696f6-2084-46e8-81f3-14c94e88395b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f43dae98-17ff-406b-92d3-08b528e47fc5" xlink:to="loc_us-gaap_EquityComponentDomain_6f8696f6-2084-46e8-81f3-14c94e88395b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cf17861d-591b-43af-b7f8-9c3a8b54d4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6f8696f6-2084-46e8-81f3-14c94e88395b" xlink:to="loc_us-gaap_CommonStockMember_cf17861d-591b-43af-b7f8-9c3a8b54d4d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3f090cc9-fd3c-476f-ace4-b34244ffe699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6f8696f6-2084-46e8-81f3-14c94e88395b" xlink:to="loc_us-gaap_RetainedEarningsMember_3f090cc9-fd3c-476f-ace4-b34244ffe699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_8880b6db-e7c7-46bc-83fb-12ea4af36f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6f8696f6-2084-46e8-81f3-14c94e88395b" xlink:to="loc_us-gaap_TreasuryStockMember_8880b6db-e7c7-46bc-83fb-12ea4af36f63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8316231f-3f9c-4daa-9773-1be26d632f11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6f8696f6-2084-46e8-81f3-14c94e88395b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8316231f-3f9c-4daa-9773-1be26d632f11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_c0ef2c8b-a9b8-4076-93d8-de449016699b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6f8696f6-2084-46e8-81f3-14c94e88395b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_c0ef2c8b-a9b8-4076-93d8-de449016699b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DivestituresDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#DivestituresDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/DivestituresDetails" xlink:type="extended" id="i0baf06f2c86c4213b2de4e5b75e66fbe_DivestituresDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_356d4757-6cb4-42c9-9ba2-6c6ef94c9235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_e15f1e9b-047b-4663-b1c1-31239c3385e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_356d4757-6cb4-42c9-9ba2-6c6ef94c9235" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_e15f1e9b-047b-4663-b1c1-31239c3385e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_ce116b7e-b057-480a-a6eb-66c5c8ea1549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_356d4757-6cb4-42c9-9ba2-6c6ef94c9235" xlink:to="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_ce116b7e-b057-480a-a6eb-66c5c8ea1549" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_7b9329e7-d1c3-400b-ae49-30b202c8fc36" xlink:href="cah-20210930.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_ce116b7e-b057-480a-a6eb-66c5c8ea1549" xlink:to="loc_cah_CordisDivestitureAxis_7b9329e7-d1c3-400b-ae49-30b202c8fc36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_7b9329e7-d1c3-400b-ae49-30b202c8fc36_default" xlink:href="cah-20210930.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_7b9329e7-d1c3-400b-ae49-30b202c8fc36" xlink:to="loc_cah_CordisDivestitureDomain_7b9329e7-d1c3-400b-ae49-30b202c8fc36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_80fa4217-fe90-4520-8260-ae7390adb6f7" xlink:href="cah-20210930.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_7b9329e7-d1c3-400b-ae49-30b202c8fc36" xlink:to="loc_cah_CordisDivestitureDomain_80fa4217-fe90-4520-8260-ae7390adb6f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_e64bc86a-46ba-4cd5-b7f7-5bdf125e7159" xlink:href="cah-20210930.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_80fa4217-fe90-4520-8260-ae7390adb6f7" xlink:to="loc_cah_CordisDivestitureMember_e64bc86a-46ba-4cd5-b7f7-5bdf125e7159" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended" id="i2edf1c2354b5426e9ed772865179b278_RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_f0f08701-7bc4-4954-8f41-2ca391bd3875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_a0bf3441-ec10-4547-9b7b-e1ae4d2a9ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f0f08701-7bc4-4954-8f41-2ca391bd3875" xlink:to="loc_us-gaap_RestructuringReserveRollForward_a0bf3441-ec10-4547-9b7b-e1ae4d2a9ba0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_dd86f5b4-124d-4444-8b6d-062beb2d52b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_a0bf3441-ec10-4547-9b7b-e1ae4d2a9ba0" xlink:to="loc_us-gaap_RestructuringReserve_dd86f5b4-124d-4444-8b6d-062beb2d52b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_20c692be-30d7-4550-8049-60eaf8330b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_a0bf3441-ec10-4547-9b7b-e1ae4d2a9ba0" xlink:to="loc_us-gaap_RestructuringCosts_20c692be-30d7-4550-8049-60eaf8330b8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_24574f68-5a62-4228-90ae-d13b059a8d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_a0bf3441-ec10-4547-9b7b-e1ae4d2a9ba0" xlink:to="loc_us-gaap_PaymentsForRestructuring_24574f68-5a62-4228-90ae-d13b059a8d22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_a0fa3f00-65e1-4ecd-b040-fd170b4babc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_99082d12-392e-405e-bb7c-230fea39e7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f0f08701-7bc4-4954-8f41-2ca391bd3875" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_99082d12-392e-405e-bb7c-230fea39e7a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_d028fd83-85ac-488d-834c-2ed92a60186b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_99082d12-392e-405e-bb7c-230fea39e7a9" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_d028fd83-85ac-488d-834c-2ed92a60186b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d028fd83-85ac-488d-834c-2ed92a60186b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d028fd83-85ac-488d-834c-2ed92a60186b" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d028fd83-85ac-488d-834c-2ed92a60186b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_48c5114c-2961-479e-8fef-925af3aec3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d028fd83-85ac-488d-834c-2ed92a60186b" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_48c5114c-2961-479e-8fef-925af3aec3b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_0bcf4a94-4b14-4cd2-83e6-a638e0fbd082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_48c5114c-2961-479e-8fef-925af3aec3b1" xlink:to="loc_us-gaap_EmployeeSeveranceMember_0bcf4a94-4b14-4cd2-83e6-a638e0fbd082" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_960cb93e-46d3-4609-829b-fdbbec16cf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_48c5114c-2961-479e-8fef-925af3aec3b1" xlink:to="loc_us-gaap_FacilityClosingMember_960cb93e-46d3-4609-829b-fdbbec16cf2a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#RestructuringandEmployeeSeveranceNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" xlink:type="extended" id="i2527512198704916b63d2c49f887314f_RestructuringandEmployeeSeveranceNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_641f2b02-91e7-4ba2-bd45-e2b1f52aaeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_1789c4ba-185c-41b3-8e49-3213abc1ec7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_641f2b02-91e7-4ba2-bd45-e2b1f52aaeb7" xlink:to="loc_us-gaap_SeveranceCosts1_1789c4ba-185c-41b3-8e49-3213abc1ec7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_a55711e2-984a-4a7a-9ea2-6c68e633e500" xlink:href="cah-20210930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_641f2b02-91e7-4ba2-bd45-e2b1f52aaeb7" xlink:to="loc_cah_FacilityExitAndOtherCosts_a55711e2-984a-4a7a-9ea2-6c68e633e500" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e672459c-cc77-49d8-b5dd-0d2cafb36a60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_641f2b02-91e7-4ba2-bd45-e2b1f52aaeb7" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e672459c-cc77-49d8-b5dd-0d2cafb36a60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_f1c8d19d-066c-4ffd-9977-8e4f1e83b705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e672459c-cc77-49d8-b5dd-0d2cafb36a60" xlink:to="loc_us-gaap_RestructuringPlanAxis_f1c8d19d-066c-4ffd-9977-8e4f1e83b705" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_f1c8d19d-066c-4ffd-9977-8e4f1e83b705_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_f1c8d19d-066c-4ffd-9977-8e4f1e83b705" xlink:to="loc_us-gaap_RestructuringPlanDomain_f1c8d19d-066c-4ffd-9977-8e4f1e83b705_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_b8dd3482-fa04-4f72-9acf-358641cf98b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_f1c8d19d-066c-4ffd-9977-8e4f1e83b705" xlink:to="loc_us-gaap_RestructuringPlanDomain_b8dd3482-fa04-4f72-9acf-358641cf98b6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended" id="i66d7f7ddb36946bd91616e30f82e4bad_GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_bbf009ce-bb49-4ca6-9fd3-7632ab3f77e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTransfers_8da00011-f244-4504-bb64-5629b790c103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillTransfers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_bbf009ce-bb49-4ca6-9fd3-7632ab3f77e1" xlink:to="loc_us-gaap_GoodwillTransfers_8da00011-f244-4504-bb64-5629b790c103" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_3b2d6e09-1d04-4368-b7a0-0178ae000cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_bbf009ce-bb49-4ca6-9fd3-7632ab3f77e1" xlink:to="loc_us-gaap_GoodwillRollForward_3b2d6e09-1d04-4368-b7a0-0178ae000cf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_23e56432-cf4d-430d-a5fc-4f7cd6c2496e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_3b2d6e09-1d04-4368-b7a0-0178ae000cf5" xlink:to="loc_us-gaap_Goodwill_23e56432-cf4d-430d-a5fc-4f7cd6c2496e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_244163c9-8ea0-487e-87b8-f00529b49a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_3b2d6e09-1d04-4368-b7a0-0178ae000cf5" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_244163c9-8ea0-487e-87b8-f00529b49a1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7951d38d-4905-4916-b57b-d66a7c39fd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_7d67d38c-48c9-4670-bcd9-49e78b9f8c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_bbf009ce-bb49-4ca6-9fd3-7632ab3f77e1" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_7d67d38c-48c9-4670-bcd9-49e78b9f8c29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7c72501d-3bfe-4580-a76e-8679ad17ad08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7d67d38c-48c9-4670-bcd9-49e78b9f8c29" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7c72501d-3bfe-4580-a76e-8679ad17ad08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7c72501d-3bfe-4580-a76e-8679ad17ad08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7c72501d-3bfe-4580-a76e-8679ad17ad08" xlink:to="loc_us-gaap_SegmentDomain_7c72501d-3bfe-4580-a76e-8679ad17ad08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e121af41-aafd-4592-86d3-f9c60f92e66c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7c72501d-3bfe-4580-a76e-8679ad17ad08" xlink:to="loc_us-gaap_SegmentDomain_e121af41-aafd-4592-86d3-f9c60f92e66c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_b7af1062-f4d0-4a0a-bfc3-cc40dd0bd19c" xlink:href="cah-20210930.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e121af41-aafd-4592-86d3-f9c60f92e66c" xlink:to="loc_cah_PharmaceuticalMember_b7af1062-f4d0-4a0a-bfc3-cc40dd0bd19c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_c5cf89b8-222a-4f93-9968-77fec2dd3166" xlink:href="cah-20210930.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e121af41-aafd-4592-86d3-f9c60f92e66c" xlink:to="loc_cah_MedicalMember_c5cf89b8-222a-4f93-9968-77fec2dd3166" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i20185223f91e4c329bfc8f12d85b998d_GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6c35fb98-dfcc-4698-a79b-6c2e4cc96128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e6fa2191-a1bf-46ad-8ff0-caf58590d5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6c35fb98-dfcc-4698-a79b-6c2e4cc96128" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e6fa2191-a1bf-46ad-8ff0-caf58590d5f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d23cfcf0-d97f-4f32-bf38-8e98a1f988fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6c35fb98-dfcc-4698-a79b-6c2e4cc96128" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d23cfcf0-d97f-4f32-bf38-8e98a1f988fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_669444bc-5d14-48ad-9286-91794dc4987b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d23cfcf0-d97f-4f32-bf38-8e98a1f988fd" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_669444bc-5d14-48ad-9286-91794dc4987b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_669444bc-5d14-48ad-9286-91794dc4987b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_669444bc-5d14-48ad-9286-91794dc4987b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_669444bc-5d14-48ad-9286-91794dc4987b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1ba060d7-3fbf-47e2-9d02-e321fe2eb545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_669444bc-5d14-48ad-9286-91794dc4987b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1ba060d7-3fbf-47e2-9d02-e321fe2eb545" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_575f03b7-2516-4a06-8543-a7eda9aac62b" xlink:href="cah-20210930.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1ba060d7-3fbf-47e2-9d02-e321fe2eb545" xlink:to="loc_cah_IPRDTrademarksandOtherMember_575f03b7-2516-4a06-8543-a7eda9aac62b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_086dc99f-4448-43a0-9400-15558411daf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c320db6c-042d-4c58-94a9-05d4eeb88cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_086dc99f-4448-43a0-9400-15558411daf3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c320db6c-042d-4c58-94a9-05d4eeb88cd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_46826dc1-94ce-4e24-8177-7d3de2c4309e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_086dc99f-4448-43a0-9400-15558411daf3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_46826dc1-94ce-4e24-8177-7d3de2c4309e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_93a12b8c-1620-4831-94c6-618644242947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_086dc99f-4448-43a0-9400-15558411daf3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_93a12b8c-1620-4831-94c6-618644242947" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_cbb4ffea-ffb5-4329-8701-506def8c789b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_086dc99f-4448-43a0-9400-15558411daf3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_cbb4ffea-ffb5-4329-8701-506def8c789b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e5452355-5dc3-4022-bdcf-cd75822f339a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_086dc99f-4448-43a0-9400-15558411daf3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e5452355-5dc3-4022-bdcf-cd75822f339a" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7b10788-c4ef-469a-838c-0000ad686f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e5452355-5dc3-4022-bdcf-cd75822f339a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7b10788-c4ef-469a-838c-0000ad686f26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e7b10788-c4ef-469a-838c-0000ad686f26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7b10788-c4ef-469a-838c-0000ad686f26" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e7b10788-c4ef-469a-838c-0000ad686f26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc8d5bb8-7b1d-48fd-b172-5787de7946e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7b10788-c4ef-469a-838c-0000ad686f26" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc8d5bb8-7b1d-48fd-b172-5787de7946e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_6076adcc-33e5-4fdf-a0ad-23b1680a16a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc8d5bb8-7b1d-48fd-b172-5787de7946e7" xlink:to="loc_us-gaap_CustomerRelationshipsMember_6076adcc-33e5-4fdf-a0ad-23b1680a16a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_3075c624-cd79-4ee6-b420-a622c0097e7c" xlink:href="cah-20210930.xsd#cah_TrademarksAndPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc8d5bb8-7b1d-48fd-b172-5787de7946e7" xlink:to="loc_cah_TrademarksAndPatentsMember_3075c624-cd79-4ee6-b420-a622c0097e7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_7fe968b7-56dc-49f6-86b0-73bf8aa06d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc8d5bb8-7b1d-48fd-b172-5787de7946e7" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_7fe968b7-56dc-49f6-86b0-73bf8aa06d3c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" xlink:type="extended" id="i07d6806ea36f461598714b3ffc5388f0_LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fba3421e-bf54-43e0-8031-a5612301305e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_958ae970-1d5f-465e-9869-ff8d78c00a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba3421e-bf54-43e0-8031-a5612301305e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_958ae970-1d5f-465e-9869-ff8d78c00a8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_cfb8afdf-a8ea-4047-b397-90b4d36136f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba3421e-bf54-43e0-8031-a5612301305e" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_cfb8afdf-a8ea-4047-b397-90b4d36136f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_52f198ed-0007-4efe-8a2f-cdedf7fabf27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba3421e-bf54-43e0-8031-a5612301305e" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_52f198ed-0007-4efe-8a2f-cdedf7fabf27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_01455ca4-7db7-446b-a59d-f68c6cdabe81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba3421e-bf54-43e0-8031-a5612301305e" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_01455ca4-7db7-446b-a59d-f68c6cdabe81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NotesPayableRepurchased_7a2be964-d20e-4fd4-af25-b13fe35b0abb" xlink:href="cah-20210930.xsd#cah_NotesPayableRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba3421e-bf54-43e0-8031-a5612301305e" xlink:to="loc_cah_NotesPayableRepurchased_7a2be964-d20e-4fd4-af25-b13fe35b0abb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_60c88c7e-e700-49bf-bc2f-d25fe9539b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba3421e-bf54-43e0-8031-a5612301305e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_60c88c7e-e700-49bf-bc2f-d25fe9539b4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_316a6bd4-8f1a-42a6-a09a-bb10f1d0e026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba3421e-bf54-43e0-8031-a5612301305e" xlink:to="loc_us-gaap_OtherShortTermBorrowings_316a6bd4-8f1a-42a6-a09a-bb10f1d0e026" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_11b9520d-438b-409a-864d-29e55fea7b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba3421e-bf54-43e0-8031-a5612301305e" xlink:to="loc_us-gaap_DebtInstrumentTable_11b9520d-438b-409a-864d-29e55fea7b4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_d4d6507c-cb2d-4d60-b814-9c5c4601d866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_11b9520d-438b-409a-864d-29e55fea7b4c" xlink:to="loc_us-gaap_CreditFacilityAxis_d4d6507c-cb2d-4d60-b814-9c5c4601d866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d4d6507c-cb2d-4d60-b814-9c5c4601d866_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_d4d6507c-cb2d-4d60-b814-9c5c4601d866" xlink:to="loc_us-gaap_CreditFacilityDomain_d4d6507c-cb2d-4d60-b814-9c5c4601d866_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ee3aa9f7-39f3-4ae8-82ee-2361f7ad1cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_d4d6507c-cb2d-4d60-b814-9c5c4601d866" xlink:to="loc_us-gaap_CreditFacilityDomain_ee3aa9f7-39f3-4ae8-82ee-2361f7ad1cb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d48235ea-c04b-4e4e-a523-58bea75b9834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_ee3aa9f7-39f3-4ae8-82ee-2361f7ad1cb8" xlink:to="loc_us-gaap_CommercialPaperMember_d48235ea-c04b-4e4e-a523-58bea75b9834" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_46f452b9-d562-4542-8515-2b3816de3aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_ee3aa9f7-39f3-4ae8-82ee-2361f7ad1cb8" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_46f452b9-d562-4542-8515-2b3816de3aaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_4aa73606-ef0b-45e0-814e-e485bb4ed64e" xlink:href="cah-20210930.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_ee3aa9f7-39f3-4ae8-82ee-2361f7ad1cb8" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_4aa73606-ef0b-45e0-814e-e485bb4ed64e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_3507dbe2-3172-4ef3-a312-3f09bf13758a" xlink:href="cah-20210930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_ShortTermCreditFacilitiesMember_4aa73606-ef0b-45e0-814e-e485bb4ed64e" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_3507dbe2-3172-4ef3-a312-3f09bf13758a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_aa6daa9b-c0f8-43dc-a8ac-3d6955a95264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_11b9520d-438b-409a-864d-29e55fea7b4c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_aa6daa9b-c0f8-43dc-a8ac-3d6955a95264" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_aa6daa9b-c0f8-43dc-a8ac-3d6955a95264_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_aa6daa9b-c0f8-43dc-a8ac-3d6955a95264" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_aa6daa9b-c0f8-43dc-a8ac-3d6955a95264_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_31ae0cc4-701e-4d00-8151-7cce10ea0101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_aa6daa9b-c0f8-43dc-a8ac-3d6955a95264" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_31ae0cc4-701e-4d00-8151-7cce10ea0101" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ba1585ee-ba9f-4c91-a296-5cf429ad6565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_11b9520d-438b-409a-864d-29e55fea7b4c" xlink:to="loc_us-gaap_DebtInstrumentAxis_ba1585ee-ba9f-4c91-a296-5cf429ad6565" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ba1585ee-ba9f-4c91-a296-5cf429ad6565_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba1585ee-ba9f-4c91-a296-5cf429ad6565" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ba1585ee-ba9f-4c91-a296-5cf429ad6565_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_07d1c98d-83c1-4a8a-b24e-4cf921983f67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba1585ee-ba9f-4c91-a296-5cf429ad6565" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_07d1c98d-83c1-4a8a-b24e-4cf921983f67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_831c29e8-8760-420f-9212-735f7e69a7a1" xlink:href="cah-20210930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07d1c98d-83c1-4a8a-b24e-4cf921983f67" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_831c29e8-8760-420f-9212-735f7e69a7a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_53a18932-3c1b-477e-bbce-90dffedcd98f" xlink:href="cah-20210930.xsd#cah_A2.616Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07d1c98d-83c1-4a8a-b24e-4cf921983f67" xlink:to="loc_cah_A2.616Notesdue2022Member_53a18932-3c1b-477e-bbce-90dffedcd98f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2616NotesMember_0b3eba46-8371-49ac-abc0-03de88beb0c6" xlink:href="cah-20210930.xsd#cah_A2616NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07d1c98d-83c1-4a8a-b24e-4cf921983f67" xlink:to="loc_cah_A2616NotesMember_0b3eba46-8371-49ac-abc0-03de88beb0c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_29cce70c-8dda-4677-ad7e-16e238c31ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_11b9520d-438b-409a-864d-29e55fea7b4c" xlink:to="loc_us-gaap_VariableRateAxis_29cce70c-8dda-4677-ad7e-16e238c31ea3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_29cce70c-8dda-4677-ad7e-16e238c31ea3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_29cce70c-8dda-4677-ad7e-16e238c31ea3" xlink:to="loc_us-gaap_VariableRateDomain_29cce70c-8dda-4677-ad7e-16e238c31ea3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a9ad3ceb-a60b-4ec0-96b2-c34284e41291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_29cce70c-8dda-4677-ad7e-16e238c31ea3" xlink:to="loc_us-gaap_VariableRateDomain_a9ad3ceb-a60b-4ec0-96b2-c34284e41291" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_679d377c-b342-4aac-9df0-0093efa87f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_11b9520d-438b-409a-864d-29e55fea7b4c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_679d377c-b342-4aac-9df0-0093efa87f7d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_679d377c-b342-4aac-9df0-0093efa87f7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_679d377c-b342-4aac-9df0-0093efa87f7d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_679d377c-b342-4aac-9df0-0093efa87f7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b00e9cd2-a9a6-4b4a-99ec-a422d587d058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_679d377c-b342-4aac-9df0-0093efa87f7d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b00e9cd2-a9a6-4b4a-99ec-a422d587d058" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d0658f9-fe70-48f3-95e1-c82aa4e48b94" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_11b9520d-438b-409a-864d-29e55fea7b4c" xlink:to="loc_srt_RangeAxis_5d0658f9-fe70-48f3-95e1-c82aa4e48b94" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d0658f9-fe70-48f3-95e1-c82aa4e48b94_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5d0658f9-fe70-48f3-95e1-c82aa4e48b94" xlink:to="loc_srt_RangeMember_5d0658f9-fe70-48f3-95e1-c82aa4e48b94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_63feb887-e1cc-46f7-8aed-b7c7a66440f7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5d0658f9-fe70-48f3-95e1-c82aa4e48b94" xlink:to="loc_srt_RangeMember_63feb887-e1cc-46f7-8aed-b7c7a66440f7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" xlink:type="extended" id="id99767066ea64870b4400b6ae754a0f5_CommitmentsContingentLiabilitiesandLitigationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_f7d9f020-fe80-42c0-8db0-8c629b27577e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_f7d9f020-fe80-42c0-8db0-8c629b27577e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_97185938-7157-48b6-8667-00282172ce3e" xlink:href="cah-20210930.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_cah_LossContingencyLawsuitsNumber_97185938-7157-48b6-8667-00282172ce3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_769ffa59-98c0-4caa-a5a4-85024aced76e" xlink:href="cah-20210930.xsd#cah_NumberofStateAttorneysGeneralfilinglawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_769ffa59-98c0-4caa-a5a4-85024aced76e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_2b16bcac-4572-4b05-8162-63eb805f2cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_us-gaap_LitigationReserve_2b16bcac-4572-4b05-8162-63eb805f2cb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2ef88acd-3aae-4d9f-ba4c-8e0d0d024343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2ef88acd-3aae-4d9f-ba4c-8e0d0d024343" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_a1dca98d-d7d9-4688-8b77-b816b43ea55c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_a1dca98d-d7d9-4688-8b77-b816b43ea55c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_52e5d59f-8deb-46ba-a40c-3a606b90c82a" xlink:href="cah-20210930.xsd#cah_AggregateAnnualAssessment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_cah_AggregateAnnualAssessment_52e5d59f-8deb-46ba-a40c-3a606b90c82a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_42dee06f-a366-4c94-b000-e6600f56d72f" xlink:href="cah-20210930.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_42dee06f-a366-4c94-b000-e6600f56d72f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_169832fa-6c7d-44a7-b924-81acc1b5748b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_169832fa-6c7d-44a7-b924-81acc1b5748b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_2dddafa4-a133-479c-b319-f67c85c8b8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_us-gaap_LitigationSettlementExpense_2dddafa4-a133-479c-b319-f67c85c8b8b5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_d75d8f11-c220-42f6-8a4e-69ac22b40fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_d75d8f11-c220-42f6-8a4e-69ac22b40fec" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_e3adfdaa-7c7f-4aea-a290-cd80415995bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_e3adfdaa-7c7f-4aea-a290-cd80415995bd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_57406788-c99e-4e94-9abf-5e0c4d01fd84" xlink:href="cah-20210930.xsd#cah_LawsuitTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_cah_LawsuitTypeAxis_57406788-c99e-4e94-9abf-5e0c4d01fd84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LitigationTypeDomain_57406788-c99e-4e94-9abf-5e0c4d01fd84_default" xlink:href="cah-20210930.xsd#cah_LitigationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_LawsuitTypeAxis_57406788-c99e-4e94-9abf-5e0c4d01fd84" xlink:to="loc_cah_LitigationTypeDomain_57406788-c99e-4e94-9abf-5e0c4d01fd84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LitigationTypeDomain_37180516-67c1-4ae2-9db3-fd1430f65aa8" xlink:href="cah-20210930.xsd#cah_LitigationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_LawsuitTypeAxis_57406788-c99e-4e94-9abf-5e0c4d01fd84" xlink:to="loc_cah_LitigationTypeDomain_37180516-67c1-4ae2-9db3-fd1430f65aa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_3be95895-f926-4902-953d-eec41a7f012b" xlink:href="cah-20210930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LitigationTypeDomain_37180516-67c1-4ae2-9db3-fd1430f65aa8" xlink:to="loc_cah_ClassActionLawsuitsMember_3be95895-f926-4902-953d-eec41a7f012b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_a21d34c7-0476-446d-8941-a86f356a6702" xlink:href="cah-20210930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LitigationTypeDomain_37180516-67c1-4ae2-9db3-fd1430f65aa8" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_a21d34c7-0476-446d-8941-a86f356a6702" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_f33eda1b-fac2-4d80-8ca3-14c458a19d7e" xlink:href="cah-20210930.xsd#cah_PlaintiffTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_cah_PlaintiffTypeAxis_f33eda1b-fac2-4d80-8ca3-14c458a19d7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_f33eda1b-fac2-4d80-8ca3-14c458a19d7e_default" xlink:href="cah-20210930.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_PlaintiffTypeAxis_f33eda1b-fac2-4d80-8ca3-14c458a19d7e" xlink:to="loc_cah_PlaintiffTypeDomain_f33eda1b-fac2-4d80-8ca3-14c458a19d7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_845b4181-63ad-4497-87b5-c0a3a5002077" xlink:href="cah-20210930.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_PlaintiffTypeAxis_f33eda1b-fac2-4d80-8ca3-14c458a19d7e" xlink:to="loc_cah_PlaintiffTypeDomain_845b4181-63ad-4497-87b5-c0a3a5002077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_c5b829f2-415b-49d5-8b9e-43407a70eabd" xlink:href="cah-20210930.xsd#cah_PrivatePartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_PlaintiffTypeDomain_845b4181-63ad-4497-87b5-c0a3a5002077" xlink:to="loc_cah_PrivatePartiesMember_c5b829f2-415b-49d5-8b9e-43407a70eabd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_14812f5c-d9bc-4799-8cd3-c09122f7d629" xlink:href="cah-20210930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_PlaintiffTypeDomain_845b4181-63ad-4497-87b5-c0a3a5002077" xlink:to="loc_cah_ClassActionLawsuitsMember_14812f5c-d9bc-4799-8cd3-c09122f7d629" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_73b7e4a6-81f0-424a-b991-3c7c99fa894b" xlink:href="cah-20210930.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_cah_OpioidLitigationAxis_73b7e4a6-81f0-424a-b991-3c7c99fa894b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_73b7e4a6-81f0-424a-b991-3c7c99fa894b_default" xlink:href="cah-20210930.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_73b7e4a6-81f0-424a-b991-3c7c99fa894b" xlink:to="loc_cah_OpioidLitigationDomain_73b7e4a6-81f0-424a-b991-3c7c99fa894b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_b33f79d5-e921-40a5-861f-168032f9e00a" xlink:href="cah-20210930.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_73b7e4a6-81f0-424a-b991-3c7c99fa894b" xlink:to="loc_cah_OpioidLitigationDomain_b33f79d5-e921-40a5-861f-168032f9e00a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_3f603880-ca4d-4686-a3ca-da0940626086" xlink:href="cah-20210930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_b33f79d5-e921-40a5-861f-168032f9e00a" xlink:to="loc_cah_TotalOpioidLitigationMember_3f603880-ca4d-4686-a3ca-da0940626086" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3d3e2ede-6840-4836-8e8f-cbc5d4dc1973" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_srt_StatementGeographicalAxis_3d3e2ede-6840-4836-8e8f-cbc5d4dc1973" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3d3e2ede-6840-4836-8e8f-cbc5d4dc1973_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_3d3e2ede-6840-4836-8e8f-cbc5d4dc1973" xlink:to="loc_srt_SegmentGeographicalDomain_3d3e2ede-6840-4836-8e8f-cbc5d4dc1973_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_97e58d31-0a9d-4d04-bfed-091998f6b13c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_3d3e2ede-6840-4836-8e8f-cbc5d4dc1973" xlink:to="loc_srt_SegmentGeographicalDomain_97e58d31-0a9d-4d04-bfed-091998f6b13c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember_4a50a6aa-6be1-497d-a445-1fbd26f9743b" xlink:href="cah-20210930.xsd#cah_AlamedaCountyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_97e58d31-0a9d-4d04-bfed-091998f6b13c" xlink:to="loc_cah_AlamedaCountyMember_4a50a6aa-6be1-497d-a445-1fbd26f9743b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember_86315ea4-ab64-4c64-b211-7011c99c7d44" xlink:href="cah-20210930.xsd#cah_OtherJurisdictionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_97e58d31-0a9d-4d04-bfed-091998f6b13c" xlink:to="loc_cah_OtherJurisdictionsMember_86315ea4-ab64-4c64-b211-7011c99c7d44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ed340680-67e4-4a99-8dcb-ea1c9f3c650e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_srt_RangeAxis_ed340680-67e4-4a99-8dcb-ea1c9f3c650e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ed340680-67e4-4a99-8dcb-ea1c9f3c650e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ed340680-67e4-4a99-8dcb-ea1c9f3c650e" xlink:to="loc_srt_RangeMember_ed340680-67e4-4a99-8dcb-ea1c9f3c650e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6270a884-9531-4875-8f21-a0003fef5201" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ed340680-67e4-4a99-8dcb-ea1c9f3c650e" xlink:to="loc_srt_RangeMember_6270a884-9531-4875-8f21-a0003fef5201" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b3ad176e-3da5-4524-97f2-b4e56ec47814" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6270a884-9531-4875-8f21-a0003fef5201" xlink:to="loc_srt_MinimumMember_b3ad176e-3da5-4524-97f2-b4e56ec47814" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6a1fc616-863f-4ef0-858a-dbd6b2d5c9b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6270a884-9531-4875-8f21-a0003fef5201" xlink:to="loc_srt_MaximumMember_6a1fc616-863f-4ef0-858a-dbd6b2d5c9b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6c227fe7-5fbe-4785-ba5d-366356927e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6c227fe7-5fbe-4785-ba5d-366356927e95" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_6c227fe7-5fbe-4785-ba5d-366356927e95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6c227fe7-5fbe-4785-ba5d-366356927e95" xlink:to="loc_us-gaap_LossContingencyNatureDomain_6c227fe7-5fbe-4785-ba5d-366356927e95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_1981ac0b-fd84-40e2-87a6-c9955542a448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6c227fe7-5fbe-4785-ba5d-366356927e95" xlink:to="loc_us-gaap_LossContingencyNatureDomain_1981ac0b-fd84-40e2-87a6-c9955542a448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_095b6b2d-0be0-43ad-98fe-6be364384e67" xlink:href="cah-20210930.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_1981ac0b-fd84-40e2-87a6-c9955542a448" xlink:to="loc_cah_OpioidLawsuitsMember_095b6b2d-0be0-43ad-98fe-6be364384e67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_ebdb2580-29d7-422f-b93a-c3a667ee3b29" xlink:href="cah-20210930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_1981ac0b-fd84-40e2-87a6-c9955542a448" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_ebdb2580-29d7-422f-b93a-c3a667ee3b29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_56b345d7-de92-49b7-a04d-51acc34fbeae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_srt_MajorCustomersAxis_56b345d7-de92-49b7-a04d-51acc34fbeae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_56b345d7-de92-49b7-a04d-51acc34fbeae_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_56b345d7-de92-49b7-a04d-51acc34fbeae" xlink:to="loc_srt_NameOfMajorCustomerDomain_56b345d7-de92-49b7-a04d-51acc34fbeae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ab77ebba-407d-4c06-a081-a7e38e05fb24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_56b345d7-de92-49b7-a04d-51acc34fbeae" xlink:to="loc_srt_NameOfMajorCustomerDomain_ab77ebba-407d-4c06-a081-a7e38e05fb24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_74b9b241-f598-4de0-bf4e-5f965012565c" xlink:href="cah-20210930.xsd#cah_CVSHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ab77ebba-407d-4c06-a081-a7e38e05fb24" xlink:to="loc_cah_CVSHealthMember_74b9b241-f598-4de0-bf4e-5f965012565c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_dc84b4bd-81e2-48cd-9d2f-4c999c4b42ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_srt_LitigationCaseAxis_dc84b4bd-81e2-48cd-9d2f-4c999c4b42ea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_dc84b4bd-81e2-48cd-9d2f-4c999c4b42ea_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_dc84b4bd-81e2-48cd-9d2f-4c999c4b42ea" xlink:to="loc_srt_LitigationCaseTypeDomain_dc84b4bd-81e2-48cd-9d2f-4c999c4b42ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_352d3d32-80db-428d-bbbc-21c9bdeceacb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_dc84b4bd-81e2-48cd-9d2f-4c999c4b42ea" xlink:to="loc_srt_LitigationCaseTypeDomain_352d3d32-80db-428d-bbbc-21c9bdeceacb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_906f3e8a-c379-4704-b74a-cf1606644980" xlink:href="cah-20210930.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_352d3d32-80db-428d-bbbc-21c9bdeceacb" xlink:to="loc_cah_OpioidLawsuitsMember_906f3e8a-c379-4704-b74a-cf1606644980" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_705c4c49-7750-4157-8df3-c15b9d3000be" xlink:href="cah-20210930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_352d3d32-80db-428d-bbbc-21c9bdeceacb" xlink:to="loc_cah_ClassActionLawsuitsMember_705c4c49-7750-4157-8df3-c15b9d3000be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_d9c283cf-2595-4910-8abd-df9ea814b71c" xlink:href="cah-20210930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_352d3d32-80db-428d-bbbc-21c9bdeceacb" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_d9c283cf-2595-4910-8abd-df9ea814b71c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_b5d1cde9-3708-45b8-8ffa-b8a7e55a54ff" xlink:href="cah-20210930.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_352d3d32-80db-428d-bbbc-21c9bdeceacb" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_b5d1cde9-3708-45b8-8ffa-b8a7e55a54ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsStateDomain_5f235800-9dfc-4ed7-b98e-7af582c1050d" xlink:href="cah-20210930.xsd#cah_OpioidLawsuitsStateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_352d3d32-80db-428d-bbbc-21c9bdeceacb" xlink:to="loc_cah_OpioidLawsuitsStateDomain_5f235800-9dfc-4ed7-b98e-7af582c1050d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DOJInvestigationMember_0a6841fd-f5ee-4205-bf89-db7c6a772918" xlink:href="cah-20210930.xsd#cah_DOJInvestigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_352d3d32-80db-428d-bbbc-21c9bdeceacb" xlink:to="loc_cah_DOJInvestigationMember_0a6841fd-f5ee-4205-bf89-db7c6a772918" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_26fc88d6-8a23-4aac-8b71-aecaf9abff25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_26fc88d6-8a23-4aac-8b71-aecaf9abff25" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_26fc88d6-8a23-4aac-8b71-aecaf9abff25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_26fc88d6-8a23-4aac-8b71-aecaf9abff25" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_26fc88d6-8a23-4aac-8b71-aecaf9abff25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d9f0bbcf-da0a-4c0a-b0a0-bc4519d2323a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_26fc88d6-8a23-4aac-8b71-aecaf9abff25" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d9f0bbcf-da0a-4c0a-b0a0-bc4519d2323a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ffd6aaed-880d-4f88-9c21-76dae85d50ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d9f0bbcf-da0a-4c0a-b0a0-bc4519d2323a" xlink:to="loc_us-gaap_SubsequentEventMember_ffd6aaed-880d-4f88-9c21-76dae85d50ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_bf6207cf-5e6c-45e8-bd1f-adc796c015da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_srt_StatementScenarioAxis_bf6207cf-5e6c-45e8-bd1f-adc796c015da" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_bf6207cf-5e6c-45e8-bd1f-adc796c015da_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_bf6207cf-5e6c-45e8-bd1f-adc796c015da" xlink:to="loc_srt_ScenarioUnspecifiedDomain_bf6207cf-5e6c-45e8-bd1f-adc796c015da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ea40106e-fb39-4f9b-84aa-b5f1fc092267" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_bf6207cf-5e6c-45e8-bd1f-adc796c015da" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ea40106e-fb39-4f9b-84aa-b5f1fc092267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_977913bb-8562-4573-8402-7fc3eca2e342" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_ea40106e-fb39-4f9b-84aa-b5f1fc092267" xlink:to="loc_srt_ScenarioForecastMember_977913bb-8562-4573-8402-7fc3eca2e342" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ef381755-9a69-4b9b-b117-09e48538f2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ef381755-9a69-4b9b-b117-09e48538f2d3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ef381755-9a69-4b9b-b117-09e48538f2d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ef381755-9a69-4b9b-b117-09e48538f2d3" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ef381755-9a69-4b9b-b117-09e48538f2d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3951610f-4802-4112-ab5f-ea1003030d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ef381755-9a69-4b9b-b117-09e48538f2d3" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3951610f-4802-4112-ab5f-ea1003030d76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_3879b838-9a00-48e0-8bed-67fb76a1ea11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3951610f-4802-4112-ab5f-ea1003030d76" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_3879b838-9a00-48e0-8bed-67fb76a1ea11" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i0617256dafda4165899f866a919a7cd1_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ad85154d-2661-458d-a1df-29d4427d6409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ad85154d-2661-458d-a1df-29d4427d6409" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a7fd0389-0b18-4a30-82be-28eb3eb51f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a7fd0389-0b18-4a30-82be-28eb3eb51f5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_37a36c6b-d689-4b5a-a836-d4f14bcc4b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_37a36c6b-d689-4b5a-a836-d4f14bcc4b43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7ea3c265-6608-4db1-9795-429f31c47653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7ea3c265-6608-4db1-9795-429f31c47653" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_466b31d4-ae3c-44aa-bb03-73ffdfaf7781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_466b31d4-ae3c-44aa-bb03-73ffdfaf7781" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_32a54323-1537-4134-b98a-db60087a6410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_32a54323-1537-4134-b98a-db60087a6410" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_db45c9dd-d3ac-4c77-a428-49df8d010f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_us-gaap_OpenTaxYear_db45c9dd-d3ac-4c77-a428-49df8d010f6a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable_f1d84b00-3946-4c22-91ca-31526b4add4a" xlink:href="cah-20210930.xsd#cah_IndemnificationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_cah_IndemnificationReceivable_f1d84b00-3946-4c22-91ca-31526b4add4a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_0dd2464f-33a1-4aeb-b41b-f2da4edf1744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_us-gaap_LitigationSettlementExpense_0dd2464f-33a1-4aeb-b41b-f2da4edf1744" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_032542c5-b95c-4c8a-9fa9-448797bb3b22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_032542c5-b95c-4c8a-9fa9-448797bb3b22" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_24a72b84-0c6e-48df-8c0c-2f84d417ad61" xlink:href="cah-20210930.xsd#cah_TaxMatterAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:to="loc_cah_TaxMatterAxis_24a72b84-0c6e-48df-8c0c-2f84d417ad61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_24a72b84-0c6e-48df-8c0c-2f84d417ad61_default" xlink:href="cah-20210930.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_TaxMatterAxis_24a72b84-0c6e-48df-8c0c-2f84d417ad61" xlink:to="loc_cah_TaxMatterDomain_24a72b84-0c6e-48df-8c0c-2f84d417ad61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_1537b14a-f387-4695-a685-208d3ba03868" xlink:href="cah-20210930.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_TaxMatterAxis_24a72b84-0c6e-48df-8c0c-2f84d417ad61" xlink:to="loc_cah_TaxMatterDomain_1537b14a-f387-4695-a685-208d3ba03868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_934af708-0f53-4355-a23c-5eebcb3de620" xlink:href="cah-20210930.xsd#cah_CareFusionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMatterDomain_1537b14a-f387-4695-a685-208d3ba03868" xlink:to="loc_cah_CareFusionMember_934af708-0f53-4355-a23c-5eebcb3de620" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_d0c8d7b4-cd81-4d1d-b830-7807aa4bcabb" xlink:href="cah-20210930.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMatterDomain_1537b14a-f387-4695-a685-208d3ba03868" xlink:to="loc_cah_PatientRecoveryBusinessMember_d0c8d7b4-cd81-4d1d-b830-7807aa4bcabb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_530d76b1-2905-4076-9dfc-7f68be65a967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_530d76b1-2905-4076-9dfc-7f68be65a967" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_530d76b1-2905-4076-9dfc-7f68be65a967_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_530d76b1-2905-4076-9dfc-7f68be65a967" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_530d76b1-2905-4076-9dfc-7f68be65a967_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5f72817-a5e0-4d17-83e8-b63bcc7938bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_530d76b1-2905-4076-9dfc-7f68be65a967" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5f72817-a5e0-4d17-83e8-b63bcc7938bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_75e2edf7-cac4-4b17-841c-22ad8802eefd" xlink:href="cah-20210930.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5f72817-a5e0-4d17-83e8-b63bcc7938bc" xlink:to="loc_cah_PatientRecoveryBusinessMember_75e2edf7-cac4-4b17-841c-22ad8802eefd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_b680341e-4253-4d55-b57b-014d47f0007b" xlink:href="cah-20210930.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:to="loc_cah_OpioidLitigationAxis_b680341e-4253-4d55-b57b-014d47f0007b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_b680341e-4253-4d55-b57b-014d47f0007b_default" xlink:href="cah-20210930.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_b680341e-4253-4d55-b57b-014d47f0007b" xlink:to="loc_cah_OpioidLitigationDomain_b680341e-4253-4d55-b57b-014d47f0007b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_8ee0aeb8-fc00-435d-9f8d-ec3adcd472fd" xlink:href="cah-20210930.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_b680341e-4253-4d55-b57b-014d47f0007b" xlink:to="loc_cah_OpioidLitigationDomain_8ee0aeb8-fc00-435d-9f8d-ec3adcd472fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_66692798-eef7-42de-babb-c8e968746eeb" xlink:href="cah-20210930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_8ee0aeb8-fc00-435d-9f8d-ec3adcd472fd" xlink:to="loc_cah_TotalOpioidLitigationMember_66692798-eef7-42de-babb-c8e968746eeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c5038d9d-6efc-47fe-a472-7f1a12c15745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c5038d9d-6efc-47fe-a472-7f1a12c15745" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c5038d9d-6efc-47fe-a472-7f1a12c15745_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c5038d9d-6efc-47fe-a472-7f1a12c15745" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c5038d9d-6efc-47fe-a472-7f1a12c15745_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9ff18ed9-f5ae-46d4-8e9a-f3943a5774dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c5038d9d-6efc-47fe-a472-7f1a12c15745" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9ff18ed9-f5ae-46d4-8e9a-f3943a5774dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_c34a1ddb-e836-4a97-bd2d-ff8a6c122df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_c34a1ddb-e836-4a97-bd2d-ff8a6c122df9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_c34a1ddb-e836-4a97-bd2d-ff8a6c122df9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c34a1ddb-e836-4a97-bd2d-ff8a6c122df9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_c34a1ddb-e836-4a97-bd2d-ff8a6c122df9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f2941fd6-8c59-42ee-988a-35d79f6c5d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c34a1ddb-e836-4a97-bd2d-ff8a6c122df9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f2941fd6-8c59-42ee-988a-35d79f6c5d6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_d879f61e-a860-4338-b47e-15cbcdaa5064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f2941fd6-8c59-42ee-988a-35d79f6c5d6d" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_d879f61e-a860-4338-b47e-15cbcdaa5064" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d264940f-440d-4bed-b3af-9d7d72336a1c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:to="loc_srt_RangeAxis_d264940f-440d-4bed-b3af-9d7d72336a1c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d264940f-440d-4bed-b3af-9d7d72336a1c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d264940f-440d-4bed-b3af-9d7d72336a1c" xlink:to="loc_srt_RangeMember_d264940f-440d-4bed-b3af-9d7d72336a1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_279faa8c-106a-40a1-a552-086b29366c63" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d264940f-440d-4bed-b3af-9d7d72336a1c" xlink:to="loc_srt_RangeMember_279faa8c-106a-40a1-a552-086b29366c63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e512b7e6-b9be-4f1f-8be6-99d7f9752916" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_279faa8c-106a-40a1-a552-086b29366c63" xlink:to="loc_srt_MinimumMember_e512b7e6-b9be-4f1f-8be6-99d7f9752916" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_66c0cbcc-262c-45e9-9664-07ff32690b3b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_279faa8c-106a-40a1-a552-086b29366c63" xlink:to="loc_srt_MaximumMember_66c0cbcc-262c-45e9-9664-07ff32690b3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_2cdc6c5b-4b90-4a77-9f9a-c36a2f8c0604" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:to="loc_srt_StatementScenarioAxis_2cdc6c5b-4b90-4a77-9f9a-c36a2f8c0604" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2cdc6c5b-4b90-4a77-9f9a-c36a2f8c0604_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_2cdc6c5b-4b90-4a77-9f9a-c36a2f8c0604" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2cdc6c5b-4b90-4a77-9f9a-c36a2f8c0604_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_536b2309-477b-4acf-9299-9d6194da403a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_2cdc6c5b-4b90-4a77-9f9a-c36a2f8c0604" xlink:to="loc_srt_ScenarioUnspecifiedDomain_536b2309-477b-4acf-9299-9d6194da403a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_01076f0e-72a0-4cf9-995c-7656e43a8eb2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_536b2309-477b-4acf-9299-9d6194da403a" xlink:to="loc_srt_ScenarioForecastMember_01076f0e-72a0-4cf9-995c-7656e43a8eb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_66f465f7-9497-41e1-be59-176585e688d0" xlink:href="cah-20210930.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:to="loc_cah_CordisDivestitureAxis_66f465f7-9497-41e1-be59-176585e688d0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_66f465f7-9497-41e1-be59-176585e688d0_default" xlink:href="cah-20210930.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_66f465f7-9497-41e1-be59-176585e688d0" xlink:to="loc_cah_CordisDivestitureDomain_66f465f7-9497-41e1-be59-176585e688d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_08f08175-f825-4cec-8dde-37d5655d9a5e" xlink:href="cah-20210930.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_66f465f7-9497-41e1-be59-176585e688d0" xlink:to="loc_cah_CordisDivestitureDomain_08f08175-f825-4cec-8dde-37d5655d9a5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_929b23a7-95f5-40a1-aa9c-ce9f24c91e7b" xlink:href="cah-20210930.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_08f08175-f825-4cec-8dde-37d5655d9a5e" xlink:to="loc_cah_CordisDivestitureMember_929b23a7-95f5-40a1-aa9c-ce9f24c91e7b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="ie55585edd31d4c36a9c779d5e407db58_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_257c7e49-02c8-4cd7-903c-f5c25510f196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_80a5ccb1-04b0-4160-a09b-7f987f7c8bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_257c7e49-02c8-4cd7-903c-f5c25510f196" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_80a5ccb1-04b0-4160-a09b-7f987f7c8bd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_3daed497-6794-41f4-86a8-948b063e8781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_80a5ccb1-04b0-4160-a09b-7f987f7c8bd3" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_3daed497-6794-41f4-86a8-948b063e8781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_865bdecf-5bbc-4a08-9762-c79fa2be7805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_80a5ccb1-04b0-4160-a09b-7f987f7c8bd3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_865bdecf-5bbc-4a08-9762-c79fa2be7805" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e1e53f1c-8a16-44b5-8e14-e13c560c1430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_257c7e49-02c8-4cd7-903c-f5c25510f196" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e1e53f1c-8a16-44b5-8e14-e13c560c1430" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_a34376c2-608e-404a-8a16-3c468ce94aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e1e53f1c-8a16-44b5-8e14-e13c560c1430" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_a34376c2-608e-404a-8a16-3c468ce94aba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1858ce57-3a69-42ac-a1e9-c46e230cfab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_257c7e49-02c8-4cd7-903c-f5c25510f196" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1858ce57-3a69-42ac-a1e9-c46e230cfab2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b5c91a2-67f5-4b1d-9681-96ee299a6589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_257c7e49-02c8-4cd7-903c-f5c25510f196" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b5c91a2-67f5-4b1d-9681-96ee299a6589" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_13610892-3408-4bb2-b3d1-d2aeaf367a58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b5c91a2-67f5-4b1d-9681-96ee299a6589" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_13610892-3408-4bb2-b3d1-d2aeaf367a58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_13610892-3408-4bb2-b3d1-d2aeaf367a58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_13610892-3408-4bb2-b3d1-d2aeaf367a58" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_13610892-3408-4bb2-b3d1-d2aeaf367a58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_222fd9bf-855e-432f-948a-478b9c520411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_13610892-3408-4bb2-b3d1-d2aeaf367a58" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_222fd9bf-855e-432f-948a-478b9c520411" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ca1ce7fb-da43-4ae8-897b-8aae3d53ee5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_222fd9bf-855e-432f-948a-478b9c520411" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ca1ce7fb-da43-4ae8-897b-8aae3d53ee5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0987563b-0cab-44b1-aeb9-d2701099ab49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b5c91a2-67f5-4b1d-9681-96ee299a6589" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0987563b-0cab-44b1-aeb9-d2701099ab49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0987563b-0cab-44b1-aeb9-d2701099ab49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0987563b-0cab-44b1-aeb9-d2701099ab49" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0987563b-0cab-44b1-aeb9-d2701099ab49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0be3206a-ded6-4f2a-b515-e864f2f9c903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0987563b-0cab-44b1-aeb9-d2701099ab49" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0be3206a-ded6-4f2a-b515-e864f2f9c903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_95821b9d-42b4-4a99-ba44-1e7b531ff85b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0be3206a-ded6-4f2a-b515-e864f2f9c903" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_95821b9d-42b4-4a99-ba44-1e7b531ff85b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_54bf16ee-d39e-4711-ab9b-ff450a4652b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0be3206a-ded6-4f2a-b515-e864f2f9c903" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_54bf16ee-d39e-4711-ab9b-ff450a4652b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f563d953-1f96-439f-86a6-a1e7f8f86c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0be3206a-ded6-4f2a-b515-e864f2f9c903" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f563d953-1f96-439f-86a6-a1e7f8f86c25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel12And3Member_c748a01b-12c4-4c9a-a399-379553459dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0be3206a-ded6-4f2a-b515-e864f2f9c903" xlink:to="loc_us-gaap_FairValueInputsLevel12And3Member_c748a01b-12c4-4c9a-a399-379553459dbc" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i9a58a99495ff4d829334c9ec16562ad4_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_71619865-577a-46a8-8761-b2e2b0c45201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_ead8836f-249e-47e3-b53e-c8c31da8aaaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_71619865-577a-46a8-8761-b2e2b0c45201" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_ead8836f-249e-47e3-b53e-c8c31da8aaaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_e6870be4-0b82-45a6-b077-bb8a35e6ab1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_71619865-577a-46a8-8761-b2e2b0c45201" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_e6870be4-0b82-45a6-b077-bb8a35e6ab1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_08b2bc2b-2764-43b0-9382-baf936d84501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_71619865-577a-46a8-8761-b2e2b0c45201" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_08b2bc2b-2764-43b0-9382-baf936d84501" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_3c4ba05b-ee99-4bd5-86f9-2a5a2b4b8cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_71619865-577a-46a8-8761-b2e2b0c45201" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_3c4ba05b-ee99-4bd5-86f9-2a5a2b4b8cdb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_44d63808-0f12-4bc5-8b06-c2708099a7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_71619865-577a-46a8-8761-b2e2b0c45201" xlink:to="loc_us-gaap_DerivativeTable_44d63808-0f12-4bc5-8b06-c2708099a7ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_648e4ca9-31fa-4595-9f1a-93a2db8883a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_44d63808-0f12-4bc5-8b06-c2708099a7ad" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_648e4ca9-31fa-4595-9f1a-93a2db8883a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_648e4ca9-31fa-4595-9f1a-93a2db8883a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_648e4ca9-31fa-4595-9f1a-93a2db8883a6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_648e4ca9-31fa-4595-9f1a-93a2db8883a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5322f88e-acfc-4a62-80ab-18227e21e8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_648e4ca9-31fa-4595-9f1a-93a2db8883a6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5322f88e-acfc-4a62-80ab-18227e21e8c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_781f7e1b-85af-49e8-81e3-1f5a7972580a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_44d63808-0f12-4bc5-8b06-c2708099a7ad" xlink:to="loc_us-gaap_HedgingDesignationAxis_781f7e1b-85af-49e8-81e3-1f5a7972580a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_781f7e1b-85af-49e8-81e3-1f5a7972580a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_781f7e1b-85af-49e8-81e3-1f5a7972580a" xlink:to="loc_us-gaap_HedgingDesignationDomain_781f7e1b-85af-49e8-81e3-1f5a7972580a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_656fa75a-8bf8-49f4-bc88-afb17713326a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_781f7e1b-85af-49e8-81e3-1f5a7972580a" xlink:to="loc_us-gaap_HedgingDesignationDomain_656fa75a-8bf8-49f4-bc88-afb17713326a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3d43116f-973d-489b-a475-06e3c54e57eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_656fa75a-8bf8-49f4-bc88-afb17713326a" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3d43116f-973d-489b-a475-06e3c54e57eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ef3f68f3-72e5-45b9-9573-87c5380101af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_44d63808-0f12-4bc5-8b06-c2708099a7ad" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ef3f68f3-72e5-45b9-9573-87c5380101af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ef3f68f3-72e5-45b9-9573-87c5380101af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ef3f68f3-72e5-45b9-9573-87c5380101af" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ef3f68f3-72e5-45b9-9573-87c5380101af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b9afac7b-c6c1-43ae-a301-7344bdb6ae5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ef3f68f3-72e5-45b9-9573-87c5380101af" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b9afac7b-c6c1-43ae-a301-7344bdb6ae5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_539b992c-8e4a-4b40-a491-268e64d5a20f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b9afac7b-c6c1-43ae-a301-7344bdb6ae5c" xlink:to="loc_us-gaap_FairValueHedgingMember_539b992c-8e4a-4b40-a491-268e64d5a20f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_48de0291-d2a9-4ce7-afbf-54bae3aa4339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_44d63808-0f12-4bc5-8b06-c2708099a7ad" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_48de0291-d2a9-4ce7-afbf-54bae3aa4339" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_48de0291-d2a9-4ce7-afbf-54bae3aa4339_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_48de0291-d2a9-4ce7-afbf-54bae3aa4339" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_48de0291-d2a9-4ce7-afbf-54bae3aa4339_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2f4207d1-63c6-4dfc-b38c-d52e46de4814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_48de0291-d2a9-4ce7-afbf-54bae3aa4339" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2f4207d1-63c6-4dfc-b38c-d52e46de4814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a7dc3bf7-e9ab-4069-84be-cd4584036170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f4207d1-63c6-4dfc-b38c-d52e46de4814" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a7dc3bf7-e9ab-4069-84be-cd4584036170" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_fcbec9e7-defd-4260-a398-5569e90cf1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f4207d1-63c6-4dfc-b38c-d52e46de4814" xlink:to="loc_us-gaap_InterestRateSwapMember_fcbec9e7-defd-4260-a398-5569e90cf1cc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended" id="if2c957c6e24b44d1bff5f61be22034b5_FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f82ef8bd-975e-4e46-9a8b-fb32054f0826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_85cc0209-76f3-449d-b9c4-c6788c59dc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f82ef8bd-975e-4e46-9a8b-fb32054f0826" xlink:to="loc_us-gaap_DebtInstrumentFairValue_85cc0209-76f3-449d-b9c4-c6788c59dc3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_4c800476-ef1e-4a05-89a2-d5a9ffdd251b" xlink:href="cah-20210930.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f82ef8bd-975e-4e46-9a8b-fb32054f0826" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_4c800476-ef1e-4a05-89a2-d5a9ffdd251b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e8f77dc-9567-47eb-a22f-5672018322e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f82ef8bd-975e-4e46-9a8b-fb32054f0826" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e8f77dc-9567-47eb-a22f-5672018322e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d8dd035-d342-4831-8b3c-4e3c7b5477fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e8f77dc-9567-47eb-a22f-5672018322e7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d8dd035-d342-4831-8b3c-4e3c7b5477fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d8dd035-d342-4831-8b3c-4e3c7b5477fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d8dd035-d342-4831-8b3c-4e3c7b5477fe" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d8dd035-d342-4831-8b3c-4e3c7b5477fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_170f0610-6947-4a62-81d3-51b71ddaf664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d8dd035-d342-4831-8b3c-4e3c7b5477fe" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_170f0610-6947-4a62-81d3-51b71ddaf664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8709a12c-010a-44e3-adc4-3d653db549b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_170f0610-6947-4a62-81d3-51b71ddaf664" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8709a12c-010a-44e3-adc4-3d653db549b2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended" id="ieea9b0f86412448d880a05a08a3b51f5_ShareholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d9eca98d-6a71-4b3a-9c68-e0896446a699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_095ff1fd-32e8-4956-9e6e-8b350ebc1d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d9eca98d-6a71-4b3a-9c68-e0896446a699" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_095ff1fd-32e8-4956-9e6e-8b350ebc1d7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_f7043839-f3d2-4c35-a672-79874285bcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d9eca98d-6a71-4b3a-9c68-e0896446a699" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_f7043839-f3d2-4c35-a672-79874285bcdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_29bf3949-872d-446d-8f04-731cb2a0d0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d9eca98d-6a71-4b3a-9c68-e0896446a699" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_29bf3949-872d-446d-8f04-731cb2a0d0fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TreasuryStockAcquiredShares_ace106cd-b07f-4277-9a1f-af40f50b5707" xlink:href="cah-20210930.xsd#cah_TreasuryStockAcquiredShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d9eca98d-6a71-4b3a-9c68-e0896446a699" xlink:to="loc_cah_TreasuryStockAcquiredShares_ace106cd-b07f-4277-9a1f-af40f50b5707" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FinalSharesReceivedfromASRProgram_cd6d31b1-1e8e-42e6-8c22-1309efd9e11d" xlink:href="cah-20210930.xsd#cah_FinalSharesReceivedfromASRProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d9eca98d-6a71-4b3a-9c68-e0896446a699" xlink:to="loc_cah_FinalSharesReceivedfromASRProgram_cd6d31b1-1e8e-42e6-8c22-1309efd9e11d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_86d01093-6925-4a03-bd53-f8de53d5adc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_d9eca98d-6a71-4b3a-9c68-e0896446a699" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_86d01093-6925-4a03-bd53-f8de53d5adc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_931a1ca3-f34b-4c67-90d2-29514e47db68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86d01093-6925-4a03-bd53-f8de53d5adc3" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_931a1ca3-f34b-4c67-90d2-29514e47db68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_931a1ca3-f34b-4c67-90d2-29514e47db68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_931a1ca3-f34b-4c67-90d2-29514e47db68" xlink:to="loc_us-gaap_LossContingencyNatureDomain_931a1ca3-f34b-4c67-90d2-29514e47db68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_ff542b20-8815-4181-82d0-24396b7d6f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_931a1ca3-f34b-4c67-90d2-29514e47db68" xlink:to="loc_us-gaap_LossContingencyNatureDomain_ff542b20-8815-4181-82d0-24396b7d6f3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a7f4d56c-b59c-4f40-ad6e-17c6f7010fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86d01093-6925-4a03-bd53-f8de53d5adc3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a7f4d56c-b59c-4f40-ad6e-17c6f7010fe4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a7f4d56c-b59c-4f40-ad6e-17c6f7010fe4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a7f4d56c-b59c-4f40-ad6e-17c6f7010fe4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a7f4d56c-b59c-4f40-ad6e-17c6f7010fe4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6a202691-177f-44dc-9916-f84a53a0ea21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a7f4d56c-b59c-4f40-ad6e-17c6f7010fe4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6a202691-177f-44dc-9916-f84a53a0ea21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_34161ba2-6c87-4241-bb92-172c18f516a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6a202691-177f-44dc-9916-f84a53a0ea21" xlink:to="loc_us-gaap_SubsequentEventMember_34161ba2-6c87-4241-bb92-172c18f516a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_534f495c-a646-4fab-b5f0-57d1e14f380c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86d01093-6925-4a03-bd53-f8de53d5adc3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_534f495c-a646-4fab-b5f0-57d1e14f380c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_534f495c-a646-4fab-b5f0-57d1e14f380c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_534f495c-a646-4fab-b5f0-57d1e14f380c" xlink:to="loc_us-gaap_EquityComponentDomain_534f495c-a646-4fab-b5f0-57d1e14f380c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_77e22306-78fc-45ff-9816-493d1dd0db31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_534f495c-a646-4fab-b5f0-57d1e14f380c" xlink:to="loc_us-gaap_EquityComponentDomain_77e22306-78fc-45ff-9816-493d1dd0db31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_c518497d-fe02-4799-a7da-9da9ecd347fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_77e22306-78fc-45ff-9816-493d1dd0db31" xlink:to="loc_us-gaap_TreasuryStockMember_c518497d-fe02-4799-a7da-9da9ecd347fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_482a5c7f-3cf0-4b12-8eb4-57ae0247724a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86d01093-6925-4a03-bd53-f8de53d5adc3" xlink:to="loc_srt_RangeAxis_482a5c7f-3cf0-4b12-8eb4-57ae0247724a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_482a5c7f-3cf0-4b12-8eb4-57ae0247724a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_482a5c7f-3cf0-4b12-8eb4-57ae0247724a" xlink:to="loc_srt_RangeMember_482a5c7f-3cf0-4b12-8eb4-57ae0247724a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c65ceb07-12ff-4016-aba3-91e170ad2f4a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_482a5c7f-3cf0-4b12-8eb4-57ae0247724a" xlink:to="loc_srt_RangeMember_c65ceb07-12ff-4016-aba3-91e170ad2f4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_39761f95-e29a-416b-8aaa-488cd65bd4d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c65ceb07-12ff-4016-aba3-91e170ad2f4a" xlink:to="loc_srt_MinimumMember_39761f95-e29a-416b-8aaa-488cd65bd4d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a03c9f86-cdb9-4c55-a2b5-a0960b1682c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86d01093-6925-4a03-bd53-f8de53d5adc3" xlink:to="loc_us-gaap_AwardTypeAxis_a03c9f86-cdb9-4c55-a2b5-a0960b1682c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a03c9f86-cdb9-4c55-a2b5-a0960b1682c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a03c9f86-cdb9-4c55-a2b5-a0960b1682c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a03c9f86-cdb9-4c55-a2b5-a0960b1682c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76ccfd52-1b8d-4f65-af36-6142a920f24d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a03c9f86-cdb9-4c55-a2b5-a0960b1682c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76ccfd52-1b8d-4f65-af36-6142a920f24d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_15d9aab2-da59-45ac-9606-010da5e02c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76ccfd52-1b8d-4f65-af36-6142a920f24d" xlink:to="loc_us-gaap_PerformanceSharesMember_15d9aab2-da59-45ac-9606-010da5e02c9c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i309ee1feecac48b887d83036053e90e2_ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_088d34c1-7a3f-4de9-9416-72d338d469d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fa89599e-ed95-4d44-bf90-00b3b9f00d69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_088d34c1-7a3f-4de9-9416-72d338d469d8" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fa89599e-ed95-4d44-bf90-00b3b9f00d69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73aa60ac-fb15-4fdd-9c5d-a28a91be455f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fa89599e-ed95-4d44-bf90-00b3b9f00d69" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73aa60ac-fb15-4fdd-9c5d-a28a91be455f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8c12d5ac-fcca-4bb5-b0dc-a2a153244164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fa89599e-ed95-4d44-bf90-00b3b9f00d69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8c12d5ac-fcca-4bb5-b0dc-a2a153244164" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_0db0d09b-eeac-40a7-ae94-358a638f5eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fa89599e-ed95-4d44-bf90-00b3b9f00d69" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_0db0d09b-eeac-40a7-ae94-358a638f5eb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7d396e54-1c7a-4fdc-86e2-27b1c08cbd55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fa89599e-ed95-4d44-bf90-00b3b9f00d69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7d396e54-1c7a-4fdc-86e2-27b1c08cbd55" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ec1528b4-6dc9-40e6-981a-ce69b9800ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_fbd686d6-41ce-4c02-8812-39c05bfca8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_088d34c1-7a3f-4de9-9416-72d338d469d8" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_fbd686d6-41ce-4c02-8812-39c05bfca8ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_07616641-9821-406c-a5b7-7e90cd820134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_fbd686d6-41ce-4c02-8812-39c05bfca8ee" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_07616641-9821-406c-a5b7-7e90cd820134" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_07616641-9821-406c-a5b7-7e90cd820134_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_07616641-9821-406c-a5b7-7e90cd820134" xlink:to="loc_us-gaap_EquityComponentDomain_07616641-9821-406c-a5b7-7e90cd820134_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bef00472-4d8a-48b9-b332-e85dbe6a9d46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_07616641-9821-406c-a5b7-7e90cd820134" xlink:to="loc_us-gaap_EquityComponentDomain_bef00472-4d8a-48b9-b332-e85dbe6a9d46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_307e722b-8463-4232-8aa9-fd106f835cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bef00472-4d8a-48b9-b332-e85dbe6a9d46" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_307e722b-8463-4232-8aa9-fd106f835cbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_110a5a30-cf39-47cf-a020-e715f52d1997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bef00472-4d8a-48b9-b332-e85dbe6a9d46" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_110a5a30-cf39-47cf-a020-e715f52d1997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_5e450674-c395-4bdd-9226-5f66b0c7e978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bef00472-4d8a-48b9-b332-e85dbe6a9d46" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_5e450674-c395-4bdd-9226-5f66b0c7e978" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ed3781da-7d6c-43d5-8ead-6b3c64a2d68e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bef00472-4d8a-48b9-b332-e85dbe6a9d46" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ed3781da-7d6c-43d5-8ead-6b3c64a2d68e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="cah-20210930.xsd#SegmentInformationTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="extended" id="i85c4e641b3754fe5839864b286914f64_SegmentInformationTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_ae020d55-ac67-4fa1-a8e3-ad8aefdcc94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_214cc0d7-3d08-4c42-b399-1b52390f7314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_ae020d55-ac67-4fa1-a8e3-ad8aefdcc94f" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_214cc0d7-3d08-4c42-b399-1b52390f7314" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f315c988-f36b-4154-9a01-265a9aa60684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_ae020d55-ac67-4fa1-a8e3-ad8aefdcc94f" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f315c988-f36b-4154-9a01-265a9aa60684" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f5d5f188-0d99-445c-89f1-c74cdc680f36" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f315c988-f36b-4154-9a01-265a9aa60684" xlink:to="loc_srt_ConsolidationItemsAxis_f5d5f188-0d99-445c-89f1-c74cdc680f36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f5d5f188-0d99-445c-89f1-c74cdc680f36_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_f5d5f188-0d99-445c-89f1-c74cdc680f36" xlink:to="loc_srt_ConsolidationItemsDomain_f5d5f188-0d99-445c-89f1-c74cdc680f36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f5c810d7-0d32-4550-86bf-812152e5338b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_f5d5f188-0d99-445c-89f1-c74cdc680f36" xlink:to="loc_srt_ConsolidationItemsDomain_f5c810d7-0d32-4550-86bf-812152e5338b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_19037714-0f3c-426b-af32-8f1bcb5ce808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f315c988-f36b-4154-9a01-265a9aa60684" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_19037714-0f3c-426b-af32-8f1bcb5ce808" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_19037714-0f3c-426b-af32-8f1bcb5ce808_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_19037714-0f3c-426b-af32-8f1bcb5ce808" xlink:to="loc_us-gaap_SegmentDomain_19037714-0f3c-426b-af32-8f1bcb5ce808_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7723ef40-82b8-44df-b64e-19a15f9390f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_19037714-0f3c-426b-af32-8f1bcb5ce808" xlink:to="loc_us-gaap_SegmentDomain_7723ef40-82b8-44df-b64e-19a15f9390f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_f980e62b-8c36-4578-a108-2d3893d3e337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f315c988-f36b-4154-9a01-265a9aa60684" xlink:to="loc_us-gaap_SubsegmentsAxis_f980e62b-8c36-4578-a108-2d3893d3e337" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_f980e62b-8c36-4578-a108-2d3893d3e337_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_f980e62b-8c36-4578-a108-2d3893d3e337" xlink:to="loc_us-gaap_SubsegmentsDomain_f980e62b-8c36-4578-a108-2d3893d3e337_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_46be223e-4157-47a4-84d4-c8ce839cd5de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_f980e62b-8c36-4578-a108-2d3893d3e337" xlink:to="loc_us-gaap_SubsegmentsDomain_46be223e-4157-47a4-84d4-c8ce839cd5de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_4d3437dd-aa05-48a2-9734-dfb3ed978d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f315c988-f36b-4154-9a01-265a9aa60684" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_4d3437dd-aa05-48a2-9734-dfb3ed978d7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_4d3437dd-aa05-48a2-9734-dfb3ed978d7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_4d3437dd-aa05-48a2-9734-dfb3ed978d7d" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_4d3437dd-aa05-48a2-9734-dfb3ed978d7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_4e68030e-02cb-4339-a14b-c337f9ac2d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_4d3437dd-aa05-48a2-9734-dfb3ed978d7d" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_4e68030e-02cb-4339-a14b-c337f9ac2d65" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#SegmentInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended" id="i23969c0b6cd0463c9d41c304094fd6df_SegmentInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6b914f1f-3323-45e9-80b4-68d19b2c1519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_5a0ee753-462a-47ba-ad0a-a41a1401288e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6b914f1f-3323-45e9-80b4-68d19b2c1519" xlink:to="loc_us-gaap_LitigationReserve_5a0ee753-462a-47ba-ad0a-a41a1401288e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_ae3a69b6-050b-4a3c-b5a1-dcd27c8cbd11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6b914f1f-3323-45e9-80b4-68d19b2c1519" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_ae3a69b6-050b-4a3c-b5a1-dcd27c8cbd11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f0c09f54-e016-4630-b0ba-ef180a8817cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6b914f1f-3323-45e9-80b4-68d19b2c1519" xlink:to="loc_us-gaap_StatementTable_f0c09f54-e016-4630-b0ba-ef180a8817cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_e9f62c71-588f-4e3e-b6e6-0ede35178f45" xlink:href="cah-20210930.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f0c09f54-e016-4630-b0ba-ef180a8817cc" xlink:to="loc_cah_OpioidLitigationAxis_e9f62c71-588f-4e3e-b6e6-0ede35178f45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_e9f62c71-588f-4e3e-b6e6-0ede35178f45_default" xlink:href="cah-20210930.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_e9f62c71-588f-4e3e-b6e6-0ede35178f45" xlink:to="loc_cah_OpioidLitigationDomain_e9f62c71-588f-4e3e-b6e6-0ede35178f45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_6b3446d5-d327-438f-983f-ad85f0dc4fb2" xlink:href="cah-20210930.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_e9f62c71-588f-4e3e-b6e6-0ede35178f45" xlink:to="loc_cah_OpioidLitigationDomain_6b3446d5-d327-438f-983f-ad85f0dc4fb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_678c8942-8044-4132-979b-25999e5ec1a9" xlink:href="cah-20210930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_6b3446d5-d327-438f-983f-ad85f0dc4fb2" xlink:to="loc_cah_TotalOpioidLitigationMember_678c8942-8044-4132-979b-25999e5ec1a9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended" id="i7b8a0c5d28cc4ac7adc0aedbf70a3a2b_SegmentInformationRevenuebyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d5ebca54-de66-4918-8649-dcc18a6f5d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6659e603-f6e7-4564-a3ad-e98277328c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d5ebca54-de66-4918-8649-dcc18a6f5d18" xlink:to="loc_us-gaap_Revenues_6659e603-f6e7-4564-a3ad-e98277328c4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_1a179458-70e8-4d62-9d02-263eee935d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d5ebca54-de66-4918-8649-dcc18a6f5d18" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_1a179458-70e8-4d62-9d02-263eee935d92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_54b6e600-9e62-4716-9065-e18104df9602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_1a179458-70e8-4d62-9d02-263eee935d92" xlink:to="loc_us-gaap_SubsegmentsAxis_54b6e600-9e62-4716-9065-e18104df9602" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_54b6e600-9e62-4716-9065-e18104df9602_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_54b6e600-9e62-4716-9065-e18104df9602" xlink:to="loc_us-gaap_SubsegmentsDomain_54b6e600-9e62-4716-9065-e18104df9602_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_625b2202-5c90-4378-a2e2-b13028a57820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_54b6e600-9e62-4716-9065-e18104df9602" xlink:to="loc_us-gaap_SubsegmentsDomain_625b2202-5c90-4378-a2e2-b13028a57820" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_01d64e6d-f2b2-4980-b51c-02400ee50799" xlink:href="cah-20210930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_625b2202-5c90-4378-a2e2-b13028a57820" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_01d64e6d-f2b2-4980-b51c-02400ee50799" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_78e5d20c-1714-4818-b910-101c3dab600d" xlink:href="cah-20210930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_625b2202-5c90-4378-a2e2-b13028a57820" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_78e5d20c-1714-4818-b910-101c3dab600d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_1bbc1041-cd5b-43fe-ac20-a2bee6d69260" xlink:href="cah-20210930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_625b2202-5c90-4378-a2e2-b13028a57820" xlink:to="loc_cah_MedicaldistributionandproductsMember_1bbc1041-cd5b-43fe-ac20-a2bee6d69260" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeSolutionsMember_ee71f0ee-bed5-4cd5-9ea1-e2e6591a1c47" xlink:href="cah-20210930.xsd#cah_CardinalHealthAtHomeSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_625b2202-5c90-4378-a2e2-b13028a57820" xlink:to="loc_cah_CardinalHealthAtHomeSolutionsMember_ee71f0ee-bed5-4cd5-9ea1-e2e6591a1c47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_b650ef99-9949-48f7-b6d3-6633dfc7880c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_1a179458-70e8-4d62-9d02-263eee935d92" xlink:to="loc_srt_ConsolidationItemsAxis_b650ef99-9949-48f7-b6d3-6633dfc7880c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b650ef99-9949-48f7-b6d3-6633dfc7880c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_b650ef99-9949-48f7-b6d3-6633dfc7880c" xlink:to="loc_srt_ConsolidationItemsDomain_b650ef99-9949-48f7-b6d3-6633dfc7880c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_3a2c7148-434c-4e06-991d-9e90d076ea51" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_b650ef99-9949-48f7-b6d3-6633dfc7880c" xlink:to="loc_srt_ConsolidationItemsDomain_3a2c7148-434c-4e06-991d-9e90d076ea51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_4715d699-08b5-47bd-951f-d39fcd79a52f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_3a2c7148-434c-4e06-991d-9e90d076ea51" xlink:to="loc_us-gaap_OperatingSegmentsMember_4715d699-08b5-47bd-951f-d39fcd79a52f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_decc4e93-ed51-4533-8ddf-0f1831ef925c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_3a2c7148-434c-4e06-991d-9e90d076ea51" xlink:to="loc_us-gaap_CorporateNonSegmentMember_decc4e93-ed51-4533-8ddf-0f1831ef925c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_64dcb077-8527-42d8-aaf9-e771024ea78b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_1a179458-70e8-4d62-9d02-263eee935d92" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_64dcb077-8527-42d8-aaf9-e771024ea78b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_64dcb077-8527-42d8-aaf9-e771024ea78b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_64dcb077-8527-42d8-aaf9-e771024ea78b" xlink:to="loc_us-gaap_SegmentDomain_64dcb077-8527-42d8-aaf9-e771024ea78b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dd3adca1-760c-44a1-8637-4a4c0655a58d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_64dcb077-8527-42d8-aaf9-e771024ea78b" xlink:to="loc_us-gaap_SegmentDomain_dd3adca1-760c-44a1-8637-4a4c0655a58d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_e883627e-f18d-4d55-adfb-4d034ff2d5a9" xlink:href="cah-20210930.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dd3adca1-760c-44a1-8637-4a4c0655a58d" xlink:to="loc_cah_PharmaceuticalMember_e883627e-f18d-4d55-adfb-4d034ff2d5a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_bb835aa5-a9f6-4db9-8233-6eb8dd389a2f" xlink:href="cah-20210930.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dd3adca1-760c-44a1-8637-4a4c0655a58d" xlink:to="loc_cah_MedicalMember_bb835aa5-a9f6-4db9-8233-6eb8dd389a2f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended" id="icbf56c0a7cf44576b5834572498c3d34_SegmentInformationSegmentProfitbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1a545555-de59-438c-90f4-9770614c45f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5268ab0a-e7e1-4111-8bb1-06151fccabf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1a545555-de59-438c-90f4-9770614c45f2" xlink:to="loc_us-gaap_OperatingIncomeLoss_5268ab0a-e7e1-4111-8bb1-06151fccabf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de4f111-a139-4cc6-875b-199b4b927a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1a545555-de59-438c-90f4-9770614c45f2" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de4f111-a139-4cc6-875b-199b4b927a50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_3f30178b-ece9-4660-bc64-5aa3f583f1ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de4f111-a139-4cc6-875b-199b4b927a50" xlink:to="loc_srt_ConsolidationItemsAxis_3f30178b-ece9-4660-bc64-5aa3f583f1ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_3f30178b-ece9-4660-bc64-5aa3f583f1ba_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_3f30178b-ece9-4660-bc64-5aa3f583f1ba" xlink:to="loc_srt_ConsolidationItemsDomain_3f30178b-ece9-4660-bc64-5aa3f583f1ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ccbb8f69-3e70-41fb-923a-433d2f13a651" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_3f30178b-ece9-4660-bc64-5aa3f583f1ba" xlink:to="loc_srt_ConsolidationItemsDomain_ccbb8f69-3e70-41fb-923a-433d2f13a651" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_9c7ba33e-614d-4fe2-973a-fd2c64b928f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ccbb8f69-3e70-41fb-923a-433d2f13a651" xlink:to="loc_us-gaap_OperatingSegmentsMember_9c7ba33e-614d-4fe2-973a-fd2c64b928f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_c081bbda-629c-47b2-804f-2a8748ec5a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ccbb8f69-3e70-41fb-923a-433d2f13a651" xlink:to="loc_us-gaap_CorporateNonSegmentMember_c081bbda-629c-47b2-804f-2a8748ec5a96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ecdb992f-cc7c-44df-b56e-795e51532382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de4f111-a139-4cc6-875b-199b4b927a50" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ecdb992f-cc7c-44df-b56e-795e51532382" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ecdb992f-cc7c-44df-b56e-795e51532382_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ecdb992f-cc7c-44df-b56e-795e51532382" xlink:to="loc_us-gaap_SegmentDomain_ecdb992f-cc7c-44df-b56e-795e51532382_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_72ceec85-524c-4b1d-95ad-56db07441bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ecdb992f-cc7c-44df-b56e-795e51532382" xlink:to="loc_us-gaap_SegmentDomain_72ceec85-524c-4b1d-95ad-56db07441bcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_f7f5ccd1-d513-4453-b002-a497982b5010" xlink:href="cah-20210930.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_72ceec85-524c-4b1d-95ad-56db07441bcc" xlink:to="loc_cah_PharmaceuticalMember_f7f5ccd1-d513-4453-b002-a497982b5010" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_86cce19b-b2d3-468a-b727-0087e5e11b82" xlink:href="cah-20210930.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_72ceec85-524c-4b1d-95ad-56db07441bcc" xlink:to="loc_cah_MedicalMember_86cce19b-b2d3-468a-b727-0087e5e11b82" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended" id="i61f73c696dbe40ebbf2c9102df51876d_SegmentInformationAssetsbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_3ffd3a8a-6c7e-4229-844a-8549f90494af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7efba76e-66d8-43d5-aa5b-502143203aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3ffd3a8a-6c7e-4229-844a-8549f90494af" xlink:to="loc_us-gaap_Assets_7efba76e-66d8-43d5-aa5b-502143203aa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_f5b6f129-017c-4963-a30d-abe9dfa36487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3ffd3a8a-6c7e-4229-844a-8549f90494af" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_f5b6f129-017c-4963-a30d-abe9dfa36487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c8f77f2d-5d96-464c-a269-bc3e8806c94a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3ffd3a8a-6c7e-4229-844a-8549f90494af" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c8f77f2d-5d96-464c-a269-bc3e8806c94a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f5d43fca-1346-4485-be6d-a519e19a06c1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c8f77f2d-5d96-464c-a269-bc3e8806c94a" xlink:to="loc_srt_ConsolidationItemsAxis_f5d43fca-1346-4485-be6d-a519e19a06c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f5d43fca-1346-4485-be6d-a519e19a06c1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_f5d43fca-1346-4485-be6d-a519e19a06c1" xlink:to="loc_srt_ConsolidationItemsDomain_f5d43fca-1346-4485-be6d-a519e19a06c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f536461a-1a35-494c-8a9e-147f7a1b6265" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_f5d43fca-1346-4485-be6d-a519e19a06c1" xlink:to="loc_srt_ConsolidationItemsDomain_f536461a-1a35-494c-8a9e-147f7a1b6265" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_2fafe388-4c21-4cda-9477-14b4e612d317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_f536461a-1a35-494c-8a9e-147f7a1b6265" xlink:to="loc_us-gaap_OperatingSegmentsMember_2fafe388-4c21-4cda-9477-14b4e612d317" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_abce6825-a416-4dcd-9f9f-8a121f28f413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_f536461a-1a35-494c-8a9e-147f7a1b6265" xlink:to="loc_us-gaap_CorporateNonSegmentMember_abce6825-a416-4dcd-9f9f-8a121f28f413" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_57fea08d-f9ee-4bdf-b63d-76ffd78124fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c8f77f2d-5d96-464c-a269-bc3e8806c94a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_57fea08d-f9ee-4bdf-b63d-76ffd78124fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_57fea08d-f9ee-4bdf-b63d-76ffd78124fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_57fea08d-f9ee-4bdf-b63d-76ffd78124fe" xlink:to="loc_us-gaap_SegmentDomain_57fea08d-f9ee-4bdf-b63d-76ffd78124fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_634fdcbc-2e55-4408-8853-dc1c380915d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_57fea08d-f9ee-4bdf-b63d-76ffd78124fe" xlink:to="loc_us-gaap_SegmentDomain_634fdcbc-2e55-4408-8853-dc1c380915d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_5e78c265-3203-4e59-bcd4-913b2080a04d" xlink:href="cah-20210930.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_634fdcbc-2e55-4408-8853-dc1c380915d7" xlink:to="loc_cah_PharmaceuticalMember_5e78c265-3203-4e59-bcd4-913b2080a04d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_c20e676c-a5e8-4c3b-9b7f-dd265369a136" xlink:href="cah-20210930.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_634fdcbc-2e55-4408-8853-dc1c380915d7" xlink:to="loc_cah_MedicalMember_c20e676c-a5e8-4c3b-9b7f-dd265369a136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_35e6db99-727e-427b-ae08-68775725d608" xlink:href="cah-20210930.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c8f77f2d-5d96-464c-a269-bc3e8806c94a" xlink:to="loc_cah_CordisDivestitureAxis_35e6db99-727e-427b-ae08-68775725d608" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_35e6db99-727e-427b-ae08-68775725d608_default" xlink:href="cah-20210930.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_35e6db99-727e-427b-ae08-68775725d608" xlink:to="loc_cah_CordisDivestitureDomain_35e6db99-727e-427b-ae08-68775725d608_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_8755d91e-6db9-42b9-873f-296076a89c34" xlink:href="cah-20210930.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_35e6db99-727e-427b-ae08-68775725d608" xlink:to="loc_cah_CordisDivestitureDomain_8755d91e-6db9-42b9-873f-296076a89c34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_f5178043-dc13-4b6b-bf60-1827667a31e4" xlink:href="cah-20210930.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_8755d91e-6db9-42b9-873f-296076a89c34" xlink:to="loc_cah_CordisDivestitureMember_f5178043-dc13-4b6b-bf60-1827667a31e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" xlink:type="extended" id="ife5a82879d514a6191ef821da440a4b2_SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_82df9f9d-60ac-4b77-92ab-bc741cbfcbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a6389d45-82a8-4e49-90ae-34642fa58bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_82df9f9d-60ac-4b77-92ab-bc741cbfcbd5" xlink:to="loc_us-gaap_Revenues_a6389d45-82a8-4e49-90ae-34642fa58bc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_963cf7ef-1e56-4711-ba91-41fa72a3815f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_82df9f9d-60ac-4b77-92ab-bc741cbfcbd5" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_963cf7ef-1e56-4711-ba91-41fa72a3815f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentAxis_88450b1d-571a-4cbf-a422-864458004bdc" xlink:href="cah-20210930.xsd#cah_MedicalSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_963cf7ef-1e56-4711-ba91-41fa72a3815f" xlink:to="loc_cah_MedicalSegmentAxis_88450b1d-571a-4cbf-a422-864458004bdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentDomain_88450b1d-571a-4cbf-a422-864458004bdc_default" xlink:href="cah-20210930.xsd#cah_MedicalSegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_MedicalSegmentAxis_88450b1d-571a-4cbf-a422-864458004bdc" xlink:to="loc_cah_MedicalSegmentDomain_88450b1d-571a-4cbf-a422-864458004bdc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentDomain_66147dac-697e-4833-9082-9d847ecc1f29" xlink:href="cah-20210930.xsd#cah_MedicalSegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_MedicalSegmentAxis_88450b1d-571a-4cbf-a422-864458004bdc" xlink:to="loc_cah_MedicalSegmentDomain_66147dac-697e-4833-9082-9d847ecc1f29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_d3bb7927-38e3-4d5f-b4e5-c6e140d5820b" xlink:href="cah-20210930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_MedicalSegmentDomain_66147dac-697e-4833-9082-9d847ecc1f29" xlink:to="loc_cah_MedicaldistributionandproductsMember_d3bb7927-38e3-4d5f-b4e5-c6e140d5820b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentAxis_b320dc62-739d-495f-afa9-2211d35af5d2" xlink:href="cah-20210930.xsd#cah_PharmaceuticalSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_963cf7ef-1e56-4711-ba91-41fa72a3815f" xlink:to="loc_cah_PharmaceuticalSegmentAxis_b320dc62-739d-495f-afa9-2211d35af5d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentDomain_b320dc62-739d-495f-afa9-2211d35af5d2_default" xlink:href="cah-20210930.xsd#cah_PharmaceuticalSegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_PharmaceuticalSegmentAxis_b320dc62-739d-495f-afa9-2211d35af5d2" xlink:to="loc_cah_PharmaceuticalSegmentDomain_b320dc62-739d-495f-afa9-2211d35af5d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentDomain_4a147363-6b0a-4e9a-91f4-ffdb9dd0c7db" xlink:href="cah-20210930.xsd#cah_PharmaceuticalSegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_PharmaceuticalSegmentAxis_b320dc62-739d-495f-afa9-2211d35af5d2" xlink:to="loc_cah_PharmaceuticalSegmentDomain_4a147363-6b0a-4e9a-91f4-ffdb9dd0c7db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_789e392c-0d2b-4113-b37a-707028f737d3" xlink:href="cah-20210930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_PharmaceuticalSegmentDomain_4a147363-6b0a-4e9a-91f4-ffdb9dd0c7db" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_789e392c-0d2b-4113-b37a-707028f737d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_fcbfd64a-5a14-4f3c-bd95-8205984363d0" xlink:href="cah-20210930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_PharmaceuticalSegmentDomain_4a147363-6b0a-4e9a-91f4-ffdb9dd0c7db" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_fcbfd64a-5a14-4f3c-bd95-8205984363d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9d1db238-475d-44e5-84a3-d7c0109a9420" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_963cf7ef-1e56-4711-ba91-41fa72a3815f" xlink:to="loc_srt_ConsolidationItemsAxis_9d1db238-475d-44e5-84a3-d7c0109a9420" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_9d1db238-475d-44e5-84a3-d7c0109a9420_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_9d1db238-475d-44e5-84a3-d7c0109a9420" xlink:to="loc_srt_ConsolidationItemsDomain_9d1db238-475d-44e5-84a3-d7c0109a9420_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_020367a5-eaba-462e-b8a4-04517e35431a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_9d1db238-475d-44e5-84a3-d7c0109a9420" xlink:to="loc_srt_ConsolidationItemsDomain_020367a5-eaba-462e-b8a4-04517e35431a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_2b25e19e-ab05-4f12-bdb3-5fd126e5fb13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_020367a5-eaba-462e-b8a4-04517e35431a" xlink:to="loc_us-gaap_OperatingSegmentsMember_2b25e19e-ab05-4f12-bdb3-5fd126e5fb13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_4bee1562-36fb-47bb-85ac-9e1e2b156d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_020367a5-eaba-462e-b8a4-04517e35431a" xlink:to="loc_us-gaap_CorporateNonSegmentMember_4bee1562-36fb-47bb-85ac-9e1e2b156d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_daf1fa3a-147a-44f9-aa2d-dbf2ac564f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_963cf7ef-1e56-4711-ba91-41fa72a3815f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_daf1fa3a-147a-44f9-aa2d-dbf2ac564f7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_daf1fa3a-147a-44f9-aa2d-dbf2ac564f7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_daf1fa3a-147a-44f9-aa2d-dbf2ac564f7c" xlink:to="loc_us-gaap_SegmentDomain_daf1fa3a-147a-44f9-aa2d-dbf2ac564f7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cab3ecb1-f133-465a-9260-a3957b44106b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_daf1fa3a-147a-44f9-aa2d-dbf2ac564f7c" xlink:to="loc_us-gaap_SegmentDomain_cab3ecb1-f133-465a-9260-a3957b44106b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_0e36da6d-768c-4d76-a388-48cea4b5b25c" xlink:href="cah-20210930.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cab3ecb1-f133-465a-9260-a3957b44106b" xlink:to="loc_cah_PharmaceuticalMember_0e36da6d-768c-4d76-a388-48cea4b5b25c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_96e19227-8721-4208-8a16-b49769c6bf73" xlink:href="cah-20210930.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cab3ecb1-f133-465a-9260-a3957b44106b" xlink:to="loc_cah_MedicalMember_96e19227-8721-4208-8a16-b49769c6bf73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_1553aaba-3859-4396-889e-03f63e1bdcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_963cf7ef-1e56-4711-ba91-41fa72a3815f" xlink:to="loc_us-gaap_SubsegmentsAxis_1553aaba-3859-4396-889e-03f63e1bdcd4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_1553aaba-3859-4396-889e-03f63e1bdcd4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_1553aaba-3859-4396-889e-03f63e1bdcd4" xlink:to="loc_us-gaap_SubsegmentsDomain_1553aaba-3859-4396-889e-03f63e1bdcd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_bd7a1e87-c0e5-4710-93d1-b3310395e8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_1553aaba-3859-4396-889e-03f63e1bdcd4" xlink:to="loc_us-gaap_SubsegmentsDomain_bd7a1e87-c0e5-4710-93d1-b3310395e8a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_71bf112d-2d09-4241-b337-2854c1f78f53" xlink:href="cah-20210930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_bd7a1e87-c0e5-4710-93d1-b3310395e8a4" xlink:to="loc_cah_MedicaldistributionandproductsMember_71bf112d-2d09-4241-b337-2854c1f78f53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_a026ee68-fe2f-46d8-ad6f-b8c91043a557" xlink:href="cah-20210930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_bd7a1e87-c0e5-4710-93d1-b3310395e8a4" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_a026ee68-fe2f-46d8-ad6f-b8c91043a557" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_9f726ba3-32ce-4457-a16d-0f119fcc35da" xlink:href="cah-20210930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_bd7a1e87-c0e5-4710-93d1-b3310395e8a4" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_9f726ba3-32ce-4457-a16d-0f119fcc35da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_5c9e1c91-485f-4778-8078-79ea16b3f6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_963cf7ef-1e56-4711-ba91-41fa72a3815f" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_5c9e1c91-485f-4778-8078-79ea16b3f6ec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_5c9e1c91-485f-4778-8078-79ea16b3f6ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_5c9e1c91-485f-4778-8078-79ea16b3f6ec" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_5c9e1c91-485f-4778-8078-79ea16b3f6ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_349153d8-c223-4273-b7e8-3a1beb2fd876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_5c9e1c91-485f-4778-8078-79ea16b3f6ec" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_349153d8-c223-4273-b7e8-3a1beb2fd876" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#SegmentInformationRevenuebyGeographicalSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" xlink:type="extended" id="i5af80a55d08142379fe4610b07fb5718_SegmentInformationRevenuebyGeographicalSegmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicLineItems_89d691aa-7712-4631-9512-07e45a97e6c8" xlink:href="cah-20210930.xsd#cah_SegmentRevenuebyGeographicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7d32ec6e-7020-4266-aedf-d24df38e94d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_SegmentRevenuebyGeographicLineItems_89d691aa-7712-4631-9512-07e45a97e6c8" xlink:to="loc_us-gaap_Revenues_7d32ec6e-7020-4266-aedf-d24df38e94d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicTable_76d42a96-48e9-421b-b84f-cc11e93f2fb7" xlink:href="cah-20210930.xsd#cah_SegmentRevenuebyGeographicTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cah_SegmentRevenuebyGeographicLineItems_89d691aa-7712-4631-9512-07e45a97e6c8" xlink:to="loc_cah_SegmentRevenuebyGeographicTable_76d42a96-48e9-421b-b84f-cc11e93f2fb7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_96aaa0c6-50c8-46a7-8b3c-bda03d88ad5f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_76d42a96-48e9-421b-b84f-cc11e93f2fb7" xlink:to="loc_srt_ConsolidationItemsAxis_96aaa0c6-50c8-46a7-8b3c-bda03d88ad5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_96aaa0c6-50c8-46a7-8b3c-bda03d88ad5f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_96aaa0c6-50c8-46a7-8b3c-bda03d88ad5f" xlink:to="loc_srt_ConsolidationItemsDomain_96aaa0c6-50c8-46a7-8b3c-bda03d88ad5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_cc034d84-e959-4cdf-bd5d-4610e7e46487" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_96aaa0c6-50c8-46a7-8b3c-bda03d88ad5f" xlink:to="loc_srt_ConsolidationItemsDomain_cc034d84-e959-4cdf-bd5d-4610e7e46487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_8aee369e-04f3-498e-acf5-0753b9d6254d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_cc034d84-e959-4cdf-bd5d-4610e7e46487" xlink:to="loc_us-gaap_OperatingSegmentsMember_8aee369e-04f3-498e-acf5-0753b9d6254d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_aca5235a-41c4-46bd-b368-883736aacdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingSegmentsMember_8aee369e-04f3-498e-acf5-0753b9d6254d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_aca5235a-41c4-46bd-b368-883736aacdcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_20ae68a6-8f69-4308-b3f1-5386c9b6d315" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_76d42a96-48e9-421b-b84f-cc11e93f2fb7" xlink:to="loc_srt_StatementGeographicalAxis_20ae68a6-8f69-4308-b3f1-5386c9b6d315" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_20ae68a6-8f69-4308-b3f1-5386c9b6d315_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_20ae68a6-8f69-4308-b3f1-5386c9b6d315" xlink:to="loc_srt_SegmentGeographicalDomain_20ae68a6-8f69-4308-b3f1-5386c9b6d315_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e8ea4ef2-0761-489f-8c73-d90eafc75f24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_20ae68a6-8f69-4308-b3f1-5386c9b6d315" xlink:to="loc_srt_SegmentGeographicalDomain_e8ea4ef2-0761-489f-8c73-d90eafc75f24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3aa07a85-70b9-4a70-aba3-3b868583f289" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e8ea4ef2-0761-489f-8c73-d90eafc75f24" xlink:to="loc_country_US_3aa07a85-70b9-4a70-aba3-3b868583f289" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_a979ac58-a8fd-4838-8257-6317670a604b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e8ea4ef2-0761-489f-8c73-d90eafc75f24" xlink:to="loc_us-gaap_NonUsMember_a979ac58-a8fd-4838-8257-6317670a604b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended" id="i488c3b271da44585b946866aa0663836_ShareBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65fea4a1-2608-4aa1-881b-82a54f2edc99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_d392b867-df30-4c59-a8a7-700d9f10e2f8" xlink:href="cah-20210930.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65fea4a1-2608-4aa1-881b-82a54f2edc99" xlink:to="loc_cah_VestingPeriodinyearsforShares_d392b867-df30-4c59-a8a7-700d9f10e2f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_dd351bea-d317-4296-be1a-7fbd468fd2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65fea4a1-2608-4aa1-881b-82a54f2edc99" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_dd351bea-d317-4296-be1a-7fbd468fd2a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bfaeaf31-a16f-4709-9aeb-c362a4cc9e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65fea4a1-2608-4aa1-881b-82a54f2edc99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bfaeaf31-a16f-4709-9aeb-c362a4cc9e8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4a13284d-305d-484f-838b-b29088d77cae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65fea4a1-2608-4aa1-881b-82a54f2edc99" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4a13284d-305d-484f-838b-b29088d77cae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e0786852-7723-4ca3-af74-145db737bf40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65fea4a1-2608-4aa1-881b-82a54f2edc99" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e0786852-7723-4ca3-af74-145db737bf40" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ExercisablePeriodOfPlansInYears_771bc0b7-c86e-4539-b2d7-54cdc19c58a2" xlink:href="cah-20210930.xsd#cah_ExercisablePeriodOfPlansInYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65fea4a1-2608-4aa1-881b-82a54f2edc99" xlink:to="loc_cah_ExercisablePeriodOfPlansInYears_771bc0b7-c86e-4539-b2d7-54cdc19c58a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_62ac9e8b-6da6-4a22-84d6-dc8402ff8278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65fea4a1-2608-4aa1-881b-82a54f2edc99" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_62ac9e8b-6da6-4a22-84d6-dc8402ff8278" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4bc42617-a8fd-4eee-b536-102916fc9e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65fea4a1-2608-4aa1-881b-82a54f2edc99" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4bc42617-a8fd-4eee-b536-102916fc9e17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9f9fd72e-caab-44a7-a37f-784b3dfe521f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4bc42617-a8fd-4eee-b536-102916fc9e17" xlink:to="loc_us-gaap_AwardTypeAxis_9f9fd72e-caab-44a7-a37f-784b3dfe521f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f9fd72e-caab-44a7-a37f-784b3dfe521f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9f9fd72e-caab-44a7-a37f-784b3dfe521f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f9fd72e-caab-44a7-a37f-784b3dfe521f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8417fca-9952-4114-885d-bc29137dc328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9f9fd72e-caab-44a7-a37f-784b3dfe521f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8417fca-9952-4114-885d-bc29137dc328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a373beea-3e2d-4423-940f-956e9af93c07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8417fca-9952-4114-885d-bc29137dc328" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a373beea-3e2d-4423-940f-956e9af93c07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7cf12951-9286-41a9-a581-17d61e8bd1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8417fca-9952-4114-885d-bc29137dc328" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7cf12951-9286-41a9-a581-17d61e8bd1a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0c535ef4-3e61-4c35-8300-c75fc53c09c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8417fca-9952-4114-885d-bc29137dc328" xlink:to="loc_us-gaap_PerformanceSharesMember_0c535ef4-3e61-4c35-8300-c75fc53c09c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_96b47cee-786b-40b0-9c0b-3333419e48af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4bc42617-a8fd-4eee-b536-102916fc9e17" xlink:to="loc_srt_RangeAxis_96b47cee-786b-40b0-9c0b-3333419e48af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_96b47cee-786b-40b0-9c0b-3333419e48af_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_96b47cee-786b-40b0-9c0b-3333419e48af" xlink:to="loc_srt_RangeMember_96b47cee-786b-40b0-9c0b-3333419e48af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ef24130b-221f-440b-8c22-a52ada57eeba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_96b47cee-786b-40b0-9c0b-3333419e48af" xlink:to="loc_srt_RangeMember_ef24130b-221f-440b-8c22-a52ada57eeba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ff84053d-9e8e-429b-b28d-3e1c38a01c87" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ef24130b-221f-440b-8c22-a52ada57eeba" xlink:to="loc_srt_MinimumMember_ff84053d-9e8e-429b-b28d-3e1c38a01c87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ac1909ed-bea2-4738-838e-e03f289cbc7f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ef24130b-221f-440b-8c22-a52ada57eeba" xlink:to="loc_srt_MaximumMember_ac1909ed-bea2-4738-838e-e03f289cbc7f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended" id="i130074536a6048428d0d1ce9a83ca1e7_ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f4335c0b-f2b3-4c37-8ff4-204ecba8cfcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3bb92064-7f3b-4a9e-9c65-5d924aa0c7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f4335c0b-f2b3-4c37-8ff4-204ecba8cfcb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3bb92064-7f3b-4a9e-9c65-5d924aa0c7a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_431f019a-8757-40ea-a654-57cac11558b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f4335c0b-f2b3-4c37-8ff4-204ecba8cfcb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_431f019a-8757-40ea-a654-57cac11558b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_afc20111-0a3a-4d6c-93e1-37b840fd167e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_431f019a-8757-40ea-a654-57cac11558b9" xlink:to="loc_us-gaap_AwardTypeAxis_afc20111-0a3a-4d6c-93e1-37b840fd167e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_afc20111-0a3a-4d6c-93e1-37b840fd167e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_afc20111-0a3a-4d6c-93e1-37b840fd167e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_afc20111-0a3a-4d6c-93e1-37b840fd167e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1d38f76-83ef-420b-a9f2-0762b42e05f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_afc20111-0a3a-4d6c-93e1-37b840fd167e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1d38f76-83ef-420b-a9f2-0762b42e05f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_69456ea2-2632-40a6-b0ad-b508c79e4b94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1d38f76-83ef-420b-a9f2-0762b42e05f0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_69456ea2-2632-40a6-b0ad-b508c79e4b94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6782daaf-802b-4d75-9b4f-6bb50753d0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1d38f76-83ef-420b-a9f2-0762b42e05f0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6782daaf-802b-4d75-9b4f-6bb50753d0f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d5cd9fa3-89fc-4f37-9112-2318b2ca8d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1d38f76-83ef-420b-a9f2-0762b42e05f0" xlink:to="loc_us-gaap_PerformanceSharesMember_d5cd9fa3-89fc-4f37-9112-2318b2ca8d07" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="extended" id="i200f69859d9442b6bbb9257c3aa28d4a_ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c2aef1-d65d-48ff-af56-33dbc8429dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_921c60fc-079f-4f1d-b99b-2bd1070ec71f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c2aef1-d65d-48ff-af56-33dbc8429dc7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_921c60fc-079f-4f1d-b99b-2bd1070ec71f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_70020849-34df-40bf-b373-5bb994922ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c2aef1-d65d-48ff-af56-33dbc8429dc7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_70020849-34df-40bf-b373-5bb994922ad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1457ba21-7052-4b9e-a21d-83e1f9bf5cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c2aef1-d65d-48ff-af56-33dbc8429dc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1457ba21-7052-4b9e-a21d-83e1f9bf5cdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d9d96208-f999-4500-abe5-4c4ca80b5e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c2aef1-d65d-48ff-af56-33dbc8429dc7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d9d96208-f999-4500-abe5-4c4ca80b5e82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bbac59ca-25db-480c-acdb-cc77d3979283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c2aef1-d65d-48ff-af56-33dbc8429dc7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bbac59ca-25db-480c-acdb-cc77d3979283" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7e8cf6c0-2be1-46f9-aaf3-200268c3eb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c2aef1-d65d-48ff-af56-33dbc8429dc7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7e8cf6c0-2be1-46f9-aaf3-200268c3eb2d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b423f52-2334-4243-81e1-cc7d15d9dcad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c2aef1-d65d-48ff-af56-33dbc8429dc7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b423f52-2334-4243-81e1-cc7d15d9dcad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f7f4e25c-5e53-4cba-8745-5efff8afc58f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b423f52-2334-4243-81e1-cc7d15d9dcad" xlink:to="loc_us-gaap_AwardTypeAxis_f7f4e25c-5e53-4cba-8745-5efff8afc58f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7f4e25c-5e53-4cba-8745-5efff8afc58f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f7f4e25c-5e53-4cba-8745-5efff8afc58f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7f4e25c-5e53-4cba-8745-5efff8afc58f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fd69864-9cf8-4186-8de2-f47d142591da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f7f4e25c-5e53-4cba-8745-5efff8afc58f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fd69864-9cf8-4186-8de2-f47d142591da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b82a45a8-5687-48e3-af74-4066aada0ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fd69864-9cf8-4186-8de2-f47d142591da" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b82a45a8-5687-48e3-af74-4066aada0ca9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended" id="ic4c4f61fa1c0471591d24796ec3eda97_ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45080c9a-7f41-4a9a-94b7-f0d3ab7e367a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6fc88355-5a07-413f-ac44-8af68ee8e19d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45080c9a-7f41-4a9a-94b7-f0d3ab7e367a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6fc88355-5a07-413f-ac44-8af68ee8e19d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66a1bc72-a5c3-4c9e-b0d7-8ddf7c499cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45080c9a-7f41-4a9a-94b7-f0d3ab7e367a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66a1bc72-a5c3-4c9e-b0d7-8ddf7c499cb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2b008890-4008-465e-9c16-0ae860cf617a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66a1bc72-a5c3-4c9e-b0d7-8ddf7c499cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2b008890-4008-465e-9c16-0ae860cf617a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ad946499-ce52-46f8-a19f-94660e41ffc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66a1bc72-a5c3-4c9e-b0d7-8ddf7c499cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ad946499-ce52-46f8-a19f-94660e41ffc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c9190733-930c-4913-8826-3b46c483064e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66a1bc72-a5c3-4c9e-b0d7-8ddf7c499cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c9190733-930c-4913-8826-3b46c483064e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fe5b75f4-37f5-425d-aa7d-36eb9f14529f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66a1bc72-a5c3-4c9e-b0d7-8ddf7c499cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fe5b75f4-37f5-425d-aa7d-36eb9f14529f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a08f04b2-67c1-4aac-94f6-b747d546297f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eb06b716-388c-423f-9298-910056f39168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45080c9a-7f41-4a9a-94b7-f0d3ab7e367a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eb06b716-388c-423f-9298-910056f39168" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c593cc4a-9d03-4534-9d28-c2f966bfc7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eb06b716-388c-423f-9298-910056f39168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c593cc4a-9d03-4534-9d28-c2f966bfc7ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ff8539d-a902-41eb-beab-dcb096cb5345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eb06b716-388c-423f-9298-910056f39168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ff8539d-a902-41eb-beab-dcb096cb5345" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f96ad8b5-f968-476b-9535-2bfc248e164c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eb06b716-388c-423f-9298-910056f39168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f96ad8b5-f968-476b-9535-2bfc248e164c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_974fc0c9-f1f3-4e63-b405-92d347c1bb94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eb06b716-388c-423f-9298-910056f39168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_974fc0c9-f1f3-4e63-b405-92d347c1bb94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4b83f82e-5332-4014-b5c7-a843660fea34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f583a164-e7e2-4726-81fd-26174221903f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45080c9a-7f41-4a9a-94b7-f0d3ab7e367a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f583a164-e7e2-4726-81fd-26174221903f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cb3f8ea6-c300-4948-9f6a-84c413aa91d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f583a164-e7e2-4726-81fd-26174221903f" xlink:to="loc_us-gaap_AwardTypeAxis_cb3f8ea6-c300-4948-9f6a-84c413aa91d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb3f8ea6-c300-4948-9f6a-84c413aa91d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cb3f8ea6-c300-4948-9f6a-84c413aa91d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb3f8ea6-c300-4948-9f6a-84c413aa91d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9df3837f-64a7-44c2-a0ee-6f2ca1a8f2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cb3f8ea6-c300-4948-9f6a-84c413aa91d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9df3837f-64a7-44c2-a0ee-6f2ca1a8f2cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_faabf0ec-abaf-4bd9-b14a-a1cb8982fa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9df3837f-64a7-44c2-a0ee-6f2ca1a8f2cc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_faabf0ec-abaf-4bd9-b14a-a1cb8982fa5e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended" id="ifda3d8f560774f5390ef1f0f2ed9d22c_ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f84c3b58-e298-41fd-b780-0fc057709148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_60596f3b-7db4-412e-80ce-9cfc942d327f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f84c3b58-e298-41fd-b780-0fc057709148" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_60596f3b-7db4-412e-80ce-9cfc942d327f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82de6ff6-aeb3-40c1-b364-262da0dd5f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f84c3b58-e298-41fd-b780-0fc057709148" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82de6ff6-aeb3-40c1-b364-262da0dd5f4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ce5a54d7-71e0-41e7-8191-20a1932cf406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82de6ff6-aeb3-40c1-b364-262da0dd5f4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ce5a54d7-71e0-41e7-8191-20a1932cf406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_08a44463-bc33-4b1e-9bbc-bac2192ff278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82de6ff6-aeb3-40c1-b364-262da0dd5f4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_08a44463-bc33-4b1e-9bbc-bac2192ff278" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7603b586-d311-4429-8ce0-b10f7ef4a392" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82de6ff6-aeb3-40c1-b364-262da0dd5f4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7603b586-d311-4429-8ce0-b10f7ef4a392" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2dc476ad-b0c6-4e6d-9ee3-d60474a311a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82de6ff6-aeb3-40c1-b364-262da0dd5f4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2dc476ad-b0c6-4e6d-9ee3-d60474a311a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d7a71a8a-f8d0-445f-bd28-e7af249af6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0df362a2-7eab-4c48-a6d0-2bfda93bbe58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f84c3b58-e298-41fd-b780-0fc057709148" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0df362a2-7eab-4c48-a6d0-2bfda93bbe58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2a397012-81ec-4e01-89d5-433ecda551e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0df362a2-7eab-4c48-a6d0-2bfda93bbe58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2a397012-81ec-4e01-89d5-433ecda551e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d975f712-8842-4e0f-9044-280389fe5779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0df362a2-7eab-4c48-a6d0-2bfda93bbe58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d975f712-8842-4e0f-9044-280389fe5779" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b7f9766f-89e6-41b6-92f3-e2edbef05376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0df362a2-7eab-4c48-a6d0-2bfda93bbe58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b7f9766f-89e6-41b6-92f3-e2edbef05376" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_25af2d41-553b-4d39-a9be-7c7bb073db71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0df362a2-7eab-4c48-a6d0-2bfda93bbe58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_25af2d41-553b-4d39-a9be-7c7bb073db71" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0179ee91-90c6-40a4-a631-aa1bd3c4ec99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3c0e6bd6-c0c1-4ab1-b3ff-ba3308c63f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f84c3b58-e298-41fd-b780-0fc057709148" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3c0e6bd6-c0c1-4ab1-b3ff-ba3308c63f7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ee0212e9-39a6-414c-bdfc-7abc06a8a8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f84c3b58-e298-41fd-b780-0fc057709148" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ee0212e9-39a6-414c-bdfc-7abc06a8a8dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c59e4705-7be6-42ab-be41-7940d488bfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f84c3b58-e298-41fd-b780-0fc057709148" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c59e4705-7be6-42ab-be41-7940d488bfc7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e5e39bd1-eb87-44c1-858c-d56e31c192ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c59e4705-7be6-42ab-be41-7940d488bfc7" xlink:to="loc_us-gaap_AwardTypeAxis_e5e39bd1-eb87-44c1-858c-d56e31c192ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5e39bd1-eb87-44c1-858c-d56e31c192ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e5e39bd1-eb87-44c1-858c-d56e31c192ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5e39bd1-eb87-44c1-858c-d56e31c192ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0a95218-7361-451d-84ea-026a3e157ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e5e39bd1-eb87-44c1-858c-d56e31c192ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0a95218-7361-451d-84ea-026a3e157ec0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_24fc6a61-a57a-4a26-a020-6cd4228ab287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0a95218-7361-451d-84ea-026a3e157ec0" xlink:to="loc_us-gaap_PerformanceSharesMember_24fc6a61-a57a-4a26-a020-6cd4228ab287" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>cah-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2425d19b-e3e9-4a9a-b18c-4fd89ecf0bc7,g:620f6444-992f-4a20-8893-967dcaed6c73-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_HedgingDesignationDomain_5ccec638-e93a-4a79-b6ff-d78f8ebd00db_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_5108c9f9-0c30-4540-be21-61e61f04a7b8_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fb39910d-624e-4813-bdab-7a0bd072e6e8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2b59589a-923a-4d63-b636-20def34d3d42_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d45709bb-7abe-46f0-a5d6-a8a94261c5bb_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss) attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_78702037-8087-4862-a36f-40840a4b30bb_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Earnings/(Loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ccf88ef8-fa39-4866-8554-35ab0361ff43_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_d0a056a1-2ec2-448b-8146-9fd17693c5ef_terseLabel_en-US" xlink:label="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares that would be antidilutive as a result of net loss</link:label>
    <link:label id="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_label_en-US" xlink:label="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares that would be antidilutive as a result of net loss</link:label>
    <link:label id="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_documentation_en-US" xlink:label="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares that would be antidilutive as a result of net loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:href="cah-20210930.xsd#cah_Sharesthatwouldbeantidilutiveasaresultofnetloss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:to="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_40046263-d58b-4d1a-9985-7b3700f35a85_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_3a389999-1c01-4be4-9f9c-3f95fb490ab1_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3e6d59e9-6c7f-47b3-ad1e-860f80b63d83_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b0379e61-a84f-4308-a6b2-018786d604f6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalMember_76bef43a-e10e-44c9-b701-e563d977cd95_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_cah_PharmaceuticalMember_label_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Member</link:label>
    <link:label id="lab_cah_PharmaceuticalMember_documentation_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember" xlink:href="cah-20210930.xsd#cah_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalMember" xlink:to="lab_cah_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2d37bb24-95bf-4f77-8eee-88c00030da25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_19c9b719-8770-4c6a-bb20-603aa33151da_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalSegmentAxis_e681ffa2-61af-4b37-b525-8ecd779457e7_terseLabel_en-US" xlink:label="lab_cah_MedicalSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Segment [Axis]</link:label>
    <link:label id="lab_cah_MedicalSegmentAxis_label_en-US" xlink:label="lab_cah_MedicalSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Segment [Axis]</link:label>
    <link:label id="lab_cah_MedicalSegmentAxis_documentation_en-US" xlink:label="lab_cah_MedicalSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Segment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentAxis" xlink:href="cah-20210930.xsd#cah_MedicalSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalSegmentAxis" xlink:to="lab_cah_MedicalSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_560ce348-6485-4f3a-9c8b-1e301c0a4c74_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_29875236-08c2-440a-8b2f-4f8975b9d7d7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2e869a07-1115-4f86-af08-110def5779fc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_a6beed63-4a1a-40a6-8da1-2b91d16dde0c_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Reportable Segment</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_f7d38f1a-26d8-4791-b715-326dcced1654_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_61272bde-8790-4bdb-8945-cfea9ddc8805_terseLabel_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_label_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_documentation_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares" xlink:href="cah-20210930.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_VestingPeriodinyearsforShares" xlink:to="lab_cah_VestingPeriodinyearsforShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_db61c077-21fc-4693-a1ad-efb4e8759ec3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_7027a86f-c752-47da-a3e5-f23c1eb958a3_terseLabel_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_label_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember" xlink:href="cah-20210930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProductLiabilityLawsuitsMember" xlink:to="lab_cah_ProductLiabilityLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_eb65cdef-3469-4626-9ce0-1063df1b413b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, without par value:</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_eefa54d9-aca9-4f6d-9e71-c7713b21b075_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes and other liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax and Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ClassActionLawsuitsMember_db5d0b27-c750-4bc1-9ae6-24002e546421_terseLabel_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_label_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember" xlink:href="cah-20210930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ClassActionLawsuitsMember" xlink:to="lab_cah_ClassActionLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1626567d-b3b2-498a-b82b-fe9f0af30032_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_143e7443-ee28-4f00-8c53-2682c6f20c46_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_f5be8d1c-ab7b-49de-8c6c-71e993f65d8d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_d5bfbc7f-c177-4255-b4fc-308ff47b612b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_0126533d-a768-41d7-b4ae-fb3528287853_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits_7b76d4e1-cf78-41fd-bb2e-62478da26e1b_terseLabel_en-US" xlink:label="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuits Against Distributors</link:label>
    <link:label id="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits_label_en-US" xlink:label="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of State Attorneys General filing lawsuits</link:label>
    <link:label id="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits_documentation_en-US" xlink:label="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of State Attorneys General filing lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:href="cah-20210930.xsd#cah_NumberofStateAttorneysGeneralfilinglawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:to="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureDomain_e6296866-5541-4050-9f6e-855d2af7443e_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:label id="lab_cah_CordisDivestitureDomain_label_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:label id="lab_cah_CordisDivestitureDomain_documentation_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain" xlink:href="cah-20210930.xsd#cah_CordisDivestitureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureDomain" xlink:to="lab_cah_CordisDivestitureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_dd8edd55-d156-4bf3-8e51-303f06827e04_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_3be5a7bc-8f8a-40ca-af60-219edf0186f8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_6931cabb-0752-4da2-8319-cce11e828a67_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Charges</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_924be62b-691b-4251-b60b-e4fcf1014bb3_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_e232df33-8f6e-4189-b468-af2def6d588e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_c75b3967-5ca6-439d-baae-803131c64957_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NuclearPrecisionHealthServicesMember_57f28169-aab0-4822-aabd-a7e9b6e3536d_terseLabel_en-US" xlink:label="lab_cah_NuclearPrecisionHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:label id="lab_cah_NuclearPrecisionHealthServicesMember_label_en-US" xlink:label="lab_cah_NuclearPrecisionHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:label id="lab_cah_NuclearPrecisionHealthServicesMember_documentation_en-US" xlink:label="lab_cah_NuclearPrecisionHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember" xlink:href="cah-20210930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NuclearPrecisionHealthServicesMember" xlink:to="lab_cah_NuclearPrecisionHealthServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5da43bd4-b64a-4859-a8a9-d12549e22a92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_1b8c4f26-3728-46f6-943f-0128e27b23c7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4a0ddc3a-8d7c-4a85-83b5-f5490d44c252_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_dd9f59e2-827b-471c-bc7b-3951428fab6d_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_2c93576b-9dff-4b6b-803e-d38ff2fa3ebb_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_447ced41-cc82-4ba7-a929-dda9412db3b9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LossOnEarlyExtinguishmentOfDebt_b0db5fe2-a02c-4b55-bc6a-d3f9158c08e9_terseLabel_en-US" xlink:label="lab_cah_LossOnEarlyExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_cah_LossOnEarlyExtinguishmentOfDebt_label_en-US" xlink:label="lab_cah_LossOnEarlyExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_cah_LossOnEarlyExtinguishmentOfDebt_documentation_en-US" xlink:label="lab_cah_LossOnEarlyExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossOnEarlyExtinguishmentOfDebt" xlink:href="cah-20210930.xsd#cah_LossOnEarlyExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LossOnEarlyExtinguishmentOfDebt" xlink:to="lab_cah_LossOnEarlyExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_9ceab5f7-7e14-4f90-a3d0-64ec921179b0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e678f52f-7fd3-43fa-8577-dc5c5f74e644_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6824e827-4174-4c65-ad8f-c350e957a922_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_360609c4-c57d-4e2c-b833-04856cf77931_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated range of decrease in unrecognized tax benefits within the next 12 months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCosts_bea4f670-91d3-4b51-8be7-1356e6bfa6a6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_c77c2753-3697-40cc-8ceb-633f50da01de_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_fe885162-b0e8-478d-8d8f-a6c45962b96e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_b8e50089-8f76-47ff-9160-91db13e74de5_terseLabel_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_label_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_documentation_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:href="cah-20210930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:to="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a05404e7-421f-4e2a-a74d-3348ac913098_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8138cb30-3576-4308-85ff-e54be2134508_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2b3f1e8f-0396-4b37-b49f-1064e65993bc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_1056e991-4c30-499f-80e5-d36105fbbe0a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets (Liabilities), at Fair Value, Net</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets (Liabilities), at Fair Value, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:to="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_bc7393cb-f9f2-43b1-abe4-4d606a7e0819_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_d5faffe9-d387-4c8d-b557-690f40c56c89_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_62bf66ef-c8b0-404c-9465-2a2747332535_terseLabel_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project Costs On Investment And Other Spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_label_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project Costs On Investment And Other Spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_documentation_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:href="cah-20210930.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:to="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_a206704d-f2ba-43ce-9086-9163305cb92a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalMember_2548bedc-5060-4711-94ac-a683f829a787_terseLabel_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical</link:label>
    <link:label id="lab_cah_MedicalMember_label_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Member</link:label>
    <link:label id="lab_cah_MedicalMember_documentation_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember" xlink:href="cah-20210930.xsd#cah_MedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalMember" xlink:to="lab_cah_MedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_73ba89ff-c92d-41ed-9cea-1f3107ecbc58_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments, Contingent Liabilities and Litigation</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DOJInvestigationMember_ac004e1d-9477-4932-83e9-5b66d1405353_terseLabel_en-US" xlink:label="lab_cah_DOJInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DOJ Investigation</link:label>
    <link:label id="lab_cah_DOJInvestigationMember_label_en-US" xlink:label="lab_cah_DOJInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DOJ Investigation [Member]</link:label>
    <link:label id="lab_cah_DOJInvestigationMember_documentation_en-US" xlink:label="lab_cah_DOJInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DOJ Investigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DOJInvestigationMember" xlink:href="cah-20210930.xsd#cah_DOJInvestigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DOJInvestigationMember" xlink:to="lab_cah_DOJInvestigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IndemnificationReceivable_7415c414-adb1-4755-92d4-f12a1068472a_terseLabel_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification receivable</link:label>
    <link:label id="lab_cah_IndemnificationReceivable_label_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Receivable</link:label>
    <link:label id="lab_cah_IndemnificationReceivable_documentation_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable" xlink:href="cah-20210930.xsd#cah_IndemnificationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IndemnificationReceivable" xlink:to="lab_cah_IndemnificationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_393192c2-fb1e-4a4f-a644-8e589d46d06f_terseLabel_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net tax withholdings from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_label_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds/(tax withholdings) from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_documentation_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:href="cah-20210930.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:to="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_25287709-f02a-441c-923f-f3c882789fc5_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeDomain_4eaef6f2-4d4a-46cb-a63f-b85be04f00cd_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_label_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain" xlink:href="cah-20210930.xsd#cah_PlaintiffTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeDomain" xlink:to="lab_cah_PlaintiffTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7309e089-4cd5-4298-b93a-65603abbee70_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_73f7213a-0948-4d0f-879a-27c97c2abcc3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target performance goal (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b17e9833-734b-45dc-8ed4-57405ec64880_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3332306e-81a8-47b6-9d13-5dbc4e9d7bbd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_92bd2846-f2a2-488c-83ef-3dc0e5f6f8a0_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a020dd95-eb90-4bc8-a681-819d9951c526_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_ea0a9770-837e-49c2-9e74-9f49b4128e23_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-term Borrowings</link:label>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermBorrowings" xlink:to="lab_us-gaap_OtherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_531bccbf-553d-407a-af56-5d6de0e80fbf_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_00bc42a9-bf96-42e2-a63f-2ca9683fb11a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_a30b5ef3-c1f3-4d91-8db4-b9d328953931_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0dea8f16-ec20-4ca8-b207-506f5f9dee91_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6a7c3ee5-27a0-4a58-b687-1e4775183d3f_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_388e6a5f-76dc-4d7a-b814-013f463b1e66_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6a2464a3-eaaa-4795-a46e-8b873c6a6344_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e942fa69-3c76-445c-aafe-39f259d62ced_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_8928f8bf-6183-4a87-af60-0f52615cf480_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b0f4a68-55a4-478e-99db-82ccfee382a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2902f07f-9239-41f5-b556-ad3b9b4818ad_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_6ed4a0e8-982d-477a-82ff-9dd8be04482b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_38013e98-bb96-45c5-9fab-fd9172fc0744_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureMember_94bae712-2a69-4c18-b7b2-d131e44b4fbf_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Member]</link:label>
    <link:label id="lab_cah_CordisDivestitureMember_label_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Member]</link:label>
    <link:label id="lab_cah_CordisDivestitureMember_documentation_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember" xlink:href="cah-20210930.xsd#cah_CordisDivestitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureMember" xlink:to="lab_cah_CordisDivestitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A2.616Notesdue2022Member_8e69be3d-7794-4400-95fa-876e80090bde_terseLabel_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022</link:label>
    <link:label id="lab_cah_A2.616Notesdue2022Member_label_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_A2.616Notesdue2022Member_documentation_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member" xlink:href="cah-20210930.xsd#cah_A2.616Notesdue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A2.616Notesdue2022Member" xlink:to="lab_cah_A2.616Notesdue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_622a169d-45f8-475c-889e-7963f8aa2c1d_terseLabel_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from investments</link:label>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_label_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of available-for-sale securities and other investments</link:label>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_documentation_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from sales of available-for-sale securities and other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:href="cah-20210930.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:to="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_b008199f-390b-4e37-bfb1-95d8c0e59aac_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_5973e01d-a49b-4ecf-af2a-95b61a38d643_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for bad debts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_6ca6737a-2dcf-438d-8b4e-a70dc52ffcfe_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8f38c562-c846-4ed6-a9de-ebd6173f0825_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations and other short-term borrowings</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_a456571d-15f6-4486-aeb8-2292d349c2f5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_590b8d22-e09d-416d-81bf-9f8978160218_terseLabel_en-US" xlink:label="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Definite and Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:label id="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="cah-20210930.xsd#cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_8694d2c1-e665-4629-963e-3ae41d367b9f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7df2a3e3-f4d1-4074-8aad-21931ae3244b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_269db177-c1cd-440c-8922-a1207071d117_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_2fba4c1f-6fb7-45a2-805f-3a6e9cc6c907_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_583f6dfc-ba8f-4412-b3ee-9f4079ec34b3_terseLabel_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_label_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_documentation_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts" xlink:href="cah-20210930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_FacilityExitAndOtherCosts" xlink:to="lab_cah_FacilityExitAndOtherCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CardinalHealthAtHomeSolutionsMember_bebe79c9-1abb-48c6-9de8-2bdede570758_terseLabel_en-US" xlink:label="lab_cah_CardinalHealthAtHomeSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home Solutions [Member]</link:label>
    <link:label id="lab_cah_CardinalHealthAtHomeSolutionsMember_label_en-US" xlink:label="lab_cah_CardinalHealthAtHomeSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home Solutions [Member]</link:label>
    <link:label id="lab_cah_CardinalHealthAtHomeSolutionsMember_documentation_en-US" xlink:label="lab_cah_CardinalHealthAtHomeSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home Solutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeSolutionsMember" xlink:href="cah-20210930.xsd#cah_CardinalHealthAtHomeSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CardinalHealthAtHomeSolutionsMember" xlink:to="lab_cah_CardinalHealthAtHomeSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuebyGeographicTable_468064ec-8664-4049-8bbd-af9a1725f386_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Geographic [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuebyGeographicTable_label_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Geographic [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuebyGeographicTable_documentation_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Geographic [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicTable" xlink:href="cah-20210930.xsd#cah_SegmentRevenuebyGeographicTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuebyGeographicTable" xlink:to="lab_cah_SegmentRevenuebyGeographicTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_f4b1b4e1-8154-4b78-ba45-bb9de1c5615a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_56209c54-ac8a-4ea4-988c-773f0ea8b090_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1ae62f92-edac-4a54-9b01-9223f9794ef0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_0299c1d6-b796-4fbd-a399-dc484225e917_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain/(loss) on derivative instruments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_6da9641a-adde-410a-836a-929ca2520ba4_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_652fba3d-7b4a-4df4-9918-ea2d81473ed8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_29a78a8e-a3b7-47dd-aa2c-e30d8f8ad2cf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_aa82dbba-8281-44d8-bd3a-27fd3dc8edb7_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_d64b2286-eed9-476d-a86a-c2b82d6854b9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase/(decrease) in accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_a3a02149-c5df-4875-a94a-f015798a8f57_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_8677f6e7-8901-47ec-bcfe-bfb23733a82a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_9cb3b97b-f63a-4163-aea1-b919f7555a45_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_d33b0c4a-9c61-488c-8ebc-e638d3c2ad37_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_b72f388b-16f6-4b04-8106-4b5a2fe5010e_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_72076863-bb8f-419a-9d6f-1520a4427c1d_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_72d6382b-753d-433c-80fc-df4fb2f6a8d4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_aee7b854-fe41-4b0d-9e1a-61b6ff2a6569_terseLabel_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_label_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_documentation_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:href="cah-20210930.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:to="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_74a57b39-4532-4671-8d0d-b1f1d366f945_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_798dc18f-94f1-48a0-a28c-c29fa2533d02_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired, average price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6b4d3b9c-6ca0-48cd-b9b5-3342ff34c8ab_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_244aa569-749d-4389-8236-aab21795a271_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_07c5899c-5226-4fa0-862b-efd23ad1bc22_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_04c2ad28-014c-43f7-8b08-79fc9299446d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities and operating items, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_e017d9de-8d86-46d6-a96a-305a97d4ca09_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_14de23dd-e077-4fdd-8311-1654983a451f_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0ba0f86a-6fcb-40f3-862c-f89efa5d862c_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution, selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_34edd007-9d53-4af6-b7ab-84293eee0c28_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8a66c361-7557-415e-b57c-b0085bde12e6_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_6efcea57-f08e-4155-bbb1-d2eb3d8abf9f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_705c108e-11cf-4c16-8fff-9c3443f0b17c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_4d3406de-5bc4-4691-bab1-8704e88b7672_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_718a9e06-7399-465f-980c-94dbadbce092_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_c8c45457-d827-4cd6-b2e9-9eea7045bac0_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a9945d18-77b7-4582-ad0b-ef59968eea31_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_19defc4f-481b-47a3-ac8f-3d719ff67c12_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_2ae341d2-a4bb-4f2e-a801-4268a4ca88b2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_151e70f8-0212-4fd5-b231-9fadd668966b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_bf1fce5e-b210-405f-b843-67064fbaabc3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2ece5179-2f45-4a6a-b8d9-f76a8464e40b_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_FinalSharesReceivedfromASRProgram_29157025-b997-4528-bd4b-70527cc59049_terseLabel_en-US" xlink:label="lab_cah_FinalSharesReceivedfromASRProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Shares Received from ASR Program</link:label>
    <link:label id="lab_cah_FinalSharesReceivedfromASRProgram_label_en-US" xlink:label="lab_cah_FinalSharesReceivedfromASRProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Shares Received from ASR Program</link:label>
    <link:label id="lab_cah_FinalSharesReceivedfromASRProgram_documentation_en-US" xlink:label="lab_cah_FinalSharesReceivedfromASRProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Shares Received from ASR Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FinalSharesReceivedfromASRProgram" xlink:href="cah-20210930.xsd#cah_FinalSharesReceivedfromASRProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_FinalSharesReceivedfromASRProgram" xlink:to="lab_cah_FinalSharesReceivedfromASRProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_8a57b75b-386f-46e7-8431-9ed08a9118bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_6f9e66a0-1b7b-4586-9cdc-a27e4aadeaf5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends on common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3c763854-2f68-4084-8649-24a07080790a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest and penalties accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_f055e44e-cc75-40d3-9e39-9e10147b92b0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8c2848b2-fe14-4802-b9e8-c35c41f8c6f5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_2844564a-7f56-429b-bf0e-b93db52a0a17_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_e8e00e50-9ef6-4088-98c6-7f501e7ac2e0_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_8fe91e29-e02f-46a7-8577-7b6ae06ee371_terseLabel_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_label_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_documentation_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term credit facilities and an unsecured line of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember" xlink:href="cah-20210930.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShortTermCreditFacilitiesMember" xlink:to="lab_cah_ShortTermCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_61612504-65ba-43ec-b2fd-2e68a70244d3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b79b084f-d90d-4e32-a359-3d9fae974a8e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9d60e9e9-cbd6-4a93-a2d2-f41c7c670cfb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1cbaca39-22e0-4bfe-a2ad-85c9635c0d6a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_82b4e478-d8bf-408e-88d5-c0ca8449c545_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1d297168-c41e-426c-bb6b-79bd5f0cf339_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_08b855f0-3bcc-43bc-8f5e-dbe230ae473e_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_8fb16bae-e8f3-4bdc-8495-f287ec887f80_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Unit</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5b8d42ae-ee32-4aa1-901e-8ea7c86bff78_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_27ca4b30-9ec4-413f-bddc-475db14ff6ba_terseLabel_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_label_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_documentation_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:href="cah-20210930.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:to="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_93440d34-db0d-4391-a974-619b86198d9e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_e7c582b7-706c-4b48-b269-9a503642914c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:to="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_ce2ae867-a343-4ad4-9aae-d649fd64fc52_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_90144ef7-51b7-4033-b9f7-c5a043658fc4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1bc1bdec-023e-4710-85a9-2d9cc23bf4db_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a520d597-e553-4c72-a146-1dc659197317_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TrademarksAndPatentsMember_df8b40a5-ba4f-4fd5-9b55-638992cd6b8f_terseLabel_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks, trade names and patents</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_label_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks And Patents Member</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_documentation_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember" xlink:href="cah-20210930.xsd#cah_TrademarksAndPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TrademarksAndPatentsMember" xlink:to="lab_cah_TrademarksAndPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_cdd2239a-74c8-474b-9e0c-15dd8afd354e_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_2f1d7e21-45e3-4035-9159-ff2f442c53dd_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_cfaa2aac-121b-4f60-85c3-67c3b3b9c109_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_e1ff4686-55d2-4960-b09a-c85b622d9c67_terseLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-term and Short-term, Combined Amount</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-term and Short-term, Combined Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_0490801e-cfd8-4dd6-be9d-ea855162545d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_a9d574b1-c015-410c-8855-ca037452e508_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared per common share</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NotesPayableRepurchased_a28b87d7-697a-409c-aa50-fd9ebabd08fa_terseLabel_en-US" xlink:label="lab_cah_NotesPayableRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable Repurchased</link:label>
    <link:label id="lab_cah_NotesPayableRepurchased_label_en-US" xlink:label="lab_cah_NotesPayableRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable Repurchased</link:label>
    <link:label id="lab_cah_NotesPayableRepurchased_documentation_en-US" xlink:label="lab_cah_NotesPayableRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount of Notes Payable Repurchased during the year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NotesPayableRepurchased" xlink:href="cah-20210930.xsd#cah_NotesPayableRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NotesPayableRepurchased" xlink:to="lab_cah_NotesPayableRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_c8599899-4481-4172-96ca-446b341a5453_terseLabel_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and patents</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_label_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D,TrademarksandOther [Member]</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_documentation_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember" xlink:href="cah-20210930.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IPRDTrademarksandOtherMember" xlink:to="lab_cah_IPRDTrademarksandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_01640c56-fadc-42c9-922a-3fb35c108b30_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1ca1311d-bc6c-440a-9784-aba4f3052004_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_363f713b-828f-4f1f-b8e5-f2163ea54269_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_50232e56-6afb-4093-930f-372a5b6b20ad_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_58b26803-b207-4ae5-bfd0-568161f14b5f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_09636212-f2a3-41a8-a285-a707375a4cef_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and other adjustments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_932e01ca-180a-4921-bdec-fcec8b1e26ee_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract_59939cea-cb18-4abc-a9d2-6e97549a1c48_terseLabel_en-US" xlink:label="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:href="cah-20210930.xsd#cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:to="lab_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_016fcfac-4600-4d19-8b78-a915fc169977_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9b747764-b929-4936-9445-314015a6215b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_c794c1b3-008b-4de7-9066-d2b0e1a12984_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_db973930-f343-459b-a28f-d7165f699673_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_aa64c8f8-4cb4-4a62-bacd-61d8524f34bd_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a1e94a39-4e6d-477a-9eba-f442741c2c2f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating earnings</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalSegmentDomain_4cef049c-c081-46e0-9af5-91574b6bb3b3_terseLabel_en-US" xlink:label="lab_cah_MedicalSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Segment [Domain]</link:label>
    <link:label id="lab_cah_MedicalSegmentDomain_label_en-US" xlink:label="lab_cah_MedicalSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Segment [Domain]</link:label>
    <link:label id="lab_cah_MedicalSegmentDomain_documentation_en-US" xlink:label="lab_cah_MedicalSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Medical Segment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentDomain" xlink:href="cah-20210930.xsd#cah_MedicalSegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalSegmentDomain" xlink:to="lab_cah_MedicalSegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_985c0046-f1d6-4337-b5b7-ad7f25c46ccb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_f41faca7-d680-450c-abcb-7eac1593a942_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_fd18e622-e156-4eae-be25-96be55838870_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_457887ee-fa1d-4863-a039-1a4289766223_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_3f4907f3-ca0b-41f6-926b-794914f8b87e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1ae915e8-9fd2-450d-8eb9-679b17eb5569_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e2ade65d-832a-4196-891d-09f3cf5b3f92_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8e0641c6-1f33-4e2e-b2b8-1bf46f368cfc_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_0f2b93f7-4011-44eb-99ce-3e93e5f032f4_terseLabel_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_label_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_documentation_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember" xlink:href="cah-20210930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicaldistributionandproductsMember" xlink:to="lab_cah_MedicaldistributionandproductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterDomain_4897d39d-cd23-4e4c-9a2d-2379630fcc31_terseLabel_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_label_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_documentation_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain" xlink:href="cah-20210930.xsd#cah_TaxMatterDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterDomain" xlink:to="lab_cah_TaxMatterDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_ef0a5a45-798f-473e-a4e3-d7145cad5e13_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_d79b3810-569e-4b17-8b1b-c96ea54bfbe1_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillTransfers_aea50a00-b3b7-483e-90ab-c4ca50c251b9_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillTransfers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Transfers</link:label>
    <link:label id="lab_us-gaap_GoodwillTransfers_label_en-US" xlink:label="lab_us-gaap_GoodwillTransfers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Transfers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTransfers" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillTransfers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillTransfers" xlink:to="lab_us-gaap_GoodwillTransfers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_01fa4766-162c-48e5-85f8-e617abf5e9d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transactions Related to Restricted Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9df20947-9f0f-4375-850f-ab2c5938ac28_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b23ecfc8-0b26-40fc-bf8d-098433795b21_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_012afb4e-3e27-47a7-bae8-3a404c5b34c7_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_26906c32-877d-47d6-a09b-88492ad2b400_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be9b4fc7-28bc-49ba-ad7b-2572f50a9b42_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLawsuitsStateDomain_8e8e5ade-b266-4d8d-9356-672aa18bdd5a_terseLabel_en-US" xlink:label="lab_cah_OpioidLawsuitsStateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits State [Domain]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsStateDomain_label_en-US" xlink:label="lab_cah_OpioidLawsuitsStateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits State [Domain]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsStateDomain_documentation_en-US" xlink:label="lab_cah_OpioidLawsuitsStateDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits State</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsStateDomain" xlink:href="cah-20210930.xsd#cah_OpioidLawsuitsStateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLawsuitsStateDomain" xlink:to="lab_cah_OpioidLawsuitsStateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_067108cf-efa2-4227-8338-319595acef9f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_c0877c62-17c7-4c4d-8bb1-53d1e497a865_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain/(Loss) on Derivatives, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_9f9290cd-f0e3-4681-9b23-b6276b66f5c6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_f73fc5f4-2f19-44d1-90af-63c3a1c3f7d4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_66ad2075-da26-4ee1-ac36-357331e62450_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8af9e5a0-a41d-4719-9973-3bbb53c8747d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7b69f27e-4805-449a-9699-53a18ad9865a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07887258-a7c4-4f4a-82b6-21adb573745a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1a92a5a1-3484-4367-b96f-5ad15aead5e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of outstanding options at period end</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_4b9de426-7ed0-40e1-8aac-c6c9a4946cb8_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_8d187c34-7816-4835-8e88-f7be9088f016_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cardinal Health, Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OtherJurisdictionsMember_f8264a87-0523-436c-bc31-e79d7f114559_terseLabel_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:label id="lab_cah_OtherJurisdictionsMember_label_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:label id="lab_cah_OtherJurisdictionsMember_documentation_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember" xlink:href="cah-20210930.xsd#cah_OtherJurisdictionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OtherJurisdictionsMember" xlink:to="lab_cah_OtherJurisdictionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_012b2edd-e38d-4d72-83cd-044247d9b9c4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d5ba844a-fcc9-40c6-b434-227bab0e0e3a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_ca1f6ac4-3ae6-4cd3-8145-a60c907b2070_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_2b2a6b1e-024d-4e41-b475-3a8dfe74efb9_terseLabel_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_label_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_documentation_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:href="cah-20210930.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:to="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_13a3a8d2-ca96-4fb7-b7a3-b22d4941eebd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_11d58353-efb7-4bad-a5c1-11fa93a407be_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, without par value:</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8d0374d0-c166-4404-a43a-f151691c3824_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of exercisable options at period end</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLitigationDomain_ce4ebdf2-5e66-4928-b30f-d9703e9aca4e_terseLabel_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:label id="lab_cah_OpioidLitigationDomain_label_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:label id="lab_cah_OpioidLitigationDomain_documentation_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain" xlink:href="cah-20210930.xsd#cah_OpioidLitigationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLitigationDomain" xlink:to="lab_cah_OpioidLitigationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_cccbd52c-d57b-45e8-86dd-279ba28341cf_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_61a7bcc4-b3e8-4b27-b5fc-671fa049da98_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Period</link:label>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_label_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_be573a0a-c8dd-491c-adc7-b549fe8bfe51_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_3f06151f-e6e2-4a67-9e69-d760ef4af71f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Early Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_4567d947-5704-4bed-9660-095bfbd3bb41_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Early Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CareFusionMember_b04d5eed-abee-4845-a257-bc3503e74ce2_terseLabel_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:label id="lab_cah_CareFusionMember_label_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:label id="lab_cah_CareFusionMember_documentation_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember" xlink:href="cah-20210930.xsd#cah_CareFusionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CareFusionMember" xlink:to="lab_cah_CareFusionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_f7e373df-435a-47e1-a107-d125154a1819_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_96885101-e38e-4c55-9729-84166236cb39_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b75bdda8-4b1c-4a97-bd6e-06b2b579dc61_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_eaba8ab8-fbf9-49d5-afc9-e30ce85a84ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LitigationTypeDomain_ae8dcc70-fe86-446d-953a-db1b146eebd7_terseLabel_en-US" xlink:label="lab_cah_LitigationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Type [Domain]</link:label>
    <link:label id="lab_cah_LitigationTypeDomain_label_en-US" xlink:label="lab_cah_LitigationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Type [Domain]</link:label>
    <link:label id="lab_cah_LitigationTypeDomain_documentation_en-US" xlink:label="lab_cah_LitigationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Litigation Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LitigationTypeDomain" xlink:href="cah-20210930.xsd#cah_LitigationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LitigationTypeDomain" xlink:to="lab_cah_LitigationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_88110199-6b12-447f-af71-c1f117a1ec57_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_913bf0c2-e64a-4733-bf26-15850d0ccfe7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_7625e3a6-5900-4e25-8e6a-2acab026dce5_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsDomain_70f60b95-6810-49b4-ba4f-fe7e2b5e147d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:to="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_3997b99b-cd99-4c58-bf0f-d5efb8ae30c3_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_7bf850e5-33b3-418f-8060-630f1790ee36_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_078a440a-24af-4983-99fd-5f00ff852356_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_a14b7453-190c-4305-8638-ecf1c8d16be7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_20a2a95e-0bf5-455b-8d1e-9d1d70c1ba5c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit related to share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1968152b-2603-49e1-addc-498e689893bf_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9382fbc4-78e4-434b-bf34-e545addb9a29_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_345d268e-e2c7-48cb-b76b-390358d47b20_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_874a575c-6f71-4405-a6c9-1892c0cead08_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_8112ff4e-b933-40ea-8d15-aaf02a54618c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_6b436410-a872-419c-94a0-4eca521a20c4_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Unit</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_135ef018-76af-4ef7-9e1a-42c2fe3ce260_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_36d9f93e-787c-4f3e-8ad4-c9e3d944a7b8_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Consolidated Statement of Shareholders' Equity</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PatientRecoveryBusinessMember_58464edf-04df-47c1-b88e-01a820ca52a4_terseLabel_en-US" xlink:label="lab_cah_PatientRecoveryBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Recovery Business [Member]</link:label>
    <link:label id="lab_cah_PatientRecoveryBusinessMember_label_en-US" xlink:label="lab_cah_PatientRecoveryBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Recovery Business [Member]</link:label>
    <link:label id="lab_cah_PatientRecoveryBusinessMember_documentation_en-US" xlink:label="lab_cah_PatientRecoveryBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Recovery Business [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember" xlink:href="cah-20210930.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PatientRecoveryBusinessMember" xlink:to="lab_cah_PatientRecoveryBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_8c31f9cf-9033-46be-9a4c-4b5e4dae8981_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_99ff0ae8-5311-4aec-a79a-08e3af7e5576_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8d003df7-0936-4b60-ba88-286629f66563_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_b52b8f5d-2b64-491a-870e-26d47193d899_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_label_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_documentation_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:href="cah-20210930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:to="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b7dd4113-79b6-4467-a6ca-56f54765beb4_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_89d8a3fe-c63e-4163-af69-ad604a32b219_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_de323294-edfd-4e8f-92d1-17849d8f4ac7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_45c09c47-83dd-4c28-bf2e-b1f4b8a35995_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9b0a21eb-bbbd-4f0f-bce1-6154dee1dd31_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0314a3dc-cca3-4ea8-97f9-c21b36bbf14a_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f614f2c0-6caf-453c-b2a8-f42a2240ab02_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_84c7c9dd-a422-42c9-908d-53cd34b7eb56_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_cbfbabb4-e06b-47d4-9a66-4d51db8c9c88_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_21f27382-9680-46b8-bd82-ce346075baaf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_869e2e05-854a-493e-a866-855227ee669e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_0256c2cc-2947-4a86-a942-a95f47005705_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_e4270c16-6015-43c1-ae79-18ffc87aa33d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_16e54228-8a34-4313-9abf-d1a7a1f4a0a3_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6da3c4f5-b3af-46aa-a684-4a6caecaef68_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_14abcff1-e35c-44aa-b618-2a39c68c4688_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_006078bd-dd59-449d-9479-c63171499f42_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_a93515e3-3aaa-41b3-aa4b-2517a93c0e59_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6c194643-3cb9-4602-9baf-c919f07cb36f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d598080b-6e43-46b3-9b16-17e627b55416_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c2eb9561-f167-4434-8769-78a63a5087f1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ba6e735d-e2f4-4891-a574-21ad4ea9aef4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_8931997c-df79-4c13-a598-80f8a80619bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_67d7016e-3122-4ea7-bc4e-58bd9cbf1a77_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_6c59fc7c-2541-4554-88a9-3158c755a395_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_8b82e4cf-6c9e-422f-ad2c-703d2d8c779a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_190640c2-80d9-42fd-b698-01f7177fd538_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_ef12955a-8c05-45db-a006-df07a5a094be_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalSegmentAxis_d21fbf94-3b87-455d-b4d4-9492f5cdf06a_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Segment [Axis]</link:label>
    <link:label id="lab_cah_PharmaceuticalSegmentAxis_label_en-US" xlink:label="lab_cah_PharmaceuticalSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Segment [Axis]</link:label>
    <link:label id="lab_cah_PharmaceuticalSegmentAxis_documentation_en-US" xlink:label="lab_cah_PharmaceuticalSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Segment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentAxis" xlink:href="cah-20210930.xsd#cah_PharmaceuticalSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalSegmentAxis" xlink:to="lab_cah_PharmaceuticalSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0038c188-06fc-4008-a509-d796e20db57c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_bce78ba4-ad75-4a2d-94c9-caaea2e63240_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Lived Assets Held-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Lived Assets Held-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:to="lab_us-gaap_LongLivedAssetsHeldForSaleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f5277e5c-8208-4545-a28d-6d35fcb2ff48_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_ae238ea8-d34c-4b62-9d34-bd6825a044fd_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_668fff5e-30a1-4ac9-adec-6523de1c218f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price per Common Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6139ee10-8e51-458b-92ad-307cad580248_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock plans activity, net of shares withheld for employee taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_db4f7d5e-c30e-4e27-bb93-74d6143bd0bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Share-based Compensation Expense by Type of Award</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_fbd391ec-b6de-441c-8a06-e1a68409fa52_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TotalOpioidLitigationMember_4770a639-d9ad-4c08-bd50-95ea1ba30d38_terseLabel_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_label_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_documentation_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember" xlink:href="cah-20210930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TotalOpioidLitigationMember" xlink:to="lab_cah_TotalOpioidLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8ea7b5d0-c56f-4a76-8ef4-f6cf02c7ff2f_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_a0941917-c1b0-4b8d-aa58-0db7359d0859_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_10544b71-e3e8-4389-89f0-6b23bb1b1eaa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3f4c0b2d-7f55-4a0a-97c9-3644371ef695_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_665f3a4d-92d3-4457-8613-6ec4b1d983f5_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings/(loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_9e9f69a0-e18b-42c3-b0de-1660fd2855be_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_eb71fbba-25d3-413a-b88f-7408c0c6f306_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_85584d7e-a6cb-43f4-8b5e-8904c884e811_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_49c490f8-da3e-41a4-8cdc-42b5a14dbddf_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_f6e961d6-9706-48aa-8ca9-1e86a37cccc2_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LawsuitTypeAxis_8920e650-ec1f-4c4c-b752-1ea7d69b7579_terseLabel_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_label_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_documentation_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis" xlink:href="cah-20210930.xsd#cah_LawsuitTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LawsuitTypeAxis" xlink:to="lab_cah_LawsuitTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_a91a1c78-cd74-4083-b489-4941a1558cc9_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_6a81fae2-0943-4f08-88b3-86ea52ad6651_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CashReclassifiedtoAssetsHeldforSale_2b83da0a-635d-4b7c-b0b5-d8ac9330c419_terseLabel_en-US" xlink:label="lab_cah_CashReclassifiedtoAssetsHeldforSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Reclassified to Assets Held for Sale</link:label>
    <link:label id="lab_cah_CashReclassifiedtoAssetsHeldforSale_label_en-US" xlink:label="lab_cah_CashReclassifiedtoAssetsHeldforSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CashReclassifiedtoAssetsHeldforSale</link:label>
    <link:label id="lab_cah_CashReclassifiedtoAssetsHeldforSale_documentation_en-US" xlink:label="lab_cah_CashReclassifiedtoAssetsHeldforSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CashReclassifiedtoAssetsHeldforSale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedtoAssetsHeldforSale" xlink:href="cah-20210930.xsd#cah_CashReclassifiedtoAssetsHeldforSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CashReclassifiedtoAssetsHeldforSale" xlink:to="lab_cah_CashReclassifiedtoAssetsHeldforSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8f1ed122-cefe-4f19-819b-57a0fb68e057_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c5986dbf-ab69-49aa-bcd9-d35a186d7ce9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_62dc33ee-2ebd-4d29-92a3-9967a6b65068_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuebyGeographicLineItems_7a5e139c-54c9-430d-9cca-751eeb05f9eb_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Geographic [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuebyGeographicLineItems_label_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue by Geographic [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuebyGeographicLineItems_documentation_en-US" xlink:label="lab_cah_SegmentRevenuebyGeographicLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Segment Revenue by Geographic [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicLineItems" xlink:href="cah-20210930.xsd#cah_SegmentRevenuebyGeographicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuebyGeographicLineItems" xlink:to="lab_cah_SegmentRevenuebyGeographicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6db84a5a-0f04-4885-820f-20b60c8bd347_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_24c18f0b-f63b-4bdc-a51c-1d5f8027641e_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_5344fb3f-d722-4622-9a89-8fe23108f4a0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_7bc2d3e6-366a-4750-8e0d-2e80d261e8d8_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_7e64d596-a02f-4567-9955-e2d9a0ff8262_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation (recoveries)/charges, net</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_92980f91-1413-4cc6-b620-ba3ab82a8c7b_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_7f06a0f2-9e43-4cef-aafa-af0ee7541127_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_8346fb63-e68b-4a95-ae50-3ac63d713d16_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_2b746bdc-cb70-4a0d-8461-2f08622834f8_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_45513eed-e65d-46ac-a38d-c3fee28f43f8_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_05f1d5df-8b31-4d78-83d2-60d067ddd805_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0934f27f-7056-4e9e-b813-53110821d221_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net earnings attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ab79f50c-51ab-4384-be87-0f7367c1fcec_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_791923b2-495d-4832-bc59-af172ef98808_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_04d4447f-0fde-4d1c-914c-6d9f2b844f2e_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_cf037e9c-649e-4dbc-a097-0b6f560d1efa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b9b28aac-2540-45d0-93ed-b114323239e6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_5137eb8f-ab22-420b-a893-fea0bd3f4932_terseLabel_en-US" xlink:label="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestitures and disposal of property and equipment and held for sale assets</link:label>
    <link:label id="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_label_en-US" xlink:label="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestitures and disposal of property and equipment and held for sale assets</link:label>
    <link:label id="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_documentation_en-US" xlink:label="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestitures and disposal of property and equipment and held for sale assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:href="cah-20210930.xsd#cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:to="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_093ecac5-44e1-4569-b143-37693ad92506_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_84aaa860-65a7-438a-8581-1fa97ff3937d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_53ee27a7-d159-4538-81f1-1c28fb36fcb6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureAxis_0e0f14d9-f4eb-4fe0-bd6e-aa01b0d5f0b8_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Axis]</link:label>
    <link:label id="lab_cah_CordisDivestitureAxis_label_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Axis]</link:label>
    <link:label id="lab_cah_CordisDivestitureAxis_documentation_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis" xlink:href="cah-20210930.xsd#cah_CordisDivestitureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureAxis" xlink:to="lab_cah_CordisDivestitureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9c15e251-02f6-44c9-8b7f-9b96c92cb873_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_6a7bb426-2679-45f2-858f-f61338f8732d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings/(loss) per common share attributable to Cardinal Health, Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_f4dffdbd-5536-4aa0-b678-ebddb47f22f8_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_78c40389-9dd2-46b6-9157-a313090cf86f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_483b7917-ca61-4c3f-8a86-90ff02d07dc7_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares&#8211;basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c041fbe9-331c-436e-8342-a278bdd4717e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_c73253e1-60e5-4088-9c34-7d72c49a7a21_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_9f498115-ca1d-40b7-8e79-3c81892fa0d2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_94fe53cc-23fe-47cd-a6d8-476d38d69e93_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_646cfd42-e481-4773-a2aa-20cb0bf143c9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_18fad3b7-66a2-46aa-b088-768fe359f9ef_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1a852c45-3f92-4c09-ad11-15e89fd396c5_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_01073917-139f-4fee-a664-7440c6d06aba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_d59b6ddd-d097-40bf-a7d8-1ca9b10f20e0_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_e74ea8a1-8a13-4c4a-805d-e6149f7cd038_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee- Related Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_cd88c26f-0644-4186-b4d2-1d4cf07838e1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_f09f8f19-1506-4610-812a-35c940cd0fd0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_5f09495b-a560-4b09-8fd4-37f3972f2efa_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_6959455b-d18d-469c-8aa0-f13d8f7e0661_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at end of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_bcc314f5-becf-40fe-b70d-5a656d69d4ae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CVSHealthMember_f2772b40-d500-4a68-93fb-f86aeb2347d6_terseLabel_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health</link:label>
    <link:label id="lab_cah_CVSHealthMember_label_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:label id="lab_cah_CVSHealthMember_documentation_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember" xlink:href="cah-20210930.xsd#cah_CVSHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CVSHealthMember" xlink:to="lab_cah_CVSHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ddddeee6-4117-4a1f-8a4e-5496d489c92e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_2ba9ca8f-c9de-4c4a-95dd-c3334cd0a01b_terseLabel_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_label_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_documentation_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember" xlink:href="cah-20210930.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NewYorkOpioidStewardshipActMember" xlink:to="lab_cah_NewYorkOpioidStewardshipActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_bfd58441-80b3-4b03-8322-775903ec54d8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ExercisablePeriodOfPlansInYears_5dc5dd2e-664f-4361-bf51-9cee2e5ac4d3_terseLabel_en-US" xlink:label="lab_cah_ExercisablePeriodOfPlansInYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable period of plans (in years)</link:label>
    <link:label id="lab_cah_ExercisablePeriodOfPlansInYears_label_en-US" xlink:label="lab_cah_ExercisablePeriodOfPlansInYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable period of plans, in years</link:label>
    <link:label id="lab_cah_ExercisablePeriodOfPlansInYears_documentation_en-US" xlink:label="lab_cah_ExercisablePeriodOfPlansInYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The instrument's contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ExercisablePeriodOfPlansInYears" xlink:href="cah-20210930.xsd#cah_ExercisablePeriodOfPlansInYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ExercisablePeriodOfPlansInYears" xlink:to="lab_cah_ExercisablePeriodOfPlansInYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_51392990-d0c0-4603-b271-7a9608bf8c3e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_273bfc73-5b2f-4bb6-b285-304981a6d7e3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_d2118de1-9732-4041-b326-1aa64906db88_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_9319dad9-fe9f-43fc-9eae-39232c6968e9_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_fff644a3-1d70-4b2d-a9e7-a39cc67e638e_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_99430975-0035-434f-994b-b7c2964d9707_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d539cfeb-2103-4e53-b985-f8f8b0c61d76_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e0c1c035-df39-4524-8321-5a2c8674029f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6a348253-6970-4383-9dbc-471e35fa5900_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_3d98e6a3-817f-43a6-ae5e-ee08bec7bef1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_eb5ba28c-dfae-4549-b319-8525c8738f81_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_10278d17-2d27-4577-91aa-fa6faeec74b9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesAbstract" xlink:to="lab_us-gaap_RestructuringChargesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_6b9244d1-5d78-44e6-bbe0-6a9e9439f406_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_65a4dcd3-a98c-422c-9e18-28d1845931af_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairments and (gain)/loss on disposal of assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_441af86d-1b5b-46d3-905f-187a8204787e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_455cfb4d-3b51-4a9c-97e7-25a714853ac6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_f99081cd-2dd1-40c2-9081-5859c9d5b034_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel12And3Member_39fe1fae-a38a-4438-b084-31307484589d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel12And3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1, 2 and 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel12And3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel12And3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1, 2 and 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel12And3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel12And3Member" xlink:to="lab_us-gaap_FairValueInputsLevel12And3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_29b0ba87-843a-4c26-af6d-2d14ab950965_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c3c75dd8-4645-48fc-9a2e-9e53abe764bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_6477a7c8-c806-4ea0-95de-d659f9ed6bf8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_7cd94f8c-2140-45d1-91ec-897d7f620d9c_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_1b954ee7-37eb-4bb9-91ee-9d551de04296_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_16e1be76-eba5-4b6e-8684-ea9eb092d705_terseLabel_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity</link:label>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_bf710823-e738-4cfb-a687-ea9fd6eb33e1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_9f3a826e-eed2-4c92-987b-35b3ef86a3d4_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_75dd3db7-1c46-4166-a578-45e42ab27a48_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_60ad453a-71a4-4128-9ead-1cb272352766_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired (using cost method), shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TreasuryStockAcquiredShares_c5f18747-3484-4b72-84fb-e5ee6abc8e6a_terseLabel_en-US" xlink:label="lab_cah_TreasuryStockAcquiredShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired Shares</link:label>
    <link:label id="lab_cah_TreasuryStockAcquiredShares_label_en-US" xlink:label="lab_cah_TreasuryStockAcquiredShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired Shares</link:label>
    <link:label id="lab_cah_TreasuryStockAcquiredShares_documentation_en-US" xlink:label="lab_cah_TreasuryStockAcquiredShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TreasuryStockAcquiredShares" xlink:href="cah-20210930.xsd#cah_TreasuryStockAcquiredShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TreasuryStockAcquiredShares" xlink:to="lab_cah_TreasuryStockAcquiredShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_ec76c090-918e-4e2f-86c3-457323966bc7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_e668b317-5ad7-473a-9756-9e21783bf5cb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_94ddf6a1-d2a6-4e27-88f5-3d0e77de41de_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_02760bdb-1939-4d9e-96e3-51575e826a6c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long Lived Assets Held-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long Lived Assets Held-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:to="lab_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeAxis_6a86584e-f236-4e12-ab15-c97a439e871c_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_label_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis" xlink:href="cah-20210930.xsd#cah_PlaintiffTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeAxis" xlink:to="lab_cah_PlaintiffTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_fa4e2631-718c-4cdf-a7e9-7809d1747a6d_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_5f861597-e02e-4f88-9557-12dfa6b5159f_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_a6f39026-58e1-449c-b296-a00f6ccb066b_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_0d31ddd1-8fc0-47c7-b4a0-2fff6b0592e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified to earnings</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_63cd7d08-e860-4b01-9694-fe3cbae8de13_verboseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_26f19927-1a28-4bd6-b1e2-f837a0d7e9d6_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_09b23453-46ef-449e-8d68-1f2dfdd8e9a4_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_77201196-2beb-4341-b70b-43dd32b651ac_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_de62ff27-21c7-46ef-a834-cbf2978433bd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_59fd1d11-6d4a-40c4-a033-67af2ea0821a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b843ad51-816d-4910-9223-9c57f66ccaf0_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_74bf5f1d-6ca6-4306-990c-dc75e3c720b3_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Loss [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_1d485312-fb72-42e7-acc8-f028594b52a0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_deaa5f99-e47e-4d05-b482-a4fe96483aef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_092d59bd-26c1-4c7a-8494-00c1dbbb7fce_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_271e63c7-8e68-4ee8-b52b-52d9bc30c641_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterAxis_d60039c5-e511-48d9-aace-a3c173fd95cc_terseLabel_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_label_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_documentation_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis" xlink:href="cah-20210930.xsd#cah_TaxMatterAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterAxis" xlink:to="lab_cah_TaxMatterAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLawsuitsMember_a2a21803-bda8-4b9c-b415-5793a28279e0_terseLabel_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_label_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_documentation_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember" xlink:href="cah-20210930.xsd#cah_OpioidLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLawsuitsMember" xlink:to="lab_cah_OpioidLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_47671e50-8ff9-4c7b-a209-631bb469bb88_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AlamedaCountyMember_1b3ff648-6e44-4f52-93c3-cbfd19c7b04f_terseLabel_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:label id="lab_cah_AlamedaCountyMember_label_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:label id="lab_cah_AlamedaCountyMember_documentation_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember" xlink:href="cah-20210930.xsd#cah_AlamedaCountyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AlamedaCountyMember" xlink:to="lab_cah_AlamedaCountyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b2136b4e-198b-407b-97b7-04ef252ad014_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bfbcbd67-58de-4ed3-82fc-2da12599a628_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a934e1d6-25ef-4a82-999b-583e8583fdda_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PrivatePartiesMember_f5ad5dab-c2bb-401a-a270-662c43f0ac6d_terseLabel_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_label_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_documentation_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember" xlink:href="cah-20210930.xsd#cah_PrivatePartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PrivatePartiesMember" xlink:to="lab_cah_PrivatePartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2c1543c9-5310-4e1c-ae8d-5e807fabcec4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_334f5206-5c3c-4103-b338-760cbd1235ba_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_537a43ec-977d-4002-8f3c-95ddd01153f2_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_8bf5553c-b2eb-4a7b-b2c4-d45780b39787_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_2a4598db-4faf-4eec-a12c-23d8d9c444e1_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_1f6f8944-ded4-4f5b-b352-31653473b379_terseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_7168cfef-ac9a-453b-9148-5a4f9a76bcf0_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_e11832c2-c2be-41f2-9e21-d5ec53bf6d66_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_09083dc4-7336-4bbf-8875-af29e6e69d5c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_26c887ee-28aa-4c0c-b62b-6d99a9980cb6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_9160fcda-05c2-4950-8e30-5670aa383d4b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b704f056-2eb3-4a00-99e9-dd9801b8d651_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLitigationAxis_10271b05-6980-4135-9430-a5eee8dd1059_terseLabel_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_label_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Axis]</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_documentation_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis" xlink:href="cah-20210930.xsd#cah_OpioidLitigationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLitigationAxis" xlink:to="lab_cah_OpioidLitigationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_a734e48c-cf1b-4e29-875b-3b8445d86c95_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Amortization Period (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_651547de-1153-4e74-a088-f61df00d8774_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AdditionalStockOptionPlanDataTableTextBlock_2a77f976-50a6-4759-b83e-482a844fd010_terseLabel_en-US" xlink:label="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Data Related to Stock Option Activity</link:label>
    <link:label id="lab_cah_AdditionalStockOptionPlanDataTableTextBlock_label_en-US" xlink:label="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock Option Plan Data [Table Text Block]</link:label>
    <link:label id="lab_cah_AdditionalStockOptionPlanDataTableTextBlock_documentation_en-US" xlink:label="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A disclosure of additional data related to all stock option activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:href="cah-20210930.xsd#cah_AdditionalStockOptionPlanDataTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:to="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_0924047f-8663-4677-99a4-670f3cc2989d_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_113996d0-7a1e-4330-868a-a4d974f5555d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transactions Related to Performance Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_597ab443-4d84-4b5d-89d4-2283efa125c9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_697419aa-2eee-4940-84cc-9a7ef1c385e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AggregateAnnualAssessment_a8c44bd2-4216-4325-ba22-a18ec91668b5_terseLabel_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_label_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_documentation_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment" xlink:href="cah-20210930.xsd#cah_AggregateAnnualAssessment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AggregateAnnualAssessment" xlink:to="lab_cah_AggregateAnnualAssessment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fc2f4a71-3756-4457-b5b4-b119e7aa45ba_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1d0130d2-d474-4c30-a61a-5cdc9037572e_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares&#8211;diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d9d22df2-f4c9-4ab7-ab42-3f7131d52d53_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income/(loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_86001340-a29f-484f-bd1e-c98a0d3a6eb3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_19d0a16d-8807-4cb1-8004-4b63500b87b8_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">litigation settlement liability recorded</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_6d970ad5-6f49-480e-9621-61141070dff6_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7a219ca2-f2b9-417b-83cf-1d518486cd20_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_9f3a326b-780e-4c11-be13-499bd7ce90c6_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_10055de1-8336-446b-afb7-1549857170be_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_411188af-18a2-4280-a582-8e432a235e95_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Transactions Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_5a445eed-b806-498d-96a4-bb2853f87026_negatedLabel_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_label_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of available-for-sale securities and other investments</link:label>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_documentation_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow from purchases of available-for-sale securities and other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:href="cah-20210930.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:to="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_96d45b85-f0b9-4b00-8151-567930359957_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_abc75aae-c3d7-4fc0-895e-26fbe73fefc8_verboseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares_76d2efff-4299-4d62-be22-eb772599c49b_terseLabel_en-US" xlink:label="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:label id="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares_label_en-US" xlink:label="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares excluded from calculation of diluted shares</link:label>
    <link:label id="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares_documentation_en-US" xlink:label="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares excluded from calculation of diluted shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Numberofsharesexcludedfromcalculationofdilutedshares" xlink:href="cah-20210930.xsd#cah_Numberofsharesexcludedfromcalculationofdilutedshares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Numberofsharesexcludedfromcalculationofdilutedshares" xlink:to="lab_cah_Numberofsharesexcludedfromcalculationofdilutedshares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0b8d20c0-64ce-4a78-bc17-3b10f5812f01_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_472ba05d-dbd8-4d12-9d48-f57351b2acea_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_f0130dcf-0db7-4bd2-8c33-1abf2eed2262_terseLabel_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_label_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_documentation_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber" xlink:href="cah-20210930.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LossContingencyLawsuitsNumber" xlink:to="lab_cah_LossContingencyLawsuitsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_dd335d0b-d8e6-4e15-8bb8-c6046c6f3d9a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_17e63b5f-b3f2-464d-9bf4-97685e9e5f05_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0137c46e-9088-4e4f-a1ab-6f467c426bdd_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_42fa5161-072f-4c6d-a2ce-c584543bc708_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4eeb4025-469e-4bf9-a314-8ad626bcf37c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_0eddc9a7-0399-4711-8e3a-c1bfa691d883_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Profit by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd682b00-50a5-404d-9a92-ad6f784d3bd7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f1751e73-6924-4f63-86b5-eb051058e017_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_be61ee61-963e-4368-9bf9-94d7c2651b26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsAxis_f870dbcf-42b8-4d22-93b6-ee38d87d0fa6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:to="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A2616NotesMember_a8e9baa9-b977-4aa3-880c-08f57496dcc0_terseLabel_en-US" xlink:label="lab_cah_A2616NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes</link:label>
    <link:label id="lab_cah_A2616NotesMember_label_en-US" xlink:label="lab_cah_A2616NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes [Member]</link:label>
    <link:label id="lab_cah_A2616NotesMember_documentation_en-US" xlink:label="lab_cah_A2616NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2616NotesMember" xlink:href="cah-20210930.xsd#cah_A2616NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A2616NotesMember" xlink:to="lab_cah_A2616NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_929c65d8-f9b7-4083-9241-dd41fca2dd1c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_0a843654-03fc-4177-a2bb-60b4e62692fc_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_44d0a3ca-9d85-4000-a43c-dd540b9e5705_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_3ca43316-f252-4de9-bc57-5b9110187052_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_b69d254e-8be2-4592-bbb8-b9092e9ba353_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_747b8c51-2b03-4708-93bf-143ed6859efd_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a0315157-a76d-46a1-a91b-914030241868_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_1877781c-6267-4015-aa31-492e3a3e6e0c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_fdf1b087-c896-41bd-87b3-49bb38655cdc_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalSegmentDomain_835c282a-3621-4949-a4fa-5d41722c74c2_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Segment [Domain]</link:label>
    <link:label id="lab_cah_PharmaceuticalSegmentDomain_label_en-US" xlink:label="lab_cah_PharmaceuticalSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Segment [Domain]</link:label>
    <link:label id="lab_cah_PharmaceuticalSegmentDomain_documentation_en-US" xlink:label="lab_cah_PharmaceuticalSegmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Pharmaceutical Segment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentDomain" xlink:href="cah-20210930.xsd#cah_PharmaceuticalSegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalSegmentDomain" xlink:to="lab_cah_PharmaceuticalSegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_0601243f-5fae-46b0-89fd-11a537143928_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2c8a5788-6829-42c7-bd9f-f5db4226d984_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_9e484121-3e8b-4230-92d6-c78e1e13eaca_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_cb802625-f475-4704-ae0b-17b5faaa6dd8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8880094f-3548-4b5c-896f-e99fae10ddfa_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Financial Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_cfa19f46-1834-42cf-b916-d375eef417a1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_9bd2bfe2-3071-483c-8aa1-1fb10bc89661_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_60f4cfc4-49c3-43b7-9b86-9593a16d88ff_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c0eb87f3-33e8-41fb-a9a7-5106d9e5db08_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_3fde2614-cee6-4293-a26a-707f5c7a1c55_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_72151483-7a45-49e8-bd2b-eaa212572e2f_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_551a6568-8f79-4775-ad4c-d8b7ff424e4b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_3e43b73c-6502-4063-8870-b31bc4ccf124_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_893108a0-c93f-4a4e-b9ab-8cb667125992_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_b24292a4-f0cf-4016-b1a1-8b475ab0bc5b_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OpenTaxYear_2e28a8ef-20ec-4b28-921a-f4dd1886f129_terseLabel_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year</link:label>
    <link:label id="lab_us-gaap_OpenTaxYear_label_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenTaxYear" xlink:to="lab_us-gaap_OpenTaxYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_e11ea5e6-ab49-41b4-a100-9647cfec775c_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_0a9e1180-dce1-4afc-8924-91342d598a49_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1603bca7-54f0-4911-b0a3-876983b2c149_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings/(loss) to net cash provided by/(used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_8056ab5a-88e8-42d3-a563-227621f8b647_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_ebda29ac-5f78-400a-ac27-a24151a0970b_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology and other</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_a5c192a3-d638-4db3-8364-141f959e863c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5bd38c49-1d81-4b16-b6ee-874b972daf39_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>cah-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2425d19b-e3e9-4a9a-b18c-4fd89ecf0bc7,g:620f6444-992f-4a20-8893-967dcaed6c73-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CoverPage" xlink:type="simple" xlink:href="cah-20210930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_611c2757-3b3b-4a58-82dd-cef80af36b8a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_DocumentType_611c2757-3b3b-4a58-82dd-cef80af36b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_7747cb86-aa4a-4d35-99aa-0c1c502d35bc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_DocumentQuarterlyReport_7747cb86-aa4a-4d35-99aa-0c1c502d35bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_2b4faa6a-2d89-47a6-bdc1-326a5d9c01a4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_DocumentPeriodEndDate_2b4faa6a-2d89-47a6-bdc1-326a5d9c01a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_59ad98f7-0da5-4e0e-896e-08036206ee3b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_DocumentTransitionReport_59ad98f7-0da5-4e0e-896e-08036206ee3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e84e857a-854b-448c-ab81-28cb117e2de5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_EntityFileNumber_e84e857a-854b-448c-ab81-28cb117e2de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_80720135-a2cd-451a-bbda-df04fe9d4b78" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_EntityRegistrantName_80720135-a2cd-451a-bbda-df04fe9d4b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_43204ef9-8bc7-4168-83b6-cb3d175ce48f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_EntityCentralIndexKey_43204ef9-8bc7-4168-83b6-cb3d175ce48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b4050c04-9c53-46a4-90cf-3de74d687c9d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_CurrentFiscalYearEndDate_b4050c04-9c53-46a4-90cf-3de74d687c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a4a83c36-58ee-4b5d-a53a-3c38c660277d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_DocumentFiscalYearFocus_a4a83c36-58ee-4b5d-a53a-3c38c660277d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_82c9ce72-024f-4994-b008-8eaaeaf78b83" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_82c9ce72-024f-4994-b008-8eaaeaf78b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_71d59926-85b1-4748-adac-eb5d11ce453f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_AmendmentFlag_71d59926-85b1-4748-adac-eb5d11ce453f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_be543145-8e0f-4a72-b23e-9bdb29b43237" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_be543145-8e0f-4a72-b23e-9bdb29b43237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3c3bbd01-8bb0-4bc7-83ec-4f5db17555a5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_EntityTaxIdentificationNumber_3c3bbd01-8bb0-4bc7-83ec-4f5db17555a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0fd83569-1042-4301-9fd4-ba82396fd701" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_EntityAddressAddressLine1_0fd83569-1042-4301-9fd4-ba82396fd701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6518d50f-2aaf-44c4-81f1-a8bcc632e1d8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_EntityAddressCityOrTown_6518d50f-2aaf-44c4-81f1-a8bcc632e1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_96308396-4374-4530-95ae-2c3de426dbec" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_EntityAddressStateOrProvince_96308396-4374-4530-95ae-2c3de426dbec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b32e8524-4726-44d9-9dfc-8f08c0e868d0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_EntityAddressPostalZipCode_b32e8524-4726-44d9-9dfc-8f08c0e868d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f24233c5-0e2f-4057-9b0c-315c123e92de" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_CityAreaCode_f24233c5-0e2f-4057-9b0c-315c123e92de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9446d1a8-0eab-4bf8-a32c-861f864d1625" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_LocalPhoneNumber_9446d1a8-0eab-4bf8-a32c-861f864d1625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9c6f614a-c8d4-4d6d-b238-659ebb5cdf99" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_EntityCurrentReportingStatus_9c6f614a-c8d4-4d6d-b238-659ebb5cdf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_48d705e1-0f73-4f08-9aad-61eda6eec330" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_EntityInteractiveDataCurrent_48d705e1-0f73-4f08-9aad-61eda6eec330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e043bdd7-99e9-4f03-9717-90a8b9350f1f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_EntityFilerCategory_e043bdd7-99e9-4f03-9717-90a8b9350f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e47d5499-33c5-40a3-855b-c8a6adeafad4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_EntitySmallBusiness_e47d5499-33c5-40a3-855b-c8a6adeafad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_463abf7e-5a74-4aa4-9648-3ca69fc1b7b2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_EntityEmergingGrowthCompany_463abf7e-5a74-4aa4-9648-3ca69fc1b7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_526a68c9-0e11-41bf-b750-e6d96a73850e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_EntityShellCompany_526a68c9-0e11-41bf-b750-e6d96a73850e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_dfcbed21-f4bd-4bb3-85fd-96c5bb8b632c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_Security12bTitle_dfcbed21-f4bd-4bb3-85fd-96c5bb8b632c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_84170c8c-9787-4b0d-b610-f464e096be02" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_TradingSymbol_84170c8c-9787-4b0d-b610-f464e096be02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_71dee8d5-e5d1-44cc-a4d6-21691691dd8b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_SecurityExchangeName_71dee8d5-e5d1-44cc-a4d6-21691691dd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_2554835c-c6d7-4771-bbac-49a74b13a409" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b0fde524-278c-429c-8e6e-efe2f847b7f0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_2554835c-c6d7-4771-bbac-49a74b13a409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20210930.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e70902cd-719d-45b1-9cd6-39ba0e76cd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_dd5a2294-29b1-4d70-98cc-bbcc90269647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e70902cd-719d-45b1-9cd6-39ba0e76cd9d" xlink:to="loc_us-gaap_Revenues_dd5a2294-29b1-4d70-98cc-bbcc90269647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ef4117f6-faa7-415d-badd-330b629eabe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e70902cd-719d-45b1-9cd6-39ba0e76cd9d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ef4117f6-faa7-415d-badd-330b629eabe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_08b63bba-6274-4420-90f5-f6d29cb5b3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e70902cd-719d-45b1-9cd6-39ba0e76cd9d" xlink:to="loc_us-gaap_GrossProfit_08b63bba-6274-4420-90f5-f6d29cb5b3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_9a3341ce-f481-4f36-ba16-bfee02e0a04e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e70902cd-719d-45b1-9cd6-39ba0e76cd9d" xlink:to="loc_us-gaap_OperatingExpensesAbstract_9a3341ce-f481-4f36-ba16-bfee02e0a04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_91ae56cd-abbd-4cff-9a36-c2d38ea675c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9a3341ce-f481-4f36-ba16-bfee02e0a04e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_91ae56cd-abbd-4cff-9a36-c2d38ea675c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_bc9efed5-b27b-4bd5-b278-f83919de74be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9a3341ce-f481-4f36-ba16-bfee02e0a04e" xlink:to="loc_us-gaap_RestructuringCharges_bc9efed5-b27b-4bd5-b278-f83919de74be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_27f164da-2abd-4c40-bed3-d120e08af5ec" xlink:href="cah-20210930.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9a3341ce-f481-4f36-ba16-bfee02e0a04e" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_27f164da-2abd-4c40-bed3-d120e08af5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_6cfdce98-0c52-4781-a0a1-b093ef3295f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9a3341ce-f481-4f36-ba16-bfee02e0a04e" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_6cfdce98-0c52-4781-a0a1-b093ef3295f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_54faeb30-da5b-47ab-aa4e-626803cd1865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9a3341ce-f481-4f36-ba16-bfee02e0a04e" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_54faeb30-da5b-47ab-aa4e-626803cd1865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_35ac9332-4388-483a-ba0c-262301c69179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e70902cd-719d-45b1-9cd6-39ba0e76cd9d" xlink:to="loc_us-gaap_OperatingIncomeLoss_35ac9332-4388-483a-ba0c-262301c69179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_95da9af8-0e71-4fa1-941d-f50e4bad073c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e70902cd-719d-45b1-9cd6-39ba0e76cd9d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_95da9af8-0e71-4fa1-941d-f50e4bad073c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0e97381e-3387-40f3-969c-c0f2fea4c0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e70902cd-719d-45b1-9cd6-39ba0e76cd9d" xlink:to="loc_us-gaap_InterestExpense_0e97381e-3387-40f3-969c-c0f2fea4c0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossOnEarlyExtinguishmentOfDebt_cec93ee7-d7ad-4b35-b469-58ddcbbc8f8f" xlink:href="cah-20210930.xsd#cah_LossOnEarlyExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e70902cd-719d-45b1-9cd6-39ba0e76cd9d" xlink:to="loc_cah_LossOnEarlyExtinguishmentOfDebt_cec93ee7-d7ad-4b35-b469-58ddcbbc8f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_928b4a3c-1987-4460-8055-3733d15ca639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e70902cd-719d-45b1-9cd6-39ba0e76cd9d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_928b4a3c-1987-4460-8055-3733d15ca639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_594e07d3-5081-4fc9-b336-9caa6f00b16b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e70902cd-719d-45b1-9cd6-39ba0e76cd9d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_594e07d3-5081-4fc9-b336-9caa6f00b16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_85073906-80f8-44f4-a2f5-98a55036ed6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e70902cd-719d-45b1-9cd6-39ba0e76cd9d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_85073906-80f8-44f4-a2f5-98a55036ed6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c85c1e29-64fa-4df3-a6b5-4940a64ad323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e70902cd-719d-45b1-9cd6-39ba0e76cd9d" xlink:to="loc_us-gaap_ProfitLoss_c85c1e29-64fa-4df3-a6b5-4940a64ad323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ae5c536d-6a8d-41c5-b000-8e8fd1f8038a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e70902cd-719d-45b1-9cd6-39ba0e76cd9d" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ae5c536d-6a8d-41c5-b000-8e8fd1f8038a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3d885d5a-06f1-4a8b-bf48-63dbd9aa9229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e70902cd-719d-45b1-9cd6-39ba0e76cd9d" xlink:to="loc_us-gaap_NetIncomeLoss_3d885d5a-06f1-4a8b-bf48-63dbd9aa9229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_bc36fdf0-d62f-4beb-a0d8-c809a298692a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e70902cd-719d-45b1-9cd6-39ba0e76cd9d" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_bc36fdf0-d62f-4beb-a0d8-c809a298692a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_17029dd0-10c7-40ac-a41e-e07d3c282f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_bc36fdf0-d62f-4beb-a0d8-c809a298692a" xlink:to="loc_us-gaap_EarningsPerShareBasic_17029dd0-10c7-40ac-a41e-e07d3c282f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0e374437-32c4-459a-946a-c1eba018d6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_bc36fdf0-d62f-4beb-a0d8-c809a298692a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0e374437-32c4-459a-946a-c1eba018d6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_764ad55b-ed72-4ec3-be7c-3c6226f8828d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e70902cd-719d-45b1-9cd6-39ba0e76cd9d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_764ad55b-ed72-4ec3-be7c-3c6226f8828d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_26891958-7a16-43d3-b66f-30e7becc1fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_764ad55b-ed72-4ec3-be7c-3c6226f8828d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_26891958-7a16-43d3-b66f-30e7becc1fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c925ea41-f5d1-4cdd-be18-4e6289818af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_764ad55b-ed72-4ec3-be7c-3c6226f8828d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c925ea41-f5d1-4cdd-be18-4e6289818af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_445fc621-900d-42c5-b0a3-4bfb8bacde67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e70902cd-719d-45b1-9cd6-39ba0e76cd9d" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_445fc621-900d-42c5-b0a3-4bfb8bacde67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20210930.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8c854fbd-5b94-490b-acd2-fd396eda4152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8b349ce6-88ba-44ae-98b8-99ad304ce420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8c854fbd-5b94-490b-acd2-fd396eda4152" xlink:to="loc_us-gaap_ProfitLoss_8b349ce6-88ba-44ae-98b8-99ad304ce420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ee28de42-1c57-4ba8-91ad-aa93f5401959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8c854fbd-5b94-490b-acd2-fd396eda4152" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ee28de42-1c57-4ba8-91ad-aa93f5401959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1b17ddee-7abf-473f-8864-d0bc8e3f0aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ee28de42-1c57-4ba8-91ad-aa93f5401959" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1b17ddee-7abf-473f-8864-d0bc8e3f0aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_4b5adbcf-7037-4fa8-8349-4f311a7c92f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ee28de42-1c57-4ba8-91ad-aa93f5401959" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_4b5adbcf-7037-4fa8-8349-4f311a7c92f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_47a13f57-4e65-440b-a988-59e66d31c946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ee28de42-1c57-4ba8-91ad-aa93f5401959" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_47a13f57-4e65-440b-a988-59e66d31c946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_935d7807-14d8-408c-b181-81ef077f7ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8c854fbd-5b94-490b-acd2-fd396eda4152" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_935d7807-14d8-408c-b181-81ef077f7ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_596ab069-dded-49ca-ac07-60d90508cf32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8c854fbd-5b94-490b-acd2-fd396eda4152" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_596ab069-dded-49ca-ac07-60d90508cf32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_705b895a-e3c9-4294-8d65-f38845595712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8c854fbd-5b94-490b-acd2-fd396eda4152" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_705b895a-e3c9-4294-8d65-f38845595712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20210930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1ffa292b-e822-477f-b330-855881b0bed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8e7e5f98-e243-4632-92f2-9c845d274021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1ffa292b-e822-477f-b330-855881b0bed2" xlink:to="loc_us-gaap_AssetsAbstract_8e7e5f98-e243-4632-92f2-9c845d274021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_95de3e40-d03e-49c1-82f9-8df3a4184dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e7e5f98-e243-4632-92f2-9c845d274021" xlink:to="loc_us-gaap_AssetsCurrentAbstract_95de3e40-d03e-49c1-82f9-8df3a4184dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ab037cc8-46be-4d8a-a15e-d2de7ffa1e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_95de3e40-d03e-49c1-82f9-8df3a4184dcc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ab037cc8-46be-4d8a-a15e-d2de7ffa1e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_e2f9ed9c-a384-47e3-bdea-5aa979fc0597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_95de3e40-d03e-49c1-82f9-8df3a4184dcc" xlink:to="loc_us-gaap_ReceivablesNetCurrent_e2f9ed9c-a384-47e3-bdea-5aa979fc0597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7315479f-c058-46c4-94f0-73a23daa66df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_95de3e40-d03e-49c1-82f9-8df3a4184dcc" xlink:to="loc_us-gaap_InventoryNet_7315479f-c058-46c4-94f0-73a23daa66df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_8398506f-2561-40c1-9d95-df84c7c16f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_95de3e40-d03e-49c1-82f9-8df3a4184dcc" xlink:to="loc_us-gaap_OtherAssetsCurrent_8398506f-2561-40c1-9d95-df84c7c16f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_686fcf44-4485-4f80-9ee0-7d305806de1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_95de3e40-d03e-49c1-82f9-8df3a4184dcc" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_686fcf44-4485-4f80-9ee0-7d305806de1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3a956ccf-4366-4e01-9a4b-0f3371e4a494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_95de3e40-d03e-49c1-82f9-8df3a4184dcc" xlink:to="loc_us-gaap_AssetsCurrent_3a956ccf-4366-4e01-9a4b-0f3371e4a494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_641adef5-f361-4f87-80b2-64cde13af731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e7e5f98-e243-4632-92f2-9c845d274021" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_641adef5-f361-4f87-80b2-64cde13af731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_22eb3029-e1cf-4d6e-8f54-3308d8e435fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e7e5f98-e243-4632-92f2-9c845d274021" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_22eb3029-e1cf-4d6e-8f54-3308d8e435fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9d65b817-fc1a-4df4-b371-a11f0c9e27f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e7e5f98-e243-4632-92f2-9c845d274021" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9d65b817-fc1a-4df4-b371-a11f0c9e27f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_023309ac-5a8b-475d-ae39-d09bb6c79bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8e7e5f98-e243-4632-92f2-9c845d274021" xlink:to="loc_us-gaap_Assets_023309ac-5a8b-475d-ae39-d09bb6c79bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cad1c3ed-870f-4d68-8506-6f566e37332a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1ffa292b-e822-477f-b330-855881b0bed2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cad1c3ed-870f-4d68-8506-6f566e37332a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_16eba059-fe7d-482c-a9ed-43278e2e471d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cad1c3ed-870f-4d68-8506-6f566e37332a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_16eba059-fe7d-482c-a9ed-43278e2e471d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6445f6ba-bf64-4f10-a9a0-de537967b499" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16eba059-fe7d-482c-a9ed-43278e2e471d" xlink:to="loc_us-gaap_AccountsPayableCurrent_6445f6ba-bf64-4f10-a9a0-de537967b499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_9f1f369b-72a6-4576-9999-be54cdb7dd96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16eba059-fe7d-482c-a9ed-43278e2e471d" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_9f1f369b-72a6-4576-9999-be54cdb7dd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a9288648-a7ee-46a5-82c5-ffb15ce8ba52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16eba059-fe7d-482c-a9ed-43278e2e471d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a9288648-a7ee-46a5-82c5-ffb15ce8ba52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_30ac5a82-2669-4ba7-9b2f-cf019a4b9b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16eba059-fe7d-482c-a9ed-43278e2e471d" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_30ac5a82-2669-4ba7-9b2f-cf019a4b9b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c813ba52-3b80-4824-b4ff-07688de2d065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16eba059-fe7d-482c-a9ed-43278e2e471d" xlink:to="loc_us-gaap_LiabilitiesCurrent_c813ba52-3b80-4824-b4ff-07688de2d065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_a26a06a2-c892-4b5d-8669-aee69edf06fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cad1c3ed-870f-4d68-8506-6f566e37332a" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_a26a06a2-c892-4b5d-8669-aee69edf06fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_8d34f8b4-8cba-4d53-961c-693ca2236a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cad1c3ed-870f-4d68-8506-6f566e37332a" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_8d34f8b4-8cba-4d53-961c-693ca2236a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8c7a5102-d934-440a-9236-d71832ddd34b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cad1c3ed-870f-4d68-8506-6f566e37332a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_8c7a5102-d934-440a-9236-d71832ddd34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_bdc289df-0938-4fd0-981b-96e54281a3de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8c7a5102-d934-440a-9236-d71832ddd34b" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_bdc289df-0938-4fd0-981b-96e54281a3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ac7e0699-f864-438c-a76d-66311fbb5dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8c7a5102-d934-440a-9236-d71832ddd34b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ac7e0699-f864-438c-a76d-66311fbb5dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_c395f52a-23cd-4006-b1ff-a206787b75d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8c7a5102-d934-440a-9236-d71832ddd34b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_c395f52a-23cd-4006-b1ff-a206787b75d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6d55aefe-e4d5-463e-9a8f-b0ff49f0b8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8c7a5102-d934-440a-9236-d71832ddd34b" xlink:to="loc_us-gaap_PreferredStockValue_6d55aefe-e4d5-463e-9a8f-b0ff49f0b8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ab4ef6ed-1591-40f3-b603-117c6e1216a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8c7a5102-d934-440a-9236-d71832ddd34b" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ab4ef6ed-1591-40f3-b603-117c6e1216a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3e732d23-fdfe-480e-a27a-0ece09407236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8c7a5102-d934-440a-9236-d71832ddd34b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3e732d23-fdfe-480e-a27a-0ece09407236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_634c1d4b-338b-41ef-849d-5613ddc0154b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8c7a5102-d934-440a-9236-d71832ddd34b" xlink:to="loc_us-gaap_CommonStockSharesIssued_634c1d4b-338b-41ef-849d-5613ddc0154b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_51acf88d-6682-45de-b487-a1bf694ea94e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8c7a5102-d934-440a-9236-d71832ddd34b" xlink:to="loc_us-gaap_CommonStockValue_51acf88d-6682-45de-b487-a1bf694ea94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_724484fb-8bae-4085-9e76-34f15d2faca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8c7a5102-d934-440a-9236-d71832ddd34b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_724484fb-8bae-4085-9e76-34f15d2faca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_4742135f-b06a-497a-ac47-ff61e987cd58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8c7a5102-d934-440a-9236-d71832ddd34b" xlink:to="loc_us-gaap_TreasuryStockValue_4742135f-b06a-497a-ac47-ff61e987cd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_dc9031bb-f4bb-41d6-a5bb-e8e3960c8361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8c7a5102-d934-440a-9236-d71832ddd34b" xlink:to="loc_us-gaap_TreasuryStockShares_dc9031bb-f4bb-41d6-a5bb-e8e3960c8361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e10091c8-c18a-46a8-84c1-d1d0980c3c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8c7a5102-d934-440a-9236-d71832ddd34b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e10091c8-c18a-46a8-84c1-d1d0980c3c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9e03886f-3324-407e-a722-90dee90a834a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8c7a5102-d934-440a-9236-d71832ddd34b" xlink:to="loc_us-gaap_StockholdersEquity_9e03886f-3324-407e-a722-90dee90a834a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_f8eef9f9-e273-4a1a-b32a-0600121b4196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8c7a5102-d934-440a-9236-d71832ddd34b" xlink:to="loc_us-gaap_MinorityInterest_f8eef9f9-e273-4a1a-b32a-0600121b4196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_709abbb6-2de4-4c26-bfbc-66909a3f4ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8c7a5102-d934-440a-9236-d71832ddd34b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_709abbb6-2de4-4c26-bfbc-66909a3f4ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6216277f-1cdd-4af7-9e34-20213c6a7f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cad1c3ed-870f-4d68-8506-6f566e37332a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6216277f-1cdd-4af7-9e34-20213c6a7f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" xlink:type="simple" xlink:href="cah-20210930.xsd#CondensedConsolidatedStatementofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d791e17e-8b3d-4d92-a166-aef6eef4fa85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_7703b549-fc3b-4d78-98db-68284a99bef1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d791e17e-8b3d-4d92-a166-aef6eef4fa85" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_7703b549-fc3b-4d78-98db-68284a99bef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f43dae98-17ff-406b-92d3-08b528e47fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_7703b549-fc3b-4d78-98db-68284a99bef1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f43dae98-17ff-406b-92d3-08b528e47fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6f8696f6-2084-46e8-81f3-14c94e88395b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f43dae98-17ff-406b-92d3-08b528e47fc5" xlink:to="loc_us-gaap_EquityComponentDomain_6f8696f6-2084-46e8-81f3-14c94e88395b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cf17861d-591b-43af-b7f8-9c3a8b54d4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6f8696f6-2084-46e8-81f3-14c94e88395b" xlink:to="loc_us-gaap_CommonStockMember_cf17861d-591b-43af-b7f8-9c3a8b54d4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3f090cc9-fd3c-476f-ace4-b34244ffe699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6f8696f6-2084-46e8-81f3-14c94e88395b" xlink:to="loc_us-gaap_RetainedEarningsMember_3f090cc9-fd3c-476f-ace4-b34244ffe699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_8880b6db-e7c7-46bc-83fb-12ea4af36f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6f8696f6-2084-46e8-81f3-14c94e88395b" xlink:to="loc_us-gaap_TreasuryStockMember_8880b6db-e7c7-46bc-83fb-12ea4af36f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8316231f-3f9c-4daa-9773-1be26d632f11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6f8696f6-2084-46e8-81f3-14c94e88395b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8316231f-3f9c-4daa-9773-1be26d632f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_c0ef2c8b-a9b8-4076-93d8-de449016699b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6f8696f6-2084-46e8-81f3-14c94e88395b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_c0ef2c8b-a9b8-4076-93d8-de449016699b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_7703b549-fc3b-4d78-98db-68284a99bef1" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_475ad43a-5713-454c-8e4b-5ae1c55ed64a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_CommonStockSharesIssued_475ad43a-5713-454c-8e4b-5ae1c55ed64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_984d6519-f427-4497-95b6-8a1a5188cd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_984d6519-f427-4497-95b6-8a1a5188cd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_f8a55ad6-2107-4e55-82be-460b4278c6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_TreasuryStockShares_f8a55ad6-2107-4e55-82be-460b4278c6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_efb2b240-8d39-4369-b749-04f7a54c5500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_TreasuryStockValue_efb2b240-8d39-4369-b749-04f7a54c5500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d6debebb-8aa9-4267-91d9-01c1e5cdb825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_NetIncomeLoss_d6debebb-8aa9-4267-91d9-01c1e5cdb825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_003b9a86-8fb1-459d-90b5-efcddf1c2925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_ProfitLoss_003b9a86-8fb1-459d-90b5-efcddf1c2925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_312f94ed-5529-48e8-9a60-8a2ed3f73ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_312f94ed-5529-48e8-9a60-8a2ed3f73ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6493b5f6-9232-4141-8ad7-a6171721a15d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6493b5f6-9232-4141-8ad7-a6171721a15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c9265f62-b0e8-43cb-aabc-15731d758d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c9265f62-b0e8-43cb-aabc-15731d758d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_b84504a6-084b-43ac-94fd-e84a549ba32a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_b84504a6-084b-43ac-94fd-e84a549ba32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_18c3742e-16ba-4649-a947-28e4de08c146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_18c3742e-16ba-4649-a947-28e4de08c146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_2aafeb15-8a79-43e3-808c-65a0e776a346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_Dividends_2aafeb15-8a79-43e3-808c-65a0e776a346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_60991d95-08fe-4ba4-8967-4f7a94d549b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_StockholdersEquityOther_60991d95-08fe-4ba4-8967-4f7a94d549b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cd0a4e69-ee5a-4323-986f-0961dd6b97ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_CommonStockSharesIssued_cd0a4e69-ee5a-4323-986f-0961dd6b97ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a04b1d9e-9be3-4824-960b-912b7a4afc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a04b1d9e-9be3-4824-960b-912b7a4afc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_25d1802f-4cdf-4c96-bd0e-3730379b27b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_TreasuryStockShares_25d1802f-4cdf-4c96-bd0e-3730379b27b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_891e6a61-32c4-4f87-ae18-90b8167cf0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5b6bd008-69dc-423f-a2d1-52b2c6f70807" xlink:to="loc_us-gaap_TreasuryStockValue_891e6a61-32c4-4f87-ae18-90b8167cf0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20210930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ae5710ae-6d2c-4151-a066-d704d9a1d8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a7e94949-6d3d-4423-9a70-02ccccfa0a43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ae5710ae-6d2c-4151-a066-d704d9a1d8d9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a7e94949-6d3d-4423-9a70-02ccccfa0a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_04b1877a-c571-4137-b7b1-4c3802572903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a7e94949-6d3d-4423-9a70-02ccccfa0a43" xlink:to="loc_us-gaap_ProfitLoss_04b1877a-c571-4137-b7b1-4c3802572903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1abfee0-cf46-4ae1-ab9e-d2aca2029af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a7e94949-6d3d-4423-9a70-02ccccfa0a43" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1abfee0-cf46-4ae1-ab9e-d2aca2029af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9087188c-fd7f-4552-a240-4a25b1146b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1abfee0-cf46-4ae1-ab9e-d2aca2029af2" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9087188c-fd7f-4552-a240-4a25b1146b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_a3edd3eb-2ec6-46a2-b1a6-b973b52c44c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1abfee0-cf46-4ae1-ab9e-d2aca2029af2" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_a3edd3eb-2ec6-46a2-b1a6-b973b52c44c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_23f6b490-ba74-4a6f-81cb-560e65366ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1abfee0-cf46-4ae1-ab9e-d2aca2029af2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_23f6b490-ba74-4a6f-81cb-560e65366ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ba10a2c9-9977-461f-9749-23153b8de0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1abfee0-cf46-4ae1-ab9e-d2aca2029af2" xlink:to="loc_us-gaap_ShareBasedCompensation_ba10a2c9-9977-461f-9749-23153b8de0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_cf65ba2e-709a-440e-99e8-1a62f3e28cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1abfee0-cf46-4ae1-ab9e-d2aca2029af2" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_cf65ba2e-709a-440e-99e8-1a62f3e28cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_993018d6-9ee0-47ba-b91e-7eb0b6fa52b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1abfee0-cf46-4ae1-ab9e-d2aca2029af2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_993018d6-9ee0-47ba-b91e-7eb0b6fa52b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_a6050d35-00a7-4bac-87fa-6e2397f923e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_993018d6-9ee0-47ba-b91e-7eb0b6fa52b7" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_a6050d35-00a7-4bac-87fa-6e2397f923e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d5e67f1e-e762-43e4-879c-538c1d82e90e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_993018d6-9ee0-47ba-b91e-7eb0b6fa52b7" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d5e67f1e-e762-43e4-879c-538c1d82e90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6da3357d-b2e6-4d37-bd44-f6a16c5345e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_993018d6-9ee0-47ba-b91e-7eb0b6fa52b7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6da3357d-b2e6-4d37-bd44-f6a16c5345e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_25fe10d3-3fcd-4efd-9d99-c48900211c41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_993018d6-9ee0-47ba-b91e-7eb0b6fa52b7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_25fe10d3-3fcd-4efd-9d99-c48900211c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2fe807e-b1ff-4ae2-9b75-4dc7aab164d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a7e94949-6d3d-4423-9a70-02ccccfa0a43" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2fe807e-b1ff-4ae2-9b75-4dc7aab164d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9a97b232-7e08-4b27-b1d2-65456cb3a0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ae5710ae-6d2c-4151-a066-d704d9a1d8d9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9a97b232-7e08-4b27-b1d2-65456cb3a0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_2b33a5f5-f6a1-41d0-b518-2c41d5d14405" xlink:href="cah-20210930.xsd#cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9a97b232-7e08-4b27-b1d2-65456cb3a0b6" xlink:to="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_2b33a5f5-f6a1-41d0-b518-2c41d5d14405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03a3526b-6955-4ee3-865f-090b601a045e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9a97b232-7e08-4b27-b1d2-65456cb3a0b6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03a3526b-6955-4ee3-865f-090b601a045e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_97276e3e-5a37-46ea-b243-bea3c835c325" xlink:href="cah-20210930.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9a97b232-7e08-4b27-b1d2-65456cb3a0b6" xlink:to="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_97276e3e-5a37-46ea-b243-bea3c835c325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_75b43d4f-6cf9-42b1-ba64-056ae6f436d6" xlink:href="cah-20210930.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9a97b232-7e08-4b27-b1d2-65456cb3a0b6" xlink:to="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_75b43d4f-6cf9-42b1-ba64-056ae6f436d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a4ca984a-9bff-4fb2-bba9-15c5222b271c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ae5710ae-6d2c-4151-a066-d704d9a1d8d9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a4ca984a-9bff-4fb2-bba9-15c5222b271c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_125b6ebe-c55f-41b2-a863-fc1a468b4b97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ae5710ae-6d2c-4151-a066-d704d9a1d8d9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_125b6ebe-c55f-41b2-a863-fc1a468b4b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_70601d4c-a5e6-4ba4-b33a-16be80cfa90d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_125b6ebe-c55f-41b2-a863-fc1a468b4b97" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_70601d4c-a5e6-4ba4-b33a-16be80cfa90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_f153829d-ccee-4836-8554-722061a35f99" xlink:href="cah-20210930.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_125b6ebe-c55f-41b2-a863-fc1a468b4b97" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_f153829d-ccee-4836-8554-722061a35f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_fb0a511f-2f16-4c91-a39a-75041e1cfd49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_125b6ebe-c55f-41b2-a863-fc1a468b4b97" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_fb0a511f-2f16-4c91-a39a-75041e1cfd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_98e94650-cbf0-4da0-8ae8-fefc7b7e9464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_125b6ebe-c55f-41b2-a863-fc1a468b4b97" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_98e94650-cbf0-4da0-8ae8-fefc7b7e9464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7ac8f948-2166-4c00-b2ca-888c6e24cc51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_125b6ebe-c55f-41b2-a863-fc1a468b4b97" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7ac8f948-2166-4c00-b2ca-888c6e24cc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_111292d7-f65c-438b-991b-e9128dc81853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ae5710ae-6d2c-4151-a066-d704d9a1d8d9" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_111292d7-f65c-438b-991b-e9128dc81853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedtoAssetsHeldforSale_d5f68586-10c0-4354-8e72-48733b9ef5e0" xlink:href="cah-20210930.xsd#cah_CashReclassifiedtoAssetsHeldforSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ae5710ae-6d2c-4151-a066-d704d9a1d8d9" xlink:to="loc_cah_CashReclassifiedtoAssetsHeldforSale_d5f68586-10c0-4354-8e72-48733b9ef5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f22509ae-001a-47fe-bbe5-10ea4ec6be95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ae5710ae-6d2c-4151-a066-d704d9a1d8d9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f22509ae-001a-47fe-bbe5-10ea4ec6be95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_db40c9dc-1595-4abe-9d3f-1de5a455492a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ae5710ae-6d2c-4151-a066-d704d9a1d8d9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_db40c9dc-1595-4abe-9d3f-1de5a455492a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f0463b03-14ad-4c5e-8890-375e1760fe77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ae5710ae-6d2c-4151-a066-d704d9a1d8d9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f0463b03-14ad-4c5e-8890-375e1760fe77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cah-20210930.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_65f62952-6c2b-4411-9559-36f9e090aa23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_8d79ef86-a205-462f-afab-9a2cacf7fba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_65f62952-6c2b-4411-9559-36f9e090aa23" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_8d79ef86-a205-462f-afab-9a2cacf7fba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cah-20210930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_02911a06-e07e-4247-8416-1a18f74c7e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b25f5df7-981b-4911-b3b0-cf38d8f90058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02911a06-e07e-4247-8416-1a18f74c7e03" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b25f5df7-981b-4911-b3b0-cf38d8f90058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e602e658-c6cf-46f6-88cb-bda74f27d415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02911a06-e07e-4247-8416-1a18f74c7e03" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e602e658-c6cf-46f6-88cb-bda74f27d415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract_ced94f76-9a29-43e3-85f2-8b1d747e07a7" xlink:href="cah-20210930.xsd#cah_BasisofPresentationandSummaryofSignificantAccountingPoliciesAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/Divestitures" xlink:type="simple" xlink:href="cah-20210930.xsd#Divestitures"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/Divestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_7e32b4e0-ba8c-4f9a-920d-0fb3f409718c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_a0a3e94b-11f4-4f95-8d9d-f5717df97659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_7e32b4e0-ba8c-4f9a-920d-0fb3f409718c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_a0a3e94b-11f4-4f95-8d9d-f5717df97659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DivestituresTables" xlink:type="simple" xlink:href="cah-20210930.xsd#DivestituresTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/DivestituresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_fc1ac51a-6b80-48fc-8b0f-a024a9674de0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DivestituresDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#DivestituresDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/DivestituresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6190e63d-237a-41b5-a0c0-6f916fd4fa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_ce116b7e-b057-480a-a6eb-66c5c8ea1549" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6190e63d-237a-41b5-a0c0-6f916fd4fa0a" xlink:to="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_ce116b7e-b057-480a-a6eb-66c5c8ea1549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_7b9329e7-d1c3-400b-ae49-30b202c8fc36" xlink:href="cah-20210930.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_ce116b7e-b057-480a-a6eb-66c5c8ea1549" xlink:to="loc_cah_CordisDivestitureAxis_7b9329e7-d1c3-400b-ae49-30b202c8fc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_80fa4217-fe90-4520-8260-ae7390adb6f7" xlink:href="cah-20210930.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_7b9329e7-d1c3-400b-ae49-30b202c8fc36" xlink:to="loc_cah_CordisDivestitureDomain_80fa4217-fe90-4520-8260-ae7390adb6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_e64bc86a-46ba-4cd5-b7f7-5bdf125e7159" xlink:href="cah-20210930.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_80fa4217-fe90-4520-8260-ae7390adb6f7" xlink:to="loc_cah_CordisDivestitureMember_e64bc86a-46ba-4cd5-b7f7-5bdf125e7159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_356d4757-6cb4-42c9-9ba2-6c6ef94c9235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable_ce116b7e-b057-480a-a6eb-66c5c8ea1549" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_356d4757-6cb4-42c9-9ba2-6c6ef94c9235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_e15f1e9b-047b-4663-b1c1-31239c3385e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleLineItems_356d4757-6cb4-42c9-9ba2-6c6ef94c9235" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_e15f1e9b-047b-4663-b1c1-31239c3385e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="simple" xlink:href="cah-20210930.xsd#RestructuringandEmployeeSeverance"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_10a4d900-6f81-496f-896f-431537cd9a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_fb258542-3d6a-479a-bc12-78d65d82a501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_10a4d900-6f81-496f-896f-431537cd9a2b" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_fb258542-3d6a-479a-bc12-78d65d82a501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="simple" xlink:href="cah-20210930.xsd#RestructuringandEmployeeSeveranceTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_f4f5d442-ae51-4790-94b5-8748ae2aa2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_c44f2968-2ac9-4d12-8983-2d6b277f25dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_f4f5d442-ae51-4790-94b5-8748ae2aa2ad" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_c44f2968-2ac9-4d12-8983-2d6b277f25dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_f44fca8a-46f5-448d-b13d-8a14fe7feae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_f4f5d442-ae51-4790-94b5-8748ae2aa2ad" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_f44fca8a-46f5-448d-b13d-8a14fe7feae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_ddbe248e-52a0-4da8-8869-761c03566f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_2cdd3f7b-a86c-4a4e-a715-540e0d95aab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_ddbe248e-52a0-4da8-8869-761c03566f0e" xlink:to="loc_us-gaap_SeveranceCosts1_2cdd3f7b-a86c-4a4e-a715-540e0d95aab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_e1bfc6e8-c4fc-473c-b0f7-933b33109bcb" xlink:href="cah-20210930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_ddbe248e-52a0-4da8-8869-761c03566f0e" xlink:to="loc_cah_FacilityExitAndOtherCosts_e1bfc6e8-c4fc-473c-b0f7-933b33109bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3678fc5a-4a32-4826-9d26-231561294cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_ddbe248e-52a0-4da8-8869-761c03566f0e" xlink:to="loc_us-gaap_RestructuringCharges_3678fc5a-4a32-4826-9d26-231561294cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_3373f9ff-9714-482a-9504-01767f6e2b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_99082d12-392e-405e-bb7c-230fea39e7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_3373f9ff-9714-482a-9504-01767f6e2b32" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_99082d12-392e-405e-bb7c-230fea39e7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_d028fd83-85ac-488d-834c-2ed92a60186b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_99082d12-392e-405e-bb7c-230fea39e7a9" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_d028fd83-85ac-488d-834c-2ed92a60186b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_48c5114c-2961-479e-8fef-925af3aec3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d028fd83-85ac-488d-834c-2ed92a60186b" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_48c5114c-2961-479e-8fef-925af3aec3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_0bcf4a94-4b14-4cd2-83e6-a638e0fbd082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_48c5114c-2961-479e-8fef-925af3aec3b1" xlink:to="loc_us-gaap_EmployeeSeveranceMember_0bcf4a94-4b14-4cd2-83e6-a638e0fbd082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_960cb93e-46d3-4609-829b-fdbbec16cf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_48c5114c-2961-479e-8fef-925af3aec3b1" xlink:to="loc_us-gaap_FacilityClosingMember_960cb93e-46d3-4609-829b-fdbbec16cf2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_f0f08701-7bc4-4954-8f41-2ca391bd3875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_99082d12-392e-405e-bb7c-230fea39e7a9" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_f0f08701-7bc4-4954-8f41-2ca391bd3875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_a0bf3441-ec10-4547-9b7b-e1ae4d2a9ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_f0f08701-7bc4-4954-8f41-2ca391bd3875" xlink:to="loc_us-gaap_RestructuringReserveRollForward_a0bf3441-ec10-4547-9b7b-e1ae4d2a9ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_dd86f5b4-124d-4444-8b6d-062beb2d52b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_a0bf3441-ec10-4547-9b7b-e1ae4d2a9ba0" xlink:to="loc_us-gaap_RestructuringReserve_dd86f5b4-124d-4444-8b6d-062beb2d52b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_20c692be-30d7-4550-8049-60eaf8330b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_a0bf3441-ec10-4547-9b7b-e1ae4d2a9ba0" xlink:to="loc_us-gaap_RestructuringCosts_20c692be-30d7-4550-8049-60eaf8330b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_24574f68-5a62-4228-90ae-d13b059a8d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_a0bf3441-ec10-4547-9b7b-e1ae4d2a9ba0" xlink:to="loc_us-gaap_PaymentsForRestructuring_24574f68-5a62-4228-90ae-d13b059a8d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_a0fa3f00-65e1-4ecd-b040-fd170b4babc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_a0bf3441-ec10-4547-9b7b-e1ae4d2a9ba0" xlink:to="loc_us-gaap_RestructuringReserve_a0fa3f00-65e1-4ecd-b040-fd170b4babc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#RestructuringandEmployeeSeveranceNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9c40d6fb-b6da-49ec-a93c-85a5d3eb2a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e672459c-cc77-49d8-b5dd-0d2cafb36a60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9c40d6fb-b6da-49ec-a93c-85a5d3eb2a1a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e672459c-cc77-49d8-b5dd-0d2cafb36a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_f1c8d19d-066c-4ffd-9977-8e4f1e83b705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e672459c-cc77-49d8-b5dd-0d2cafb36a60" xlink:to="loc_us-gaap_RestructuringPlanAxis_f1c8d19d-066c-4ffd-9977-8e4f1e83b705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_b8dd3482-fa04-4f72-9acf-358641cf98b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_f1c8d19d-066c-4ffd-9977-8e4f1e83b705" xlink:to="loc_us-gaap_RestructuringPlanDomain_b8dd3482-fa04-4f72-9acf-358641cf98b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_641f2b02-91e7-4ba2-bd45-e2b1f52aaeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e672459c-cc77-49d8-b5dd-0d2cafb36a60" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_641f2b02-91e7-4ba2-bd45-e2b1f52aaeb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_1789c4ba-185c-41b3-8e49-3213abc1ec7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_641f2b02-91e7-4ba2-bd45-e2b1f52aaeb7" xlink:to="loc_us-gaap_SeveranceCosts1_1789c4ba-185c-41b3-8e49-3213abc1ec7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_a55711e2-984a-4a7a-9ea2-6c68e633e500" xlink:href="cah-20210930.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_641f2b02-91e7-4ba2-bd45-e2b1f52aaeb7" xlink:to="loc_cah_FacilityExitAndOtherCosts_a55711e2-984a-4a7a-9ea2-6c68e633e500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="cah-20210930.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_225149e1-8efd-4d33-b1de-02ca6779af27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_02715fa5-ed78-4745-9ebe-5bcff9b3a541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_225149e1-8efd-4d33-b1de-02ca6779af27" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_02715fa5-ed78-4745-9ebe-5bcff9b3a541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="cah-20210930.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d95597fa-6743-4b88-932c-511e1e242284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_127b16ef-55af-4394-810d-66b92db658cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d95597fa-6743-4b88-932c-511e1e242284" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_127b16ef-55af-4394-810d-66b92db658cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_362d1232-340a-4861-8422-036769f3b9c4" xlink:href="cah-20210930.xsd#cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d95597fa-6743-4b88-932c-511e1e242284" xlink:to="loc_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock_362d1232-340a-4861-8422-036769f3b9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c4629c55-06e8-45a5-ae78-594cf8dbbb15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_7d67d38c-48c9-4670-bcd9-49e78b9f8c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c4629c55-06e8-45a5-ae78-594cf8dbbb15" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_7d67d38c-48c9-4670-bcd9-49e78b9f8c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7c72501d-3bfe-4580-a76e-8679ad17ad08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7d67d38c-48c9-4670-bcd9-49e78b9f8c29" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7c72501d-3bfe-4580-a76e-8679ad17ad08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e121af41-aafd-4592-86d3-f9c60f92e66c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7c72501d-3bfe-4580-a76e-8679ad17ad08" xlink:to="loc_us-gaap_SegmentDomain_e121af41-aafd-4592-86d3-f9c60f92e66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_b7af1062-f4d0-4a0a-bfc3-cc40dd0bd19c" xlink:href="cah-20210930.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e121af41-aafd-4592-86d3-f9c60f92e66c" xlink:to="loc_cah_PharmaceuticalMember_b7af1062-f4d0-4a0a-bfc3-cc40dd0bd19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_c5cf89b8-222a-4f93-9968-77fec2dd3166" xlink:href="cah-20210930.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e121af41-aafd-4592-86d3-f9c60f92e66c" xlink:to="loc_cah_MedicalMember_c5cf89b8-222a-4f93-9968-77fec2dd3166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_bbf009ce-bb49-4ca6-9fd3-7632ab3f77e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7d67d38c-48c9-4670-bcd9-49e78b9f8c29" xlink:to="loc_us-gaap_GoodwillLineItems_bbf009ce-bb49-4ca6-9fd3-7632ab3f77e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillTransfers_8da00011-f244-4504-bb64-5629b790c103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillTransfers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_bbf009ce-bb49-4ca6-9fd3-7632ab3f77e1" xlink:to="loc_us-gaap_GoodwillTransfers_8da00011-f244-4504-bb64-5629b790c103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_3b2d6e09-1d04-4368-b7a0-0178ae000cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_bbf009ce-bb49-4ca6-9fd3-7632ab3f77e1" xlink:to="loc_us-gaap_GoodwillRollForward_3b2d6e09-1d04-4368-b7a0-0178ae000cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_23e56432-cf4d-430d-a5fc-4f7cd6c2496e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_3b2d6e09-1d04-4368-b7a0-0178ae000cf5" xlink:to="loc_us-gaap_Goodwill_23e56432-cf4d-430d-a5fc-4f7cd6c2496e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_244163c9-8ea0-487e-87b8-f00529b49a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_3b2d6e09-1d04-4368-b7a0-0178ae000cf5" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_244163c9-8ea0-487e-87b8-f00529b49a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7951d38d-4905-4916-b57b-d66a7c39fd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_3b2d6e09-1d04-4368-b7a0-0178ae000cf5" xlink:to="loc_us-gaap_Goodwill_7951d38d-4905-4916-b57b-d66a7c39fd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_afa07d3d-68da-44f5-9308-9627a7a3a9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d23cfcf0-d97f-4f32-bf38-8e98a1f988fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_afa07d3d-68da-44f5-9308-9627a7a3a9c3" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d23cfcf0-d97f-4f32-bf38-8e98a1f988fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_669444bc-5d14-48ad-9286-91794dc4987b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d23cfcf0-d97f-4f32-bf38-8e98a1f988fd" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_669444bc-5d14-48ad-9286-91794dc4987b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1ba060d7-3fbf-47e2-9d02-e321fe2eb545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_669444bc-5d14-48ad-9286-91794dc4987b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1ba060d7-3fbf-47e2-9d02-e321fe2eb545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_575f03b7-2516-4a06-8543-a7eda9aac62b" xlink:href="cah-20210930.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1ba060d7-3fbf-47e2-9d02-e321fe2eb545" xlink:to="loc_cah_IPRDTrademarksandOtherMember_575f03b7-2516-4a06-8543-a7eda9aac62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6c35fb98-dfcc-4698-a79b-6c2e4cc96128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_d23cfcf0-d97f-4f32-bf38-8e98a1f988fd" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6c35fb98-dfcc-4698-a79b-6c2e4cc96128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e6fa2191-a1bf-46ad-8ff0-caf58590d5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6c35fb98-dfcc-4698-a79b-6c2e4cc96128" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e6fa2191-a1bf-46ad-8ff0-caf58590d5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e5452355-5dc3-4022-bdcf-cd75822f339a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_afa07d3d-68da-44f5-9308-9627a7a3a9c3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e5452355-5dc3-4022-bdcf-cd75822f339a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7b10788-c4ef-469a-838c-0000ad686f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e5452355-5dc3-4022-bdcf-cd75822f339a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7b10788-c4ef-469a-838c-0000ad686f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc8d5bb8-7b1d-48fd-b172-5787de7946e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7b10788-c4ef-469a-838c-0000ad686f26" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc8d5bb8-7b1d-48fd-b172-5787de7946e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_6076adcc-33e5-4fdf-a0ad-23b1680a16a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc8d5bb8-7b1d-48fd-b172-5787de7946e7" xlink:to="loc_us-gaap_CustomerRelationshipsMember_6076adcc-33e5-4fdf-a0ad-23b1680a16a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_3075c624-cd79-4ee6-b420-a622c0097e7c" xlink:href="cah-20210930.xsd#cah_TrademarksAndPatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc8d5bb8-7b1d-48fd-b172-5787de7946e7" xlink:to="loc_cah_TrademarksAndPatentsMember_3075c624-cd79-4ee6-b420-a622c0097e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_7fe968b7-56dc-49f6-86b0-73bf8aa06d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fc8d5bb8-7b1d-48fd-b172-5787de7946e7" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_7fe968b7-56dc-49f6-86b0-73bf8aa06d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_086dc99f-4448-43a0-9400-15558411daf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e5452355-5dc3-4022-bdcf-cd75822f339a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_086dc99f-4448-43a0-9400-15558411daf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c320db6c-042d-4c58-94a9-05d4eeb88cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_086dc99f-4448-43a0-9400-15558411daf3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c320db6c-042d-4c58-94a9-05d4eeb88cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_46826dc1-94ce-4e24-8177-7d3de2c4309e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_086dc99f-4448-43a0-9400-15558411daf3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_46826dc1-94ce-4e24-8177-7d3de2c4309e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_93a12b8c-1620-4831-94c6-618644242947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_086dc99f-4448-43a0-9400-15558411daf3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_93a12b8c-1620-4831-94c6-618644242947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_cbb4ffea-ffb5-4329-8701-506def8c789b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_086dc99f-4448-43a0-9400-15558411daf3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_cbb4ffea-ffb5-4329-8701-506def8c789b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_db7bf785-ece0-4da6-83b4-cb9d5f292c95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_afa07d3d-68da-44f5-9308-9627a7a3a9c3" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_db7bf785-ece0-4da6-83b4-cb9d5f292c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_90d28705-07f3-431e-a194-befe7c697e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_afa07d3d-68da-44f5-9308-9627a7a3a9c3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_90d28705-07f3-431e-a194-befe7c697e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_009f2813-9196-44a1-b7a9-2703b7483874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_254be7c6-342a-4967-b62f-218188dc0639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_009f2813-9196-44a1-b7a9-2703b7483874" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_254be7c6-342a-4967-b62f-218188dc0639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_81aad294-d6f1-47c6-ac35-afc90d962400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_009f2813-9196-44a1-b7a9-2703b7483874" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_81aad294-d6f1-47c6-ac35-afc90d962400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c96a5ad4-f1de-4b15-bf91-60032f4d4716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_009f2813-9196-44a1-b7a9-2703b7483874" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c96a5ad4-f1de-4b15-bf91-60032f4d4716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_601feb97-4851-4496-83cc-84fb3c3ae96d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_009f2813-9196-44a1-b7a9-2703b7483874" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_601feb97-4851-4496-83cc-84fb3c3ae96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8a84d7f0-f86d-4fe4-a40a-bf3bba34f715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_009f2813-9196-44a1-b7a9-2703b7483874" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8a84d7f0-f86d-4fe4-a40a-bf3bba34f715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3231fef1-afc8-4e00-8667-7a9bce29792b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_009f2813-9196-44a1-b7a9-2703b7483874" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3231fef1-afc8-4e00-8667-7a9bce29792b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="simple" xlink:href="cah-20210930.xsd#LongTermObligationsandOtherShortTermBorrowings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6d478470-f80c-45d9-be12-e05efb9cd9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_16cabbe9-2b4f-44ba-8051-31a658966291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6d478470-f80c-45d9-be12-e05efb9cd9a1" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_16cabbe9-2b4f-44ba-8051-31a658966291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1bcc884b-28be-47a5-b3ad-1ee5cd074b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_11b9520d-438b-409a-864d-29e55fea7b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1bcc884b-28be-47a5-b3ad-1ee5cd074b23" xlink:to="loc_us-gaap_DebtInstrumentTable_11b9520d-438b-409a-864d-29e55fea7b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_d4d6507c-cb2d-4d60-b814-9c5c4601d866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11b9520d-438b-409a-864d-29e55fea7b4c" xlink:to="loc_us-gaap_CreditFacilityAxis_d4d6507c-cb2d-4d60-b814-9c5c4601d866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ee3aa9f7-39f3-4ae8-82ee-2361f7ad1cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_d4d6507c-cb2d-4d60-b814-9c5c4601d866" xlink:to="loc_us-gaap_CreditFacilityDomain_ee3aa9f7-39f3-4ae8-82ee-2361f7ad1cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d48235ea-c04b-4e4e-a523-58bea75b9834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_ee3aa9f7-39f3-4ae8-82ee-2361f7ad1cb8" xlink:to="loc_us-gaap_CommercialPaperMember_d48235ea-c04b-4e4e-a523-58bea75b9834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_46f452b9-d562-4542-8515-2b3816de3aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_ee3aa9f7-39f3-4ae8-82ee-2361f7ad1cb8" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_46f452b9-d562-4542-8515-2b3816de3aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_4aa73606-ef0b-45e0-814e-e485bb4ed64e" xlink:href="cah-20210930.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_ee3aa9f7-39f3-4ae8-82ee-2361f7ad1cb8" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_4aa73606-ef0b-45e0-814e-e485bb4ed64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_3507dbe2-3172-4ef3-a312-3f09bf13758a" xlink:href="cah-20210930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_ShortTermCreditFacilitiesMember_4aa73606-ef0b-45e0-814e-e485bb4ed64e" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_3507dbe2-3172-4ef3-a312-3f09bf13758a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_aa6daa9b-c0f8-43dc-a8ac-3d6955a95264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11b9520d-438b-409a-864d-29e55fea7b4c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_aa6daa9b-c0f8-43dc-a8ac-3d6955a95264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_31ae0cc4-701e-4d00-8151-7cce10ea0101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_aa6daa9b-c0f8-43dc-a8ac-3d6955a95264" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_31ae0cc4-701e-4d00-8151-7cce10ea0101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ba1585ee-ba9f-4c91-a296-5cf429ad6565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11b9520d-438b-409a-864d-29e55fea7b4c" xlink:to="loc_us-gaap_DebtInstrumentAxis_ba1585ee-ba9f-4c91-a296-5cf429ad6565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_07d1c98d-83c1-4a8a-b24e-4cf921983f67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba1585ee-ba9f-4c91-a296-5cf429ad6565" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_07d1c98d-83c1-4a8a-b24e-4cf921983f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_831c29e8-8760-420f-9212-735f7e69a7a1" xlink:href="cah-20210930.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07d1c98d-83c1-4a8a-b24e-4cf921983f67" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_831c29e8-8760-420f-9212-735f7e69a7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_53a18932-3c1b-477e-bbce-90dffedcd98f" xlink:href="cah-20210930.xsd#cah_A2.616Notesdue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07d1c98d-83c1-4a8a-b24e-4cf921983f67" xlink:to="loc_cah_A2.616Notesdue2022Member_53a18932-3c1b-477e-bbce-90dffedcd98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2616NotesMember_0b3eba46-8371-49ac-abc0-03de88beb0c6" xlink:href="cah-20210930.xsd#cah_A2616NotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_07d1c98d-83c1-4a8a-b24e-4cf921983f67" xlink:to="loc_cah_A2616NotesMember_0b3eba46-8371-49ac-abc0-03de88beb0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_29cce70c-8dda-4677-ad7e-16e238c31ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11b9520d-438b-409a-864d-29e55fea7b4c" xlink:to="loc_us-gaap_VariableRateAxis_29cce70c-8dda-4677-ad7e-16e238c31ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a9ad3ceb-a60b-4ec0-96b2-c34284e41291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_29cce70c-8dda-4677-ad7e-16e238c31ea3" xlink:to="loc_us-gaap_VariableRateDomain_a9ad3ceb-a60b-4ec0-96b2-c34284e41291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_679d377c-b342-4aac-9df0-0093efa87f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11b9520d-438b-409a-864d-29e55fea7b4c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_679d377c-b342-4aac-9df0-0093efa87f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b00e9cd2-a9a6-4b4a-99ec-a422d587d058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_679d377c-b342-4aac-9df0-0093efa87f7d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_b00e9cd2-a9a6-4b4a-99ec-a422d587d058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d0658f9-fe70-48f3-95e1-c82aa4e48b94" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11b9520d-438b-409a-864d-29e55fea7b4c" xlink:to="loc_srt_RangeAxis_5d0658f9-fe70-48f3-95e1-c82aa4e48b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_63feb887-e1cc-46f7-8aed-b7c7a66440f7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5d0658f9-fe70-48f3-95e1-c82aa4e48b94" xlink:to="loc_srt_RangeMember_63feb887-e1cc-46f7-8aed-b7c7a66440f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fba3421e-bf54-43e0-8031-a5612301305e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11b9520d-438b-409a-864d-29e55fea7b4c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_fba3421e-bf54-43e0-8031-a5612301305e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_958ae970-1d5f-465e-9869-ff8d78c00a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba3421e-bf54-43e0-8031-a5612301305e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_958ae970-1d5f-465e-9869-ff8d78c00a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_cfb8afdf-a8ea-4047-b397-90b4d36136f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba3421e-bf54-43e0-8031-a5612301305e" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_cfb8afdf-a8ea-4047-b397-90b4d36136f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_52f198ed-0007-4efe-8a2f-cdedf7fabf27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba3421e-bf54-43e0-8031-a5612301305e" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_52f198ed-0007-4efe-8a2f-cdedf7fabf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_01455ca4-7db7-446b-a59d-f68c6cdabe81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba3421e-bf54-43e0-8031-a5612301305e" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_01455ca4-7db7-446b-a59d-f68c6cdabe81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NotesPayableRepurchased_7a2be964-d20e-4fd4-af25-b13fe35b0abb" xlink:href="cah-20210930.xsd#cah_NotesPayableRepurchased"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba3421e-bf54-43e0-8031-a5612301305e" xlink:to="loc_cah_NotesPayableRepurchased_7a2be964-d20e-4fd4-af25-b13fe35b0abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_60c88c7e-e700-49bf-bc2f-d25fe9539b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba3421e-bf54-43e0-8031-a5612301305e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_60c88c7e-e700-49bf-bc2f-d25fe9539b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_316a6bd4-8f1a-42a6-a09a-bb10f1d0e026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fba3421e-bf54-43e0-8031-a5612301305e" xlink:to="loc_us-gaap_OtherShortTermBorrowings_316a6bd4-8f1a-42a6-a09a-bb10f1d0e026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="simple" xlink:href="cah-20210930.xsd#CommitmentsContingentLiabilitiesandLitigation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d48ff6a5-ca48-4158-a395-d18f1cd56cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ff6795d8-9a5a-4b10-bb0a-434db5037834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d48ff6a5-ca48-4158-a395-d18f1cd56cec" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ff6795d8-9a5a-4b10-bb0a-434db5037834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f7b566f1-e7aa-4939-82fc-def20f86872c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f7b566f1-e7aa-4939-82fc-def20f86872c" xlink:to="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_57406788-c99e-4e94-9abf-5e0c4d01fd84" xlink:href="cah-20210930.xsd#cah_LawsuitTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_cah_LawsuitTypeAxis_57406788-c99e-4e94-9abf-5e0c4d01fd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LitigationTypeDomain_37180516-67c1-4ae2-9db3-fd1430f65aa8" xlink:href="cah-20210930.xsd#cah_LitigationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeAxis_57406788-c99e-4e94-9abf-5e0c4d01fd84" xlink:to="loc_cah_LitigationTypeDomain_37180516-67c1-4ae2-9db3-fd1430f65aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_3be95895-f926-4902-953d-eec41a7f012b" xlink:href="cah-20210930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LitigationTypeDomain_37180516-67c1-4ae2-9db3-fd1430f65aa8" xlink:to="loc_cah_ClassActionLawsuitsMember_3be95895-f926-4902-953d-eec41a7f012b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_a21d34c7-0476-446d-8941-a86f356a6702" xlink:href="cah-20210930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LitigationTypeDomain_37180516-67c1-4ae2-9db3-fd1430f65aa8" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_a21d34c7-0476-446d-8941-a86f356a6702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_f33eda1b-fac2-4d80-8ca3-14c458a19d7e" xlink:href="cah-20210930.xsd#cah_PlaintiffTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_cah_PlaintiffTypeAxis_f33eda1b-fac2-4d80-8ca3-14c458a19d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_845b4181-63ad-4497-87b5-c0a3a5002077" xlink:href="cah-20210930.xsd#cah_PlaintiffTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeAxis_f33eda1b-fac2-4d80-8ca3-14c458a19d7e" xlink:to="loc_cah_PlaintiffTypeDomain_845b4181-63ad-4497-87b5-c0a3a5002077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_c5b829f2-415b-49d5-8b9e-43407a70eabd" xlink:href="cah-20210930.xsd#cah_PrivatePartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeDomain_845b4181-63ad-4497-87b5-c0a3a5002077" xlink:to="loc_cah_PrivatePartiesMember_c5b829f2-415b-49d5-8b9e-43407a70eabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_14812f5c-d9bc-4799-8cd3-c09122f7d629" xlink:href="cah-20210930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeDomain_845b4181-63ad-4497-87b5-c0a3a5002077" xlink:to="loc_cah_ClassActionLawsuitsMember_14812f5c-d9bc-4799-8cd3-c09122f7d629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_73b7e4a6-81f0-424a-b991-3c7c99fa894b" xlink:href="cah-20210930.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_cah_OpioidLitigationAxis_73b7e4a6-81f0-424a-b991-3c7c99fa894b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_b33f79d5-e921-40a5-861f-168032f9e00a" xlink:href="cah-20210930.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_73b7e4a6-81f0-424a-b991-3c7c99fa894b" xlink:to="loc_cah_OpioidLitigationDomain_b33f79d5-e921-40a5-861f-168032f9e00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_3f603880-ca4d-4686-a3ca-da0940626086" xlink:href="cah-20210930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_b33f79d5-e921-40a5-861f-168032f9e00a" xlink:to="loc_cah_TotalOpioidLitigationMember_3f603880-ca4d-4686-a3ca-da0940626086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3d3e2ede-6840-4836-8e8f-cbc5d4dc1973" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_srt_StatementGeographicalAxis_3d3e2ede-6840-4836-8e8f-cbc5d4dc1973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_97e58d31-0a9d-4d04-bfed-091998f6b13c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_3d3e2ede-6840-4836-8e8f-cbc5d4dc1973" xlink:to="loc_srt_SegmentGeographicalDomain_97e58d31-0a9d-4d04-bfed-091998f6b13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember_4a50a6aa-6be1-497d-a445-1fbd26f9743b" xlink:href="cah-20210930.xsd#cah_AlamedaCountyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_97e58d31-0a9d-4d04-bfed-091998f6b13c" xlink:to="loc_cah_AlamedaCountyMember_4a50a6aa-6be1-497d-a445-1fbd26f9743b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember_86315ea4-ab64-4c64-b211-7011c99c7d44" xlink:href="cah-20210930.xsd#cah_OtherJurisdictionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_97e58d31-0a9d-4d04-bfed-091998f6b13c" xlink:to="loc_cah_OtherJurisdictionsMember_86315ea4-ab64-4c64-b211-7011c99c7d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ed340680-67e4-4a99-8dcb-ea1c9f3c650e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_srt_RangeAxis_ed340680-67e4-4a99-8dcb-ea1c9f3c650e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6270a884-9531-4875-8f21-a0003fef5201" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ed340680-67e4-4a99-8dcb-ea1c9f3c650e" xlink:to="loc_srt_RangeMember_6270a884-9531-4875-8f21-a0003fef5201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b3ad176e-3da5-4524-97f2-b4e56ec47814" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6270a884-9531-4875-8f21-a0003fef5201" xlink:to="loc_srt_MinimumMember_b3ad176e-3da5-4524-97f2-b4e56ec47814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6a1fc616-863f-4ef0-858a-dbd6b2d5c9b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6270a884-9531-4875-8f21-a0003fef5201" xlink:to="loc_srt_MaximumMember_6a1fc616-863f-4ef0-858a-dbd6b2d5c9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6c227fe7-5fbe-4785-ba5d-366356927e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6c227fe7-5fbe-4785-ba5d-366356927e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_1981ac0b-fd84-40e2-87a6-c9955542a448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6c227fe7-5fbe-4785-ba5d-366356927e95" xlink:to="loc_us-gaap_LossContingencyNatureDomain_1981ac0b-fd84-40e2-87a6-c9955542a448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_095b6b2d-0be0-43ad-98fe-6be364384e67" xlink:href="cah-20210930.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_1981ac0b-fd84-40e2-87a6-c9955542a448" xlink:to="loc_cah_OpioidLawsuitsMember_095b6b2d-0be0-43ad-98fe-6be364384e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_ebdb2580-29d7-422f-b93a-c3a667ee3b29" xlink:href="cah-20210930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_1981ac0b-fd84-40e2-87a6-c9955542a448" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_ebdb2580-29d7-422f-b93a-c3a667ee3b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_56b345d7-de92-49b7-a04d-51acc34fbeae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_srt_MajorCustomersAxis_56b345d7-de92-49b7-a04d-51acc34fbeae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ab77ebba-407d-4c06-a081-a7e38e05fb24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_56b345d7-de92-49b7-a04d-51acc34fbeae" xlink:to="loc_srt_NameOfMajorCustomerDomain_ab77ebba-407d-4c06-a081-a7e38e05fb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_74b9b241-f598-4de0-bf4e-5f965012565c" xlink:href="cah-20210930.xsd#cah_CVSHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ab77ebba-407d-4c06-a081-a7e38e05fb24" xlink:to="loc_cah_CVSHealthMember_74b9b241-f598-4de0-bf4e-5f965012565c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_dc84b4bd-81e2-48cd-9d2f-4c999c4b42ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_srt_LitigationCaseAxis_dc84b4bd-81e2-48cd-9d2f-4c999c4b42ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_352d3d32-80db-428d-bbbc-21c9bdeceacb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_dc84b4bd-81e2-48cd-9d2f-4c999c4b42ea" xlink:to="loc_srt_LitigationCaseTypeDomain_352d3d32-80db-428d-bbbc-21c9bdeceacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_906f3e8a-c379-4704-b74a-cf1606644980" xlink:href="cah-20210930.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_352d3d32-80db-428d-bbbc-21c9bdeceacb" xlink:to="loc_cah_OpioidLawsuitsMember_906f3e8a-c379-4704-b74a-cf1606644980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_705c4c49-7750-4157-8df3-c15b9d3000be" xlink:href="cah-20210930.xsd#cah_ClassActionLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_352d3d32-80db-428d-bbbc-21c9bdeceacb" xlink:to="loc_cah_ClassActionLawsuitsMember_705c4c49-7750-4157-8df3-c15b9d3000be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_d9c283cf-2595-4910-8abd-df9ea814b71c" xlink:href="cah-20210930.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_352d3d32-80db-428d-bbbc-21c9bdeceacb" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_d9c283cf-2595-4910-8abd-df9ea814b71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_b5d1cde9-3708-45b8-8ffa-b8a7e55a54ff" xlink:href="cah-20210930.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_352d3d32-80db-428d-bbbc-21c9bdeceacb" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_b5d1cde9-3708-45b8-8ffa-b8a7e55a54ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsStateDomain_5f235800-9dfc-4ed7-b98e-7af582c1050d" xlink:href="cah-20210930.xsd#cah_OpioidLawsuitsStateDomain"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_352d3d32-80db-428d-bbbc-21c9bdeceacb" xlink:to="loc_cah_OpioidLawsuitsStateDomain_5f235800-9dfc-4ed7-b98e-7af582c1050d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DOJInvestigationMember_0a6841fd-f5ee-4205-bf89-db7c6a772918" xlink:href="cah-20210930.xsd#cah_DOJInvestigationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_352d3d32-80db-428d-bbbc-21c9bdeceacb" xlink:to="loc_cah_DOJInvestigationMember_0a6841fd-f5ee-4205-bf89-db7c6a772918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_26fc88d6-8a23-4aac-8b71-aecaf9abff25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_26fc88d6-8a23-4aac-8b71-aecaf9abff25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d9f0bbcf-da0a-4c0a-b0a0-bc4519d2323a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_26fc88d6-8a23-4aac-8b71-aecaf9abff25" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d9f0bbcf-da0a-4c0a-b0a0-bc4519d2323a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ffd6aaed-880d-4f88-9c21-76dae85d50ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d9f0bbcf-da0a-4c0a-b0a0-bc4519d2323a" xlink:to="loc_us-gaap_SubsequentEventMember_ffd6aaed-880d-4f88-9c21-76dae85d50ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_bf6207cf-5e6c-45e8-bd1f-adc796c015da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_srt_StatementScenarioAxis_bf6207cf-5e6c-45e8-bd1f-adc796c015da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ea40106e-fb39-4f9b-84aa-b5f1fc092267" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_bf6207cf-5e6c-45e8-bd1f-adc796c015da" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ea40106e-fb39-4f9b-84aa-b5f1fc092267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_977913bb-8562-4573-8402-7fc3eca2e342" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_ea40106e-fb39-4f9b-84aa-b5f1fc092267" xlink:to="loc_srt_ScenarioForecastMember_977913bb-8562-4573-8402-7fc3eca2e342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ef381755-9a69-4b9b-b117-09e48538f2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ef381755-9a69-4b9b-b117-09e48538f2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3951610f-4802-4112-ab5f-ea1003030d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ef381755-9a69-4b9b-b117-09e48538f2d3" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3951610f-4802-4112-ab5f-ea1003030d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_3879b838-9a00-48e0-8bed-67fb76a1ea11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3951610f-4802-4112-ab5f-ea1003030d76" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_3879b838-9a00-48e0-8bed-67fb76a1ea11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_9fa28882-5b44-4fdd-9d24-555908c1ee5f" xlink:to="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_f7d9f020-fe80-42c0-8db0-8c629b27577e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_f7d9f020-fe80-42c0-8db0-8c629b27577e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_97185938-7157-48b6-8667-00282172ce3e" xlink:href="cah-20210930.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_cah_LossContingencyLawsuitsNumber_97185938-7157-48b6-8667-00282172ce3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_769ffa59-98c0-4caa-a5a4-85024aced76e" xlink:href="cah-20210930.xsd#cah_NumberofStateAttorneysGeneralfilinglawsuits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_769ffa59-98c0-4caa-a5a4-85024aced76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_2b16bcac-4572-4b05-8162-63eb805f2cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_us-gaap_LitigationReserve_2b16bcac-4572-4b05-8162-63eb805f2cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2ef88acd-3aae-4d9f-ba4c-8e0d0d024343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2ef88acd-3aae-4d9f-ba4c-8e0d0d024343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_a1dca98d-d7d9-4688-8b77-b816b43ea55c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_a1dca98d-d7d9-4688-8b77-b816b43ea55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_52e5d59f-8deb-46ba-a40c-3a606b90c82a" xlink:href="cah-20210930.xsd#cah_AggregateAnnualAssessment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_cah_AggregateAnnualAssessment_52e5d59f-8deb-46ba-a40c-3a606b90c82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_42dee06f-a366-4c94-b000-e6600f56d72f" xlink:href="cah-20210930.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_42dee06f-a366-4c94-b000-e6600f56d72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_169832fa-6c7d-44a7-b924-81acc1b5748b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_169832fa-6c7d-44a7-b924-81acc1b5748b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_2dddafa4-a133-479c-b319-f67c85c8b8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_us-gaap_LitigationSettlementExpense_2dddafa4-a133-479c-b319-f67c85c8b8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_d75d8f11-c220-42f6-8a4e-69ac22b40fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_d75d8f11-c220-42f6-8a4e-69ac22b40fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_e3adfdaa-7c7f-4aea-a290-cd80415995bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9ff01d5f-a8b6-4c88-9ddd-7714e476bec4" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_e3adfdaa-7c7f-4aea-a290-cd80415995bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3d13f381-6ff3-4fac-9239-9d9d64bb374d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3d13f381-6ff3-4fac-9239-9d9d64bb374d" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_24a72b84-0c6e-48df-8c0c-2f84d417ad61" xlink:href="cah-20210930.xsd#cah_TaxMatterAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:to="loc_cah_TaxMatterAxis_24a72b84-0c6e-48df-8c0c-2f84d417ad61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_1537b14a-f387-4695-a685-208d3ba03868" xlink:href="cah-20210930.xsd#cah_TaxMatterDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterAxis_24a72b84-0c6e-48df-8c0c-2f84d417ad61" xlink:to="loc_cah_TaxMatterDomain_1537b14a-f387-4695-a685-208d3ba03868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_934af708-0f53-4355-a23c-5eebcb3de620" xlink:href="cah-20210930.xsd#cah_CareFusionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterDomain_1537b14a-f387-4695-a685-208d3ba03868" xlink:to="loc_cah_CareFusionMember_934af708-0f53-4355-a23c-5eebcb3de620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_d0c8d7b4-cd81-4d1d-b830-7807aa4bcabb" xlink:href="cah-20210930.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterDomain_1537b14a-f387-4695-a685-208d3ba03868" xlink:to="loc_cah_PatientRecoveryBusinessMember_d0c8d7b4-cd81-4d1d-b830-7807aa4bcabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_530d76b1-2905-4076-9dfc-7f68be65a967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_530d76b1-2905-4076-9dfc-7f68be65a967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5f72817-a5e0-4d17-83e8-b63bcc7938bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_530d76b1-2905-4076-9dfc-7f68be65a967" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5f72817-a5e0-4d17-83e8-b63bcc7938bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_75e2edf7-cac4-4b17-841c-22ad8802eefd" xlink:href="cah-20210930.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5f72817-a5e0-4d17-83e8-b63bcc7938bc" xlink:to="loc_cah_PatientRecoveryBusinessMember_75e2edf7-cac4-4b17-841c-22ad8802eefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_b680341e-4253-4d55-b57b-014d47f0007b" xlink:href="cah-20210930.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:to="loc_cah_OpioidLitigationAxis_b680341e-4253-4d55-b57b-014d47f0007b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_8ee0aeb8-fc00-435d-9f8d-ec3adcd472fd" xlink:href="cah-20210930.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_b680341e-4253-4d55-b57b-014d47f0007b" xlink:to="loc_cah_OpioidLitigationDomain_8ee0aeb8-fc00-435d-9f8d-ec3adcd472fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_66692798-eef7-42de-babb-c8e968746eeb" xlink:href="cah-20210930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_8ee0aeb8-fc00-435d-9f8d-ec3adcd472fd" xlink:to="loc_cah_TotalOpioidLitigationMember_66692798-eef7-42de-babb-c8e968746eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c5038d9d-6efc-47fe-a472-7f1a12c15745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c5038d9d-6efc-47fe-a472-7f1a12c15745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9ff18ed9-f5ae-46d4-8e9a-f3943a5774dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c5038d9d-6efc-47fe-a472-7f1a12c15745" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9ff18ed9-f5ae-46d4-8e9a-f3943a5774dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_c34a1ddb-e836-4a97-bd2d-ff8a6c122df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_c34a1ddb-e836-4a97-bd2d-ff8a6c122df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f2941fd6-8c59-42ee-988a-35d79f6c5d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_c34a1ddb-e836-4a97-bd2d-ff8a6c122df9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f2941fd6-8c59-42ee-988a-35d79f6c5d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_d879f61e-a860-4338-b47e-15cbcdaa5064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f2941fd6-8c59-42ee-988a-35d79f6c5d6d" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_d879f61e-a860-4338-b47e-15cbcdaa5064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d264940f-440d-4bed-b3af-9d7d72336a1c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:to="loc_srt_RangeAxis_d264940f-440d-4bed-b3af-9d7d72336a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_279faa8c-106a-40a1-a552-086b29366c63" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d264940f-440d-4bed-b3af-9d7d72336a1c" xlink:to="loc_srt_RangeMember_279faa8c-106a-40a1-a552-086b29366c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e512b7e6-b9be-4f1f-8be6-99d7f9752916" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_279faa8c-106a-40a1-a552-086b29366c63" xlink:to="loc_srt_MinimumMember_e512b7e6-b9be-4f1f-8be6-99d7f9752916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_66c0cbcc-262c-45e9-9664-07ff32690b3b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_279faa8c-106a-40a1-a552-086b29366c63" xlink:to="loc_srt_MaximumMember_66c0cbcc-262c-45e9-9664-07ff32690b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_2cdc6c5b-4b90-4a77-9f9a-c36a2f8c0604" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:to="loc_srt_StatementScenarioAxis_2cdc6c5b-4b90-4a77-9f9a-c36a2f8c0604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_536b2309-477b-4acf-9299-9d6194da403a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_2cdc6c5b-4b90-4a77-9f9a-c36a2f8c0604" xlink:to="loc_srt_ScenarioUnspecifiedDomain_536b2309-477b-4acf-9299-9d6194da403a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_01076f0e-72a0-4cf9-995c-7656e43a8eb2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_536b2309-477b-4acf-9299-9d6194da403a" xlink:to="loc_srt_ScenarioForecastMember_01076f0e-72a0-4cf9-995c-7656e43a8eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_66f465f7-9497-41e1-be59-176585e688d0" xlink:href="cah-20210930.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:to="loc_cah_CordisDivestitureAxis_66f465f7-9497-41e1-be59-176585e688d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_08f08175-f825-4cec-8dde-37d5655d9a5e" xlink:href="cah-20210930.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_66f465f7-9497-41e1-be59-176585e688d0" xlink:to="loc_cah_CordisDivestitureDomain_08f08175-f825-4cec-8dde-37d5655d9a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_929b23a7-95f5-40a1-aa9c-ce9f24c91e7b" xlink:href="cah-20210930.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_08f08175-f825-4cec-8dde-37d5655d9a5e" xlink:to="loc_cah_CordisDivestitureMember_929b23a7-95f5-40a1-aa9c-ce9f24c91e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_3b7b5d5f-6e12-44cf-b852-db048c6e3578" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ad85154d-2661-458d-a1df-29d4427d6409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ad85154d-2661-458d-a1df-29d4427d6409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a7fd0389-0b18-4a30-82be-28eb3eb51f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a7fd0389-0b18-4a30-82be-28eb3eb51f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_37a36c6b-d689-4b5a-a836-d4f14bcc4b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_37a36c6b-d689-4b5a-a836-d4f14bcc4b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7ea3c265-6608-4db1-9795-429f31c47653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7ea3c265-6608-4db1-9795-429f31c47653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_466b31d4-ae3c-44aa-bb03-73ffdfaf7781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_466b31d4-ae3c-44aa-bb03-73ffdfaf7781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_32a54323-1537-4134-b98a-db60087a6410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_32a54323-1537-4134-b98a-db60087a6410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_db45c9dd-d3ac-4c77-a428-49df8d010f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_us-gaap_OpenTaxYear_db45c9dd-d3ac-4c77-a428-49df8d010f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable_f1d84b00-3946-4c22-91ca-31526b4add4a" xlink:href="cah-20210930.xsd#cah_IndemnificationReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_cah_IndemnificationReceivable_f1d84b00-3946-4c22-91ca-31526b4add4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_0dd2464f-33a1-4aeb-b41b-f2da4edf1744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_us-gaap_LitigationSettlementExpense_0dd2464f-33a1-4aeb-b41b-f2da4edf1744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_032542c5-b95c-4c8a-9fa9-448797bb3b22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_48130794-a48b-4a9d-8e9e-622dc75714da" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_032542c5-b95c-4c8a-9fa9-448797bb3b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cah-20210930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e74b5f96-482a-4fea-ac40-b7faea8810cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_54c495af-4b62-4558-b739-a719df6a97d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e74b5f96-482a-4fea-ac40-b7faea8810cf" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_54c495af-4b62-4558-b739-a719df6a97d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cah-20210930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_aa2f6491-0b2f-4902-b5cb-759b835e0814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_ec07589e-9873-4f64-8458-9e40d4390b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_aa2f6491-0b2f-4902-b5cb-759b835e0814" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_ec07589e-9873-4f64-8458-9e40d4390b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cah-20210930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_91eacaf3-ee92-4172-a413-c016f0926d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0d76c954-fefc-4c47-b038-d073fc5547bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_91eacaf3-ee92-4172-a413-c016f0926d78" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0d76c954-fefc-4c47-b038-d073fc5547bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2786d14e-5a17-4e9e-bf32-083c083d93a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b5c91a2-67f5-4b1d-9681-96ee299a6589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2786d14e-5a17-4e9e-bf32-083c083d93a8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b5c91a2-67f5-4b1d-9681-96ee299a6589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_13610892-3408-4bb2-b3d1-d2aeaf367a58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b5c91a2-67f5-4b1d-9681-96ee299a6589" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_13610892-3408-4bb2-b3d1-d2aeaf367a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_222fd9bf-855e-432f-948a-478b9c520411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_13610892-3408-4bb2-b3d1-d2aeaf367a58" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_222fd9bf-855e-432f-948a-478b9c520411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ca1ce7fb-da43-4ae8-897b-8aae3d53ee5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_222fd9bf-855e-432f-948a-478b9c520411" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ca1ce7fb-da43-4ae8-897b-8aae3d53ee5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0987563b-0cab-44b1-aeb9-d2701099ab49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b5c91a2-67f5-4b1d-9681-96ee299a6589" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0987563b-0cab-44b1-aeb9-d2701099ab49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0be3206a-ded6-4f2a-b515-e864f2f9c903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0987563b-0cab-44b1-aeb9-d2701099ab49" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0be3206a-ded6-4f2a-b515-e864f2f9c903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_95821b9d-42b4-4a99-ba44-1e7b531ff85b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0be3206a-ded6-4f2a-b515-e864f2f9c903" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_95821b9d-42b4-4a99-ba44-1e7b531ff85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_54bf16ee-d39e-4711-ab9b-ff450a4652b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0be3206a-ded6-4f2a-b515-e864f2f9c903" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_54bf16ee-d39e-4711-ab9b-ff450a4652b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f563d953-1f96-439f-86a6-a1e7f8f86c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0be3206a-ded6-4f2a-b515-e864f2f9c903" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f563d953-1f96-439f-86a6-a1e7f8f86c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel12And3Member_c748a01b-12c4-4c9a-a399-379553459dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel12And3Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0be3206a-ded6-4f2a-b515-e864f2f9c903" xlink:to="loc_us-gaap_FairValueInputsLevel12And3Member_c748a01b-12c4-4c9a-a399-379553459dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_257c7e49-02c8-4cd7-903c-f5c25510f196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3b5c91a2-67f5-4b1d-9681-96ee299a6589" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_257c7e49-02c8-4cd7-903c-f5c25510f196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_80a5ccb1-04b0-4160-a09b-7f987f7c8bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_257c7e49-02c8-4cd7-903c-f5c25510f196" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_80a5ccb1-04b0-4160-a09b-7f987f7c8bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_3daed497-6794-41f4-86a8-948b063e8781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_80a5ccb1-04b0-4160-a09b-7f987f7c8bd3" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_3daed497-6794-41f4-86a8-948b063e8781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_865bdecf-5bbc-4a08-9762-c79fa2be7805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_80a5ccb1-04b0-4160-a09b-7f987f7c8bd3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_865bdecf-5bbc-4a08-9762-c79fa2be7805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e1e53f1c-8a16-44b5-8e14-e13c560c1430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_257c7e49-02c8-4cd7-903c-f5c25510f196" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e1e53f1c-8a16-44b5-8e14-e13c560c1430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_a34376c2-608e-404a-8a16-3c468ce94aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e1e53f1c-8a16-44b5-8e14-e13c560c1430" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_a34376c2-608e-404a-8a16-3c468ce94aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1858ce57-3a69-42ac-a1e9-c46e230cfab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_257c7e49-02c8-4cd7-903c-f5c25510f196" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1858ce57-3a69-42ac-a1e9-c46e230cfab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstruments" xlink:type="simple" xlink:href="cah-20210930.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a90d2aca-be55-4781-bea2-30ad473041dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_392d5b3a-d081-4370-b5d8-41082a2105e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a90d2aca-be55-4781-bea2-30ad473041dc" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_392d5b3a-d081-4370-b5d8-41082a2105e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="cah-20210930.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_500ac48a-1ff4-4b04-ab30-132ab402a35f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_6787ce4e-1771-4510-9ffe-33302b68339c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_500ac48a-1ff4-4b04-ab30-132ab402a35f" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_6787ce4e-1771-4510-9ffe-33302b68339c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c70d8ec4-6562-43a5-b4e6-aedea503fa2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_44d63808-0f12-4bc5-8b06-c2708099a7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c70d8ec4-6562-43a5-b4e6-aedea503fa2b" xlink:to="loc_us-gaap_DerivativeTable_44d63808-0f12-4bc5-8b06-c2708099a7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_648e4ca9-31fa-4595-9f1a-93a2db8883a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_44d63808-0f12-4bc5-8b06-c2708099a7ad" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_648e4ca9-31fa-4595-9f1a-93a2db8883a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5322f88e-acfc-4a62-80ab-18227e21e8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_648e4ca9-31fa-4595-9f1a-93a2db8883a6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5322f88e-acfc-4a62-80ab-18227e21e8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_781f7e1b-85af-49e8-81e3-1f5a7972580a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_44d63808-0f12-4bc5-8b06-c2708099a7ad" xlink:to="loc_us-gaap_HedgingDesignationAxis_781f7e1b-85af-49e8-81e3-1f5a7972580a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_656fa75a-8bf8-49f4-bc88-afb17713326a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_781f7e1b-85af-49e8-81e3-1f5a7972580a" xlink:to="loc_us-gaap_HedgingDesignationDomain_656fa75a-8bf8-49f4-bc88-afb17713326a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3d43116f-973d-489b-a475-06e3c54e57eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_656fa75a-8bf8-49f4-bc88-afb17713326a" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3d43116f-973d-489b-a475-06e3c54e57eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ef3f68f3-72e5-45b9-9573-87c5380101af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_44d63808-0f12-4bc5-8b06-c2708099a7ad" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ef3f68f3-72e5-45b9-9573-87c5380101af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b9afac7b-c6c1-43ae-a301-7344bdb6ae5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ef3f68f3-72e5-45b9-9573-87c5380101af" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b9afac7b-c6c1-43ae-a301-7344bdb6ae5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_539b992c-8e4a-4b40-a491-268e64d5a20f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b9afac7b-c6c1-43ae-a301-7344bdb6ae5c" xlink:to="loc_us-gaap_FairValueHedgingMember_539b992c-8e4a-4b40-a491-268e64d5a20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_48de0291-d2a9-4ce7-afbf-54bae3aa4339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_44d63808-0f12-4bc5-8b06-c2708099a7ad" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_48de0291-d2a9-4ce7-afbf-54bae3aa4339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2f4207d1-63c6-4dfc-b38c-d52e46de4814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_48de0291-d2a9-4ce7-afbf-54bae3aa4339" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2f4207d1-63c6-4dfc-b38c-d52e46de4814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a7dc3bf7-e9ab-4069-84be-cd4584036170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f4207d1-63c6-4dfc-b38c-d52e46de4814" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a7dc3bf7-e9ab-4069-84be-cd4584036170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_fcbec9e7-defd-4260-a398-5569e90cf1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2f4207d1-63c6-4dfc-b38c-d52e46de4814" xlink:to="loc_us-gaap_InterestRateSwapMember_fcbec9e7-defd-4260-a398-5569e90cf1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_71619865-577a-46a8-8761-b2e2b0c45201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_44d63808-0f12-4bc5-8b06-c2708099a7ad" xlink:to="loc_us-gaap_DerivativeLineItems_71619865-577a-46a8-8761-b2e2b0c45201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_ead8836f-249e-47e3-b53e-c8c31da8aaaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_71619865-577a-46a8-8761-b2e2b0c45201" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_ead8836f-249e-47e3-b53e-c8c31da8aaaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_e6870be4-0b82-45a6-b077-bb8a35e6ab1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_71619865-577a-46a8-8761-b2e2b0c45201" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_e6870be4-0b82-45a6-b077-bb8a35e6ab1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_08b2bc2b-2764-43b0-9382-baf936d84501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_71619865-577a-46a8-8761-b2e2b0c45201" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_08b2bc2b-2764-43b0-9382-baf936d84501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_3c4ba05b-ee99-4bd5-86f9-2a5a2b4b8cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_71619865-577a-46a8-8761-b2e2b0c45201" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_3c4ba05b-ee99-4bd5-86f9-2a5a2b4b8cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_53fdda6b-4bc0-4df4-9d30-14de2cc24c77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e8f77dc-9567-47eb-a22f-5672018322e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_53fdda6b-4bc0-4df4-9d30-14de2cc24c77" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e8f77dc-9567-47eb-a22f-5672018322e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d8dd035-d342-4831-8b3c-4e3c7b5477fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e8f77dc-9567-47eb-a22f-5672018322e7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d8dd035-d342-4831-8b3c-4e3c7b5477fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_170f0610-6947-4a62-81d3-51b71ddaf664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d8dd035-d342-4831-8b3c-4e3c7b5477fe" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_170f0610-6947-4a62-81d3-51b71ddaf664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8709a12c-010a-44e3-adc4-3d653db549b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_170f0610-6947-4a62-81d3-51b71ddaf664" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8709a12c-010a-44e3-adc4-3d653db549b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f82ef8bd-975e-4e46-9a8b-fb32054f0826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4e8f77dc-9567-47eb-a22f-5672018322e7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f82ef8bd-975e-4e46-9a8b-fb32054f0826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_85cc0209-76f3-449d-b9c4-c6788c59dc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f82ef8bd-975e-4e46-9a8b-fb32054f0826" xlink:to="loc_us-gaap_DebtInstrumentFairValue_85cc0209-76f3-449d-b9c4-c6788c59dc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_4c800476-ef1e-4a05-89a2-d5a9ffdd251b" xlink:href="cah-20210930.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f82ef8bd-975e-4e46-9a8b-fb32054f0826" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_4c800476-ef1e-4a05-89a2-d5a9ffdd251b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_615fb04e-cbcb-4704-8840-0e94797e17f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ebdb6966-8f55-4d31-ba8c-9fb5011bec08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_615fb04e-cbcb-4704-8840-0e94797e17f6" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ebdb6966-8f55-4d31-ba8c-9fb5011bec08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_112c4311-30b5-476d-b4a5-27e111cb06de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1320cb53-b4d9-431d-90f1-d9a2ea40859d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_112c4311-30b5-476d-b4a5-27e111cb06de" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_1320cb53-b4d9-431d-90f1-d9a2ea40859d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2db9460c-3feb-4a64-8d1c-a8eac1c02bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_86d01093-6925-4a03-bd53-f8de53d5adc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2db9460c-3feb-4a64-8d1c-a8eac1c02bf4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_86d01093-6925-4a03-bd53-f8de53d5adc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_931a1ca3-f34b-4c67-90d2-29514e47db68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86d01093-6925-4a03-bd53-f8de53d5adc3" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_931a1ca3-f34b-4c67-90d2-29514e47db68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_ff542b20-8815-4181-82d0-24396b7d6f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_931a1ca3-f34b-4c67-90d2-29514e47db68" xlink:to="loc_us-gaap_LossContingencyNatureDomain_ff542b20-8815-4181-82d0-24396b7d6f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a7f4d56c-b59c-4f40-ad6e-17c6f7010fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86d01093-6925-4a03-bd53-f8de53d5adc3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a7f4d56c-b59c-4f40-ad6e-17c6f7010fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6a202691-177f-44dc-9916-f84a53a0ea21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a7f4d56c-b59c-4f40-ad6e-17c6f7010fe4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6a202691-177f-44dc-9916-f84a53a0ea21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_34161ba2-6c87-4241-bb92-172c18f516a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6a202691-177f-44dc-9916-f84a53a0ea21" xlink:to="loc_us-gaap_SubsequentEventMember_34161ba2-6c87-4241-bb92-172c18f516a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_534f495c-a646-4fab-b5f0-57d1e14f380c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86d01093-6925-4a03-bd53-f8de53d5adc3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_534f495c-a646-4fab-b5f0-57d1e14f380c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_77e22306-78fc-45ff-9816-493d1dd0db31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_534f495c-a646-4fab-b5f0-57d1e14f380c" xlink:to="loc_us-gaap_EquityComponentDomain_77e22306-78fc-45ff-9816-493d1dd0db31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_c518497d-fe02-4799-a7da-9da9ecd347fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_77e22306-78fc-45ff-9816-493d1dd0db31" xlink:to="loc_us-gaap_TreasuryStockMember_c518497d-fe02-4799-a7da-9da9ecd347fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_482a5c7f-3cf0-4b12-8eb4-57ae0247724a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86d01093-6925-4a03-bd53-f8de53d5adc3" xlink:to="loc_srt_RangeAxis_482a5c7f-3cf0-4b12-8eb4-57ae0247724a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c65ceb07-12ff-4016-aba3-91e170ad2f4a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_482a5c7f-3cf0-4b12-8eb4-57ae0247724a" xlink:to="loc_srt_RangeMember_c65ceb07-12ff-4016-aba3-91e170ad2f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_39761f95-e29a-416b-8aaa-488cd65bd4d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c65ceb07-12ff-4016-aba3-91e170ad2f4a" xlink:to="loc_srt_MinimumMember_39761f95-e29a-416b-8aaa-488cd65bd4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a03c9f86-cdb9-4c55-a2b5-a0960b1682c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86d01093-6925-4a03-bd53-f8de53d5adc3" xlink:to="loc_us-gaap_AwardTypeAxis_a03c9f86-cdb9-4c55-a2b5-a0960b1682c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76ccfd52-1b8d-4f65-af36-6142a920f24d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a03c9f86-cdb9-4c55-a2b5-a0960b1682c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76ccfd52-1b8d-4f65-af36-6142a920f24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_15d9aab2-da59-45ac-9606-010da5e02c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76ccfd52-1b8d-4f65-af36-6142a920f24d" xlink:to="loc_us-gaap_PerformanceSharesMember_15d9aab2-da59-45ac-9606-010da5e02c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d9eca98d-6a71-4b3a-9c68-e0896446a699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_86d01093-6925-4a03-bd53-f8de53d5adc3" xlink:to="loc_us-gaap_ClassOfStockLineItems_d9eca98d-6a71-4b3a-9c68-e0896446a699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_095ff1fd-32e8-4956-9e6e-8b350ebc1d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d9eca98d-6a71-4b3a-9c68-e0896446a699" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_095ff1fd-32e8-4956-9e6e-8b350ebc1d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_f7043839-f3d2-4c35-a672-79874285bcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d9eca98d-6a71-4b3a-9c68-e0896446a699" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_f7043839-f3d2-4c35-a672-79874285bcdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_29bf3949-872d-446d-8f04-731cb2a0d0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d9eca98d-6a71-4b3a-9c68-e0896446a699" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_29bf3949-872d-446d-8f04-731cb2a0d0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TreasuryStockAcquiredShares_ace106cd-b07f-4277-9a1f-af40f50b5707" xlink:href="cah-20210930.xsd#cah_TreasuryStockAcquiredShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d9eca98d-6a71-4b3a-9c68-e0896446a699" xlink:to="loc_cah_TreasuryStockAcquiredShares_ace106cd-b07f-4277-9a1f-af40f50b5707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FinalSharesReceivedfromASRProgram_cd6d31b1-1e8e-42e6-8c22-1309efd9e11d" xlink:href="cah-20210930.xsd#cah_FinalSharesReceivedfromASRProgram"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d9eca98d-6a71-4b3a-9c68-e0896446a699" xlink:to="loc_cah_FinalSharesReceivedfromASRProgram_cd6d31b1-1e8e-42e6-8c22-1309efd9e11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b71e74db-a282-4f6d-9e48-674926015d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_fbd686d6-41ce-4c02-8812-39c05bfca8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b71e74db-a282-4f6d-9e48-674926015d9c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_fbd686d6-41ce-4c02-8812-39c05bfca8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_07616641-9821-406c-a5b7-7e90cd820134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_fbd686d6-41ce-4c02-8812-39c05bfca8ee" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_07616641-9821-406c-a5b7-7e90cd820134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bef00472-4d8a-48b9-b332-e85dbe6a9d46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_07616641-9821-406c-a5b7-7e90cd820134" xlink:to="loc_us-gaap_EquityComponentDomain_bef00472-4d8a-48b9-b332-e85dbe6a9d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_307e722b-8463-4232-8aa9-fd106f835cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bef00472-4d8a-48b9-b332-e85dbe6a9d46" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_307e722b-8463-4232-8aa9-fd106f835cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_110a5a30-cf39-47cf-a020-e715f52d1997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bef00472-4d8a-48b9-b332-e85dbe6a9d46" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_110a5a30-cf39-47cf-a020-e715f52d1997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_5e450674-c395-4bdd-9226-5f66b0c7e978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bef00472-4d8a-48b9-b332-e85dbe6a9d46" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_5e450674-c395-4bdd-9226-5f66b0c7e978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ed3781da-7d6c-43d5-8ead-6b3c64a2d68e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bef00472-4d8a-48b9-b332-e85dbe6a9d46" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ed3781da-7d6c-43d5-8ead-6b3c64a2d68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_088d34c1-7a3f-4de9-9416-72d338d469d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_fbd686d6-41ce-4c02-8812-39c05bfca8ee" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_088d34c1-7a3f-4de9-9416-72d338d469d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fa89599e-ed95-4d44-bf90-00b3b9f00d69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_088d34c1-7a3f-4de9-9416-72d338d469d8" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fa89599e-ed95-4d44-bf90-00b3b9f00d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73aa60ac-fb15-4fdd-9c5d-a28a91be455f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fa89599e-ed95-4d44-bf90-00b3b9f00d69" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73aa60ac-fb15-4fdd-9c5d-a28a91be455f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8c12d5ac-fcca-4bb5-b0dc-a2a153244164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fa89599e-ed95-4d44-bf90-00b3b9f00d69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8c12d5ac-fcca-4bb5-b0dc-a2a153244164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_0db0d09b-eeac-40a7-ae94-358a638f5eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fa89599e-ed95-4d44-bf90-00b3b9f00d69" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_0db0d09b-eeac-40a7-ae94-358a638f5eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7d396e54-1c7a-4fdc-86e2-27b1c08cbd55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fa89599e-ed95-4d44-bf90-00b3b9f00d69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7d396e54-1c7a-4fdc-86e2-27b1c08cbd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ec1528b4-6dc9-40e6-981a-ce69b9800ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_fa89599e-ed95-4d44-bf90-00b3b9f00d69" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ec1528b4-6dc9-40e6-981a-ce69b9800ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="simple" xlink:href="cah-20210930.xsd#EarningsPerShareAttributabletoCardinalHealthInc"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_09318fe7-95bf-4ad5-af3b-f566d0b18023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_f80363a8-8f6c-4c22-8ffe-0838fcc7f9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_09318fe7-95bf-4ad5-af3b-f566d0b18023" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_f80363a8-8f6c-4c22-8ffe-0838fcc7f9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="simple" xlink:href="cah-20210930.xsd#EarningsPerShareAttributabletoCardinalHealthIncTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fd3626bf-a78e-4471-a9a1-05e218c16f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_7dc02c63-e5bc-44c5-ae84-8e2a0660b2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fd3626bf-a78e-4471-a9a1-05e218c16f96" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_7dc02c63-e5bc-44c5-ae84-8e2a0660b2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ccad2ec9-102b-4e93-ba71-34a5f734a239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_764fac3b-971b-4220-8e6d-ed0845541e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ccad2ec9-102b-4e93-ba71-34a5f734a239" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_764fac3b-971b-4220-8e6d-ed0845541e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_47a03c1f-c16e-4e0c-b67d-f9b47878c85e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ccad2ec9-102b-4e93-ba71-34a5f734a239" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_47a03c1f-c16e-4e0c-b67d-f9b47878c85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_22440774-6cf2-4b11-886c-c74c78b19940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ccad2ec9-102b-4e93-ba71-34a5f734a239" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_22440774-6cf2-4b11-886c-c74c78b19940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a38d6660-0732-49be-9d9e-930d9ca0c8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ccad2ec9-102b-4e93-ba71-34a5f734a239" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a38d6660-0732-49be-9d9e-930d9ca0c8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3ce51ac1-e996-40e2-9bd4-81d8e17ffffb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Numberofsharesexcludedfromcalculationofdilutedshares_c8186043-938b-4e90-94b8-7e910c8406f5" xlink:href="cah-20210930.xsd#cah_Numberofsharesexcludedfromcalculationofdilutedshares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3ce51ac1-e996-40e2-9bd4-81d8e17ffffb" xlink:to="loc_cah_Numberofsharesexcludedfromcalculationofdilutedshares_c8186043-938b-4e90-94b8-7e910c8406f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_e14294c5-9379-427c-b31d-b7d3e42debde" xlink:href="cah-20210930.xsd#cah_Sharesthatwouldbeantidilutiveasaresultofnetloss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3ce51ac1-e996-40e2-9bd4-81d8e17ffffb" xlink:to="loc_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_e14294c5-9379-427c-b31d-b7d3e42debde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformation" xlink:type="simple" xlink:href="cah-20210930.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_61e80e9a-bc3a-4dbb-bbc2-33477f34a30d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_4a574f05-e160-4f70-a329-cac68af76bab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_61e80e9a-bc3a-4dbb-bbc2-33477f34a30d" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_4a574f05-e160-4f70-a329-cac68af76bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="cah-20210930.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_cd373fa7-334b-4922-b757-87adef9f03e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f315c988-f36b-4154-9a01-265a9aa60684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cd373fa7-334b-4922-b757-87adef9f03e0" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f315c988-f36b-4154-9a01-265a9aa60684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f5d5f188-0d99-445c-89f1-c74cdc680f36" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f315c988-f36b-4154-9a01-265a9aa60684" xlink:to="loc_srt_ConsolidationItemsAxis_f5d5f188-0d99-445c-89f1-c74cdc680f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f5c810d7-0d32-4550-86bf-812152e5338b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_f5d5f188-0d99-445c-89f1-c74cdc680f36" xlink:to="loc_srt_ConsolidationItemsDomain_f5c810d7-0d32-4550-86bf-812152e5338b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_19037714-0f3c-426b-af32-8f1bcb5ce808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f315c988-f36b-4154-9a01-265a9aa60684" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_19037714-0f3c-426b-af32-8f1bcb5ce808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7723ef40-82b8-44df-b64e-19a15f9390f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_19037714-0f3c-426b-af32-8f1bcb5ce808" xlink:to="loc_us-gaap_SegmentDomain_7723ef40-82b8-44df-b64e-19a15f9390f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_f980e62b-8c36-4578-a108-2d3893d3e337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f315c988-f36b-4154-9a01-265a9aa60684" xlink:to="loc_us-gaap_SubsegmentsAxis_f980e62b-8c36-4578-a108-2d3893d3e337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_46be223e-4157-47a4-84d4-c8ce839cd5de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_f980e62b-8c36-4578-a108-2d3893d3e337" xlink:to="loc_us-gaap_SubsegmentsDomain_46be223e-4157-47a4-84d4-c8ce839cd5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_4d3437dd-aa05-48a2-9734-dfb3ed978d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f315c988-f36b-4154-9a01-265a9aa60684" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_4d3437dd-aa05-48a2-9734-dfb3ed978d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_4e68030e-02cb-4339-a14b-c337f9ac2d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_4d3437dd-aa05-48a2-9734-dfb3ed978d7d" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_4e68030e-02cb-4339-a14b-c337f9ac2d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_ae020d55-ac67-4fa1-a8e3-ad8aefdcc94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_f315c988-f36b-4154-9a01-265a9aa60684" xlink:to="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_ae020d55-ac67-4fa1-a8e3-ad8aefdcc94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_214cc0d7-3d08-4c42-b399-1b52390f7314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_ae020d55-ac67-4fa1-a8e3-ad8aefdcc94f" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_214cc0d7-3d08-4c42-b399-1b52390f7314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_3187d28b-9ace-4bd7-b7a1-fada9960422b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cd373fa7-334b-4922-b757-87adef9f03e0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_3187d28b-9ace-4bd7-b7a1-fada9960422b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_fa3ef647-8276-4779-919c-1c959e70d03f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cd373fa7-334b-4922-b757-87adef9f03e0" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_fa3ef647-8276-4779-919c-1c959e70d03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_a7d3f6f6-91a7-4ccf-b2bb-d23e802feebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cd373fa7-334b-4922-b757-87adef9f03e0" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_a7d3f6f6-91a7-4ccf-b2bb-d23e802feebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5038308d-c2d2-40d7-b264-f62005196170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f0c09f54-e016-4630-b0ba-ef180a8817cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5038308d-c2d2-40d7-b264-f62005196170" xlink:to="loc_us-gaap_StatementTable_f0c09f54-e016-4630-b0ba-ef180a8817cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_e9f62c71-588f-4e3e-b6e6-0ede35178f45" xlink:href="cah-20210930.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f0c09f54-e016-4630-b0ba-ef180a8817cc" xlink:to="loc_cah_OpioidLitigationAxis_e9f62c71-588f-4e3e-b6e6-0ede35178f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_6b3446d5-d327-438f-983f-ad85f0dc4fb2" xlink:href="cah-20210930.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_e9f62c71-588f-4e3e-b6e6-0ede35178f45" xlink:to="loc_cah_OpioidLitigationDomain_6b3446d5-d327-438f-983f-ad85f0dc4fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_678c8942-8044-4132-979b-25999e5ec1a9" xlink:href="cah-20210930.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_6b3446d5-d327-438f-983f-ad85f0dc4fb2" xlink:to="loc_cah_TotalOpioidLitigationMember_678c8942-8044-4132-979b-25999e5ec1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6b914f1f-3323-45e9-80b4-68d19b2c1519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f0c09f54-e016-4630-b0ba-ef180a8817cc" xlink:to="loc_us-gaap_StatementLineItems_6b914f1f-3323-45e9-80b4-68d19b2c1519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_5a0ee753-462a-47ba-ad0a-a41a1401288e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6b914f1f-3323-45e9-80b4-68d19b2c1519" xlink:to="loc_us-gaap_LitigationReserve_5a0ee753-462a-47ba-ad0a-a41a1401288e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_ae3a69b6-050b-4a3c-b5a1-dcd27c8cbd11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6b914f1f-3323-45e9-80b4-68d19b2c1519" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_ae3a69b6-050b-4a3c-b5a1-dcd27c8cbd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_9bda7b01-ee76-4856-a606-a420c48c9a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5038308d-c2d2-40d7-b264-f62005196170" xlink:to="loc_us-gaap_NumberOfOperatingSegments_9bda7b01-ee76-4856-a606-a420c48c9a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_432db6ad-fd03-478b-bcc8-ccfb3092896f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5038308d-c2d2-40d7-b264-f62005196170" xlink:to="loc_us-gaap_NumberOfReportableSegments_432db6ad-fd03-478b-bcc8-ccfb3092896f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_a8e033b7-719d-4340-9027-5b1128211b5a" xlink:href="cah-20210930.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5038308d-c2d2-40d7-b264-f62005196170" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_a8e033b7-719d-4340-9027-5b1128211b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_fb6c59dc-e9d2-4fd3-8275-bacbee13dfac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_1a179458-70e8-4d62-9d02-263eee935d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_fb6c59dc-e9d2-4fd3-8275-bacbee13dfac" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_1a179458-70e8-4d62-9d02-263eee935d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_54b6e600-9e62-4716-9065-e18104df9602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_1a179458-70e8-4d62-9d02-263eee935d92" xlink:to="loc_us-gaap_SubsegmentsAxis_54b6e600-9e62-4716-9065-e18104df9602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_625b2202-5c90-4378-a2e2-b13028a57820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_54b6e600-9e62-4716-9065-e18104df9602" xlink:to="loc_us-gaap_SubsegmentsDomain_625b2202-5c90-4378-a2e2-b13028a57820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_01d64e6d-f2b2-4980-b51c-02400ee50799" xlink:href="cah-20210930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_625b2202-5c90-4378-a2e2-b13028a57820" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_01d64e6d-f2b2-4980-b51c-02400ee50799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_78e5d20c-1714-4818-b910-101c3dab600d" xlink:href="cah-20210930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_625b2202-5c90-4378-a2e2-b13028a57820" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_78e5d20c-1714-4818-b910-101c3dab600d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_1bbc1041-cd5b-43fe-ac20-a2bee6d69260" xlink:href="cah-20210930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_625b2202-5c90-4378-a2e2-b13028a57820" xlink:to="loc_cah_MedicaldistributionandproductsMember_1bbc1041-cd5b-43fe-ac20-a2bee6d69260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeSolutionsMember_ee71f0ee-bed5-4cd5-9ea1-e2e6591a1c47" xlink:href="cah-20210930.xsd#cah_CardinalHealthAtHomeSolutionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_625b2202-5c90-4378-a2e2-b13028a57820" xlink:to="loc_cah_CardinalHealthAtHomeSolutionsMember_ee71f0ee-bed5-4cd5-9ea1-e2e6591a1c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_b650ef99-9949-48f7-b6d3-6633dfc7880c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_1a179458-70e8-4d62-9d02-263eee935d92" xlink:to="loc_srt_ConsolidationItemsAxis_b650ef99-9949-48f7-b6d3-6633dfc7880c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_3a2c7148-434c-4e06-991d-9e90d076ea51" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_b650ef99-9949-48f7-b6d3-6633dfc7880c" xlink:to="loc_srt_ConsolidationItemsDomain_3a2c7148-434c-4e06-991d-9e90d076ea51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_4715d699-08b5-47bd-951f-d39fcd79a52f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_3a2c7148-434c-4e06-991d-9e90d076ea51" xlink:to="loc_us-gaap_OperatingSegmentsMember_4715d699-08b5-47bd-951f-d39fcd79a52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_decc4e93-ed51-4533-8ddf-0f1831ef925c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_3a2c7148-434c-4e06-991d-9e90d076ea51" xlink:to="loc_us-gaap_CorporateNonSegmentMember_decc4e93-ed51-4533-8ddf-0f1831ef925c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_64dcb077-8527-42d8-aaf9-e771024ea78b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_1a179458-70e8-4d62-9d02-263eee935d92" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_64dcb077-8527-42d8-aaf9-e771024ea78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dd3adca1-760c-44a1-8637-4a4c0655a58d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_64dcb077-8527-42d8-aaf9-e771024ea78b" xlink:to="loc_us-gaap_SegmentDomain_dd3adca1-760c-44a1-8637-4a4c0655a58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_e883627e-f18d-4d55-adfb-4d034ff2d5a9" xlink:href="cah-20210930.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dd3adca1-760c-44a1-8637-4a4c0655a58d" xlink:to="loc_cah_PharmaceuticalMember_e883627e-f18d-4d55-adfb-4d034ff2d5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_bb835aa5-a9f6-4db9-8233-6eb8dd389a2f" xlink:href="cah-20210930.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dd3adca1-760c-44a1-8637-4a4c0655a58d" xlink:to="loc_cah_MedicalMember_bb835aa5-a9f6-4db9-8233-6eb8dd389a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d5ebca54-de66-4918-8649-dcc18a6f5d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_1a179458-70e8-4d62-9d02-263eee935d92" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_d5ebca54-de66-4918-8649-dcc18a6f5d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6659e603-f6e7-4564-a3ad-e98277328c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d5ebca54-de66-4918-8649-dcc18a6f5d18" xlink:to="loc_us-gaap_Revenues_6659e603-f6e7-4564-a3ad-e98277328c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_cd4762d9-2565-490c-bee4-c934881413b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de4f111-a139-4cc6-875b-199b4b927a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cd4762d9-2565-490c-bee4-c934881413b2" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de4f111-a139-4cc6-875b-199b4b927a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_3f30178b-ece9-4660-bc64-5aa3f583f1ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de4f111-a139-4cc6-875b-199b4b927a50" xlink:to="loc_srt_ConsolidationItemsAxis_3f30178b-ece9-4660-bc64-5aa3f583f1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ccbb8f69-3e70-41fb-923a-433d2f13a651" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_3f30178b-ece9-4660-bc64-5aa3f583f1ba" xlink:to="loc_srt_ConsolidationItemsDomain_ccbb8f69-3e70-41fb-923a-433d2f13a651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_9c7ba33e-614d-4fe2-973a-fd2c64b928f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ccbb8f69-3e70-41fb-923a-433d2f13a651" xlink:to="loc_us-gaap_OperatingSegmentsMember_9c7ba33e-614d-4fe2-973a-fd2c64b928f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_c081bbda-629c-47b2-804f-2a8748ec5a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ccbb8f69-3e70-41fb-923a-433d2f13a651" xlink:to="loc_us-gaap_CorporateNonSegmentMember_c081bbda-629c-47b2-804f-2a8748ec5a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ecdb992f-cc7c-44df-b56e-795e51532382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de4f111-a139-4cc6-875b-199b4b927a50" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ecdb992f-cc7c-44df-b56e-795e51532382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_72ceec85-524c-4b1d-95ad-56db07441bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ecdb992f-cc7c-44df-b56e-795e51532382" xlink:to="loc_us-gaap_SegmentDomain_72ceec85-524c-4b1d-95ad-56db07441bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_f7f5ccd1-d513-4453-b002-a497982b5010" xlink:href="cah-20210930.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_72ceec85-524c-4b1d-95ad-56db07441bcc" xlink:to="loc_cah_PharmaceuticalMember_f7f5ccd1-d513-4453-b002-a497982b5010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_86cce19b-b2d3-468a-b727-0087e5e11b82" xlink:href="cah-20210930.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_72ceec85-524c-4b1d-95ad-56db07441bcc" xlink:to="loc_cah_MedicalMember_86cce19b-b2d3-468a-b727-0087e5e11b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1a545555-de59-438c-90f4-9770614c45f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4de4f111-a139-4cc6-875b-199b4b927a50" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1a545555-de59-438c-90f4-9770614c45f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5268ab0a-e7e1-4111-8bb1-06151fccabf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_1a545555-de59-438c-90f4-9770614c45f2" xlink:to="loc_us-gaap_OperatingIncomeLoss_5268ab0a-e7e1-4111-8bb1-06151fccabf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_60057b46-8428-4179-b47c-721192a6e0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c8f77f2d-5d96-464c-a269-bc3e8806c94a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_60057b46-8428-4179-b47c-721192a6e0c9" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c8f77f2d-5d96-464c-a269-bc3e8806c94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f5d43fca-1346-4485-be6d-a519e19a06c1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c8f77f2d-5d96-464c-a269-bc3e8806c94a" xlink:to="loc_srt_ConsolidationItemsAxis_f5d43fca-1346-4485-be6d-a519e19a06c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f536461a-1a35-494c-8a9e-147f7a1b6265" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_f5d43fca-1346-4485-be6d-a519e19a06c1" xlink:to="loc_srt_ConsolidationItemsDomain_f536461a-1a35-494c-8a9e-147f7a1b6265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_2fafe388-4c21-4cda-9477-14b4e612d317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_f536461a-1a35-494c-8a9e-147f7a1b6265" xlink:to="loc_us-gaap_OperatingSegmentsMember_2fafe388-4c21-4cda-9477-14b4e612d317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_abce6825-a416-4dcd-9f9f-8a121f28f413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_f536461a-1a35-494c-8a9e-147f7a1b6265" xlink:to="loc_us-gaap_CorporateNonSegmentMember_abce6825-a416-4dcd-9f9f-8a121f28f413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_57fea08d-f9ee-4bdf-b63d-76ffd78124fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c8f77f2d-5d96-464c-a269-bc3e8806c94a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_57fea08d-f9ee-4bdf-b63d-76ffd78124fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_634fdcbc-2e55-4408-8853-dc1c380915d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_57fea08d-f9ee-4bdf-b63d-76ffd78124fe" xlink:to="loc_us-gaap_SegmentDomain_634fdcbc-2e55-4408-8853-dc1c380915d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_5e78c265-3203-4e59-bcd4-913b2080a04d" xlink:href="cah-20210930.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_634fdcbc-2e55-4408-8853-dc1c380915d7" xlink:to="loc_cah_PharmaceuticalMember_5e78c265-3203-4e59-bcd4-913b2080a04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_c20e676c-a5e8-4c3b-9b7f-dd265369a136" xlink:href="cah-20210930.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_634fdcbc-2e55-4408-8853-dc1c380915d7" xlink:to="loc_cah_MedicalMember_c20e676c-a5e8-4c3b-9b7f-dd265369a136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_35e6db99-727e-427b-ae08-68775725d608" xlink:href="cah-20210930.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c8f77f2d-5d96-464c-a269-bc3e8806c94a" xlink:to="loc_cah_CordisDivestitureAxis_35e6db99-727e-427b-ae08-68775725d608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_8755d91e-6db9-42b9-873f-296076a89c34" xlink:href="cah-20210930.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_35e6db99-727e-427b-ae08-68775725d608" xlink:to="loc_cah_CordisDivestitureDomain_8755d91e-6db9-42b9-873f-296076a89c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_f5178043-dc13-4b6b-bf60-1827667a31e4" xlink:href="cah-20210930.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_8755d91e-6db9-42b9-873f-296076a89c34" xlink:to="loc_cah_CordisDivestitureMember_f5178043-dc13-4b6b-bf60-1827667a31e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_3ffd3a8a-6c7e-4229-844a-8549f90494af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c8f77f2d-5d96-464c-a269-bc3e8806c94a" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_3ffd3a8a-6c7e-4229-844a-8549f90494af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7efba76e-66d8-43d5-aa5b-502143203aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3ffd3a8a-6c7e-4229-844a-8549f90494af" xlink:to="loc_us-gaap_Assets_7efba76e-66d8-43d5-aa5b-502143203aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_f5b6f129-017c-4963-a30d-abe9dfa36487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3ffd3a8a-6c7e-4229-844a-8549f90494af" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_f5b6f129-017c-4963-a30d-abe9dfa36487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1abdad38-3865-455c-8b84-324477bc53a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_963cf7ef-1e56-4711-ba91-41fa72a3815f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1abdad38-3865-455c-8b84-324477bc53a1" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_963cf7ef-1e56-4711-ba91-41fa72a3815f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentAxis_88450b1d-571a-4cbf-a422-864458004bdc" xlink:href="cah-20210930.xsd#cah_MedicalSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_963cf7ef-1e56-4711-ba91-41fa72a3815f" xlink:to="loc_cah_MedicalSegmentAxis_88450b1d-571a-4cbf-a422-864458004bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalSegmentDomain_66147dac-697e-4833-9082-9d847ecc1f29" xlink:href="cah-20210930.xsd#cah_MedicalSegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_MedicalSegmentAxis_88450b1d-571a-4cbf-a422-864458004bdc" xlink:to="loc_cah_MedicalSegmentDomain_66147dac-697e-4833-9082-9d847ecc1f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_d3bb7927-38e3-4d5f-b4e5-c6e140d5820b" xlink:href="cah-20210930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_MedicalSegmentDomain_66147dac-697e-4833-9082-9d847ecc1f29" xlink:to="loc_cah_MedicaldistributionandproductsMember_d3bb7927-38e3-4d5f-b4e5-c6e140d5820b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentAxis_b320dc62-739d-495f-afa9-2211d35af5d2" xlink:href="cah-20210930.xsd#cah_PharmaceuticalSegmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_963cf7ef-1e56-4711-ba91-41fa72a3815f" xlink:to="loc_cah_PharmaceuticalSegmentAxis_b320dc62-739d-495f-afa9-2211d35af5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalSegmentDomain_4a147363-6b0a-4e9a-91f4-ffdb9dd0c7db" xlink:href="cah-20210930.xsd#cah_PharmaceuticalSegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PharmaceuticalSegmentAxis_b320dc62-739d-495f-afa9-2211d35af5d2" xlink:to="loc_cah_PharmaceuticalSegmentDomain_4a147363-6b0a-4e9a-91f4-ffdb9dd0c7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_789e392c-0d2b-4113-b37a-707028f737d3" xlink:href="cah-20210930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PharmaceuticalSegmentDomain_4a147363-6b0a-4e9a-91f4-ffdb9dd0c7db" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_789e392c-0d2b-4113-b37a-707028f737d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_fcbfd64a-5a14-4f3c-bd95-8205984363d0" xlink:href="cah-20210930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PharmaceuticalSegmentDomain_4a147363-6b0a-4e9a-91f4-ffdb9dd0c7db" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_fcbfd64a-5a14-4f3c-bd95-8205984363d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9d1db238-475d-44e5-84a3-d7c0109a9420" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_963cf7ef-1e56-4711-ba91-41fa72a3815f" xlink:to="loc_srt_ConsolidationItemsAxis_9d1db238-475d-44e5-84a3-d7c0109a9420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_020367a5-eaba-462e-b8a4-04517e35431a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_9d1db238-475d-44e5-84a3-d7c0109a9420" xlink:to="loc_srt_ConsolidationItemsDomain_020367a5-eaba-462e-b8a4-04517e35431a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_2b25e19e-ab05-4f12-bdb3-5fd126e5fb13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_020367a5-eaba-462e-b8a4-04517e35431a" xlink:to="loc_us-gaap_OperatingSegmentsMember_2b25e19e-ab05-4f12-bdb3-5fd126e5fb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_4bee1562-36fb-47bb-85ac-9e1e2b156d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_020367a5-eaba-462e-b8a4-04517e35431a" xlink:to="loc_us-gaap_CorporateNonSegmentMember_4bee1562-36fb-47bb-85ac-9e1e2b156d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_daf1fa3a-147a-44f9-aa2d-dbf2ac564f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_963cf7ef-1e56-4711-ba91-41fa72a3815f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_daf1fa3a-147a-44f9-aa2d-dbf2ac564f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cab3ecb1-f133-465a-9260-a3957b44106b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_daf1fa3a-147a-44f9-aa2d-dbf2ac564f7c" xlink:to="loc_us-gaap_SegmentDomain_cab3ecb1-f133-465a-9260-a3957b44106b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_0e36da6d-768c-4d76-a388-48cea4b5b25c" xlink:href="cah-20210930.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cab3ecb1-f133-465a-9260-a3957b44106b" xlink:to="loc_cah_PharmaceuticalMember_0e36da6d-768c-4d76-a388-48cea4b5b25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_96e19227-8721-4208-8a16-b49769c6bf73" xlink:href="cah-20210930.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cab3ecb1-f133-465a-9260-a3957b44106b" xlink:to="loc_cah_MedicalMember_96e19227-8721-4208-8a16-b49769c6bf73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_1553aaba-3859-4396-889e-03f63e1bdcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_963cf7ef-1e56-4711-ba91-41fa72a3815f" xlink:to="loc_us-gaap_SubsegmentsAxis_1553aaba-3859-4396-889e-03f63e1bdcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_bd7a1e87-c0e5-4710-93d1-b3310395e8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_1553aaba-3859-4396-889e-03f63e1bdcd4" xlink:to="loc_us-gaap_SubsegmentsDomain_bd7a1e87-c0e5-4710-93d1-b3310395e8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_71bf112d-2d09-4241-b337-2854c1f78f53" xlink:href="cah-20210930.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_bd7a1e87-c0e5-4710-93d1-b3310395e8a4" xlink:to="loc_cah_MedicaldistributionandproductsMember_71bf112d-2d09-4241-b337-2854c1f78f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_a026ee68-fe2f-46d8-ad6f-b8c91043a557" xlink:href="cah-20210930.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_bd7a1e87-c0e5-4710-93d1-b3310395e8a4" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_a026ee68-fe2f-46d8-ad6f-b8c91043a557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_9f726ba3-32ce-4457-a16d-0f119fcc35da" xlink:href="cah-20210930.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_bd7a1e87-c0e5-4710-93d1-b3310395e8a4" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_9f726ba3-32ce-4457-a16d-0f119fcc35da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_5c9e1c91-485f-4778-8078-79ea16b3f6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_963cf7ef-1e56-4711-ba91-41fa72a3815f" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_5c9e1c91-485f-4778-8078-79ea16b3f6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_349153d8-c223-4273-b7e8-3a1beb2fd876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_5c9e1c91-485f-4778-8078-79ea16b3f6ec" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_349153d8-c223-4273-b7e8-3a1beb2fd876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_82df9f9d-60ac-4b77-92ab-bc741cbfcbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_963cf7ef-1e56-4711-ba91-41fa72a3815f" xlink:to="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_82df9f9d-60ac-4b77-92ab-bc741cbfcbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a6389d45-82a8-4e49-90ae-34642fa58bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_82df9f9d-60ac-4b77-92ab-bc741cbfcbd5" xlink:to="loc_us-gaap_Revenues_a6389d45-82a8-4e49-90ae-34642fa58bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#SegmentInformationRevenuebyGeographicalSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7a62486f-48e5-41e3-ad20-11bde62a3d57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicTable_76d42a96-48e9-421b-b84f-cc11e93f2fb7" xlink:href="cah-20210930.xsd#cah_SegmentRevenuebyGeographicTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7a62486f-48e5-41e3-ad20-11bde62a3d57" xlink:to="loc_cah_SegmentRevenuebyGeographicTable_76d42a96-48e9-421b-b84f-cc11e93f2fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_96aaa0c6-50c8-46a7-8b3c-bda03d88ad5f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_76d42a96-48e9-421b-b84f-cc11e93f2fb7" xlink:to="loc_srt_ConsolidationItemsAxis_96aaa0c6-50c8-46a7-8b3c-bda03d88ad5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_cc034d84-e959-4cdf-bd5d-4610e7e46487" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_96aaa0c6-50c8-46a7-8b3c-bda03d88ad5f" xlink:to="loc_srt_ConsolidationItemsDomain_cc034d84-e959-4cdf-bd5d-4610e7e46487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_8aee369e-04f3-498e-acf5-0753b9d6254d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_cc034d84-e959-4cdf-bd5d-4610e7e46487" xlink:to="loc_us-gaap_OperatingSegmentsMember_8aee369e-04f3-498e-acf5-0753b9d6254d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_aca5235a-41c4-46bd-b368-883736aacdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingSegmentsMember_8aee369e-04f3-498e-acf5-0753b9d6254d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_aca5235a-41c4-46bd-b368-883736aacdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_20ae68a6-8f69-4308-b3f1-5386c9b6d315" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_76d42a96-48e9-421b-b84f-cc11e93f2fb7" xlink:to="loc_srt_StatementGeographicalAxis_20ae68a6-8f69-4308-b3f1-5386c9b6d315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e8ea4ef2-0761-489f-8c73-d90eafc75f24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_20ae68a6-8f69-4308-b3f1-5386c9b6d315" xlink:to="loc_srt_SegmentGeographicalDomain_e8ea4ef2-0761-489f-8c73-d90eafc75f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3aa07a85-70b9-4a70-aba3-3b868583f289" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e8ea4ef2-0761-489f-8c73-d90eafc75f24" xlink:to="loc_country_US_3aa07a85-70b9-4a70-aba3-3b868583f289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_a979ac58-a8fd-4838-8257-6317670a604b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e8ea4ef2-0761-489f-8c73-d90eafc75f24" xlink:to="loc_us-gaap_NonUsMember_a979ac58-a8fd-4838-8257-6317670a604b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuebyGeographicLineItems_89d691aa-7712-4631-9512-07e45a97e6c8" xlink:href="cah-20210930.xsd#cah_SegmentRevenuebyGeographicLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuebyGeographicTable_76d42a96-48e9-421b-b84f-cc11e93f2fb7" xlink:to="loc_cah_SegmentRevenuebyGeographicLineItems_89d691aa-7712-4631-9512-07e45a97e6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7d32ec6e-7020-4266-aedf-d24df38e94d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuebyGeographicLineItems_89d691aa-7712-4631-9512-07e45a97e6c8" xlink:to="loc_us-gaap_Revenues_7d32ec6e-7020-4266-aedf-d24df38e94d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8fb89b1e-0796-462b-9943-9d647646a29d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e6ce60f7-dfab-4338-aa64-fe714b6edddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8fb89b1e-0796-462b-9943-9d647646a29d" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e6ce60f7-dfab-4338-aa64-fe714b6edddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89204418-d269-4b6a-88bc-2cd5967537f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_02f93458-e16b-43ad-8361-c394fbe09648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89204418-d269-4b6a-88bc-2cd5967537f7" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_02f93458-e16b-43ad-8361-c394fbe09648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_27b37a3f-67f2-4538-8283-2dc15712a4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89204418-d269-4b6a-88bc-2cd5967537f7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_27b37a3f-67f2-4538-8283-2dc15712a4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AdditionalStockOptionPlanDataTableTextBlock_19a5f284-a9b2-4c4a-98d4-94e09d582562" xlink:href="cah-20210930.xsd#cah_AdditionalStockOptionPlanDataTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89204418-d269-4b6a-88bc-2cd5967537f7" xlink:to="loc_cah_AdditionalStockOptionPlanDataTableTextBlock_19a5f284-a9b2-4c4a-98d4-94e09d582562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_86a3f5d7-819d-426f-94fa-923e06a0ecb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89204418-d269-4b6a-88bc-2cd5967537f7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_86a3f5d7-819d-426f-94fa-923e06a0ecb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_76236b11-6089-44af-8ba8-6e6d5a01a464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89204418-d269-4b6a-88bc-2cd5967537f7" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_76236b11-6089-44af-8ba8-6e6d5a01a464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9e3e0bd-ffcc-464b-93bb-b24efc693d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4bc42617-a8fd-4eee-b536-102916fc9e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9e3e0bd-ffcc-464b-93bb-b24efc693d4f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4bc42617-a8fd-4eee-b536-102916fc9e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9f9fd72e-caab-44a7-a37f-784b3dfe521f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4bc42617-a8fd-4eee-b536-102916fc9e17" xlink:to="loc_us-gaap_AwardTypeAxis_9f9fd72e-caab-44a7-a37f-784b3dfe521f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8417fca-9952-4114-885d-bc29137dc328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9f9fd72e-caab-44a7-a37f-784b3dfe521f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8417fca-9952-4114-885d-bc29137dc328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a373beea-3e2d-4423-940f-956e9af93c07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8417fca-9952-4114-885d-bc29137dc328" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a373beea-3e2d-4423-940f-956e9af93c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7cf12951-9286-41a9-a581-17d61e8bd1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8417fca-9952-4114-885d-bc29137dc328" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7cf12951-9286-41a9-a581-17d61e8bd1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0c535ef4-3e61-4c35-8300-c75fc53c09c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8417fca-9952-4114-885d-bc29137dc328" xlink:to="loc_us-gaap_PerformanceSharesMember_0c535ef4-3e61-4c35-8300-c75fc53c09c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_96b47cee-786b-40b0-9c0b-3333419e48af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4bc42617-a8fd-4eee-b536-102916fc9e17" xlink:to="loc_srt_RangeAxis_96b47cee-786b-40b0-9c0b-3333419e48af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ef24130b-221f-440b-8c22-a52ada57eeba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_96b47cee-786b-40b0-9c0b-3333419e48af" xlink:to="loc_srt_RangeMember_ef24130b-221f-440b-8c22-a52ada57eeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ff84053d-9e8e-429b-b28d-3e1c38a01c87" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ef24130b-221f-440b-8c22-a52ada57eeba" xlink:to="loc_srt_MinimumMember_ff84053d-9e8e-429b-b28d-3e1c38a01c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ac1909ed-bea2-4738-838e-e03f289cbc7f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ef24130b-221f-440b-8c22-a52ada57eeba" xlink:to="loc_srt_MaximumMember_ac1909ed-bea2-4738-838e-e03f289cbc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65fea4a1-2608-4aa1-881b-82a54f2edc99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4bc42617-a8fd-4eee-b536-102916fc9e17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65fea4a1-2608-4aa1-881b-82a54f2edc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_d392b867-df30-4c59-a8a7-700d9f10e2f8" xlink:href="cah-20210930.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65fea4a1-2608-4aa1-881b-82a54f2edc99" xlink:to="loc_cah_VestingPeriodinyearsforShares_d392b867-df30-4c59-a8a7-700d9f10e2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_dd351bea-d317-4296-be1a-7fbd468fd2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65fea4a1-2608-4aa1-881b-82a54f2edc99" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_dd351bea-d317-4296-be1a-7fbd468fd2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bfaeaf31-a16f-4709-9aeb-c362a4cc9e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65fea4a1-2608-4aa1-881b-82a54f2edc99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bfaeaf31-a16f-4709-9aeb-c362a4cc9e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4a13284d-305d-484f-838b-b29088d77cae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65fea4a1-2608-4aa1-881b-82a54f2edc99" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4a13284d-305d-484f-838b-b29088d77cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e0786852-7723-4ca3-af74-145db737bf40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65fea4a1-2608-4aa1-881b-82a54f2edc99" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e0786852-7723-4ca3-af74-145db737bf40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ExercisablePeriodOfPlansInYears_771bc0b7-c86e-4539-b2d7-54cdc19c58a2" xlink:href="cah-20210930.xsd#cah_ExercisablePeriodOfPlansInYears"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65fea4a1-2608-4aa1-881b-82a54f2edc99" xlink:to="loc_cah_ExercisablePeriodOfPlansInYears_771bc0b7-c86e-4539-b2d7-54cdc19c58a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_62ac9e8b-6da6-4a22-84d6-dc8402ff8278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65fea4a1-2608-4aa1-881b-82a54f2edc99" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_62ac9e8b-6da6-4a22-84d6-dc8402ff8278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_527a4da6-ac2a-4d9c-b949-b4c7003ddfaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_431f019a-8757-40ea-a654-57cac11558b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_527a4da6-ac2a-4d9c-b949-b4c7003ddfaa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_431f019a-8757-40ea-a654-57cac11558b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_afc20111-0a3a-4d6c-93e1-37b840fd167e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_431f019a-8757-40ea-a654-57cac11558b9" xlink:to="loc_us-gaap_AwardTypeAxis_afc20111-0a3a-4d6c-93e1-37b840fd167e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1d38f76-83ef-420b-a9f2-0762b42e05f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_afc20111-0a3a-4d6c-93e1-37b840fd167e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1d38f76-83ef-420b-a9f2-0762b42e05f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_69456ea2-2632-40a6-b0ad-b508c79e4b94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1d38f76-83ef-420b-a9f2-0762b42e05f0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_69456ea2-2632-40a6-b0ad-b508c79e4b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6782daaf-802b-4d75-9b4f-6bb50753d0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1d38f76-83ef-420b-a9f2-0762b42e05f0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6782daaf-802b-4d75-9b4f-6bb50753d0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d5cd9fa3-89fc-4f37-9112-2318b2ca8d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1d38f76-83ef-420b-a9f2-0762b42e05f0" xlink:to="loc_us-gaap_PerformanceSharesMember_d5cd9fa3-89fc-4f37-9112-2318b2ca8d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f4335c0b-f2b3-4c37-8ff4-204ecba8cfcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_431f019a-8757-40ea-a654-57cac11558b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f4335c0b-f2b3-4c37-8ff4-204ecba8cfcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3bb92064-7f3b-4a9e-9c65-5d924aa0c7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f4335c0b-f2b3-4c37-8ff4-204ecba8cfcb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3bb92064-7f3b-4a9e-9c65-5d924aa0c7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5327bc2b-f1a0-4335-b4bb-18e9d207761c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa10b0a6-24a7-4322-9675-1890d7f9600c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5327bc2b-f1a0-4335-b4bb-18e9d207761c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa10b0a6-24a7-4322-9675-1890d7f9600c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b6514649-2c3b-4ace-9779-fec715936e09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa10b0a6-24a7-4322-9675-1890d7f9600c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b6514649-2c3b-4ace-9779-fec715936e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_592dfced-d864-4325-8414-46576b658df6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa10b0a6-24a7-4322-9675-1890d7f9600c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_592dfced-d864-4325-8414-46576b658df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f1324507-2a21-433c-931a-76d3f2887c28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa10b0a6-24a7-4322-9675-1890d7f9600c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f1324507-2a21-433c-931a-76d3f2887c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_a2f093fc-e9c3-4990-bcd4-5a8de4adcd57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa10b0a6-24a7-4322-9675-1890d7f9600c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_a2f093fc-e9c3-4990-bcd4-5a8de4adcd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b5d58ea2-f4a8-4e04-a5c6-5fcc2535cf66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_aa10b0a6-24a7-4322-9675-1890d7f9600c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b5d58ea2-f4a8-4e04-a5c6-5fcc2535cf66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_199e91a7-ae1b-43de-921e-24e0f97198fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5327bc2b-f1a0-4335-b4bb-18e9d207761c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_199e91a7-ae1b-43de-921e-24e0f97198fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e1587612-3afc-453f-9339-2ebf951d1a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5327bc2b-f1a0-4335-b4bb-18e9d207761c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e1587612-3afc-453f-9339-2ebf951d1a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fefb81dd-1542-4a97-82ba-e6c62ab7cec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e1587612-3afc-453f-9339-2ebf951d1a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fefb81dd-1542-4a97-82ba-e6c62ab7cec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_236c5eac-325e-4e44-b4aa-37d5a3c7f696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e1587612-3afc-453f-9339-2ebf951d1a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_236c5eac-325e-4e44-b4aa-37d5a3c7f696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3b535864-9b4f-4ad9-90ea-ed6df1f25904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e1587612-3afc-453f-9339-2ebf951d1a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3b535864-9b4f-4ad9-90ea-ed6df1f25904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_5fa374b7-6d80-45d6-a1ca-79b15f703073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e1587612-3afc-453f-9339-2ebf951d1a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_5fa374b7-6d80-45d6-a1ca-79b15f703073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bf918575-0bdc-4b96-ac0d-bf431a0007ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e1587612-3afc-453f-9339-2ebf951d1a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bf918575-0bdc-4b96-ac0d-bf431a0007ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_39fea866-81ad-4b39-9792-a4ec8857ee3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e1587612-3afc-453f-9339-2ebf951d1a3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_39fea866-81ad-4b39-9792-a4ec8857ee3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00eee014-37ea-4bc4-9e4b-9fae4385ff6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b423f52-2334-4243-81e1-cc7d15d9dcad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00eee014-37ea-4bc4-9e4b-9fae4385ff6f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b423f52-2334-4243-81e1-cc7d15d9dcad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f7f4e25c-5e53-4cba-8745-5efff8afc58f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b423f52-2334-4243-81e1-cc7d15d9dcad" xlink:to="loc_us-gaap_AwardTypeAxis_f7f4e25c-5e53-4cba-8745-5efff8afc58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fd69864-9cf8-4186-8de2-f47d142591da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f7f4e25c-5e53-4cba-8745-5efff8afc58f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fd69864-9cf8-4186-8de2-f47d142591da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b82a45a8-5687-48e3-af74-4066aada0ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fd69864-9cf8-4186-8de2-f47d142591da" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b82a45a8-5687-48e3-af74-4066aada0ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c2aef1-d65d-48ff-af56-33dbc8429dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b423f52-2334-4243-81e1-cc7d15d9dcad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c2aef1-d65d-48ff-af56-33dbc8429dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_921c60fc-079f-4f1d-b99b-2bd1070ec71f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c2aef1-d65d-48ff-af56-33dbc8429dc7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_921c60fc-079f-4f1d-b99b-2bd1070ec71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_70020849-34df-40bf-b373-5bb994922ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c2aef1-d65d-48ff-af56-33dbc8429dc7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_70020849-34df-40bf-b373-5bb994922ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1457ba21-7052-4b9e-a21d-83e1f9bf5cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c2aef1-d65d-48ff-af56-33dbc8429dc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1457ba21-7052-4b9e-a21d-83e1f9bf5cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d9d96208-f999-4500-abe5-4c4ca80b5e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c2aef1-d65d-48ff-af56-33dbc8429dc7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d9d96208-f999-4500-abe5-4c4ca80b5e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bbac59ca-25db-480c-acdb-cc77d3979283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c2aef1-d65d-48ff-af56-33dbc8429dc7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bbac59ca-25db-480c-acdb-cc77d3979283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7e8cf6c0-2be1-46f9-aaf3-200268c3eb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9c2aef1-d65d-48ff-af56-33dbc8429dc7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7e8cf6c0-2be1-46f9-aaf3-200268c3eb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5942ebc2-0c6d-40f5-9608-1721315f6143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f583a164-e7e2-4726-81fd-26174221903f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5942ebc2-0c6d-40f5-9608-1721315f6143" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f583a164-e7e2-4726-81fd-26174221903f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cb3f8ea6-c300-4948-9f6a-84c413aa91d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f583a164-e7e2-4726-81fd-26174221903f" xlink:to="loc_us-gaap_AwardTypeAxis_cb3f8ea6-c300-4948-9f6a-84c413aa91d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9df3837f-64a7-44c2-a0ee-6f2ca1a8f2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cb3f8ea6-c300-4948-9f6a-84c413aa91d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9df3837f-64a7-44c2-a0ee-6f2ca1a8f2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_faabf0ec-abaf-4bd9-b14a-a1cb8982fa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9df3837f-64a7-44c2-a0ee-6f2ca1a8f2cc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_faabf0ec-abaf-4bd9-b14a-a1cb8982fa5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45080c9a-7f41-4a9a-94b7-f0d3ab7e367a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f583a164-e7e2-4726-81fd-26174221903f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45080c9a-7f41-4a9a-94b7-f0d3ab7e367a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6fc88355-5a07-413f-ac44-8af68ee8e19d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45080c9a-7f41-4a9a-94b7-f0d3ab7e367a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6fc88355-5a07-413f-ac44-8af68ee8e19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66a1bc72-a5c3-4c9e-b0d7-8ddf7c499cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45080c9a-7f41-4a9a-94b7-f0d3ab7e367a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66a1bc72-a5c3-4c9e-b0d7-8ddf7c499cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2b008890-4008-465e-9c16-0ae860cf617a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66a1bc72-a5c3-4c9e-b0d7-8ddf7c499cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2b008890-4008-465e-9c16-0ae860cf617a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ad946499-ce52-46f8-a19f-94660e41ffc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66a1bc72-a5c3-4c9e-b0d7-8ddf7c499cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ad946499-ce52-46f8-a19f-94660e41ffc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c9190733-930c-4913-8826-3b46c483064e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66a1bc72-a5c3-4c9e-b0d7-8ddf7c499cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c9190733-930c-4913-8826-3b46c483064e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fe5b75f4-37f5-425d-aa7d-36eb9f14529f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66a1bc72-a5c3-4c9e-b0d7-8ddf7c499cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fe5b75f4-37f5-425d-aa7d-36eb9f14529f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a08f04b2-67c1-4aac-94f6-b747d546297f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_66a1bc72-a5c3-4c9e-b0d7-8ddf7c499cb5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a08f04b2-67c1-4aac-94f6-b747d546297f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eb06b716-388c-423f-9298-910056f39168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45080c9a-7f41-4a9a-94b7-f0d3ab7e367a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eb06b716-388c-423f-9298-910056f39168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c593cc4a-9d03-4534-9d28-c2f966bfc7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eb06b716-388c-423f-9298-910056f39168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c593cc4a-9d03-4534-9d28-c2f966bfc7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ff8539d-a902-41eb-beab-dcb096cb5345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eb06b716-388c-423f-9298-910056f39168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ff8539d-a902-41eb-beab-dcb096cb5345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f96ad8b5-f968-476b-9535-2bfc248e164c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eb06b716-388c-423f-9298-910056f39168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f96ad8b5-f968-476b-9535-2bfc248e164c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_974fc0c9-f1f3-4e63-b405-92d347c1bb94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eb06b716-388c-423f-9298-910056f39168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_974fc0c9-f1f3-4e63-b405-92d347c1bb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4b83f82e-5332-4014-b5c7-a843660fea34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_eb06b716-388c-423f-9298-910056f39168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4b83f82e-5332-4014-b5c7-a843660fea34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20210930.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a7534ca1-a8df-4a10-8942-ba34854ce298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c59e4705-7be6-42ab-be41-7940d488bfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a7534ca1-a8df-4a10-8942-ba34854ce298" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c59e4705-7be6-42ab-be41-7940d488bfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e5e39bd1-eb87-44c1-858c-d56e31c192ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c59e4705-7be6-42ab-be41-7940d488bfc7" xlink:to="loc_us-gaap_AwardTypeAxis_e5e39bd1-eb87-44c1-858c-d56e31c192ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0a95218-7361-451d-84ea-026a3e157ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e5e39bd1-eb87-44c1-858c-d56e31c192ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0a95218-7361-451d-84ea-026a3e157ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_24fc6a61-a57a-4a26-a020-6cd4228ab287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0a95218-7361-451d-84ea-026a3e157ec0" xlink:to="loc_us-gaap_PerformanceSharesMember_24fc6a61-a57a-4a26-a020-6cd4228ab287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f84c3b58-e298-41fd-b780-0fc057709148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c59e4705-7be6-42ab-be41-7940d488bfc7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f84c3b58-e298-41fd-b780-0fc057709148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_60596f3b-7db4-412e-80ce-9cfc942d327f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f84c3b58-e298-41fd-b780-0fc057709148" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_60596f3b-7db4-412e-80ce-9cfc942d327f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82de6ff6-aeb3-40c1-b364-262da0dd5f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f84c3b58-e298-41fd-b780-0fc057709148" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82de6ff6-aeb3-40c1-b364-262da0dd5f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ce5a54d7-71e0-41e7-8191-20a1932cf406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82de6ff6-aeb3-40c1-b364-262da0dd5f4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ce5a54d7-71e0-41e7-8191-20a1932cf406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_08a44463-bc33-4b1e-9bbc-bac2192ff278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82de6ff6-aeb3-40c1-b364-262da0dd5f4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_08a44463-bc33-4b1e-9bbc-bac2192ff278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7603b586-d311-4429-8ce0-b10f7ef4a392" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82de6ff6-aeb3-40c1-b364-262da0dd5f4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7603b586-d311-4429-8ce0-b10f7ef4a392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2dc476ad-b0c6-4e6d-9ee3-d60474a311a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82de6ff6-aeb3-40c1-b364-262da0dd5f4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2dc476ad-b0c6-4e6d-9ee3-d60474a311a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d7a71a8a-f8d0-445f-bd28-e7af249af6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_82de6ff6-aeb3-40c1-b364-262da0dd5f4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d7a71a8a-f8d0-445f-bd28-e7af249af6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0df362a2-7eab-4c48-a6d0-2bfda93bbe58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f84c3b58-e298-41fd-b780-0fc057709148" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0df362a2-7eab-4c48-a6d0-2bfda93bbe58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2a397012-81ec-4e01-89d5-433ecda551e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0df362a2-7eab-4c48-a6d0-2bfda93bbe58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2a397012-81ec-4e01-89d5-433ecda551e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d975f712-8842-4e0f-9044-280389fe5779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0df362a2-7eab-4c48-a6d0-2bfda93bbe58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d975f712-8842-4e0f-9044-280389fe5779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b7f9766f-89e6-41b6-92f3-e2edbef05376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0df362a2-7eab-4c48-a6d0-2bfda93bbe58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b7f9766f-89e6-41b6-92f3-e2edbef05376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_25af2d41-553b-4d39-a9be-7c7bb073db71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0df362a2-7eab-4c48-a6d0-2bfda93bbe58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_25af2d41-553b-4d39-a9be-7c7bb073db71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0179ee91-90c6-40a4-a631-aa1bd3c4ec99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0df362a2-7eab-4c48-a6d0-2bfda93bbe58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0179ee91-90c6-40a4-a631-aa1bd3c4ec99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3c0e6bd6-c0c1-4ab1-b3ff-ba3308c63f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f84c3b58-e298-41fd-b780-0fc057709148" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3c0e6bd6-c0c1-4ab1-b3ff-ba3308c63f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ee0212e9-39a6-414c-bdfc-7abc06a8a8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f84c3b58-e298-41fd-b780-0fc057709148" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ee0212e9-39a6-414c-bdfc-7abc06a8a8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cah-20210930_g1.jpg
<TEXT>
begin 644 cah-20210930_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *_!#_@XH^-W_!176O\ @MK\(_V(/V)OVS?&
M7PV/Q#^'FAVMA9:;XXU'2M*&HW.JZI#]IN%L]Q&5CC5G6-VVQJ,' %?O?7\Y
MG_!R_P#&WQ[^S;_P<-_ CX]_"WX>/XM\1^$?AQX=U/1?#,<4KMJ=Q%K6KLD
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M7Z9\5+K5KOPHCZNLD*3:;(@CL3%!F A"=C'8.*^S?C%^U/\ LQ?L[W5E8_M
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M\2WME;(6/)"06\2#V05^OO\ P1B_Y1+_ +.'_9&/#W_I!%0!],4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %?@[_ ,%A_P#E;1_9%_[ ?A+_ -/N
MKU^\5% !7X9_\'P'_) /@'_V.6L_^DEO7[F44 ?DQ_P>8_\ *)C0?^RT:/\
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M@#\3/^"_O_*K_P# S_L'?#W_ -,QKYK_ ."Z/A3XCV?_  3@_P"";?QN\6>
M=5\4?!?PK\*/#@\<:38R/';M</I>C.(IW7B)KBWBGBBD/W2) ""WS?TCU!J6
MF:;K-A-I6KZ?!=VMQ&4GMKF(21R*>JLK @CV- '\KG_!77]O?]E_]KG6OV<_
MBK^Q!^Q-JWPK^ /PI\9/:R>)+GP9::/::EJUS)97$]K''9L\3F"WT\$MO9R9
M'W #:7^S?^#@SPI\:/\ @G5_P5U^"O\ P70^%7PTN?%_@>SL+2P\6FP9O+AG
MC2>U>.29598%N;"Z"0RD%?,B?.?E5OW5TO2M+T/3X=(T73;>SM+=-D%K:PK'
M'&OHJJ  /85)=VEK?VLEC?6T<T,R%)894#*ZD8*D'@@CM0!^(G[,'_!<7]OW
M_@L3_P %8_AQX0_X)V^&_$OP^^!'ANWMYOB\OB+0["^6ZM$F::X:>8Q2"TDF
M14M8%BD\PLQD/R[@GS1\:]&^ O\ P1"_X+9_&7QI_P %)OV!K#XO_!'XR7^H
M:WX*U;4/ VG:U]D>[NS>JUF-1 A,D+236LT7F1R;=DF2NP2?TD>'?"_AGPAI
MHT;PGX=L=+LU<LMIIUHD$08]3M0 9/TI=?\ #?AWQ7IKZ+XIT&RU*SD(,EIJ
M%JDT3$=,JX(/Y4 ?DM_P;N?'-OVV/VA_B;^TE\-/^"4?P-^"_P '='^TV/PX
M\>^%?A7;:/XBOS+.H6R>[@Q'<*L",TYA5561HDRW6O@G_@EG_P %('_X-\OV
MW/VF/V6?VJ/V9O'WB+6/&/B>WB\-Z=X4L8FNKF[M+F^%J5CF>/S+:[CO$=)H
M]YPJE4??Q_3/9V5GIUI'8:?:1000H$AAAC"I&H& H X 'H*KW7AOP[?:S;^(
M[W0+*;4+-&2TOY;5&F@5NH1R-R@]P#S0!^"?_!KIJ?Q8U_\ X+-_M<>*_COX
M'?PQXTUVPOM7\4^')'W-I=]=ZXMS-:L?[T;RE#GD%2#S7G?_  1"_;8LO^":
M/_!:;X]?L7?&WX0>()?$/QJ^,UKX<TN>$I$FFS)JM_Y<\RR89X9([U)$9,[E
MVD?*P8?T>U0;PIX7?Q"OBY_#=@=52'R4U,V:?:%CY^028W!>3QG')H _#?\
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MWJO[1NH>%M5?XC^/K+PG:S+;:/;W+WEWJ<U_N:Y6..R3RA"51$8$ ]!)_5F
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M 4444 %%%% !1110 4444 %%%% !1110 5^6/_!37]AK_@D!_P %TOVI+_\
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MNZK/>RW=Y+(TCQI-.?,>&(,(49\,RQAF +$  ]LHHHH **** "BBB@ HHHH
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MP>58Z3'/X<25;2W3^"&(.(T7LJ 5T'_!TW_R</\ \$_?^PS=_P#I7X>KS_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]@?V9YWVJY>?9]G^T3[=N_;GS#G&<#I7,_\ !:+_ ()7_P##WK]E+2/V8O\
MA>W_  KW^RO'5IXC_MS_ (1C^UO-\BTO+?R/)^U6^W=]KW;]YQY>-IW9'US1
M0!^)WQ4_X,]Y_%OBC3?AMX"_X*2>--%^!B:E'J=]\,+G3Y[J.SO,?OWLE>[^
MSQF0F39))$[Q!\,9\$M]K?\ !1#_ ((I_#+]LS_@FSX3_P"":?P:^):?"KPM
MX+U/2Y]$OU\.G5RD%E#-$(FB-S;EWD,Q=I3)DMN)!+$U]MT4 ?G;_P %&?\
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M *+%_P"6]J/_ ,CT >VT5XE_P\7_ &-O^BQ?^6]J/_R/1_P\7_8V_P"BQ?\
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M110 4444 %%%% !1110 4444 %%%% %37_\ D!7O_7I)_P"@FOQ6K]J=?_Y
M5[_UZ2?^@FOQ6H **** "BBB@ HHHH **** /N7_ ((]?\@+Q[_U]Z=_Z#<5
M]GU\8?\ !'K_ ) 7CW_K[T[_ -!N*^SZ "BBB@ HHHH **** "BBB@ HHHH
M**** /$/BI_R/^H_]=$_]%K7/5T/Q4_Y'_4?^NB?^BUKGJ "BBB@ HHHH **
M** "NH^#O_(_VG_7.7_T6U<O74?!W_D?[3_KG+_Z+:@#VBBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M44 %%%% !1110 4444 %%%% %37_ /D!7O\ UZ2?^@FOQ6K]J=?_ .0%>_\
M7I)_Z":_%:@#RK]L#]EC0OVM?A5'X!O_ !3=Z!J>FZK#JOAWQ!8Q[I=.O8MP
M20+N4L,.P(#*>0000#7C/[%?_!.N;P=\/M6U_P#:8\2:EK_B+Q3X0N/#%QIU
MVJ1II&DR32,]M$4=P6D8^:7!&"W !W%OKNB@#Y ^$7_!+7Q%X0\?^$+SXK_M
M/ZQXR\&_#G4/MO@7PC<Z8L"VLP8/$99!(WF",A< *,[0!M7*&3XL?\$N_$?Q
M&^)GBN?1_P!J'7-%^'OCW6X]6\8^"8+ 2-=3JXD98YVD_=HS_,!L(7@$.%7'
MUW10!YAJ'[/OB2/XX>"?B'X0^,&IZ)X2\(:!-IDWP\M%E^PZD#$\4+R8G"9B
M#(5W1N?W8Y'4?/MS_P $C-2>[G^%UG^T_K4'P;NO$8UF;X<KIB[M^X-]G%SY
MF1'D#!V]@=I<;Z^T:* &P00VT*6UO$L<<:A8T08"J!@ #L*=110!]R_\$>O^
M0%X]_P"OO3O_ $&XK[/KXP_X(]?\@+Q[_P!?>G?^@W%?9] !1110 4444 %%
M%% !1110 4444 %%%% 'B'Q4_P"1_P!1_P"NB?\ HM:YZNA^*G_(_P"H_P#7
M1/\ T6M<]0!^4_[5?_! 3X@>.?VW)O%/P!_:7\5>$?A?\6=1U[4?B9I.F6,4
MBZ--=VZ"\2!GF7Y=0!>$XC/EJN&\Q-J#W7]J[_@C9=^-_%?PV^+O[#'[36J_
M WQQ\,_ L/@K3-7L=+&H0WN@1(4BMIHVD3+IN<B0EMQ(RN51E^XZ* /@O_AP
MG\#O^'=<W[#Q^,.OMXBG\9#QK)\56MP;\^* NS^T/*\S[GEYB\KS-VTD^9YA
M,E:_[)G_  26^*WPC^(/C[]I/]I3]M;6OB9\8_%_@67PEH?CIM$%@OAK3V3"
MM;PQS9,HD$<F]6C.5;'S.[M]NT4 >2?LO_LY_$/X&_LDZ3^SC\5_VA]:^)?B
M"QTR^M-1^(/B&*8WFHFXGGD1Y%FN)W/EI*L8#3-E8A@J, 8/_!-/]B/_ (=X
M?LA>'OV4_P#A9O\ PF']@WE_/_;W]B_V?Y_VF[EN-OD>=-MV^9MSO.<9XS@>
M\T4 %=1\'?\ D?[3_KG+_P"BVKEZZCX._P#(_P!I_P!<Y?\ T6U 'M%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 5-?_Y 5[_UZ2?^@FOQ6K]J=?\ ^0%>_P#7I)_Z":_%:@ H
MHHH **** "BBB@ HHHH ^Y?^"/7_ " O'O\ U]Z=_P"@W%?9]?&'_!'K_D!>
M/?\ K[T[_P!!N*^SZ "BBB@ HHHH **** "BBB@ HHHH **** /$/BI_R/\
MJ/\ UT3_ -%K7/5T/Q4_Y'_4?^NB?^BUKGJ "BBB@ HHHH **** "NH^#O\
MR/\ :?\ 7.7_ -%M7+UU'P=_Y'^T_P"N<O\ Z+:@#VBBBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /$M4_:E^,MAJ=S
M86W[%OC>ZC@G>..YBN;;;,H8@.,MT(&1]:@_X:P^-G_1C_CO_P "K;_XJO=*
M* /"_P#AK#XV?]&/^.__  *MO_BJ/^&L/C9_T8_X[_\  JV_^*KW2B@#PO\
MX:P^-G_1C_CO_P "K;_XJC_AK#XV?]&/^.__  *MO_BJ]THH \%O_P!J;XV7
MUC-9?\,1^.U\Z%DW?:;8XR",XW5\5_\ #$GQL_Z)5X[_ /";MO\ Y-K]3J*
M/RQ_X8D^-G_1*O'?_A-VW_R;1_PQ)\;/^B5>._\ PF[;_P"3:_4ZB@#\L?\
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M_P#BJ]THH \+_P"&L/C9_P!&/^.__ JV_P#BJ/\ AK#XV?\ 1C_CO_P*MO\
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M%6W_ ,57NE% 'A?_  UA\;/^C'_'?_@5;?\ Q5'_  UA\;/^C'_'?_@5;?\
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M!7TM0 4444 %%%% !1110 4444 %%%% !1110 45\ ?$O]LW_@HU^VK^U/\
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M@\/^%O@I>VNCZYXH^+VGZG<OXIU^2TCNY+.TCLI(Q;6T22QQR2MN8NP*9&<
M'W=17R'\!?\ @KQ\$]>_X)I6W_!0O]JB.+X=0Z5<7NC^-="$C7;VNO6=Y+8S
M6-J$!:Y:2>(^2JY8K(N3PQ%C_@CO^WU\5/\ @HO\!?'OQK^+/PQ/@RZT7XR:
M[X:TOPM<VCPWNEV-F+?RK>]5V)^UH9'67 4!P0%&* /K2BBB@ HHHH ****
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MI\YO.\W[3]SRTV;/O-G@ SO^"L'_ "BS_:5_[(!XR_\ 3'>5\8?\$[?V0_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cah-20210930_g2.jpg
<TEXT>
begin 644 cah-20210930_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK\/Q9U6RBUKQ;K<^H726R66GLD(EF9F"*TCD+G +L>YK[RM?VN/V4;WXL/\
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M??\ P:H_&CX _"C3S>>+E^+]]K7A:Q# &\N[&'2+C[,N<#?+$DL29(&^122
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M0F6%Y)K6:+S(Y-NR3)78)/Z3M+TK3-$T^+2=&TZ"TM8$V06UK"L<<:^BJH
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M+_P4?\!_%3]F&Q_X)HV/P]U>T\1_"[0]5UZ_\0SS1FSO8+K67D6.-1\X=3>
M'=@?)QG/'[.50T3PKX7\,O<R^&_#=AI[7LQEO&L;-(C/(<Y=]H&YN3R<GFK]
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ',_%CXU
M_!KX"^%U\<?'/XM^&/!>BO=I:IK'BS7K?3K5IW#%8A+<.B%R$8A<Y(4\<&O-
MX_\ @IC_ ,$X)I%AA_X*!_!%W=@%5?BMHY))Z #[37P;_P 'DW_*)'2_^RPZ
M-_Z1ZA7A/[&/_!HE_P $[OVG/V'/A3^T1XC^._QITWQ-\0/A7H?B*_CLM<TA
MK"UOK[3H+F01PMIGF&%9)2 AE+;0 7)^:@#]Q_#'BGPQXVT"U\5^#/$=AJ^E
MWT7FV.I:7>)<6]PG3<DD9*N.#R"15^OP7_X,YOB1\3O /QT_:/\ V')O'C^(
M_ WA"\COM'NHI"UI%>QWL]G)/;C)"+=1HCD D'R%([D_:'[7/_!T?_P2M_8]
M_:"U']G#Q7XB\9^*]9T/4&L/$>I>!_#\-YI^E72-MEADFEN(C(\9!#B!9=K
MJ?F5E !^C%%?+GQO_P""PW[$OP3_ &%M%_X*.CQ=JWBWX3Z]?6UK::[X-TDW
M<D+3-)&#-#(T;P[98S"ZN Z2L$90<X]*TK]M?X :Q^Q2G_!0"T\3RCX;-\/6
M\9MJ+V^)TTU;0W3 Q9XF5 4,6<^8"G6@#UFBOEOX ?\ !8?]B;X__L/>(O\
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M ,([I O)/M A:8[U+IM7:AYR>: /HRBO"OVU_P#@H_\ LG?\$^OV=;?]IO\
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M'Y_?\'H?_**7PE_V732?_35K%>F?\&F;$_\ !%/P&">GB?Q"![?\3*:O,_\
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M!?L,^/W7ELAE3T=V-=!_P6F_X+[:O_P3S^,/AG]BS]D3X!'XL?'/Q9!#<0:
M4GFM]-CF8K;QM!:_OKJXF*L5@1D(3#EL,H;Y>_X+B_\ *SO^P_\ [OAG_P!2
M2\K'^#%UH/A7_@]6^('_  O"XACU#4M$D3P//J) #3R>'++[.L3-QN-H+B,8
MY)W+U.* /</^";O_  <9?M%^.OVVM,_X)W_\%8_V0H/@U\0?%!BB\):A96-Y
M8V]Q=2@F"WEM;V25U6<@I%.DKJTFV/;\VX;7_!1[_@XG^*G[ ?\ P5&/[#%A
M^RS!X\T>X\*6USH=MH!N6US5]9O+:3[%8Q*NY LEUY*%A&[!&8JKL I^=O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;Q)J'VZ>3[88%*Q?NW<I'M!(^15SWS0!UM%%% 'W+_P1Z_Y 7CW_ *^]._\
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M* "BBB@ HHHH **** "BBB@ HHHH J:__P @*]_Z])/_ $$U^*U?M3K_ /R
MKW_KTD_]!-?BM0 4444 %%%% !1110 4444 ?<O_  1Z_P"0%X]_Z^]._P#0
M;BOL^OC#_@CU_P @+Q[_ -?>G?\ H-Q7V?0 4444 %%%% !1110 4444 %%%
M% !1110!XA\5/^1_U'_KHG_HM:YZNA^*G_(_ZC_UT3_T6M<]0 4444 %%%%
M!1110 5U'P=_Y'^T_P"N<O\ Z+:N7KJ/@[_R/]I_USE_]%M0![11110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'B6J?M
M2_&6PU.YL+;]BWQO=1P3O''<Q7-MMF4,0'&6Z$#(^M0?\-8?&S_HQ_QW_P"!
M5M_\57NE% 'A?_#6'QL_Z,?\=_\ @5;?_%4?\-8?&S_HQ_QW_P"!5M_\57NE
M% 'A?_#6'QL_Z,?\=_\ @5;?_%4?\-8?&S_HQ_QW_P"!5M_\57NE% '@M_\
MM3?&R^L9K+_AB/QVOG0LF[[3;'&01G&ZOBO_ (8D^-G_ $2KQW_X3=M_\FU^
MIU% 'Y8_\,2?&S_HE7CO_P )NV_^3:/^&)/C9_T2KQW_ .$W;?\ R;7ZG44
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M4 >%_P##6'QL_P"C'_'?_@5;?_%4?\-8?&S_ *,?\=_^!5M_\57NE% 'A?\
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M_?JV_P#CM'_"7?&S_HTWQW_WZMO_ ([7UY10!\A_\)=\;/\ HTWQW_WZMO\
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M^'.FKX=^'VG^+O'7Q*^*>GW]U90QZB\@T_3[.VM7C9YI$A:5Y'8HJ$C < $
M^V**^:?^"9/[9OQ6_:T^'GCCPE^TAX"T3PW\5/A'\0KWP7\0[#PQ<RRZ5=7<
M$<4T=]8F4F06T\,\;JLA+J0P;H*^EJ "BBB@ HHHH **** "BBB@ HHHH **
M** "BO@#XE_MF_\ !1K]M7]J?X@_LU?\$K[?X=>%/!WP?U<:%\0_C)\2;&YO
MTN_$ C5YM)TRT@8!FMPRB:27@,<#;A#+V'["W[=/[59_:IU__@G#_P %)/ O
MA/2OBQIGA=?%'@OQAX!><:%XWT+SO(EFACN"9+>ZAD*K+"3SEF55106 /L^B
MO@;XN_\ !:;P_?\ _!4SX4?\$[/V8='C\1V5[XZU+0OC#XVDT^5[#2+VVTR\
MN%T6VG!5'OED@#S?>$2ILP79_+^^: "BOS#^$'[5?_!>[]LWXF?&^]_9,UK]
ME;2/!/PR^/GBGX?:7#\0=%\0#4YDTNZ"1RR&TE>)RT4D66&W+A_D48KN?VAO
MVTO^"FW_  3J^%/PF_:#_;HMO@[KW@V3XBMH?QZU#X:Z1JBQ:!I-\R0Z;JUM
M)=RAD2&=MMRKQON\R,1[2Q( /T#HKY2_X*+_ +;_ ,5_@OXH^$?[+O['&G>'
MM<^,/QK\5I;>'EUZVEN].T;0+8+/JFM7,<$L3/##!A4 D7>\@VEMI4^??$7]
MJO\ X*E?M,?M/_%+X-_\$Y-!^$'A_P +?!2]M='USQ1\7M/U.Y?Q3K\EI'=R
M6=I'921BVMHDECCDE;<Q=@4R,X /NZBOD/X"_P#!7CX)Z]_P32MO^"A?[5$<
M7PZATJXO='\:Z$)&NWM=>L[R6QFL;4("URTD\1\E5RQ61<GAB+'_  1W_;Z^
M*G_!1?X"^/?C7\6?AB?!EUHOQDUWPUI?A:YM'AO=+L;,6_E6]ZKL3]K0R.LN
M H#@@*,4 ?6E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ?+O\ P6RT+Q7XD_X)(_M$:3X+BFDO
MV^%&KR>7 "7>".!I)U ')S"L@QWSBO0?V+/B!\,+G]B'X,>*?#OB+3;70-6^
M'?AV+P_))=)''*);" 00ID@%SPH0<Y&,9XKUO4M-T[6=.N-(U>PANK2ZA>&Z
MM;F(/'-&P*LC*<AE()!!X(-?EW\<?^#>3X[:_P#"O6_V.?V=O^"BG_".?L[:
MWK#:CIWPO\;_  OM/$<_A"5IC,W]CZA+-'/;JKNYB&0T6XD.S,SL >B?\$ZM
M \*_%'_@J1_P42N#H=AK'@+6_%?@SP]>6%W;)/8WM];^''M]7MY(V!23+R*D
MJ,"#DAASBNE_9:M+33_^"ZW[4%A86L<$$'P=^'<<,,*!4C0?VH J@<     =
M*Z3_ ()(?\$_/C)_P32\&>./V</$GC_PWXQ\"7'B9_$'@_QBMG/#XEU6[O6D
M>_.M[F:*>9"END=Q&V9$X94V 'T_X9?L;_\ "N?V\/BE^VU_PL;[9_PLOPAX
M>T/_ (1G^Q_+_L[^R_M7[[[3YS>=YOVG[GEILV?>;/ !G?\ !6#_ )19_M*_
M]D \9?\ ICO*^,/^"=O[(?\ P6\O?V6_@7XTT#_@KWX7LO 4W@#PQ>V7@M_@
M3I<DMOI!L;:1-/-V?G9E@Q%YQ^8D;NM?H?\ M8? S_AJ#]EGXE_LT_\ "4?V
M'_PL3X?ZSX9_MK[#]I_L_P"WV,UK]H\G?'YOE^;OV;TW;<;ESD6/V9O@W_PS
MK^S?\/OV??\ A(_[8_X03P1I/A[^U_L?V?[=]BLXK;S_ "M[^5O\K=LWMMW8
MW-C) /FC_@O)\#[3Q]_P3X\3?M"^'-9;1/'WP!/_  LSX<>)8(MTMAJ6DJ;E
MHSR-T4\*20NA.T[U8@[ *ZO_ ((Y?L[Z7\!OV#/!WB:]UN36_&'Q4M4^(?Q'
M\4W,86?6M=UB-+RXF?'9!(D"#M'"G&<UZU^V/^SW_P -:?LG?$C]E_\ X2__
M (1__A87@C4_#W]N?V?]K^P?:[9X//\ )\R/S=F_=LWINQC<.M-\(_ CQ7\/
M/V.M+_9D\!_%0Z;KFA_#2#POHOC==(W&UNX=/6TAU$6OFC.UU6;R?-YQMW_Q
M4 ?&7[;_ ,0]>_X*_P#QOU7_ ()0_LS7$Q^%7AC6[7_AJ7XI6K$6\,<$R3CP
MII\HXEOIGC07#J=MO&"K;F+1U]$?\%"/V^/!W[ GPQT'PQX(\!3^,_BAXWN?
M[#^#GPHT, 76OZ@$ 48'^HLX 5>>=L)%'WRR@_*'[,G_  1+_P""KG[&_P (
M;+X$_LV?\%YX/#/A>PN;BYAL(_V4?#]S))//*TLTTUQ<W<DUQ*[L29)79L8&
M<* .T_:+_P""/W[>7Q/_ &[I?V]?@=_P5MA^'OB5? 5CX3TV*Z_9_P!+U]M/
MLXHXVNC"U[>>7";FZ$UPQBBC8";RMS*N2 >\?\$N/V+?&W[&G[/^JCXW^,;?
MQ'\5OB7XPOO&_P 6M>LU(MI]=OMGF06P/*VT$<<4$8X!$98*N_:/I.O%/V(_
M@=^V+\"O!&L:%^V7^W1_PO?6;W51/I.O?\*RT_PO_9MKY2J;;R+%W2;+AG\Q
MB&^;'05[70 4444 %%%% !1110 4444 %%%% !1110!\"?\ !OU?:?X>_9L^
M-_A?Q/>16_B+PU^U%X\B\<FY<(\=Y]N$IEE)Z PM$0YX*CK@5%^UWK.A^//^
M"\G[$2_#?5+:_N=*\ _$;6_$EQI\RR!M$NM,MK>RE9E)#1/=!MC="0<=:Z+]
MJ_\ X),?%CQ1^T'XI_:I_8#_ &P&^#/B?XCZ7'I_Q9\,ZOX)M?$7AKQE''$8
M8Y[BPN&58KD1,8VE7.]>"H+R,_EW_!+_ /X(;_'+_@EA^U-IOQC\%_M"^$_B
M1HGBKPW<Z)\1SX@\*R:7>^'[<37%[;Q>'8X)9(;>T>[>-9;1]J +YJ'($:@'
MH/\ P4-\(>$_!G_!0;]AVR\'^%].TF&]^-_BO4+R'3;*.!9[NX\/7\L]PX0
M-+)([.[G+.S%B2237W=7B/[3/[&__#1?[1'P)^/?_"QO['_X4IXOU'7/[)_L
M?[1_;/VK3)K'R?-\Y/L^WSO,W[9,[=NT9W#VZ@#\9/V _P!FW_@JS\7/B7^U
MEXG_ &)?^"D^@?"+PC'^VA\0[>Z\+ZG\([#79)K];Z-I+H7%Q\ZAD:%/+' \
MHG^(U^GUC^S5KOQ9_8PD_96_;?\ &UG\2[[Q#X1FT3Q]K]MHL6FQZP9D9))X
M[>+*6S ,"NS[C*&'(%8W["?[%'_#%-M\7K?_ (67_P )-_PM7X[^)/B1N_L;
M[%_9?]K21/\ 8/\ 72^?Y7EX\[Y-^[_5ICGW:@#\N?\ @W3_ &<O$[7WQ1_:
M'^/_ ,4KGQYXS^&7B:]^ W@C5KZV"'2_"_AR945(QDD/<S.))"22?)CY^]GZ
M0_X*4_M_>-?@=J6B?L:?L;>&8?&/[2'Q/LY%\$>'CS:^';+)CE\0ZJV"(+*W
M.X@,,S2)Y:@X8KW_ .P/^Q/_ ,,/>%/B/X8_X69_PD__  L#XR^(O'OG_P!C
M?8OL']JSK-]BV^=+YOE;<>;E-^<[%Z5\M>*/^"-?_!1+1_VT_BW^V=^S9_P6
M3A^'NJ?%C5(GOK.;]G/2==GL=-MP4LM.2ZO[QV$4,6U3Y:Q+(R[V3., 'U'^
MPS^P/\+_ -C;]C[P'^RM>QV_C%_",IU6^U_7;%)I;_7I;B2[N=3 DW&.0W,T
MKH<EHU*J&.W->-_\$0?^1=_:G_[/=^)7_IPCKZ1_9(^%W[1OP>^"]IX(_:J_
M:F_X7)XPAO;B6Z\<_P#"#V?A[[1"[YBA^Q6;-$GEK\NX'+=37._L0?L;_P##
M&NG?%.P_X6-_PD?_  LOXW^)?B'O_L?['_9O]K7"S?8<>=)YWE;=OG?)OSGR
MTZ4 >W4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cah-20210930_g3.jpg
<TEXT>
begin 644 cah-20210930_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$/5_%%AX#\(:A8>&M4UVX\VZ71Y-$M[FPMY'  8PVL\,/ 5?W>%55 4>P_\
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MY8VE7-R9%?8R_(%(P>:^L_\ @H__ ,%;?V)_^"6'@_3/$G[5?Q NH=1UTO\
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M]/$F5B(^;.=H) !\R_\ !8[X-_"_X#?\'-7[&'B#X,^ M(\+R>)=5\*'6H=
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MFOZ#HOBK0KWPQXCTR&]T[4K22UO[.Y0-'/#(I1XV!ZJRD@CN#7R)_P $9O\
M@G%\6?\ @EO\(O'_ .S-XE^)>D>)? <WQ(OM;^%K6LDYOM.TNY"C[)=B1%0.
MIC1\QLP9Y93D<"OL:B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^+
MO^"7?_!,7X@?L@?'S]H#]L']I#QQH/B7XF?'+QY+J#77A_SFMM(T1'9[6PC:
M=$<E3(5;C!6" <E<U]HT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45P_BKXR_\
M",Z_<Z'_ ,(WY_V=E'F_;-N[*@]-AQU]:S_^&@_^I1_\G_\ [70!Z117F_\
MPT'_ -2C_P"3_P#]KH_X:#_ZE'_R?_\ M= 'I%%>;_\ #0?_ %*/_D__ /:Z
M/^&@_P#J4?\ R?\ _M= 'I%%>;_\-!_]2C_Y/_\ VNC_ (:#_P"I1_\ )_\
M^UT >D45YO\ \-!_]2C_ .3_ /\ :ZU/!WQ?_P"$LU^'0_\ A'OL_FJQ\W[7
MOQM4GIL'IZT =I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% %37_P#D!7O_ %Z2?^@FOQ6K]J=?
M_P"0%>_]>DG_ *":_%:@ HHHH **** "BBB@ HHHH ^Y?^"/7_("\>_]?>G?
M^@W%?9]?&'_!'K_D!>/?^OO3O_0;BOL^@ HHHH **** "BBB@ HHHH ****
M"BBB@#Q#XJ?\C_J/_71/_1:USU=#\5/^1_U'_KHG_HM:YZ@ HHHH **** "B
MBB@ KJ/@[_R/]I_USE_]%M7+UU'P=_Y'^T_ZYR_^BVH ]HHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M16+\1OB#X4^%'@/5_B5XXU,6>D:'I\MYJ%P5)*QHI)P!RS'H%')) ')KY_\
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M^N<O_HMJY>NH^#O_ "/]I_USE_\ 1;4 >T4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4U_P#Y
M 5[_ ->DG_H)K\5J_:G7_P#D!7O_ %Z2?^@FOQ6H *\3_;R^ ]G^T1\'+'P3
M9_$VR\)^(['Q-9ZIX+U6_N B#58=ZPI@G+%A(ZC:"P)!"MC:?;*\J_; _98T
M+]K7X51^ ;_Q3=Z!J>FZK#JOAWQ!8Q[I=.O8MP20+N4L,.P(#*>0000#0!\V
M?\$T_CS\2_%VDR_L0_'[P;;6BW/@>[U3PWX@TJ3:VHZ>]U);3%QD@/YKR;6
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MMP1ZEJ$$88R2P6S.)944(Y9E4@!&R1@USWQ[_92^ 7[3M]X/U+XX^ O[<F\
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MK&:R_P"&(_':^="R;OM-L<9!&<;J^*_^&)/C9_T2KQW_ .$W;?\ R;7ZG44
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M%6W_ ,57NE% 'A?_  UA\;/^C'_'?_@5;?\ Q5'_  UA\;/^C'_'?_@5;?\
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M_P"._P#P*MO_ (JC_AK#XV?]&/\ CO\ \"K;_P"*KW2B@#PO_AK#XV?]&/\
MCO\ \"K;_P"*H_X:P^-G_1C_ ([_ / JV_\ BJ]THH \^^#/QC\>_$W4[VQ\
M7_ 'Q#X.CM8%DAN=:FB9;ABV"B[">0.>:]!HHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK'^(7CWPC\*O .N?%#Q_K
M<6FZ#X;T>YU36]1GSLM;2WB:6:5L<X5$9C["OSM^%/[1'_!>G]O_ , 1_MC?
MLF:=\#OA1\-=:1KWX8>!_B?I6H7VL>)-,R3!=ZA/;.%LUN%VNBP\A7&2PQ(X
M!^E5%?,'[ W_  4E\.?M2_LR>,/BS\?/"L'PM\6_"#5]3T3XW^&M6U!6@\,W
M^G1^;<S"<X#VC0XG2;[NW<-S;"Q\X_X)H_\ !7*\_P""DW[:'QG\ _#WP+<:
M9\*?!'AC0+SX?ZUJ^D3VE]XD6[FODFU,+*01:2FW40#8&*1[V(+E$ /N:BO+
MOVXOC/XL_9P_8J^,'[0_@*UL9]=\!?"[Q!XBT6#4X6DMI+NQTV>YA6549&:,
MO$H8*RDKD!@>:^)O@1X[_P"#F+]H'X'^#/CUX3\;?L66FE>-_"FG:_IEIJ.B
M^*5N(;>\MH[B-)0CLH<+( P5F&0<$CF@#]*J*^./!_[<G[1OPA_X*>Z=^PC^
MV3IGA&+0/B;\/H=9^#/BWPU8W%NEYK%E$O\ ;6D3M-*XED4DW$)58\0[ VYW
MXNW?[?/Q,\=_\%*?$W[-?P=L-#/PH^!W@-]8^/?B^\T^:XN5U:YB:6PT>Q:.
M5425(4:YF9DE^7]WB-\$@'UU17Y:ZC_P4X_X*\Z%^R='_P %;M=^"GP?@^ 1
M\O6I_A,1J(\90^$WN!&+\WQE%H;WRF$_D^7Y?EG'W^*]R_:#_;&_;G^-_P"U
MRW['/_!-#2OASIJ^'?A]I_B[QU\2OBGI]_=64,>HO(-/T^SMK5XV>:1(6E>1
MV**A(P' ! /MBBOFG_@F3^V;\5OVM/AYXX\)?M(> M$\-_%3X1_$*]\%_$.P
M\,7,LNE75W!'%-'?6)E)D%M/#/&ZK(2ZD,&Z"OI:@ HHHH **** "BBB@ HH
MHH **** "BBB@ HKX ^)?[9O_!1K]M7]J?X@_LU?\$K[?X=>%/!WP?U<:%\0
M_C)\2;&YOTN_$ C5YM)TRT@8!FMPRB:27@,<#;A#+V'["W[=/[59_:IU_P#X
M)P_\%)/ OA/2OBQIGA=?%'@OQAX!><:%XWT+SO(EFACN"9+>ZAD*K+"3SEF5
M5106 /L^BO@;XN_\%IO#]_\ \%3/A1_P3L_9AT>/Q'97OCK4M"^,/C:33Y7L
M-(O;;3+RX71;:<%4>^62 /-]X1*FS!=G\O[YH **_,/X0?M5_P#!>[]LWXF?
M&^]_9,UK]E;2/!/PR^/GBGX?:7#\0=%\0#4YDTNZ"1RR&TE>)RT4D66&W+A_
MD48KN?VAOVTO^"FW_!.KX4_";]H/]NBV^#NO>#9/B*VA_'K4/AKI&J+%H&DW
MS)#INK6TEW*&1(9VVW*O&^[S(Q'M+$@ _0.BOE+_ (*+_MO_ !7^"_BCX1_L
MN_L<:=X>USXP_&OQ6EMX>77K:6[T[1M M@L^J:U<QP2Q,\,,&%0"1=[R#:6V
ME3Y]\1?VJ_\ @J5^TQ^T_P#%+X-_\$Y-!^$'A_PM\%+VUT?7/%'Q>T_4[E_%
M.OR6D=W)9VD=E)&+:VB26..25MS%V!3(S@ ^[J*^0_@+_P %>/@GKW_!-*V_
MX*%_M41Q?#J'2KB]T?QKH0D:[>UUZSO);&:QM0@+7+23Q'R57+%9%R>&(L?\
M$=_V^OBI_P %%_@+X]^-?Q9^&)\&76B_&37?#6E^%KFT>&]TNQLQ;^5;WJNQ
M/VM#(ZRX"@." HQ0!]:4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!\N_\ !;+0O%?B3_@DC^T1
MI/@N*:2_;X4:O)Y< )=X(X&DG4 <G,*R#'?.*]!_8L^('PPN?V(?@QXI\.^(
MM-M= U;X=^'8O#\DETD<<HEL(!!"F2 7/"A!SD8QGBO6]2TW3M9TZXTC5["&
MZM+J%X;JUN8@\<T; JR,IR&4@D$'@@U^7?QQ_P"#>3X[:_\ "O6_V.?V=O\
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M_P %#?"'A/P9_P %!OV';+P?X7T[28;WXW^*]0O(=-LHX%GN[CP]?RSW#A
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M9?\ :TD3_8/]=+Y_E>7CSODW[O\ 5ICGW:@#\N?^#=/]G+Q.U]\4?VA_C_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cah-20210930_g4.jpg
<TEXT>
begin 644 cah-20210930_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#/\6>*O#O@7PKJ?C?Q=JT-AI.C:?-?:I?7#8CMK>%
M#))(Q[*J*S'V%?SKV/[0_P#P6T_X.7/VG/&Y_8>^/&I_!?X&^#=0^SV4T/B.
M[T:V2)BWD+=2V*M<7U[*B>:T7,,/ ^3*M)^S?_!:;4->TS_@DI^T9=^&WD6Y
M_P"%/ZZC-%G(A>SD28\?],F?/M7R'_P9RV/AFV_X)%W5UH<<0N[GXL:R^LL@
M&XW @LE7=[^2(?PQ0!\5?"S]HG_@M%_P;Z_\%$_AO^SO^W#\<=;^,7PH^)5_
M'"K2:W>Z[!<69F2*XN+![M?M-M<VAE222W ".' (8.DB_P!!OB;XN?"CP5XI
MTOP/XR^)WA[2-:UR14T71]3UJ"WNM08L$"P1.X>4EB% 4'DXZU^#/BW_ (/.
MOVD/ [6VI>.O^"5%MHYEWQVEQJWC"\MR_P!TNJ-)IXST4D#T&>U5?^#K_1_'
M'Q;_ ."B/[(GACX<>(9M \0^+=$BL-&U2UE826%U>:I#%'*K*0P*-*"""#QD
M$&@#]X_A?\?_ (#_ !PGU6U^"WQL\(^+Y="N_LNMQ^%_$EKJ#:?/DCRIQ!(W
MDOE6&U\'Y3QQ6*W[8_[(B?%/_A1;_M4?#<>-OM/V;_A#CXXT_P#M7SLX\O[)
MYWG;\_P[<U^/W_!0#]CCX>?\&RG_  27^*NM?L1?%?QA=^,/CMXGT'PDWB[7
MY[<7VE*MM>RS-;/;11>7F%+W8<;XVG4AV9%:O(K+_@U<^"=W_P $6U_;';XN
M>+/^%XR_"W_A8:/]LB_LKFR_M :88?+WY\G]WYWFY\_Y_N?NZ /Z([FYMK*V
MDO+RX2*&)"\LLKA510,EB3P !SFO,_ /[;G[&'Q6\<_\*Q^%W[77PP\2^)=[
M)_PCV@>/M.O+[<H)(\B&9I,@ Y&WC%?@Y\3?V\?VQ_VV_P#@THOO$EEXAUO5
MM=\"?$ZW\$_%/7K>61[O4/#UO%'<)-<./G9<7>FPS.2?,".TA(9Z^??V>?A9
M_P &[7[77P[^&7@GX?\ [2OQ&_91^-FD7^GR:YXT\9+-J>GZG=QQCS6@N8[A
M(+-C.%DCN'-J(\$&-OEP ?U1>,/&?@_X>>&KSQIX_P#%>FZ'H^GQ>;?ZMK%_
M';6ULF<;I)9"$09(Y) YKD?@W^UE^RQ^T7>W6F_L^?M+_#_QW<6*%KZW\&^,
MK'5'MU#;276VE<H-W&3CGBOQG_X.^KKXK>%/AE^RMIGQ)U7Q)XO^#=IK<W_"
MSKS0IUM#KU]$ECY;R.H:*&>:V%^T!(959YB 0M>4_P#!.7X(?\$(_P!H?]O[
MX.?&_P#X)C_MM^./V=_&_AK4HYKCX5>/-,EN+GQ/.)$Q:P7TUTT \Z,S6\L"
MRS-,D@"1H0VX _HNK^9O_@Y@_P""@7_!0?X#?\%;/&?PM_9S_;#^*7A'PWIO
MA+1;Q- \*>-KZRM(-UC&\LHAAE51EB68@>I/>OZ9*_G-_P""KOP(_P"&G/\
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MO6U^34HELA;%=PF\\MY?EXYWYQCG-?S>?M-?\$_O^"&_[*.J?&F\_P""F_\
MP5,U?XT?'37M8O[C3)?A]9SB]L+YD+-]KA@-S EU]H+ATN)U1455"J<UV/\
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MK!<!EVC!+%3GL>M?TY?&'_DD?BG_ +%R^_\ 2=Z_D]_X(X?MU_\ !8']A_\
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M/PE\"X[WQ!X.NK75K9;Z>ZT[6-*B@6ZD-L4DC*W,F\(D9)"X*X.0#^D_XO\
MQ\^!?[/F@1>*_CY\:?"7@?2YYO)@U+Q?XCM=,MY),9V+)<R(I;'8'-:W@?Q[
MX&^)WA6S\=?#7QII/B'1-1C\S3]9T/48KNUN4R1NCEB9D<9!&03TK^:?]J/X
MV_L._P#!1?\ X+[?&2W_ ."O?[3.I>#O@W\([G5/"_@?0[26Z"7-QI]XED;=
M&MX96B661+J[D< ,Q")N"@ >U_\ !MW^T'\)_P!G/_@LA\8/^">?[(/[0%_\
M0?V?/%VB3ZY\/[^\,H"7L$5K/O"RQQE9%AEN;:5Q&GFM:Q-C"K0!_0'1110
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ME;>9(L<?F3SLJ)ND=$&2,LR@<D"OY$O^"Z7AWQE=_P#!9_\ ::^(G@N=X)O
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M^"Q/Q8?PKIO@_6+._LM+NKZRN-0DAM[A;A+2RLK$FUL(F=,.[E7R=QCE))H
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M\%VVJ>%O&FGZ1!%J<MW;O%YDLMTJ^9.;H%UD#LP8RAL;D0K\3^,/V1_VV/\
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M?&[XAXD71ECM'DFO8IIUE=IK:)!-!&UYYJ;$_=%F*GZA_P""2/\ P1(_;<\
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M+_\ [8?P1^%L*P^&_"=GXBTG0K99"XM[2#Q+;QQ0[B26,:J$R>3MKF/V?/\
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M.MS>;[EPEQ/=,('N"2S -N(C4 _>"BBB@ HHHH **** "BBB@ HHHH ****
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M%:V\;,BM(V&/S,JJJ,S, I->._\ !(__ (+7?L]?\%AK+QS/\"?A3XX\-/X
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M[>34K#7EA":SI\X4QW]F8Y&+0[9+=CO"L!=1<')Q]&T %%%% !1110 4444
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MP1QV;E2&/ERS,) N&"PR=,9KY"_X),?\$BM=/_!#7X]?L&^+OVE/A#\5=/\
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MO#@C_P#'P<?0U^VE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKM[9S0_8+=K2TMH["/SIYF:*,6NY3E0/-*A %R?JRB@#Y\_X*7_\$V_V?_\
M@J5^S+>_LU_'Z&[MHA>)J'AWQ%I>T7FB:@BLJ7,6X%6&UW1XV&'1V'!VLOYA
M_![_ (,[]:N?B)X;TW]LC_@H[XE^(_PM\&7 .A>!+/2KFT\R $$VZM->3)81
M-M <0*69<A70X8?M_10!\;?\%AO^"0^A?\%4OV-O"G['?A?XPVWPKTSPEXRL
M-:TZ\L_"(U.%(+2PO+*.R2W%S;"-0MV"&#D*(@NT[LK]0_!'X;_\*;^"_A#X
M0_VS_:7_  BOA?3]'_M'[/Y/VK[-;1P>;Y>YMF[9NV[FQG&3C-=110!\5_\
M!;;_ ((__P##XWX'>$/@S_PT/_PKG_A%/%;:U_:7_")?VO\ :LVTL'D^7]KM
MMG^LW;MS=,8YR/J/1?@MX4_X4!:?L[>/+.V\1:&/!\?AW68+RUVPZG:_91;2
MJ\>YL+(FX%<G 8C)ZUV-% 'YQ?\ !)C_ (-_KK_@E1\6_B=>^'_VOSX[^%?Q
M.TJ:PU3X7:WX!$(2,2O]E=[O[=(LSQP2SP.?(43+,Q*IA0/F7XB_\&B'Q*T#
MQ3XM\!_L=_\ !4;QA\.O@UX]O?,\2?#F:PNYT:#)(MYA#?0Q:BJ#Y4,Z*P7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !17S#\=_\ DK.L?]=8_P#T4E<C0!]F
M45\9T4 ?9E%?&=% 'V917QG10!]F45\9UW'[.G_)6=/_ .N4_P#Z*:@#Z4HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"'4;O\ L_3Y[_R]_D0M)LSC=M!.,]NE?!?_  _%_P"K
M8/\ R]?_ +BK[N\1_P#(O7__ %Y2_P#H!K\%Z /OK_A^+_U;!_Y>O_W%1_P_
M%_ZM@_\ +U_^XJ^!:* /OK_A^+_U;!_Y>O\ ]Q4?\/Q?^K8/_+U_^XJ^!:*
M/OK_ (?B_P#5L'_EZ_\ W%1_P_%_ZM@_\O7_ .XJ^!:* /OK_A^+_P!6P?\
MEZ__ '%1_P /Q?\ JV#_ ,O7_P"XJ^!:* /U]_8@_;7_ .&RM/\ $=__ ,*S
M_P"$;_X1^:UCV?VS]L\_SA*<Y\F/;CR_?.>V.?=Z^$O^"(/_ "+WQ&_Z_=,_
M] N:^[: "BBB@ HHHH **** "BBB@ HHHH **** /F'X[_\ )6=8_P"NL?\
MZ*2N1KKOCO\ \E9UC_KK'_Z*2N1H **** "BBB@ HHHH *[C]G3_ )*SI_\
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MNE:LRVTB)#>1!3)$&=0LA7< 2A8 \9R"*W: /T'_ ."(/_(O?$;_ *_=,_\
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M_P#0+FONV@ HHHH **** "BBB@ HHHH **** "BBB@#YA^.__)6=8_ZZQ_\
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MG$U[$G1)2@+@>P;->B?LZ?\ )6=/_P"N4_\ Z*:N'KN/V=/^2LZ?_P!<I_\
MT4U 'TI1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% %/Q'_R+U__ ->4O_H!K\%Z_>CQ'_R+U_\
M]>4O_H!K\%Z "BBB@ HHHH **** "BBB@#]!_P#@B#_R+WQ&_P"OW3/_ $"Y
MK[MKX2_X(@_\B]\1O^OW3/\ T"YK[MH **** "BBB@ HHHH **** "BBB@ H
MHHH ^8?CO_R5G6/^NL?_ **2N1KKOCO_ ,E9UC_KK'_Z*2N1H **** "BBB@
M HHHH *[C]G3_DK.G_\ 7*?_ -%-7#UW'[.G_)6=/_ZY3_\ HIJ /I2BBB@
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M]&/^._\ P*MO_BJ]THH \+_X:P^-G_1C_CO_ ,"K;_XJC_AK#XV?]&/^._\
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M.L_!GQ;X:L;BW2\UBRB7^VM(G::5Q+(I)N(2JQXAV!MSOQ=N_P!OGXF>._\
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MMXP5;<Q:.OHC_@H1^WQX._8$^&.@^&/!'@*?QG\4/&]S_8?P<^%&A@"ZU_4
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MI?/\KR\>=\F_=_JTQS[M0!^7/_!NG^SEXG:^^*/[0_Q_^*5SX\\9_#+Q->_
M;P1JU];!#I?A?PY,J*D8R2'N9G$DA))/DQ\_>S](?\%*?V_O&OP.U+1/V-/V
M-O#,/C']I#XGV<B^"/#QYM?#MEDQR^(=5;!$%E;G<0&&9I$\M0<,5[_]@?\
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M_P#A9?QO\2_$/?\ V/\ 8_[-_M:X6;[#CSI/.\K;M\[Y-^<^6G2@#VZBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>cah-20210930_g5.jpg
<TEXT>
begin 644 cah-20210930_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *_!#_@XH^-W_!176O\ @MK\(_V(/V)OVS?&
M7PV/Q#^'FAVMA9:;XXU'2M*&HW.JZI#]IN%L]Q&5CC5G6-VVQJ,' %?O?7\Y
MG_!R_P#&WQ[^S;_P<-_ CX]_"WX>/XM\1^$?AQX=U/1?#,<4KMJ=Q%K6KLD
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M7Z9\5+K5KOPHCZNLD*3:;(@CL3%!F A"=C'8.*^S?C%^U/\ LQ?L[W5E8_M
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M\2WME;(6/)"06\2#V05^OO\ P1B_Y1+_ +.'_9&/#W_I!%0!],4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %?@[_ ,%A_P#E;1_9%_[ ?A+_ -/N
MKU^\5% !7X9_\'P'_) /@'_V.6L_^DEO7[F44 ?DQ_P>8_\ *)C0?^RT:/\
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M@#\3/^"_O_*K_P# S_L'?#W_ -,QKYK_ ."Z/A3XCV?_  3@_P"";?QN\6>
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MVD?*P8?T>U0;PIX7?Q"OBY_#=@=52'R4U,V:?:%CY^028W!>3QG')H _#?\
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MWJO[1NH>%M5?XC^/K+PG:S+;:/;W+WEWJ<U_N:Y6..R3RA"51$8$ ]!)_5F
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M,_V[_@S\1[O5_!_P[T6[U'QKIBZ<8]7TA;:!KAXI;5R#O,:,4(8QR8.US@X
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M8L)&I4$N<9))_H;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%Y,?AB71X+NWFLIF@>:W6X6XFF6YBF"-&LT)0"0@%2-VSR_Q7I.GZK_P>\Z
M=0M4E%KX5\^%9%R!(O@N?:V#W!.1Z$ ]JE_X+'P0P?\ !U[^QK<PQA7E\-^&
M1(RC!;&OZR.?PX^E '[GU^-?Q:_X.5_VO/#G[?WQF_X)[_ O]@^S^)'C3PSX
MANM$^%VF^'Y;DRW\T$I,MUJ!W$)!' KNP39D[07C7<X_92OPL_X([:98WG_!
MV'^V+?75LDDMGX=\3O;,RY,;-KNCJ6'H=I89]&/K0!+\ /\ @ZK_ &X/&5YX
MP_9#^('_  38;6/VH;3Q =(\&^"/",%U;V4L\?F_:Q?PSRRS0?95B+L5D*R
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M13ZKXCDLMW_/+^W+U3CVWK)7Z*4 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/BI_R/\ J/\ UT3_ -%K7/5T/Q4_Y'_4?^NB?^BUKGJ "BBB@ HHHH ****
M"NH^#O\ R/\ :?\ 7.7_ -%M7+UU'P=_Y'^T_P"N<O\ Z+:@#VBBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD>*/@BB?"PKIMVDNM6FF>'=4%_<DO"OER#S#(YDV%FD)4'MZ)XZ2UM?V"?\
M@E_<>&%4:BOQDT#[%Y7WM[7B&4#'K)MS[U^@/[-__!'G]GC]G_\ :-^-_P ;
MFT3PKJ>D?%VVM;/2?"EGX%M[!/"=DMK<6UY;6T\<C?)=)/\ O!&D(^0 A^H\
MF_93_P"""FI_ 7X^> O%_P 4/VSO$/C_ .&_P:U2^U'X/?#G4=%2!=&N;F3S
M/,GN%E;SC&^'&U$RZ*PV+F-@##_X*X?%#PBEYJ?_  25_P""?/P5\-O\9/VA
M)S<_$2XT+2(;6#2=.F(:YU/4Y(4&Z>6,-EWRXC9G.6:$2???[-WP5T;]F_\
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MC_CO_P "K;_XJO=** /"_P#AK#XV?]&/^.__  *MO_BJ/^&L/C9_T8_X[_\
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MH _+'_AB3XV?]$J\=_\ A-VW_P FT?\ #$GQL_Z)5X[_ /";MO\ Y-K]3J*
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M"K;_ .*KW2B@#Y3\5?$OXV>)M?N=<_X9#\=P?:&4^5MMFVX4#KYHST]*S_\
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MMC/KO@+X7>(/$6BP:G"TEM)=V.FSW,*RJC(S1EXE#!64E<@,#S7Q-\"/'?\
MP<Q?M _ _P &?'KPGXV_8LM-*\;^%-.U_3+34=%\4K<0V]Y;1W$:2A'90X60
M!@K,,@X)'- 'Z545\<>#_P!N3]HWX0_\%/=._81_;)TSPC%H'Q-^'T.L_!GQ
M;X:L;BW2\UBRB7^VM(G::5Q+(I)N(2JQXAV!MSOQ=N_V^?B9X[_X*4^)OV:_
M@[8:&?A1\#O ;ZQ\>_%]YI\UQ<KJUS$TMAH]BT<JHDJ0HUS,S)+\O[O$;X)
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MS_8_E_V=_9?VK]]]I\YO.\W[3]SRTV;/O-G@ SO^"L'_ "BS_:5_[(!XR_\
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MG\,O$U[\!O!&K7UL$.E^%_#DRHJ1C)(>YF<22$DD^3'S][/TA_P4I_;^\:_
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M7CG_ (0>S\/?:(7?,4/V*S9HD\M?EW Y;J:YW]B#]C?_ (8UT[XIV'_"QO\
MA(_^%E_&_P 2_$/?_8_V/^S?[6N%F^PX\Z3SO*V[?.^3?G/EITH ]NHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>cah-20210930_g6.jpg
<TEXT>
begin 644 cah-20210930_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK\/Q9U6RBUKQ;K<^H726R66GLD(EF9F"*TCD+G +L>YK[RM?VN/V4;WXL/\
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M??\ P:H_&CX _"C3S>>+E^+]]K7A:Q# &\N[&'2+C[,N<#?+$DL29(&^122
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M0F6%Y)K6:+S(Y-NR3)78)/Z3M+TK3-$T^+2=&TZ"TM8$V06UK"L<<:^BJH
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M+_P4?\!_%3]F&Q_X)HV/P]U>T\1_"[0]5UZ_\0SS1FSO8+K67D6.-1\X=3>
M'=@?)QG/'[.50T3PKX7\,O<R^&_#=AI[7LQEO&L;-(C/(<Y=]H&YN3R<GFK]
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]V);=]DA*0S2J%)Z'?DCL* /<**** "BBB@ HHKYR_;K_P""EWP=_P"">_Q
M^$/A;XZ>$==_L3XN>,3X:M?&-BL)T_0KYO+\G[:7D5TCD\QB&0-M6&1FP%Y
M/HVBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=>&?L5:!I%C_ ,&=>MV=O8QK')^SIX^NI%"#YIFDU>4N?4[^<^PKYX_X)@?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#\;_V\?#$G[$W_  =.?LW?MAWL9M_"GQVT
M"3P?JMXPPLFKBWDTY(RW0<SZ0PSUVMZ9KZJ_:^_X(O\ _#5G_!6GX.?\%1_^
M&DO[!_X5-HVFV'_"#?\ "'?:O[5^R7U_=[_MOVR/R-_VW9CR)-OE9R=V%]S_
M &]O^">?[/O_  48^&V@_#CX]?VW9_\ "+>*K7Q'X9U[PQJ"6FHZ7J$ 8))#
M,T<@ (<AE*D'"GJJD>Y(I5 K.6(&"QQD^_% 'PU>_P#!%_[9_P %O+3_ (+)
M?\-);?LNC&P_X5Q_PAV=V=%?2]_]H?;./O\ FX^S]MF?XJ/VRO\ @B]_PUO_
M ,%6_@Q_P4Z_X:3_ .$?_P"%1:;IEI_PA'_"'?:_[6^R:A>7F[[9]LC\C?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\0^*G_(_P"H_P#71/\
MT6M<]0!](45\WT4 ?2%%?-]% 'TA17S?10!](45\WUU'P=_Y'^T_ZYR_^BVH
M ]HHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4@%2"" 016?\,?C;\+/C-;ZU>?#'QC;ZO#X>UJ;2=7F@CD5(+R(*9(PSJ X
M93O3*G/!- 'Z"?\ #XO_ *MT_P#+N_\ N2C_ (?%_P#5NG_EW?\ W)7YJ^ /
MVU/V5/BG\1'^$_P]^.6A:KX@5G6/3[:=OWY0$L(G("3$ $_(S< GH#4OC_\
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MUW2/VMO&7BWX\?%7XD16'Q>T2;Q3+?Z;K&ERSQK>3*DD:2^3&DC 23 DLIE
M5HL"[_P6C_9H\9? SQ+XQ_; ^+/[<7C1_C1XO\;VD'[*_@KP+>W44=O:PW5M
M&]F8%C8>8L4ZEF1T5I"&^=I2A\U_X)4_\%2/V3/'_P"W?<_M:_MP77C#Q)\?
M?B1XH@\,^ ;33]"CET7P=I]U,MM!!;.\X9"?-*,X0E8RYRSS2EO7O^"L7_!2
M;X2?$WP;\=OV"?VR?V-)K?XM:9?3:3\!#9: ^IRZQ!=21BUU*TN6C#6[,T<4
MKI']\*L7SLK* #O_ -N/P_\ %K]O?_@H=\ /^"9/QY^)WB/PIX?;X*MXW^*%
MIX(U1;26^U@I/#Y>\*Z%8I[;*@JR@2O@9(9?8O\ @WW^.'Q2^)?[(?BWX1_&
M/QO?>(]8^$'Q4U?P9;ZWJ<S2W%U8VPA> R.Q+,5\V2,9)(2-!GBOEOXB>(/'
M?_!,#]K_ /9*_;D_;>T_7WT%?V:X/ /Q!UZULGOIM-UJ&">81W!3):1C/&F2
M27,4K MM8U]*?\&['PV\;Z)^R%XV^/7CGPK>Z,WQB^+NL^,-$L=0B,<HTR=8
M4@=E/(W-'*RGHR,C#(8$@'W[74?!W_D?[3_KG+_Z+:N7KJ/@[_R/]I_USE_]
M%M0![11110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% %37_P#D!7O_ %Z2?^@FOQ6K]J=?_P"0%>_]
M>DG_ *":_%:@ K\__P#@KS\.OB%X:^*NC?M,0?#,^*O",/A&/0M6V1>8VBS#
M41<"Z"D';YBL(=V,8W*2NY<_H!7QA_P5(T']K3PY*OQ.^$U]_;O@&ZT>VT[Q
M1X4N+](EM+E;^*6&\C#$9+N(8B1N*C=QAB0 =%\(_"?PL_:3_8M?PQ_P3Z\<
MWGPWT36O$C_V]+ME>\TXMM:\MT5Y'\J1E,>T1NJ!6!4@'!X[_@E1\)="O_V;
M_C5\"EU?4K;3)?B3K6A?;K6=5NX[<VD%OYBN5*B3;R&VX#<X[5[1^P'\ _B-
M\$?AQXEUOXOV.GV'B?QYXVO_ !-JVC:5('M]+:XV8MD925;:$R2I(^; )VY/
M&?LG_!S]I3]G;X)?&V6'X;K_ ,)9K?CS6]9\#Z;)JEHZWPFAC%M(SB4I&I=<
ME9&4X4Y R* /'?BE\"O@;X1_:=^ W['O[+'AJ*;Q3X#\20Z[XP\30V\7VRVT
M^)TF<7D\2*'DD'.UL 9B4 "0"M+_ (*?_ /X9_"#X5>+-;\(_ N[UO4_BAKH
MOO$_Q"U&![N/PBL5Q;MYV](GDAB;S&4(A' ;[P4(<K]B/X7?\%+?V:O%LPUK
M]D70+Z7Q?XGBN?''CC5_%-E/J3V[S#S6S'>\A%:1PH4DL22&.!78_M&>"_\
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MZ,?\=_\ @5;?_%5[I10!X7_PUA\;/^C'_'?_ (%6W_Q5'_#6'QL_Z,?\=_\
M@5;?_%5[I10!\I^*OB7\;/$VOW.N?\,A^.X/M#*?*VVS;<*!U\T9Z>E9_P#P
MEWQL_P"C3?'?_?JV_P#CM?7E% 'R'_PEWQL_Z--\=_\ ?JV_^.T?\)=\;/\
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M#/QC\>_$W4[VQ\7_  !\0^#H[6!9(;G6IHF6X8M@HNPGD#GFO0:** "BBB@
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=%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>cah-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cah="http://www.cardinal.com/20210930"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cah-20210930.xsd" xlink:type="simple"/>
    <context id="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i69b6e01c61e147bea8030d462af3a3bc_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id9d0f0b222df4670b2ba4b4e53c27817_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibf64c21f338848a589b8d482d67160ff_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia948c3e5ec6f4bec8e7f879a025a4df5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i08d940f3e6e149168d29549187b0c935_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iac6fdb45d09c424594b1a7bb495c5d01_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i695097f71a9b487091fa06cabd23f062_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2e1d62562ca244c38872c9cd9f2d56d4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie839ddea5fe24b80978766903acfb01d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia86d33171aed42cebf549309afad5112_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2352ec975b7b4dc3a57ecbebd33ecc7c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icec93b4af83f4695949286d23b67ad01_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia991af9ea6734d9083e76f365cd48a8d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i954dd0951ce9473ea15bb33f2f8caec7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6e29ade5dda14bfab570a6115c5476c8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic178968d51e943dfb82c89ad5adcb211_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idf7bc38abb2a4471b3588c1876befe2b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4a286add769446a6929995db38cf0158_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id6acc8dd1eef4390892185a561efdeef_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib5014be6e8244864b10d1e1aa7df0341_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if05b260cc3734bb0880248ead532a4be_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie7ce698d5e7544a6b287f38be1c72b5f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2c33d8f65b3b43cd8bc1cbe9d77c7e55_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i392aa0279fd84587b4a7422ec0b66687_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibe913233736944e3bcf988a459159180_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i163ce554361540e0a609c2fd0c186340_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iebeac2f399c74f29a931725a06a2073a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9a679feb77be4335bffc03ffaca2dd77_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i40062e4a7eef43cca2bffc1aa8b87712_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i891d482236f444278ce33e2e68e222ef_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie9d099974be34de59535e552a582515a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id62fb91e9cb944639c928bf48edbe8ec_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if8fbd60c13564882aea3ce4f031ac439_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifdda9bbed4994da0971162f929b72100_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6acbbe6b726149c8bb61fc9ac5b6a503_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i01b3c57121b8495d8065ad7fce4a9b2d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i196f17b7be4b4ddd93ed4aca9bcc505d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9de9a16f990643ea9672976a861c7419_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6ae9641dcdf64751a47407f1c250d242_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6a95952d91f24a96acde3076dc633d9c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib92ed0577dac4bbc9b8ad80b5f67b420_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iaddf0bca9420410db9178ce7262fc4d7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibcfd5d7a31364ca9903baa61bbbb046b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3e6de765995148a588beb68d12e77abd_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6abff27b2a984366ad5cc02faa9ea0f8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i91113dadf04744e2ad236c765eb25aa8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iacaa4d2e469a4a02ae9218aa67d40c64_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5e5bb242480346b0b189d9c91c958e6c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iaa0b5e3b96bc4154b048e676455845f3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3f4e5c6594c84545986f558f8997e266_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iee7a3bfba2ad48c9b5b2b1646931e919_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib71d7e3c32bb4a169cea90f54c789e35_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibf622980e47e43b0b3979cfd30243861_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5e0815e6302b4d62b7c5d4e8d1168325_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0346feda6c3043a68c4a5ff7af149304_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i55bcf168ab754a59940d4801f6fa8bc8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i85771b30728a4925a481cfb73f86c250_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i96c38f0127214920937fcab46ec74b11_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibfe31bf069634c55be5450be71e3f036_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic77dd428b1ff4601871e6896e86dd282_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic758f5072c934983b122d89f93601f02_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2616NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iece19fdd095e453a867d2238196e3c8e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i89c1a8ce62804d04a9257ca991dbc676_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if36f5f5d5c97414c9f7c71d8c7230c33_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibbd8c1e471554454b0fa1b9c40012912_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iaba53fd0a02e4df1a2c874629b263ee5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i61d8bd08ced14bfaa33ff22a90a9d2ca_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6e5595e73ee346d2a2b82eb33142c333_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic7bc766a995e48b4954e62dc20520496_I20211104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-04</instant>
        </period>
    </context>
    <context id="i089f62a751ee489da5e10d6b58b6adc9_I20211104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsStateDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-04</instant>
        </period>
    </context>
    <context id="ie46ae6d3a39f4f97bd6436e7342a9a4d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i638a4b60fc7140b7b4525502482b8b12_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i28701b9327404d53941d5dd148cdf77c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie546f3bca04b4fe2b2764f97ebc4ad00_I20211104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-04</instant>
        </period>
    </context>
    <context id="if11b202b8ca343b0a9e421d1841eebd6_I20211104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-04</instant>
        </period>
    </context>
    <context id="if50f5130dc374149935c142a609db653_D20211104-20211104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="i73badf44a1bd45889e11d4037d77a5a5_D20211104-20211104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:AlamedaCountyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="i987d5b5da3a84e95a610a63bb8f2de3a_D20211104-20211104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="i0ae57499f11845a387078309fc16ffc6_D20211104-20211104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:OtherJurisdictionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="i224e04590a6a4682baab9a6e6d77ce88_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iab6062bf74dd4e29a56a98ea3760db61_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i63cac0f2590c417e85f3d03334418831_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:DOJInvestigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0b29eeee66ff478fa0d4886f822b6a59_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i19d2a3c94ab340b884ea4bca21d04b54_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if54e4cb700254d5493fff77ca38ac9ef_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i424036b844734cb19b42015632d7a6f2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3e9abc9dd3db43cc9b26b208cbdb777c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibc981e52c59246c48326101ada65bb8b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i658749f8d08c4de3bd8ca178ca6268c4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i406b689ab44d4833a222efac0f41c896_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7ff0423111af46e796881f5bffabb11e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib2c2db2160bf4119bcf457d76b23d394_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iddc20db237214f5184481bac8f6153dc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie17b5134d5df4708a1d031b82fbcd4f4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1e2495c58af141e0b5b5d488b2935e1a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i150d8e19b4da44c7a10fc5832479dab4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibce62dee245a48b29809b554a26358b2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1376d1860df846879ab972c82dc8cbb9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie58736b6311e43b89041dc436c54fde9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i72e76abd2c8d45b7930ed6de435b0dee_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idc2293adf8c64ed9925346fe6e72f47c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0a025dd5a49343da902e9c0daf87d367_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie9cb0d331acd45e9a57603b0a7ac9478_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic590157c0c22464e839daa43f09f244d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i028247a5bde846f48b6ee152d76c2b8a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibeb6754446a54c41bf8d158d19745b40_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i90f84269f6144c8183e95a9e6a7c25eb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i92892038fe0545f0844bfb3e0c3e12db_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i262b04e9d11d48e58b8a57b9ab73f4e4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4ff1053e5ba649348bc766dea62879d6_D20200701-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0cd4350b18ea48f3b33db6247ab8f74e_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1fe42d24cb094502a3486fea0c6fc0df_I20211004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-04</instant>
        </period>
    </context>
    <context id="iff81891dbe0e4df49e09522cba431ade_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie756e95338db4f58953d714720e792ab_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2ffff5afcbf04bf6bdee0da00d3f865a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i14182b7268e14c209c705768a780f9d0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5a50bb415d6a42b6b624e81424aefc10_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i80a6c9c0ca9b46349d58b2c256d04d1f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1f3db035e1db41b1a0fa80e065300460_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic3c87fae83994349b2c47f4e40df266f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie36e8fee435f4698b1f72b0de63b4f97_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iefb0192320f84cfda947570718acc52f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i695daf356dd24a7f8a07c54cd6667482_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idb22d9ed2a2a48baa6338106943e33db_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i643e811d7ea24162a6e23957fa7b8020_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2589a59e7c8147fb90fc1516771ba4c2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib3b3f2699d6140d3a9e1c4884e78c829_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6582c36519d04664abfb836348244e53_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0a173f94955146cf8459ca2fc0f76a88_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i260095721ed44bfa8813a4ea26fe309e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i93278c2e2d4e42ff9942bc487ad10984_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia19a7508f5d64fa8b59c18df01e2fb5a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1be6ae19d08940a8a9cc5b7717ec3ae5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib5ff458415a4478c9e01d28e78e58858_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5ad9f408a4c44aeb8a44818cd8464a81_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ida3d87ac199c44409567f200919b5238_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic2b8a8b2269b4ec6b13d67f67f63e6de_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i86109f8fb89f41a5b8bd3da54e768eb3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1e1c40e4b0da424cbb1f9ef2eec48d5d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id59a8d61ab224417a39a8f45243726b0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic4a68ab932984e5c81cf1ec9c6d852ee_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaf9b1163079c47d1b91c576edc8b1a8b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3dc4e83510674b0bac2dc681fd406ecd_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0eb34e93d9354dfabdb815166d96003b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia067d8f29be54d07bf02fce520fc3f4c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5857bb7827354cf887e8a93a6c60a3d2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia5fcface43a14646b53fcb8c4afba8d4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie4520b1ea4514c88b03060a55539c44e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifa2d5d99524d44f1810ced80bd09e54b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i17c1a096a6384157896d5f66dfc3de76_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib23ff3fa19d64f74860e3a433d7fe8a5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if9cd1675b513491fb7ce8cd5c3b5a391_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8be3f11faae246dc81f8ac9ec37aed05_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic1569a630e924c95afa6b719377b7025_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2b18c3fa14da40a09bb0bf1cd8763c77_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9e6d62cc5ac7432b86e6e4ed282c63d5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i391a019a0c87456d8f0328ccefc57190_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic10011e202de4b40a88998de77fc7694_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idf166df979c64f28abf562745a86e1d8_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9d137a22c5e34b8289f6e4b71689c66a_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4af342838d3b4e8183c8fd3d425f8a54_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i453244191a32475ea14a9891190b3277_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1e27bef357c84648b27ccce1e084f1c5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib69f1eb355b548178f5017ddcca5b762_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2d5d341ebc974f369b72b8f04af882c0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="lawsuit">
        <measure>cah:lawsuit</measure>
    </unit>
    <unit id="stateag">
        <measure>cah:StateAG</measure>
    </unit>
    <unit id="plaintiff">
        <measure>cah:plaintiff</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>cah:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV80L2ZyYWc6ZGRmMDhlOTY3ZTk0NGI3ZGE1MTA3YTI1ZTNmMTNlZDYvdGFibGU6Njc5ODczY2NlYWQ1NDU0YTgzMWUxMTFlMGM1ZGE1YWYvdGFibGVyYW5nZTo2Nzk4NzNjY2VhZDU0NTRhODMxZTExMWUwYzVkYTVhZl8yLTEtMS0xLTA_f96ab262-fb3b-450d-a696-24eb0932a14e">0000721371</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV80L2ZyYWc6ZGRmMDhlOTY3ZTk0NGI3ZGE1MTA3YTI1ZTNmMTNlZDYvdGFibGU6Njc5ODczY2NlYWQ1NDU0YTgzMWUxMTFlMGM1ZGE1YWYvdGFibGVyYW5nZTo2Nzk4NzNjY2VhZDU0NTRhODMxZTExMWUwYzVkYTVhZl8zLTEtMS0xLTA_6c6c8c61-fde5-4b75-afb2-77a88e65ff58">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV80L2ZyYWc6ZGRmMDhlOTY3ZTk0NGI3ZGE1MTA3YTI1ZTNmMTNlZDYvdGFibGU6Njc5ODczY2NlYWQ1NDU0YTgzMWUxMTFlMGM1ZGE1YWYvdGFibGVyYW5nZTo2Nzk4NzNjY2VhZDU0NTRhODMxZTExMWUwYzVkYTVhZl80LTEtMS0xLTA_66444a80-f147-4f23-99f3-e08aea0c035c">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV80L2ZyYWc6ZGRmMDhlOTY3ZTk0NGI3ZGE1MTA3YTI1ZTNmMTNlZDYvdGFibGU6Njc5ODczY2NlYWQ1NDU0YTgzMWUxMTFlMGM1ZGE1YWYvdGFibGVyYW5nZTo2Nzk4NzNjY2VhZDU0NTRhODMxZTExMWUwYzVkYTVhZl81LTEtMS0xLTA_fa4a0fae-1106-4715-90fd-b71077bf3ee6">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV80L2ZyYWc6ZGRmMDhlOTY3ZTk0NGI3ZGE1MTA3YTI1ZTNmMTNlZDYvdGFibGU6Njc5ODczY2NlYWQ1NDU0YTgzMWUxMTFlMGM1ZGE1YWYvdGFibGVyYW5nZTo2Nzk4NzNjY2VhZDU0NTRhODMxZTExMWUwYzVkYTVhZl82LTEtMS0xLTA_3fe0e7f4-b43a-4f48-84bb-f39f3bf6b816">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl84NA_ccc6338d-7656-4951-8015-be4faa8c9609">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6YmE3NzYxMGZlZjZjNDMyMGFlMjg4NmU3ZjRmYWY4N2MvdGFibGVyYW5nZTpiYTc3NjEwZmVmNmM0MzIwYWUyODg2ZTdmNGZhZjg3Y18wLTAtMS0xLTA_cf87d4d1-a237-437c-be98-c81a9cc26201">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl8xMjE_473ad0a8-d0c3-449a-a773-f176eebd844b">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6NDVlYzkxNGYyNTc4NDgyMTg2Mjc1MTUyNTc5MmI0NmQvdGFibGVyYW5nZTo0NWVjOTE0ZjI1Nzg0ODIxODYyNzUxNTI1NzkyYjQ2ZF8wLTAtMS0xLTA_a093dddd-d7a9-4124-8c1f-6cf66c3623fe">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl8xOTA2_8fe17d2d-43b0-4ee1-af18-f53530efb532">1-11373</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl8xOTA3_3b80d83c-f8fe-473d-967a-4f7487c6685f">Cardinal Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6NDZhMTJmNDViMGNhNGUxY2FiMDk5N2EwYjU2MTMwMjUvdGFibGVyYW5nZTo0NmExMmY0NWIwY2E0ZTFjYWIwOTk3YTBiNTYxMzAyNV8wLTAtMS0xLTA_3b413f94-8623-46d2-a16c-6e8fc4a74279">OH</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6NDZhMTJmNDViMGNhNGUxY2FiMDk5N2EwYjU2MTMwMjUvdGFibGVyYW5nZTo0NmExMmY0NWIwY2E0ZTFjYWIwOTk3YTBiNTYxMzAyNV8wLTYtMS0xLTA_03e72029-ddca-4884-9862-0d59dc4c703e">31-0958666</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6NDZhMTJmNDViMGNhNGUxY2FiMDk5N2EwYjU2MTMwMjUvdGFibGVyYW5nZTo0NmExMmY0NWIwY2E0ZTFjYWIwOTk3YTBiNTYxMzAyNV8zLTAtMS0xLTA_b7c3205a-3cb6-40ba-be21-fbd51f70307e">7000 Cardinal Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6NDZhMTJmNDViMGNhNGUxY2FiMDk5N2EwYjU2MTMwMjUvdGFibGVyYW5nZTo0NmExMmY0NWIwY2E0ZTFjYWIwOTk3YTBiNTYxMzAyNV8zLTItMS0xLTA_4e15947d-34b4-458f-8fc5-ea24b8df4935">Dublin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6NDZhMTJmNDViMGNhNGUxY2FiMDk5N2EwYjU2MTMwMjUvdGFibGVyYW5nZTo0NmExMmY0NWIwY2E0ZTFjYWIwOTk3YTBiNTYxMzAyNV8zLTQtMS0xLTA_7b03104b-3ba7-4d27-b205-c15d03b7096c">OH</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6NDZhMTJmNDViMGNhNGUxY2FiMDk5N2EwYjU2MTMwMjUvdGFibGVyYW5nZTo0NmExMmY0NWIwY2E0ZTFjYWIwOTk3YTBiNTYxMzAyNV8zLTYtMS0xLTA_f6a59970-6915-498d-8243-6a520207e625">43017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl8xOTA4_73b2bf28-e61e-4780-86c7-81cac9345be3">614</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl8xOTAx_bf5d31b9-51bc-46ec-9f56-cae766317484">757-5000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6MWZmZWYzN2RmMjhmNGY1MDhmNGQ0Yjc1MzI2ZWFhZWUvdGFibGVyYW5nZToxZmZlZjM3ZGYyOGY0ZjUwOGY0ZDRiNzUzMjZlYWFlZV8yLTAtMS0xLTA_8f6868f8-44aa-4ef4-a4e5-a33fafef42a2">Common shares (without par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6MWZmZWYzN2RmMjhmNGY1MDhmNGQ0Yjc1MzI2ZWFhZWUvdGFibGVyYW5nZToxZmZlZjM3ZGYyOGY0ZjUwOGY0ZDRiNzUzMjZlYWFlZV8yLTEtMS0xLTA_8649651a-7bfd-461a-9963-806d4ea19eab">CAH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6MWZmZWYzN2RmMjhmNGY1MDhmNGQ0Yjc1MzI2ZWFhZWUvdGFibGVyYW5nZToxZmZlZjM3ZGYyOGY0ZjUwOGY0ZDRiNzUzMjZlYWFlZV8yLTItMS0xLTA_5504e517-8f04-49b0-bd38-4d0218225a02">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl8xOTAy_312a2b96-4c76-49c4-82ca-3dbab2a0fb67">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl8xOTAz_ce873f33-10c7-4122-b718-150c559a12e7">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6ZTUwNmQ4NDgzMzc3NDE2OTk5MDU0NDNmNjAwMDFjNzUvdGFibGVyYW5nZTplNTA2ZDg0ODMzNzc0MTY5OTkwNTQ0M2Y2MDAwMWM3NV8wLTAtMS0xLTA_a0a8830a-08ec-491c-a660-d7333d1cca88">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6ZTUwNmQ4NDgzMzc3NDE2OTk5MDU0NDNmNjAwMDFjNzUvdGFibGVyYW5nZTplNTA2ZDg0ODMzNzc0MTY5OTkwNTQ0M2Y2MDAwMWM3NV8xLTQtMS0xLTA_146d737e-a3c4-419d-9afa-767042624df1">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGFibGU6ZTUwNmQ4NDgzMzc3NDE2OTk5MDU0NDNmNjAwMDFjNzUvdGFibGVyYW5nZTplNTA2ZDg0ODMzNzc0MTY5OTkwNTQ0M2Y2MDAwMWM3NV8yLTQtMS0xLTA_a77c3266-e0f5-4c9a-a7a6-010df5fa122c">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl8xOTA0_6d2d2622-4dab-43d6-97f3-6df10c8945a6">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i69b6e01c61e147bea8030d462af3a3bc_I20211031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xL2ZyYWc6YjliMDQxZTE2MDJjNGI0Njg3NzY2NjMzZjEwNTc2ZDIvdGV4dHJlZ2lvbjpiOWIwNDFlMTYwMmM0YjQ2ODc3NjY2MzNmMTA1NzZkMl8xODk5_df39b915-97b0-4423-8d07-5ae44b18e63e"
      unitRef="shares">281788002</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMi0xLTEtMS0w_3180b5c7-3881-46c8-bb7b-8a959f69047d"
      unitRef="usd">43968000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMi0zLTEtMS0w_24a6153a-ff34-4d4f-af61-7dc3af4074b6"
      unitRef="usd">39065000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMy0xLTEtMS0w_6d2144ef-3ce3-4a53-82ec-9cb4cea71586"
      unitRef="usd">42326000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMy0zLTEtMS0w_c16dd45d-51bf-41db-ae9f-933600941daf"
      unitRef="usd">37350000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfNC0xLTEtMS0w_a8836ce1-b372-4a38-aa24-b86e30bc352e"
      unitRef="usd">1642000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfNC0zLTEtMS0w_4a832da3-4d89-4315-8706-21f7e20f85e7"
      unitRef="usd">1715000000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfNy0xLTEtMS0w_247c55f9-7655-4625-8263-a6d2e1d7312c"
      unitRef="usd">1114000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfNy0zLTEtMS0w_885037d9-a758-4f5b-a706-5bce207f2b63"
      unitRef="usd">1137000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfOC0xLTEtMS0w_13a61f57-b1eb-42cf-92ee-eb0dd32dfba8"
      unitRef="usd">18000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfOC0zLTEtMS0w_389680a0-3abe-4384-b33d-5315aaad2b9d"
      unitRef="usd">37000000</us-gaap:RestructuringCharges>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfOS0xLTEtMS0w_5e750d28-de1e-444b-a7d9-3431ae04293d"
      unitRef="usd">79000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfOS0zLTEtMS0w_5129e853-84f3-4309-8ff0-810e9c1897a5"
      unitRef="usd">118000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTAtMS0xLTEtMA_6f588c03-9846-49d4-b867-a8b29bfdcc47"
      unitRef="usd">2000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTAtMy0xLTEtMA_824de8fb-edc1-4253-8c7f-1aaee8e7264c"
      unitRef="usd">-9000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTEtMS0xLTEtMA_6e392ab8-ed4f-4de0-94e9-d1a80aaafea9"
      unitRef="usd">-18000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTEtMy0xLTEtMA_6d437d78-124d-40f4-bebe-080e4e5bc875"
      unitRef="usd">-1038000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:OperatingIncomeLoss
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTItMS0xLTEtMA_bcd76dbc-9d99-464f-8bef-e82864ef004b"
      unitRef="usd">415000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTItMy0xLTEtMA_d69f48f8-550a-47e9-b17f-38851c3864e8"
      unitRef="usd">-624000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTQtMS0xLTEtMA_758d976b-d54a-4d66-b7bd-d5fead7718d7"
      unitRef="usd">4000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTQtMy0xLTEtMA_c695e248-7142-461c-a8dd-865088a1f4b4"
      unitRef="usd">7000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTUtMS0xLTEtMA_80ed179c-12d0-4388-b5d5-23176007e11f"
      unitRef="usd">40000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTUtMy0xLTEtMA_47053e80-3562-425f-870e-0ebbba190b59"
      unitRef="usd">45000000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTYtMS0xLTEtMA_d26bcde2-3098-44dd-b35b-8ac62c9e1748"
      unitRef="usd">-10000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <cah:LossOnEarlyExtinguishmentOfDebt
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTYtMy0xLTEtMA_d3a79a93-8036-48f8-bf9a-1aa589e2401e"
      unitRef="usd">1000000</cah:LossOnEarlyExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTctMS0xLTEtMA_616db4de-16aa-4c8e-ab19-fc353e95f016"
      unitRef="usd">369000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTctMy0xLTEtMA_ffecd50b-b943-4506-b5d5-6ad2a35b197d"
      unitRef="usd">-663000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTktMS0xLTEtMA_a6508780-8281-48e7-9403-5cc91cc9e0c3"
      unitRef="usd">97000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMTktMy0xLTEtMA_8f1f1e3c-e1d6-4ec3-9ae5-a4025fa18c53"
      unitRef="usd">-410000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMjAtMS0xLTEtMA_215f4c56-f4fd-4290-8a00-1dda1327df87"
      unitRef="usd">272000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMjAtMy0xLTEtMA_e7722f6b-e1cc-4fef-b61a-cf41d593f0f0"
      unitRef="usd">-253000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMjUtMS0xLTEtMA_bd34877d-74d5-4754-8bea-cb275f71666d"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMjUtMy0xLTEtMA_ba719671-8cb5-480c-9348-c4664ba896a3"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMjYtMS0xLTEtMA_cbed7b79-d7e1-491e-a455-1da27d50f179"
      unitRef="usd">271000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMjYtMy0xLTEtMA_4b379d96-34ad-4f30-81cb-7be268b712bb"
      unitRef="usd">-253000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMjktMS0xLTEtMA_766eeca8-08c2-4793-bd37-1332e6a6717d"
      unitRef="usdPerShare">0.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMjktMy0xLTEtMA_8a224997-bdb2-4fb1-9392-f8a38d5a21da"
      unitRef="usdPerShare">-0.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMzAtMS0xLTEtMA_5a88b1e2-1eec-4003-8791-e76717895a33"
      unitRef="usdPerShare">0.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMzAtMy0xLTEtMA_00b00cc7-17f6-4121-a8a0-ee269e072327"
      unitRef="usdPerShare">-0.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMzMtMS0xLTEtMA_e8f14262-989e-4077-a76d-957af362bf48"
      unitRef="shares">287000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMzMtMy0xLTEtMA_49ad7097-b79b-4b34-879c-131ae50c9eb1"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMzQtMS0xLTEtMA_311f75af-973e-4782-9047-26d5c0c0d7ff"
      unitRef="shares">289000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMzQtMy0xLTEtMA_0ef68a2a-f333-42d0-bae2-206e799b047e"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMzYtMS0xLTEtMA_e5c28cff-0018-48d8-8c82-c6df0c557b02"
      unitRef="usdPerShare">0.4908</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV81OC9mcmFnOjJmMmMwMGJhYzM3ODQ1ZjI5YTQ2ZmM2YjdlY2E5NDU3L3RhYmxlOjM0ZGZiOGI5OTM1OTRkNjE5YjRhNzUyNmZhODBlNDJiL3RhYmxlcmFuZ2U6MzRkZmI4Yjk5MzU5NGQ2MTliNGE3NTI2ZmE4MGU0MmJfMzYtMy0xLTEtMA_14c29115-d93a-4342-8525-001e4f797193"
      unitRef="usdPerShare">0.4859</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ProfitLoss
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfMi0xLTEtMS0w_215f4c56-f4fd-4290-8a00-1dda1327df87"
      unitRef="usd">272000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfMi0zLTEtMS0w_e7722f6b-e1cc-4fef-b61a-cf41d593f0f0"
      unitRef="usd">-253000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfNS0xLTEtMS0w_ae0f5ab7-b975-4d27-be15-f255bb3d9ab4"
      unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfNS0zLTEtMS0w_85219802-e5b1-4376-8f38-406eefa76a27"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfNi0xLTEtMS0w_95e494d1-6b2e-4311-8063-23b588684e05"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfNi0zLTEtMS0w_92a45ff6-4dc4-4239-b608-ad38e37879e0"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfNy0xLTEtMS0w_5b8c6d9c-a398-4479-81fd-f80ca0b83395"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfNy0zLTEtMS0w_ec0d350e-b96b-4241-976c-8d214efff6af"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfOS0xLTEtMS0w_f899cf71-33a9-44cd-ba3a-aaa0e656f1e1"
      unitRef="usd">245000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfOS0zLTEtMS0w_3f77a05d-0eea-43ee-bde2-36fb3564fe27"
      unitRef="usd">-236000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfMTEtMS0xLTEtMA_ec655fbd-4104-44cc-a48b-59a10d38d216"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfMTEtMy0xLTEtMA_d1bf2ad9-097f-4854-935c-c8c22fef7c01"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfMTMtMS0xLTEtMA_e02a1e72-a658-4746-ba6e-c28b817f5e4f"
      unitRef="usd">244000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82MS9mcmFnOjc4NzIyYjg1YWRlNDRkN2JhZDAzNDFmNGI5OWI3ZmZhL3RhYmxlOmZlNWUwZGZiMGZhOTQwNjM4MmVmNWEwNDA5YjQ4NGY1L3RhYmxlcmFuZ2U6ZmU1ZTBkZmIwZmE5NDA2MzgyZWY1YTA0MDliNDg0ZjVfMTMtMy0xLTEtMA_da09e3a8-763f-47ae-92a3-3d6aaaa0a0e8"
      unitRef="usd">-236000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMy0xLTEtMS0w_e2df75b5-6e68-4f3f-a26f-f98b81b21cba"
      unitRef="usd">2463000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMy0zLTEtMS0w_cc28383b-c8ca-4066-aff0-3fc7577dc01f"
      unitRef="usd">3407000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfNC0xLTEtMS0w_c75feead-4937-442a-b53f-0a911c453f55"
      unitRef="usd">9305000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfNC0zLTEtMS0w_82b3e6e7-8699-4e81-9400-5052eeeade9f"
      unitRef="usd">9103000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfNS0xLTEtMS0w_4857f414-d6f6-409a-8f6e-26d1711cfe92"
      unitRef="usd">14720000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfNS0zLTEtMS0w_d5631ae9-4cb4-48cf-b7b3-c52beb1efe30"
      unitRef="usd">14594000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfNi0xLTEtMS0w_f024f3b8-0059-4052-b842-847f5e21bf55"
      unitRef="usd">3243000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfNi0zLTEtMS0w_0140b70f-40bb-4dd4-b7a9-8c3409c65176"
      unitRef="usd">2843000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfNy0xLTEtMS0w_7a680e18-7abe-4377-876d-e9cd2c084367"
      unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfNy0zLTEtMS0w_e3fc676f-821f-4c3f-a5a5-f686b9abeb65"
      unitRef="usd">1101000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsCurrent
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfOC0xLTEtMS0w_84975b6c-4a37-490a-9d33-d02b28c0ba09"
      unitRef="usd">29731000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfOC0zLTEtMS0w_167d610c-b2b2-40b1-97aa-86859e57a82a"
      unitRef="usd">31048000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTAtMS0xLTEtMA_e2485204-edff-4a1a-bac7-2c70735466ca"
      unitRef="usd">2336000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTAtMy0xLTEtMA_6d4bd7e2-9838-44eb-a286-96fa8b0290c7"
      unitRef="usd">2360000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTEtMS0xLTEtMA_157559fc-7b41-46c0-8975-b7f3513c7d1a"
      unitRef="usd">10005000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTEtMy0xLTEtMA_9317f2e6-f4d9-4dec-9e39-0c13aea0b2eb"
      unitRef="usd">10094000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTMtMS0xLTEtMA_30a51ccf-ce1f-4a61-be57-e5235bbe3552"
      unitRef="usd">921000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTMtMy0xLTEtMA_3fce8636-23d5-4061-844a-1b2a03930943"
      unitRef="usd">951000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTQtMS0xLTEtMA_ff1e4830-7f67-4a4e-9039-9f7258f3a346"
      unitRef="usd">42993000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTQtMy0xLTEtMA_c3658c4a-539b-4c42-a5d4-f4175612e56c"
      unitRef="usd">44453000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTgtMS0xLTEtMA_6da966e8-a90b-4705-a8d5-ad4461961dfc"
      unitRef="usd">23408000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTgtMy0xLTEtMA_2b5f39c8-50f5-4b65-81bc-9abae59484fe"
      unitRef="usd">23700000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTktMS0xLTEtMA_24e3d029-65ec-45c6-8a49-6aeac12cd5cd"
      unitRef="usd">301000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMTktMy0xLTEtMA_0b585ed1-bd39-4509-bf89-914b7b76ba4e"
      unitRef="usd">871000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjAtMS0xLTEtMA_58f097c9-622d-40a0-87da-3ca323193e19"
      unitRef="usd">2790000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjAtMy0xLTEtMA_16b5ec53-85f8-4c31-989f-49a43c5e68ad"
      unitRef="usd">2957000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjEtMS0xLTEtMA_9874bc74-207b-4684-9987-47d868bbf549"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjEtMy0xLTEtMA_87fe1405-61a6-495a-9e5a-e9dd3f790bd9"
      unitRef="usd">96000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesCurrent
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjItMS0xLTEtMA_b930c0e8-2c03-480d-840a-b938198b7964"
      unitRef="usd">26499000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjItMy0xLTEtMA_e538ec5f-3b88-4840-b147-bca1d9587db2"
      unitRef="usd">27624000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjQtMS0xLTEtMA_0e21649b-6561-4483-995d-6c03bee903ed"
      unitRef="usd">5353000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjQtMy0xLTEtOTMzMg_8dfc2357-f312-4ca2-9fb1-aee6b00f5cd5"
      unitRef="usd">5365000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjUtMS0xLTEtMA_16fafd65-8aa0-4102-b1ab-1719101cf598"
      unitRef="usd">9745000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjUtMy0xLTEtOTM0Nw_6a341ed4-101c-460f-ada4-72a678064308"
      unitRef="usd">9670000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjg4NTZjMWU1OWRkNzQwNmJiMmU3N2M2YjFhNDFjZTQzXzE1_22b68081-4a81-46e2-85f8-8f3e1eea77ed"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjg4NTZjMWU1OWRkNzQwNmJiMmU3N2M2YjFhNDFjZTQzXzE1_77613cea-57a6-4927-9906-51eaad209863"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjg4NTZjMWU1OWRkNzQwNmJiMmU3N2M2YjFhNDFjZTQzXzMz_00e81e12-f5f5-4aae-b5bd-3284ecd37a2a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjg4NTZjMWU1OWRkNzQwNmJiMmU3N2M2YjFhNDFjZTQzXzMz_471c1673-d167-43e1-9c24-0ab8c4f7708c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjktMS0xLTEtMA_a9711db2-a081-4325-a064-f28b9b492565"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMjktMy0xLTEtMA_f8b176cc-e77a-47d8-838e-5339c198e558"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM5Y2Q2YWY2YjU4NDRhNjJiNWRlZGIyODRjMGUxYzlmXzE1_6b53dfab-0bab-42b0-9bb0-6de03b7ba115"
      unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM5Y2Q2YWY2YjU4NDRhNjJiNWRlZGIyODRjMGUxYzlmXzE1_e13e4714-9ba4-49cf-b142-7de1b54301ae"
      unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM5Y2Q2YWY2YjU4NDRhNjJiNWRlZGIyODRjMGUxYzlmXzMz_538bfc6d-c484-493e-9ef8-c67610b0be37"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmM5Y2Q2YWY2YjU4NDRhNjJiNWRlZGIyODRjMGUxYzlmXzMz_b417735b-8d96-461a-8605-2bf994568256"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzEtMS0xLTEtMA_e0764b55-72af-43ff-8b9a-644a60dd853a"
      unitRef="usd">2666000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzEtMy0xLTEtMA_28558df1-dbbd-4847-84d9-d1e2fc07719e"
      unitRef="usd">2806000000</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzItMS0xLTEtMA_54307110-f753-413b-b146-21dab46e85bb"
      unitRef="usd">1335000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzItMy0xLTEtMA_4fe54292-7829-46f9-910d-27190df450a7"
      unitRef="usd">1205000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjVjODQ5ZTRiZDE2NDQ0MGZiMGRiYjFlYjdiZTc1MTQxXzQw_6668be9c-3cc3-45e2-a2c4-3dc531fdaf2c"
      unitRef="shares">43000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjVjODQ5ZTRiZDE2NDQ0MGZiMGRiYjFlYjdiZTc1MTQxXzU0_f38fac44-a870-4774-8530-841d17f044f6"
      unitRef="shares">36000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzMtMS0xLTEtMA_6401e9a9-f3fe-4638-9fc5-19b8e45d5436"
      unitRef="usd">2547000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzMtMy0xLTEtMA_161cd9fe-da37-41cc-8436-a4de5d7f6193"
      unitRef="usd">2186000000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzQtMS0xLTEtMA_35c2245a-e21f-48c6-8754-ddcf8ac46849"
      unitRef="usd">-61000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzQtMy0xLTEtMA_e2579a98-7943-43d3-a716-6e793ad72f76"
      unitRef="usd">-34000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzUtMS0xLTEtMA_a9a996c3-8768-4a23-b472-0c0bc6dd4bea"
      unitRef="usd">1393000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzUtMy0xLTEtMA_dd745ca6-0115-4d3d-909c-6d9503219a53"
      unitRef="usd">1791000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzYtMS0xLTEtMA_a5bf8324-4a46-43e9-824b-bb6ded39f972"
      unitRef="usd">3000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzYtMy0xLTEtMA_3e7ce439-b3b5-4772-8e18-f914b247f55d"
      unitRef="usd">3000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzctMS0xLTEtMA_4d4fffe1-4ab5-4350-bdd6-dd0f603f6517"
      unitRef="usd">1396000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzctMy0xLTEtMA_b55d9192-606f-4a5b-9acf-0147005186be"
      unitRef="usd">1794000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzgtMS0xLTEtMA_cf9dbcd8-d109-495f-98d7-68498581d02a"
      unitRef="usd">42993000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82NC9mcmFnOmJhNTY4ZjZlZTIzNDRhM2I5NmQwMWYyZmJmMzBlYjhmL3RhYmxlOjk4YjM2M2MxYmU5MjQ5ZTg5N2I1NGJmNGE3MThiZjVhL3RhYmxlcmFuZ2U6OThiMzYzYzFiZTkyNDllODk3YjU0YmY0YTcxOGJmNWFfMzgtMy0xLTEtMA_1d2ce725-cf93-43a8-a535-3e2019d0dc6d"
      unitRef="usd">44453000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia948c3e5ec6f4bec8e7f879a025a4df5_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMy0xLTEtMS0w_1cce03a2-3bea-4206-94d9-bd5b2273116a"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia948c3e5ec6f4bec8e7f879a025a4df5_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMy0zLTEtMS0w_7218fc90-5200-47de-8c66-c6397a34077d"
      unitRef="usd">2806000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i08d940f3e6e149168d29549187b0c935_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMy01LTEtMS0w_51805c0f-85dd-47b4-b743-a44fb2cf37f6"
      unitRef="usd">1205000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="iac6fdb45d09c424594b1a7bb495c5d01_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMy03LTEtMS0w_f91cc3e2-05f6-45a6-8588-fc4552a033b4"
      unitRef="shares">36000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="iac6fdb45d09c424594b1a7bb495c5d01_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMy05LTEtMS0w_284ca568-03ce-44b8-bab0-5885ea135814"
      unitRef="usd">2186000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i695097f71a9b487091fa06cabd23f062_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMy0xMS0xLTEtMA_1d137f4c-3d71-4e98-b1bf-14dc66e6ce9c"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e1d62562ca244c38872c9cd9f2d56d4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMy0xMy0xLTEtMA_44a76862-555f-4291-8f53-a99a164235bf"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMy0xNS0xLTEtMA_076db29b-5329-4c22-9393-b08b57306f24"
      unitRef="usd">1794000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNC01LTEtMS0w_cbed7b79-d7e1-491e-a455-1da27d50f179"
      unitRef="usd">271000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="ie839ddea5fe24b80978766903acfb01d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNC0xMy0xLTEtMA_2e54f96e-0959-4b54-9017-6c6874f39a83"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNC0xNS0xLTEtMA_eb45b453-8c0b-402e-980b-c25caadd01bd"
      unitRef="usd">272000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia86d33171aed42cebf549309afad5112_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNS0xMS0xLTEtMA_f7113617-5126-4cbe-abff-fc99377f4f93"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNS0xNS0xLTEtMA_7a636a2e-061f-4239-bd78-7b1410a8fba5"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2352ec975b7b4dc3a57ecbebd33ecc7c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNy0xLTEtMS0w_7b6d8685-8078-48d5-9c71-bf068559da94"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2352ec975b7b4dc3a57ecbebd33ecc7c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNy0zLTEtMS0w_2427e99e-e56e-47a3-9206-90935e7900a2"
      unitRef="usd">40000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="icec93b4af83f4695949286d23b67ad01_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNy03LTEtMS0w_23658923-3c48-4cec-8224-ad88e2a87082"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icec93b4af83f4695949286d23b67ad01_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNy05LTEtMS0w_484dfa53-1613-450c-8125-1827d9599bad"
      unitRef="usd">39000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfNy0xNS0xLTEtMA_e76af622-af5a-4aec-8ff7-25d2821e736c"
      unitRef="usd">-1000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i2352ec975b7b4dc3a57ecbebd33ecc7c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfOC0zLTEtMS0w_5343c881-3924-4c4a-8fe8-9b671e342b13"
      unitRef="usd">100000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="icec93b4af83f4695949286d23b67ad01_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfOC03LTEtMS0w_c7822e70-60be-49f7-b020-4ea04901fcde"
      unitRef="shares">8000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="icec93b4af83f4695949286d23b67ad01_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfOC05LTEtMS0w_70d53ff1-b22c-442d-8892-9dc33a293641"
      unitRef="usd">400000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfOC0xNS0xLTEtMA_99736234-5bc0-4b52-93a7-5a42a3460606"
      unitRef="usd">500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:Dividends
      contextRef="ia991af9ea6734d9083e76f365cd48a8d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfOS01LTEtMS0w_00cc40fe-fcf7-4f08-8090-6f9cbd9b2b69"
      unitRef="usd">141000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfOS0xNS0xLTEtMA_faae49ce-b2d1-46c6-84cb-b89b5752eb69"
      unitRef="usd">141000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="ie839ddea5fe24b80978766903acfb01d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTAtMTMtMS0xLTA_94d15aeb-7fcd-4820-9e57-4a152328b77c"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTAtMTUtMS0xLTA_1e6440d3-b08f-4020-bace-fa84b159e325"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i954dd0951ce9473ea15bb33f2f8caec7_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTItMS0xLTEtMA_cefe23d1-1b06-48a3-b13e-2c6bc52a24a0"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i954dd0951ce9473ea15bb33f2f8caec7_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTItMy0xLTEtMA_1eedebf6-2bfa-4221-8ce0-c9fd4dc402ce"
      unitRef="usd">2666000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6e29ade5dda14bfab570a6115c5476c8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTItNS0xLTEtMA_4651b989-14ca-45b9-8fda-dac93c8d659a"
      unitRef="usd">1335000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="ic178968d51e943dfb82c89ad5adcb211_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTItNy0xLTEtMA_db0f33aa-bccb-410f-8ba0-e44b9bee277a"
      unitRef="shares">43000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ic178968d51e943dfb82c89ad5adcb211_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTItOS0xLTEtMA_6f34d568-2b2d-4b65-aefe-b241147535ca"
      unitRef="usd">2547000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idf7bc38abb2a4471b3588c1876befe2b_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTItMTEtMS0xLTA_851e9d1a-2408-4901-a445-969983a4cdf7"
      unitRef="usd">-61000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a286add769446a6929995db38cf0158_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTItMTMtMS0xLTA_d24e026d-26f5-4b27-adce-385cb701ca97"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOmNlNTg4OWEzNzI1MTQ0NWZhZTk0M2Q0NTI0N2E4Njk4L3RhYmxlcmFuZ2U6Y2U1ODg5YTM3MjUxNDQ1ZmFlOTQzZDQ1MjQ3YTg2OThfMTItMTUtMS0xLTA_270bc959-c6a9-4c16-a1f6-9ebb5b9e2c3b"
      unitRef="usd">1396000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="id6acc8dd1eef4390892185a561efdeef_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMS0xLTEtMS0w_8de8599e-d106-4611-a47f-b48fc525e061"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id6acc8dd1eef4390892185a561efdeef_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMS0zLTEtMS0w_6d20800f-d60b-4408-840a-1b876793ad62"
      unitRef="usd">2789000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib5014be6e8244864b10d1e1aa7df0341_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMS01LTEtMS0w_0f644ecb-c33d-4bae-bfea-adfb78d969c8"
      unitRef="usd">1170000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="if05b260cc3734bb0880248ead532a4be_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMS03LTEtMS0w_3762a9af-9561-43b7-81fe-6f69df824295"
      unitRef="shares">35000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="if05b260cc3734bb0880248ead532a4be_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMS05LTEtMS0w_556ea6f1-48fc-44c7-b816-bfaef7077907"
      unitRef="usd">2066000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7ce698d5e7544a6b287f38be1c72b5f_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMS0xMS0xLTEtMA_88e2e674-3ea6-4df2-8e3b-7b8deaed59ad"
      unitRef="usd">-104000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2c33d8f65b3b43cd8bc1cbe9d77c7e55_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMS0xMy0xLTEtMA_53e6400a-7138-4d6e-bfe3-4e0bfcea8908"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i392aa0279fd84587b4a7422ec0b66687_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMS0xNS0xLTEtMA_2bfaf531-b2d9-407c-a7a0-666c939e921b"
      unitRef="usd">1792000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMi01LTEtMS0w_80c59f74-9143-43a1-80c4-8ecfb05cb5b8"
      unitRef="usd">-253000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="ibe913233736944e3bcf988a459159180_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMi0xMy0xLTEtMA_0f87e947-3fab-4f73-bd46-f5cd6656d177"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMi0xNS0xLTEtMA_d464d6b9-5d63-43d7-b115-8b2a494ec74e"
      unitRef="usd">-253000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i163ce554361540e0a609c2fd0c186340_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMy0xMS0xLTEtMA_73b6bab6-6551-4ac5-8881-ed46af2aea2e"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMy0xNS0xLTEtMA_a676f16c-d158-474b-a5d1-711538e5d650"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="iebeac2f399c74f29a931725a06a2073a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfNS0xLTEtMS0w_e011cee5-fc72-41af-aa50-917671fbef97"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iebeac2f399c74f29a931725a06a2073a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfNS0zLTEtMS0w_65cdb73a-0143-4377-8746-8413dac4c3d1"
      unitRef="usd">29000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i9a679feb77be4335bffc03ffaca2dd77_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfNS03LTEtMS0w_c3ae6d50-85f7-4aa8-80ce-78f908db2aaa"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9a679feb77be4335bffc03ffaca2dd77_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfNS05LTEtMS0w_650cb777-44c9-4cd5-8a5b-787aef43df43"
      unitRef="usd">44000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfNS0xNS0xLTEtMA_561d9513-a2ce-4335-810e-90c8ed55a1f7"
      unitRef="usd">15000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:Dividends
      contextRef="i40062e4a7eef43cca2bffc1aa8b87712_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfNy01LTEtMS0w_8e1faaf6-7c97-4c88-8620-56c6f7534c29"
      unitRef="usd">146000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfNy0xNS0xLTEtMA_3487370f-d6b5-4da5-9e58-60da953dfc90"
      unitRef="usd">146000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesIssued
      contextRef="i891d482236f444278ce33e2e68e222ef_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMTAtMS0xLTEtMA_add725b2-0b17-4d0a-99bd-d94b99b6c54f"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i891d482236f444278ce33e2e68e222ef_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMTAtMy0xLTEtMA_e08fb3a5-8e68-447a-931c-8cbe67b13cf5"
      unitRef="usd">2760000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie9d099974be34de59535e552a582515a_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMTAtNS0xLTEtMA_4d52261d-de3d-4949-80ef-6df2f405155a"
      unitRef="usd">771000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="id62fb91e9cb944639c928bf48edbe8ec_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMTAtNy0xLTEtMA_c66e3205-486d-4117-b851-5d277e9ad09a"
      unitRef="shares">33000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="id62fb91e9cb944639c928bf48edbe8ec_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMTAtOS0xLTEtMA_938db50d-7eeb-4334-b445-ea1d1c1937c4"
      unitRef="usd">2022000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if8fbd60c13564882aea3ce4f031ac439_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMTAtMTEtMS0xLTA_72722542-c258-4af1-83d2-30b1a3ccadc1"
      unitRef="usd">-87000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifdda9bbed4994da0971162f929b72100_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMTAtMTMtMS0xLTA_4ef163a1-2776-4482-8682-4df9eef544aa"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6acbbe6b726149c8bb61fc9ac5b6a503_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV82Ny9mcmFnOjQxZjk4MWExNGM2OTRlNDY4YjYxYzdjOWI5OGVhYmMwL3RhYmxlOjg2NDBhOWY1Zjc1OTQxYzM4MmM2ZmUyODVmOTdhNThkL3RhYmxlcmFuZ2U6ODY0MGE5ZjVmNzU5NDFjMzgyYzZmZTI4NWY5N2E1OGRfMTAtMTUtMS0xLTA_dd6ab6a0-a170-41e8-8280-0b39066067f8"
      unitRef="usd">1425000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMy0xLTEtMS0w_215f4c56-f4fd-4290-8a00-1dda1327df87"
      unitRef="usd">272000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMy0zLTEtMS0w_e7722f6b-e1cc-4fef-b61a-cf41d593f0f0"
      unitRef="usd">-253000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfNi0xLTEtMS0w_5bd13468-20f7-4e5d-ac7d-51fc8cd35f6b"
      unitRef="usd">168000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfNi0zLTEtMS0w_96acdc85-a820-414a-8c3a-149d36ece1c0"
      unitRef="usd">205000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfOC0xLTEtMS0w_4458609d-6ff6-4205-8fba-b3d52009f6da"
      unitRef="usd">2000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfOC0zLTEtMS0w_6635782d-a306-497a-8cbc-62e087b5904b"
      unitRef="usd">-9000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfOS0xLTEtMS0zMzkwNg_9769dd31-3033-46f3-b967-c079fd0fe97e"
      unitRef="usd">-10000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfOS0zLTEtMS0zMzg5Nw_4d61f3f4-d83d-49aa-85ac-c1ec1301294a"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfOS0xLTEtMS0w_8c350fae-f71f-48a6-a69b-3f88d97adf87"
      unitRef="usd">24000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfOS0zLTEtMS0w_be8bf10c-cbe2-47e3-a159-9c6da5410dcf"
      unitRef="usd">28000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTAtMS0xLTEtMA_ca8e1ff1-40bd-4564-940b-69010067e98a"
      unitRef="usd">12000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTAtMy0xLTEtMA_c55f3e87-a57d-4e02-8327-726408dd6ccd"
      unitRef="usd">16000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTMtMS0xLTEtMA_ea3b74aa-b606-4e7b-bdd0-fb8b98f9d600"
      unitRef="usd">214000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTMtMy0xLTEtMA_b304a5fa-78bb-46e9-b025-126476b886be"
      unitRef="usd">388000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTQtMS0xLTEtMA_a90ddacc-81c3-4664-88e8-9fdba869110f"
      unitRef="usd">129000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTQtMy0xLTEtMA_bc034e57-8aca-4c21-bc8f-b6d7fc7b70e4"
      unitRef="usd">245000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTUtMS0xLTEtMA_7c73413d-ac25-4c8a-a83d-ea796e9315c3"
      unitRef="usd">-292000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTUtMy0xLTEtMA_b63c7d97-0993-458b-b181-7a0842be3672"
      unitRef="usd">313000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTYtMS0xLTEtMA_c19d11f0-46ee-40fe-9278-f901eb3588cd"
      unitRef="usd">495000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTYtMy0xLTEtMA_5ea0984c-2efd-4a96-83b4-47a1bfa42523"
      unitRef="usd">-585000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTctMS0xLTEtMA_ff72d83f-2d54-46e7-899e-f0db8ad5b7f9"
      unitRef="usd">-646000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMTctMy0xLTEtMA_9e744e5e-7f3a-490c-bfb0-7212e71ea922"
      unitRef="usd">270000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjItMS0xLTEtMzc2NDc_35de2128-e02b-4677-84bd-ca1ffb36a3c5"
      unitRef="usd">927000000</cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets>
    <cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjItMy0xLTEtMzc2NDc_c69e2dd5-b834-4935-b1bc-cb817ba52c9c"
      unitRef="usd">0</cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjEtMS0xLTEtMA_aa21cf0c-793f-4bf7-ad6d-d8df8496e495"
      unitRef="usd">67000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjEtMy0xLTEtMA_eea184b3-fd56-4d97-9bb0-fe1524ebcbdf"
      unitRef="usd">78000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <cah:Purchaseofavailableforsalesecuritiesandotherinvestments
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjItMS0xLTEtMA_48fb014a-827c-4802-92d9-a28a1fb4fcf8"
      unitRef="usd">2000000</cah:Purchaseofavailableforsalesecuritiesandotherinvestments>
    <cah:Purchaseofavailableforsalesecuritiesandotherinvestments
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjItMy0xLTEtMA_8317a952-f940-4f97-ace2-1dbecbc14516"
      unitRef="usd">17000000</cah:Purchaseofavailableforsalesecuritiesandotherinvestments>
    <cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjMtMS0xLTEtMA_a0896649-91d9-49e8-9b19-009fc1c2c058"
      unitRef="usd">4000000</cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments>
    <cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjMtMy0xLTEtMA_9dfc10c4-34b9-46e4-b023-7c9fc84df00c"
      unitRef="usd">1000000</cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjYtMS0xLTEtMA_8dac207c-5a2d-4be5-b466-19dc36b26b6c"
      unitRef="usd">862000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMjYtMy0xLTEtMA_cf138b18-9261-470c-872a-1b4ae38ed131"
      unitRef="usd">-94000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzEtMS0xLTEtMA_0c4cee78-0977-4e6e-9a55-d41381d1fd17"
      unitRef="usd">587000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzEtMy0xLTEtMA_4f5eb9ba-1729-4214-b5ae-5d908bc35e65"
      unitRef="usd">40000000</us-gaap:RepaymentsOfLongTermDebt>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzMtMS0xLTEtMA_eb54f970-ea38-42fe-be31-c9c1907796e0"
      unitRef="usd">-28000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzMtMy0xLTEtMA_140ab5a7-610e-4241-b543-be78aa0b3ac3"
      unitRef="usd">-12000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzQtMS0xLTEtMA_e9f1c37a-56e7-49ab-94b2-304ea54407dd"
      unitRef="usd">149000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzQtMy0xLTEtMA_749f4b15-9dab-4fd0-a344-abfb24b4c32d"
      unitRef="usd">146000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzUtMS0xLTEtMA_49432759-16fa-4d05-80ba-c3f386322498"
      unitRef="usd">500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzUtMy0xLTEtMA_9125b9d3-dc52-4390-ad66-ba3a1a8c6fcf"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzYtMS0xLTEtMA_3eab2f3f-fbd0-4d67-bb68-acfa1f94342d"
      unitRef="usd">-1264000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzYtMy0xLTEtMA_f0c5e13f-fba8-4748-a5d4-4d7c0b194801"
      unitRef="usd">-198000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzgtMS0xLTEtMA_646769a8-9e6f-45cf-b711-39b745d78fd5"
      unitRef="usd">-5000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzgtMy0xLTEtMA_76784ff1-60f6-4996-969d-262d9415df5f"
      unitRef="usd">-3000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <cah:CashReclassifiedtoAssetsHeldforSale
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzktMS0xLTEtNjgyMg_e6e94caf-87b5-4bac-a6b1-617e5af5c82c"
      unitRef="usd">109000000</cah:CashReclassifiedtoAssetsHeldforSale>
    <cah:CashReclassifiedtoAssetsHeldforSale
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfMzktMy0xLTEtNjg0NA_d7bc06b2-c507-4004-aff7-6b3bfa13ef90"
      unitRef="usd">0</cah:CashReclassifiedtoAssetsHeldforSale>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfNDAtMS0xLTEtMA_64e0f200-55a9-4deb-b78b-65496815586a"
      unitRef="usd">-944000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfNDAtMy0xLTEtMA_4b1b5008-189e-41a4-bb21-b97cc1968b68"
      unitRef="usd">-25000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfNDItMS0xLTEtOTI5MA_baaadd47-ff66-42b2-ba2f-b0ac2c2f565c"
      unitRef="usd">3407000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i392aa0279fd84587b4a7422ec0b66687_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfNDItMy0xLTEtOTI3OA_1a8f7ea3-0c44-4a67-b96d-4cc3464670f7"
      unitRef="usd">2771000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfNDItMS0xLTEtMA_3fdd1850-dbde-45d7-ac81-04801d1edba8"
      unitRef="usd">2463000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6acbbe6b726149c8bb61fc9ac5b6a503_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83MC9mcmFnOjJhNWJlNDI4MDA0MzQ2ZWU5NDgwYTU0MTNhZTA4MmIyL3RhYmxlOmFjZTc2MjRkNmYwNTQyYzU4ZjA2MGI0OWFkODk3NTZhL3RhYmxlcmFuZ2U6YWNlNzYyNGQ2ZjA1NDJjNThmMDYwYjQ5YWQ4OTc1NmFfNDItMy0xLTEtMA_79c8c1e2-708f-4e0a-ae21-b337c47d0bef"
      unitRef="usd">2746000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83Ni9mcmFnOjEzODJmZTgzNTRmYzRmM2E5NzVlOWQ3YTY5NTU4YTUxL3RleHRyZWdpb246MTM4MmZlODM1NGZjNGYzYTk3NWU5ZDdhNjk1NThhNTFfMzgwNg_1a4a02b1-1f38-4d25-b1e3-483bb8cdd15d">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;1. Basis of Presentation and Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2022 and 2021 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2022 and June 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2022 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2022. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the "2021 Form 10-K"). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Issued Financial Accounting Standards Not Yet Adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the three months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83Ni9mcmFnOjEzODJmZTgzNTRmYzRmM2E5NzVlOWQ3YTY5NTU4YTUxL3RleHRyZWdpb246MTM4MmZlODM1NGZjNGYzYTk3NWU5ZDdhNjk1NThhNTFfMzgwOA_b91dc61b-f0d4-40dc-ae60-12f1e1642b85">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2022 and 2021 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2022 and June 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.&lt;/span&gt;&lt;/div&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2022 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2022. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the "2021 Form 10-K").</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83Ni9mcmFnOjEzODJmZTgzNTRmYzRmM2E5NzVlOWQ3YTY5NTU4YTUxL3RleHRyZWdpb246MTM4MmZlODM1NGZjNGYzYTk3NWU5ZDdhNjk1NThhNTFfMzI5ODUzNDkwMTM5NA_34bd5660-2f19-41a7-b3ea-49c460f185d5">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Issued Financial Accounting Standards Not Yet Adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the three months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMjEzL2ZyYWc6MjAwMTU1M2I3ZTM0NDJkMjkwOWU5Nzk3MWMxZmZjOTYvdGV4dHJlZ2lvbjoyMDAxNTUzYjdlMzQ0MmQyOTA5ZTk3OTcxYzFmZmM5Nl8zMjk4NTM0ODg5NjU1_5fe75baf-ea2b-4cb2-a504-4f65644f9685">&lt;div style="text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;2. Divestitures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, we sold our Cordis business to Hellman &amp;amp; Friedman for proceeds of $927 million, net of cash transferred, and we retained certain working capital accounts and certain liabilities. The purchase price is subject to adjustments based on working capital requirements as set forth in the agreement. Cardinal Health will retain product liability associated with lawsuits and claims related to inferior vena cava ("IVC") filters in the U.S. and Canada, as well as authority for these matters discussed in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i1938304362d7436fbafe0221fdeb43e5_94" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 6&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Cordis business operated within our Medical segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i01b3c57121b8495d8065ad7fce4a9b2d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMjEzL2ZyYWc6MjAwMTU1M2I3ZTM0NDJkMjkwOWU5Nzk3MWMxZmZjOTYvdGV4dHJlZ2lvbjoyMDAxNTUzYjdlMzQ0MmQyOTA5ZTk3OTcxYzFmZmM5Nl8zMjk4NTM0ODg4NjI1_20449f40-bbec-4e68-b1f2-584b1cda93c7"
      unitRef="usd">927000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RleHRyZWdpb246N2FmNmZkMThkYTM2NDczODg2Zjk2MWY4NmJhZGMzNWNfOTIw_632860be-08cf-4e8c-94dd-ad270dfd2873">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;3. Restructuring and Employee Severance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance costs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of professional, project management and other service fees to support divestitures, vendor transition fees, accelerated depreciation, lease costs associated with vacant facilities, project consulting fees, and certain other divestiture-related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2021 and 2020, restructuring costs primarily related to the implementation of certain enterprise-wide cost-savings measures. Restructuring costs during the three months ended September&#160;30, 2021 also included costs related to the divestiture of the Cordis business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;79&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RleHRyZWdpb246N2FmNmZkMThkYTM2NDczODg2Zjk2MWY4NmJhZGMzNWNfOTU1_cc47d4ed-e4e5-460c-b326-407b1715622c">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance costs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjAwOGM1NTNiZTY3ODQxOThhMjA5OWJkMGM5NDUwZDc1L3RhYmxlcmFuZ2U6MDA4YzU1M2JlNjc4NDE5OGEyMDk5YmQwYzk0NTBkNzVfMi0xLTEtMS0w_0b2ff880-ab7f-432b-b09a-04a00a211364"
      unitRef="usd">8000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjAwOGM1NTNiZTY3ODQxOThhMjA5OWJkMGM5NDUwZDc1L3RhYmxlcmFuZ2U6MDA4YzU1M2JlNjc4NDE5OGEyMDk5YmQwYzk0NTBkNzVfMi0zLTEtMS0w_1adef815-5fc9-421f-91a0-fe43c6d0ec6f"
      unitRef="usd">24000000</us-gaap:SeveranceCosts1>
    <cah:FacilityExitAndOtherCosts
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjAwOGM1NTNiZTY3ODQxOThhMjA5OWJkMGM5NDUwZDc1L3RhYmxlcmFuZ2U6MDA4YzU1M2JlNjc4NDE5OGEyMDk5YmQwYzk0NTBkNzVfMy0xLTEtMS0w_767f900f-dcb4-4ab8-a3d0-59d6784975da"
      unitRef="usd">10000000</cah:FacilityExitAndOtherCosts>
    <cah:FacilityExitAndOtherCosts
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjAwOGM1NTNiZTY3ODQxOThhMjA5OWJkMGM5NDUwZDc1L3RhYmxlcmFuZ2U6MDA4YzU1M2JlNjc4NDE5OGEyMDk5YmQwYzk0NTBkNzVfMy0zLTEtMS0w_87f4e097-88d1-4e62-9982-c68868dbf1f1"
      unitRef="usd">13000000</cah:FacilityExitAndOtherCosts>
    <us-gaap:RestructuringCharges
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjAwOGM1NTNiZTY3ODQxOThhMjA5OWJkMGM5NDUwZDc1L3RhYmxlcmFuZ2U6MDA4YzU1M2JlNjc4NDE5OGEyMDk5YmQwYzk0NTBkNzVfNC0xLTEtMS0w_13a61f57-b1eb-42cf-92ee-eb0dd32dfba8"
      unitRef="usd">18000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjAwOGM1NTNiZTY3ODQxOThhMjA5OWJkMGM5NDUwZDc1L3RhYmxlcmFuZ2U6MDA4YzU1M2JlNjc4NDE5OGEyMDk5YmQwYzk0NTBkNzVfNC0zLTEtMS0w_389680a0-3abe-4384-b33d-5315aaad2b9d"
      unitRef="usd">37000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RleHRyZWdpb246N2FmNmZkMThkYTM2NDczODg2Zjk2MWY4NmJhZGMzNWNfOTU2_405edb60-9c0b-4b90-b7bd-b0e8b1a06503">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;79&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i196f17b7be4b4ddd93ed4aca9bcc505d_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfMS0xLTEtMS0w_44cc5b19-85e2-4eb4-abfa-75255ca17f07"
      unitRef="usd">53000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i9de9a16f990643ea9672976a861c7419_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfMS0zLTEtMS0w_e3a8e674-54b3-4fcd-889b-bea627827e87"
      unitRef="usd">26000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfMS01LTEtMS0w_3cbc11c7-a294-4fad-a091-3e3c3f2a34b8"
      unitRef="usd">79000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCosts
      contextRef="i6ae9641dcdf64751a47407f1c250d242_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfMi0xLTEtMS0w_fd7d21b8-ac8b-4d17-beba-dd09f4fd26f4"
      unitRef="usd">8000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i6a95952d91f24a96acde3076dc633d9c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfMi0zLTEtMS0w_99358bff-25ea-443e-adf9-e4a5fd968577"
      unitRef="usd">1000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfMi01LTEtMS0w_8cb0b5b3-02dd-42ae-a58e-b300a3dbf1e2"
      unitRef="usd">9000000</us-gaap:RestructuringCosts>
    <us-gaap:PaymentsForRestructuring
      contextRef="i6ae9641dcdf64751a47407f1c250d242_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfMy0xLTEtMS0w_53788172-2994-46d2-80f2-771abc4536d5"
      unitRef="usd">12000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i6a95952d91f24a96acde3076dc633d9c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfMy0zLTEtMS0w_998d673e-a718-4771-90c6-dedaf811c67d"
      unitRef="usd">2000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfMy01LTEtMS0w_ba8bb02c-3615-4e7a-bc26-9d1fd5ace6e1"
      unitRef="usd">14000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="ib92ed0577dac4bbc9b8ad80b5f67b420_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfNC0xLTEtMS0w_4e61bac3-16c6-40a8-a7dd-ab8ae33f16a9"
      unitRef="usd">49000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="iaddf0bca9420410db9178ce7262fc4d7_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfNC0zLTEtMS0w_c8927ec9-7f2f-4afc-8dcd-3d67f5d2cf0b"
      unitRef="usd">25000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV83OS9mcmFnOjdhZjZmZDE4ZGEzNjQ3Mzg4NmY5NjFmODZiYWRjMzVjL3RhYmxlOjY4MzdhYmUxZTdhZTQwNjZhZWM3ZjQ4NTU1MTk2MDgyL3RhYmxlcmFuZ2U6NjgzN2FiZTFlN2FlNDA2NmFlYzdmNDg1NTUxOTYwODJfNC01LTEtMS0w_f8583051-0b22-4d34-b9ca-cca52aebb1fb"
      unitRef="usd">74000000</us-gaap:RestructuringReserve>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfNDcy_5634b079-acbb-43ba-9923-de8c69218cf1">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,989&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill acquired, net of purchase price adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,659&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,320&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,325&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,039&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,286&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;552&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;216&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,038&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;526&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,901&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,014&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,927&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,901&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total amortization of intangible assets was $78 million and $115 million for the three months ended September&#160;30, 2021 and 2020, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2022 through 2026 is as follows: $236 million, $287 million, $264 million, $238 million, and $212 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfNDc4_82938f00-33a9-468e-9124-e7a5e73f0d4f">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,989&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill acquired, net of purchase price adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,659&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,320&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ibcfd5d7a31364ca9903baa61bbbb046b_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfMS0xLTEtMS0w_85c3969c-ba4c-42b3-b9bd-58ac906aaea5"
      unitRef="usd">2659000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3e6de765995148a588beb68d12e77abd_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfMS0zLTEtMS0w_8a600d60-436e-4090-9317-7778e8d638a6"
      unitRef="usd">5330000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfMS01LTEtMS0w_249e1201-5719-494e-9662-68e6a2f0cbf6"
      unitRef="usd">7989000000</us-gaap:Goodwill>
    <us-gaap:GoodwillTransfers
      contextRef="i6abff27b2a984366ad5cc02faa9ea0f8_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfMi0xLTEtMS0w_f852d04a-82da-456e-8933-6aa180625dba"
      unitRef="usd">0</us-gaap:GoodwillTransfers>
    <us-gaap:GoodwillTransfers
      contextRef="i91113dadf04744e2ad236c765eb25aa8_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfMi0zLTEtMS0w_1ec58b30-9c3b-4833-bb36-823ee1fbe92d"
      unitRef="usd">0</us-gaap:GoodwillTransfers>
    <us-gaap:GoodwillTransfers
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfMi01LTEtMS0w_9c0f3479-f4e0-483f-b711-992536d82202"
      unitRef="usd">0</us-gaap:GoodwillTransfers>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i6abff27b2a984366ad5cc02faa9ea0f8_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfMy0xLTEtMS0w_24e4d5c1-7901-498e-87eb-af363919a57d"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i91113dadf04744e2ad236c765eb25aa8_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfMy0zLTEtMS0w_409778c0-aa22-4164-882b-983ca5123348"
      unitRef="usd">10000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfMy01LTEtMS0w_66715601-640e-4ed7-ae6c-aa1bca52bea8"
      unitRef="usd">10000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="iacaa4d2e469a4a02ae9218aa67d40c64_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfNC0xLTEtMS0w_0c74bd92-2089-4c3c-9494-37ca83e4e29b"
      unitRef="usd">2659000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5e5bb242480346b0b189d9c91c958e6c_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfNC0zLTEtMS0w_fcf3e354-04f6-4ca4-b2f1-979f7eef8549"
      unitRef="usd">5320000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjAwMmJjYjAwOTg4ZDRmNzI5ZjA1NDlmZTM4OWJiZmM3L3RhYmxlcmFuZ2U6MDAyYmNiMDA5ODhkNGY3MjlmMDU0OWZlMzg5YmJmYzdfNC01LTEtMS0w_84b386f2-b0f1-4303-804b-e8196983b380"
      unitRef="usd">7979000000</us-gaap:Goodwill>
    <cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfNDgw_8131af5b-68a8-4b1d-af78-5c917528dd4c">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,325&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,039&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,286&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;552&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;216&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,038&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;526&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,915&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,901&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,014&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,927&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,901&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and patents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iaa0b5e3b96bc4154b048e676455845f3_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfMy0xLTEtMS0w_7feba8d8-1078-4329-92be-f00d48ee3473"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iaa0b5e3b96bc4154b048e676455845f3_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfMy01LTEtMS0w_89e26c18-7a37-44b2-b17c-d99f43257836"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfNC0xLTEtMS0w_18066296-3174-4c77-ac77-9f158c0b90ef"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfNC01LTEtMS0w_d29d6571-9d6c-469d-b072-e8d41126fd1e"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3f4e5c6594c84545986f558f8997e266_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfNy0xLTEtMS0w_7aeac0d4-8eca-410f-bb1a-d0709f285477"
      unitRef="usd">3325000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3f4e5c6594c84545986f558f8997e266_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfNy0zLTEtMS0w_3d8fb712-de63-46e1-957f-b188f5b49dc6"
      unitRef="usd">2039000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3f4e5c6594c84545986f558f8997e266_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfNy01LTEtMS0w_f1afe355-0cd7-440c-9872-238e3477adb3"
      unitRef="usd">1286000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="iee7a3bfba2ad48c9b5b2b1646931e919_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfNy03LTEtMS0w_35dd3e4a-1f94-41bc-88f2-6f526327f378">P11Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib71d7e3c32bb4a169cea90f54c789e35_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfOC0xLTEtMS0w_e030695c-e185-4da8-af05-313359fcca2b"
      unitRef="usd">552000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib71d7e3c32bb4a169cea90f54c789e35_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfOC0zLTEtMS0w_cb248066-4390-421f-8abd-56a3ef093a9e"
      unitRef="usd">336000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib71d7e3c32bb4a169cea90f54c789e35_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfOC01LTEtMS0w_a1d6e556-6ab3-4c2e-815f-9bfcb21597f0"
      unitRef="usd">216000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="ibf622980e47e43b0b3979cfd30243861_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfOC03LTEtMS0w_8e4a3bef-c199-4bb4-9cf1-a6805e1e6c19">P9Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5e0815e6302b4d62b7c5d4e8d1168325_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfOS0xLTEtMS0w_e3b89ebb-b6f7-421d-8f46-95c3228a85ad"
      unitRef="usd">1038000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5e0815e6302b4d62b7c5d4e8d1168325_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfOS0zLTEtMS0w_48ba2d8c-b6c1-4b3b-bcb4-101ee2518c6f"
      unitRef="usd">526000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5e0815e6302b4d62b7c5d4e8d1168325_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfOS01LTEtMS0w_f9eb8da4-67b4-4c0a-85d5-4e0fbc4b8c6e"
      unitRef="usd">512000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i0346feda6c3043a68c4a5ff7af149304_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfOS03LTEtMS0w_2c13507c-db20-4bef-8d0e-6a0e4b834a72">P9Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfMTAtMS0xLTEtMA_45470289-4b3c-423d-9e34-bc19114c30d9"
      unitRef="usd">4915000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfMTAtMy0xLTEtMA_9c167248-01e9-46e8-9343-eb120c3204ff"
      unitRef="usd">2901000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfMTAtNS0xLTEtMA_a2ba06a6-df68-4ae3-9167-4ab691247f22"
      unitRef="usd">2014000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfMTAtNy0xLTEtMA_0e9c52dc-146f-4fba-bee7-8cf1c9615f77">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfMTEtMS0xLTEtMA_05040cd5-fb6c-4f27-8848-9c600f4e95e2"
      unitRef="usd">4927000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfMTEtMy0xLTEtMA_57fc362c-a49f-46f1-856e-f07c5fc19c71"
      unitRef="usd">2901000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOjBlYjBjZTcxOGY2MzQ1YjI4YWVhZGM0OTUzYWRjOGY3L3RhYmxlcmFuZ2U6MGViMGNlNzE4ZjYzNDViMjhhZWFkYzQ5NTNhZGM4ZjdfMTEtNS0xLTEtMA_cb875480-bc2e-4adf-8e07-5d9af69ce4fa"
      unitRef="usd">2026000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i55bcf168ab754a59940d4801f6fa8bc8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfMy0xLTEtMS0w_2067407c-ef78-4e75-8fdf-d44cc0ef6c28"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i55bcf168ab754a59940d4801f6fa8bc8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfMy01LTEtMS0w_195bae28-21c6-4512-ac8f-6aa52ece5da8"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfNC0xLTEtMS0w_6535aad3-e513-43a7-aebd-2ac52df7f675"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfNC01LTEtMS0w_10874446-b838-4573-8955-6734fef2c5b5"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i85771b30728a4925a481cfb73f86c250_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfNy0xLTEtMS0w_1bab3939-257b-4f8f-8339-86d716ede392"
      unitRef="usd">3330000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i85771b30728a4925a481cfb73f86c250_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfNy0zLTEtMS0w_94467006-ba05-41c3-9f5d-879c279ea46f"
      unitRef="usd">1989000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i85771b30728a4925a481cfb73f86c250_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfNy01LTEtMS0w_edbb0d9b-1679-43d1-926d-c1d5e960e684"
      unitRef="usd">1341000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i96c38f0127214920937fcab46ec74b11_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfOC0xLTEtMS0w_6638d681-8448-461e-b1b6-12e237acf54c"
      unitRef="usd">551000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i96c38f0127214920937fcab46ec74b11_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfOC0zLTEtMS0w_e50e34da-cd45-40fb-bf9e-1954d41e0cc8"
      unitRef="usd">328000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i96c38f0127214920937fcab46ec74b11_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfOC01LTEtMS0w_3f74bf2a-4aa3-4d80-92d2-70aea32dea7b"
      unitRef="usd">223000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibfe31bf069634c55be5450be71e3f036_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfOS0xLTEtMS0w_f7b5c9c4-eec6-4964-b623-c68e5fe4e157"
      unitRef="usd">1035000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibfe31bf069634c55be5450be71e3f036_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfOS0zLTEtMS0w_4c633092-fdcb-41af-a86d-00b26c51ffd9"
      unitRef="usd">506000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibfe31bf069634c55be5450be71e3f036_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfOS01LTEtMS0w_1be267a7-4ed4-48d0-858e-7ba8bc002e07"
      unitRef="usd">529000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfMTAtMS0xLTEtMA_d265e434-538d-4024-96f2-2518eeb3518f"
      unitRef="usd">4916000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfMTAtMy0xLTEtMA_8adffed0-cb28-4c4a-9e55-090aa3f30b93"
      unitRef="usd">2823000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfMTAtNS0xLTEtMA_e117e4ae-627a-412c-9fe0-fa9db7ddf507"
      unitRef="usd">2093000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfMTEtMS0xLTEtMA_843153a3-fa51-4a9a-9698-7882f023fb89"
      unitRef="usd">4928000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfMTEtMy0xLTEtMA_7ada9826-0a19-46e3-9c61-c74e6cf7e957"
      unitRef="usd">2823000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RhYmxlOmU2YTM1ZDhiNzdiYTRlYzBiZWQ4NmU2N2ZlZmRkMjM4L3RhYmxlcmFuZ2U6ZTZhMzVkOGI3N2JhNGVjMGJlZDg2ZTY3ZmVmZGQyMzhfMTEtNS0xLTEtMA_7070d9f4-614a-4315-b00d-592d8b33c4ca"
      unitRef="usd">2105000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfMjYz_3165fb71-9770-4b85-b667-d1ae6fdaaecd"
      unitRef="usd">78000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfMjcw_03cfb3df-5a85-4df8-9093-8bbf8783e440"
      unitRef="usd">115000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfNDMz_113f4147-3069-411a-aee1-87fd12e439f1"
      unitRef="usd">236000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfNDM3_f8e907b8-9ee3-46c6-babe-a9487c83e2e6"
      unitRef="usd">287000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfNDQx_2408c61e-d59c-4988-8ed6-bd9aad993575"
      unitRef="usd">264000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfNDQ1_0f4fbdaa-d393-4241-8e6b-70ecdc044160"
      unitRef="usd">238000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV84Mi9mcmFnOjRkMGNlNjlhOGE4MDRkOWU5OTZjMzViZTFlZjRiOTM3L3RleHRyZWdpb246NGQwY2U2OWE4YTgwNGQ5ZTk5NmMzNWJlMWVmNGI5MzdfNDUz_2aab06c1-8375-465e-9d79-367984dd1f8f"
      unitRef="usd">212000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfMTk1MQ_55c7170d-6e70-45cc-89b9-43f00be0c40c">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;5. Long-Term Obligations and Other Short-Term Borrowings &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had total long-term obligations, including the current portion and other short-term borrowings, of $5.7 billion and $6.2 billion at September 30, 2021 and June 30, 2021, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $23.4 billion and $23.7 billion at September 30, 2021 and June 30, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2021, we redeemed all outstanding $572 million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $10&#160;million loss on early extinguishment of debt. The early redemption was funded with available cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2020, we early repurchased a total of $37 million of notes due in 2022 with available cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Financing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$2.0 billion&#160;commercial paper program backed by a $2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion committed receivables sales facility. At September 30, 2021, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#x201c;CHF&#x201d;) through September 30, 2022. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose-bankruptcy remote entity whose assets are available solely to satisfy the claims of its creditors. &lt;/span&gt;&lt;/div&gt;Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. At September 30, 2021, we were in compliance with this financial covenant.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfMTI2_e3c22127-f926-4b24-acea-2852624db167"
      unitRef="usd">5700000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfMTMz_fa47e711-ec90-403c-b591-c25678cf05b5"
      unitRef="usd">6200000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfMzI5ODUzNDg5MTE3OA_e44e5ce5-ee13-4133-8efc-9d0cde21bab7"
      unitRef="usd">23400000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfMzI5ODUzNDg5MTE3NA_ab8292e2-2804-4193-8149-6a5eacf65016"
      unitRef="usd">23700000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="ic77dd428b1ff4601871e6896e86dd282_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfMzI5ODUzNDg4NjQzOA_47f75466-2650-4155-be14-58c8106e7262"
      unitRef="usd">572000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic758f5072c934983b122d89f93601f02_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfMzI5ODUzNDg4NjQ3Ng_eed16355-333b-46f0-931c-b04c183a02ab"
      unitRef="usd">10000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <cah:NotesPayableRepurchased
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfMzI5ODUzNDg4NjQzMg_5db07834-e4b7-4153-9262-07a021d032cd"
      unitRef="usd">37000000</cah:NotesPayableRepurchased>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iece19fdd095e453a867d2238196e3c8e_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfNzkw_08cfec6b-21ce-4e7e-9af3-91e305f7aa28"
      unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i89c1a8ce62804d04a9257ca991dbc676_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfODMw_ac555cfa-6755-4b76-a4d0-d1b35684273a"
      unitRef="usd">2000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="if36f5f5d5c97414c9f7c71d8c7230c33_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfODc1_ea5e4c35-b166-415a-b9e3-b115ae52ec97"
      unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:OtherShortTermBorrowings
      contextRef="ibbd8c1e471554454b0fa1b9c40012912_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85MS9mcmFnOjJiMWRlYTU4MjI4ZjRmODI5ZmNkY2VmNDgyYmRjNDkzL3RleHRyZWdpb246MmIxZGVhNTgyMjhmNGY4MjlmY2RjZWY0ODJiZGM0OTNfMzI5ODUzNDg5MTE5MQ_f1dd2acf-8e24-4d6e-8168-bd2e0a054267"
      unitRef="usd">0</us-gaap:OtherShortTermBorrowings>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfMTQ3ODU_9c141e91-ae13-4659-8645-2cd5b2630a6e">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;6. Commitments, Contingent Liabilities and Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Generic Sourcing Venture with CVS Health Corporation ("CVS Health")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New York Opioid Stewardship Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. In October 2021, the U.S. Supreme Court declined to review the decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41 million for calendar years 2017 and 2018 during the three months ended September 30, 2020 based on the probable estimated payment amount, which is our best estimate of the OSA payments probable at September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We become involved from time to time in disputes, litigation and regulatory matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected &lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we become aware through employees, internal audits or other parties of possible product quality, regulatory or compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings/(loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Opioid Lawsuits and Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately 3,300 lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;States &amp;amp; Political Subdivisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 2,900 of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the &#x201c;MDL&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, 25 state attorneys general have filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general; the framework is designed to resolve pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). We continued to build out the Settlement Framework and to negotiate the terms of the settlement with the leadership group and other representatives of states and political subdivisions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July, 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement (the &#x201c;Proposed Settlement Agreement&#x201d;) and settlement process that, if all conditions are satisfied, would result in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. The settlement process does not contemplate participation by any non-governmental or non-political entities or individuals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the three distributors determined that enough states had agreed to participate in the Proposed Settlement Agreement to proceed to the next phase of the settlement process, which is the subdivision sign-on period. However, the Proposed Settlement Agreement is still subject to contingencies and will not become effective unless and until the three distributors each make separate independent determinations that a sufficient number of political subdivisions, including those that have not sued, have agreed to participate in the Agreement (or otherwise have had their claims foreclosed) to proceed to effectiveness. Prior to that determination, the participating states will also have an opportunity to make a determination as to whether a sufficient number of political subdivisions have agreed to the Proposed Settlement Agreement (or otherwise had their claims foreclosed) to proceed with the Proposed Settlement Agreement. This process is currently contemplated to end in February 2022, although it may be extended by agreement. It is possible that a sufficient number of states and subdivisions will not agree to the Proposed Settlement &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Agreement or that other required contingencies will not be satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the required contingencies are satisfied, the Proposed Settlement Agreement would become effective sixty (60) days after the distributors determine that there is sufficient participation to proceed to effectiveness. During this 60-day period, the participating states and the distributors would cooperate to obtain consent judgments embodying the terms of the Settlement in each participating state. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Proposed Settlement Agreement includes a cash component, pursuant to which the Company would pay up to approximately $6.37&#160;billion, the majority of which would be paid over 18 years. The exact payment amount will depend on several factors, including the participation rate of states and political subdivisions, the extent to which states take action to foreclose opioid lawsuits by political subdivisions (e.g., laws barring or limiting opioid lawsuits by political subdivisions), and the extent to which political subdivisions in participating states file additional opioid lawsuits against the Company after the Proposed Settlement Agreement becomes effective. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Proposed Settlement Agreement also includes injunctive relief terms related to distributors&#x2019; controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating controlled substances monitoring programs; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring. A monitor will be selected to oversee compliance with these provisions for a period of five years. In addition, we and the two other settling distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting, which distributors will fund the for ten years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors entered into a settlement with each of the States of New York and Ohio and their participating subdivisions. If the Proposed Settlement Agreement becomes effective, New York and Ohio and their participating subdivisions will become a part of it. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups. In September 2021 we announced that we, along with two other national distributors, had reached an agreement with the Cherokee Nation in connection with ongoing negotiations toward a broader agreement with Native American tribes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A trial before a federal judge in West Virginia brought by Cabell County and City of Huntington against us and two other national distributors concluded in July 2021. The judge has not yet issued a decision. In addition, a trial in the case brought by the Washington Attorney General against the Company and the same two other national distributors is scheduled to begin in November 2021 and the Washington Attorney General has issued a press release stating that Washington will not agree to the Proposed Settlement &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Agreement. A trial in the case brought by the Rhode Island Attorney General is scheduled to begin in January 2022 and a trial in the Dallas County case is scheduled to begin in Texas in February 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2021, we paid into escrow the majority of our first annual payment, which is reflected in prepaid expenses and other assets in our condensed consolidated balance sheets. We also made certain payments under the separate New York and Ohio settlements. In total, we have $6.68&#160;billion accrued at September&#160;30, 2021, of which $441&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. During the three months ended September 30, 2020, we recorded total pre-tax charges of $1.02&#160;billion in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings/(loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Justice Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Private Plaintiffs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Proposed Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately 446 lawsuits as of November 4, 2021. Of these, 129 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are vigorously defending ourselves in these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Insurance Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above. In October 2020, we filed a complaint for declaratory &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;judgment against National Union Fire Insurance Company of Pittsburgh, PA (&#x201c;National Union&#x201d;) seeking a declaration that National Union is obligated to reimburse us for defense costs incurred in connection with the lawsuits described above. In January, 2021, Swiss Re International SE commenced an arbitration in London seeking a determination that it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cordis IVC Filter Matters &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability Lawsuits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of November 4, 2021, we are named as a defendant in 434 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,614 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products. Another 33 lawsuits involving similar claims by approximately 38 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately 1,300 claims. This agreement is subject to certain contingencies. We continue to vigorously defend ourselves in these lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2021, we had a total of $547&#160;million net of estimated insurance recoveries, accrued for losses and legal defense costs, related to the Cordis IVC filter lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $1.07&#160;billion, net of estimated insurance recoveries. The sale of the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Mexico Attorney General Action &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations made are similar to those made in the product liability lawsuits, described above. We intend to vigorously defend ourselves against these claims. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SEC Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, we received a subpoena from the U.S. Securities and Exchange Commission requesting the production of documents from 2015 through 2019 relating to inventory in the Cordis business, analysis of goodwill of the Medical segment and other matters. We are cooperating with this inquiry and related &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;requests and cannot predict the outcome or duration of the investigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shareholder Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Louisiana Sheriffs' Pension &amp;amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In November 2020, we filed a motion to dismiss the amended complaint, which was denied in September 2021. We dispute these allegations and intend to vigorously defend against them.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Specialty Solutions DOJ Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the United States Attorney&#x2019;s Office for the District of Massachusetts (the "USAO") commenced an investigation pertaining to the U.S. federal healthcare fraud and abuse laws. These requests sought, among other things, documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. We are cooperating with these requests and are engaged in resolution discussions with the USAO and Department of Health and Human Services, Office of Inspector General. In connection with these discussions, we recorded $13 million of expense within litigation (recoveries)/charges, net in our consolidated statements of earnings/(loss) during the fiscal year ended June&#160;30, 2021. We cannot predict the outcome of the discussions and it is possible that we may incur additional losses or agree to other remedial measures; however, we are not currently able to estimate a range of reasonably possible additional losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Civil Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Generic Pharmaceutical Pricing Antitrust Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Active Pharmaceutical Ingredient Impurity Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. &lt;/span&gt;&lt;/div&gt;In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the &#x201c;Sartan MDL&#x201d;) alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We are vigorously defending ourselves in this matter.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LongtermPurchaseCommitmentPeriod
      contextRef="iaba53fd0a02e4df1a2c874629b263ee5_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfMjUz_34bd3fb5-dcea-48b1-b18c-ce1d75ec3c19">P10Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <cah:AggregateAnnualAssessment
      contextRef="i61d8bd08ced14bfaa33ff22a90a9d2ca_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNjk0_6afefd75-1892-4696-a965-38bcdfafd2b0"
      unitRef="usd">100000000</cah:AggregateAnnualAssessment>
    <cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct
      contextRef="i6e5595e73ee346d2a2b82eb33142c333_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfMTgyOA_edb50336-735f-4500-bfd2-5584110706f1"
      unitRef="usd">41000000</cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct>
    <cah:LossContingencyLawsuitsNumber
      contextRef="ic7bc766a995e48b4954e62dc20520496_I20211104"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4Mzg1MA_3e0512d6-957d-4b0f-a14a-2c306b9c69f6"
      unitRef="lawsuit">3300</cah:LossContingencyLawsuitsNumber>
    <cah:LossContingencyLawsuitsNumber
      contextRef="i089f62a751ee489da5e10d6b58b6adc9_I20211104"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4Mzg1NA_0eb624af-787d-46bc-83e4-3d12512be896"
      unitRef="lawsuit">2900</cah:LossContingencyLawsuitsNumber>
    <cah:NumberofStateAttorneysGeneralfilinglawsuits
      contextRef="ic7bc766a995e48b4954e62dc20520496_I20211104"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4Mzg1OA_d7563ae9-90f5-4347-85d0-cefd5c9d9330"
      unitRef="stateag">25</cah:NumberofStateAttorneysGeneralfilinglawsuits>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ie46ae6d3a39f4f97bd6436e7342a9a4d_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4Mzg3NQ_e3528a1b-d99f-488a-8b52-456eb4ca1aef"
      unitRef="usd">6370000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LitigationReserve
      contextRef="ie46ae6d3a39f4f97bd6436e7342a9a4d_I20210930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4Mzk2NA_dd97305c-0755-47c7-92bc-45a4bb7d2fdb"
      unitRef="usd">6680000000</us-gaap:LitigationReserve>
    <us-gaap:LitigationReserve
      contextRef="i638a4b60fc7140b7b4525502482b8b12_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNzE0NjgyNTcwNTg1MQ_c0b7acbf-a8e6-414e-8a78-b2c2ce84bff9"
      unitRef="usd">441000000</us-gaap:LitigationReserve>
    <us-gaap:LitigationSettlementExpense
      contextRef="i28701b9327404d53941d5dd148cdf77c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfMzI5ODUzNTAxOTUyNA_9458ba26-399c-473f-aa6c-c6b583914744"
      unitRef="usd">1020000000.00</us-gaap:LitigationSettlementExpense>
    <cah:LossContingencyLawsuitsNumber
      contextRef="ie546f3bca04b4fe2b2764f97ebc4ad00_I20211104"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4Mzg5OQ_b8898d63-9343-4532-9a68-666b07ef82ce"
      unitRef="lawsuit">446</cah:LossContingencyLawsuitsNumber>
    <cah:LossContingencyLawsuitsNumber
      contextRef="if11b202b8ca343b0a9e421d1841eebd6_I20211104"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4MzkwMw_d2836ea4-f7c3-411f-bc70-7267798e1494"
      unitRef="lawsuit">129</cah:LossContingencyLawsuitsNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="if50f5130dc374149935c142a609db653_D20211104-20211104"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4MzkwNw_cd2af0df-ab79-45dd-91ce-0977065cf313"
      unitRef="lawsuit">434</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i73badf44a1bd45889e11d4037d77a5a5_D20211104-20211104"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4MzkxMQ_fdb99e21-1e86-4115-b1d1-944ea7831e16"
      unitRef="plaintiff">5614</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i987d5b5da3a84e95a610a63bb8f2de3a_D20211104-20211104"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4MzkxNQ_32d7205a-d79b-4296-8d3d-2615993fa3cd"
      unitRef="lawsuit">33</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i0ae57499f11845a387078309fc16ffc6_D20211104-20211104"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4MzkxOQ_e8737483-405f-4172-8cba-5ccd8c761274"
      unitRef="plaintiff">38</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyClaimsSettledNumber
      contextRef="i987d5b5da3a84e95a610a63bb8f2de3a_D20211104-20211104"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfMzI5ODUzNTAxOTYxMg_56e56d19-1549-403a-8c6c-3bcfe439ec89"
      unitRef="lawsuit">1300</us-gaap:LossContingencyClaimsSettledNumber>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i224e04590a6a4682baab9a6e6d77ce88_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4MzkyMw_6037d218-481d-41de-8317-d405a3f39a06"
      unitRef="usd">547000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="iab6062bf74dd4e29a56a98ea3760db61_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4MzkzMg_e2cd4103-58a3-43ef-9b23-b1327bda0ce6"
      unitRef="usd">1070000000.00</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i63cac0f2590c417e85f3d03334418831_D20200701-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85NC9mcmFnOmMxN2Q4MzBjMmZlNTQxNzE5YTNiYWNkMGVlMjAxNWRlL3RleHRyZWdpb246YzE3ZDgzMGMyZmU1NDE3MTlhM2JhY2QwZWUyMDE1ZGVfNDk0NzgwMjM4MzkzOQ_adb2c308-7bda-42b0-8c94-0d8dbaa4dffc"
      unitRef="usd">13000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNjYyOQ_ff7ac685-56c8-4ac0-b7c6-32ed341df01d">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;7. Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fluctuations in our provision for/(benefit from) income taxes as a percentage of pre-tax loss (&#x201c;effective tax rate&#x201d;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cordis Divestiture&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2021, we completed the divestiture of the Cordis business. In connection with the closing, we recorded net tax expense of $9&#160;million. The tax effects of these matters during the three months ended September 30, 2021 were included in our full year effective tax rate forecast. We currently estimate that the tax expense associated with this matter for the full fiscal 2022 will be $38&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tax Effects of Opioid Litigation Charges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the $1.02&#160;billion pre-tax charges for the opioid litigation during the three months ended September 30, 2020, the net tax benefit was $450&#160;million for the three months ended September 30, 2020, and $228&#160;million for fiscal 2021. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $34 million during the three months ended September 30, 2020, and $219&#160;million for fiscal 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible Congress or the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit may differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Effective Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2021 and 2020, the effective tax rate was 26.3 percent and 61.8 percent, respectively. The decrease in the effective tax rate for the three months ended September 30, 2021 compared to the prior year period was primarily due to the treatment of the tax impacts of the opioid litigation accrual recorded in prior year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unrecognized Tax Benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had $931 million and $932 million of unrecognized tax benefits at September 30, 2021 and June&#160;30, 2021, respectively. The September 30, 2021 and June&#160;30, 2021 balances include $848 million and $849 million, respectively, of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2021 and June&#160;30, 2021, we had $51 million and $49 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of $20 million, exclusive of penalties and interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Tax Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), which has been acquired by Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $72 million at both September&#160;30, 2021 and June&#160;30, 2021, and is included in other assets in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition. The indemnification receivable was&#160;$12 million at both September&#160;30, 2021 and June&#160;30, 2021, and is included in other assets in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i01b3c57121b8495d8065ad7fce4a9b2d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzI5ODUzNDkxMjMwNA_19bded08-9389-4a4c-a486-9619ba6a636f"
      unitRef="usd">9000000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i0b29eeee66ff478fa0d4886f822b6a59_D20210701-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzI5ODUzNDkxMjMxNg_5219bd7e-c285-43dc-a54d-f32a90b2b15e"
      unitRef="usd">38000000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:LitigationSettlementExpense
      contextRef="i28701b9327404d53941d5dd148cdf77c_D20200701-20200930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzA3_3a365e69-9002-4840-96a9-c700895053b8"
      unitRef="usd">1020000000.00</us-gaap:LitigationSettlementExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i28701b9327404d53941d5dd148cdf77c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzI5ODUzNDkxMjIzNQ_5e006ce8-95fa-494b-b9a9-d0d9d3f88478"
      unitRef="usd">450000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i19d2a3c94ab340b884ea4bca21d04b54_D20200701-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzI5ODUzNDkxMjI0OQ_93026598-a1cd-455a-9c6b-6e08c04d71a1"
      unitRef="usd">228000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if54e4cb700254d5493fff77ca38ac9ef_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNzU0_8dae2889-a612-4ae6-b9e3-07051d2e1f34"
      unitRef="usd">34000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i424036b844734cb19b42015632d7a6f2_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzI5ODUzNDkxMjI2Mw_d0339b18-f8bc-4d40-8cec-e221508f236e"
      unitRef="usd">219000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzUxOA_8e77bd76-c6b7-4b1f-b3e1-c3a600f98396"
      unitRef="number">0.263</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzUzMw_961c5e60-7397-4cc3-84d2-cc721f30b4d8"
      unitRef="number">0.618</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzg0OQ_cb16e6ff-9e6e-4e4e-9eba-b864eb947fe6"
      unitRef="usd">931000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzg1Ng_3d2b1add-3d6d-49aa-a812-00b0cdca0dd2"
      unitRef="usd">932000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzk0Nw_5f0ddb01-98ed-46f5-9d04-da7727d0819d"
      unitRef="usd">848000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzk1NA_c5bd4a8e-491e-46cd-a36e-5f1ecc93cd2e"
      unitRef="usd">849000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNDA5MQ_4e38ddbb-d24f-4b6c-b144-68c4da853951"
      unitRef="usd">51000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNDA5OA_67a5d94b-a930-48cc-aa9c-83523192014a"
      unitRef="usd">49000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i3e9abc9dd3db43cc9b26b208cbdb777c_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNDk1Ng_b5fb1f64-d257-4611-8c98-616d5e4892c7"
      unitRef="usd">0</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="ibc981e52c59246c48326101ada65bb8b_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfOTg5NTYwNDY1OTUzOA_8ff60503-d01d-4216-9600-de95d588957c"
      unitRef="usd">20000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:OpenTaxYear
      contextRef="i658749f8d08c4de3bd8ca178ca6268c4_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNTI1Mw_35f4459e-bd77-4688-ba97-0c3b1b9db955">2015</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i406b689ab44d4833a222efac0f41c896_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfMzI5ODUzNDkxMjI3Nw_50860d4a-edab-4a5c-8b97-f9f1eefc41e9">2020</us-gaap:OpenTaxYear>
    <cah:IndemnificationReceivable
      contextRef="i7ff0423111af46e796881f5bffabb11e_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNTk4Ng_2f51c73d-3e12-47a8-a3a7-905f7dc58e3b"
      unitRef="usd">72000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="ib2c2db2160bf4119bcf457d76b23d394_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNTk4Ng_69d0e7e3-862a-4315-a619-733ee2ca00e5"
      unitRef="usd">72000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="iddc20db237214f5184481bac8f6153dc_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNjMzOA_47f5389f-9937-40d6-89cd-e69c4d4d6c36"
      unitRef="usd">12000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="ie17b5134d5df4708a1d031b82fbcd4f4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV85Ny9mcmFnOmUyYmZmMjFmMzI4YTQ3ZTk5OWM5OGFiZjNiMWEwYjQ2L3RleHRyZWdpb246ZTJiZmYyMWYzMjhhNDdlOTk5Yzk4YWJmM2IxYTBiNDZfNjMzOA_c7e16f89-57bc-44ea-8a55-d8c4545fbde7"
      unitRef="usd">12000000</cah:IndemnificationReceivable>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90ZXh0cmVnaW9uOjY3ZDBlOTg1N2UyMDRmMWQ4NTk3NmU0ZTE0OTM2MWMyXzEyNjI_ea8e323a-f57e-4570-8222-32f0a5c70f34">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;8. Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;812&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;812&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;(2)   The fair value of interest rate swaps, foreign currency contracts and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90ZXh0cmVnaW9uOjY3ZDBlOTg1N2UyMDRmMWQ4NTk3NmU0ZTE0OTM2MWMyXzEyNDg_733face2-27b6-45dc-9198-26a4c2b0198f">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;812&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;812&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;(2)   The fair value of interest rate swaps, foreign currency contracts and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1e2495c58af141e0b5b5d488b2935e1a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzMtMS0xLTEtMA_11556b6a-fbd1-4b38-8c7e-7f1e26314b58"
      unitRef="usd">812000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i150d8e19b4da44c7a10fc5832479dab4_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzMtMy0xLTEtMA_422a6a3c-c575-4405-aa88-f755d062f1f8"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibce62dee245a48b29809b554a26358b2_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzMtNS0xLTEtMA_c3672f97-707b-4d63-86ab-53fde3ece487"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1376d1860df846879ab972c82dc8cbb9_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzMtNy0xLTEtMA_52e14edf-aad5-4038-a1a6-c0b2cd647a04"
      unitRef="usd">812000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1e2495c58af141e0b5b5d488b2935e1a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzQtMS0xLTEtMA_6d32285b-71c0-47ef-be2b-9fb152e902dc"
      unitRef="usd">119000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i150d8e19b4da44c7a10fc5832479dab4_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzQtMy0xLTEtMA_900d8fb2-bbe9-4b7f-a996-6d3c6ca8ee99"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ibce62dee245a48b29809b554a26358b2_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzQtNS0xLTEtMA_6722b770-a182-440a-9884-9d7fc6f698b1"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ie58736b6311e43b89041dc436c54fde9_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzQtNy0xLTEtMA_a476e535-79ba-44de-850a-0592f8620b46"
      unitRef="usd">119000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i1e2495c58af141e0b5b5d488b2935e1a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzYtMS0xLTEtMA_18431d0f-3397-4baa-a732-aae18674d141"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i150d8e19b4da44c7a10fc5832479dab4_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzYtMy0xLTEtMA_214fc881-dc1a-40d5-be1d-fcc67937d338"
      unitRef="usd">47000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="ibce62dee245a48b29809b554a26358b2_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzYtNS0xLTEtMA_dd7ab771-7670-4414-bf80-d938258960e0"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="ie58736b6311e43b89041dc436c54fde9_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTphODZlOTQzODc2ZTQ0MjAyYjQyYmUzMTZlYTM5YmM1NS90YWJsZXJhbmdlOmE4NmU5NDM4NzZlNDQyMDJiNDJiZTMxNmVhMzliYzU1XzYtNy0xLTEtMA_052751f4-8dc4-4d88-9952-0ca231f0ceb8"
      unitRef="usd">47000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i72e76abd2c8d45b7930ed6de435b0dee_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzMtMS0xLTEtMA_b1704b12-c52b-4293-9178-5ce57336601a"
      unitRef="usd">1883000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idc2293adf8c64ed9925346fe6e72f47c_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzMtMy0xLTEtMA_a129429d-b07c-431e-a951-48bd2d1ef4d4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0a025dd5a49343da902e9c0daf87d367_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzMtNS0xLTEtMA_9b3b2f3c-a21a-41e7-b52e-7c54a52f18a9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie9cb0d331acd45e9a57603b0a7ac9478_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzMtNy0xLTEtMA_bdb356a0-0c16-4257-8b18-665b3e506955"
      unitRef="usd">1883000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i72e76abd2c8d45b7930ed6de435b0dee_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzQtMS0xLTEtMA_4dbf3792-54b3-4ecc-8c09-79a61479705b"
      unitRef="usd">126000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="idc2293adf8c64ed9925346fe6e72f47c_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzQtMy0xLTEtMA_b2e248d0-508f-4375-9b42-4eb2958386ef"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0a025dd5a49343da902e9c0daf87d367_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzQtNS0xLTEtMA_1edfcb19-555c-4b03-a123-b9eeb2f027ef"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic590157c0c22464e839daa43f09f244d_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzQtNy0xLTEtMA_e4c48b3f-6d5a-402b-9051-92615f56fe72"
      unitRef="usd">126000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i72e76abd2c8d45b7930ed6de435b0dee_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzYtMS0xLTEtMA_3ccde15d-85b5-4d91-858d-cddf090f39e5"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="idc2293adf8c64ed9925346fe6e72f47c_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzYtMy0xLTEtMA_a0fbfa2b-43c7-4dbf-800f-f8fcd288b90b"
      unitRef="usd">42000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i0a025dd5a49343da902e9c0daf87d367_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzYtNS0xLTEtMA_dcf8ab1e-b433-4418-8bab-efef2360b731"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="ic590157c0c22464e839daa43f09f244d_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDAvZnJhZzo2N2QwZTk4NTdlMjA0ZjFkODU5NzZlNGUxNDkzNjFjMi90YWJsZTo0YmZlYWIwMTc4Yjg0Y2JhYTljODA4YmMwOGQxYjRjNy90YWJsZXJhbmdlOjRiZmVhYjAxNzhiODRjYmFhOWM4MDhiYzA4ZDFiNGM3XzYtNy0xLTEtMA_75a014c5-9f3b-45d5-8c97-3e5bf1ba828c"
      unitRef="usd">42000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90ZXh0cmVnaW9uOmYyNmJlZjUyNTg0YTQ1Mjk4NGY3NGE1ZmNiNTdlOTE2Xzc3MTY_5671f09b-6a51-4db0-af22-20f753ce7fbe">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;9. Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Interest Rate Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Currency Exchange Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commodity Price Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three months ended September&#160;30, 2021 and 2020, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During three months ended September&#160;30, 2021, we entered into a pay-floating interest rate swap with a total notional amount of $100 million. This swap has been designated as a fair value hedge of our fixed rate debt and is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Cash Flow Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax gains and losses recognized in other comprehensive loss were immaterial during the three months ended September&#160;30, 2021 and 2020. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three months ended September&#160;30, 2021 and 2020. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Net Investment Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $5&#160;million gain and a $25&#160;million loss during the three months ended September&#160;30, 2021 and 2020, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $6&#160;million and $5&#160;million during the three months ended September&#160;30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Economic (Non-Designated) Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. The gain and losses recognized in the three months ended September 30, 2021 and 2020 were immaterial. The principal currencies managed through foreign currency contracts are Euro, Chinese renminbi, and Canadian dollar.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2021 and June 30, 2021 approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,132&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,654&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90ZXh0cmVnaW9uOmYyNmJlZjUyNTg0YTQ1Mjk4NGY3NGE1ZmNiNTdlOTE2XzMyNzU_46aaf093-41f5-4183-9f46-756fc3d51c6f"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i028247a5bde846f48b6ee152d76c2b8a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90ZXh0cmVnaW9uOmYyNmJlZjUyNTg0YTQ1Mjk4NGY3NGE1ZmNiNTdlOTE2XzEwOTk1MTE2Mjg2Mjg0_0686939d-fe16-4fab-a7f4-e09f020c1743"
      unitRef="usd">100000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ibeb6754446a54c41bf8d158d19745b40_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90ZXh0cmVnaW9uOmYyNmJlZjUyNTg0YTQ1Mjk4NGY3NGE1ZmNiNTdlOTE2XzU3NTQ_2f78397a-b25e-4da0-8255-9e7f759f3b5d"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i90f84269f6144c8183e95a9e6a7c25eb_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90ZXh0cmVnaW9uOmYyNmJlZjUyNTg0YTQ1Mjk4NGY3NGE1ZmNiNTdlOTE2XzU3Njg_9d196719-5d22-4e50-9b45-0681bd89f323"
      unitRef="usd">25000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ibeb6754446a54c41bf8d158d19745b40_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90ZXh0cmVnaW9uOmYyNmJlZjUyNTg0YTQ1Mjk4NGY3NGE1ZmNiNTdlOTE2XzEwOTk1MTE2Mjg2MzIy_45452dd7-14c4-4d2c-9ba4-c5db6d71f79d"
      unitRef="usd">6000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i90f84269f6144c8183e95a9e6a7c25eb_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90ZXh0cmVnaW9uOmYyNmJlZjUyNTg0YTQ1Mjk4NGY3NGE1ZmNiNTdlOTE2XzEwOTk1MTE2Mjg2MzI5_f9bfff39-762b-4b1c-917b-a064a9e687bd"
      unitRef="usd">5000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90ZXh0cmVnaW9uOmYyNmJlZjUyNTg0YTQ1Mjk4NGY3NGE1ZmNiNTdlOTE2Xzc3MTU_70d8d2bf-9895-444b-a720-b3ff84e6b571">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,132&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,654&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i92892038fe0545f0844bfb3e0c3e12db_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90YWJsZTpiMDZjZTNiNjM5MDY0MzE5YTE5MmI5Y2IxMGVmZWQxNS90YWJsZXJhbmdlOmIwNmNlM2I2MzkwNjQzMTlhMTkyYjljYjEwZWZlZDE1XzEtMS0xLTEtMA_17486ed6-3edc-4c64-a0bb-e2740dc2a661"
      unitRef="usd">6132000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i262b04e9d11d48e58b8a57b9ab73f4e4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90YWJsZTpiMDZjZTNiNjM5MDY0MzE5YTE5MmI5Y2IxMGVmZWQxNS90YWJsZXJhbmdlOmIwNmNlM2I2MzkwNjQzMTlhMTkyYjljYjEwZWZlZDE1XzEtMy0xLTEtMA_62bff652-522e-4479-802c-7d0b7ad7e368"
      unitRef="usd">6751000000</us-gaap:DebtInstrumentFairValue>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90YWJsZTpiMDZjZTNiNjM5MDY0MzE5YTE5MmI5Y2IxMGVmZWQxNS90YWJsZXJhbmdlOmIwNmNlM2I2MzkwNjQzMTlhMTkyYjljYjEwZWZlZDE1XzItMS0xLTEtMA_05d3343f-b9d3-4212-acc3-7576b6d269fd"
      unitRef="usd">5654000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDMvZnJhZzpmMjZiZWY1MjU4NGE0NTI5ODRmNzRhNWZjYjU3ZTkxNi90YWJsZTpiMDZjZTNiNjM5MDY0MzE5YTE5MmI5Y2IxMGVmZWQxNS90YWJsZXJhbmdlOmIwNmNlM2I2MzkwNjQzMTlhMTkyYjljYjEwZWZlZDE1XzItMy0xLTEtMA_7219fc51-3e1d-4c59-9753-cf6b988e279e"
      unitRef="usd">6236000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90ZXh0cmVnaW9uOjEwNTViYTJiMzMyNjQyYjFhOTg0NjUxNDdhNDIxZjkxXzc1Ng_40c7f49b-93b9-4505-b340-9aacade226c5">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;10. Shareholders' Equity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2021, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 7.8 million common shares using a reference price of $51.53. The program concluded on October 4, 2021 at a volume weighted average price per common share of $51.10 resulting in a final delivery of 2.0&#160;million common shares. We funded the repurchases with available cash. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The common shares repurchased are held in treasury to be used for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i4ff1053e5ba649348bc766dea62879d6_D20200701-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90ZXh0cmVnaW9uOjEwNTViYTJiMzMyNjQyYjFhOTg0NjUxNDdhNDIxZjkxXzE2Ng_4594374b-f0f6-4970-943a-4b82967dd7c9"
      unitRef="usd">500000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <cah:TreasuryStockAcquiredShares
      contextRef="i9a679feb77be4335bffc03ffaca2dd77_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90ZXh0cmVnaW9uOjEwNTViYTJiMzMyNjQyYjFhOTg0NjUxNDdhNDIxZjkxXzIwNQ_75155d13-6f44-42f4-add4-9b96251a9333"
      unitRef="shares">7800000</cah:TreasuryStockAcquiredShares>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i9a679feb77be4335bffc03ffaca2dd77_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90ZXh0cmVnaW9uOjEwNTViYTJiMzMyNjQyYjFhOTg0NjUxNDdhNDIxZjkxXzcxNDY4MjU1ODM4NDA_5eafd946-bf03-434a-a8b7-19cd763768d6"
      unitRef="usdPerShare">51.53</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i0cd4350b18ea48f3b33db6247ab8f74e_D20210701-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90ZXh0cmVnaW9uOjEwNTViYTJiMzMyNjQyYjFhOTg0NjUxNDdhNDIxZjkxXzI2OTM4MDM0ODg0MDA1_36c1f8ec-cd9e-4cc4-a2d5-8db080e16421"
      unitRef="usdPerShare">51.10</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <cah:FinalSharesReceivedfromASRProgram
      contextRef="i1fe42d24cb094502a3486fea0c6fc0df_I20211004"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90ZXh0cmVnaW9uOjEwNTViYTJiMzMyNjQyYjFhOTg0NjUxNDdhNDIxZjkxXzI2OTM4MDM0ODg0MDEz_9fee92cb-fd80-443a-ba77-3840c3397533"
      unitRef="shares">2000000</cah:FinalSharesReceivedfromASRProgram>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90ZXh0cmVnaW9uOjEwNTViYTJiMzMyNjQyYjFhOTg0NjUxNDdhNDIxZjkxXzc2Mw_f1f305cd-1b41-45b1-ae28-d1295f513f85">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff81891dbe0e4df49e09522cba431ade_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzEtMS0xLTEtMA_d7379fcf-ad3c-4a66-9d26-ef27ae174dc3"
      unitRef="usd">-46000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie756e95338db4f58953d714720e792ab_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzEtMy0xLTEtMA_27cd6b1f-0a0f-4d9d-8acd-1e1e807ed9f2"
      unitRef="usd">12000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2ffff5afcbf04bf6bdee0da00d3f865a_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzEtNS0xLTEtMA_523ef2bb-bb64-4d85-a76d-7ea8fe45aceb"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i14182b7268e14c209c705768a780f9d0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzItMS0xLTEtMA_85cef895-5e54-44cd-9d45-8350558f9b2b"
      unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i5a50bb415d6a42b6b624e81424aefc10_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzItMy0xLTEtMA_586e9187-d300-4657-bb5a-87ee31e509f5"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ia86d33171aed42cebf549309afad5112_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzItNS0xLTEtMA_326b6c03-0454-4f89-b6bd-5b83e496eb6f"
      unitRef="usd">-26000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i14182b7268e14c209c705768a780f9d0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzMtMS0xLTEtMA_8b63f1c1-be92-4a22-8531-602b81d2b593"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i5a50bb415d6a42b6b624e81424aefc10_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzMtMy0xLTEtMA_1c654581-d86e-41dd-b663-91783007920a"
      unitRef="usd">1000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ia86d33171aed42cebf549309afad5112_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzMtNS0xLTEtMA_75d89327-99ac-4cad-bf84-7df9e7e3d371"
      unitRef="usd">1000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i14182b7268e14c209c705768a780f9d0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzQtMS0xLTEtMA_290e186a-35d4-4601-ad74-25458f050069"
      unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5a50bb415d6a42b6b624e81424aefc10_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzQtMy0xLTEtMA_913a41a3-6692-4b6a-8f09-9ff8aa766abd"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i80a6c9c0ca9b46349d58b2c256d04d1f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzQtNS0xLTEtMA_822b27eb-6a53-4b9a-ae6f-abe2313de854"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1f3db035e1db41b1a0fa80e065300460_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzUtMS0xLTEtMA_1667ec2f-ceb1-420c-be3f-24814e981a1d"
      unitRef="usd">-71000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic3c87fae83994349b2c47f4e40df266f_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzUtMy0xLTEtMA_a75d93a9-b5e5-4280-b808-f4e41539cbe6"
      unitRef="usd">10000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie36e8fee435f4698b1f72b0de63b4f97_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDYvZnJhZzoxMDU1YmEyYjMzMjY0MmIxYTk4NDY1MTQ3YTQyMWY5MS90YWJsZToxZDE4ZjBjNDI3YTY0ZmVlYThlZTFhZmNmMTZmMzU1NC90YWJsZXJhbmdlOjFkMThmMGM0MjdhNjRmZWVhOGVlMWFmY2YxNmYzNTU0XzUtNS0xLTEtMA_0a63d09a-032e-4b27-8b72-b33264ce600e"
      unitRef="usd">-61000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90ZXh0cmVnaW9uOmU0OWQ2NWY2OTBlMzRkNWViMDAxYjMzYzE4NDQxY2ZkXzcwNQ_6ca40200-6ad2-44e3-aa6d-2bab70810116">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;11. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units, and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for the three months ended September 30, 2021 were 4 million.&lt;/span&gt;&lt;/div&gt;For the three months ended September 30, 2020, 7&#160;million employee stock options, restricted share units and performance share units were excluded from the calculation of diluted shares outstanding, 2&#160;million of which would be anti-dilutive as a result of the net loss for the period.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90ZXh0cmVnaW9uOmU0OWQ2NWY2OTBlMzRkNWViMDAxYjMzYzE4NDQxY2ZkXzY5OQ_e313885a-a600-441c-9d61-d922bdd5881f">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;287&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units, and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90YWJsZTplMzM4ZjJhZWJjYWU0MWE5YTVjYmUyMGU3OTYzMjUxMi90YWJsZXJhbmdlOmUzMzhmMmFlYmNhZTQxYTlhNWNiZTIwZTc5NjMyNTEyXzItMS0xLTEtMA_01a716dc-1f32-47b1-8698-c35f1481837d"
      unitRef="shares">287000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90YWJsZTplMzM4ZjJhZWJjYWU0MWE5YTVjYmUyMGU3OTYzMjUxMi90YWJsZXJhbmdlOmUzMzhmMmFlYmNhZTQxYTlhNWNiZTIwZTc5NjMyNTEyXzItMy0xLTEtMA_4b4ea1e0-fcc4-45a9-aa30-d24b11b94a71"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90YWJsZTplMzM4ZjJhZWJjYWU0MWE5YTVjYmUyMGU3OTYzMjUxMi90YWJsZXJhbmdlOmUzMzhmMmFlYmNhZTQxYTlhNWNiZTIwZTc5NjMyNTEyXzQtMS0xLTEtMA_8161d933-e515-4097-ba16-be763ddc0f45"
      unitRef="shares">2000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90YWJsZTplMzM4ZjJhZWJjYWU0MWE5YTVjYmUyMGU3OTYzMjUxMi90YWJsZXJhbmdlOmUzMzhmMmFlYmNhZTQxYTlhNWNiZTIwZTc5NjMyNTEyXzQtMy0xLTEtMA_c6302186-ef01-463f-9405-7d6cd4734cda"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90YWJsZTplMzM4ZjJhZWJjYWU0MWE5YTVjYmUyMGU3OTYzMjUxMi90YWJsZXJhbmdlOmUzMzhmMmFlYmNhZTQxYTlhNWNiZTIwZTc5NjMyNTEyXzUtMS0xLTEtMA_56800089-f6df-4c0f-a88d-1f98f14a787d"
      unitRef="shares">289000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90YWJsZTplMzM4ZjJhZWJjYWU0MWE5YTVjYmUyMGU3OTYzMjUxMi90YWJsZXJhbmdlOmUzMzhmMmFlYmNhZTQxYTlhNWNiZTIwZTc5NjMyNTEyXzUtMy0xLTEtMA_bf6a76af-dda7-4938-8d2c-aaf5bb4bbc60"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <cah:Numberofsharesexcludedfromcalculationofdilutedshares
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90ZXh0cmVnaW9uOmU0OWQ2NWY2OTBlMzRkNWViMDAxYjMzYzE4NDQxY2ZkXzcxNDY4MjU1ODIyNDE_405b9708-5226-4a4a-a9eb-2f7ca69311d1"
      unitRef="shares">4000000</cah:Numberofsharesexcludedfromcalculationofdilutedshares>
    <cah:Numberofsharesexcludedfromcalculationofdilutedshares
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90ZXh0cmVnaW9uOmU0OWQ2NWY2OTBlMzRkNWViMDAxYjMzYzE4NDQxY2ZkXzcxNDY4MjU1ODMxNTA_b1fff4f6-a32a-4904-9c03-e5470f7120de"
      unitRef="shares">7000000</cah:Numberofsharesexcludedfromcalculationofdilutedshares>
    <cah:Sharesthatwouldbeantidilutiveasaresultofnetloss
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMDkvZnJhZzplNDlkNjVmNjkwZTM0ZDVlYjAwMWIzM2MxODQ0MWNmZC90ZXh0cmVnaW9uOmU0OWQ2NWY2OTBlMzRkNWViMDAxYjMzYzE4NDQxY2ZkXzcxNDY4MjU1ODMxNjE_c0ce5c54-b773-45bf-8d0e-83bc3d6da262"
      unitRef="shares">2000000</cah:Sharesthatwouldbeantidilutiveasaresultofnetloss>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzQ3NjM_635e770e-b8fb-423b-a3c4-ade6934245d8">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;12. Segment Information &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,614&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;208&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,567&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;582&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,149&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,971&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,968&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Products and services offered by our Specialty Solutions division are referred to as &#x201c;specialty pharmaceutical products and services".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;42,841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,971&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,968&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;amp;A") expenses. Segment SG&amp;amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not allocate the following items to our segments: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;last-in first-out, or ("LIFO"), inventory charges/(credits); &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;surgical gown recall costs/(income);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;restructuring and employee severance;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;amortization and other acquisition-related costs;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;impairments and (gain)/loss on disposal of assets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;litigation (recoveries)/charges, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;state opioid assessment related to prior fiscal years;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;other (income)/expense, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;interest expense, net;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;loss on early extinguishment of debt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;(gain)/loss on sale of equity interest in naviHealth; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt"&gt;provision for income taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $7 million and $5 million for the three months ended September 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the opioid litigation as discussed further in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#i1938304362d7436fbafe0221fdeb43e5_94" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 6&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we recognized a pre-tax charge of $1.02&#160;billion during the three months ended September 30, 2020 which was retained at Corporate. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents segment profit by reportable segment and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;406&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;529&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;415&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for each reportable segment and Corporate at: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23,955&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;14,156&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;42,993&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzEwMg_5989b91f-c7b1-4b09-a5dd-a8abe42ed83a"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzEwMg_820c1016-1c5c-4574-82b7-a0e7acbd6e8e"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzQ3NjU_83984fc7-beb2-44a8-bec9-b010f77e058e">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,614&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;208&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,567&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;582&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,149&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,971&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,968&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Products and services offered by our Specialty Solutions division are referred to as &#x201c;specialty pharmaceutical products and services".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="iefb0192320f84cfda947570718acc52f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzItMS0xLTEtMA_309d2967-f1c6-490b-a8d8-ebfa19dcc262"
      unitRef="usd">39614000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i695daf356dd24a7f8a07c54cd6667482_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzItMy0xLTEtMA_bc1a576c-e57d-4d45-ae86-cedee15dbc81"
      unitRef="usd">34916000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idb22d9ed2a2a48baa6338106943e33db_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzMtMS0xLTEtMA_2fa29564-a811-4d17-8592-4f457189d83f"
      unitRef="usd">208000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i643e811d7ea24162a6e23957fa7b8020_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzMtMy0xLTEtMA_cd145ec2-5464-484d-b0be-7b7901d58f95"
      unitRef="usd">196000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2589a59e7c8147fb90fc1516771ba4c2_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzQtMS0xLTEtMA_6c0129b7-a5bd-4680-b1a4-da0eb9e5f9c9"
      unitRef="usd">39822000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib3b3f2699d6140d3a9e1c4884e78c829_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzQtMy0xLTEtMA_85e1941b-6a3c-4a65-8fae-a5d0899473f2"
      unitRef="usd">35112000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6582c36519d04664abfb836348244e53_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzUtMS0xLTEtMA_54825faa-2491-451d-945d-405ac1178c0d"
      unitRef="usd">3567000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0a173f94955146cf8459ca2fc0f76a88_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzUtMy0xLTEtMA_0d37574a-52b3-4367-979d-b9b72eeb672f"
      unitRef="usd">3438000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i260095721ed44bfa8813a4ea26fe309e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzYtMS0xLTEtMA_459db73a-ac43-4830-bafd-baeab8a1fbd1"
      unitRef="usd">582000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i93278c2e2d4e42ff9942bc487ad10984_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzYtMy0xLTEtMA_7d47b100-8e3b-4695-be43-92839ccbbf15"
      unitRef="usd">519000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia19a7508f5d64fa8b59c18df01e2fb5a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzctMS0xLTEtMA_a4fca1c7-dcb2-44f1-be9f-f5e279e69db8"
      unitRef="usd">4149000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1be6ae19d08940a8a9cc5b7717ec3ae5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzctMy0xLTEtMA_bc3346d5-6784-4783-bb43-06f08959cc84"
      unitRef="usd">3957000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5ff458415a4478c9e01d28e78e58858_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzgtMS0xLTEtMA_cbdfb69b-6248-42c9-ab58-25b4991efcc2"
      unitRef="usd">43971000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5ad9f408a4c44aeb8a44818cd8464a81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzgtMy0xLTEtMA_d470de8d-27a3-41a0-832b-43aaacb8b3fa"
      unitRef="usd">39069000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida3d87ac199c44409567f200919b5238_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzktMS0xLTEtMA_afd9e376-ccfc-45ae-8c87-d93f62255c29"
      unitRef="usd">-3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic2b8a8b2269b4ec6b13d67f67f63e6de_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzktMy0xLTEtMA_1883ee8f-d166-4c36-8618-b5d9145c9ddf"
      unitRef="usd">-4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzEwLTEtMS0xLTA_3180b5c7-3881-46c8-bb7b-8a959f69047d"
      unitRef="usd">43968000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo0NmJiNWE0ODFlYmU0MTVhYTI3MGFiNDNjYTJmYzRkMi90YWJsZXJhbmdlOjQ2YmI1YTQ4MWViZTQxNWFhMjcwYWI0M2NhMmZjNGQyXzEwLTMtMS0xLTA_baa20b98-5702-4f8b-8b91-86392bccde40"
      unitRef="usd">39065000000</us-gaap:Revenues>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzQ3Njc_c0ee1828-ea69-460d-af80-3095b8df8840">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.319%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;42,841&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,971&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,968&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="i86109f8fb89f41a5b8bd3da54e768eb3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzItMS0xLTEtMA_52480599-0025-4589-9baa-31e597886dd7"
      unitRef="usd">42841000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1e1c40e4b0da424cbb1f9ef2eec48d5d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzItMy0xLTEtMA_85d8fa02-821d-416b-9c40-1990f7094b03"
      unitRef="usd">37976000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id59a8d61ab224417a39a8f45243726b0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzMtMS0xLTEtMA_1d97ca26-725e-4ec7-8be3-57d1467c8d93"
      unitRef="usd">1130000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic4a68ab932984e5c81cf1ec9c6d852ee_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzMtMy0xLTEtMA_bb7d50cb-ae59-43e1-9a7b-dc46d20c00e3"
      unitRef="usd">1093000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5ff458415a4478c9e01d28e78e58858_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzQtMS0xLTEtMA_cbdfb69b-6248-42c9-ab58-25b4991efcc2"
      unitRef="usd">43971000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5ad9f408a4c44aeb8a44818cd8464a81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzQtMy0xLTEtMA_c18b3731-13f8-416a-9444-6b61760f81d5"
      unitRef="usd">39069000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ida3d87ac199c44409567f200919b5238_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzUtMS0xLTEtMA_afd9e376-ccfc-45ae-8c87-d93f62255c29"
      unitRef="usd">-3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic2b8a8b2269b4ec6b13d67f67f63e6de_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzUtMy0xLTEtMA_1ed4ad8e-5f50-4827-bd91-b1b680e9560f"
      unitRef="usd">-4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzYtMS0xLTEtMA_3180b5c7-3881-46c8-bb7b-8a959f69047d"
      unitRef="usd">43968000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTpkYjNjZDdmMzM2NmM0MDY3Yjg1YmYxYWIyYjdmYjIxZC90YWJsZXJhbmdlOmRiM2NkN2YzMzY2YzQwNjdiODViZjFhYjJiN2ZiMjFkXzYtMy0xLTEtMA_679762ec-cf54-4574-ab06-085bd78f1c9a"
      unitRef="usd">39065000000</us-gaap:Revenues>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzQzMTI_2692f6ce-7d04-49f0-9181-8335a07e2a53"
      unitRef="usd">7000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzQzMTk_08680e86-1dcd-42f3-8501-1f47ec7f4f05"
      unitRef="usd">5000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <us-gaap:LitigationSettlementExpense
      contextRef="i28701b9327404d53941d5dd148cdf77c_D20200701-20200930"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzQ0ODc_081e769a-e931-4f5b-8d9a-cf528467cdac"
      unitRef="usd">1020000000.00</us-gaap:LitigationSettlementExpense>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzQ3Njg_0be4470a-9df1-4b8b-9349-c55395207957">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents segment profit by reportable segment and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;406&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;529&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;415&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2589a59e7c8147fb90fc1516771ba4c2_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzItMS0xLTEtMA_1f7c795b-e911-4d3a-8db5-74e634cb0fe8"
      unitRef="usd">406000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib3b3f2699d6140d3a9e1c4884e78c829_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzItMy0xLTEtMA_6f98de88-6494-4791-8090-92ab8c557057"
      unitRef="usd">402000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia19a7508f5d64fa8b59c18df01e2fb5a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzMtMS0xLTEtMA_b9437bb4-40d5-4101-9d0a-371a6413e4e0"
      unitRef="usd">123000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1be6ae19d08940a8a9cc5b7717ec3ae5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzMtMy0xLTEtMA_d1bffc7d-a0b3-41fa-bb3c-77dd8e35f37c"
      unitRef="usd">230000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib5ff458415a4478c9e01d28e78e58858_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzQtMS0xLTEtMA_ea7c6ae0-eb9f-4c10-88db-5902871fa170"
      unitRef="usd">529000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5ad9f408a4c44aeb8a44818cd8464a81_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzQtMy0xLTEtMA_4e3abbd8-5f2e-4a4b-8a7c-d73ce44f5f08"
      unitRef="usd">632000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ida3d87ac199c44409567f200919b5238_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzUtMS0xLTEtMA_9510bdfe-aa1e-458d-8bc1-238cbd19e2fd"
      unitRef="usd">-114000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic2b8a8b2269b4ec6b13d67f67f63e6de_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzUtMy0xLTEtMA_9f598847-e134-4a5b-aa08-08da92cf27e7"
      unitRef="usd">-1256000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzYtMS0xLTEtMA_bcd76dbc-9d99-464f-8bef-e82864ef004b"
      unitRef="usd">415000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo1YzQ2ZmEwNzNjYjI0N2RmYTkzODI2NDA1NzUyYmEyNC90YWJsZXJhbmdlOjVjNDZmYTA3M2NiMjQ3ZGZhOTM4MjY0MDU3NTJiYTI0XzYtMy0xLTEtMA_8fef9461-b78c-47ee-9b2d-e2a0fce115ee"
      unitRef="usd">-624000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzQ3NzA_43e28a45-cc3d-4f1a-b146-2a2542a34f07">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for each reportable segment and Corporate at: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23,955&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;14,156&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;42,993&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets
      contextRef="iaf9b1163079c47d1b91c576edc8b1a8b_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo2ZjQ4YTg5NDlmMjg0OTQzODU4MmM5NzVlMGFjZWVjNS90YWJsZXJhbmdlOjZmNDhhODk0OWYyODQ5NDM4NTgyYzk3NWUwYWNlZWM1XzEtMS0xLTEtMA_f60d2b91-8b9a-4d0c-8bd8-f04acc20eab5"
      unitRef="usd">23955000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i3dc4e83510674b0bac2dc681fd406ecd_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo2ZjQ4YTg5NDlmMjg0OTQzODU4MmM5NzVlMGFjZWVjNS90YWJsZXJhbmdlOjZmNDhhODk0OWYyODQ5NDM4NTgyYzk3NWUwYWNlZWM1XzEtMy0xLTEtMA_21e35c9c-5e2a-48d8-b0d1-1e082135a8fd"
      unitRef="usd">23624000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0eb34e93d9354dfabdb815166d96003b_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo2ZjQ4YTg5NDlmMjg0OTQzODU4MmM5NzVlMGFjZWVjNS90YWJsZXJhbmdlOjZmNDhhODk0OWYyODQ5NDM4NTgyYzk3NWUwYWNlZWM1XzItMS0xLTEtMA_474f2cc8-9629-4678-b97d-d280a0a134d1"
      unitRef="usd">14156000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ia067d8f29be54d07bf02fce520fc3f4c_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo2ZjQ4YTg5NDlmMjg0OTQzODU4MmM5NzVlMGFjZWVjNS90YWJsZXJhbmdlOjZmNDhhODk0OWYyODQ5NDM4NTgyYzk3NWUwYWNlZWM1XzItMy0xLTEtMA_c2039b8e-2a30-4169-8e30-c8b13e4c63c0"
      unitRef="usd">15408000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5857bb7827354cf887e8a93a6c60a3d2_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo2ZjQ4YTg5NDlmMjg0OTQzODU4MmM5NzVlMGFjZWVjNS90YWJsZXJhbmdlOjZmNDhhODk0OWYyODQ5NDM4NTgyYzk3NWUwYWNlZWM1XzMtMS0xLTEtMA_a97bcf1a-e83c-4de4-a7eb-31f0290560c1"
      unitRef="usd">4882000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ia5fcface43a14646b53fcb8c4afba8d4_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo2ZjQ4YTg5NDlmMjg0OTQzODU4MmM5NzVlMGFjZWVjNS90YWJsZXJhbmdlOjZmNDhhODk0OWYyODQ5NDM4NTgyYzk3NWUwYWNlZWM1XzMtMy0xLTEtMA_2b9b6464-6a85-4766-b476-d4acdd8bf1bc"
      unitRef="usd">5421000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo2ZjQ4YTg5NDlmMjg0OTQzODU4MmM5NzVlMGFjZWVjNS90YWJsZXJhbmdlOjZmNDhhODk0OWYyODQ5NDM4NTgyYzk3NWUwYWNlZWM1XzQtMS0xLTEtMA_ff1e4830-7f67-4a4e-9039-9f7258f3a346"
      unitRef="usd">42993000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90YWJsZTo2ZjQ4YTg5NDlmMjg0OTQzODU4MmM5NzVlMGFjZWVjNS90YWJsZXJhbmdlOjZmNDhhODk0OWYyODQ5NDM4NTgyYzk3NWUwYWNlZWM1XzQtMy0xLTEtMA_a728458b-41eb-45f4-b317-7eeb3aa3a692"
      unitRef="usd">44453000000</us-gaap:Assets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="ie4520b1ea4514c88b03060a55539c44e_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTIvZnJhZzozYmQ4MDQzYmFiNTM0MWFmODIxMWFmNTY4MmI3N2UxNy90ZXh0cmVnaW9uOjNiZDgwNDNiYWI1MzQxYWY4MjExYWY1NjgyYjc3ZTE3XzMyOTg1MzQ4ODg1NzM_968c3752-9250-43e2-9e24-62897325f0bb"
      unitRef="usd">1100000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzIzNDI_ef65d762-0e33-49d4-9886-1778d7e3e5b3">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;13. Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain stock incentive plans (collectively, the &#x201c;Plans&#x201d;) for the benefit of certain of our officers, directors and employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock option expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total tax benefit related to share-based compensation was $4 million for both the three months ended September&#160;30, 2021 and 2020 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Restricted Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50.67&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $116 million, which is expected to be recognized over a weighted-average period of two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all stock option transactions under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price per&lt;br/&gt;Common Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69.31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercisable at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69.48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $0.3 million, which is expected to be recognized over a weighted-average period of two years.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide additional detail related to stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of outstanding options at period end&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of exercisable options at period end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of outstanding options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of exercisable options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Performance Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance share units vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount for the fiscal 2020 and 2021 grants and zero to 234 percent for the fiscal 2022 grant. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51.31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September 30, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $36 million, which is expected to be recognized over a weighted-average period of two years if the performance goals are achieved.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzIzNjA_7035fdab-b4c3-4f9e-8dd7-c98722b172ed">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock option expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTowMzAwNzBiOTVkYzI0OGViOWNkNmFiMmNhMzc4YTFlZi90YWJsZXJhbmdlOjAzMDA3MGI5NWRjMjQ4ZWI5Y2Q2YWIyY2EzNzhhMWVmXzItMS0xLTEtMA_e0923625-cdac-4916-8b35-83ab341b562f"
      unitRef="usd">18000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifa2d5d99524d44f1810ced80bd09e54b_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTowMzAwNzBiOTVkYzI0OGViOWNkNmFiMmNhMzc4YTFlZi90YWJsZXJhbmdlOjAzMDA3MGI5NWRjMjQ4ZWI5Y2Q2YWIyY2EzNzhhMWVmXzItMy0xLTEtMA_e07f1b3f-ce53-4643-bc0b-4dd1a57c480f"
      unitRef="usd">19000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i17c1a096a6384157896d5f66dfc3de76_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTowMzAwNzBiOTVkYzI0OGViOWNkNmFiMmNhMzc4YTFlZi90YWJsZXJhbmdlOjAzMDA3MGI5NWRjMjQ4ZWI5Y2Q2YWIyY2EzNzhhMWVmXzMtMS0xLTEtMA_da311572-6024-494b-b274-ecc51edbb276"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib23ff3fa19d64f74860e3a433d7fe8a5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTowMzAwNzBiOTVkYzI0OGViOWNkNmFiMmNhMzc4YTFlZi90YWJsZXJhbmdlOjAzMDA3MGI5NWRjMjQ4ZWI5Y2Q2YWIyY2EzNzhhMWVmXzMtMy0xLTEtMA_47117b8b-9fb0-4d60-91e9-6db837a18328"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTowMzAwNzBiOTVkYzI0OGViOWNkNmFiMmNhMzc4YTFlZi90YWJsZXJhbmdlOjAzMDA3MGI5NWRjMjQ4ZWI5Y2Q2YWIyY2EzNzhhMWVmXzQtMS0xLTEtMA_37da2d4c-0da7-42a9-93de-4222e0b2e711"
      unitRef="usd">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if9cd1675b513491fb7ce8cd5c3b5a391_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTowMzAwNzBiOTVkYzI0OGViOWNkNmFiMmNhMzc4YTFlZi90YWJsZXJhbmdlOjAzMDA3MGI5NWRjMjQ4ZWI5Y2Q2YWIyY2EzNzhhMWVmXzQtMy0xLTEtMA_2f844311-a2cc-4e18-a8a9-77577ab76432"
      unitRef="usd">9000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTowMzAwNzBiOTVkYzI0OGViOWNkNmFiMmNhMzc4YTFlZi90YWJsZXJhbmdlOjAzMDA3MGI5NWRjMjQ4ZWI5Y2Q2YWIyY2EzNzhhMWVmXzUtMS0xLTEtMA_18f4a0d2-ac73-4e05-87c1-7447a7cdd265"
      unitRef="usd">24000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7d885fce3ffe46638d946d968a3742fc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTowMzAwNzBiOTVkYzI0OGViOWNkNmFiMmNhMzc4YTFlZi90YWJsZXJhbmdlOjAzMDA3MGI5NWRjMjQ4ZWI5Y2Q2YWIyY2EzNzhhMWVmXzUtMy0xLTEtMA_3c2d68ca-79b1-4165-a3e5-bc00f04ca47b"
      unitRef="usd">28000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzI5MQ_5eee497a-cc51-4ab4-9bf1-dbbabf1d384a"
      unitRef="usd">4000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzQ1Nw_e460a5ee-754e-4822-b06b-3b8d6367367c">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzIzMDM_f002ad91-1a44-4838-b7d7-4225c91cb993">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50.67&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i8be3f11faae246dc81f8ac9ec37aed05_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzEtMS0xLTEtMA_f9d63228-7eec-49a6-bfd3-06d58eeeca4f"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i8be3f11faae246dc81f8ac9ec37aed05_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzEtMy0xLTEtMA_a0fd5ace-2352-40e2-b8f3-240f17e0217e"
      unitRef="usdPerShare">49.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzItMS0xLTEtMA_7e0d6316-234a-4fbb-adf5-f9728c156f2a"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzItMy0xLTEtMA_f7e3cdbd-ac47-457e-8cf6-ad54a353f011"
      unitRef="usdPerShare">51.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzMtMS0xLTEtMA_f1acacc6-580d-4bf1-95cc-ba5b1fe0d0a6"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzMtMy0xLTEtMA_6aeee790-2944-4f9d-806a-3eb8bd68cbe2"
      unitRef="usdPerShare">48.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzQtMS0xLTEtMA_bc81052e-07fa-46d6-975c-7e260299a23a"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzQtMy0xLTEtMA_163f18ef-4dbf-4b42-be73-bf5c8633d4de"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic1569a630e924c95afa6b719377b7025_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzUtMS0xLTEtMA_8432596a-6098-4081-b7e9-5e10ccff234c"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic1569a630e924c95afa6b719377b7025_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo5Nzg1ZTA5Yjg3NjA0ZGY0YmE0NTM5YmU5N2MxMTBkNi90YWJsZXJhbmdlOjk3ODVlMDliODc2MDRkZjRiYTQ1MzliZTk3YzExMGQ2XzUtMy0xLTEtMA_d0432ad0-ec89-45f0-97d6-b7f6100abc20"
      unitRef="usdPerShare">50.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ic1569a630e924c95afa6b719377b7025_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzgwNA_23b2e4fe-695e-4a3d-a054-8068cee46bb6"
      unitRef="usd">116000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0Xzk4OTU2MDQ2NTI2NzY_3cd22fd5-3305-4855-9b5b-2c695307ca13">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i17c1a096a6384157896d5f66dfc3de76_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0Xzk5MQ_3c992bd4-c8a5-45f5-be71-bcb3df2ade0d">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cah:ExercisablePeriodOfPlansInYears
      contextRef="i17c1a096a6384157896d5f66dfc3de76_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzEwMTg_e7b6998a-dc6f-4a97-a8ce-e52310b34ba4">P10Y</cah:ExercisablePeriodOfPlansInYears>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzIzNjE_f1504cf2-b85c-4983-a4c8-84c7510b2941">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all stock option transactions under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price per&lt;br/&gt;Common Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69.31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercisable at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;69.48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzEtMS0xLTEtMA_19f29bfe-67b0-4bb1-8f50-c078357c1b9f"
      unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibf64c21f338848a589b8d482d67160ff_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzEtMy0xLTEtMA_8cb3478f-b174-48d3-a79b-8270fe908a5d"
      unitRef="usdPerShare">68.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzItMS0xLTEtMA_e793415f-e8b1-455d-9e31-343e551bcdad"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzItMy0xLTEtMA_b6cfa978-9d58-4ff4-8e3b-a29501cd3309"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzMtMS0xLTEtMA_b0dab17c-1ff4-43a0-8367-a7f04bfea748"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzMtMy0xLTEtMA_b2791f32-0e93-4c90-9117-880391df8a2e"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzQtMS0xLTEtMA_779e5579-9634-4fc2-9718-a23921816ef1"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzQtMy0xLTEtMA_ea344b01-98f9-424d-ba27-ab83ea0a87c1"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzUtMS0xLTEtMA_d41c3105-36d4-4946-b911-7df7e74c7e23"
      unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzUtMy0xLTEtMA_a3e09bda-abdf-4b61-a811-caf51e6366c6"
      unitRef="usdPerShare">69.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzYtMS0xLTEtMA_b8a76693-b322-4d46-b93d-85a1f7dab4ca"
      unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="id9d0f0b222df4670b2ba4b4e53c27817_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo0NjA3YzNhOWZiMTM0ZjBjODRiY2I1ODUyZjFhMjk0Yi90YWJsZXJhbmdlOjQ2MDdjM2E5ZmIxMzRmMGM4NGJjYjU4NTJmMWEyOTRiXzYtMy0xLTEtMA_813504fa-80f4-4f1f-82c2-ec4e349f17b5"
      unitRef="usdPerShare">69.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i2b18c3fa14da40a09bb0bf1cd8763c77_I20210930"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzEwOTk1MTE2MjgwNTAy_b2c86b37-1b9f-4634-aaa5-a20f7a55bff8"
      unitRef="usd">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i17c1a096a6384157896d5f66dfc3de76_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzEwOTk1MTE2MjgwNDgy_8ae515ae-5f05-4ae4-990b-2cbb883c70a7">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <cah:AdditionalStockOptionPlanDataTableTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzIzNDk_297a3dd3-178d-456c-99f4-99287be1c84e">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide additional detail related to stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of outstanding options at period end&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of exercisable options at period end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of outstanding options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of exercisable options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cah:AdditionalStockOptionPlanDataTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i2b18c3fa14da40a09bb0bf1cd8763c77_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTpmMjJlZTVlYmZhODk0YjM2YjljZWQ3OTRiYTNjMDFhMS90YWJsZXJhbmdlOmYyMmVlNWViZmE4OTRiMzZiOWNlZDc5NGJhM2MwMWExXzEtMS0xLTEtMA_5b570df3-bd27-414b-8deb-b13d123fd195"
      unitRef="usd">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i9e6d62cc5ac7432b86e6e4ed282c63d5_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTpmMjJlZTVlYmZhODk0YjM2YjljZWQ3OTRiYTNjMDFhMS90YWJsZXJhbmdlOmYyMmVlNWViZmE4OTRiMzZiOWNlZDc5NGJhM2MwMWExXzEtMy0xLTEtMA_ed70dd09-c3e4-4e0d-97d2-2cc215502bce"
      unitRef="usd">11000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i2b18c3fa14da40a09bb0bf1cd8763c77_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTpmMjJlZTVlYmZhODk0YjM2YjljZWQ3OTRiYTNjMDFhMS90YWJsZXJhbmdlOmYyMmVlNWViZmE4OTRiMzZiOWNlZDc5NGJhM2MwMWExXzItMS0xLTEtMA_849c66b2-cc57-43bc-b935-d13ae155d422"
      unitRef="usd">3000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i9e6d62cc5ac7432b86e6e4ed282c63d5_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTpmMjJlZTVlYmZhODk0YjM2YjljZWQ3OTRiYTNjMDFhMS90YWJsZXJhbmdlOmYyMmVlNWViZmE4OTRiMzZiOWNlZDc5NGJhM2MwMWExXzItMy0xLTEtMA_9b08f1d6-93fe-4825-aa6d-eefb0a8e2822"
      unitRef="usd">11000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i17c1a096a6384157896d5f66dfc3de76_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTozZWMxMGRjNTdlZmM0NjYyOTM0ZWMwNzIwNmVmNDU1YS90YWJsZXJhbmdlOjNlYzEwZGM1N2VmYzQ2NjI5MzRlYzA3MjA2ZWY0NTVhXzEtMS0xLTEtMA_b7ae1499-b058-445c-a359-2a837be432a6">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i391a019a0c87456d8f0328ccefc57190_D20200701-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTozZWMxMGRjNTdlZmM0NjYyOTM0ZWMwNzIwNmVmNDU1YS90YWJsZXJhbmdlOjNlYzEwZGM1N2VmYzQ2NjI5MzRlYzA3MjA2ZWY0NTVhXzEtMy0xLTEtMA_ff5ae56e-b214-47dc-9fa0-9e6a4f49b758">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i17c1a096a6384157896d5f66dfc3de76_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTozZWMxMGRjNTdlZmM0NjYyOTM0ZWMwNzIwNmVmNDU1YS90YWJsZXJhbmdlOjNlYzEwZGM1N2VmYzQ2NjI5MzRlYzA3MjA2ZWY0NTVhXzItMS0xLTEtMA_2859bd80-fa67-43b9-be81-8f28bf7552da">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i391a019a0c87456d8f0328ccefc57190_D20200701-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTozZWMxMGRjNTdlZmM0NjYyOTM0ZWMwNzIwNmVmNDU1YS90YWJsZXJhbmdlOjNlYzEwZGM1N2VmYzQ2NjI5MzRlYzA3MjA2ZWY0NTVhXzItMy0xLTEtMA_6365f516-8ff6-4c4b-a413-9ecf10f77ccf">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <cah:VestingPeriodinyearsforShares
      contextRef="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzE2MDI_e80e4e5b-bf22-402d-8767-00034001ee59"
      unitRef="number">3</cah:VestingPeriodinyearsforShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ic10011e202de4b40a88998de77fc7694_D20200701-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzMyOTg1MzQ4ODYzMzM_823d2988-d63e-41fe-8390-47ce65a53381"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="idf166df979c64f28abf562745a86e1d8_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzMyOTg1MzQ4ODYzMzM_a633ab1c-cdaf-4ea0-b08b-5073eedc0959"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i9d137a22c5e34b8289f6e4b71689c66a_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzMyOTg1MzQ4ODYzMzc_6a532076-4e3d-4863-a039-f77d790c0930"
      unitRef="number">2.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i4af342838d3b4e8183c8fd3d425f8a54_D20200701-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzMyOTg1MzQ4ODYzMzc_6f1ab47b-ef83-4a87-8e6b-c46bc9d8911e"
      unitRef="number">2.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i453244191a32475ea14a9891190b3277_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzMyOTg1MzQ4ODYzMTQ_49dad06a-da0c-4080-9583-edccd74a267d"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i1e27bef357c84648b27ccce1e084f1c5_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzMyOTg1MzQ4ODYzMjE_b090e25b-a27d-4310-8b41-5630a7389b92"
      unitRef="number">2.34</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzIzMzQ_e04828f1-24bb-4361-8ede-f40115b28c6e">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;51.31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib69f1eb355b548178f5017ddcca5b762_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzEtMS0xLTEtMA_0db622ce-2cb2-49b3-ab70-128e56c306cb"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib69f1eb355b548178f5017ddcca5b762_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzEtMy0xLTEtMA_6b0d6882-187c-4bfe-bf2f-6953af2b747b"
      unitRef="usdPerShare">54.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzItMS0xLTEtMA_651611dc-95ac-4a8c-8780-9017b266525f"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzItMy0xLTEtMA_79ae65d8-cc53-4177-a774-7ee8a79af20c"
      unitRef="usdPerShare">51.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzMtMS0xLTEtMA_7bf71a85-9da1-4ba1-9230-5b4aedd6919b"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzMtMy0xLTEtMA_7c354635-4622-4786-a652-8195d2035f7d"
      unitRef="usdPerShare">52.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzQtMS0xLTEtMA_c941cbf5-af54-4356-9a3e-372ced09905d"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzQtMy0xLTEtMA_62d59891-a4c6-4ef5-a842-2370ab48f357"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2d5d341ebc974f369b72b8f04af882c0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzUtMS0xLTEtMA_4069ba25-62f3-4cf9-9699-dc6411bc7067"
      unitRef="shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2d5d341ebc974f369b72b8f04af882c0_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90YWJsZTo4ZDAxZGI0Y2FkM2Y0NGZmOTc4ZWE0MTBkOTY3Yjk0My90YWJsZXJhbmdlOjhkMDFkYjRjYWQzZjQ0ZmY5NzhlYTQxMGQ5NjdiOTQzXzUtMy0xLTEtMA_876e6e4d-93bb-4637-9719-530b2e6afe7b"
      unitRef="usdPerShare">51.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i2d5d341ebc974f369b72b8f04af882c0_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzIxODA_cdcc1444-a5ff-4a98-81e4-8edc6d6fe434"
      unitRef="usd">36000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6efa88826c1943f0bef4619b4919fd99_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE5MzgzMDQzNjJkNzQzNmZiYWZlMDIyMWZkZWI0M2U1L3NlYzoxOTM4MzA0MzYyZDc0MzZmYmFmZTAyMjFmZGViNDNlNV8xMTUvZnJhZzo2MWQ5MTM2YjVmM2Q0YTU4OGY3MGJjYzBkNmY0ZWE0NC90ZXh0cmVnaW9uOjYxZDkxMzZiNWYzZDRhNTg4ZjcwYmNjMGQ2ZjRlYTQ0XzIyNTM_7d2333e6-20ed-4ec8-84a2-8e0be707ea5f">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950657008424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cardinal Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000721371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-0958666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Cardinal Place<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">43017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">757-5000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares (without par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CAH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,788,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950657008008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 43,968<span></span>
</td>
<td class="nump">$ 39,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Goods and Services Sold</a></td>
<td class="nump">42,326<span></span>
</td>
<td class="nump">37,350<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">1,642<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Distribution, selling, general and administrative expenses</a></td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">1,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and employee severance</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Amortizationandotheracquisitionrelatedcosts', window );">Amortization and other acquisition-related costs</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation (recoveries)/charges, net</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">1,038<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating earnings/(loss)</a></td>
<td class="nump">415<span></span>
</td>
<td class="num">(624)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/expense, net</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossOnEarlyExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on Early Extinguishment of Debt</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings/(loss) before income taxes</a></td>
<td class="nump">369<span></span>
</td>
<td class="num">(663)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">97<span></span>
</td>
<td class="num">(410)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">272<span></span>
</td>
<td class="num">(253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net earnings attributable to noncontrolling interests</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings/(loss) attributable to Cardinal Health, Inc.</a></td>
<td class="nump">$ 271<span></span>
</td>
<td class="num">$ (253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings/(loss) per common share attributable to Cardinal Health, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in shares)</a></td>
<td class="nump">$ 0.94<span></span>
</td>
<td class="num">$ (0.86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in shares)</a></td>
<td class="nump">$ 0.94<span></span>
</td>
<td class="num">$ (0.86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per common share</a></td>
<td class="nump">$ 0.4908<span></span>
</td>
<td class="nump">$ 0.4859<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Amortizationandotheracquisitionrelatedcosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Amortizationandotheracquisitionrelatedcosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LossOnEarlyExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss on early extinguishment of debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LossOnEarlyExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950657031320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">$ 272<span></span>
</td>
<td class="num">$ (253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income/(loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments and other</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net unrealized gain/(loss) on derivative instruments, net of tax</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive income/(loss)</a></td>
<td class="nump">245<span></span>
</td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: comprehensive income attributable to noncontrolling interests</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income attributable to Cardinal Health, Inc.</a></td>
<td class="nump">$ 244<span></span>
</td>
<td class="num">$ (236)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950572795640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents</a></td>
<td class="nump">$ 2,463<span></span>
</td>
<td class="nump">$ 3,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">9,305<span></span>
</td>
<td class="nump">9,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">14,720<span></span>
</td>
<td class="nump">14,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">3,243<span></span>
</td>
<td class="nump">2,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">29,731<span></span>
</td>
<td class="nump">31,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,336<span></span>
</td>
<td class="nump">2,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and other intangibles, net</a></td>
<td class="nump">10,005<span></span>
</td>
<td class="nump">10,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other Assets</a></td>
<td class="nump">921<span></span>
</td>
<td class="nump">951<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">42,993<span></span>
</td>
<td class="nump">44,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable, Current</a></td>
<td class="nump">23,408<span></span>
</td>
<td class="nump">23,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations and other short-term borrowings</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">2,790<span></span>
</td>
<td class="nump">2,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Disposal Group, Including Discontinued Operation, Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">26,499<span></span>
</td>
<td class="nump">27,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, less current portion</a></td>
<td class="nump">5,353<span></span>
</td>
<td class="nump">5,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes and other liabilities</a></td>
<td class="nump">$ 9,745<span></span>
</td>
<td class="nump">$ 9,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Value, Issued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued</a></td>
<td class="nump">$ 2,666<span></span>
</td>
<td class="nump">$ 2,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">1,335<span></span>
</td>
<td class="nump">1,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Value</a></td>
<td class="num">$ (2,547)<span></span>
</td>
<td class="num">$ (2,186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, Shares</a></td>
<td class="nump">43,000<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">$ (61)<span></span>
</td>
<td class="num">$ (34)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Cardinal Health, Inc. shareholders' equity</a></td>
<td class="nump">1,393<span></span>
</td>
<td class="nump">1,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders' equity</a></td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 42,993<span></span>
</td>
<td class="nump">$ 44,453<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950572323848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Shareholders' Equity - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Treasury Shares</div></th>
<th class="th"><div>AOCI Attributable to Parent</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2020</a></td>
<td class="num">$ (1,792)<span></span>
</td>
<td class="num">$ (2,789)<span></span>
</td>
<td class="num">$ (1,170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,066)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Statement of Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Earnings/(Loss)</a></td>
<td class="num">(253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="num">(253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Employee stock plans activity, net of shares withheld for employee taxes</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">$ (29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Sep. 30, 2020</a></td>
<td class="num">$ (1,425)<span></span>
</td>
<td class="num">$ (2,760)<span></span>
</td>
<td class="num">(771)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,022)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2021</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2021</a></td>
<td class="num">$ (1,794)<span></span>
</td>
<td class="num">$ (2,806)<span></span>
</td>
<td class="num">(1,205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2021</a></td>
<td class="num">(36,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2021</a></td>
<td class="num">$ (2,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Statement of Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Earnings/(Loss)</a></td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="nump">272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Employee stock plans activity, net of shares withheld for employee taxes</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">$ (40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Stockholders' Equity, Other</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Sep. 30, 2021</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Sep. 30, 2021</a></td>
<td class="num">$ (1,396)<span></span>
</td>
<td class="num">$ (2,666)<span></span>
</td>
<td class="num">$ (1,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Sep. 30, 2021</a></td>
<td class="num">(43,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Sep. 30, 2021</a></td>
<td class="num">$ (2,547)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,547)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950572984552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">$ 272<span></span>
</td>
<td class="num">$ (253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings/(loss) to net cash provided by/(used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on Early Extinguishment of Debt</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Increase in trade receivables</a></td>
<td class="num">(214)<span></span>
</td>
<td class="num">(388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(129)<span></span>
</td>
<td class="num">(245)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase/(decrease) in accounts payable</a></td>
<td class="num">(292)<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other accrued liabilities and operating items, net</a></td>
<td class="num">(495)<span></span>
</td>
<td class="nump">585<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by/(used in) operating activities</a></td>
<td class="num">(646)<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets', window );">Proceeds from divestitures and disposal of property and equipment and held for sale assets</a></td>
<td class="nump">927<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(67)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Purchaseofavailableforsalesecuritiesandotherinvestments', window );">Purchases of investments</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments', window );">Proceeds from investments</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="nump">862<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Reduction of long-term obligations</a></td>
<td class="num">(587)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation', window );">Net tax withholdings from share-based compensation</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends on common shares</a></td>
<td class="num">(149)<span></span>
</td>
<td class="num">(146)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares</a></td>
<td class="num">(500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(1,264)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and equivalents</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CashReclassifiedtoAssetsHeldforSale', window );">Cash Reclassified to Assets Held for Sale</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total</a></td>
<td class="num">(944)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents at beginning of period</a></td>
<td class="nump">3,407<span></span>
</td>
<td class="nump">2,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents at end of period</a></td>
<td class="nump">$ 2,463<span></span>
</td>
<td class="nump">$ 2,746<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CashReclassifiedtoAssetsHeldforSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CashReclassifiedtoAssetsHeldforSale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CashReclassifiedtoAssetsHeldforSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Netproceedstaxwithholdingsfromsharebasedcompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from divestitures and disposal of property and equipment and held for sale assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of available-for-sale securities and other investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Purchaseofavailableforsalesecuritiesandotherinvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from purchases of available-for-sale securities and other investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Purchaseofavailableforsalesecuritiesandotherinvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950570260792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2022 and 2021 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2022 and June 30, 2021, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2022 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2022. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the "2021 Form 10-K"). </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards Not Yet Adopted </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the three months ended September 30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950571818008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Disposal Groups, Including Discontinued Operations, Disclosure</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Divestitures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we sold our Cordis business to Hellman &amp; Friedman for proceeds of $927 million, net of cash transferred, and we retained certain working capital accounts and certain liabilities. The purchase price is subject to adjustments based on working capital requirements as set forth in the agreement. Cardinal Health will retain product liability associated with lawsuits and claims related to inferior vena cava ("IVC") filters in the U.S. and Canada, as well as authority for these matters discussed in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i1938304362d7436fbafe0221fdeb43e5_94" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Cordis business operated within our Medical segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950570260792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Restructuring and Employee Severance </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance costs:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related costs</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of professional, project management and other service fees to support divestitures, vendor transition fees, accelerated depreciation, lease costs associated with vacant facilities, project consulting fees, and certain other divestiture-related costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021 and 2020, restructuring costs primarily related to the implementation of certain enterprise-wide cost-savings measures. Restructuring costs during the three months ended September&#160;30, 2021 also included costs related to the divestiture of the Cordis business.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950571759528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets Disclosure</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,330&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,989</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,659</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,320</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,979</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,325</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,039</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,286</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">552</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">336</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">216</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,038</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">526</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">512</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,915</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,901</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,014</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,927</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,901</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,026</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,916&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,823&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,093&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,823&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,105&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets was $78 million and $115 million for the three months ended September&#160;30, 2021 and 2020, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2022 through 2026 is as follows: $236 million, $287 million, $264 million, $238 million, and $212 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950570261640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Obligations and Other Short-Term Borrowings</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Long-Term Obligations and Other Short-Term Borrowings </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had total long-term obligations, including the current portion and other short-term borrowings, of $5.7 billion and $6.2 billion at September 30, 2021 and June 30, 2021, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $23.4 billion and $23.7 billion at September 30, 2021 and June 30, 2021, respectively. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we redeemed all outstanding $572 million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $10&#160;million loss on early extinguishment of debt. The early redemption was funded with available cash.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020, we early repurchased a total of $37 million of notes due in 2022 with available cash.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$2.0 billion&#160;commercial paper program backed by a $2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion committed receivables sales facility. At September 30, 2021, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#8220;CHF&#8221;) through September 30, 2022. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose-bankruptcy remote entity whose assets are available solely to satisfy the claims of its creditors. </span></div>Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. At September 30, 2021, we were in compliance with this financial covenant.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950570099544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments, Contingent Liabilities and Litigation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Commitments, Contingent Liabilities and Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. In October 2021, the U.S. Supreme Court declined to review the decision. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41 million for calendar years 2017 and 2018 during the three months ended September 30, 2020 based on the probable estimated payment amount, which is our best estimate of the OSA payments probable at September 30, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected </span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible product quality, regulatory or compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings/(loss).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately 3,300 lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 2,900 of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the &#8220;MDL&#8221;).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, 25 state attorneys general have filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general; the framework is designed to resolve pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). We continued to build out the Settlement Framework and to negotiate the terms of the settlement with the leadership group and other representatives of states and political subdivisions. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July, 2021, we announced that we and two other national distributors have negotiated a proposed settlement agreement (the &#8220;Proposed Settlement Agreement&#8221;) and settlement process that, if all conditions are satisfied, would result in the settlement of the vast majority of opioid lawsuits filed by state and local governmental entities. The settlement process does not contemplate participation by any non-governmental or non-political entities or individuals. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the three distributors determined that enough states had agreed to participate in the Proposed Settlement Agreement to proceed to the next phase of the settlement process, which is the subdivision sign-on period. However, the Proposed Settlement Agreement is still subject to contingencies and will not become effective unless and until the three distributors each make separate independent determinations that a sufficient number of political subdivisions, including those that have not sued, have agreed to participate in the Agreement (or otherwise have had their claims foreclosed) to proceed to effectiveness. Prior to that determination, the participating states will also have an opportunity to make a determination as to whether a sufficient number of political subdivisions have agreed to the Proposed Settlement Agreement (or otherwise had their claims foreclosed) to proceed with the Proposed Settlement Agreement. This process is currently contemplated to end in February 2022, although it may be extended by agreement. It is possible that a sufficient number of states and subdivisions will not agree to the Proposed Settlement </span></div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement or that other required contingencies will not be satisfied.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the required contingencies are satisfied, the Proposed Settlement Agreement would become effective sixty (60) days after the distributors determine that there is sufficient participation to proceed to effectiveness. During this 60-day period, the participating states and the distributors would cooperate to obtain consent judgments embodying the terms of the Settlement in each participating state. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Proposed Settlement Agreement includes a cash component, pursuant to which the Company would pay up to approximately $6.37&#160;billion, the majority of which would be paid over 18 years. The exact payment amount will depend on several factors, including the participation rate of states and political subdivisions, the extent to which states take action to foreclose opioid lawsuits by political subdivisions (e.g., laws barring or limiting opioid lawsuits by political subdivisions), and the extent to which political subdivisions in participating states file additional opioid lawsuits against the Company after the Proposed Settlement Agreement becomes effective. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Proposed Settlement Agreement also includes injunctive relief terms related to distributors&#8217; controlled substance anti-diversion programs, including with respect to: (1) governance; (2) independence and training of the personnel operating controlled substances monitoring programs; (3) due diligence for new and existing customers; (4) ordering limits for certain products; and (5) suspicious order monitoring. A monitor will be selected to oversee compliance with these provisions for a period of five years. In addition, we and the two other settling distributors will engage a third-party vendor to act as a clearinghouse for data aggregation and reporting, which distributors will fund the for ten years.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the negotiations of the Proposed Settlement Agreement, we and the two other national distributors entered into a settlement with each of the States of New York and Ohio and their participating subdivisions. If the Proposed Settlement Agreement becomes effective, New York and Ohio and their participating subdivisions will become a part of it. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West Virginia subdivisions and Native American tribes are not a part of this settlement process and we have been involved in separate negotiations with these groups. In September 2021 we announced that we, along with two other national distributors, had reached an agreement with the Cherokee Nation in connection with ongoing negotiations toward a broader agreement with Native American tribes. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A trial before a federal judge in West Virginia brought by Cabell County and City of Huntington against us and two other national distributors concluded in July 2021. The judge has not yet issued a decision. In addition, a trial in the case brought by the Washington Attorney General against the Company and the same two other national distributors is scheduled to begin in November 2021 and the Washington Attorney General has issued a press release stating that Washington will not agree to the Proposed Settlement </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement. A trial in the case brought by the Rhode Island Attorney General is scheduled to begin in January 2022 and a trial in the Dallas County case is scheduled to begin in Texas in February 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we paid into escrow the majority of our first annual payment, which is reflected in prepaid expenses and other assets in our condensed consolidated balance sheets. We also made certain payments under the separate New York and Ohio settlements. In total, we have $6.68&#160;billion accrued at September&#160;30, 2021, of which $441&#160;million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. During the three months ended September 30, 2020, we recorded total pre-tax charges of $1.02&#160;billion in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings/(loss). </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Proposed Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately 446 lawsuits as of November 4, 2021. Of these, 129 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. We are vigorously defending ourselves in these matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above. In October 2020, we filed a complaint for declaratory </span></div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgment against National Union Fire Insurance Company of Pittsburgh, PA (&#8220;National Union&#8221;) seeking a declaration that National Union is obligated to reimburse us for defense costs incurred in connection with the lawsuits described above. In January, 2021, Swiss Re International SE commenced an arbitration in London seeking a determination that it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of September&#160;30, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis IVC Filter Matters </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability Lawsuits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 4, 2021, we are named as a defendant in 434 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,614 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products. Another 33 lawsuits involving similar claims by approximately 38 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately 1,300 claims. This agreement is subject to certain contingencies. We continue to vigorously defend ourselves in these lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2021, we had a total of $547&#160;million net of estimated insurance recoveries, accrued for losses and legal defense costs, related to the Cordis IVC filter lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $1.07&#160;billion, net of estimated insurance recoveries. The sale of the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we retained. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Action </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations made are similar to those made in the product liability lawsuits, described above. We intend to vigorously defend ourselves against these claims. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEC Investigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we received a subpoena from the U.S. Securities and Exchange Commission requesting the production of documents from 2015 through 2019 relating to inventory in the Cordis business, analysis of goodwill of the Medical segment and other matters. We are cooperating with this inquiry and related </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requests and cannot predict the outcome or duration of the investigation. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In November 2020, we filed a motion to dismiss the amended complaint, which was denied in September 2021. We dispute these allegations and intend to vigorously defend against them.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specialty Solutions DOJ Investigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the United States Attorney&#8217;s Office for the District of Massachusetts (the "USAO") commenced an investigation pertaining to the U.S. federal healthcare fraud and abuse laws. These requests sought, among other things, documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. We are cooperating with these requests and are engaged in resolution discussions with the USAO and Department of Health and Human Services, Office of Inspector General. In connection with these discussions, we recorded $13 million of expense within litigation (recoveries)/charges, net in our consolidated statements of earnings/(loss) during the fiscal year ended June&#160;30, 2021. We cannot predict the outcome of the discussions and it is possible that we may incur additional losses or agree to other remedial measures; however, we are not currently able to estimate a range of reasonably possible additional losses.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly </span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Active Pharmaceutical Ingredient Impurity Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. </span></div>In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the &#8220;Sartan MDL&#8221;) alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We are vigorously defending ourselves in this matter.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950571643432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Income Taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our provision for/(benefit from) income taxes as a percentage of pre-tax loss (&#8220;effective tax rate&#8221;) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis Divestiture</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we completed the divestiture of the Cordis business. In connection with the closing, we recorded net tax expense of $9&#160;million. The tax effects of these matters during the three months ended September 30, 2021 were included in our full year effective tax rate forecast. We currently estimate that the tax expense associated with this matter for the full fiscal 2022 will be $38&#160;million.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Opioid Litigation Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the $1.02&#160;billion pre-tax charges for the opioid litigation during the three months ended September 30, 2020, the net tax benefit was $450&#160;million for the three months ended September 30, 2020, and $228&#160;million for fiscal 2021. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $34 million during the three months ended September 30, 2020, and $219&#160;million for fiscal 2021. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible Congress or the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits. The actual amount of the tax benefit may differ materially from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021 and 2020, the effective tax rate was 26.3 percent and 61.8 percent, respectively. The decrease in the effective tax rate for the three months ended September 30, 2021 compared to the prior year period was primarily due to the treatment of the tax impacts of the opioid litigation accrual recorded in prior year.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $931 million and $932 million of unrecognized tax benefits at September 30, 2021 and June&#160;30, 2021, respectively. The September 30, 2021 and June&#160;30, 2021 balances include $848 million and $849 million, respectively, of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021 and June&#160;30, 2021, we had $51 million and $49 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of $20 million, exclusive of penalties and interest.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through 2020. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), which has been acquired by Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $72 million at both September&#160;30, 2021 and June&#160;30, 2021, and is included in other assets in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition. The indemnification receivable was&#160;$12 million at both September&#160;30, 2021 and June&#160;30, 2021, and is included in other assets in the condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950571748520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Fair Value Measurements </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">812</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">812</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div>(2)   The fair value of interest rate swaps, foreign currency contracts and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950570367528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments Disclosure</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three months ended September&#160;30, 2021 and 2020, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During three months ended September&#160;30, 2021, we entered into a pay-floating interest rate swap with a total notional amount of $100 million. This swap has been designated as a fair value hedge of our fixed rate debt and is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gains and losses recognized in other comprehensive loss were immaterial during the three months ended September&#160;30, 2021 and 2020. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three months ended September&#160;30, 2021 and 2020. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $5&#160;million gain and a $25&#160;million loss during the three months ended September&#160;30, 2021 and 2020, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $6&#160;million and $5&#160;million during the three months ended September&#160;30, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. The gain and losses recognized in the three months ended September 30, 2021 and 2020 were immaterial. The principal currencies managed through foreign currency contracts are Euro, Chinese renminbi, and Canadian dollar.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2021 and June 30, 2021 approximate fair value due to their short-term maturities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,132</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,751&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,654</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,236&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950571603960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Shareholders' Equity </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 7.8 million common shares using a reference price of $51.53. The program concluded on October 4, 2021 at a volume weighted average price per common share of $51.10 resulting in a final delivery of 2.0&#160;million common shares. We funded the repurchases with available cash. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(71)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(61)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950570383608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc.<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share Attributable to Cardinal Health, Inc.</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">287</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units, and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">289</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for the three months ended September 30, 2021 were 4 million.</span></div>For the three months ended September 30, 2020, 7&#160;million employee stock options, restricted share units and performance share units were excluded from the calculation of diluted shares outstanding, 2&#160;million of which would be anti-dilutive as a result of the net loss for the period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950571773480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Segment Information </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,614</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,916&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">208</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,822</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,112&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,567</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">582</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,149</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,957&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,971</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,069&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,968</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,065&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services".</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42,841</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,976&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,130</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,971</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,069&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,968</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,065&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">last-in first-out, or ("LIFO"), inventory charges/(credits); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">surgical gown recall costs/(income);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">restructuring and employee severance;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">amortization and other acquisition-related costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">impairments and (gain)/loss on disposal of assets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">litigation (recoveries)/charges, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">state opioid assessment related to prior fiscal years;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other (income)/expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">interest expense, net;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">loss on early extinguishment of debt; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">(gain)/loss on sale of equity interest in naviHealth; or</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">provision for income taxes </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $7 million and $5 million for the three months ended September 30, 2021 and 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the opioid litigation as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i1938304362d7436fbafe0221fdeb43e5_94" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized a pre-tax charge of $1.02&#160;billion during the three months ended September 30, 2020 which was retained at Corporate. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">406</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">529</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">415</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(624)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23,955</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,624&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,156</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,882</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,421&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42,993</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,453&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950679881880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13. Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors and employees. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock option expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $4 million for both the three months ended September&#160;30, 2021 and 2020 respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.05&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.83&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50.67</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $116 million, which is expected to be recognized over a weighted-average period of two years.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all stock option transactions under the Plans:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:51.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price per<br/>Common Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.46&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69.31</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69.48</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $0.3 million, which is expected to be recognized over a weighted-average period of two years.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide additional detail related to stock options:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of outstanding options at period end</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of exercisable options at period end</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of outstanding options</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of exercisable options</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount for the fiscal 2020 and 2021 grants and zero to 234 percent for the fiscal 2022 grant. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.89&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.36&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51.31</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $36 million, which is expected to be recognized over a weighted-average period of two years if the performance goals are achieved.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950572306488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2022 and 2021 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2022 and June 30, 2021, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed, the pandemic began to materially affect our businesses during the third quarter of fiscal 2020. The length and severity of the pandemic and its impacts on our businesses and results of operations are uncertain.</span></div>In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2022 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2022. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2021 (the "2021 Form 10-K").<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Financial Accounting Standards</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Issued Financial Accounting Standards Not Yet Adopted </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2021 Form 10-K. There were no accounting standards issued in fiscal 2022 that will have a material impact on our condensed consolidated financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the three months ended September 30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950663301736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance costs:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related costs</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950571576632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,330&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,989</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,659</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,320</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,979</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Definite and Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,325</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,039</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,286</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">552</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">336</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">216</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,038</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">526</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">512</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,915</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,901</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,014</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,927</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,901</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,026</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and patents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,916&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,823&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,093&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,823&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,105&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950573589576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">812</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">812</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div>(2)   The fair value of interest rate swaps, foreign currency contracts and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950571678472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,132</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,751&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,654</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,236&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950571594232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(34)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(71)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(61)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950571760360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">287</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units, and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">289</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950575803336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by geographic area:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42,841</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,976&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,130</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,971</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,069&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,968</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,065&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Segment Reporting Information, by Segment [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,614</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,916&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">208</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,822</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,112&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,567</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">582</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,149</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,957&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,971</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,069&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,968</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,065&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services".</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Segment Profit by Reportable Segment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">406</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">529</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">415</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(624)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Assets by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23,955</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,624&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,156</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,882</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,421&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">42,993</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,453&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingRevenueReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950575862200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Total Share-based Compensation Expense by Type of Award</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock option expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Transactions Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all stock option transactions under the Plans:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.382%"><tr><td style="width:1.0%"/><td style="width:51.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price per<br/>Common Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.46&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69.31</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69.48</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_AdditionalStockOptionPlanDataTableTextBlock', window );">Schedule of Additional Data Related to Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide additional detail related to stock options:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of outstanding options at period end</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of exercisable options at period end</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of outstanding options</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of exercisable options</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Transactions Related to Restricted Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.05&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.83&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50.67</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of Transactions Related to Performance Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.89&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.36&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at September 30, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51.31</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AdditionalStockOptionPlanDataTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A disclosure of additional data related to all stock option activity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AdditionalStockOptionPlanDataTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950571652664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember', window );">Cordis Divestiture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleLineItems', window );"><strong>Long Lived Assets Held-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from Divestiture of Businesses</a></td>
<td class="nump">$ 927<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsHeldForSaleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsHeldForSaleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CordisDivestitureAxis=cah_CordisDivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950663217752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee-related costs</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring and employee severance</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950573314792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">$ 79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee- Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Facility Exit and Other Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950571675384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950572976744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillTransfers', window );">Goodwill, Transfers</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">7,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">7,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillTransfers', window );">Goodwill, Transfers</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">2,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">2,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillTransfers', window );">Goodwill, Transfers</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">5,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 5,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillTransfers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillTransfers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950656776200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">4,915<span></span>
</td>
<td class="nump">4,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">2,901<span></span>
</td>
<td class="nump">2,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 2,014<span></span>
</td>
<td class="nump">2,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Intangible, Total other intangible assets</a></td>
<td class="nump">$ 4,927<span></span>
</td>
<td class="nump">4,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Intangible, Total other intangible assets</a></td>
<td class="nump">2,026<span></span>
</td>
<td class="nump">2,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember', window );">Trademarks and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">3,325<span></span>
</td>
<td class="nump">3,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">2,039<span></span>
</td>
<td class="nump">1,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 1,286<span></span>
</td>
<td class="nump">1,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember', window );">Trademarks, trade names and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 552<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 1,038<span></span>
</td>
<td class="nump">1,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">526<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 512<span></span>
</td>
<td class="nump">$ 529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950684150008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</a></td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Finite-Lived Intangible Asset, Expected Amortization, Year One</a></td>
<td class="nump">287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Two</a></td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Three</a></td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Four</a></td>
<td class="nump">$ 212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950573522408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Debt, Long-term and Short-term, Combined Amount</a></td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="nump">23,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NotesPayableRepurchased', window );">Notes Payable Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on Early Extinguishment of Debt</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member', window );">2.616% Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of Notes Payable</a></td>
<td class="nump">572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A2616NotesMember', window );">2.616% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on Early Extinguishment of Debt</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember', window );">Short Term Credit Facilities Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Other Short-term Borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember', window );">Short Term Credit Facilities Member | Committed Receivables Sales Facility Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_NotesPayableRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal Amount of Notes Payable Repurchased during the year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_NotesPayableRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A2616NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A2616NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950573340104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 04, 2021 </div>
<div>lawsuit </div>
<div>StateAG </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18)<span></span>
</td>
<td class="num">$ (1,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NumberofStateAttorneysGeneralfilinglawsuits', window );">Lawsuits Against Distributors | StateAG</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number | lawsuit</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsSettledNumber', window );">Loss Contingency, Claims Settled, Number | lawsuit</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember', window );">New York Opioid Stewardship Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_AggregateAnnualAssessment', window );">Aggregate Annual Assessment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct', window );">Estimated Liability for New York Opioid Stewardship Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsStateDomain', window );">Opioid Lawsuits State [Domain] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_DOJInvestigationMember', window );">DOJ Investigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=cah_CVSHealthMember', window );">CVS Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Long-term Purchase Commitment, Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number | lawsuit</a></td>
<td class="nump">434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Product Liability Lawsuits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=cah_AlamedaCountyMember', window );">Alameda County [Member] | Product Liability Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number | plaintiff</a></td>
<td class="nump">5,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember', window );">Other Jurisdictions [Member] | Product Liability Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number | plaintiff</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">litigation settlement liability recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member] | Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">litigation settlement liability recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_PlaintiffTypeAxis=cah_PrivatePartiesMember', window );">Private Parties [Member] | Opioid Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="nump">446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember', window );">Class Action Lawsuits [Member] | Private Parties [Member] | Opioid Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AggregateAnnualAssessment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Annual Assessment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AggregateAnnualAssessment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Liability for New York Opioid Stewardship Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LossContingencyLawsuitsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Lawsuits, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LossContingencyLawsuitsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_NumberofStateAttorneysGeneralfilinglawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of State Attorneys General filing lawsuits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_NumberofStateAttorneysGeneralfilinglawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsSettledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsSettledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_OpioidLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsStateDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_OpioidLawsuitsStateDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_DOJInvestigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_DOJInvestigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cah_CVSHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cah_CVSHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_AlamedaCountyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_AlamedaCountyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_PlaintiffTypeAxis=cah_PrivatePartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_PlaintiffTypeAxis=cah_PrivatePartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950577124936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">$ (97)<span></span>
</td>
<td class="nump">$ 410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent</a></td>
<td class="nump">26.30%<span></span>
</td>
<td class="nump">61.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, interest and penalties accrued</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember', window );">Cordis Divestiture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Discontinued Operation, Tax Effect of Discontinued Operation</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Cordis Divestiture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Discontinued Operation, Tax Effect of Discontinued Operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TaxMatterAxis=cah_CareFusionMember', window );">CareFusion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_IndemnificationReceivable', window );">Indemnification receivable</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TaxMatterAxis=cah_PatientRecoveryBusinessMember', window );">Patient Recovery Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_IndemnificationReceivable', window );">Indemnification receivable</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_IndemnificationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_IndemnificationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CordisDivestitureAxis=cah_CordisDivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TaxMatterAxis=cah_CareFusionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TaxMatterAxis=cah_CareFusionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TaxMatterAxis=cah_PatientRecoveryBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TaxMatterAxis=cah_PatientRecoveryBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950656799528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Disposal Group, Including Discontinued Operation, Liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Derivative Assets (Liabilities), at Fair Value, Net</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">1,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Derivative Assets (Liabilities), at Fair Value, Net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Derivative Assets (Liabilities), at Fair Value, Net</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Derivative Assets (Liabilities), at Fair Value, Net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Fair Value, Inputs, Level 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents, Fair Value Disclosure</a></td>
<td class="nump">$ 812<span></span>
</td>
<td class="nump">$ 1,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=117331979&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950577332424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest Income (Expense), Nonoperating, Net</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Notional Amount</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950570227080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings', window );">Carrying Amount of Long-Term and other Short-Term Borrowings</a></td>
<td class="nump">$ 5,654<span></span>
</td>
<td class="nump">$ 6,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="nump">$ 6,132<span></span>
</td>
<td class="nump">$ 6,751<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying Amount of Long-Term and other Short-Term Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CarryingAmountofLongTermandotherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950656797064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity Narrative (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (using cost method), shares</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TreasuryStockAcquiredShares', window );">Treasury Stock Acquired Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Treasury Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_FinalSharesReceivedfromASRProgram', window );">Final Shares Received from ASR Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FinalSharesReceivedfromASRProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Final Shares Received from ASR Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FinalSharesReceivedfromASRProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TreasuryStockAcquiredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock Acquired Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TreasuryStockAcquiredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950657006632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="nump">$ 1,794<span></span>
</td>
<td class="nump">$ 1,792<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive loss, before reclassifications</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized Gain/(Loss) on Derivatives, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive loss, before reclassifications</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to earnings</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive loss, before reclassifications</a></td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to earnings</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">$ (61)<span></span>
</td>
<td class="num">$ (87)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950575751144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares&#8211;basic (in shares)</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Weighted Average Number Diluted Shares Outstanding Adjustment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares&#8211;diluted (in shares)</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950572357304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Numberofsharesexcludedfromcalculationofdilutedshares', window );">Weighted Average Number Diluted Shares Outstanding Adjustment</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss', window );">shares that would be antidilutive as a result of net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Numberofsharesexcludedfromcalculationofdilutedshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares excluded from calculation of diluted shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Numberofsharesexcludedfromcalculationofdilutedshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>shares that would be antidilutive as a result of net loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Sharesthatwouldbeantidilutiveasaresultofnetloss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950663359448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="num">$ (18)<span></span>
</td>
<td class="num">$ (1,038)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ProjectCostsOnInvestmentAndOtherSpending', window );">Project Costs On Investment And Other Spending</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Estimated Litigation Liability</a></td>
<td class="nump">$ 6,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ProjectCostsOnInvestmentAndOtherSpending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ProjectCostsOnInvestmentAndOtherSpending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950656776200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Revenue by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 43,968<span></span>
</td>
<td class="nump">$ 39,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">43,971<span></span>
</td>
<td class="nump">39,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">39,822<span></span>
</td>
<td class="nump">35,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">4,149<span></span>
</td>
<td class="nump">3,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember', window );">Nuclear Precision Health Services [Member] | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember', window );">Pharmaceutical Distribution and Specialty [Member] | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">39,614<span></span>
</td>
<td class="nump">34,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember', window );">Medical distribution and products [Member] | Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">3,567<span></span>
</td>
<td class="nump">3,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeSolutionsMember', window );">Cardinal Health At Home Solutions [Member] | Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 582<span></span>
</td>
<td class="nump">$ 519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950573054616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">$ 415<span></span>
</td>
<td class="num">$ (624)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">406<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="num">$ (114)<span></span>
</td>
<td class="num">$ (1,256)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950572321080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information (Assets by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 42,993<span></span>
</td>
<td class="nump">$ 44,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical | Cordis Divestiture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">23,955<span></span>
</td>
<td class="nump">23,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">14,156<span></span>
</td>
<td class="nump">15,408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 4,882<span></span>
</td>
<td class="nump">$ 5,421<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CordisDivestitureAxis=cah_CordisDivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950660955336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information Disaggregated Revenue Within Reportable Segments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 43,968<span></span>
</td>
<td class="nump">$ 39,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">43,971<span></span>
</td>
<td class="nump">39,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">39,822<span></span>
</td>
<td class="nump">35,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical | Nuclear Precision Health Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical | Pharmaceutical Distribution and Specialty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">39,614<span></span>
</td>
<td class="nump">34,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">4,149<span></span>
</td>
<td class="nump">3,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical | Medical distribution and products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">3,567<span></span>
</td>
<td class="nump">3,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingRevenueReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950577279288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information Revenue by Geographical Segments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 43,968<span></span>
</td>
<td class="nump">$ 39,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">42,841<span></span>
</td>
<td class="nump">37,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,130<span></span>
</td>
<td class="nump">1,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">43,971<span></span>
</td>
<td class="nump">39,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuebyGeographicLineItems', window );"><strong>Segment Revenue by Geographic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SegmentRevenuebyGeographicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Segment Revenue by Geographic [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SegmentRevenuebyGeographicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950573412744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit related to share-based compensation</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ExercisablePeriodOfPlansInYears', window );">Exercisable period of plans (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 116,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_VestingPeriodinyearsforShares', window );">Vesting Period in years for Shares</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 36,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="nump">234.00%<span></span>
</td>
<td class="nump">240.00%<span></span>
</td>
<td class="nump">240.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ExercisablePeriodOfPlansInYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The instrument's contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ExercisablePeriodOfPlansInYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_VestingPeriodinyearsforShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Period in years for Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_VestingPeriodinyearsforShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950657186184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950577266744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares) | shares</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares) | shares</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 68.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">69.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 69.48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950662984216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) - Stock Options - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of outstanding options at period end</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of exercisable options at period end</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950661407192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) - Restricted Share Units<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 49.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">51.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">48.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 50.67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139950675091688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Performance Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 54.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">51.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">52.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 51.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M>%A?*W QF(P,HZI,F=K_B:IPC.-<N-P3.HR5KU/<F:> Y.98 5_7<N "3<Y
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MTA/<%<I\ .]74NK]C?F!\C!U\B]02P,$%     @ YDAI4Y"]T23 !0  C!4
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M"BT [S><J]<;_8'Z ';Q'U!+ P04    " #F2&E3*AB=WU<#   C"@  &
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;)U6VX[3,!#]%2OB :3=S:V7W55;
M:;> 0&)A1;D\(![<9MH8'+O8TW;AZQD[:>@V:4"\)+[,C,\YX[$]VFGSW>8
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M##$AG;:Y'<YL-)P&%M74#RRV8 2!WQH=HOW$&H435V76S(X^!;3;\KR?CBF
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M*_9DYMPM+]YDI[T1$R)+:60$C;\E79"U# 0:GUO,7F>2%7>?-^A7XCM\F>E
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MU'6/,^*RW@M7^655@4=UO\1Q04I:58+20>G=O.\:?%&Y!5R2LA/.I2K K/0
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M7@00\D%?-=X Q80DX%#)@V971SE*9GPB2F/2<HR\5%>0X62Q'XH&/@-[_9_
MZT!IU9 +"K41_7O$?',8A@.HNY.#C"10/%T-EDA8A\-$W% B.E)@6C.07)I;
MX!-^+A%'5<U6X:O:AZ;J52*X=K, C;,0ZD7?ET434#2W6F.9 !-4<<H(!'WQ
M9U^N0B)RCF"T6/:"+BWS5FIZE(M,WX1 9KP$#V!/X"5]I$&##^OI<94IMZF,
M,"4(P2\:8@X,AA%4&"]<INPAL%UB9C5\PM#(Z4CFHEG5[K_)7'&C\<EBX"8V
M*#_1$ ^BL@ON-QJ68-*;A=K.A?%K<=S@<3==:PA-5!Q&K!&IA6>@SGY<-/EU
M3OI ]G#H$\K'\QZ3+&@/EG[T9+$V[8HZ 8WE<SP1!GV: V*FHJE<*92+V0X2
MMBP0QC&-XI\<<T>(_4,:[$V.=E^/'&IQ/<Y#[M8-3(2I["B3-0O9-4IICT]3
MEV9HK98,)DD)K221RP=A+X3OZ>SIZ>F N7/\,.08YHE+S#XO6A=@EVYARX/8
M4-E,\*P4NC2EM_:])*:ZP'6 C*6Z'=H]Q@NEV0#!^"%.-0)UK.:5U+F#FJ85
MY4O;C7"(: "#L&+P50/LE4!L4=2]H^.W/+=5Y2A)T2C\22]DZQ81K_I#AH85
M,XK%K6LJDU):P:G0M4'K&=<M=)=JUG\Q"T2-%KKTNEY6/5<H0Q5"<&KQKET9
M"'>8D"E/_AKWH(@K9)U\]%)#+%3Y1@YTFIP>I3D9$$ MJOC0'=-N@$&R4H#D
M=1?* KE<G&@JUQ=_,YOMR^*ZH?QS^IM^7KI;2:YX)J<RR3F??07)4:N=DSH(
MH.* .5/G#"&H-IN^%B"IM0E$F$.-8IL6]?FBD*T)[)VI:LVR74D&+ C>K?'T
MU7]"6E1^)O3M+$,*(0US2Y(I@BV91J8=-M&UIO8PD6U 4B,=ASH\AGY,L">5
MK'A+6_LX)2"S"LSP*)_\6"[S9WCVO5SFN[5K-&/^MW][<7Y^^O+MJS?RU]G+
M1Y/@X_Q9C!$ZF(O:WH4Z!VB632HG!D$+N/DA$Y,=B4X=V1\1M4AKL/MEB@1X
MVK=N%#;<TA5#A,M/CA[$AL?=45;NV5NS7+I%D*P!_$B<W:TI&A&F#WG'LZ^T
M5L/Z3*E9"^S;;2L!8Z985< V6-%V7:61!P+3C66Y6N-7(^$+]) U#69=MQ)N
M'J;PI3K1-(.@2N]6*;OIF1<;TJW81P 1P>R.\R2*T:%K7A7Y?HV:(0+L)+65
MD*@D!@ $?*C"W Q;_"$2R++,'S;A4R%RWCO6&#"=IC_W1RG(:X8J6ZI(I3)!
MQD_AHH# *1\'56^M5$!QEA0?GSC\T)9/8I5REI7DZAI6:2&I;D#57<B?[9JP
MCF)[3#0J&XEXI\V4$OXTVX9N*]O'4.++=?0Z/IDQZC(^&;57J,BF$F/AO1 Y
M(\YF;8N(PZD?D:@,I'JFO&:AT#2$NQ,&!Y;OF<BI2"7+'827B:Z&7!VI4O0E
M:G</$%TV.!9*&J6&2:\4_=('Q&R>J24$>CR:&VK/[X;S3(XK) QN74D8+$<[
M))V'ZH%FQD>'EP!U.'-;2S8NB,_:E%'WI3@7J;21CP^>7T@4+L)P/E_;#QT]
M\5 @V&=1EFN7!P:A+6@+'M-= 'HV"'M^;':L_LP^@19'P^RJ*L]BCC$T3W3'
M)W@Z(4&FY1[:Y+Z66%0!$B:ZCZ%2 95BM+=@F/*JM+19&@1G4;*/(:'O:9H=
M'ZA[.31)<1XV58/C@=7V(:Q4)03AB([+@'@?/+F!,\<QN;5S/C@KGOLHT0%G
M8QE-V?+1Y%03AY@_.\$AN)A6,Y/=AE!_$'7L(,B9L%T\I!).',WP'<@(RABK
M^V8\'^$:?HJ!X&=Q<<J@C\O/E$N?QJ!DO1^<G,9"$P5B(O"GI ,D:,_,A/);
M8K=1T?*<R2_( A77=1+"LB8G;11JLLRPTFO-2<14[T,"F/F0$>^2DLBTG\8^
M06Y8*CJL4/(?:V"F?8,!3ZFD>P9-K/W'28F-!Q,%]^X#9.WX^>DCQ%[ )$9R
M>:. ;V0P=3_<CA7C,G!P;,T?5)=7L6R)&9Z?/L;"P;8]H"PQ1S0B2S>U:!H,
M%T@!GSV7= #!.:D:TB]P"TUYE\JE.?#(&(:A8LL.T*#.[2/V5OM;///I3&NP
MIH#8EJ54R>$9]0]JZKGT%1Z@V].=L!$$&(<@<Q1A??'\Y.F7Q5S+PLJDW&GK
M=*FU!&%XJ1G/LQ>QVXFDVP_,"(Y+O"I]:JD9;WMZ%I@-1I(3P#\Y&O9PACKP
M)R!-Z2*@;F;[#\.TBK*(8I-LRAX689+]L%T[MB>KDYF6C>:F%>F"[DD/AOS]
MJ3,]FB5!FU)[?U1Z4%X)G/+P9 ^KA_ J%X)!^1Z6,M5B/ZC5IXBF.)HDGZ[^
MLZ_5!(0\C&K$..V;-(V@].S+EX=3'U)Q T> TT-4RQ:DD>R(1P 8W2H&^4=Q
M?/8H0$A.\;(X/G^4(8:0DT'$[:3E*.@IM-PW=6W)32I\5HL<4>294'*@6]I4
M CE8XRF,7$\3$A,_C"G9X\/%[ ?L5V8,A3".N'A4L%U#)A)I&B<=8\G[I<QP
M_.P1:/!;R((D<C@PH^2DN(R?5.MH[Z6;6?G=2$>/W2N&:M8"2T61D];&8#&E
M0L13#'H^BOAC*$-[E\(9@9[<S]B2DB!;K\R*B$-J6(^U+@&C72JXH?4P8MH0
ME7%'<+Y>F5B:SJ1^EB$'FTK"JD+[*R[[0)\D.6R=;6/!DU:KD/!$C+?RYK('
MI?X>'AP.Z2S+,Q+P2Y0_#4?%+T2/H4J>-SQR%<G&A.5<.S4,XSCT$ZC?5_39
M/[E>%#BM?\N#VK+*4!Y6Z'?7KJ!J9CR(,_^LR9G+#1MB#;-@;A[PAX"A-)=X
M\P.AGP08>8$U-?JP"!NCA=')9F(O0?^AV.Y@Y$Y(V$1S\Y'CG@F<;7FJL1TK
M8:4H;U<8W;R'3OZ<Z@%3L<1R3=X]K %.HWV Q;QMF+^8SGV8J300FD.<6WI!
MC(_Y2,(8"6+&IS67+A(IYEZ9.9/55W3JVIUP%=#!C]JUT5$KAUKXI^0XV!RB
M[;HN]7:SC8O.1BEB+8]B<,<B"/MI2HE78A/>R!J9L+D0BBT8#F<;X'=_ #,%
M4B]#FDQ;TYFN.^0P@V9[YL,_MAN*)\^Z#TU.TM$JC;"PO(-<Q3D?HH7;3MME
M%DH<I^6.Z/X5+4$BLSG^B?!AD(<'6/;+NBEM\=I7I'N/T'OW_).I4R"E#37C
MI5Z9JL(F@SC)PO?.]2N I=\+SS*8_VG=B9J-$_ J%ICUI6:W!W99:%NZUG>Q
MXSL VBR!TMIE<*OBHZW,:3]L69O+2R!:<?Q(]6YN*O'%<B5'4]L"I390[ $(
MQ [(/G6&)].V;[$'*ZF63;JX9\E* NT_?Q'1?JC0EX=;*F<#_/_B(NL<=;$Z
MICP(VPTS59,[(1IFLO.!M$^&LC34JE<4Y]&9#R,>YI-]'B,_4SQ.Q_VSVODN
M91?SH0C56&F@/3LY/4_<^W^IX,8^A ,EZG]%,T)LB0J]Y_^2'@3UOC%H&3@8
MB^D?ZTH@59_=>\ O:81 1F@NX"PZX6Q(>7GIFI7$-H//P7*R^:'W(>(TW+:3
MWL2A';X%G&U+J9UEB2TMA.SL@&KF6NI)S<Y8D+=EN%[6BI+R25F<QSW9U+8_
MM*6,:B9RUP1A2[VJ[F)[C1XKV[E,;$@J8]YR5 "N VK18E &+4:%*JF=/U2H
M<NJY.4.Y<=ZG[H?8I\,PA226C00OKVC/NE@\^ E!DH,R3QH58MTOE?PB@$$(
M!KK_[-N[K+P77.@!5#5N*(2K":$>HRU-[J5J:?1Y?_?%.RGUI8+I]\9W]]W]
M2(;O!VDIO0F+!WBO9=B#&SX^>O7NIU ".U#BU,+FPT5+-9R8)M8F3[0-'F'X
M[9!@\W;*A="K&X-?)5=T[F  /COX&VQ:ROO'JR$T@J.+2K'5,GBW@S%VNH\6
MTV\ISC]$?'JZKZ-R!4LH#,\:AXCK4JU^.LEU*%1>#X7*CV<^4O$):BI8;:B1
M3AHQ9^-K:G3G*1#24]-FY!#45$MI2NZE:KUN$/G3)_D[B-UF?Y!T,$L87TJ'
M1FR_M;$U*96RU SH'1MF/ 2647<&!L3.4<8P$1&.<X87%\\SHZ&Q:@2Z%_%"
MQKO Z%EQ=OZ5G$]H(;1226;X%IMD?Q4 VGOULB%?IYVY22/]J(0L.6H'2&)"
M;81)O7Q$Z,D9AB0IN76K!KOR-(_2FR)9H+[UMKI5H#$QKJ]KW[<"+[+^BC!9
M'G#N]P>G6-%Q"OJV+ <F-OG68 O1*"[U.5E*L 0S)M'B)'Z7TAPU)VR;-\S/
MC>\U*9:)W;&I(U]3*1:,;[5U+3KN%/S\'".;WRB8Q0]P[]G68U@$(J]=U_EY
MWZ[6L^+ZLC@.E>?Q^%1J9F>67N6*JTLREI9HLB+[37%HJ\B@UKK-G.?"F%+)
M7Q) A1LCJ<7S@(W_*,-"C!*1[@U<M2]^L;'M/-!U\WUJ M<POIV[KDWQ^ALX
M#<EK#SO,JVFR1Y?9B%2*TUV&I/2]VPR::S=2LTLQQC^_[^A62,MP62PX&#&=
M>K-9^K0#EIU(K-C-*!,'L)L:@T/WLZZP'$[X]>]7$*V*R>BW8<QUN'#R)L&#
MU*]X>="VS!*>BLV'9F@S(ULNGEX<N%"3& .O EIJ$Z*XRXK3F!B0WO22_FQ#
MBQ0>N#*5 V>8%5%]%\20#/W8-CZ;/3^[R$V5%@2UEWYL<[5#+C6KIA,,M_T"
MQ]YMN^]-$(=?6[.5#W#\2B1P-NM!MP;H ;P]>D35)W=C_A@HIE97\?3IP()A
M']&*WK>?IR^F=C=V"Z7@CUOQ]+?)FOMI:^:HUY*7V$IGQRU?=;CZ9O=;-E-G
MS7#ZXWQJ/;[OKIATLH\SZ4'578;RL!GU,F1=#!DV2>'6'LC>\R.'G,@(6I-Y
MF@?7R#FD][(6X2S*4'%(28#,CUT>CM9W6D0W(7QEN/KLXLL4MC,298"9FIX'
M/1ZT?98">5J"$&](8X[XMI$!GDV=6:;A008S<?O,-,B 6$,U.(N2QGW;UD\K
M0%/_'4/HNAD*DPC_-!FEL\H"<\L!0V &Q:T5,FIL>'CLD%N)K).LDJO=IM_$
M0?D V5^VB)406]H0XB5HH4G28--B[=G):5:L_:0S#8U3;.D.\X>#8G#8^'!W
M>SNXJ8!0#UC0R8$/)QTE7J,;R1";VI0F@E[)KE"0V7W ..FM_> 6S7Y2\5*=
MV?3M%M)?,WTV75_/7Q 1)@[XITY@,H"<J$^9D$Z:F\==J DM!_.H.;AA(42&
MO]5+7EN]YFL[I!L4>YCA9[:JNS($@;$3.WP*U/QJ/FS-'=F'WT,J8QJE'T2Z
M6?S^@*.;'80 O"FD_9(/6; L)9XN?IT $%V-P_(#U_UW68AN4D0^7.G0&_<6
M(&9($W[_8;$6H9<7Q_CP%B<)=%-[@&XSA(]EL^@U[23SGI^>/2OBQ5<VV8[N
M&##2J_5.<YTK0(R2&*&:ZLX[01NKIBDEHQZT14^2F8Y5NLNF%B%/O]P3K4K&
MDZFRN]%5FA3$A^O'VBA[(&9M>0_?Y/F#4=@*1O*5'>NFHEAF3,TBE5R7V'W,
M2=XTO?,.N\9X& FXE;\7U^'M6=J=_XM6[G]@$34&$X?CMRS&B$)S901?5?$E
M,;++Z%2U$4M[C9MV(YU13%6$:S3IVG(R*;6\["*413_G91R2$$]$\QIH?F.-
M/:[X<<'>R=;'?$>XYB%O0F%RJ-NQKOC6X#F5,M+XULBKB%X$8*)OT3E5UH;V
M_NVVH:*5Q=G95U]!;U[_EEYS1%'Y/NTRLETX#2@KEU.3NP_UDY&[C._Y&?B^
M2_<AW:26>1H3I-,A"DA]2@GE]W?T2HI-J2M?G)T>SQ^%=T,<FT?9NR@.:O&E
M\O_L*^#P.6])27P$Q<[[JE/R(RC\?G"\^(M2&J*MSJ[&BC!1XA N14W7'CM]
MI](Z]%,@PMGXW($?L .EX-7P/@)QH2-H&B\1B:1.KQM%853>EMQPEMT?[36^
MX68X#M^,SP08>%#YF+YYZ)1P-)=QQ.@DY@'_$ 7P=3U!MAEA3/34=\UB],X>
MN9T<>X-?C\N9XT3#IHGQ+#C*72HGIG*7 ('<#*K= 9$]$WN:9:[]V"OJ.=_O
MPS+/M8%]Y-%A<XCK4KV#Z=$]+Y9M+;XC:&QY(OX(_4I[*>'<\KR%>32+=<](
M)-YW^.WF\AW"LU%"863,R>@N="7E;[N)>>[[7U80WD6@@5?R+5Y2=S-B4&:X
MQ&51]%<$!LE_*CN'-'+N.!F.$+_&RL \=*8L)?;2UULPY5CF4=,ACJ>^IX]E
M=D>.<1(O/10G";/ 8!DWSJYG/NC''F /TM;>$JC-X@GBH=>BXVR?"NCROCXA
M;\>EH+QN^,79TQ1N$99KQB8:G,^L%7YBA3#7UB4(@YRPSRE4.L4W#3F8/^R#
M8&,9NV 3;T4X#O0W[ZS4UB05=:!"U;1#*T+L3V;(SZN$UL@-XI?%.EXUR(IC
M0Y?V_[I,=E*\DY6OI&J2X:'X/L+)Q==K?$=&7O(*2$NX-,90^3O$@*(F-R3'
MW2!9"*$W 4&=/71+-M1T1G JH/?A>DQ\<\4$K<07"99MO\HNH\9:0=39_*IF
MB@;WITQ]&+'G"B:=Q=3T_J],?"F=H:$1#\IC+ MF;FJTH9@;' EU\,"'ZFA
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M2+EXN1I_!-O(A2;\#[:2QX)PUG.\ -]7UH;N!V_0WW"?_P=02P,$%     @
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MBL V<[K9D*G";%P:XDD;E@4_;6B] I_GAK.ZV7@'[6,Y_0=02P,$%     @
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M04_/K,IK-W<TU364>E-*;;M.[&0%;SD=Y0:A2[ZB'69UR::ED;Q/VG.I$S(
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MS>S:Q@D.1T_MZ50:O^V\/?/,[-AG*Z7OS!+1PD.6YN:\M[2V.!T,3+S$3)A
M%9C3D[G2F;!TJ1<#4V@4B1/*TD$T'!X/,B'SWL69NW>M+\Y4:5.9X[4&4V:9
MT.M+3-7JO!?VZAOOY6)I^<;@XJP0"[Q!^[&XUG0U:+0D,L/<2)6#QOEY;QJ>
M7HYYO5OP2>+*M,Z!(YDI=<<7OR7GO2$[A"G&EC4(.MSC%:8I*R(W/E<Z>XU)
M%FR?U]I_=K%3+#-A\$JEMS*QR_/>I <)SD69VO=J]2M6\1RQOEBEQOW"RJ\=
MCWH0E\:JK!(F#S*9^Z-XJ'!H"4R&.P2B2B!R?GM#SLN?A!479UJM0/-JTL8G
M+E0G3<[)G)-R8S4]E21G+VZ60N/A)<65P)7**-=&,%QG TO:><T@KC1=>DW1
M#DTC>*MRNS3P)D\PV90?D%>-:U'MVF7TK,(;+ (8#?L0#:/P&7VC)M21TS=Z
M-M29"_5:K(E9%J9:BWR![OS/Z<Q8333YZQECX\;8V!D;?P-<G]<4C@+8I0UN
M$;CR+/T'XDI\!S*/*1AB.A2IR WL$T-<"=QCNNZ#72+\^,,DBH:OK_FY.P]?
M'P#5MWLXPQSGTH*:0XS:*:9356HZS"7=,GU(I":-2AL0>0*8%:E:(YH /I""
M.=E3*YDOP(I92FYH=2\3-&"5%2F85A;B=BCXP.?DP!KLND"V*E9")Z>D52-N
ML N(&Q:S&6I'D'UR,I-I2FK,@:,+_PSA/5)"96Q)P)F%,J?(:D-[$$[XYP3>
M5!%4$*IBPR&&*(Q>-\=KU*X9$M!=:H_A!#X\'^H>1&/^F3C /"Y6/#38:TP%
M.VW5;ATK86!O7(?MTC=3=NER:!U@F0<,.P!S$''N'$P:35$S)&B#YF@''RDZ
MTXVE@075#]\KR8HGD*,5+"@4+=)T#?<D2*P$_%Q2F"+/^2!S0T&G7'<&U+T3
M99_7*+0)=AD3<:Q+A%B8)7&06<7T^US*>Y$Z378I+/#Z0JP=^<J"L&$/F(_$
M*';0L6H'6?W>)+\07<D]H'9 >+O]P[2SHKO]VP+A=(.8?6)(3%F @M9X*9&I
MDMP^V(7YK=M3,#F<$D*T1<(?*N=@:!G%^7N9XV,V1T2H\4DP/()?JI2$<!0&
MKT+XY"7VPP,83X+)"*Z8NBDK(?B(.'.4O&";YQO&.OC#%H^&P?$KF'8]][W&
MDYOFA4,F^ :#8V5L'W)TO893E#EX*X=*PKC?QCQOW-F!?JXL\8>K)U:+G'*8
M^"()P^,Z"7U8+66\!&E<N<:5ZAFVA1P=!:QJ\$4%/N5-JL2Q:*5JIMZXCO&N
M\!3I;"3?ITA<\CAX?$ =2^/HZYHXYM6*N5:9L^;L0T)(!C E6F]ZMZV$2X@R
M1KV^<H<08BU4&'<$+]5:B74M44*IS?@T5/Q/UZZ<Z&'51^EOVXD7E-Y&*]ZH
MPW]=93Y73XKJ76D)YSQA5YZ4%??IXTDP/F[*:KM,WGCH.IZ\L,ZV['=4FG/B
M)!B%M;$Z3[O7CB?_=55NDFI7,0Z#T?<KQ@Y:F7K^ )$DDGVCP!.DN2;=V&;;
MSI]N#10=*&^29+I8:%R0+BI9ZDSTQA(_EHEJI;<I.5L'P#O8GFNEX3_H:9=H
MMYX1ZV#7'1PO\/MV&U6-/$VRIS$-#SP+<_VG<KXSDC']^THU78&PFO9<U=X%
MN^<MXWMFQ8_1(<?,8#1+*V#\Z.3>_Y82[_VH3U[PR"-IH-V062B1$H\N:QFN
M%7RP+$(D\71U]2/T JUOG97>I ]U(?AFF(DUN)<+WX>_H%:L)!H/V61<N?&H
MS<\E5;=JQO&Y-#%AY^:T:F +?2OU.T"C=C1NU#Z5C;Q(L!/+_\UD5>QP<'OK
MW&_RVH&>.7CYIM!&Y&OFK3"(>/X9!Y.39FL8!D<\<YT\SES4[@[@* I&Q]]J
MZ@H#[O!DA7:#_[C#[\K-KEX_^FYS%TA/N">UNU&10==[_*#UK21#H@Y_$3($
M"M'!?S9I[C8?G:;^6\OC<O_%ZBTQCYHTI#@GT6'PZJ@'VG\%\A=6%>[+"[V8
M696YTR4*(C(OH.=SI6Q]P0::3W$7?P-02P,$%     @ YDAI4RT84U2K!0
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MS,,,E5Z-@SA83US)94YN(IR,*K'$:Z1OU:7A4=BA9++ TDI=@L'%.)C&P]G
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M)J[NOIOS<XK&;>#UA=:T'C@'W0,]^0=02P,$%     @ YDAI4Y2<)A8S!
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M4T@ZA<3C;AUYE#?,LNE$JQ5H)TW6W,:'ZK4)')>N* ]6TU=.>G;Z3JEBQ84
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M,B8&PI\"[8?'.D,[;@H<2$W-J12=,X+XC/>H(!G^Z?"?PXWQ0@WE.(5SX2K
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M",.*7FFT[$#VTA#I8<()QG=_\Q]02P,$%     @ YDAI4\T[;2;) @  $ 8
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M*TL3Q&\+&MFHG0/=9TK9G>$2='\"\W]02P,$%     @ YDAI4X^]B[OW @
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M0=<!H<#$.@5&?R^X0"&<$&'\:32#UJ4SW!_OU'_XV"F6F!E<*/'$4YM/@F$
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MF;(+\'TII>E>K('^YGKV#U!+ P04    " #F2&E3.] CFYT$  #"#@  &0
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M!XW*3TSYC9&9.Z4LI*$SCQNNZ9")RDZ@]TLIS?'&!BB.K9-_ 5!+ P04
M" #F2&E3A]ZYJC8"  #/!   &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q]E-MNVD 0AE]E9.4BD1H,!I(V,I8XM$HDD%!0VHNJ%XL]QJOLP=U9A_3M
MN[L&ETB%&WL/\W_SSWK'Z5Z;5ZH0+;Q+H6@25=;6#W%,>86244_7J-Q.J8UD
MUDW-+J;:("N"2(HXZ??O8LFXBK(TK*U-ENK&"JYP;8 :*9GY,T.A]Y-H$!T7
MGOFNLGXASM*:[7"#]J5>&S>+.TK!)2KB6H'!<A)-!P^SL8\/ =\Y[NED#+Z2
MK=:O?O)43**^-X0"<^L)S+W><(Y">)"S\?O C+J47G@Z/M*_A=I=+5M&.-?B
M!R]L-8D^1U!@R1IAG_7^$0_U!(.Y%A2>L&]C1^,(\H:LE@>Q<R"Y:M_L_7 .
M)X)D<$:0' 1)\-TF"BX7S+(L-7H/QD<[FA^$4H/:F>/*?Y2--6Z7.YW-%NY,
MR'+;&"2X7J!E7- -7 %7L.)"N).C-+8NDX^/\P-UUE*3,]0AK+2R%<%756#Q
M41\[AYW-Y&ASEEP$;K#NP;#_"9)^,GC9+.#ZZN8"=MA5/PS8T1GL7)N"$YP<
M OQ<H=RB^76!/NKHHT ?GJ$OM=K!TK$+F!*A)7A$4=RZ3KHE)ERJI1/ DT5)
ME]*-NW3CB\6LC<X1"X+2:/FA)EW"K"$7[ES\]VNVX+L ]FW\EGU)[M/X[=1-
M?'+)))I=:"6"7#?*MO>M6^VZ==I>TG_A;:NOF-EQ12"P=-)^[][E-VW[M!.K
MZW!EM]JZ!@C#ROUQT/@ MU]J;8\3GZ#[AV5_ 5!+ P04    " #F2&E3P WD
M])H"  "R!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6R-55U/VS 4
M_2M6Q -(@Z1)6Q!*([4%M#V@H79L#],>W.2VL7#LS+YIR[^?[7RLE%#QDMC.
M/>>>^^&;>"?5B\X!D.P++O3$RQ'+6]_7:0X%U5>R!&&^K*4J*)JMVOBZ5$ S
M!RJX'P;!V"\H$UX2N[,GE<2R0LX$/"FBJZ*@ZG4&7.XFWL!K#Q9LDZ,]\).X
MI!M8 CZ73\KL_(XE8P4(S:0@"M83;SJXG8^MO3/XR6"G#];$1K*2\L5NOF43
M+[""@$.*EH&:UQ;FP+DE,C+^-IQ>Y]("#]<M^X.+W<2RHAKFDO]B&>83[\8C
M&:QIQ7$A=U^AB6=D^5+)M7N276,;>"2M-,JB 1L%!1/UF^Z;/!P #$\_(&P
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M2QF=?K&R=#L[V@VIVC^_)T7V,?ME:<<M:I=@S^=*T7KC"O0#//L'4$L#!!0
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MI26-XY_*:*_V62IN7C]9_V""U\'<$TDO>/:#I6I^UHM[(*53LLS4+5_]3JN
MHM+>A&?2_ 6K2C;L@<E2*IY7RAI!SHKU+_E5)6)#0=MQ*Z!* 345^AT*N%+
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M"[OG2B^CYG).]8 4I8!^/^5</=V4#NKCU-%_4$L#!!0    ( .9(:5.,>,J
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M965T,S<N>&ULM9E?;]HZ%,"_BH7VL$E=B6,'VHE68M!MG=H.C;M=74U[,,2
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MN+5\3I,#OK1UYHKT^47Z_$PMJE%[QZ6T:9N:;/VXTV/ K:*Q_.FP@ H+*+.
M:RQ\U.$'KXV=-^ KC71.0J!XN1XT3%1$30E5I6BCO9-I-]1:7;^%%[WVJIR
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M&*5BNM"[-V!W%V=@1 7C816A#NB%'GBD1$B7DY9;OIM;+]XD^!9)?J>I'%@
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M;7)SH_@R^_@VX4KQ.+M<4!)280;HYS/.U?;&?,\KOA!?_P=02P,$%     @
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M+*A=@=V?*44O$W=W-9^J_A]02P,$%     @ YDAI4PDXH622 P  )0P  !D
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MA&G!/HW6!_#_I3&T6_@#6N<?_0-02P,$%     @ YDAI4]SZ$*38 @  B0<
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M<-DUIT46C;^8:)&[WCD7VG1B-TS-6XG2&ICO2R'T=F(#5*_OX#]02P,$%
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M3]'%Y1IH"#(WT/>70JBW09Z@_G0R_@]02P,$%     @ YDAI4TJ<[%,I P
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M:TKP7I%4_NTPJ%<:U+,&]5H,^HCW8$D865&E-X<$*[V@XD#6UH]J=C855K[
MP"Y@-J^'<2^PGZ'_T&!9O[2L[[1LH7AT#_[(S++2X>F@Y!L<1^C/2X/.G0[F
MI ]$*LK6("."\AB<4 8>"1;-/>PF#'.DP[2+TK0+=^R;8E"%Z11\X,P8KA];
M+TYU1*72HTJ;H, MB?B:T<]$/YBD?,M4DS,7S^HF=)3-96GZY6N9/L]3HB7[
M,-S6 FZ34&=>8%")0.#D>K<G(J(2+Q-R*!F^ EF"F>RHG0YB&'1;69,JZ"2[
MU0$6-#)!MOD =SIV3FI44:/C:&-8[>DP_-Z-W,'8W<FPVN"A>X=_E5Z&ST4
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ME?2=K@,QSLF2J4>^^HYE0FW#%W$F[2^LREC/@6@I%4]+L%:0TJSX)V]E(6H
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M:E1V SW?26G.$QN@[M27/P%02P,$%     @ YDAI4WD^[[5- P  K H  !D
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MDZCL II?2FFV';M!7:"._@)02P,$%     @ YDAI4X8GU$2< P  #PP  !D
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MZ#-VHUG&U_5\G74",/8^SD[+4FP^"9[+@KG-OSC@=$Q;OV"I-'^TT:!5%M;
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MLU&:6>F=,>-DM-UQKWS4Y:OF60-Y)^>A;8ER?BL!9)R<#.& "^U#;'NTQY?
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .9(:5/!G /;[P   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( .9(
M:5.97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ YDAI4V#TE2\L!0  6!4  !@
M ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( .9(
M:5.0O=$DP 4  (P5   8              " @7 -  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " #F2&E3*AB=WU<#   C"@  &
M        @(%F$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ YDAI4\-6874S!@  "1H  !@              ("!\Q8  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( .9(:5.I#*V43 8  &D?   8
M              " @5P=  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " #F2&E3O8_C0H,&  !0&0  &               @('>(P  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ YDAI4S,/O=N*!@
M5A$  !@              ("!ERH  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( .9(:5/HE1.&2@,  -<&   8              " @5<Q
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #F2&E3<@^]
MJAX$   '"@  &               @('7-   >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ YDAI4U>,JM%M!   <PL  !D
M ("!*SD  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #F
M2&E3O$7.5,4%  #'#0  &0              @('//0  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( .9(:5/,#/7O"!X  !5:   9
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M970Q-BYX;6Q02P$"% ,4    " #F2&E35+4+2?H"   X!P  &0
M    @('+?0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M .9(:5.V<=9M5@H  "X<   9              " @?R   !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ YDAI4Z37\;<]!@  EA,  !D
M             ("!B8L  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " #F2&E3+1A35*L%  "N#@  &0              @(']D0  >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( .9(:5/(\1=."P,
M *P'   9              " @=^7  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ YDAI4Y2<)A8S!   [@H  !D              ("!
M(9L  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #F2&E3
M]@R2&W(#   #"   &0              @(&+GP  >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( .9(:5/-.VTFR0(  ! &   9
M      " @32C  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ YDAI4X^]B[OW @  E08  !D              ("!-*8  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #F2&E35 Q'F>8"  !U!@
M&0              @(%BJ0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( .9(:5//J.EX/@4  ,4.   9              " @7^L  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ YDAI4SO0(YN=
M!   P@X  !D              ("!]+$  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " #F2&E3A]ZYJC8"  #/!   &0
M@('(M@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( .9(
M:5/ #>3TF@(  +(&   9              " @36Y  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ YDAI4YF-H;PU P  ?PL  !D
M         ("!!KP  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M    " #F2&E32'A2?6$"  #,!0  &0              @(%ROP  >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( .9(:5/BAQ(/3P,  (L,
M   9              " @0K"  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
M4$L! A0#%     @ YDAI4^TKY)JG!   6A4  !D              ("!D,4
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #F2&E3C'C*
M@. "  "/"   &0              @(%NR@  >&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;%!+ 0(4 Q0    ( .9(:5-].R07)00  +(/   9
M  " @87-  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
MYDAI4P[;Q,OG!0  +1X  !D              ("!X=$  'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " #F2&E3/?J+ZB4%  !.%@  &0
M            @('_UP  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( .9(:5-!4MMBV@,  'D1   9              " @5O=  !X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ YDAI4S(&EM \ P
MU0@  !D              ("!;.$  'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    " #F2&E3]1_3L:D"  "V!@  &0              @('?
MY   >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( .9(:5,)
M.*%DD@,  "4,   9              " @;_G  !X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ YDAI4UC+G)^#!   GQ,  !D
M     ("!B.L  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .9(:5-*G.Q3*0,  #<,   9              "
M@63]  !X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ YDAI
M4T%6O*8  P  P H  !D              ("!Q  ! 'AL+W=O<FMS:&5E=',O
M<VAE970T.2YX;6Q02P$"% ,4    " #F2&E3JF3LV\4#  #^#P  &0
M        @('[ P$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0
M   ( .9(:5.[8<P1 @,  (8*   9              " @?<' 0!X;"]W;W)K
M<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ YDAI4U_*/RX=!   _Q,
M !D              ("!, L! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q0
M2P$"% ,4    " #F2&E3@9,BN_,"  !#"@  &0              @(&$#P$
M>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( .9(:5-SJRT@
M0@,  +4+   9              " @:X2 0!X;"]W;W)K<VAE971S+W-H965T
M-30N>&UL4$L! A0#%     @ YDAI4WD^[[5- P  K H  !D
M ("!)Q8! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " #F
M2&E3AB?41)P#   /#   &0              @(&K&0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( .9(:5,NJE&)K0,  ' ,   9
M          " @7X= 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#
M%     @ YDAI4\T>Z9(= P  $!(   T              ( !8B$! 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " #F2&E3EXJ[',     3 @  "P
M    @ &J) $ 7W)E;',O+G)E;'-02P$"% ,4    " #F2&E3]X3I$9H$   Z
M)@  #P              @ &3)0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ YDAI4_,@BWGI 0  $B(  !H              ( !6BH! 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ YDAI4[)H2=C5 0  OR$
M !,              ( !>RP! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ $$ 00"^$0  @2X!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>169</ContextCount>
  <ElementCount>311</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings</Role>
      <ShortName>Condensed Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statement of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Statement of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/Divestitures</Role>
      <ShortName>Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Restructuring and Employee Severance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</Role>
      <ShortName>Restructuring and Employee Severance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Commitments, Contingent Liabilities and Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2123108 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2126109 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2130110 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2134111 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2138112 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2146113 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Restructuring and Employee Severance (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</Role>
      <ShortName>Restructuring and Employee Severance (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Goodwill and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2324304 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstruments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2335307 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2339308 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2347309 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Divestitures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/DivestituresDetails</Role>
      <ShortName>Divestitures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/Divestitures</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails</Role>
      <ShortName>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails</Role>
      <ShortName>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Restructuring and Employee Severance Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails</Role>
      <ShortName>Restructuring and Employee Severance Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Goodwill and Other Intangible Assets Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Commitments, Contingent Liabilities and Litigation Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Income Taxes Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Fair Value Measurements Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - Financial Instruments Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails</Role>
      <ShortName>Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - Shareholders' Equity Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails</Role>
      <ShortName>Shareholders' Equity Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquityTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2436417 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2437418 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2440419 - Disclosure - Segment Information Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2441420 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Revenue by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2442421 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Segment Profit by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2443422 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Assets by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2444423 - Disclosure - Segment Information Disaggregated Revenue Within Reportable Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails</Role>
      <ShortName>Segment Information Disaggregated Revenue Within Reportable Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2445424 - Disclosure - Segment Information Revenue by Geographical Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails</Role>
      <ShortName>Segment Information Revenue by Geographical Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2448425 - Disclosure - Share-Based Compensation Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2449426 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2450427 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2451428 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2452429 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="cah-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2453430 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cah-20210930.htm">cah-20210930.htm</File>
    <File>a22q1_10qx093021xexhibit311.htm</File>
    <File>a22q1_10qx093021xexhibit312.htm</File>
    <File>a22q1_10qx093021xexhibit321.htm</File>
    <File>a22q1_10qx093021xexhibit991.htm</File>
    <File>cah-20210930.xsd</File>
    <File>cah-20210930_cal.xml</File>
    <File>cah-20210930_def.xml</File>
    <File>cah-20210930_lab.xml</File>
    <File>cah-20210930_pre.xml</File>
    <File>performanceshareunitsagree.htm</File>
    <File>restatedcodeofregulationsn.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cah-20210930_g1.jpg</File>
    <File>cah-20210930_g2.jpg</File>
    <File>cah-20210930_g3.jpg</File>
    <File>cah-20210930_g4.jpg</File>
    <File>cah-20210930_g5.jpg</File>
    <File>cah-20210930_g6.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>82
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cah-20210930.htm": {
   "axisCustom": 5,
   "axisStandard": 24,
   "contextCount": 169,
   "dts": {
    "calculationLink": {
     "local": [
      "cah-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cah-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cah-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cah-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cah-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cah-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 466,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 5
   },
   "keyCustom": 24,
   "keyStandard": 287,
   "memberCustom": 26,
   "memberStandard": 36,
   "nsprefix": "cah",
   "nsuri": "http://www.cardinal.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cardinal.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Goodwill and Other Intangible Assets",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets",
     "shortName": "Goodwill and Other Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Commitments, Contingent Liabilities and Litigation",
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation",
     "shortName": "Commitments, Contingent Liabilities and Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Income Taxes",
     "role": "http://www.cardinal.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123108 - Disclosure - Fair Value Measurements",
     "role": "http://www.cardinal.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126109 - Disclosure - Financial Instruments",
     "role": "http://www.cardinal.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130110 - Disclosure - Shareholders' Equity",
     "role": "http://www.cardinal.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134111 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138112 - Disclosure - Segment Information",
     "role": "http://www.cardinal.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146113 - Disclosure - Share-Based Compensation",
     "role": "http://www.cardinal.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Statements of Earnings",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
     "shortName": "Condensed Consolidated Statements of Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Restructuring and Employee Severance (Tables)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables",
     "shortName": "Restructuring and Employee Severance (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Goodwill and Other Intangible Assets (Tables)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables",
     "shortName": "Goodwill and Other Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324304 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.cardinal.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Shareholders' Equity (Tables)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335307 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339308 - Disclosure - Segment Information (Tables)",
     "role": "http://www.cardinal.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2347309 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i01b3c57121b8495d8065ad7fce4a9b2d_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Divestitures (Details)",
     "role": "http://www.cardinal.com/role/DivestituresDetails",
     "shortName": "Divestitures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i01b3c57121b8495d8065ad7fce4a9b2d_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
     "shortName": "Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "ibf64c21f338848a589b8d482d67160ff_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
     "shortName": "Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "ibf64c21f338848a589b8d482d67160ff_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Restructuring and Employee Severance Narrative (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails",
     "shortName": "Restructuring and Employee Severance Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillTransfers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillTransfers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "id9d0f0b222df4670b2ba4b4e53c27817_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cah:ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "id9d0f0b222df4670b2ba4b4e53c27817_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Goodwill and Other Intangible Assets Narrative (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Other Intangible Assets Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "id9d0f0b222df4670b2ba4b4e53c27817_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "id9d0f0b222df4670b2ba4b4e53c27817_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Commitments, Contingent Liabilities and Litigation Narrative (Details)",
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
     "shortName": "Commitments, Contingent Liabilities and Litigation Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "ic7bc766a995e48b4954e62dc20520496_I20211104",
      "decimals": "0",
      "lang": "en-US",
      "name": "cah:LossContingencyLawsuitsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Income Taxes Narrative (Details)",
     "role": "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "id9d0f0b222df4670b2ba4b4e53c27817_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Fair Value Measurements Narrative (Details)",
     "role": "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "ie58736b6311e43b89041dc436c54fde9_I20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "id9d0f0b222df4670b2ba4b4e53c27817_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "id9d0f0b222df4670b2ba4b4e53c27817_I20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - Financial Instruments Narrative (Details)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "id9d0f0b222df4670b2ba4b4e53c27817_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails",
     "shortName": "Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "id9d0f0b222df4670b2ba4b4e53c27817_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - Shareholders' Equity Narrative (Details)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails",
     "shortName": "Shareholders' Equity Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i4ff1053e5ba649348bc766dea62879d6_D20200701-20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "ibf64c21f338848a589b8d482d67160ff_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "iff81891dbe0e4df49e09522cba431ade_I20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436417 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:Numberofsharesexcludedfromcalculationofdilutedshares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437418 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:Numberofsharesexcludedfromcalculationofdilutedshares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440419 - Disclosure - Segment Information Narrative (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
     "shortName": "Segment Information Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441420 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
     "shortName": "Segment Information (Revenue by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i260095721ed44bfa8813a4ea26fe309e_D20210701-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442421 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
     "shortName": "Segment Information (Segment Profit by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "ib5ff458415a4478c9e01d28e78e58858_D20210701-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "id9d0f0b222df4670b2ba4b4e53c27817_I20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443422 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
     "shortName": "Segment Information (Assets by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "ie4520b1ea4514c88b03060a55539c44e_I20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "id6acc8dd1eef4390892185a561efdeef_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statement of Shareholders' Equity",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
     "shortName": "Condensed Consolidated Statement of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "id6acc8dd1eef4390892185a561efdeef_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444423 - Disclosure - Segment Information Disaggregated Revenue Within Reportable Segments (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
     "shortName": "Segment Information Disaggregated Revenue Within Reportable Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445424 - Disclosure - Segment Information Revenue by Geographical Segments (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
     "shortName": "Segment Information Revenue by Geographical Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i86109f8fb89f41a5b8bd3da54e768eb3_D20210701-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448425 - Disclosure - Share-Based Compensation Narrative (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
     "shortName": "Share-Based Compensation Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449426 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
     "shortName": "Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "ibf64c21f338848a589b8d482d67160ff_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450427 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "ibf64c21f338848a589b8d482d67160ff_I20210630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i17c1a096a6384157896d5f66dfc3de76_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451428 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
     "shortName": "Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cah:AdditionalStockOptionPlanDataTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i2b18c3fa14da40a09bb0bf1cd8763c77_I20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i9e3872ff520c4bc198c3da42481249ea_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452429 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i8be3f11faae246dc81f8ac9ec37aed05_I20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "ib69f1eb355b548178f5017ddcca5b762_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453430 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "ib69f1eb355b548178f5017ddcca5b762_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Divestitures",
     "role": "http://www.cardinal.com/role/Divestitures",
     "shortName": "Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Restructuring and Employee Severance",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeverance",
     "shortName": "Restructuring and Employee Severance",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210930.htm",
      "contextRef": "i770b4bac49144b3e9384da8dd5ec1694_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 64,
   "tag": {
    "cah_A2.616Notesdue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.616% Notes due 2022",
        "label": "2.616% Notes due 2022 [Member]",
        "terseLabel": "2.616% Notes due 2022"
       }
      }
     },
     "localname": "A2.616Notesdue2022Member",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A2616NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.616% Notes",
        "label": "2.616% Notes [Member]",
        "terseLabel": "2.616% Notes"
       }
      }
     },
     "localname": "A2616NotesMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_AdditionalStockOptionPlanDataTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A disclosure of additional data related to all stock option activity",
        "label": "Additional Stock Option Plan Data [Table Text Block]",
        "terseLabel": "Schedule of Additional Data Related to Stock Option Activity"
       }
      }
     },
     "localname": "AdditionalStockOptionPlanDataTableTextBlock",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cah_AggregateAnnualAssessment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Annual Assessment",
        "label": "Aggregate Annual Assessment",
        "terseLabel": "Aggregate Annual Assessment"
       }
      }
     },
     "localname": "AggregateAnnualAssessment",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_AlamedaCountyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alameda County [Member]",
        "label": "Alameda County [Member]",
        "terseLabel": "Alameda County [Member]"
       }
      }
     },
     "localname": "AlamedaCountyMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Amortizationandotheracquisitionrelatedcosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Amortization and other acquisition-related costs",
        "terseLabel": "Amortization and other acquisition-related costs"
       }
      }
     },
     "localname": "Amortizationandotheracquisitionrelatedcosts",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_CVSHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CVS Health [Member]",
        "label": "CVS Health [Member]",
        "terseLabel": "CVS Health"
       }
      }
     },
     "localname": "CVSHealthMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CardinalHealthAtHomeSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health At Home Solutions [Member]",
        "label": "Cardinal Health At Home Solutions [Member]",
        "terseLabel": "Cardinal Health At Home Solutions [Member]"
       }
      }
     },
     "localname": "CardinalHealthAtHomeSolutionsMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CareFusionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CareFusion [Member]",
        "label": "CareFusion [Member]",
        "terseLabel": "CareFusion [Member]"
       }
      }
     },
     "localname": "CareFusionMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CarryingAmountofLongTermandotherShortTermBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "label": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "terseLabel": "Carrying Amount of Long-Term and other Short-Term Borrowings"
       }
      }
     },
     "localname": "CarryingAmountofLongTermandotherShortTermBorrowings",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_CashReclassifiedtoAssetsHeldforSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CashReclassifiedtoAssetsHeldforSale",
        "label": "CashReclassifiedtoAssetsHeldforSale",
        "terseLabel": "Cash Reclassified to Assets Held for Sale"
       }
      }
     },
     "localname": "CashReclassifiedtoAssetsHeldforSale",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ClassActionLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Action Lawsuits [Member]",
        "label": "Class Action Lawsuits [Member]",
        "terseLabel": "Class Action Lawsuits [Member]"
       }
      }
     },
     "localname": "ClassActionLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CommittedReceivablesSalesFacilityProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.",
        "label": "Committed Receivables Sales Facility Program [Member]",
        "terseLabel": "Committed Receivables Sales Facility Program [Member]"
       }
      }
     },
     "localname": "CommittedReceivablesSalesFacilityProgramMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CordisDivestitureAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture",
        "label": "Cordis Divestiture [Axis]",
        "terseLabel": "Cordis Divestiture [Axis]"
       }
      }
     },
     "localname": "CordisDivestitureAxis",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_CordisDivestitureDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture [Domain]",
        "label": "Cordis Divestiture [Domain]",
        "terseLabel": "Cordis Divestiture [Domain]"
       }
      }
     },
     "localname": "CordisDivestitureDomain",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CordisDivestitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture",
        "label": "Cordis Divestiture [Member]",
        "terseLabel": "Cordis Divestiture [Member]"
       }
      }
     },
     "localname": "CordisDivestitureMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_DOJInvestigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DOJ Investigation",
        "label": "DOJ Investigation [Member]",
        "terseLabel": "DOJ Investigation"
       }
      }
     },
     "localname": "DOJInvestigationMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Liability for New York Opioid Stewardship Act",
        "label": "Estimated Liability for New York Opioid Stewardship Act",
        "terseLabel": "Estimated Liability for New York Opioid Stewardship Act"
       }
      }
     },
     "localname": "EstimatedLiabilityForNewYorkOpioidStewardshipAct",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ExercisablePeriodOfPlansInYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The instrument's contractual term.",
        "label": "Exercisable period of plans, in years",
        "terseLabel": "Exercisable period of plans (in years)"
       }
      }
     },
     "localname": "ExercisablePeriodOfPlansInYears",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cah_FacilityExitAndOtherCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.",
        "label": "Facility Exit and Other Costs",
        "terseLabel": "Facility Exit and Other Costs"
       }
      }
     },
     "localname": "FacilityExitAndOtherCosts",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_FinalSharesReceivedfromASRProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final Shares Received from ASR Program",
        "label": "Final Shares Received from ASR Program",
        "terseLabel": "Final Shares Received from ASR Program"
       }
      }
     },
     "localname": "FinalSharesReceivedfromASRProgram",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cah_IPRDTrademarksandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "IPR&amp;D,TrademarksandOther [Member]",
        "terseLabel": "Trademarks and patents"
       }
      }
     },
     "localname": "IPRDTrademarksandOtherMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_IndemnificationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.",
        "label": "Indemnification Receivable",
        "terseLabel": "Indemnification receivable"
       }
      }
     },
     "localname": "IndemnificationReceivable",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_LawsuitTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lawsuit Type [Axis]",
        "label": "Lawsuit Type [Axis]",
        "terseLabel": "Lawsuit Type [Axis]"
       }
      }
     },
     "localname": "LawsuitTypeAxis",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_LitigationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Litigation Type [Axis]",
        "label": "Litigation Type [Domain]",
        "terseLabel": "Litigation Type [Domain]"
       }
      }
     },
     "localname": "LitigationTypeDomain",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_LossContingencyLawsuitsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Lawsuits, Number",
        "label": "Loss Contingency, Lawsuits, Number",
        "terseLabel": "Loss Contingency, Lawsuits, Number"
       }
      }
     },
     "localname": "LossContingencyLawsuitsNumber",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_LossOnEarlyExtinguishmentOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss on early extinguishment of debt",
        "label": "Loss on early extinguishment of debt",
        "terseLabel": "Loss on early extinguishment of debt"
       }
      }
     },
     "localname": "LossOnEarlyExtinguishmentOfDebt",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_MedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical [Member]",
        "label": "Medical Member",
        "terseLabel": "Medical"
       }
      }
     },
     "localname": "MedicalMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicalSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Segment [Axis]",
        "label": "Medical Segment [Axis]",
        "terseLabel": "Medical Segment [Axis]"
       }
      }
     },
     "localname": "MedicalSegmentAxis",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_MedicalSegmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Medical Segment [Axis]",
        "label": "Medical Segment [Domain]",
        "terseLabel": "Medical Segment [Domain]"
       }
      }
     },
     "localname": "MedicalSegmentDomain",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicaldistributionandproductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical distribution and products [Member]",
        "label": "Medical distribution and products [Member]",
        "terseLabel": "Medical distribution and products [Member]"
       }
      }
     },
     "localname": "MedicaldistributionandproductsMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Netproceedstaxwithholdingsfromsharebasedcompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.",
        "label": "Net proceeds/(tax withholdings) from share-based compensation",
        "terseLabel": "Net tax withholdings from share-based compensation"
       }
      }
     },
     "localname": "Netproceedstaxwithholdingsfromsharebasedcompensation",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_NewYorkOpioidStewardshipActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New York Opioid Stewardship Act",
        "label": "New York Opioid Stewardship Act [Member]",
        "terseLabel": "New York Opioid Stewardship Act [Member]"
       }
      }
     },
     "localname": "NewYorkOpioidStewardshipActMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NotesPayableRepurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal Amount of Notes Payable Repurchased during the year",
        "label": "Notes Payable Repurchased",
        "terseLabel": "Notes Payable Repurchased"
       }
      }
     },
     "localname": "NotesPayableRepurchased",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_NuclearPrecisionHealthServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nuclear Precision Health Services [Member]",
        "label": "Nuclear Precision Health Services [Member]",
        "terseLabel": "Nuclear Precision Health Services [Member]"
       }
      }
     },
     "localname": "NuclearPrecisionHealthServicesMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NumberofStateAttorneysGeneralfilinglawsuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of State Attorneys General filing lawsuits",
        "label": "Number of State Attorneys General filing lawsuits",
        "terseLabel": "Lawsuits Against Distributors"
       }
      }
     },
     "localname": "NumberofStateAttorneysGeneralfilinglawsuits",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_Numberofsharesexcludedfromcalculationofdilutedshares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares excluded from calculation of diluted shares",
        "label": "Number of shares excluded from calculation of diluted shares",
        "terseLabel": "Weighted Average Number Diluted Shares Outstanding Adjustment"
       }
      }
     },
     "localname": "Numberofsharesexcludedfromcalculationofdilutedshares",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cah_OpioidLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Lawsuits [Member]",
        "label": "Opioid Lawsuits [Member]",
        "terseLabel": "Opioid Lawsuits [Member]"
       }
      }
     },
     "localname": "OpioidLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OpioidLawsuitsStateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Lawsuits State",
        "label": "Opioid Lawsuits State [Domain]",
        "terseLabel": "Opioid Lawsuits State [Domain]"
       }
      }
     },
     "localname": "OpioidLawsuitsStateDomain",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OpioidLitigationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Litigation",
        "label": "Opioid Litigation [Axis]",
        "terseLabel": "Opioid Litigation"
       }
      }
     },
     "localname": "OpioidLitigationAxis",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_OpioidLitigationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Litigation [Domain]",
        "label": "Opioid Litigation [Domain]",
        "terseLabel": "Opioid Litigation [Domain]"
       }
      }
     },
     "localname": "OpioidLitigationDomain",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OtherJurisdictionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Jurisdictions [Member]",
        "label": "Other Jurisdictions [Member]",
        "terseLabel": "Other Jurisdictions [Member]"
       }
      }
     },
     "localname": "OtherJurisdictionsMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PatientRecoveryBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patient Recovery Business [Member]",
        "label": "Patient Recovery Business [Member]",
        "terseLabel": "Patient Recovery Business [Member]"
       }
      }
     },
     "localname": "PatientRecoveryBusinessMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalDistributionandSpecialtyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical Distribution and Specialty [Member]",
        "label": "Pharmaceutical Distribution and Specialty [Member]",
        "terseLabel": "Pharmaceutical Distribution and Specialty [Member]"
       }
      }
     },
     "localname": "PharmaceuticalDistributionandSpecialtyMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical [Member]",
        "label": "Pharmaceutical Member",
        "terseLabel": "Pharmaceutical"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical Segment [Axis]",
        "label": "Pharmaceutical Segment [Axis]",
        "terseLabel": "Pharmaceutical Segment [Axis]"
       }
      }
     },
     "localname": "PharmaceuticalSegmentAxis",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_PharmaceuticalSegmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Pharmaceutical Segment [Axis]",
        "label": "Pharmaceutical Segment [Domain]",
        "terseLabel": "Pharmaceutical Segment [Domain]"
       }
      }
     },
     "localname": "PharmaceuticalSegmentDomain",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PlaintiffTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiff Type [Axis]",
        "label": "Plaintiff Type [Axis]",
        "terseLabel": "Plaintiff Type [Axis]"
       }
      }
     },
     "localname": "PlaintiffTypeAxis",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_PlaintiffTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Plaintiff Type [Axis]",
        "label": "Plaintiff Type [Domain]",
        "terseLabel": "Plaintiff Type [Domain]"
       }
      }
     },
     "localname": "PlaintiffTypeDomain",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PrivatePartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Parties [Member]",
        "label": "Private Parties [Member]",
        "terseLabel": "Private Parties [Member]"
       }
      }
     },
     "localname": "PrivatePartiesMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from divestitures and disposal of property and equipment and held for sale assets",
        "label": "Proceeds from divestitures and disposal of property and equipment and held for sale assets",
        "terseLabel": "Proceeds from divestitures and disposal of property and equipment and held for sale assets"
       }
      }
     },
     "localname": "Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of available-for-sale securities and other investments.",
        "label": "Proceeds from sale of available-for-sale securities and other investments",
        "terseLabel": "Proceeds from investments"
       }
      }
     },
     "localname": "Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ProductLiabilityLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability Lawsuits [Member]",
        "label": "Product Liability Lawsuits [Member]",
        "terseLabel": "Product Liability Lawsuits [Member]"
       }
      }
     },
     "localname": "ProductLiabilityLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_ProjectCostsOnInvestmentAndOtherSpending": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.",
        "label": "Project Costs On Investment And Other Spending",
        "terseLabel": "Project Costs On Investment And Other Spending"
       }
      }
     },
     "localname": "ProjectCostsOnInvestmentAndOtherSpending",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_Purchaseofavailableforsalesecuritiesandotherinvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from purchases of available-for-sale securities and other investments.",
        "label": "Purchase of available-for-sale securities and other investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "Purchaseofavailableforsalesecuritiesandotherinvestments",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]",
        "label": "Schedule of Definite and Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Definite and Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofDefiniteandIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cah_SegmentRevenuebyGeographicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Segment Revenue by Geographic [Table]",
        "label": "Segment Revenue by Geographic [Line Items]",
        "terseLabel": "Segment Revenue by Geographic [Line Items]"
       }
      }
     },
     "localname": "SegmentRevenuebyGeographicLineItems",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_SegmentRevenuebyGeographicTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Revenue by Geographic [Table]",
        "label": "Segment Revenue by Geographic [Table]",
        "terseLabel": "Segment Revenue by Geographic [Table]"
       }
      }
     },
     "localname": "SegmentRevenuebyGeographicTable",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_Sharesthatwouldbeantidilutiveasaresultofnetloss": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "shares that would be antidilutive as a result of net loss",
        "label": "shares that would be antidilutive as a result of net loss",
        "terseLabel": "shares that would be antidilutive as a result of net loss"
       }
      }
     },
     "localname": "Sharesthatwouldbeantidilutiveasaresultofnetloss",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cah_ShortTermCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other short-term credit facilities and an unsecured line of credit",
        "label": "Short Term Credit Facilities Member",
        "terseLabel": "Short Term Credit Facilities Member"
       }
      }
     },
     "localname": "ShortTermCreditFacilitiesMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TaxMatterAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Matter [Axis]",
        "label": "Tax Matter [Axis]",
        "terseLabel": "Tax Matter [Axis]"
       }
      }
     },
     "localname": "TaxMatterAxis",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_TaxMatterDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Tax Matter [Axis]",
        "label": "Tax Matter [Domain]",
        "terseLabel": "Tax Matter [Domain]"
       }
      }
     },
     "localname": "TaxMatterDomain",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TotalOpioidLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Opioid Litigation",
        "label": "Total Opioid Litigation [Member]",
        "terseLabel": "Total Opioid Litigation [Member]"
       }
      }
     },
     "localname": "TotalOpioidLitigationMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TrademarksAndPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Trademarks And Patents Member",
        "terseLabel": "Trademarks, trade names and patents"
       }
      }
     },
     "localname": "TrademarksAndPatentsMember",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TreasuryStockAcquiredShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury Stock Acquired Shares",
        "label": "Treasury Stock Acquired Shares",
        "terseLabel": "Treasury Stock Acquired Shares"
       }
      }
     },
     "localname": "TreasuryStockAcquiredShares",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cah_VestingPeriodinyearsforShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Period in years for Shares",
        "label": "Vesting Period in years for Shares",
        "terseLabel": "Vesting Period in years for Shares"
       }
      }
     },
     "localname": "VestingPeriodinyearsforShares",
     "nsuri": "http://www.cardinal.com/20210930",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements, Captions [Line Items]",
        "terseLabel": "Statement of Stockholders' Equity"
       }
      }
     },
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r103",
      "r141",
      "r154",
      "r155",
      "r156",
      "r157",
      "r159",
      "r161",
      "r165",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r250",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r103",
      "r141",
      "r154",
      "r155",
      "r156",
      "r157",
      "r159",
      "r161",
      "r165",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r250",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r173",
      "r320",
      "r322",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r258",
      "r295",
      "r333",
      "r336",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r522",
      "r525",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r258",
      "r295",
      "r333",
      "r336",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r522",
      "r525",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r173",
      "r320",
      "r322",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r258",
      "r295",
      "r323",
      "r333",
      "r336",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r522",
      "r525",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r258",
      "r295",
      "r323",
      "r333",
      "r336",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r522",
      "r525",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r113",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r113",
      "r118",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "auth_ref": [
      "r103",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements [Table]",
        "terseLabel": "Condensed Consolidated Statement of Shareholders' Equity"
       }
      }
     },
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r169",
      "r170",
      "r320",
      "r321",
      "r523",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r320",
      "r321",
      "r523",
      "r533",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r113",
      "r118",
      "r226",
      "r334",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r40",
      "r469"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts Payable, Current"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r492",
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r55",
      "r60",
      "r67",
      "r68",
      "r69",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r56",
      "r60",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized Gain/(Loss) on Derivatives, net of tax"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r32",
      "r58",
      "r59",
      "r60",
      "r507",
      "r530",
      "r531"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r57",
      "r60",
      "r67",
      "r68",
      "r69",
      "r105",
      "r106",
      "r107",
      "r407",
      "r526",
      "r527",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net earnings/(loss) to net cash provided by/(used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r338",
      "r361",
      "r368"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r93",
      "r186",
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r57",
      "r60",
      "r67",
      "r68",
      "r69",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r100",
      "r149",
      "r156",
      "r163",
      "r176",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r251",
      "r253",
      "r254",
      "r401",
      "r408",
      "r451",
      "r467",
      "r469",
      "r487",
      "r506"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r18",
      "r19",
      "r52",
      "r100",
      "r176",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r251",
      "r253",
      "r254",
      "r401",
      "r408",
      "r451",
      "r467",
      "r469"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r2",
      "r3",
      "r11",
      "r12",
      "r14",
      "r201"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "terseLabel": "Total assets held for sale",
        "verboseLabel": "Total assets held for sale"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r340",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r422",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r332",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r332",
      "r335",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r16",
      "r37",
      "r95"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and equivalents at end of period",
        "periodStartLabel": "Cash and equivalents at beginning of period",
        "terseLabel": "Cash and equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and Cash Equivalents, Fair Value Disclosure"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r90",
      "r452"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r435"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "terseLabel": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r235",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments, Contingent Liabilities and Litigation"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared per common share"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r105",
      "r106",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common shares, without par value:"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "terseLabel": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r29",
      "r469"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Stock, Value, Issued"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r63",
      "r65",
      "r66",
      "r77",
      "r497",
      "r517"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r63",
      "r65",
      "r76",
      "r399",
      "r412",
      "r496",
      "r516"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive income/(loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r159",
      "r165",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate",
        "verboseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r81",
      "r482"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of Goods and Services Sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r96",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r272",
      "r279",
      "r280",
      "r282",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r99",
      "r103",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r283",
      "r284",
      "r285",
      "r286",
      "r465",
      "r488",
      "r489",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r270",
      "r283",
      "r284",
      "r450"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r44",
      "r99",
      "r103",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r283",
      "r284",
      "r285",
      "r286",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r44",
      "r99",
      "r103",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r310",
      "r313",
      "r314",
      "r315",
      "r462",
      "r463",
      "r465",
      "r466",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
        "label": "Debt, Long-term and Short-term, Combined Amount",
        "terseLabel": "Debt, Long-term and Short-term, Combined Amount"
       }
      }
     },
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Estimated range of decrease in unrecognized tax benefits within the next 12 months"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.",
        "label": "Deferred Tax and Other Liabilities, Noncurrent",
        "terseLabel": "Deferred income taxes and other liabilities"
       }
      }
     },
     "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r93",
      "r144"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.",
        "label": "Derivative Assets (Liabilities), at Fair Value, Net",
        "terseLabel": "Derivative Assets (Liabilities), at Fair Value, Net"
       }
      }
     },
     "localname": "DerivativeAssetsLiabilitiesAtFairValueNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative, Name [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r53",
      "r423",
      "r424",
      "r427",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r420",
      "r423",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r415",
      "r416",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Notional Amount"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r414",
      "r417",
      "r418",
      "r420",
      "r421",
      "r426",
      "r427",
      "r433",
      "r434",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "verboseLabel": "Developed technology and other"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table Text Block]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r10",
      "r13",
      "r371",
      "r385",
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Discontinued Operation, Tax Effect of Discontinued Operation"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r15",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations, Disclosure"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/Divestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r316",
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "terseLabel": "Dividends"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r78",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r119",
      "r121",
      "r123",
      "r124",
      "r125",
      "r130",
      "r131",
      "r439",
      "r440",
      "r498",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings/(loss) per common share attributable to Cardinal Health, Inc.:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r78",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r121",
      "r123",
      "r124",
      "r125",
      "r130",
      "r131",
      "r439",
      "r440",
      "r498",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r126",
      "r128",
      "r129",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share Attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r452"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefit related to share-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee- Related Costs"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r67",
      "r68",
      "r69",
      "r105",
      "r106",
      "r107",
      "r109",
      "r115",
      "r117",
      "r133",
      "r177",
      "r309",
      "r316",
      "r364",
      "r365",
      "r366",
      "r382",
      "r383",
      "r438",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r459",
      "r526",
      "r527",
      "r528",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FacilityClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Facility Closing [Member]",
        "terseLabel": "Facility Exit and Other Costs"
       }
      }
     },
     "localname": "FacilityClosingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r441",
      "r442",
      "r443",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r270",
      "r283",
      "r284",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r442",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r441",
      "r442",
      "r444",
      "r445",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel12And3Member": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3).",
        "label": "Fair Value, Inputs, Level 1, 2 and 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1, 2 and 3"
       }
      }
     },
     "localname": "FairValueInputsLevel12And3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r270",
      "r324",
      "r325",
      "r330",
      "r331",
      "r442",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r270",
      "r283",
      "r284",
      "r324",
      "r325",
      "r330",
      "r331",
      "r442",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r270",
      "r283",
      "r284",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r442",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r270",
      "r283",
      "r284",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r472",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r446",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments Disclosure"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year One"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Four"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Three"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Year Two"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r187",
      "r189",
      "r192",
      "r196",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r192",
      "r484"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Intangible"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r187",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "verboseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r192",
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Net Intangible"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Weighted- Average Remaining Amortization Period (Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r53",
      "r324",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contract [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedTerseLabel": "Impairments and (gain)/loss on disposal of assets, net"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r225"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Litigation (recoveries)/charges, net",
        "terseLabel": "Gain (Loss) Related to Litigation Settlement"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r93",
      "r287",
      "r288"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on Early Extinguishment of Debt",
        "terseLabel": "Loss on Early Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r179",
      "r180",
      "r469",
      "r486"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillTransfers": {
     "auth_ref": [
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers into (out of) an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Transfers",
        "terseLabel": "Goodwill, Transfers"
       }
      }
     },
     "localname": "GoodwillTransfers",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r80",
      "r100",
      "r149",
      "r155",
      "r159",
      "r162",
      "r165",
      "r176",
      "r240",
      "r241",
      "r242",
      "r245",
      "r246",
      "r247",
      "r249",
      "r251",
      "r253",
      "r254",
      "r451"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross margin"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r420",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r73",
      "r149",
      "r155",
      "r159",
      "r162",
      "r165",
      "r485",
      "r493",
      "r500",
      "r519"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Earnings/(loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r200",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r373",
      "r379",
      "r380",
      "r384",
      "r386",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Tax Disclosure"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r102",
      "r116",
      "r117",
      "r147",
      "r371",
      "r385",
      "r387",
      "r520"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Increase/(decrease) in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities, net of effects from acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedTerseLabel": "Other accrued liabilities and operating items, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedTerseLabel": "Increase in trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r188",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Intangible"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r188",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Gross Intangible, Total other intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r185",
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Net Intangible, Total other intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Goodwill and other intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r71",
      "r143",
      "r461",
      "r464",
      "r499"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest Income (Expense), Nonoperating, Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r17",
      "r50",
      "r469"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Other investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r35",
      "r100",
      "r176",
      "r451",
      "r469",
      "r491",
      "r510"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r43",
      "r100",
      "r176",
      "r240",
      "r241",
      "r242",
      "r245",
      "r246",
      "r247",
      "r249",
      "r251",
      "r253",
      "r254",
      "r402",
      "r408",
      "r409",
      "r451",
      "r467",
      "r468",
      "r469"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r2",
      "r3",
      "r11",
      "r12",
      "r14",
      "r201"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r45",
      "r225"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Estimated Litigation Liability",
        "verboseLabel": "litigation settlement liability recorded"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation Charges"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongLivedAssetsHeldForSaleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Long Lived Assets Held-for-sale [Line Items]",
        "terseLabel": "Long Lived Assets Held-for-sale [Line Items]"
       }
      }
     },
     "localname": "LongLivedAssetsHeldForSaleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "terseLabel": "Current portion of long-term obligations and other short-term borrowings"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r44",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Long-term Purchase Commitment, Period",
        "terseLabel": "Long-term Purchase Commitment, Period"
       }
      }
     },
     "localname": "LongtermPurchaseCommitmentPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r234",
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r234",
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r225"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss Contingency Accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyClaimsSettledNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims settled.",
        "label": "Loss Contingency, Claims Settled, Number",
        "terseLabel": "Loss Contingency, Claims Settled, Number"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r229",
      "r233",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss Contingency, Estimate of Possible Loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r234",
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Loss Contingency, New Claims Filed, Number"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r49",
      "r100",
      "r176",
      "r240",
      "r245",
      "r246",
      "r247",
      "r253",
      "r254",
      "r451",
      "r490",
      "r509"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by/(used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r90",
      "r91",
      "r94"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by/(used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r14",
      "r61",
      "r64",
      "r69",
      "r74",
      "r94",
      "r100",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r116",
      "r117",
      "r122",
      "r149",
      "r155",
      "r159",
      "r162",
      "r165",
      "r176",
      "r240",
      "r241",
      "r242",
      "r245",
      "r246",
      "r247",
      "r249",
      "r251",
      "r253",
      "r254",
      "r440",
      "r451",
      "r494",
      "r514"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Earnings/(Loss)",
        "totalLabel": "Net earnings/(loss) attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r61",
      "r64",
      "r69",
      "r116",
      "r117",
      "r404",
      "r411"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Less: comprehensive income attributable to noncontrolling interests",
        "negatedTerseLabel": "Less: Net earnings attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Financial Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r316",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of Reportable Segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Open Tax Year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r149",
      "r155",
      "r159",
      "r162",
      "r165"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Total operating earnings",
        "totalLabel": "Operating earnings/(loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157",
      "r159",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r42"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r51",
      "r469"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r60",
      "r67",
      "r68",
      "r70",
      "r453",
      "r455",
      "r459"
     ],
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "verboseLabel": "Other comprehensive loss, before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r56",
      "r58"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Net unrealized gain/(loss) on derivative instruments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r62",
      "r65",
      "r67",
      "r68",
      "r70",
      "r75",
      "r309",
      "r453",
      "r458",
      "r459",
      "r495",
      "r515"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive income/(loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income/(loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r62",
      "r65",
      "r399",
      "r400",
      "r406"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income)/expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherShortTermBorrowings": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.",
        "label": "Other Short-term Borrowings",
        "terseLabel": "Other Short-term Borrowings"
       }
      }
     },
     "localname": "OtherShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchase of treasury shares",
        "terseLabel": "Payments for Repurchase of Common Stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r88",
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedLabel": "Payments and other adjustments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends on common shares"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Share Units",
        "verboseLabel": "Performance Share Unit"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred shares, without par value:"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r28",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r28",
      "r469"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred Stock, Value, Issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from Divestiture of Businesses"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r14",
      "r61",
      "r64",
      "r69",
      "r89",
      "r100",
      "r108",
      "r116",
      "r117",
      "r149",
      "r155",
      "r159",
      "r162",
      "r165",
      "r176",
      "r240",
      "r241",
      "r242",
      "r245",
      "r246",
      "r247",
      "r249",
      "r251",
      "r253",
      "r254",
      "r399",
      "r403",
      "r405",
      "r411",
      "r412",
      "r440",
      "r451",
      "r500"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net earnings/(loss)",
        "totalLabel": "Net earnings/(loss)",
        "verboseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r23",
      "r24",
      "r199",
      "r469",
      "r501",
      "r512"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r79",
      "r178"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for bad debts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r30",
      "r36",
      "r469",
      "r511",
      "r532"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r60",
      "r67",
      "r68",
      "r70",
      "r453",
      "r457",
      "r459"
     ],
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Amounts reclassified to earnings"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "auth_ref": [
      "r156",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "terseLabel": "Assets by Reportable Segment"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r155",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r155",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Segment Profit by Reportable Segment"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r154",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "verboseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Reduction of long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "terseLabel": "Repayments of Notes Payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Restricted Share Unit"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r206",
      "r208",
      "r211",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring and Employee Severance"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeverance"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r93",
      "r205",
      "r214",
      "r217"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "totalLabel": "Total restructuring and employee severance",
        "verboseLabel": "Restructuring and employee severance"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges [Abstract]",
        "terseLabel": "Restructuring Charges [Abstract]"
       }
      }
     },
     "localname": "RestructuringChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r207",
      "r208",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCosts": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "RestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r208",
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r31",
      "r316",
      "r367",
      "r469",
      "r508",
      "r529",
      "r531"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r105",
      "r106",
      "r107",
      "r109",
      "r115",
      "r117",
      "r177",
      "r364",
      "r365",
      "r366",
      "r382",
      "r383",
      "r438",
      "r526",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r72",
      "r100",
      "r140",
      "r141",
      "r154",
      "r160",
      "r161",
      "r168",
      "r169",
      "r173",
      "r176",
      "r240",
      "r241",
      "r242",
      "r245",
      "r246",
      "r247",
      "r249",
      "r251",
      "r253",
      "r254",
      "r451",
      "r500"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyGeographicalSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r60",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Total Share-based Compensation Expense by Type of Award"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r187",
      "r191",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill by Reportable Segment"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r195",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfLongLivedAssetsHeldForSaleTable": {
     "auth_ref": [
      "r9",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description and amounts of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).",
        "label": "Schedule of Long Lived Assets Held-for-sale [Table]",
        "terseLabel": "Schedule of Long Lived Assets Held-for-sale [Table]"
       }
      }
     },
     "localname": "ScheduleOfLongLivedAssetsHeldForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DivestituresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Transactions Related to Performance Share Units Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r217",
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r212",
      "r213",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of Restructuring and Employee Severance"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r208",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r149",
      "r152",
      "r158",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r340",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Transactions Related to Restricted Share Units Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r343",
      "r355",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Transactions Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r46",
      "r97",
      "r134",
      "r135",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r302",
      "r307",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r136",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r154",
      "r155",
      "r156",
      "r157",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r173",
      "r210",
      "r219",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r136",
      "r138",
      "r139",
      "r149",
      "r153",
      "r159",
      "r163",
      "r164",
      "r165",
      "r166",
      "r168",
      "r172",
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingRevenueReconcilingItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Distribution, selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance Costs",
        "verboseLabel": "Employee-related costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled and forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested at end of period (in shares)",
        "periodStartLabel": "Nonvested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Performance Share Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested at end of period (in usd per share)",
        "periodStartLabel": "Nonvested at beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share",
        "verboseLabel": "Weighted-Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled and forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of outstanding options at period end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r345",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in usd per share)",
        "periodStartLabel": "Outstanding at beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price per Common Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r337",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Target performance goal (as a percent)",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of exercisable options at period end"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r8",
      "r136",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r154",
      "r155",
      "r156",
      "r157",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r173",
      "r183",
      "r202",
      "r210",
      "r219",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Operating and Reportable Segment"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r48",
      "r67",
      "r68",
      "r69",
      "r105",
      "r106",
      "r107",
      "r109",
      "r115",
      "r117",
      "r133",
      "r177",
      "r309",
      "r316",
      "r364",
      "r365",
      "r366",
      "r382",
      "r383",
      "r438",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r459",
      "r526",
      "r527",
      "r528",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r133",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r28",
      "r29",
      "r309",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r29",
      "r309",
      "r316",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r28",
      "r29",
      "r316",
      "r339",
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "negatedTerseLabel": "Employee stock plans activity, net of shares withheld for employee taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r29",
      "r33",
      "r34",
      "r100",
      "r175",
      "r176",
      "r451",
      "r469"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Cardinal Health, Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r68",
      "r100",
      "r105",
      "r106",
      "r107",
      "r109",
      "r115",
      "r176",
      "r177",
      "r316",
      "r364",
      "r365",
      "r366",
      "r382",
      "r383",
      "r397",
      "r398",
      "r410",
      "r438",
      "r451",
      "r453",
      "r454",
      "r459",
      "r527",
      "r528",
      "r552"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "negatedPeriodEndLabel": "Balance at end of period",
        "negatedPeriodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r98",
      "r294",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r316",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "terseLabel": "Stockholders' Equity, Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsConsolidationItemsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.",
        "label": "Subsegments Consolidation Items [Axis]",
        "terseLabel": "Subsegments Consolidation Items [Axis]"
       }
      }
     },
     "localname": "SubsegmentsConsolidationItemsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsConsolidationItemsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.",
        "label": "Subsegments Consolidation Items [Domain]",
        "terseLabel": "Subsegments Consolidation Items [Domain]"
       }
      }
     },
     "localname": "SubsegmentsConsolidationItemsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationDisaggregatedRevenueWithinReportableSegmentsDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r460",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r460",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r460",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationNarrativeDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Treasury shares acquired, average price per share (in usd per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r47",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Shares"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r47",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "negatedPeriodEndLabel": "Treasury, balance at end of period (in shares)",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period (in shares)",
        "terseLabel": "Treasury Stock, Shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r29",
      "r309",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Treasury shares acquired (using cost method), shares"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r47",
      "r317",
      "r318"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedPeriodEndLabel": "Treasury, balance at end of period",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period",
        "negatedTerseLabel": "Treasury Stock, Value"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r207",
      "r208",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r370",
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, interest and penalties accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Weighted Average Number Diluted Shares Outstanding Adjustment"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r120",
      "r125"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares\u2013diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r119",
      "r125"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares\u2013basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average number of common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=d3e5283-111683"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r546": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r547": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r548": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r549": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r550": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r551": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0000721371-21-000116-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000721371-21-000116-xbrl.zip
M4$L#!!0    ( .9(:5/FY]P1_0<  #XG   ?    83(R<3%?,3!Q># Y,S R
M,7AE>&AI8FET,S$Q+FAT;>U::V\;-Q;]OK^"M;&I ^@U>L22[!AP;1<Q-G&[
MA8M@/RVH&8[$-6<X)3F2M;]^SR5'EF3+B5RWCFIL@2J>X>7E)7EX[B&'Q]^=
M_W1V_:^?+]C$98K]_.L/'R_/V%Z]V?S<.6LVSZ_/V8?K3Q]9M]&*V+7AN95.
MZIRK9O/B:H_M39PKALWF;#9KS#H-;<;-ZU^:Y*K;5%I;T4A<LG=R3&_P*WAR
M\K?C[^IU=J[C,A.Y8[$1W(F$E5;F8_8Y$?:&U>N5U9DNYD:.)XZU6^V(?=;F
M1DYY*'?2*7&R\'/<#,_'3=_(\4@G\Y/C1$Z93-[OR5XTZ,=IMY6FK</NNTZG
MWQ\-1*O%VZ+/>W&O_>\(039A'NI8-U?B_5XF\_I$4/O#;KMQV"O<T4PF;C*,
M6JV_[ZV9.G'KZES)<3Z,$8XP*'9\I,3"8*1-(DP]UDKQPHKAXH^C1-I"\?E0
MYDKFHNXK'67<C-'X2#NGLR$U/!7&R9BKJA'?7BBN8AH,&MVH1V$Y@_^31<-5
MQ T?<=,E#\LZ46/0[S]:W&I$CY9]T6V[T>ZW_PRWW<[CQ:MNFWXDPFA@O&W!
M\_=[G;U%A8(G"4 W;+&H<"O^_AC3=G%+QD<KR/!0OC^381+A,]58#I43^-5F
MN-_R_QU123WEF53SX?>G1G+%KK@Q>O9]S6)%UJTP,@U65OY7 )YHUS_. GH/
MX<2CJT)SP._%[42.I&.8_^BX2?:KX];T2%Q9%2%"+"TJK*S]ZX?K9@V][]8'
MX3^E=3*=_[D=[M[O<)LZ?%ECGV0\X4*QLP;[!R_3C.=YC<4T(^F<N0EW;_9[
M_:/U_GVQ9]5TUY5(W;"SN:_AE<P3,,.P'O4]A%Z\]U%CT:T7;GI]C"*@[1V-
MP"6;\*E@1DREF"$#N(FT[$=M,A:UZO]D.F5GW* >8O@@N'*3&KO,XP8F:/ Z
M)ZB]8Q/T [>8%IVS;,YN<CU3(AF+6I@G(PIM'$NTL"S72.-H@LN<\7S.RMR9
MDA(?$KO/\9A*SC(\^7A3'N.583H#]S@=[!X8Y"(6UG(S)Y.,WPBTN^+3XEV"
M8-"D\@(!;9!!+ T$ <QR5$<DR+EL-L&B9[:DGV7]F3"B<D(=R*154 XD0F;2
M3=!!6XC8!TA^"X2FB>_!WAB4T7QU&%XO)#M_%4@*EH(I\IA:7TYR#7B$.8K-
M2KG,4[ ,)QV+OV-5)O )(*W,: T@E$;-60$<$(0)VDHM,5K!P]YK&LL@\0*Y
M1A:E@@& J8$>WYSU\<3<3EBJ],PN4&O$6%H'=>T8IY<A;D196P&?703S(-K7
MB[_NCN'O>FVRWNSWV]'AD:T05LD(HA"=IA*/!_:MG\E+QHWPF $&).T*,+=,
M6))8TDZH!IEE8%!B47K&MB!6VI:H1]QJ(#2]36%T+!*\MNP 6$D$P!< <7$+
M:9./!3L%;?U2*EA$'5Z/>@<B1!'UDO 4'B5M4_( 6O+/B-M6L!RP1;%LW5"Z
MUE"*AJB?]Q$."\K\SU):A^T=1NT!?[L3L/7=/Q<6 X29\PGPZ["J46Z.>6FW
MKT))<B0 D:JED'9U:>  W#65UC,BK$3N_9#07G+I*A\;H;C'7)5WE[BI55Q-
MA1*\BEBL5C+QIP>V'%F92&XD=4 &=> S1$Z>2DL9VZ]2Z].[YT]M!0)RX&NJ
M5'#:EI6*$^VC6SZ(9>9'C: C5N4/_AH),@0SH[Y(GL7$NXWIT<YB>FLB>P#M
M[2EP:X1C54QE0L#E5N?^!(A;@)X$*:'9;VG&%;:5Y".II)N3$-C4+*TS#T*/
MK[!$UDQ7!*U/*;=5AXK2%,"W]<(ECK5)? !>VHY%#CVB '.4B(+6#YE M@<H
M8YW) JS^BL$<[PB8&UTO*RZF7)6>R&BR19I"6LHIILEND(AWJF,+8@Z/FU6C
MAR\J@E1MT*8C7;K'(]@F=? [:T'"._WZWHF-%I+>KT@11@+Q>/11 Z\3@<F.
M(-#3:9C9APBAW7RE]7S)1A@^@40I[>LX+@WA8"7';O"::>OPG@[3X<O&</1;
MB10-UP>/5$D!:-#;/>LJ<&RZA#^(H#.*O+R+ZVV(:L+MG2 A8O0+0"0^8_CQ
MJ-A\SI2\$:HZE;AG7WOV$#T;]#N]F^N]EMV</[A,%JNFMN0PHM15Y"[IC+#W
M!*'R0/[>1<<A@9TV]DX;^!=PF672.2&^D#!&&NJ#RA.)^+R3 ^ ;_&R)__$O
M"?'%HA2_E1+A^P58YK$_OWC[_TW;BS#RJ8*TPQ!) (_VS+3[CJ4 3*JD?K=Y
MF@E^0UDZ2#V?I[U(]2>LBW.G)X&OVN>$$XL-M,<35+3BCO4>!6HE;5$%:(,"
MK06I8*$3;)D!*Q@AWYDJVVP\H7OE,F"7=E6GR/:I 9W4  'A21 @\H?C%=IJ
M(5G*?*K55%#&S/FX.N,W%6^*K%!Z+E ZF^C E'P-R\#>'R(G&E]#A-/%</!M
MYO4< ^:IDETA_&PDS)O]Z%WK:% +-QFV";WG0W_92P3=PU:C736\^1;!VN?O
M]<+NX:+N8Q_U?V=A)QHT6MM6KC[Z+RP6TU)UZJF?[&EU?(LO]@]@Y;_8O]GO
M8HGX7_;I\NS#Z<5'_R7[]-<?/YU>7:U]Q'_"18;?,605$@FG<,3\21Q;]/Z)
MXPDGWV(P-UP%>,$!_&N,T=E$BI1=W(JXI., ]E-0PL\:I^TOEJSPXKUK6(4.
M]]"&X;QX*AZ]F%6Q7VM9A8^ UM(]K/*5"R[5;[A9YN^XG?P/4$L#!!0    (
M .9(:5-L)T_: P@  +4G   ?    83(R<3%?,3!Q># Y,S R,7AE>&AI8FET
M,S$R+FAT;>U::V\;-Q;]WE_!VFCJ 'J-'K8E.P9<VT5<I$DWZT6PGQ;4#$=B
MS1E.28YD]=?ON>1(EOR4UXE7-5J@BF=X>7E)'IY[R.'A]Z>?3B[^_=L9&[M,
ML=_^]=.'\Q.V56\VOW1.FLW3BU/V_N+7#ZS;:$7LPO#<2B=USE6S>?9QBVV-
MG2L&S>9T.FU,.PUM1LV+STURU6TJK:UH)"[9.CJD-_@5/#GZ[O#[>IV=ZKC,
M1.Y8; 1W(F&EE?F(?4F$O63U>F5UHHN9D:.Q8^U6.V)?M+F4$Q[*G71*',W]
M'#;#\V'3-W(XU,GLZ#"1$R:3=UMRM[O;[K7V^OLQ[W=[4;<OXCC=[?=;HI5$
M?+?UGPA!-F$>ZE@W4^+=5B;S^EA0^X-NN['7*]S!5"9N/(A:K1^V5DR=N')U
MKN0H'\0(1Q@4.SY48FXPU"81IAYKI7AAQ6#^QT$B;:'X;"!S)7-1]Y4.,FY&
M:'RHG=/9@!J>".-DS%75B&\O%%<Q]?N-;M2CL)S!_\F\X2KBAH^XZ9+;99VH
MT=_?O[>XU8CN+7O0;;O1WF]_"[?=SOW%RVZ;?B3":&"\;<'S=UN=K7F%@B<)
M0#=HL:AP2_Z^CFF[N"+C@R5D>"C?G,DPB?"9:BR'R@G\:C/8;OG_#JBDGO),
MJMG@QV,CN6(?N3%Z^F/-8D76K3 R#596_BD 3[3K'Z<!O7MPXM%5H3G@]^QJ
M+(?2,<Q_^[!)]LOCUO1(7%H5(4(L+2JLK/WKV^MF!;V[JX/P>VF=3&??ML/=
MFQUN4X?/:^P7;G7.?FVP][3^3(W%-!OIC+DQ=V^V>_L'JWU[L%?55->52-V@
M<W<_PRN9)V"%03W:]_!Y\9Y'C7FW7KCIU3&*HD:T2R-PSL9\(I@1$RFF8'\W
MEI;]K$W&HE;]'TRG[(0;U$,,[P57;EQCYWG<P 3U7^<$M3=L@G[B%M."I9+-
MV&6NITHD(U$+\V1$H8UCB1:6Y1HI'$UPF3.>SUB9.U-2TD-2]_D=4\E9AB<?
M;\ICO#),9^ =IX/=+8-<Q,):;F9DDO%+@7:7?%J\2Q ,FE1>'* -,HBE@1B
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M=:@H30%\6R]<XEB;Q ?@I>U(Y- C"C!'B2AH_9 )9'N ,M:9+,#JKQC,\8:
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MT1=L#[ M@-P C!-40X6W_RZ9<M@R'M'C#V;?9 T3AP8Z[DI4_AT 4C4 ($7
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M6<0HV)744L,MITD2QYPJL#=#:8!(([X6N&NZ741Y*TDLP\"/DL (#N)6@9U
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M9V&"'<_#GT&B$U NG$G"!1<J8(E6$=CGB0(G:X'K_BTH7F9580C<65\1*WE
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MP_L@_U'9GBNW7DZ#(U1)TVX5Y9]>UL\]556=<F^5U;[<Y\/*&'F5,(W0N\R
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M> JP#L#S)$:<BY[7+[!OCBM-6#6J!*:N+K[W%> _=6V>RKPNMZNRS.'8]7L
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M8%M7*ZXPL74/8CJ30@[ .E,#([@?&&GG7F"X9Q=(%DU9$7;G*>6L';7B!7.
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M=_ XPW9T6J5F7.(3G:SG*:NS=IT'A?E#_4X+Z10?ZL-;K;L ZE+ZVO([[@P
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M!@7&:13RPA7D:U=5.<M\ISS5PVU6:4S#^@O#]60CA1C:93BR+%A2+J$^R9X
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MW^SM9:T=_>%3D6J]1-HI\@"9)Q0N+[ZII#3/P)Z[YG(%6VS'$YP!YNAT)UN
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ML-1A##15F$;-!%N DV!%PZL%0EN)\!?%187%O"+9#6-&P2<Y'"H3RF>8<G;
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MMQ/,Z/C/A,R""*:Q>J2WPDO9>Q!^PV'?M?5M9)]C]PUM/=MA(ZP:K6\Z]H,
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MKUHA#55OH!/5#RT]L(=FJ(4:"!S[/FZN1RZ$6[7Y$9DP)C<X"7J[F'BL*^6
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M0#("H_F/'!(!4AK2V<:TV3_:Y*4\47@QR9L\42A&LEF+DW/FXYS]\,W+5W?
M\$O9[/@;X)/]ADMAS]ANYQ0BK[0"@00?F3>10 7+ (IZPU/FHEW/D]^0T>FS
MT7]E-W\93>=%)/99;.<LL8^7V,E&9,@Z%875:2( 1=9&54\XT-1YYD3@2)$D
ML4A.J_P7D=AU=_)/N(*&)0)MIW76]2>^W8N<H=;L]%Z3W_]Y"$,O/F/\[3;4
M3*Q%4<_KS>1*?"@*.OX5EZ/N^_OA0/_,.+00#MVH@4R8Q9BF[D!1?P J4]MW
MP2APS@89#1(N4Y<Q/MW+>7X0RA[WM:,-66Y?1FXGFE1@)B+AET H2@ EC@ =
M5PUP+Q313N @DK]@ND'%B\CMLC[V1?IBE(!9S%:E@Z9>;W0WCC;^\A^OF_V3
MS5J4AZV!TV98D>[_&]:B>TP]XFIVV:E&Z$%A^ S7ZFVQ4AG %@*P+S<K"FBE
MN"61;G )J,8$&"HP@!8:RYVCQNLBU$!5MOG"$B#V',Z4IVOU56D0JD8$0P:A
MQX/0F$4Y)RBSF@.($ /4$0<45!9PIQ@D&"G-2 (AH:8-H)*"P;K[:5)![_BA
M;J<9WSNN-:( =GVO_YI\,\]"C&["SEZCW>E&L/DPG.X,.@N!SN$-YL-,D 33
M2'HH3R7&%)"8&F ,=]X1%93 T72K*NO)[IYUHR<9"E8+!6/^0;RPGA(%##$L
M17U@(#V2("A$#:8B,.9F04'UHB6KVZG]/J=.[\Z& MF)4Q4GSH>V;9ZG*?U[
MT/)TI]_O-LQY7YNF/^C<I)L9\Y;"/#M)?ZBC$8Q\*G^>,(\P"(QS'+BX^AR2
MP!D2 \=/U?-AL^.G$L!55<=/!J[G *XQ63.1C"FD,."0AXA>S "E;0 0T:C[
M&)+<^(&SZ-%MX<ON+!H.;'"Q.(+;8UM/MC?1,[0(,)Z?_3W;?,X$UE)-Y7^]
MW-R40=E4@R5/-%#<:;M\YO!(-7(\R7]M4,Y8)X&+JP2H8@$HZ01(D5:22>1@
MZE1!\::J[LGG4ZF))W8@KF2\MPGTJ\3^V;OHE6-_-0R-C/VKQOZ)J'^'K1>8
M@:@$4M2>ED SP@#Q&**HV)WE+F(_W:1L54[?%\?@PL;XM;!*1PEW$_716[I[
MW&B/AD=N@I?UR6Q=J4PB^)!0XD$JHZ^U._U(]/N=)(/.MWL^*9-V,4%%ED!H
MM'7;ICOV^O&%5AQL;^MF9N%2#[K];]/]=?O."PW'*>)2_G[6Z372WOBMZYLZ
MI3;^?M%P_9,1LDQ\:WA?./Z*-O%1SOMW?V5E(Y[O0L4.&0^WV)5QK9OZK.=_
M&_WRNVOTSIKZ\K=&NUBTXDN_W[Q!,B1O[<CB?H.WQX^[!0>//+1_AW<>OKU5
MO'5+R ;O$;R%";GS;;B%[GSOI2Y+Y[KL[%[9[+Y6V3/!PWLL,%VHG<.+7><!
M#TA)BGP\C%HS6/H3WGZV%8OI WG5*YG7T25>6D\,ZJK<C.J^+_5^N N?:.[_
M]PFR_N><@X_WI?D_[5._W$._:R06G$H+X-J[2*YK"(*/"V__:2BZ290F?Z:M
M7_!MI(@DD!*.G8@_@]'!QV&@X+RAQ+-O/-53'WSII#N^Y;$'INOU=Z!#E);?
M=/-"7_8V?KVIJJ,:G208S\\-JL0$,-WB$J]<93.XI=#=7UWVLAAM(2@680+S
M.U \C58INV5L3*K@P?LK##(=FC=/!"SOKKG]YVMN/T][K#F??WXJL]BE[H20
M!R1N=<"-'YQ?/*A'-C*IWDR:5./)KG5"[?.-Y*BW-T]6;C_6Q%8Z/>_U&^'R
M:?G [.?ZY4M;G[M&?)9_S3/2%S)^E-IBC"QE^Y M1.Y^>UEHHEM2J*6N>O][
MC,Z'=^LZ5K9%!:_(6*LTKU4:J]K":#FWPO./56Y17I7]JK:@F \)9_M5$+['
ML?(@45#SF-(#]5*:DXYA$=)!J<$YV-0";&F5'ZWBU(Z*,ZUV<N.HIF+_[J*E
MLT\,2CQEDP5_BFH5A:%ZHV1%\<I?]Q7^R?-Y5V+>AP<3\U[EW-T37U;LML_3
M,67%ZV^GX\IFJQ6LYE KY0X4& S+>=OIZN*HZCP:B]WTJ6A@-=JCBJ>]J5(F
M<Y\(E'B#S!:N :P/FWX^QA'QF$B6I[I/^:=_I]4Y;_=7,.\KG-KJS-ZHZ\(
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M++/9_2+ L@)ZGX&E%, R81P(S0G7T22 '*7#_]0-W0D)A$$402V#T:P\P/(
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M+<JO9%1=$%7WQX20!T(=XQ)@@QV@AC.@?4C!C10A*AAA5B?/0+0",K!F8,W
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M8.TUCNH3K2I#KHR=7<MRC5>-*2N@V1E37A)3)BBYYH('Q"UPB$E !35 ,X>
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M*J.]?.;(Y!K$WYN^")ELNYV)I<A:? $M7F],&"K,.$0HEW$Q4ELZSQS05CC
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MTS\0E]YB I,$;B@-$_?OI0$4$=RCY1X.9'-\S\E74-4E9U' '>/=6=>?Z>X
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M.V'*CFH:WLK3OF73ODB&:/S#=W_X/RX/+L_B>RGHX!5GB>)O%#+O#(= 66@
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M$@@D 8U2"12T'#CO=) (62[<QG:6SM))YVR[8!'I7+EAD*5S-=(Y-@^,EL9
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MSYT740040T7="6F\X=(A[(70YIXZ7QG+GAS+)OH=:PZAXQ!0PCV@4$&@"!)
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M.O09H 8:>#U0JIVBX^/<51E_FVVM&'516-]'L/?L"/,\>Z<.?@Y!2 PA>M!
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M0EA?ZR4NU,Z$'@55)GJ<4Z@)OP.@G=)9DC'M<V&M<*Q0::8*Z13/L\3JC/Z
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M[TV/?MPY>$^>;=3/-^@WS43C$J^ER5)MUPA&[^\L_E>A:#K8>?+/H][XZL.
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M[7 R+?.EJZR,^2ZKOJ6SA)S4.&X.O)F+?F3W6&CF4E:I*%.).?T49IX^VIR
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MV=D?-6F%GS^1_?8.@$+]HGX, --^]V,_-6W=!J#:>\_V]][#\_9%_>/,:3
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MQ-#6=!3B#3OQV?<=H4/%.!FB7TK K6'7J<WSPGL&_GQ69TVU7QYCO]1_-/9
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M&=K+M6K^GT=I##4W@$_K'!9A %\!EG64H0JTN ]V4!F&3[<>,X0*N%1(RQ"
M^@[.+[U+\$.M8[XWRSK3?X")7ZW04ZU0]B#FOBO)#5NJC]K _ C]NVR3U?#G
MO0/["L98^KY'+MGD(NH/,@#T 9-]]H>/?GF23+/4H"0)99+&W/X$G35]2',!
M'R47^91W>VS!C6Z7?:,WG]S4WEU]BY%3OG4^<JGW2_=C]G4E_E1^-2_,Y0OW
MNL<A^?X'1R:1+]A(O?RJO>P6AXD<CS>YZH<.S5X[VS##R4D6S4E(_G]XB['+
M_\_@S&GRVY\DH8 OI0?#]?TP?FRS#QB:WBH#:O+U!W>:)VG2-W^6?,7Y?<O+
MQR[OP=@1/G]2AJ[EL;O\S/1K_[%R05G.'/W^3SDI?R6C?;<S'LSKCM]- O)Q
M.*:U/\-_0,W;"WCF5UIH&@L7D/28(ZXC1IHH@A1CPF 9J!%LXY6\<@8_JO>8
M]]R=9.!)8C4J&5A8!KY]Q2K%4ZL"$>\\@D5@2 F8?Q*Y#$Y&'K'8>'4U#N-2
M!H9@!/^GJJCM;JZ*&JY614UM"TB6F+2TF^FDZP16"""J=3[G!'U>6Z+;RGNW
MS0\T;$"S)23YUQ^I'<&PG'WYP=4"X!N+WOSFVN'BVMKA"]0"7P\5#D/KA'*+
M)V60%WWH=YCP"9G45*SO3OO]?&S<RQH9%,<M[&H9Q?GGLJL;*M?^IUF-%ZG!
MS@%T_#]- CJ18<X*ZB7\&:V) 5-*(IA'G 7Q5?.RV4"M^,_?S"/$O2XH#$,B
MX;J'';C*UTRJ*(Z G Y/^Q*GN8M:H H0/U4]D1QS+YCFQ OO"5?.1REO50OR
M3B%\_WTIK!_#8-#*U&BG)$*7VD#_?-H [VX[T 8DR$(;!/2,(!Z%1:"C38K4
MHRH5/_+&;;PB6YA>$YAGAUK!EX=<BRH&7#L[:KJC3"I+AIK$:HJ43JN(QVZ?
M '=TS58SB\ENW!VQ\C) ZK_!;$ZM%8:Q./V][E]@JZ28P61D_-R=% Z_8ALX
ME]@@[2/(D%46:<8U<@)VMJ!8:B%OZJ2P&@KOQKX)TP$VJ7U"+R23M6QR,/QE
MHCJ7\OO3]E,0>(L_0HL"2K>8*-:DGT)^V<6:/U3]%*I^"E4_A:J?0M5/8?Z
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M#TNJOHU5W\:J;V/5MW&! 7\ TQI(8K*ZL\+-+IJ1BJT2+U]JSM"#3TIU8,!
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M_5,@_=@.8([Z0CF#I+8D%:43R+ @TEDMCI@[PZ4%I%]60;IG1]P%6CVM279
MF00P,#\N$V,FL@.OS0TX,_T[99TN@;S=(?UT= C],?2^-UV8O^OWS(\_RQ&G
M!EDO$0\>D!0CZN^_BA "U]*@='B)N+$<:1L)\M8:^-O#$IJ-5U?)VR@*/&=<
M@<P?Y;2K00Z6;Y?!\F$Z6+X$@5$Z:<ZY2L .DM@_&65V;5V;=?+8>XDNE/(W
M$>";Y:WV"79#?^WR[>;&*?=KASW329_E>/^\GCFYKG8(.ZAG6JWS6LH=KC4[
MM? _IRE%N--)?S4[?4"75DY*JW4!46LWY<S=*]9U A9@S.YW?]H[ _3OA\Z5
M?+JY,#"1-_?G^=6LNI3PE/_XG'*C.X?_P&MW/?GI$.$]:9Q]!3:&#< "DH('
MQ!6ER.+"(F:5+U@AX3^W\:K<Z>?!]/JS2G&K=HU\&>=ZIZ'F3/\HY:$W?4AY
ME_]SVOP.")S;UAV902U]_\2<YQ2RTQ- F._EHJ34M"23.3VM?ULZ>OGI[(8<
M[@*9=OM)M]_,Z2U9%0+\C-/)_C7ME1ON7SR^Q%A@&Z>#ZR^YP\Y_]9^V]]NK
MAV+(VJ3<,;I%V?*SV![SMOPNR7$SHB:R_7R7-)]ATOJ#TX6>XCX/30A\>&K<
M?(IPF8GZE*JUK! -X-3LP,W^*Y@6L*(;G%SWK4XP^R+SG:[_NWSWVH)34'M/
MGFW4-\WWXX[Z33,9$HG2TMH;H"LU@M'[^><ECR[^V;9]7.F?/_U,SAGQ74LQ
MW4E33OYYU!M/YR%8M+U@OB$3 0E^-ZTS<][?^&WZT?#<24:PL#*_I^9^<C6M
M]9;$]#Y:FO(M29??(5?@+:WT\E/8X;9ZL9SZ.Y\,!TXB$S/.J$GU6/Y^B<%M
M0_?7(VW11G>0JT+4WH":ZKATVX\#,RAKBBR>XWSK1"S.-^YVJR= DXG[7:&[
M,V6N2@OQUF)'4_><V=TV562YLI>[)\,]S-46)7SL6W_\0C3S3>BQ3?<Q)7UD
MQT=I."??37-P_M.7F*EOU[]&C*GQFB!B. ?CF2EDI4_A=50X39S5FKV4$C/]
MTS:\+MP$+/M6JS;HP?U+[V!_TKW<F^\,F'$RW5IO9GXUL&MK-:Y-*WJR1>E]
MR\%<?UNBMB19S&Y=@5;T B!NJ15H5OOP>-$"*YNU\,,%4(LGL%/*O6/:P$T&
M+ZQ)_2U>]1?;J'[^;'S)_P@>O88W CLFTY2WR35?VP9,K;TQS5[^[+-IG88L
M&WG6?JI**XUN)[F%4]W3F3JE#\G/>%AXRIJ$8F0@Z<\<W2H;6"0D&A,H+[Q3
M)"KC='!,FN"QN+Y@\)*.7W;^YQ0XY+L.(,%I-D5V@1KT]HY,9S=G%_<O5QP(
ML V]M3^W'<9QB,;%(8'[BOWC0]8X?HT/WN[C_39\9Z\N]MN?1(/6X1EP[94X
MCF]L=_LSC*'5W-UVM+[]X1NPT2:P45*_:#4/]KZQ_8N='XFESC:0U[Y@E*I4
M #S5+C$%LM$SA LO5(#/#(\;KQY<"KPJ(;*JZ%F5$)D)9/DGE+56EX**]!E
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MU(%A4S%/4SWHEA7X]$AU>]:D&ME<0I:.1;0I& Z:<J>%B::PDF@FI968CD(
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M\SN9R@J0T:B&BN%%JI1X@$0'25S$TI[KCCNM7+WEO"V*R60U0E4<H:1D? B
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M^\1HH(VV6][ LD^#]"/P[<9FS.V,56T(_MMXVO4+!:PS2LD$M5X1J@PZ=&"
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M?AQGD%;KHE??N'3E6WR@.M1I+'7F\!*6_W^> 7_U";W_]!C>^1F\RAEB:3O
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M1^G;0MW K+-!21*$=T2R($AP6J*#CDQF&GD(;18+'IKO/&#IY,NQ@!F?"A=
M$IM+^YJ4++$E9BJ;^%4&3I-N4PV^GX<W-N+)-\YEO(\!*O:(/>LACA<:P=\G
ML#KYXL5IZ?#XWV6M168(( *0&%D)IW,D+F#B9X)V)F4*N=%12)N@VZ=L:D>D
MJ6ZTJ@>R+X]>+AY^.,I+KU^PE5]^/3WSX[Y,2QZ>^/X8U>"5L#'(2, ;#((#
M!!P#/ X$("F5FG+,U9I0Z[Y(GT(136V>-;5F5<Y]^Y!XF3T&KYX22U71@64$
M\RY!M 5ON75<)]Z,9-^$]A2*:EJPJIZ]ZG72*W6&/_M%:?>E.D.9I3,\.2($
M^E+)2M5^LI0D(XV)"5-UWR8(O!W//J4B.^)+!</4;-5[/A[P]J^[_F4W#[,\
MGZQ[=XR4Y\%1YPG- H5T&,#YB'Y0"^ "E%-<M5EQ^A:J30BC?U^$J6:DBMOK
MKF?<ES8+CU*@$2P(XA#:LJ3) <_%VD!#BESJ-C'0-V%M0ASS.QN:ZMFI(776
M>PB+L%G%S#@FB<Q94]HR8L#%:20*$0'+6E':9H;VF[ VH8[]W5/GH79J2)UK
M;:9&$*@2W' 2+5=$RECB=>8)A.3 A=+QO,V(=2>T32CD?E_#5EUS-6318M/Z
M9^E7#:?*AN:L9;2>EQ:/-J'TY:A4*26Q 32F?T%'UV:>:'.,&TTQTM^];ZIB
MPJ:;AA=K&/,XF_<(T$_3J].S27<!\![.$?4TPDHW%^]@T3IRUMWYB<-NF TO
M2^O:R4-V&K=&5&-[\DZU5FE/\Q4$ZYFD',O)I%Z2[$J=9':*6,. 0+3@@S39
M0YL>%+>AV7IJX8HNV4@G;;1#[RVI03_N.>8@0"V18'/2PEMOVT1MUX#LTWK+
MUBRX,6VPA=*KK&&_]K&T0KMX]6D\6Q_FML RDCRSX#(GC,?2+3>B+X_)$Q&9
M"]J@9(+>X8R^>8-]6A*I9M=Z*FTZ;BUFJZXT1SY<K*D/XRFBW;#7\<,'J:JW
MKS$BM=-'I>%GHY[3L12]!H-A$0MEOW!"PK*R84@[9D5T.:LVP]']>X/7U<#/
M98,+?*GDB,MVLE\4$UF,F+Z2I%4JYU"FTJTJD&2S"9++<O;TSA5S!^A]&O:J
ML^_6#F,[,&[%0S^NPGF-.MO 3:RZ+"TKG#Y+P$&G"(":LS02&3!K<L(:0G6F
M,E(F;6I3#5Y3BKW:R]F<L(]F_Z9AP?JD%,2W&!$OGYPZZPY7U_\5_&1V@@*A
M$KIIB746-^[6'0?*)X<R1X ?017,9V5=#/4T32_'$WR57KU]__#88?<8:P08
MCZS92E'(/Q</+Z07)6DYAK_/3P/TI7G)XN9+>$?SV5#V\Z&T(Y:#=_@D$9>9
MQN<*77-@.A'AI''9B<!UF[U8]P2Z[6CPE=O=N,_"6J/L=!2.>R*C9*5PP)8>
M4YI0FC.F=X+GW"9,NQ?,?8H_6O+NNF=O9\MJP<>M$+^FC!?IW_/E#N^1XTKQ
MX *1QDC\ 8+XI 3A912$#)K3'1+O;L#[-$/PZ!2L;-\-XXC5^^5'Z6[VTW?_
M#U!+ P04    " #F2&E3]0< ^B)C  !2?P0 %    &-A:"TR,#(Q,#DS,%]D
M968N>&UL[+UIDQM'DB;\?7Z%7NW7UUMQ'VVC6:,HJ4=KE$@C.3.[G\KB)#&-
M M@ BB+WUZ\'CCI0 "J!C$A4%7O&C,VCE/F$/YX>[AX>[O_Z/[]<CK_[G&;S
MT73RX_?T+^3[[](D3.-H\N''[__C_:]@OO^?__8O__*O_Q_ __[I[:OO?IZ&
MJ\LT67SW<I;<(L7O_APM/G[W7S'-__Y=GDTOO_NOZ>SOH\\.X-^6_]'+Z:>O
ML]&'CXOO&&%T^U]G?V6"R4BMA\23!>&L T]- )&CL2EDXH/^_S_\53&2E1 "
MK&49?XP1,,9RL$K'X%)40?/E0\>CR=__6G[Q;IZ^P\5-YLL__OC]Q\7BTU]_
M^.'//__\RQ<_&_]E.OOP R.$_[#YZ>_7/_[EWL__R9<_3:VU/RS_]?I'YZ-=
M/XB/I3_\[]]?O0L?TZ6#T62^<)-P\P)\?5Q<_X>WT<@?5O^(/SH?_76^_.]?
M38-;+.EY< G?[?V)\B?8_!B4OP+*@-._?)G'[__M7[[[;B4Y-PNSZ3B]3?F[
M]6__X^UO]Y&.)HL?XNCRA_7/_.#&8T2\?,+BZZ?TX_?ST>6G<=K\W<=9RGO1
M;Y9<0,D"YW^4I_W0&]-'!#(+5SX!_FV:% 6OB''7T_MCOGX6Q)3=U7A1$?']
M9U?%.[UTHYH"OO?H"FB7#X++=.G3K";4.\^]A7,#<AMA>61P,S2R;OR7,+W\
M80GOY702<<DIXF_FT_$H%OOZ;H&_%H,[S>\^NEGZ.!U'M-:__.-JM/CZ\!J"
M^PC%\!++R1+K"2^YM2#4G-%D5(S1*_SC^DT%?..EI2^+A$^(WW\WBC]^/\I<
M)VFRHH9[$9(W@0CF"<TV9L:SNSCA?661FV6.I^'.Z\?% D^O56;L?!HO__9B
M/EO<O.Q77/0DC-SX^DWSE^Y3D=8<Q95^P[^;7TBO?"3$@+(1MSF$"XY%"I)Y
M%E36Q!!]7P_G&[W.;NZ7FHAO_J$P^T,:+^;E3TN>@="U4?\?1T-;$7V\#*[F
M\,&Y3_BRR\OIY-UB&OZ^E._\M_G\*L4+H:6+@CN0FG(04@0P27B0+M$@)6[>
MPG59\?H]MU:]_IOME3\ Z.XZ;U3ZQ6RSXK7!.-&B%#=H".U83.O+?\4U+N_[
M[Z8S_#I^_)[T58LEH#O?VF^3,+XJ'N:;Z6PI^,5B-O)7"^?'Z?WTCRGZGY,%
MRA>?^.&WR2+A4A87UHBH)+60!=,@A-5@45I@''62&A.BV&&_*VA1'?S/5>G.
MP.Y]':5]=?0]!C/SJ]G76Q_/139.XH>C '=/A)2D!,/0WQ.*> 1I@@JTB<+M
M /-<M:>OW.^K JNJ"O_IQE?I(F6/:Q$8<D:.,2I7%KP6%HC(VJ$YE9*0]IJP
MQ/)-*,+Q4K^O![RO'OR1%FC)II?IU70^OX@J)I^\1X/D$ Q3:)]H1# TT"1#
M](;))BIP!\9S9?]T6=\G7O0E_LULFD>+)1)"N+?.X#:4/47/R4:PQ$M(.<28
M:6"V$>LW&)XKY2=*^3[?LB_?KQ<?TPQ]YT\8$9:,P^=THXNHF*_S>_=EIROS
M!K>KR>*"4Y:M2!&D9*BN)AFP3J'9<BQ%GC5WH5- =[22] 3^7#5K2#[OJZ.J
M$BZM(K>?KV;%C4ZST32NG*/EKS^Y96+C\A.N;ID8OE#"<B^S LLX T$%1;11
M@U-44\VHHS*VBXV. _M<U:XU;_=533=2M:7[M0=QL$PA8 :>X'<A>/#@G ]
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M&7\H9840/H",Y3:&P0_(,J/ 4FU%#,*:1@7#1P(]?^*FOLH<9_QZ4=<@P'\
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M:X+H"3,N)89.RW;WK%Q%#1E"U-(PECFW;?J.=,<X5#:XN38UHF67R3I'YO?
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M[$)UGF*$OHP=5( >XAY*%5+BSMFL@=O,0;ADP+"4@'%%LW:1!M^F1<)P*O!
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M+J ;K*1-BG#(*N$'*Y4 9"5"LH9IS9&T1OW@-PC.?ZF@-_M[;A(<)]S'<RV
M.JJMD 8T209$5&AO(V' %$\I62ZC98U4XBE="VB@-LWI.G?TN>_06HKB\A$"
M^+F4"7H8GUFB)"1J*!$Q6T7:J-S3+NLYBOH'RGJ.H6"0NHXN@+[%LIZCB'JP
MP.,4*0]"OV+2,V0&9+ $(XE2Q\(2 T\Y8<9);1AYRK0?6=93E_5CA%LY2/[C
M*HR3F[V9I3 JDOCWY,:+C^_2[/,H7(\@(30JD52$S#RNUAH"7M( A E"4I)$
MVR[1<I=WG6FF_>ET3!O*LJ(36O"]^>C00PKI:C$*;OSS:+[J2(%(W22^^X2H
M$>_7-4YM$@:))  MA<O"H.OD+25 "0T\.H_*'SMP?LP[GS+WS61;^7O_/<4"
M,-X%^&DVC5=A<3URR/N 9HQ"B+)4:.0$+C!21FDE5%UEF2(=N._RKJ?,>759
M5KRB4_"]7">35G;HQ>+?IY?IW72\!+J!EY*F&>T.^!0E" 2)6YJCD%C":!D]
MVB!T!ZH[O.HI,UU;DA4+\0]<5?1*DI2M!6LQYA4F:_ J<E"*\YB#-H9T.E7^
M=NYSGQ+!52*@XK=_\+II%TS?WGWNHYCJ<JOW%#$/=9^;NW+ )U#!N0@@$L'@
MQ=*(YLJ22+1*3G8J0'J$U!]_G[LZ\\=(M\6D(;22KB1$-W9NO3UAC"K1V[!
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ME=0-B*L*Y8>KXRS;J',V;,4B=!ND:O@K%2"K&IU+-?M.@\J7(/V*/' )+K!
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MT*S;'1734S8,YR/4\8_%EJZOHBNF'W>)R*:<C;Z_U3>S[?B)%T[PNE9^4:,
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MTLSJ\2=@H3Y6$O,-3;>3DEJDQC8)O++]VAT6_"SX6I!Z<Y [(2]X>V%FS/C
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M7&6<M*F3M I1BV?-UB%5.)6;5S'-GB>^[+(\IQ]1#FH>^GP:IQ:7K? G+TD
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MFVQOT>60+S=X$PY[83 A+3O9B]N++U:>GVO<D1]4H[O5-'_5\LQ:G90/+"&
MKU[>$LI_0654@6@%EZ]BN;=C4ZCU+=75'G3BB2&]I^S>B=1;^;2]'.?0U;E1
M!F^2)(8H&W0_[';MX-.6^UIQ["@\+&?:3:W_0YGMK2#NY9QT A\;%_E.\NAK
M#'TTGST+7!B45VU>O'(K03=&:<L:5NO? %A?WA+$?XG.*@!J<_].Z]+NDH*O
M/UBJX^W.:JDP+TS!/5GTC5(MV%E=1MB9G?7MRM*YR.2N^0--J*'^PD\%J8?.
M=L*D:6*A>[RCCBS% =BINO'&?0'09G57^JW-1ZW@G#_&)>XAFN=C[V J-E*D
M^ TH0ZM YXN&Y6>X44U\]-K@/JQCQ0^UC-1=<N]H'_O 1Y^=L#<+N.Q-/6^?
M*.E<31<R?+>3(HM.=PYL;:.S#Z&EMJ]3%:U5LAS]#.+.2;NF@GC3=AOK@0VU
MSX9.9S@=&*:L_FUKL"'I^RZ6\Z/W:Q_M=,4\^U&>"6S\+QXP6BJ2WU*_R5GB
M^04::,XZ_)&""_BH>1FW4(;FAAW#()+Q[';NCP$!$(%3C2$S_B[,R-\Y&:*I
M\A$.K-HC "0:4BO\A&GCO6$#-YUKEQ^&7[?:IS)R:O567C** <9(.[4!"RM(
M(Y)COFP#KBWDB_(40F89=.U^2.U/_+B;FWKXAL9F1YW?A#.IIJD%6YLN3KY,
M.'MNGERG/YL27@VV;K11)[7C&L"$BC>03!F$Z_ZB&??@_H)>KD/2\+1NL5),
M3_>&QC&_,T)YWBH,-0"ZADB\90]R=?AY5$8*71X,0XF/?89Y-:%#K;O]%<&+
MXYYN?>"I<=6:IOO!32::9,/#Q*NZS2G90=(1)^#>7SI'\3?I[/T8VF835(%:
M_0Z\S#2.O8>>3FU0A5)85E4NLO"^C\2MD0]V&R(] -(CKW<[\MN;G(5#G?[N
M$V>S=V].;>&COE^+HJ,1:LA[5+8SGA8Y:3*;S-L-2]MH\XMLM,>GE<Y"729*
MP<X*^?MK;0F7P@IF)SJ:+F9_?)>DT0IGPT\+*&K0<1X:1*W=5/9^_CX68?8V
MBIW?H7UWX,/0B<F)TW$4*:B6Q>J?&KA?H+7JR]WS/EXE3JU2NVMCWQJU0&MK
M&&MV6^ 8J3BVRSRM:1('R\YST=J=%$GZA*\C=V"$3D"9WZ(PJ<-D67A3[+V"
M3_<; E,=2",*I-.=T96C;W@[1.L6"GN)A7=1&5S_],HC,J1AW*FXDIF;<*1R
MUQZ&Q^(@REC+G+2&O=-QVZVA[W6;LE/.OMJ!?8F&SG[RF##W(Q\M]WY6H"2)
MCJU/2T>T8+OA!HM/)GXCQ*/GJKJ9,WYJ.I9A%O)UJMM% R\>K2.F'*LM?TD*
MBKF&R#3Q[S680#M.DCZZ427"^V;'HCF'<!H34 *4["(KN1^D;?,HP>#F=+U<
M)\*V*O4K)'PU/BO4"K:VT\6(+JBA(%15-=(;^A.EZYKO/H>8Q$W&5']0FO3(
M?/_YI('LTM6):65CH;[/^X9L8^FP0M?O2>Q<!4\=DN<&\DMQ#!H]ARSYAYKF
MS@UG4E5'X>V?[CWSVL&(N=]XM?W>_H7EQWXWBFY=T_']X*B#O$7M$X]CW+C4
M!"NF<=>#EZEK&K(TK+J_R ]/CL"RD0\=CGQA,3?D;PK[=E9R?_$F%;$NI?WI
MY.OFI.A6=@FR9HC?6 'Y\;#$$T_!1)(&6^Q>1-1\MHTZQ_JB6FK9NJTJ(B-'
M3X3(F?,DBC@R+^P5:K<$GTOX(80R[];WVWVLH-^,/DC?^#;GM]W0!8I\3%^;
M"?;*!;[;L%/HC!7O&;S#9$/Q3B#FOJ-_W@D5,3>1M1(U/ 0CQ[\J ,Z ">2G
M3:_[UA+70AK,7(G/02U;2]JY1V+B[%+[4TN',>L3:>9BMNZ)*@2=I)-3QAU\
M#)K20F"K"2X</ZX^63B;44-Z1Y>>)T;=)>H-_<J]$O7*I=,SJJ&W66_*WK_T
M:.PYZ<]O?@9;/<TXF5^Y7LGU$A6RM$<D)WDH"+3:@0$F:3@9M V]C&7?G+F$
MZ=#[]"?4!'(PX^/>-&RWD(TMF:_1LEN>L!O2??YAB^0=S#4TG7YH')HYQB]'
M7Y6N?*@\.^!R[J&3><>'\R=H\^VS[UV>ZXS$HS(^<U9#.JGBZXTMFCHEQ]RM
MKYK]3,0]@&<&< Q6+J23-G>.%XF\%P"K6G20-S0==P$@UR)IL%RJA@PT-95.
M&Z2'9>>*U#Y+N9\4JI*^][7ERSF=%#?H-R*%0T,+;5Z3"T$&!:6+\\F(-FD0
M!&#M@$<Q.$\ODS7P9O:'ZOL_ZWI7#R^HOSK/^=4@EN%/%WUL(%$8/7\W(%5W
M]<E5&&BG!>MB4Q78>A3TQR:WZ$#8:N)Q-B7-1CW(9WT6\TR60GX?*_A7@]/E
MY[4Y.R;S;E=F.3>EI]CIGM]ZLGLN8Q)'$P#<1WPJ&$B@S7!18R:)$\]!\C7$
M;9SC11P-?F&[AM.;H5E6<T.,TF&QDE4;.M4F[-Z/-]GNV)>RVV 1@TC_7?E*
MX%=10VZ;,M+F*GEB$S0:' VIBA;3@I4MV+MIV:Z.&N\WJ-ZWL;]-.)_3JA.0
ML[]TMU>*VV_\6#13&5Y7P@,1.AUC8T6:<%\BUS6UFZ3YN'.7TIK%6>Z##,Z1
MSHT%3H%UJ2O,&C7FL%G^B<R./+&%5$1%F'LI<^.=5?^EPR[ UG@6$-:Y-M!B
M#J$8+/H,Q=R=I/=T#6H860*2[MI&-$.M10\N1+0SAX==($?GNZ<=[P]>ZU,?
M[(GQ/GA_V_Z>CU\!3.T/B@H_@1I!3B:S#\^/9=GQ'Y.$@]7XN:E1XST]H58$
M^3%;0@PE_"QW0=DAX 9@HBZ;ME/E@Z5[W4<A6\7?([!"'2+EQ19&)$^P,2[\
M"C!81KK3,C7Y8<PC^NZFY#;+"\H6&Z9#XS+ZB_1+%65G&Z[*/[MU@_'UJM"B
MD6(?K M=NT,\ QUGDK,U%9*FC4PZ2=C:8;-12L6Q(J-?=QPGY3;7B9ZMV2:\
M=LU9%\\%'+1Q'E;P8[C <DO<&!>:'S>]W]KY00S)9:U7$ LCY;$G,HJ;,>"^
MKS:XS/MF1FUT8%[KK-#\=?=N?*,[K,3C[N6G"@!_:@JN,; +*Q6S,-]&5@D+
MJX&-0N\$#=?A]Q:Z2<>K/,]Q>C"P;<.I-=W$[;O??$?9$0$#&;K//D4#BLU)
M:S,1(4:R^ZX0"#9FG]^*7Z:W>SHW=)S=YABHRG,L^*ZMTCN+.XL3XHOMMJDI
M;_'D/T 3N89:AYG-Y9V#C=% !N%#;'IV#3&<$^:!LK*ML17!;@,_/_(?<9UV
M(/V&A9LVG':XV3A*ET[:%D-Y&/3_V@2PW(-("@#4V\80VK.*BGQ"-D)6K3ZR
M(T0C%C49L7S&IEZ!]5D!E[UI?>J61FW+VRSKMUF[2U1?=6PB)FQQ$.^O_R]H
MK?['(*)D0G2:7]F 'U-')'4Y5:R1U :EAN$(ZRUF&DHQY+"\D].1W:=TL[DQ
MP\QOXDTW2H=^Z\]N99I(DUKQ[)")I@X-/%,\C7BFCJCUR?I<30R^\^+><)R/
M9?(NEFT4EM,5_C7).MICN!%DS#O%'R% VA>?ZI6JOTMCK;F\-'XIUB<LTW3N
MNQF88W"'7WY_\!>.,;2]Y( !UXV?4W^4T'2_;];@).FZT'<4$T%&C3)=B,H8
M?_N7OOQ]PQ^;6BK]K#]JJND)%,R,4S6LWYC=HNULXZBX8?.[][K!AS#&L8R1
M%.)!%!DKJ(S[R'I^B1DX+LX-0#UZQL.;:-AO:.@+Y7+$.XI)9<:W:'7IP]/J
MVJLY-ZM9M^%$JZ)$8H24P]'O/E@!<&.]>1]/75X '(V[M$)GYB3>'05;;RM;
M1E5G!TN3/A2_ZK_B"IR)C0@,7"E2:8P_%"2\B)++Y[RS,3A$:B=/,4:9V\EV
M3SO3?X<3=?G^TOYGS^1:;L<1SNDVO%=_[3U=MT]OA';O8U6X]RB63&=?PL+E
MA6UXKK<9F6\>JOB3S XN0><6.<I6T:_,@/>*-\$'[U-,4;T^"H!O"BUR*"7\
MB3*BGU4>=S"W+F"A'0( D?+FF2,]6.D6"PB+2,;H\HN)NY@3ZNWADZ"\;9S&
M<(-N0[-;_DG;2/GE[7EO#0_EU;5N4VJ;/Z-K/PJR/7#09I-9 ? (;%4FRJ!!
M(L1.F^UEN&2WK.%T9UQ('6S6XARU]WII%:R;.>O@GRXG.M3\I$=R_545!R'M
M?/JX>!=5V!P#F4MY7^QQ'51O6\+6X=)F%\_6E'K2I4,WAC.%D4OW6.6*O)X-
M:V/%J*8V6SUB<KJ1U0.0V\KT@2<GB1=*O74<R1#7,K5F6TO7\>N(SD?Q1K0^
M]Y=:#")ZZ MEJA^8H>:2N$A>[1F3*J-]I('])5G\AM_=;ER:W/'Z)A=&ZGJ6
MF<^[!'>T'1!W%@!OV]&[<."L:;0 N$?2I*!%,SF;^DT(]R27GZ6)MAF?W-06
M,9 E 3F$VHN'=LHE5+X!^P\0;X'J;\MOLL'"J*&36$@/O<X^'7?:),5F^U!S
MF!D.M5-&Z>:/EU>64N&YD.^BO-40?Z3@38"+_47SCV!K,)710J/"\GV3F%3P
M=-^8/$,6>LKIZ[RZ[YQ8PI'8ZL71[Z<;.?5*U)87SVY6*2:J2AS<&;8M=3D.
MD<X2  96""KX+RA0 !QQ>M<-;8VZ [DC&#<H40!(M[%4_L@X[<^SQMB4[Y:Q
M+EU7R[/LZ.V:##+65OEZN^<3*V%7.R*)4E]Q55(_R9+?6(^R,A!6S.7N36:,
M=& 55,K9!64!?K%^A'-1&_6D8\,)_C>& M??/7JWIEIOE N/IZ+U(@Y9HP\]
MY*%]?>OAW-FMOCS#ULE>S<FV@A%+C<:$"*^30W]*>H)M.OWD:KY*ZX[DIUR.
M:%7-K'HB1;J(VKBF<L#:'K6@$3^+J,S.=/"'[KS@&&D4B<V=+G$?='?Z0+^)
MJ;>_=)1.LAJ:I[DX#OZA0+N.,C5**T.NV94JID;9GTS4\5GWZ=N5EK)^CTMK
M-PKW4T_W03N:N#]+$"D_)JH1RG$QW'7]B))/S$K,'?;CXI,6!4L7MYT4YZD?
M--8K,F85[-^RG!<;YZ^_?BY \R_F_=T8,(6,M8CRJ28HGA1AV0<(HX-.4#7'
MM-U2X1(Y:YYH;Y8Z\-%1Y.ARL$+D^)6'BIW/8TNCU+_+IGS>1D+97-)"ZVH\
M^SQEUB!NW2DGO7M,CXG77Q]P#C[#NA1135W^^SXJ?=B>=P1L/=R\CX>B4*LV
MCE'AL_HC->C!HL<OF,!N/P0E7>!']#YF-=7&I9^INQAWGL._H=/TS.-3OL=S
MN7  >PQLU< Q&JCU:6@CX 0M<3'\9JK_/G83BYYHZ#S7Q]VOK.UR6Z&SY<O^
MHKM;G&J#[E]I_BD75%3D(&4!V:=&+>-\<R$KW@GVFAN;ZMCTN9WL8:N>E^O/
M2;SRVJES@C-!FW%\#JQ\<; :QL"RH8A4*VJ;$Q"(GBVS$(DE]+=O_S4WCF;E
M/6^G>Z'*5\=N.[F4RNSZ(_&^<+M.:QS!J'Z;[X>?PM??W]KVB<IVNWF/BGJ<
M OI9[9+60W#BP>=/SO+H@=Y'O<[T-7:6L'L!$NT_Z5.^?_63OP4ZK%3'=?\D
M ,+F(5UR5VZ"S[I!S_D3K]A9TS[8ABNF.BNI9,-H+KN2=\0Q["EFY6=RJ_EO
M#"SGOG\0#8-'9':X6PIOBRU'D8@#'\1@#D/15:':+KS@ ?^&(D9*MF:8CR_/
M9.SNV*L=5\\;_)%J-N&B6)042^I#NTN7GR0M&O*!4',B&"L+A^(RHTS6X$,D
MC5)+P"T=Y>_,KQR4K4T?\0UL:U<1"?\J_&T.ATC(<S&0%G\)EJU$U-K!\2C?
M.#2KL<C:@V%=SS6KZGBXN<\"H&HADILX0MHQYM/)1-6B<U%?3;M .@( -C&Q
M> \%1C&QD N5J3J>N\/!9HB+K2\M$0!#R_#D_.J1X0NNXKUD-HJE^I6PY0QW
MTT?0CPYYT=FW!,#ID.*4*5@'/XH=*XVFU?C$DP-Y^WD7Y\?)6Z947_\\V0<K
M92&2> & N<2_7I\[EH4H-\$&]%F*AF=,+MJKR.;.$2S>U#<W+5B3&[SF)KBO
MQI=NQ<;0HOWC(VT!DC[Q&!H-NZ8XA$PS>NJ75:BE\F,&;2&5XNN7;B^U2]^V
MB7LP.[^5MU3K_I)G?6:O_YA.GE4'=G5@JQ&W"5;8ATA4LGNX:$.4% :Y()*5
M[%"6)W$SNRGISR[C>#D^T3+J_-43^\SVZJ5_'B^,7=U).ZKG%*$CUS$RCNH\
M18 5 A$)%-?1\L5;193@I^&850* B6)XBOZ]GXT@^SK8)LT5 '/DVF#'RE\\
MB_$RG@V_](SUV/:I")<OU0( VAP-RV(136\.ADOBS,-F=%@+SRZGZ))GR>P4
M 1 ,AL^7N%R+F&]LY8;%)ZMV4&<BX1V$YA]W4*2/,($VH![:CLHQSP#_HJB:
M$R)+A8YJHU"0:8&LG6\$P^)SCQ3S$!MD3'EL:;D%OU*T?6[BP\5L+&18":^5
M9LS#BH$=+\2[\5*P)Q7RYA#:N/WCP5_,!Q8%0'UW+&%=JL?I9QG^&4M=LUT[
M)_.\+:[N2T@$]VR\@^G!0[K=L+HS<WZ4SKV3Q67QG^)"PO&3A9TR%D;,GE=N
MP\<:!\\LP&51VI]=S$8B'X.&89U*AE^UMU54UL:@]$$"S61)- "H;7BV!P@%
MF]2BQ->H(CX941R!M<:1(;0[??D2M2V!=VI, &!]SMA\H$=&D,+;?X5L%&:2
MQP<1B5>H\='B(ZH+H>Q%5$H I*+-\F4_1.'>ET(<O '+3HMOX@7.7JK 3\[A
MP[)F>4NQL0MWQZ]\YM/0=A;:E NK/Z8W1,^=Q3'NX)_:SZ6QL EDY1JM_2/F
MWFN^G$D[G*>U5G)H;BHI](3G6NVK#R_<.!8@K'R&O[T\ ;<3S>?K5/9N*Y=1
M)V[>,#4"I.5R:SB8;I<KGKV7"\Y"53ZIQYPM=\KZY;6[6/\^>?#TGK4W)O9V
MG% $=E(D(5/F0QSJ0:LTEG+7A"6N ?+C^D'1:[*+$]3+U>X.AX=S(W^PO/BN
MV4OU?B.*/ T?Y7\LBUE3T3H]JHG#3L!J\9&N0X@^-#S5:6/.P6;\$7E!_43X
MKG-U0.=<HEJ=P[N2F."[.ZVN ''W% [O%OT_XS]G*"KR1T;#SKQ:6(K=4C?W
MP33AD"E>$?S[J?#T!&[A%TJE#@"\D$RH$,$J"P"WGP*@$"6$YP^C((>RK:H+
M J '#=GG&X7G'AFP\! 1S_>J1+SI_+?VL(T)4HV6">-YY.L=3.,#2@;(Y(!_
M(LC+T>"2+I8-45>:7."75%Y^@@VMO$57 *1UHC#\ OPV(0 ^7_^7,G!R1W]S
MF]&L>/)TA (R?03 *="W-Z($;&@9FHHMWW=K^?!<=^'\+6YGW*[_LA;PGX]C
M(P+@JRA:AGSRP1]Z5,4J;B5: *XJSO,O.0J .\6PV[]8V\ \!QFY^(55G'E^
M_$_ZBDQG/!FO K9J4K^*3M)7>(/41?5,GDV"U,;R?W58[V-5PKDKN?P++GRE
MAC[W?9RCB#W?'GFACV1Y3CWX)[OJ:RI03,SEDO]\P/.5AGI&#K.C$7N>R\J4
M"9(5 G S_XTI_E?&YE !L+ *A2R*(VY1'I\YQ#M*$0!OI):05VBE_>A,,G 5
MLE5D@FQ7 DV]FU[7U.IM>@3R7(FBIA./LF:P:X(OE=8\;QCT?RZW]?E53:E'
M'1/GA4XYG)*ZBKE0WO)W_UQ@3!/W[3"LO:MR3M;:1HO=P5TUT_;%+/0-;?J$
M]9)C]9F]7_Q.)1T?.[MJ,M)?M -E,02\*M2-2"4R"6.AS/M5:M#FW@9UC/Q!
MP\FK(9;7M\M_X-Q]?._J[AFIJY<UQI?\%>]@GCQXC,G$R<':[$CF=PK'OKMP
MP"MH1>/:!+Y7049[LTGY ]V,'4 <EU(",LCXQK1.%]K@)*4SJ-G[WN<@9%W_
MY,!W=F4:)4P[D_7A2]3-M+RDM(LWY'8Z&+ZS8![Z+"?TYPJ:9-CS*-3],_>V
M;$$UW 6^D>ZF_EFJ!']8*'+C_\T@BT'G7<;^P:[\(*\8A9;6I/V3"$#M[$>T
MY2REM"C -B.DC=#4$25/_=3%T&IWC^;-'GM""?+.AC?7W7Z0?7:7P>\F[M]&
M.#F ?Q<76H))HLN# =Y@JX\4!ZD(#V#7=5KL;JYU-GI:K$-5W4P-/FEM9ZRP
M+?F[<0" O7?!O0?\N\=ILTN[":1;V&IDP K,:EZ/;!JQMGTLC5D#':(?]]I)
M6"6S)%]T\'Q8CH[!M:>U"UW-$9]MRI/PE@HE$18/PB[YNPH_H/25D*$=1QG'
MF^;6H4CB,KL\>1%R5^[ 0GN^0S\V8$>K:BXLG&O2=.<0?ELL@\T+W)$?YH#B
M)Z*& ,A#!I'G/0*@G/;\TK3-&C3F4&8A $Y^$P#]X;LU^VT54(/\[PU19Q#9
M[4[]\U,?20KE>%)#H@3 LA *-"-WR2N2E,X0P*"=2I@XRCV#$YV%I7ENXW23
MU&9WEK3W9OKAVEQQE^;X7L76PKM:JZR4UU\I2W03>;BD]ATQA#= YSA]KPNI
M,C8&T!'ZB7Z3-O[]=XS:A<K-TS_V:0N_"5B?ZPG $_RKI,VD?@$@M$A0A+&0
M]J3S/I;HJ^XV]=RU4.">)+V7);L_X>I);]<Y5+V\_3APZP/7\8]SZZZ]@?6A
M%,Y1QLB</%O^0 EW*Z>47!T3HH'O>SJTNFVI4]G]B>4$76:X-2$W]OQ6/;DM
M]U(MW']4SD;SU(B&_%SB*J(5HU>NOZ'D2U3OI1WT7JK6YR[,S5_'CWL F7N_
M*G4YFM-B"AE@V[P*\2A[JHLB"_G-:>JQK[MOC0&/\L)^<FV?97=O61CJ.!_A
MICWEUG5^2]"J/X69B IL_V+86KDRYMJ>D<H!?0=SOI[TFXC2=T<<CSU+5]K:
MZ'IUG?#"K0N48M"/NNQ GS,7 -Z+&+Y>?DL:!+)-F/@VNDI,97>+"+MI-(J@
MAK>/9852FUQ,QO6=>?BPG!Y-ZV[FJIQ+9S>RHU_WI90"4"Z+D$628S>-6>^;
M5&HBR(5@(TI=&E44'N-?1F_2_.BPK!A)-Q,:1D-$:,D$EIU!=OOL0@'LE94
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MQ0N$#:D2,7'[4%88R,/V(!^0'I[[?,O@E,7M[_S*7['!=8%?PMA"**L7/24
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MHP@4QC.?@HRI^R!#]!3!]Q6',+=<.N17SGJK6LPX[3&Z8WU7M^:9'U5"RP(
M5M)!)%TG:*O!YEIY9 PK:Q(5E1_QKI,@56^\.OW%='BQV%A):6&NBW[.MF,)
MMF?HH<U9L=):<3G0(B*SAE\)!H$C-MPRJ)5!'*GDYD*4R>L&>.&1#SX%T&![
M^)58ER_JWZQ#;;^>46=U9>RXV$XZ4$S^Y-;#\A8 HN;\+#SC]OC:SREY&P=
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M+6OC*0G5]I<G/[PZK6&O,/Z]9=P&6+5CI$?:1(PPQCQY0DRC%=VGS0+@5K8
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M;<8BP>$3+#IKD;.[$V0?IRJ2/X"80(/=[,>,\!BZ"[0\P?M@&I!\ZU/)6;]
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M_3E]OKNV+F?;]X/9T^O;@NXJ)IP8$EI"@1ZAG ;K4$=;)VZSJ@6 E#J+RJZ
M-S)9LH@\=0[$\8QY.!:AD>=P;SP\ETNM^_;D S6RLFE5.*P<ASCZ\ X+@&&
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M2X@U\!] +_\E__<+*!C^?P!02P,$%     @ YDAI4ZZ@BDV)6@  IVD  !,
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MAH(NW6]L/\)VEEA5?(T(&J%Y\K,.C1=BC/"NC%\ZNUR]#)C6.OM[PPW6K.V
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M.EU5#KM#)!%+2LB-6S:?$+VDK/8NST1N_.78J2NO_LSOXV25#5FLELU)HR7
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MX:-',D?*@ID=8R[7BJ=Q[]X:%]#4_7H0QZ,D,PX++QEN?VE!1_X8,_B)&I>
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M23H>5<[=YBVW2[[D7P^C[D2/];EIXP66XD/8H,9XV@"J&0W")0TK"7!F7#9
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M'LLZCG=]88&9$3C&9=]&[!(!1,NGD19\Q=#$32\PXMT-GY,!+N6OO<3_H\/
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MLN4DPO-J@7S(O\#_;/Q_^]=MTI+^?P-02P,$%     @ YDAI4WIY:F1-2@
MU5D  !,   !C86@M,C R,3 Y,S!?9S4N:G!G[+P)/%3QWS]Z)#M-]A C1(64
M+"V82K8D:2-B*LD66LB4,4=DWT*HE%&22DQBR#K9DY!]BUDDV7(F&B>S_8_?
M_][_O<_SW.=_[_-_GO^]]_7Z/\?K.\;,]WS/9WU_WI^SX _S:<#&H]9VUH#
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M\<1U\O&2T*:>8(P,QS+@1KL94=9]?(;5J^6_Y4.27D],C<]SZ<ZZ*9$+OUL
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M]D1%BER5YA?;^D\*Z.TN6SI,3'?[K6;S))K8!IR;W#*0]@ KSP>ND$9("!F
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MM(VCY1I 93TPG L-M9TX0VY.;WKH9=/\ZEY@ Q IN!8FD -Q[!3+#U'Z!V&
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MS#$>)*C!18UG>\;G+-28NT>9(Y]JLFB[3Q\XJ%XQ=5[DU*>K0Q+0$D^\AF:
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M%!=A721P0\>/B+%"#BX\_;AS,NUI8H3HU@^H&"ITU'Y1&)YLJ@Y*P/BZ^WO
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M ><,TV#2.Y[,?GJ3IX1JNQ;^[,%?MX"<0+D-]3[=CD>[$2_4()Y3#D*,OSB
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MJP[5JN@TG_W*,_=#2P4G.UWZ:I3SPS9XW'74OLI2P_) 0)5S\LKMM#A6EA9
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MP&7'WOA[OZ0:BP0)M"^7YNFFPK;>O2+ L2(0$'13IW^SI&AHFDL3 0G9(B"
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M4X1ZM4.5^,2(F_#Y5M>&NV^WU;K3?]7EVT6$>'8K.RV;>7S1WLI5^@<M';R
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M:[AF9VPE317>VCJ2K1[^=E<Z9Y&6K,-PK\ZRD-3O[BK>L'G-YZ35[%K\6.#
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M!1J#TD17?Y,2A87B^U1A\TK/S>^],6/^5;7]26F#17\*J39EZJ( "Q(@)N.
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M"8PXC2$*B8",4@FQ%_IZ)Q@C$KGM]ZRZG1N-&JFA[N@>9#LAK\!2%@5H$EN
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MD0IB&"8FI4^L8DA0J/07&F 9)"P(N=,)TXE^YK:(;L0$+3E[%10]A:O=FC8
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MUFV0Y6M:W%47($**GY_^4AAZ>E^Y4J2KVVM31Z;RLMCN-1.A AK*$"HD?%,
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M%I@=5H5Y%9@=97B<"\R.(\4X=SJ[6!U"$TRQA#0TL3J)$- 4%($R] 16F(J
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MISB&X]W,;<)OI*QL=V#D=#4=CH)I:R]<"M'H1L(^.B,DQNQ&86!KX&A7$YL
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M"2/&$40Q\2&CVL+ B8<DQBR)$R<'WE,=S8T0FH+TYAO?2NKL1W8<4MO-S^5
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MFS:W_7G%#Q+86[S2,V"OL?M,)=;'5,B5*+2Q>)^MJB">1:R(C&/J09\ES/B
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M]&(I0[N2YQ9]S8TP*G&KS0NH!08[B4$MLKUOVCF<NWEC8/1&WV].")R]2]^
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MW=#OBXAA@0+#%,8C E'J0^)IBQ!+FG <,Z42[!CN[M+_W%BY)3[(JBTP;RL
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M)?(5J(4&C=1Z][6V#RQT@-YNCSLLH".3P\58NCOI6\,SK#O^^6ZG=;RWAN'
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MU<4M3PCB/@NAYV&F34&90.+%,10!\Z1/_8!@I[(*^QW,;2YOY*O/-_O<B!]
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M)!<UUH](S<6>V;57*6KJ>SQSRJR0KRBG"10Q]B"*/ XIXPPFDG(_(B$ER*D
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M)?$CB2%1IOY<Y F()2,P3@CS$\FBR"ZYGU.O<Z/!UQ>'S-N!+0,J9!QIB,.
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MOG'9]4:=IJ7@. ">\72DSX9'*@]YC:Z'89,(RS554A8I,)JZ:SQ$ 98C#I2
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M4Y5*:730LA F?FZ$?[S_/>C?T>-YVVQZ ]>!P $*#4'$AGW"B$,$Q&^(+80
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M&P;06<VQ@9\96G]LZ^(![NJU77NMV__+XWN^LTNRN_#2_NO'*BS.(18%SA&
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M2J,,90P#K8P"6%,#6*8@@ 7%EIP-YC*HA%J [+FYG&_Z>R.)QZ32/ZD,"*R
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MS0 C-'4W,NP>4-E_E!IADA:YX-RTON?G:?!]ZDA^_G\"9M_CU9M_E:.?H@Y
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M3UD_\M>'Y@3]L.O&>O/X7N\6:4K2@@H%E,J9I66F ,,%<[=G80$Q8P9G88E
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M'HUA15>'X1F_PFJ@'M.74QT&U,7:J0,_%:L%1'6O;J$-S)C=,P$JT]QNII0
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M<U'+,_(__.RV+Y?5[\<^W5P$/5/-?67[RZ.[9W)RAUH); IE-R\2I1I@G15
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MV5I3@!%E@#*3 B(R) 044/.@@FM!TN=&&T=!OR/U _V5,/S]J&0T5$=FF,N
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M35=+DK'/:H)0>XX.)<]]WA($T,!.)9'.3"XE#NVKU<$T*ZB"!<A45EBJ*PK
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MB=('5R]IO3HN:/AY_=[:Y?I,KI?V,U_>KNSTU=NVI3HSB-.,N')&*K,<PS+
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MLS]TQ3QJ#&H(:8$D<H=Q&F!H$&#:4HPJM;1+S!!%@EHO=EJ9VT)KF\[RVME
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M0["KQB:-N6X-^6F0=?/Z\'?+OVJ[AUSN'R 2=\O]2B^0I+RL* 6$(@:PC9V
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M:RP""QQ[S,UMB;I^DR<W@ZL8^X#U>PZ/!U?BI=PX"FI/SR [9O)8;T>M5/1
M9>P"Q3Z34]<E>@R_HQS1YU/#Q# 7A7;OYPH)2)DC@'/7')A6.1 %%!)+:2#"
MBT_U^T.[[=KN_5BCO7W(%_ZID73?_>_T^^5Z[?)(!+>_D(%$<<2.L@+FE.=
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MHS2@7<Z@@DZ 6B+0[UPTA@EKCP/%(R_>"1.^7TP,P<^N(+$-C;:+<"+ZF*T
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MMNXU4KQ>\01%LZP")F;E4]D71^#G2;K&:9+5%$K#R>%8C30(KC;IRQ2D7"Z
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M/Y%^L@?K.P#-B_1?YZOUMN!C\2Y3>!*GLWPK^^K#8F]6<@PE9P:Q* .*/ 7
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M"\@*(!,*O;%U\FT_2K A8 [WWAYZRN"0:>%+'8H9PSW+1B80TF+-#-,$E\C
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MQ<,.=,VO.)VO7B]6J[QZ,__YZYH<O?/IZE/ET9M2>38Q+#H7;08*=RG>]:%
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MUX49"&'_?WMOMMS6L:0+W__ODO^I>;@Y$9*'W8YP6P[)NSOZBI$U23A- 6H
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M2<?NH8;@*!P]M++.Q[P.C/VG"W>8-=P8Q<$[ HPB"P)0!PNV[M](3C N&Q6
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M8U%#QD"29D2&X% !4YK;++62O.7\Q$X[7 9Q]I .ER%D[B!IMK?5(@B=N<^
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MB<7@C-..I,8]M4-NE>/__W[QY__:?>(6(+O?;/"Q=;COOF]"&(S#M,5)%.S
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MG4QIF:IAY63EIIO)[XI>CK>%7D"G 4V.U%[@LA>DR++%O"[*^7(R(&-\(\A
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M\T4N/>N.P4KX.H]5NJ.&$NM0]R/Z7P)$LX$54=?>+. ^]6<M5E_;\^^-II,
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M=AOX(AZC+X)8>[(;AVH(Z;89.UXLB+:=P1KM6#P8:9 VZ30L[.9R'JJPX.F
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MR364=7CX=F+8D-JTSS1QBCVGS+7TM]+ZSZY@WYM%?:SNU%@ZZ7_>M,/ZM<W
M,R>E6T]>G^5GLZ?N Q";BS!]LAGB;V4 XERA<8/=JN J  GC55BGV M4,O3]
M]:EEB=#HF.%Y.Y?XD'L;FPW3%;6/"_<L)>+PFMV%ZZAPU*6LW0G#,"L[A;:3
MQ@=/"Y.OP3/B?5]8NVL0G33F!*B4!\)2IC8D$S9#?$5I4"CFG87=$EU;S1^^
MO;1J\&D3.2>#GP]G1^W+_=A7W& )@OX0?F),G5=#VMQMPLNP'6M'?%BE#L/K
M3ARV4] >$RHK)$N/<5M"S01THRD%0?R@.(B-YU/I06=.WQ/171(1>> ,Q]!B
MYL*G0N\N90+PB($#L1^Z<\B:VZ3V%';98K'Y=$O$Y@=\D%7&:N_=>+Q.D?GK
M(BC_NX2DO+^#DJORRI0!3A$.X[QDL8F85WO%&%@@=BS2%9<H8"$($O>Z50*!
M$N4->JH"_E)QC7%?87S/9A6G)GY"_09\\,2Z/9GO#7HOL9$"S&-Y*X6V9S+(
MVXI)&R",ONL9$0\N"U9PC:T+XZ"UK&.LKMKX&+WSOISW;@LE82;9?D?/Q(,N
MS#9%,BS[>E][\=N'.S>'+S[;$KZ()2V0XTR+#$F8V.1&V!-83B '&X(F9%(R
M@XFV$3-+V:C/ [4C4CF2HN(&Q+?NWQ;#A:]4%NB:G+E*%H1G2-^5H#\\V R*
M/MD_/EY.TIB9BU2"YWTI/M_G8OZ N9C98A-X&/6Z8F.-FHF8IE 9FYYH#U;B
MLS1*1D\MIV7F1IC<[@?I8XMD3SH]:"!7Z0F8JZ6<P+P)SFV,:6%LW\".K0C6
MW8?6QRH U\'="ZNJ&XT3G:&W6Z=)*[%O3PO)?B9$EYO^T89KF]ABR<H83).!
MHQ-2VEC/QAF2NAO64 H^&/>N8V#"5-0F=A!5:A?@^J8NA83R>X," QKL0[)-
M6)0HK6MVP0?>\^58^:%M2K"3/?>R4=JHJ2 #_=$0<*HJP9ZHRY5]'!B'SXUO
M%'=1[L3?<?>0Z*G^R7T-TXUBCN\]@;:$I%RKSO?>%2?#@ V!=6[+#>7^9+_O
M,NY&G?8EOED#A;5,I3ER&^/-F>$8241%EDJ8:-YA"-8V'$G\BY2^)MH&$\,D
M&9N,>!!9; OQ@&U:D:.IC+(BP;\]'Z?5!^7LX+7!10W3\.#$&B?XSOW,IN,U
ML!*N/ AN<5D2K,+6+&8,O6'TAG-A)&Y6SZP3O3"8W^&WTN[!;L*!V69?MFY+
ML"U>,CIN87Z+Q]GMP!7BW=H/JIRY%L$\,06NKJ9%J?YR3*TALPIW?N@';H]E
MTGN;N4E-K!/V#FMSYYX224K;8DAZB.2XM5O0]@<9,)T!D]#P)OLB]5A,RHEH
M0XRT0)EQ%AMK!*'XH+FY7&(;OK4%9WAI<>#Y\./A':'(SN=$RC3\20;"%2LM
M.O(BO&YX42A#+*2H\-M&,-?E>KGZURXR&_ACVYDLS: Q5: S=" 91=F2BU-S
M+LX&9%<:GS).H*DKT=7N3SI[$FZ$5QRDS<UK1*2:-]"18F_6AWWY5Q6=&V16
M'FZ&[%QM5KX"6BX)K_E&7!/PY%\RKYF1GBL]QYI.'R1YW8@/PP_."BQSA_3[
M!J]*]%*N5\Y>=OI236A1WN&1B6L'7/U8F8C(NZDJ8M>\BU5J!G2 [%+SC+&N
MV(XV4PD[:V"<N+\ KJZQ2Z],^]_9;$",",(9K#81WZ:9:W\W:V0@KM,8;AX+
MG+YV8X/;!YP-F_1%C;1D:;#54S5WU1[L>_*4**AH>Y5-Y-B\;T@=PA^Y?I5D
MJ/0U"@]2=D;2_<R>,]DX1!X#XGD5R;"\PDO&Z1;(7TED&+-2FU:'*%;@6IGP
M&-EJ1?M=,RS2#),<45\($D99K=65Y-IM3J>RY0Z3HBYAZ:ABF:6_A.5]@L,%
MK@PL&U0T.A8;A[?[;IJ,DKW8F "BWV'!)A#CCHL:3L/[_EV#;9LJIT41*^=)
MK*\/\4#S04<]MF]LJS=>NRV>BS^3[0X:+5B*,7TS!O8H<'M$YO1).-!*-K1)
MEU=FU"V@ :"(&9Z8:YA-54?+ CB*Q!ZNOM,91[=,)UK32Q6[9(S'*#0[ZJ2I
M;0W' _<-==*,VBRV^_LPD@LI"JMB@JDLL2XHOM@N(U =E=5"#?6&)-L7^&FI
MWM[IT])*K0\H<5(BV&E^U1CS"(#)<NWM%J1_P$0*IH<*=[X(U+[N)69M1;7+
M PLFWONTO*\7IUJ'MF53X$@2-W@6FR4J-Z!(]*(%?2Y7,+#Q^*NA,];&.MDA
MD2IMLUG)WB#CCB\]7L%3#Y<%I1",&!*HC=;=:.B;V'5H)%LL*>\W7OY&6U$K
MY)D])1F6)'%2QW'-@I!*<.&T;\?M*H":.^\5-W.XPGI(2GR 4M4:9VU@4MC)
MB-P;W1[A7QCBWE1+Y&A;+!%,>0 "N<3BY(B]*+%V_"F(P[?49'J=%L8?KE8T
M59\>G"F0TM'!X6,O*@GQ:311<CLD)7F8J9-#&24@QO$_33C%WT"K\!6E40*I
M9#L61H)WH6[J)#I"U>$>H9N;HLF-'^)EHP(*$>;'FX:]U)V,I>P8P5P)=R@>
M<N49;=EX6-&]@[^1BAR!*5C_2<6+P8(X_!=E^3+04(!D!$ML$?M^8]@=-O,J
MB2E-A+,OY;PH[3V&>XTNRPE?;+0QM.E1=J6*S*5<96BU4M'PD5]A3R-Z.Q%<
MN351>-VHZ=>*2EC -Z#T*?[28(Y\%VGZWLYP]81L,Q/M2M )1O_#L)4'[J1%
M4C/D5V66F]HIN1]Y[2=VM0JPKC[&<<SX3#Q:BJPOK7J;.=CQMG"P4U8Z^E(_
MUNL?:5OZSE8B@V2.5%_U*]+<ESFT2[DT.9"QI"8:0>)OJ^US;^I,_W1(2QMA
MF1Z[>;#!H7AN^T2-C]&Z;&ZT%.O&#9XC3S-Z/8!+@^4& X35;#J>!;:WQG4&
M5X_O7A680FBCX9KZC:?N&CA* UM(C2(L&\">226BKXWY[Y*" GL^QNICV-:=
MW"W(D0(@(%J@1#VBKWP9,#(L+S]GJQ1AN\OHHS0)$-ZS3'(,=\]P^/D</4!!
M)Y56]Q6K\7&X( GLM?9/A]TD83#)1J!HODF="6[&@=[N,*ZRJF9:C.L:$^J1
MG$I<S,WL1?>84HF&*V9-P4Z/Z]PX>OI.VL@]DI2#X-!4:C"V1 #):O4X;3H7
MVX!\\I%E(O^^%-63;6'S[TN@)] +&D$^1P#KYO1#SE/N5B2O6.4SA-=TF@!7
MBVV3HQ5\/$9.8"I/2M.^H>V%9T!+SGW+V 5IHFDP<$W^^:;O*&8,!BA599%C
M0D7X7(!+'BU(V4R87]PJ^-I3.X0B7OZ9()_3BX(F6LBC0K!VZA[RHH7MI@3J
M'7J'@ZURO[Z6HTC#=L56:#X[P+(2CKO[1*KOZV(_VI:+?>%(#TR\#&O/LGIP
MYMWCP4_>DPA2\[7W> ]#P2"MJ$ ,%1IMZF,Q">#4E*6@Y1ELB-$\3"*/NY4#
MU268D5A;-36BV.R##<&C>*+(14T(K*4]STP6MHW4-&4<7G;/$JBXC#;*!T:?
MI>ZZRX-HAI^;;,RL9] 0I-V(BN@PZ9.SH-R.-<=)0Z)9\G;;!QRW*-_#,VTR
MOD@O-&A^C7QR'!*=5R:@T>T$9ONO<3UGYDE=/<-QVF83H2;/#.M6:I,Q:@]>
MN^"2"2JQ@!AX1%C&J]VBPV72Y( ^OB]^MR%=?5;S.W:LK3<O@OUC.(W87FCX
M+W?UD-B8KA'S6>?=WE <;>4FI4,*^4C:N]E4)%JA*UM" >XJVF"V;Z#]&&TG
M N XD),:-\>=PL]CAXXC#%%23'+"[3#. LTHC$%1P2?T &+J*"6DD0DT :6!
M!H.KGL5&3W*YN69_L ;8O-#4XA@,7H3SQ(V)2@HC(KMBT]*RI=9RC:8'-%.B
MV[U5QK6_\.JR>_EWO[L/OOW-X%NXCJ!.TS>]P\ZR_4V*#.O#O\Z389#7)LSX
M"8SM#?+WV#)[H^=[CFU;<X/L.#D^.'RRT=,]1=\58\4P\!"=394<&Z08*].N
M ,X[=I+<=CFWU K6L@EK$6LMA(>5<D:_;OQ4[J&$X3C+WQ1V/$1LA-Y8)%K!
M-LK-EG^#.8S?)PQU0\K_W,#T]@D"@=\7& 00_AN)GGDDD'=T94X9Z[]V9UO#
M1RN<VS[(=1!^*04M)7-+X=LO_%*B'9,%$6Z%_]IF0+#)?"V,$__*W_S?:C"_
M"*M;EPF#+=GS;8H;X!_D1I8V5^O7@CSYX^B< K=%:;*XVB\(6 25/NAXMPW/
M"3'EUF7N<AA\\]A;3-2P0$W!UPF5="@]!#3@<6W0N4N9"9O,PM!+>VLS4(V
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M(IS9E4&6\L"0%, 81C'\7(J5D;!Z=-I[G)155N<G[C@*S1,J;M<%B['JV4W
MU'*5YNVX0I''NE,M&FO](R6!*--9:70\]H(2CYDU3)R3W%Y7DY_;\:9$S/6$
MG$2W?MPV*.=NX%31 W&I-M5DO&*&NI0ZGS"Q&,V,F6P^<V[.)'+3/94.=!Y<
MI-!]J="JE8(Z<]9+QNSM@PY.:G&(&,O0X<A:;BJUXE>F1L_G9.NFL*2RR'MZ
M&?<N0_8/[-1:#;=>+E!T&W#[=Z=)-='TV5JZKG\0<9ZF!#V)4<\W*JAA#5E<
M(1#_9L8QUG22Z;D)B*UR]L+'?O*G94IPHS@ES&JPD#IC"PT<AD"Q3V! 6">]
MZ28,0)Z=C>_J!N]97\A(1WP(!BM#$QQK_LH=Y$@R&YN0(@S5&>/"NE^HKP _
M.\WX?6'U;ZVP9V (C-40@N:@@;]2853R; WT_:(IDFPYQ,L"OO,,,S_D$=(G
MSZ(=N[<G-NY28-2F]C>*Z:;C9Y)#%A@VRBJ[R-M!N-K1WB-VSK--KLPH%NT;
MSE^E:B\B=?*/73!PQ[5U;H!?:\KC8(]U""&2IBZ*UBKM&8"<TVW^"2*HH-LD
M7.1?Z )_&[P&!<3M$VR9Z1?W]_YP*<)GCS-%N.9LIO@L2)/Y%XI8 6.1GFA#
M<S"$,?0 NR&_4:6\"GH'^7FI8<HJR_8U^J_7^U"NY$P28QX$HCE^)+W!<'^W
ML;G!-1UR]@9%=K%B-VI#^0!._!/%&K\4LWYF&;T!(=)*K:X.#-TJ1@(-"8.9
MO)8=<=IWEW4#Z\^B=[00;4;,$AXNFG])<XX^1A>@@61JAH;/Z:YK9\[1X3Y6
M(Z76= OS@DY#M60S#*17B;V6WM",@-B524W&<KG=?@^%>@,S(:49,)G5?=7I
MWA)L[RO56["'15T5;>=\$^TT\#,*A6?U=;7+UDYDMB.FG9Q;LTL'>\^=!%0,
MDO4I@B3_MYD>Y6YED%:,3\.CGU2\;TG*N7TCL>P&7GHVYE2!, $3UJM.HYP3
M72L>U+>4*'2[5T4'C)\NP8VKF\-$!9S__]CQZC*BVX>AT?Z&[ _)0]3^!%[D
M6)?Z.4Z!\\>(Z/G@,M>35C0[F R]:%G.L>^QW!NA>E6^*J0?$ZUQ*Q/R45WE
MNJIYL4"QT*?,-JH)PGE!L6?*DRMFNZ.=MH0TD:JKOL)A\9CZWW$3FKNZ3LMF
M.00,&>U2XYBY6V6EFLR=<GQ*YWI%R!<@FN:#U( ]FOTN+7(.<&8X=I6D8->Q
M&X:/39,Y<J0T+TT;$2!J-^+(6XD^/R3)@''N[38=))GB5//FMVMA#7%1]77?
MTD0L&_A"P6D-R)?#2/!HS&EWQ#()/Y3B>CP;B<(;9APU=M77,E=:/_PJ29.*
MNJSJ-.UEEA&G!Q-J[M8%_3:B94#M(3M8)3"!0= CC$B84E>YI(*0N;C2&#AP
MT?LO5E!I4J9HHZ-7GR"%2YO/K;J^58O(-M6\(_NNELC)C8@"L;9"[FBL*BP&
M;)L(XPY;;!R<Y6=;?8H0YP^?6+3>7:T(J/3^NI)6?Q!V[WF.QB# %CL2SQ-D
M!LID!$QW*'K<R+Q@"N-CDPPW2#+1:4I6LQ)O+.IA\S&D"=J<_V[G90'J!>Q4
M_*:E7NBTGDTD98>-T30,PS1"\X0YUA_%OS26%Z]"8IVZ_;'U7]3S1.J^TUKL
ME@$;@]&F8AR$\:&6W4K']?J@*K[I.E4:MKOQ.'P"@@@*D'2?$"O%TY"^<8>\
MK<'3Q"+0@.9[2&!H1(^L0Y.95_8@=$P@C[KU>YE:",Z*85I,=Q>U0VO%'VKI
M-ZWQQ&9@Y9XFR[#@^;I"1KGUR<4%5IVB5"G\\,%@\.=PG5F=MW;4 MQOLHA+
M+]9(:<\)G+J$&5ELA</%MQ:#/2.)H3(NF888&,Z1"O0#[DA48!"VD8W 7KH]
MK Y2IZ<VJNO (.A%_,[8+L3*[FHDZAT8@QY<CXM&+STN!OF) T.6=2/PI" N
M83'++&1'G#!).V/[#*'3@)J9Y>JLQ?;9U05&@6V';3DUO@V);PY&T2* ;TLI
M=2XJL'\9!V;:4_><$O,[_UL\<'X,%L[#LK;9*267GF]4=FHUHW>JY,+46EBD
M*+VML8GR.43H_1 )%X.=30$O7Y0WDK"%5P;VRF?SLKYACM9!)5U3#=X7.>QX
M&VSV55*XQ=&)O]$;XT>_$6N$[$GE]744_R7_&KG[-E'B(X]1D%=#NU'ANA%R
M2XC9O>6*]9_%5@&.V%I:?BEG"^[C?Z6+\W563^;2H183[XO#/3.K[/'VBO"1
M$DGELN,ZU5J\PU +PG6TCG!SR A-UX)[B%B\[9CR_POXZE\FMO6WO8][%$X"
M2Q@L<_V96-)XF/2";4XA P3CHR //DT,7<;7S:SG^N=L+<Z0/+:2<_7_QE;Q
M+MU.\FS3@7]/EX%!,&7,0OU@5VKVK$ITQJA[YE:GC:O5.64DUC*&UN (X SP
M&& G+PVZWK0':2838#R1+$74<(,N*2H!F;$L9PK:']KWT?-C;%A\%\T[PBAP
MT_45ED!-N<Y^6C!O-$7[&5^GK DJ9]=ZV#!?-'#"K2A<H+]-@T8<[*J%&_M8
ME?%)H2"Y]&_EQ5J4 A*Q5D!K')A%O,=6T,>&>&,@P<EE1HNPY%:\G;?JIGHH
MD7MC%2\P+$/L W*R'5P[%BSGR":(+.IE@T?J%S$EF63+SCG(<$WA[8YBO-<8
M^21-#*\5TYRD6/_-GAC.OK-&+^E@? %&;]-+P%RO97&XW'DA#'>,S:)9\N:%
M:LE0>\]0<7KN$Q-"TEYZ8=I:"C DUTF!ZK(G_^QV?E,[@&VML7+3EESPI:DC
MLYM74.6J'&S^!;S= E?+,*_\'6T;$PF!\NFQ5#LW<MH45Y9$.8-75 1K(J<O
MHXG8425BQHR"Z,5IW_6->HJ+KTUL3H)!QX)TBHFN5\.DIK:D0$+\ERSL,L\N
M.,<\G>(YR>BII,2,$LL8RGKDN&WTSXND(*>(Q (.HL++=-[$%3PF(."NP",U
M+\7"XZML(&3@>JPU!&E8EPP#7J$$(H/E25E0H ]LFJY #0,*I\$=;C[G';7Y
M?R'3@R;YD!P.4XZ.U/E9'?BHN6$6\5<6$7O0P@\&M074QM(0,<.Y:!JF>]"R
M).GH&(,4O]!A=_,A@4U)+%ZWJ5PE..K-JMX&J@2187ZE;P3L6T5]JYC0]N5O
M'RQ'-B?(;^5)6K9GP$XT)(H/%EG>>I[Z_<VL]38P?EW*P# '9#?=(DW2[&3A
M>YH>;T#G<D>\XX[G&<&TMC7P(B=V+874Y&@F\$=:0K @3#L-HZMLAX9$18 \
M%L2553.CNKDE=K*B5<$$#J=2#"2SS)ZAK+"-%+,TX1%/[KVWY8J\@V.UZ<"M
MX*4+:FI16V+ VJQ+<BQ+">Y9DP$9, #$%;LY/*D#<^ZQ?(6? *4V57X3TKX\
M_=K("S--XJKF5D=;X \G/3XDA+S>G'*V#*<L/'!UQNT=#KFLDTH*QA393/UK
MZ$\Z7++=:-@EA0?XMTI[A!!]9+U2%']+OG$Z_>;5B=_]6+]^QF,]J)4*A.\0
MX%$5C,%N(R7SJ0M;H$N!8 ?ID60W&@ \4;CKEKZIHMWX9#-;]2-C%"F+HR=C
M'K\S\#8&K&&0Y-D6*L"3>8@#!1<H2Q0LW1.]'\R?#*8E;=,5:F]?/,YTQ9@L
M6 7K!T9OC1=%&GDH9M6W0.KX(0HBQ$0*)Z!K:52*+5A[:P[:@I_NT+QY/D(J
M>C6IU84WX^1KS.!!M<JFG^SOD_?;RM1.BFNJ%'% CNVTF#SBB=J(W^B@TW8F
M!\5P1^U8:< =BMF'&-,;62[B@^_ 1C!XB'B3',!L;N@?">7RQI)J0\#7&I%C
M*-AD#!]3_<SSFHU5@'D=J_L;55-'Y'%1@X\P36@\S20OB_R*'<@>EM;G)DBG
M!VBQ/XQ@=K@"*@=07TXQ&%OE"/>04)P('INQ\S!+/DM!JUJ%GKB$*"+H-PM-
MIT63]C/<LU1/7-$.S UWFM$/D>AG15OF-%:!8&HX$GE5U"6U-&#2P9G5$I,4
MBRT)1N&[HN4!NWA.29/MW8KR\HP3I&V0Q"U<9)EA&"48*6Q5GBU@L9J#4[46
MUC[9\QCQG8(B!$%ZAJR]L0UYZ7HVY 7$(I[Y>XJ%V"@+'RRUNVW=^S:M>Z'R
M-=1OUDP.=VI=[(WHD/EY>B:AL>59+ 7@Y7WH]ZLP0E:T0\4B&DY4^=*QAT<6
M>()2'N)7A^)$G)I=9N =/Z[U[AD2,%;(?=Q4\7S16_=S8&Y0+U.R1#T>OYL5
ML[4J$OU"!UWW)NF2T.OM<J^(:GJ.1^L?^U9G93>]/ !GZ<Y-:[T=1M!9Y8F,
MST1WN6^ <!'WNV@%(-($&<[/1@ILV&W89)\A6=8)8.M@G+.4&V#E;:<KXA;E
M+^@WVVF]^19^NYY#/D/JX# =UD"HU*M(:$1FPKE14F5=ATLL!OT!(WN,>28]
MA7'8F1$*/5)E-LIS')ZR^]6;-K#<@PY47B]49Z\+PL?*ZUG9'/F;Y\'+%@J)
MLF6+O""GPTTHA,KZG;?$BD)\1YF#HXIG0L. -I6ISR3J&N3'C6!OU(.(O3*8
M)19[%$:Y2TT(%F2(/<@Y9 1(<4^12X#^ ;1R?+S&M'* 0:..<Q5BY9@*KOL,
MD!HR6\R%<WX>8"E;50V.&OE69DEA#L^>>8F4BN=]A9NBNU_&K$89J*C$YJWR
MALQ+HGMDD]B2I?9>D,33)63%C$H .@U@ZHW 6Q2W2Q$/NU7RUNK%]^6@,PDO
M(/"V 7Y%]B\?:8!_K47)(8L2+3VH>[^1%+Y/JZ)H@%W XZ,((\ZQ1<K6@D8X
MVYAA9!Q0(%G,<PKH3LL>W5$]X\O-PC+FI*Y7%4$/II%4YZL"PLXN,E7EJ ;#
MPAD-K#%)EL2(#&->V-.!35'=T Q3(7!0J_@SLZ9;<59BNXA5O5->70!=>V_$
M'\).N"/ R7GRIB++1.0"9PG LSWK]"U8V_R\8X*7$:-:EG1\.N)D[?*C53PR
MT2@00B92Q>;@.Q_LE+LCM_/S"GYE% >?52NBA_,0/BWKB$:R%-QJOP0DQ,[;
MOVO]*MN:%:VTX:D8JFU2X=\NJFI8T?IT1+\QM_;G(<!*G(4H]8]1\C:V [RF
MC-%6X!AZYXG%L[X2[=L:;K6A1'#+7#QQU3FGJ8OZ@OI<H&X;JD^3)_C!_59X
M>CBT>YH4-&>*UO[ R+\7OV>%_O>W]HZ9J3P+1@V4R77+<?U!<C*(>G(C<[EA
MDW!EMW+YU\AKKK5>.;),5*-<VK;';!]\5A8JH]'"^<UTC3-N)=8)EMS]3]M>
MP^%S^H7 B*0D&ON3%KA&EI$8)G6W\7E8Y6YN;_./+A@*6GTZY.@[.)91*=/>
MF<>HZ0IN,)-"9Y<#R5Z5%*LEBV1Z)W.4M/_E7I^V20[=F+V.I=<$!\7,0'>,
M$C-&'8"O*F[HP#%NQ$PI1S';ONAD9@2FALE;4%$!.CO0"AD<*0HQW3?!G3;4
M=(TE_6I]WJY;;<>A%T;5K=_WL1*"H@1?_!B9T\:1-U%JD$[TQWF0^K$5<>!D
M0UZ>T6L8/G-CJX-[Z@)<9RM10]6-@PD\OC%VVC&4YQQ \UE0!>[9Z)]8L]%"
M\%]"50'EOZ@'!POIN<?&<WD_F"SON&E$:6,U[XSZ3X!LZ3<DY,S-DRM0?G2&
MRCHP2=N[/(_UG&K^%9O <U?I_TTP94#,P-3>:$HU/62YD )=JQ7;AH;IWJ!>
M\^-M5@J,.K.M^)N:S*>^ SYGU *&.R"Z0QJW/]15?HG!X"*8G<YE,A[*I6^C
M:W>"30;6&I%8U+0CU=%+)5>(Q&_:%_$N69-<T_0Q[QZ;FN05 *])KN#7%T!0
M+$[G.3"E0X!U:2W-4^PC ?MF,/#-']8]4$TTZ2GI;-]A,'+NECP$CCS;L=(0
MTB$(FP'TDQ$&+&9.F[)8_!3UNQ/U.R>H-2T:,D0JW RRY.TL!JZ0C/AE,1BM
MHNU,D(JOAK,H<#PD/[B5\(.CYD>THP'*Q&S$J%*RFW,5-I3! O03-)Z_!Y2T
MC>DICCO8?YQ!O36J!S2H.T?[K)0%*E*93?3=LWU?8=L,B>2J6G K'R&6>,EN
MG'.Y))8N9!:8=Q"*&D::@ED/E3*AW.6OU@-N%95R^U*A7&M)^/4KJ9[OO5BF
M)&S(_ET]?_7D> \)XPKSUVE2"@%BBS=7BZVNN^&V,Q$+]T"=GYOL]="_ ^-(
M[ZK-AKGRF9'!K!PH9N1&V+AFQYHNCY$A+.+YL^Z;2C4=-A26XKAD"$\\P5[,
M;@ZFG4JZ#K'8I[4J0I7\DK=*70IS 6?/:(DSBIHG.%&5*Z>E'P\K9ZG)/3/=
MCOS5KO8LX"Y6KWJHJ-#&&J5-W.PQIJ<CH&\_!)SH,C[=;64F(XZF[;,/N@Q:
M@V4@F5>^*29+1E*D5-6(/Z)XF-.;K:I73#/JX,>L"2ES1,R$FLS-!JO^5N7&
M(GIU3C&P_ E5I> *J5N9."J6H61FO*5?.+0X-H3E0B9E$P!47'(<^+--][5_
M#?C:")#!WO4W)& UFEK5/.B ".,\)BF%I/T?Y3.L@FDDO#4"W+,0:=-*GK$C
M/X2T=!QT%6$R0(B, 69/[EH*K2V<M1O!$_T&?31K06^?O BOCN'>FLVAPA94
M*08CP<;:&VEKNK75>5.#+-CK_0]#<;8=@_MR^_@MNWW-K0-S:\%UK5LH\SMT
M2!X>E/$[WC#V9X'"CK7[?H<&@BLQBP>QP6' G$%S":Q?(_:H!QJY%GH7+ .D
M%9%'2(4/R6SY/E+I7K!2YL[ !NH9K7G.@Y?^1^0H'I;R/: 9GM\"S?#=6<KI
M,4C,Z'>,W?L$.G9V1(,(73GOT(O'D1/2IJ?\H*5S +$,(U*5!O,R5^4XPA!T
M&:RV2@JTES0!WYKA(9";$:MS4.N0M.,Y#<&]L7L?U8Z-Y$BPO$;7(L"S06+A
M.XZ4#R%GY6BHPD81>8[QOSLQ=2E<[PW5"Z@6AI-5 CVG7B)7Z^G)@AK]\2S@
M@(Z:8>4+SP.+&>9+/2^V\.3F=<$#D#6RO:[_G""T7-/GL:Z0X6H99HO1<IEX
MX;L$LYG214VV,B.%QRY;<\WMC:_E;)X*9;GM)*A=>[/H6-Q7CLW[J@)!4Z3#
M;DS1B<H0S$#L(*:G\]*TKV57#6OS..V;7'#T&!JPX5[:H#31@%K4[!R>GS7>
M FW1VRA6\3:^K^/[!]OX_D/E8K:>7<E_$&><IA0'_0-+@3+@PFW?\3?H.UXQ
MY$-8V0B"BU57H$I"LZ+EPAHQ^BH%G3I:*<T_I2EI!,'@O*W2 E\*+EA3S@N5
M7M"-\35,@ ]#\\55H'*VF&Y\5/>.-D.$0C>]S%MGWL=XEQ69/*;+*@ +%AA[
M9$,&6V-*QZ(J.-5L-[9;9KSZY:_Y',IMADR[<8LM5GFL43O3%.8%*\[U&K'P
MN>7V3%,)2% =>CJ-MWJOX=\*!IJ9F63XD*46>S=K ]4LD8HC;RA3R,"IX$EH
M5/A"X:)G.=:ZHN_!.^6#O?A%F+%_!>-9J<#5^1G+208YEXD<!E[+U'+V%N!Y
MP)D$HE?.I+*#S5K3VPLC8P-<7[2<#>',8FQ'?N=>OS&N797>.J65)'B19O.N
MZ!!D*IB6C5[H=97)35=C^A.N;] A.67Q??#RX)BG<LX(#3S&=F.]SD2B1PK)
MG<%AI18Y;0K4.Z55A$SCE!3T?H-8R*DI&[?[(>"']!;3O&IQJ)&U(:A!KXI4
MH>I_[<>8:MNBC7R$>NIMD"WK;N:YI)D*7@NUT)SL/T-S$#MJ3%GHFY&)(W .
M/?94 D'J_3XZLO>;/:\-Y7S54*ULG4N:7R*F0:)2[CM>.SL<2HMQ(&HW4Q60
ME=2<N35\5MN[&7@-#TK1;LGNT&KFR?@HR:XH\R=+=&)">$M[$3IJ.[4Y-%0<
MD:C6W!!T#%-"W6PH+;P16K#[R<:TPO@Y,1!8BI,U',K"T0""#D;'AX4Y5,0_
MV&85AKH?@-B&.CB+2C'$C,-]<*?+!8,VRV,%WF7P/870P.+]/$8RK3M@0YK4
M%M8 8%EXDX=0#]70<IGL(2/@[P6#: /#4<A/ZQ-ZFR+4%4D2QQC/;FPT./K:
M37('7\;<;Q(&FEOF&#@%SELV&$[MNK7D39KP.^?D@BN[[QSXP,@=*G76%6WD
M2;0B6L'GQ&\O@>QSH26\)N@=2*H@2#4X$MWD]N]%[NJ%1RBK!Q.M#&\QAX'1
M6P0[[:(6($/':A$RV"E!'N&+8K9NEI0@"[O=1;@Z2;?@I8V]K*ME[D>YT_'W
M0LTO[R;IK/'UH!UQF62C4DCM;,QTW&J=0R9D*T< CG6.%@6VK4K!7NNDF&*O
M/)+ 4GFW:6WXBWC)\Z+A>>9F5*7 S"$)YF(ZFAU!FG-S5#GM"C=O.K;)**XE
M[;#J@!]U<^*H<.93+<V,VW"[#K<?;L/M#[1':BT0C"QQ;&O-SVI\&2>7_<%O
M"UM1P]$X,W8J*4K,:'FAH2!S$5"S>)S6')OJH1IN))KFN#1!# ;+MO4[7RIR
MKQ@H2C9PQ #:U&"^&+OCHI:@3>YV4E,N-R>W _R'QM]V# PJ3U:J;ZD&$$B+
M NJYHE0:V.9VI)JC#@)LN"Q@UR:JLQTA98J(*1,IZ)'&%N7J%;)5'$[9WFY!
MJC550 HT4=5]FXV=37HET+4!EW9'A2=9@"AH&R"/.KNQ^T]'M?:N-].';LB_
M8[AJJM>>-WDW<BI2UD55!0KX(+'L=_&<3>T-TEP&E*-;W^=S&A@:NKG$UOB]
M@*8()H6*%6Q <*\<''$.6%P9'/.]81:.#7X@V=HU^!>,KNDK[C77@E775<#^
MELFU*W6U!Z.W/[U,BF:6Z/C%S.VL"=I4UF! RXVPJA[#Z11=6P';BS7P80$
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M&.I<M;Q$V%%E?.!<(SHSUA/OOD*;4@A',:?N. @'7B2A?>Q)6I."!Q81.);
M$)+7P.G2P0_A2F/SA>MHW.F<=-]JX$9T:/-.7:$/#F[,9Q<"%[F_)?,M_.+E
M&/CTPZ>W9[^?1X?W%-NK6ODBP?BK$D9OE##:- /S<&\]5=)_@"?7P%/^0.>&
MY!N=Q6HS$Z4>UV""HUX>3QM<BM$SF>%BFD=9L5FU2"%G-P^8M'<W9-<ZB1;&
M>ALCUY6=O.*3P[7DDW>Z/6P@HE9FPIF6-2NA-L(FHBS]N,QX'(AM"X,F<0D"
MXHJ[U'AD1%6S)N5'="/KH:JA%.-"'&J?YM>J4K+"K%3%O5OF F-<'%@CYLPZ
MIGV#C*H#&_KVRN@)K<*+Y.33J90LMB!=NEQ#$J#!:DP1_O7=FE8?ARXZ6DL>
M0Z+-J]:@H)Y_F1/PP,HYS:<DU#M6_HC,Y=19?3N6R"4G:\"&.DU+%7BF%%4_
M#BUL;JF@'R."J"):'39N/;0+ ;^4>6?)/$E)D39\"_9R"(C"7CF5R];J ;"<
M-\[2)ZCWBMD$I^9JX[MH##PE183HU)"O^Z8Q72#SO"$4G,H.:F<]>S]NZY'<
M@RYK@&U+B=YH''7Q*UI'MV_5\-=3P\=K*2+.K?+R]5'$VC8T8%)2@Q:<=:B\
M<^M=G*'-E!P;"XEBZ1O^T/SD@52_%AT^BNI.UI+J/HE9\)YDZTK)[4U $TD;
M?+"]!0,Z%JA*JZ_6,-2F_YJ:R@)#B/@*NWBH)\A$]X9XI>KLS]@3\WZF!B0U
M9J @(H;,ZBN<E$Q-?;3!A-24)]WE%H745$,</^)JB+42,<_64L1\$#98&[UV
M*DZ=4ZOI#;#7<D5;AC/*?5F\; K.DA:Y7N7I"8(H7I07\PK!)1I=3QDAD&=-
M8^IKD#Z3&#MX>_BP1<7@H2&C0:W\X(SW6G' >O9V_3U)P3,H5NSMG497M(X;
M9:4%&U*UKY+HRU/JNY!&*!W26!"4B!773 NLP^=DM*9EFPN K:2:T@Y<7F&I
M_R6-CH*+;JA<R68+3IBOM4MTO^#%>G8[O6\NDJKXETYVKE6-O^5,W*7JRZWX
MMRPY72J/5R$&OE$%6/"&N$*$T,-VGJE_,"WW"^^:F)6D6!A<><PAR[.KXZ4D
M)-@H(-5DM[0%3+W> 2?E:77DD")#OZZS[]@,(0AN[1V0Q7('P;(-!)O'SVO:
MK@.'(2RS%JS\UU# *Q3E!FJE2;?8#X@1>^GS&L-?$![G,M4',33?O<BG@QE3
MC90;U=2R4339@(,WL*3P<%U+"KG#NUT;RI:&*&XDCZW:'U)=H1"ZU6QJJS:N
MFID1S%,^PAHTAY:":'AS3>1"SB*Y4^%]IW901=.E-E>#T:&#315,]X;>07]@
M77T&K,J*?D4%1SVCC&./KWU9S)3>]M2:7V38@4LUOZPIV><,L3XX! >O;UJ[
M!#I+9, .I44>H/L>SPY/>(<%7P9W4%@ ]FZ:?(G9)6WJJDBQM:HTM5'6%^[D
M(F^C<>\S<C;<??XAMC==L+U_V_NX9_84OJZHUBX%JBRX;0W+XAAIRYY+[_31
M9!D60 LNAN$*A27'7V/>NBK:2U:=UF6#B8U#XU2G&/G4U1T59A7S6IM7SH2I
M5&7F/U?UM10^RRR(1VA##IIF[PYJ$-M;(]I"G6&%DVD),)''(O/&.B77(Q@I
M;O'Z@IPO;+\+E:*^]G!CJ"9>8\?X72\*X84EJW$YROR"Y'/;H\%58$4E3L%M
M'PSHHC7D")K+%K#E7I;A>A8#&E(Y=0$\Q$Y<J9EHT;&[N&0)#M0,KDU \?>Y
M5Q$KC(#VJ!Z#&TX*FAEH\#HPNL8U5 PW6-4]$+2/L+&)I+J>]7C_)5@T<!A_
MA=-@*_0T73F5G@ZB5*%Z-)!WR:1D<\ &_110NY4- %YQ[0D6?]8!(%4JS[7X
M=7G%*]AH>@AT-_#I9-1!?1_L);]&DOM,O4"-:P8HY$$7L6!R8UTFH!;:G;7F
MQ*+1,R>YA_&:LK1#H.:&6-(%5O\E8EZ2FUMSQ:3&*/#A$BP1.L"AXJTCJ 5G
M[R2HFJBI1K<&9_U>OT6]?<9?[\PSPF>\$*LJ'BS,@IEP )S,#@R+\[B0(;1,
ME=N4HE1M73;26\.-.O5T+UQ&2"^&R!2$0CWR;H-LJU/.6M6J+[FU?01R^PIJ
M]JDDG\F@Q?HN!O8FU3Q&C@@"P\QR);,2-Z(R<@;;.@U=IW'RB.LTUM+^6,]:
MY?<**TE!_*Z\"'&(WA101HNR!B0^;@&LF1%B<8X]CQ.2<QP'=9H79W5FYELO
ME[C;1+MY/0MH3S6R\3\DE #__+W(^W5Q\[#]5"PM@3<4W [33(]&6?(YKQB[
MT;,"!U&7T ]U39(5$9'Y1W8I$C?S4U66P&^@H6#%8.2?P$1 C10T852"L=R6
MO:.3)/U\ 99>E3V1S9W2?UY_GR[2T= R,+WUJ8XUDPD\*UIJ9<9F AJWP" '
MV N1JL;O1.&MMVY<B0PF$@=FW 9AV"2=&OI,#0S#6K#&/@AG;\E'5YNOSD6W
M%ON0"2NC:P>K?/UH 865LE 3'G+-K$=G,T8GMQ()38ZJ.@7,[M\ZUP=6*/[9
M1#6PGA7M9\JH7[W=X@IL+J,S?3Z.(Y9,:@R:"(:4\5$QOX55J!AUUNY*ZX5<
M:.(8N_E%2PZE_3.K$HJ1P"ACE%\(3)3&7[2\H<9^EF!@)0M:EZU'2#,E+F::
M8XM4;/MM#,4TI<) *F%5E9'C-8E6N]=(!MP,]=5C*ASD20(&BWFL+F\PR/ R
MT.H<.C7Y,6Z TK8Z\"\;9!YAC1D)%>!>4!Y.-8G=NO$&JTWFKO'Y*N]\,*?T
MUCP106"P:VY>1Y?U)6R>:+Q[=VG6*&JSN1J92!$4)5R*;E!#8Z$(M=*CBDIP
M*G2E]9G8Z&-+](T/NW+(VKA[50LYIQ"T[<T5'$18NCUI!%YH+9+(6IJO9_/
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M6?G+_P502P$"% ,4    " #F2&E3YN?<$?T'   ^)P  'P
M@ $     83(R<3%?,3!Q># Y,S R,7AE>&AI8FET,S$Q+FAT;5!+ 0(4 Q0
M   ( .9(:5-L)T_: P@  +4G   ?              "  3H(  !A,C)Q,5\Q
M,'%X,#DS,#(Q>&5X:&EB:70S,3(N:'1M4$L! A0#%     @ YDAI4XM$7B#O
M!   ;Q<  !\              ( !>A   &$R,G$Q7S$P<7@P.3,P,C%X97AH
M:6)I=#,R,2YH=&U02P$"% ,4    " #F2&E3*6VE/,X:   *H0  'P
M        @ &F%0  83(R<3%?,3!Q># Y,S R,7AE>&AI8FET.3DQ+FAT;5!+
M 0(4 Q0    ( .9(:5/0+@X0F\X! '6B%  0              "  ;$P  !C
M86@M,C R,3 Y,S N:'1M4$L! A0#%     @ YDAI4\LJ-Z0($0  K+0  !
M             ( !>O\! &-A:"TR,#(Q,#DS,"YX<V102P$"% ,4    " #F
M2&E3>"X;Y8P6  #1SP  %               @ &P$ ( 8V%H+3(P,C$P.3,P
M7V-A;"YX;6Q02P$"% ,4    " #F2&E3]0< ^B)C  !2?P0 %
M    @ %N)P( 8V%H+3(P,C$P.3,P7V1E9BYX;6Q02P$"% ,4    " #F2&E3
M%6IY-X!.  #470  $P              @ '"B@( 8V%H+3(P,C$P.3,P7V<Q
M+FIP9U!+ 0(4 Q0    ( .9(:5-Q0(QT!4,  $%1   3              "
M 7/9 @!C86@M,C R,3 Y,S!?9S(N:G!G4$L! A0#%     @ YDAI4W_I-2'Q
M-   ET0  !,              ( !J1P# &-A:"TR,#(Q,#DS,%]G,RYJ<&=0
M2P$"% ,4    " #F2&E3KJ"*38E:  "G:0  $P              @ '+40,
M8V%H+3(P,C$P.3,P7V<T+FIP9U!+ 0(4 Q0    ( .9(:5-Z>6ID34H  -59
M   3              "  86L P!C86@M,C R,3 Y,S!?9S4N:G!G4$L! A0#
M%     @ YDAI4YF.DH'U/P  @TX  !,              ( ! _<# &-A:"TR
M,#(Q,#DS,%]G-BYJ<&=02P$"% ,4    " #F2&E3[47@>@+:  !#&0D %
M            @ $I-P0 8V%H+3(P,C$P.3,P7VQA8BYX;6Q02P$"% ,4
M" #F2&E3]A?)(SJ0  #!PP8 %               @ %=$04 8V%H+3(P,C$P
M.3,P7W!R92YX;6Q02P$"% ,4    " #F2&E34L^O"YLO  ")10$ '@
M        @ ')H04 <&5R9F]R;6%N8V5S:&%R975N:71S86=R964N:'1M4$L!
M A0#%     @ YDAI4QB\@F//5   %;0" !X              ( !H-$% ')E
M<W1A=&5D8V]D96]F<F5G=6QA=&EO;G-N+FAT;5!+!08     $@ 2 -8$  "K
%)@8    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
